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Preface to “Pharmacist Services”
Welcome to the Special Issue “Pharmacist Services” of Pharmacy—an open access journal with
a focus on pharmacy education and practice. Articles in this Special Issue reveal how pharmacist
services can progress in (1) societal relevance, (2) innovative delivery, (3) integration into broader
systems, (4) enhanced image to both payers and consumers, and (5) growth into new roles and
markets. The articles reveal the overwhelming opportunities that pharmacists can embrace and
fill, such as (1) medication optimization, (2) wellness and prevention, (3) chronic care management,
(4) acute care management, (5) patient education, (6) care transitions, (7) population health,
(8) emergency preparedness, (9) health informatics, and (10) patient-centered, living-in-place care.
We trust that you will find the articles in this Special Issue not only informative, but inspiring
as well. We greatly appreciate the colleagues who worked to meet a short deadline and were willing
to share their work with us. We also wish to thank the editorial staff who coordinated the review
and publishing processes. Their professionalism is highly valued. Finally, we wish to thank you, the
reader. Please apply the ideas in these articles to your work. Expand upon them. Challenge them.
And, then, share your work with us.
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	

Welcome to the “Pharmacist Services” special issue in the journal Pharmacy, an open access journal
with a focus on pharmacy education and practice. In 2018, an invitation was dispersed to scholars
in the pharmacist services domain asking them to submit a manuscript to this special issue no later
than 31 July 2019. We invited these colleagues to think about a full breadth of topics including, but not
limited to: (1) The history and development of pharmacist services, (2) service settings, (3) service
management, (4) service profitability, (5) service recovery, (6) service relationships, (7) service quality,
(8) service tailoring, (9), service design and standards, (10) service performance, and (11) service
evaluation. We sought manuscripts of all types including: (1) reviews, (2) commentaries, (3) idea
papers, (4) case studies, (5) demonstration studies, and (6) research studies. The call for papers was
delineated using ideas published by renowned experts in the services management and marketing
domains including: Teresa Swartz, Dawn Iacobucci, Roland Rust, Richard Oliver, Valerie Zeithaml,
and Mary Jo Bitner. With this foundational context described and the invitations sent, we waited to
learn about what would be submitted in a timeframe of just several months.
We are pleased to report that over 30 articles have been published in this special issue
and represent the work of about 100 scholars in this domain. To receive such a response from
busy colleagues in such a short time-frame is incredible. The overall goal of this special issue
on “Pharmacist Services” is to give the reader a state-of-the-art synopsis of the pharmacist
services domain in the year 2019. To accomplish this goal, we sought papers that address the
social, psychosocial, political, legal, historic, clinical, and economic factors that are associated with
pharmacist services. Papers that translate concepts from other domains into the pharmacist services
realm were welcomed. As we review the articles in this special issue, a great deal can be learned about
(1) pharmacist professionalism, (2) pharmacist practice, and (3) pharmacist progression.
Pharmacist Professionalism
The articles reveal that pharmacist services vary by country, design, delivery environment,
payment schemes, end-user, requisite training, regulatory standards, and more. As different as
pharmacist services are, they are all linked by the individuals who provide them. Whether dispensing
or immunizing, reconciling medication lists or performing medication management, pharmacists use
their expertise related to medications to pursue excellent, affordable, and accessible healthcare for
a common beneficiary: their patients. Pharmacist professionalism is a driving force for translating
pharmacists’ expertise into medication use, for helping people achieve medication experiences that are
life enhancing.
Pharmacist Practice
Another emergent theme for pharmacist services described in this special issue is to view them
through the Joint Commission of Pharmacy Practitioners (JCPP) Pharmacist Patient Care Process
(PPCP), which was created and is supported by pharmacist organizations representing managed
care, education, consultants, in-patient practice, outpatient practice, governmental regulatory bodies,
Pharmacy 2019, 7, 141; doi:10.3390/pharmacy7040141 www.mdpi.com/journal/pharmacy1
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and more. This model identifies a consistent process of care in the delivery of patient care services
consisting of the following five steps: (1) Collect, (2) Assess, (3) Plan, (4) Implement, and (5) Follow-up:
Monitor and Evaluate. The articles in this special issue give readers a state-of-the-art snapshot regarding
the diversity of pharmacist services through the prism of the JCPP Pharmacist Patient Care Process.
Pharmacist Progression
Finally, many articles in this special issue reveal how pharmacist services can progress in (1)
societal relevance, (2) innovative delivery, (3) integration into broader systems, (4) enhanced image
to both payers and consumers, and (5) growth into new roles and markets. The articles reveal the
overwhelming opportunities that pharmacists can embrace and fill such as: (1) Medication optimization,
(2) wellness and prevention, (3) chronic care management, (4) acute care management, (5) patient
education, (6) care transitions, (7) population health, (8) emergency preparedness, (9) health informatics,
and (10) patient-centered, living-in-place care.
We trust that you will find the articles in this special issue not only informative, but inspiring as
well. We greatly appreciate the colleagues who worked to meet a short deadline and were willing to
share their work with us. We also wish to thank the editorial staff who coordinated the review and
publishing processes. Their professionalism is highly valued. Finally, we wish to thank you, the reader.
Please apply the ideas in these articles to your work. Expand upon them. Challenge them. And then,
share your work with us.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
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Abstract: The history of community pharmacy in America since the 1920s is one of slow progress
towards greater professional standing through changes in pharmacy education and practice.
The history of American community pharmacy in the modern era can be divided into four periods:
1920–1949 (Soda Fountain Era), 1950–1979 (Lick, Stick, Pour and More Era), 1980–2009 (Pharmaceutical
Care Era), and 2010–present (Post-Pharmaceutical Care Era). As traditional compounding has waned,
leaders within community pharmacy have sought to shift focus from product to patient. Increasing
degree requirements and postgraduate training have enhanced pharmacists’ ability to provide patient
care services not directly associated with medication dispensing. However, the realities of practice
have often fallen short of ideal visions of patient-focused community pharmacy practice. Positive
trends in the recognition of the impact of community pharmacists on healthcare value and the need
for more optimal medication management suggest that opportunities for community pharmacists to
provide patient care may expand through the 21st century.
Keywords: history of pharmacy; 20th century history; 21st century history; community pharmacy
services; pharmacy education
1. Introduction
As long there has been a belief in the medicinal properties of natural substances, there have
been people whose duty it was to transform these materia medica into medicines. By the 1800s,
however, this traditional role of pharmacy had begun to change. The Industrial Revolution led to mass
manufacture of medicinal products which once only the pharmacist could produce. Additionally, new
medicines were being discovered which could not be easily derived from traditional materia medica.
As traditional compounding began to wane and proprietary products began to replace those which
the pharmacist used to make himself, merchandising in pharmacies began to increase. The erosion of
traditional roles led to a crisis of professionalism within American community pharmacy, requiring the
profession to rethink its role in society. It is with this backdrop that the modern era of community
pharmacy in the United States begins.
For this narrative review, the history of American community pharmacy in the modern era can be
divided into four periods: 1920–1949 (Soda Fountain Era), 1950–1979 (Lick, Stick, Pour and More Era),
1980–2009 (Pharmaceutical Care Era), and 2010–present (Post-Pharmaceutical Care Era). A slow march
towards greater patient care and higher professional standing can be observed across each of these
periods as the profession of pharmacy has struggled with what defines community pharmacy and how
community pharmacy adds value to society.
2. 1920–1949: Soda Fountain Era
2.1. Education
By the time the modern era of pharmacy dawned in the 1920s, pharmacy education was rapidly
adopting three and four-year degrees as the standard for education [1]. Old-fashioned short courses,
Pharmacy 2019, 7, 98; doi:10.3390/pharmacy7030098 www.mdpi.com/journal/pharmacy3
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designed as supplements to apprenticeship, were falling out of favor and would soon be made obsolete.
Pharmacy education in the early part of the 20th century was guided by The Pharmaceutical Syllabus [1].
This detailed guide to pharmacy education, created by the American Association of Colleges of
Pharmacy (AACP), helped to standardize degree programs as training became more formalized.
The first major study of pharmacy practice, Basic Material for a Pharmaceutical Curriculum, was
published in 1927 [2]. This study sought to revise the curriculum contained in the Pharmaceutical
Syllabus by developing a new curriculum based on the functional needs of the pharmacy profession [2].
Reflecting the makeup of the profession in the 1920s, the Pharmaceutical Curriculum was focused
solely on the needs of pharmacists working in retail settings. The report focused on many areas of study
deemed essential to pharmacy practice at the time, including basic sciences of chemistry and physics;
medicine-related subjects such as pharmacognosy, botany, pharmacology, physiology, and public
health; and practice-related subjects such as small-scale pharmaceutical manufacturing, prescription
filling, and retail sales operations. The Pharmaceutical Curriculum did not, however, include any
information on diagnosis and treatment of disease. While the authors acknowledged that a pharmacist
has a duty to assist their “customers” who have questions on “the cure for an ailment,” they were
concerned that too much education would lead to counter-prescribing—dispensing pharmaceuticals to
treat a disease without or contrary to a prescription from a physician.
Merchandising and commercial aspects of pharmacy practice were only begrudgingly included in
the Pharmaceutical Curriculum. It was acknowledged that merchandising and commercial interests
were rampant within the community pharmacy practice. However, one goal of creating a standardized
curriculum was to raise professional standards and train more professionally-oriented graduates
who were better able to engage with other healthcare practitioners [1]. As such, it was thought that
inclusion of merchandising and commercial interests would undermine pharmacy’s professionalism
and these aspects of pharmacy practice were excluded from the Pharmaceutical Curriculum. Aided
in educational transformation during the Soda Fountain Era was the founding of the Accreditation
Council for Pharmaceutical Education (ACPE) in 1932. The ACPE established the first national
standards for pharmacy degree program accreditation and, as a result, by 1941, 64 out of 67 colleges of
pharmacy had adopted a four-year degree standard.
The educational change began in The Pharmaceutical Syllabus was furthered by the Pharmaceutical
Survey which was commissioned by the American Council on Education in 1946 [3]. The Pharmaceutical
Survey recognized the growing tension between pharmacists as distributors of mass manufactured
products and pharmacists as healthcare professionals. The distribution and merchandising roles were
seen as undermining pharmacy’s professionalism. Additionally, the four-year degree was thought to
be too short a course of study for the pharmacist to complete a general education as well as a pharmacy
education [4], and did not “confer the status that is desired by pharmacists, particularly those who
work in rather intimate professional association with physicians, dentists, and members of other health
professions who hold professional doctor’s degrees. [4]”
Therefore, to provide a complete education and firm the professional foundation of pharmacy
practice, the report recommended the establishment of a six-year Doctor of Pharmacy program to afford
“new opportunities for raising the level of preparation for the professional areas of pharmacy [5].”
However, the recommendation to lengthen the curriculum was met with opposition by pharmacy
educators, and the majority of pharmacy school deans at the time favored the status quo [4]. The debate
within the American Association of Colleges of Pharmacy about degree standards would result in
substantial changes to pharmacy education in the 1950s.
2.2. Practice
As compounding waned, pharmacy in the 1920s found itself questioning its own professional
standing. This is reflected in practice as well as education. Concurrently, the enactment of national
prohibition in 1919 was a boon to pharmacies’ front-end commercial interest in two major ways [6].
First, the sale and consumption of “medicinal” alcohol was allowed and this created a legal loophole
4
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which many pharmacists and physicians exploited. Second, soda fountains became very popular
destinations for those seeking alcohol-alternatives. Neither was considered a “professional” activity,
but both were surely profitable.
Accordingly, traditional prescription compounding and dispensing became a minor part of
pharmacy operations in the 1920s and 1930s. Although 75% of prescriptions still required some
compounding [7], less than 1% of pharmacies of pharmacies had more than 50% of their sales from
prescription drugs [8]. Even when drugs were dispensed, ethical standards at the time limited
pharmacists’ engagement with patients. For example, the 1922 American Pharmaceutical Association
(APhA) Code of Ethics [9] stated that:
“[The pharmacist] should never discuss the therapeutic effect of a Physician’s prescription with
a patron nor disclose details of composition which the Physician has withheld, suggesting to the patient
that such details can be properly discussed with the prescriber only”.
In the 1920s, the transition away from compounding and towards premanufactured proprietary
products led to a crisis within the community pharmacy—pharmacy’s traditional role was waning,
and it was not clear what the role of a pharmacist was, if not, compounding. The answer, in many
ways, was to increase front-end commercial interests through expanding soda fountains and other
goods for purchase. Prescription dispensing was essential to the identity of the pharmacy, but was
de-emphasized as a part of the pharmacy’s business. This would change as advances in pharmaceutical
research in the mid-20th century led to an explosion of new prescription drug products.
3. 1950–1979: Lick, Stick, Pour and More Era
As the patient care roles of the pharmacist and educational standards increased from the 1950s
through the 1970s, the highest professional activity was no longer dispensing, as it was in the 1920s.
The provision of patient care services replaced dispensing as the highest professional activity. This
created a cultural shift within community pharmacy practice—and gave rise to the tension between
dispensing and patient care which persists into the 21st century. Arguments over the degree needed to
support this new version of professionalism were heated, and would not be ended until the 1980s.
3.1. Education
The recommendations of the Pharmaceutical Survey laid the foundation for changes to pharmacy
education throughout the 1950s, 60s, and 70s. Leaders in pharmacy education acknowledged that the
four-year degree was insufficient for the level of training needed to become a pharmacist. There was
strong resistance, however, to a mandatory professional doctorate as the entry level practice degree.
An uneasy compromise was made with the adoption of a five-year degree standard, despite specific
recommendations against the degree from the Pharmaceutical Survey.
As clinical pharmacy and the desire for higher professional standing began to permeate throughout
the profession in the 1960s and early 1970s, the movement towards a degree which provided the
appropriate professional foundation for clinical pharmacy accelerated. The first pharmacy program
to adopt an all-Doctor of Pharmacy (PharmD) standard was the University of Southern California in
1950 [10]. Other programs followed USC’s lead, and by the mid-1970s there were 20 PharmD programs.
Through its emphasis on clinical education and experience, proponents of the PharmD redefined
professionalism as not just an avoidance of merchandising or commercial endeavors, but also
de-emphasized medication dispensing as a professional activity befitting a PharmD-trained pharmacist.
Indeed, dispensing was called a “temporary obfuscation” of the clinical objective of the profession [10].
Educational changes associated with the clinical pharmacy movement also re-emphasized the practice
component of pharmacy education, reducing educational focus on theory-based training in basic
sciences [11].
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3.2. Practice
By 1950, the percent of prescriptions which were compounded had fallen to 25% [7]. This percentage
would decrease further to less than 5% by 1960 and 1% by 1970 [7]. Concurrent with decreases
in traditional compounded prescriptions was a large increase in the number and diversity of
premanufactured drug products. An explosion of newly discovered drugs led to an increase of
over 50% in the number of drugs dispensed during the 1950s [6]. By the mid-1950s, pharmacists were
stepping away from soda fountain and were back behind the pharmacy counter. However, the role
had changed substantially from the 1920s. Pharmacists were primarily dispensing premanufactured
capsules and tablets, and ethical standards at the time still prohibited them from discussing the
contents of prescriptions with patients [12]. Prescription labels from that era commonly omitted the
name of the product dispensed—with the idea that labeling the vial with the name of the drug would
violate the physician-patient relationship. This was the origin of the modern “lick, stick, and pour”
pharmacy practice.
This new version of pharmacy irked many patient care-oriented pharmacists at the time because
they desired to do more than simply dispense a product. Eugene White, among the more well-known
visionaries of what would become patient care-oriented community pharmacy practice, began working
in 1950 at a typical retail-oriented pharmacy. He quickly became disillusioned with practice standards
at the time, saying, “After five months of selling lawn seed and paint, cutting glass for window frames,
and dispensing a few prescription orders in between, I could longer take it . . . [13]” White purchased
his own pharmacy in 1957 and in 1960 completely transformed his pharmacy into what he termed
a “pharmaceutical center.” Gone was the soda fountain and self-serve retail space for candy, stationary,
billfolds, toys, and gifts. He added a record system to keep track of families’ prescriptions. He hired
a receptionist to greet patients when they entered and built a semi-private patient counseling area. His
model even served as the basis for professional pharmacies promoted and designed by McKesson in
the mid-1960s [14].
Also innovating during this era were pharmacists in community pharmacy practice settings
like the Indian Health Service, which in 1966 required private patient counseling areas in all new
pharmacies [15]. The 1960s also witnessed the birth of clinical pharmacy services, with major innovation
stemming from experiments including the Ninth Floor Project led by University of California, San
Francisco School of Pharmacy faculty [16]. This project revolutionized the provision of pharmacy
services in hospitals by building a satellite pharmacy to dispense unit-dose medications specific to
each order and to prepare admixtures by pharmacists instead of nurses, which at the time were
radical advancements. In addition, the pharmacist was available for consultation on drug information
and other clinical questions as they arose. This experiment spurred the development of similar
clinically-focused pharmacy roles nationwide would substantially influence changes in pharmacy
practice philosophy in the 1980s.
Eugene White and innovators like him replaced customers with patients, and through this they
redefined how a professional community pharmacy operated. Combined with the growth in clinical
pharmacy in hospitals during this same time, this transformation revolutionized how the profession
saw itself. This was change was reflected in the 1969 revision to APhA’s Code of Ethics [17] which
referred to a pharmacist’s duty to his patient in the first section:
A pharmacist should hold the health and safety of patients to be of first consideration; he should render
to each patient the full measure of his ability as an essential health practitioner.
Practice changes continued through the 1970s. Products became more diverse, and spillover from
the clinical pharmacy movement began to expand the array of non-dispensing services provided in
pharmacies. Additionally, the first computer systems in the 1970s expanded pharmacists’ abilities to
keep dispensing records and check for drug–drug interactions [6].
The period from the 1950s to 1970s was a pivotal time for American pharmacy. The emphasis
on front-end merchandising and soda fountains waned as dispensing increased. A new version of
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professionalism had started to arise within community pharmacy—one focused not on dispensing
alone but on dispensing as a part of care for a patient’s medication-related needs. Education also
witnessed a similar evolution, with new PharmD degree programs supporting the training needed to
provide robust patient care services. Ethical standards likewise evolved, with the 1969 APhA Code
of Ethics calling for pharmacists to engage in activity that would have been ethically suspect under
previous codes. These changes built the foundation for changes in the 1980s that would further propel
the notion that community pharmacists had an obligation to their patients which extended beyond
simple dispensing of products.
4. 1980–2009: Pharmaceutical Care Era
4.1. Education
The final major change to pharmacy education in the last 100 years was the transition from the
five-year, entry-level B.S. degree with the optional post-graduate PharmD training to the PharmD
becoming the entry level degree. Echoing the Pharmaceutical Survey from nearly 40 years prior, the Final
Report of the Task Force on Pharmacy Education, commissioned by the American Pharmaceutical
Association (APhA) and released in 1984, called for a universal six-year PharmD degree [18]. Following
this call, the universal PharmD degree was put to a vote in the American Association of College of
Pharmacy (AACP) House of Delegates in 1985 but was defeated by a narrow margin. Nevertheless,
major national conferences and academic papers throughout the end of the 1980s helped sway opinion
towards a universal PharmD and acceptance of pharmacy as a clinical profession which needed
a professional doctorate. In 1989, A Declaration of Intent was made by ACPE to adopt the PharmD
as the universal standard for pharmacy education as soon as 2000 [19,20]. Through the early 1990s,
APhA, the National Association of Retail Druggists, and the American Society of Hospital Pharmacists,
the American College of Clinical Pharmacy, the National Association of Boards of Pharmacy, and AACP
came to actively support the single degree standard but the organization representing chain pharmacies,
the National Association of Chain Drug Stores, continued to oppose the concept [20–22]. On schedule,
the last student to enter an accredited BSPharm program enrolled in 2000 and the transition to
a universal PharmD was completed in 2005 [23].
The most evident education-related aspect of the patient care movement within community
pharmacy was the development of the first community pharmacy residency programs in the mid-1980s.
Training on the provision of clinical services was an explicit goal of these first community pharmacy
residencies [24], and this focus has expanded over time [25]. Community pharmacy residency sites
have often served as laboratories for advanced practice, requiring community pharmacists to engage
in practice-based research and expanding the scope of services offered [26]. The development of
formal postgraduate training focused on patient care in community pharmacy settings, combined with
a universal PharmD, created a strong foundation for the expanded delivery of patient care services in
community pharmacies.
4.2. Practice
The 1980s witnessed major change to the philosophy of practice as pharmacy leaders considered
pharmacy’s role in the 21st century. Many of these changes were, however, aspirational with some
innovative pharmacies leading the way and most lagging behind. In many ways, the movement to
bring clinical pharmacy into the community setting was seen as idealistic and out-of-touch with the
busy community pharmacy work environment [27].
Nevertheless, the declaration of pharmacy as a clinical profession at the 1985 Hilton Head
Conference [28] and the conceptualization of pharmacists’ duties vis-à-vis pharmaceutical care in
1989 through a presentation at the Second Hilton Head Conference [29] and a seminal paper entitled
“Opportunities and Responsibilities in Pharmaceutical Care” [30] were a boost to those seeking
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a greater patient care orientation for community pharmacy practice. Hepler and Strand’s definition of
pharmaceutical care placed patient care at the center of pharmacy practice:
Pharmaceutical care is the responsible provision of drug therapy for the purpose of achieving
definite outcomes that improve a patient’s quality of life. These outcomes are (1) cure of a disease,
(2) elimination or reduction of a patient’s symptomatology, (3) arresting or slowing of a disease process,
or (4) preventing a disease or symptomatology.
These changes to practice philosophy were boosted when the federal government in 1990 required
prescription counseling as a part of the Medicaid program [31]. The combination of these elements
enthusiastically propelled community pharmacy into the last decade of the 20th century. Several
pilot projects in the 1990s demonstrated that pharmacists could provide and be remunerated for
pharmaceutical care services, which would later be rebranded as medication therapy management
(MTM) in the 2000s. The Minnesota Pharmaceutical Care Demonstration Project [32], private and
public initiatives in Iowa [33], and the Asheville Project [34], for example, are well-known examples of
projects which paid community pharmacists for non-dispensing related services. Training programs,
like that of the Iowa Center for Pharmaceutical Care [33], were used nationally and internationally to
prepare pharmacists to provide services tested through these demonstration projects. By the end of
the 1990s, the market for pharmaceutical care services was sufficiently well-developed to support the
launch of OutcomesMTM® in 1999.
The progress of pharmaceutical care era culminated in 2003 with the passing of the Medicare
Prescription Drug, Improvement, and Modernization Act (MMA). This act created the Medicare Part
D benefit, the first Medicare benefit for retail prescription drugs. The MMA required Part D plan
sponsors to include MTM as a part of their benefit structure. Pharmacy viewed MTM as a major
victory—finally, the federal government was recognizing the need for more optimal medication use
and creating a payment mechanism for it. The enthusiasm was short-lived, however, as the benefit
allowed a variety of non-pharmacist providers to deliver MTM, and many Part D plan sponsors sought
cost-minimal ways to offer the mandatory benefit.
Also growing during the 1990s was the new role of pharmacists as immunizers. The first
immunization training programs were developed by state and national pharmacy organizations in the
mid-1990s [35]. By 2003, 34 states allowed pharmacists to provide immunizations but many restrictions
were placed on pharmacists’ immunization-related scope of practice [36], but by the end of the decade,
all states allowed pharmacists at least some level of immunization authority, and many of the earlier
restrictions had been lifted [37]. Pharmacists were critical vaccine distribution sites during the response
to the 2009-10 H1N1 influenza pandemic [38] and research from the time suggests that this expanded
role had a positive impact on public health [39]. Pharmacist-provided immunizations expanded the
total number of patients who were vaccinated, not just shift sites of care from primary care offices
to pharmacies.
Despite this momentum, the National Pharmacy Workforce Survey found that in 2004 only 5–10%
of community pharmacists reported that their pharmacy provided MTM services [40]. Other services
such as health screenings, immunizations, and smoking cessation were more common, but none of
these enhanced services were provided at the majority of pharmacies where respondents worked.
The 2009 National Pharmacy Workforce Survey, delivered after the full implementation of Medicare
Part D, found slightly higher engagement in patient care services, but pharmacists still only spent
8–11% of their time providing patient care services and 70–78% of their time dispensing [41].
As the 21st century dawned, the long-awaited opportunity for community pharmacists to shift
from dispensing to patient care services seemed nearly at hand. many hoped that the universal
PharmD, evidence supporting the positive impact of pharmacist services, and the Part D MTM benefit
would create new opportunities for pharmacists to transition from a product focus to a patient focus.
However, the vast majority of community pharmacists still found themselves dispensing by the end of
the 2000s. Substantial progress had been made since the 1980s, but the pace of change was slower than
what pharmacy’s leaders had hoped for.
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5. 2010–Present: Post-Pharmaceutical Care Era
5.1. Education
By 2010, the all-PharmD requirement had been fully implemented for a decade. Instead of
changes to degrees, the largest changes in pharmacist education occurred after graduation. Pursuit of
residencies has increased steadily in the post-pharmaceutical care era, with the number of students
pursuing residencies over this period more than doubling between 2009 and 2018 [42,43] and percent
of students pursuing residencies increasing from 21.8% to 29.0% [42,43]. Residencies have become
a prerequisite for entry-level clinical pharmacy jobs in inpatient settings, but community pharmacy
residencies have not become the de facto standard for entry into community pharmacy practice.
The number of sites remains small, and few graduating students pursue them. This may change in the
future, but residencies for community pharmacists remain limited primarily to those pharmacists who
intend to provide an exceptional amount of non-dispensing services [27].
5.2. Practice
Immunizations and patient care services have both increased in the 2010s. Community pharmacists’
immunization-related scope of practice has continued to increase and pharmacies have become
an accepted place to receive an immunization. The majority of patients report feeling comfortable
receiving vaccines in pharmacy settings [44], and more than 22% of all people who got vaccinated for
influenza during the 2014–15 flu having received their immunization from a pharmacy or store [45].
Evidence supports the role of the pharmacist in positively impacting vaccination rates for a variety of
immunizations [46], and immunizations will remain a feature of community pharmacy practice for the
foreseeable future.
Other non-dispensing services have increased throughout the second decade of the 2000s, but the
rate of increase has been slow. More than 20 years after the publication of his landmark paper on the
opportunities and responsibilities of pharmaceutical care, Dr. Hepler referred to the idea of pharmacy
as a clinical profession as a “dream deferred” when giving the 2010 Whitney Lecture [47]. This frames
well the state of pharmaceutical care services in the 2010s—not dead, but not as viable as pharmacy
leaders in the 1980s and 1990s had hoped. Results of the most recent pharmacy workforce survey
find that pharmacists in community settings spend about an hour of each day providing patient care
services not associated with dispensing [48]. This is more than past workforce surveys, but more than
two-thirds of community pharmacists’ time remains spent dispensing [48], and dispensing remains
the role patients perceive as most valuable [44].
Accordingly, the promise of MTM in Part D had lost some of its shine by 2010. Low beneficiary
uptake and lackluster offerings resulted in the federal government efforts to strengthen requirements
for offering MTM [49]. Additionally, the federal government began to include the comprehensive
medication review (CMR) completion rate as a quality measure for the Medicare Stars Rating
program [50]. Higher quality scores within this program result in greater marketing and revenue
opportunities for Part D plan sponsors, and since the CMR completion rate measure was first introduced,
completion rates have increased from 15.4% to 38.0% and 30.9% to 71.0% for standalone prescription
drug plans and Medicare Advantage prescription drug plans respectively [51]. OutcomesMTM®,
a major facilitator of pharmacist-provided MTM services, processed 2.4 million MTM claims in 2016
alone [52]. This was an increase over prior years [53], but was still less than a claim a week for the
50,000 pharmacists actively participating in the OutcomesMTM network.
One potential opportunity to expand services is through provider status in Medicare Part B
Legislation that would expand billing opportunities for pharmacists in Medicare Part B was introduced
during the 114th and 115th Congress but failed to pass [54]. This would create a sustainable source
of revenue for non-dispensing services, but the passage of federal legislation is uncertain. More
movement towards provider status has happened at the state level [55], but these efforts oftentimes
expand privileges without expanding opportunities to bill insurers.
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The brightest light for the post-pharmaceutical care area are the opportunities beginning to emerge
for community pharmacies as partners with payers and care givers to improve medication-related
quality measures and decrease total cost of care. These engagements have taken two general
forms. The first is pharmacists being held to account on quality measures like medication adherence,
and receiving upside and downside payment adjustment based on performance. Nearly all pharmacies
in the US have the ability to support performance measurement for intermediate outcomes like
medication adherence [44], and nearly 60% of 2019 Medicare beneficiaries are in a plan that has
a performance-based pharmacy payment program related to quality measures [56]. The second type of
engagement is contracting between community pharmacies and payers or other provider groups to
share risk and provide enhanced services aimed deliberately at impacting cost and quality. These types
of engagements are relatively new, but are being supported by groups such as CPESN USA [57] which
brings together community pharmacies willing to provide enhanced services into clinically integrated
networks able to manage populations of patients across groups of pharmacies. This approach is a step
far beyond one-off pharmacy collaborations, and could finally establish a working business model for
the professional service-oriented pharmacy.
6. Conclusions
Throughout the modern era, pharmacy has pursued higher professional standing. In the 1920s,
this meant eschewing the soda fountain and front-end sales to focus on compounding and dispensing.
By the 1950s, professional standing had begun to be defined more by patient care services than by
simple dispensing. However, dispensing has remained stubbornly prominent in community pharmacy
practice, and the opportunities to provide patient care services have not been as plentiful as hoped.
Over the same period, there has been an interplay between education and practice, with education
driving higher professional standing through the eventual adoption of the universal PharmD standard,
and entrepreneurial pharmacists developing new, innovative practices focused on providing greater
patient care services. Looking towards the future, it is hard to imagine a community pharmacist in the
mid-21st century doing nothing but dispensing, but it is equally hard to imagine that dispensing would
not be a part of how the average community pharmacist spends his or her day. Immunizations will
almost certainly remain a common feature of pharmacy practice, as will some degree of patient care
services not associated with dispensing. Evidence linking the provision of these services to reductions
in healthcare spending and improvements in healthcare quality is growing. If community pharmacists
can demonstrate that their services have a meaningful impact on healthcare value, it is likely their
non-dispensing roles will continue to increase. Absent this evidence, one wonders how the community
pharmacist in 2050 will spend their day. Nevertheless, developments in the last 100 years have created
new opportunities for community pharmacists to provide patient care services not associated with
dispensing, and as society evolves community pharmacy practice will continue to evolve alongside it.
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Abstract: While several studies have attested the presence of systematic gender and age variations
in pharmacists’ satisfaction with their jobs, only a few of them have considered both classifications
simultaneously. None have done so while systematically examining multiple facets of practitioners’
work. This article estimated U.S. pharmacists’ satisfaction levels with various facets of their work,
compared them simultaneously between genders and among age groups, and tested for the presence
of gender–age interaction effects. The study was based on self-reported survey data collected from
701 pharmacists (31.0% response rate). Mean and standard deviation values for 18 indices related to
pharmacists’ work were calculated. When age groups were controlled, female pharmacists expressed
overall higher levels of satisfaction with their job than male pharmacists; they also expressed greater
satisfaction with multiple specific facets and with the profession, as well as greater workload and
stress than male pharmacists. The findings revealed few significant differences among age groups
and a limited gender–age interaction effect for pharmacists’ satisfaction with key facets of their work.
These findings should contribute to the development and refinement of rational criteria for increasing
sources of satisfaction in pharmacy settings.
Keywords: age disparities; gender disparities; job satisfaction; job-related preferences;
pharmacist workforce
1. Introduction
Organizational commitment issues (i.e., turnover, absenteeism, tardiness, theft, etc.) and quality
of services rendered by pharmacists throughout the world have been linked to practitioners’ levels of
satisfaction and dissatisfaction with various facets of their work [1–15]. While intuitively most analysts
would agree that it is in the best interests of employers to keep their pharmacist employees happy,
satisfaction with one’s work is an elusive concept pervaded by subjectivity and difficult to conceptualize
and measure in an operational context. Not only is it interpreted differently by different persons that
may experience a common set of conditions such as working in the same location or performing the
same kind of work, but there are tradeoffs involved that often are perceived unequally. For example,
the prospect of a higher paying job or a promotion may be a strong source of satisfaction for some
practitioners, but the additional hours of work, stress, or possible relocation that the prospect entails
may be even stronger sources of dissatisfaction for other practitioners. Further blurring the concept is
a recent empirical finding of a weak association between pharmacists’ overall job satisfaction responses
and reported satisfaction with several facets that were hypothesized to configure job satisfaction [16].
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2. Background
The existence of systematic gender and age variations in how the facets of pharmacists’ jobs
constitute sources of satisfaction or dissatisfaction, the tradeoffs among them, and their intensity is
a commonly held platitude in the literature [17,18]. Work-related decisions usually are made within
the context of household decision packages configured by the size and composition of the household,
which are largely influenced by the gender-role ideology and age of the marital partners. Traditionally
men and women experience socially defined, differentiated involvement with childcare and household
responsibilities, with women picking up the brunt of the burden. Thus, compared to men, women are
more likely to work part-time [19–22] and exhibit job-related preferences compatible with work-family
balance such as hours of work, scheduling flexibility, and proximity of job site to home.
Work-related differences between men and women transcend family commitments and delve
into intrinsic traits. Maier [23] argues that men primarily engage in competition to win and strive
for success, subordinating other life activities to the pursuit of career goals, while women tend to
search for equilibrium in life activities and are more interested than men in advancing others as well
as themselves. He further argues that men use communication as a tool to solve problems, establish
status, and convey independence while women use communication largely to establish connections.
If these views are correct, one would expect male practitioners to be more motivated than their female
counterparts by the adequacy of salaries and benefits, autonomy, and availability of advancement
opportunities facets of their work, and female practitioners to be more motivated than their male peers
by facets such as fairness in the workplace, job atmosphere, and relations with coworkers.
Age differences in pharmacists’ satisfaction and dissatisfaction with various facets of their work
also have been reported across the continents [1,4,5,10,11,15,24–31]. Invariably these studies have
found that younger pharmacists are more dissatisfied with their job, or some part of it, than older
pharmacists. Younger practitioners possess little workforce experience and may not be able to assess
their working conditions accurately; the gap between expectations and reality may contribute to
their dissatisfaction. As they grow older, their aspirations are reduced and they realize that they
face limited choices in the workplace [32,33] and are likely to attach less importance to professional
ambitions, acquiring more awareness of areas within the profession from which they derive greater
levels of satisfaction.
Younger versus older worker comparisons have a deeper perspective that goes beyond mere age
differences. This perspective focuses on the role that work plays in practitioners’ lives. Baby boomers,
who comprise the older segment of the pharmacist workforce, commonly are portrayed as a generation
characterized by solid work ethics, with clearly defined professional goals, a drive for material success,
and commitment to their employers. They frequently consider work as the most important part of
their lives, and define themselves in terms of what they do. Conversely, pharmacists younger than
baby boomers exhibit a preference for autonomy and flexible work schedules, express more interest in
family and close friends than in material success, are motivated by the latest technologies, and view
organizations with cynicism and contempt [34]. Younger pharmacists criticize baby boomers for
being too competitive, overly cautious, and loyal to their organizations beyond reason, while baby
boomers view younger pharmacists’ emphasis on balancing work and leisure as lack of commitment
and an erosion of work ethics. In short, their values and expectations are different, which probably
translates into different sources of satisfaction and dissatisfaction with the various facets of their work.
Independently of their respective trends and influence on the configuration of job satisfaction
patterns, gender and age may have some interaction effect. For example, younger women are prone
to experience more work-family conflicts than other gender-age group combinations [35] for several
reasons. Besides being in the family formation years, which makes them more susceptible to children’s
time intensive demands, their jobs are frequently viewed by themselves and others as a secondary
income source, with needs and preferences of their own that may not coincide with the needs and
preferences of older women or younger men. Their participation in the labor force tends to be
countercyclical; when many men become unemployed or are forced to work fewer hours during
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a downturn of the business cycle, younger women tend to work more to compensate for the loss of
household income [36,37]. Another asymmetry is found in the distribution of costs and benefits of
family migration; younger women are less likely than their husbands to initiate moves, or resist moves
initiated by their husbands, because their gains/losses from migration frequently are surpassed by
their husbands’ losses/gains [38].
At the other end of the spectrum, older workers continue to work more years than their predecessors
partly because of their relatively better health and longevity. The trend away from defined benefit
pension plans and toward defined contribution plans, plus the ability to receive full social security
benefits beyond a certain age regardless of labor force participation, provide incentives to remain
active in the workforce [39,40], oftentimes on a part-time basis [41]. Older male pharmacists experience
issues that may be of little or no concern to younger male practitioners or older female practitioners,
so their perceived sources of satisfaction or dissatisfaction at work may be different from those of other
practitioners of the same gender and/or the same age group. Their motivating factors to seek part-time
employment include, among others, avoiding depletion of savings, supplementing retirement benefits,
fighting boredom, and validating their personal worth [42].
3. Objectives
Within the context of the background outlined in the previous section, this article sought to
(1) estimate U.S. pharmacists’ levels of satisfaction with various facets of their work, (2) compare
simultaneously levels of satisfaction between genders and among age groups, and (3) test for the
presence of a gender–age interaction effect. While many studies have addressed the influence of both
gender and age on the configuration of pharmacists’ job satisfaction patterns, only a few of them have
taken into account both classifications at the same time and none has done so in examining systematically
multiple facets of practitioners’ work. It is important to analyze both classifications simultaneously
in order to avoid attributing variation in satisfaction to one classification that should be attributed
to the other classification or to the interaction of both. The study is important because a uniform set
of job-related rewards and incentives (or disincentives) offered by employers to practitioners of both
genders and all age groups may not be adequate if indeed significant differences are observed.
4. Methods
This study was based on self-reported survey data. Participants were asked to assess their
satisfaction with key facets of their work as pharmacists using 0-to-10 intensity scales, with 10 denoting
the greatest intensity. This procedure posed the advantage of response homogeneity, as practitioners
were able to rate their experience with various facets of their work using a common measurement
standard, with more room for discrimination in their responses than is normally provided by the
traditional Likert scale. The rather narrow range of options ensured the adequacy of the mean as
a measure of central tendency since there was no room for outliers. The indicator used here has been
applied successfully in previous studies.
4.1. Indices
Eighteen assessment indices related to pharmacists’ work were included in the analysis. Most of
these had to do with important aspects of their job, but three were not job-related: assessment of
satisfaction with the profession, own capability as a pharmacist, and own performance as a pharmacist.
The other indices focused on adequacy of earnings and benefits, importance of earnings and benefits,
amount of workload, stress, job security, availability of advancement opportunities, autonomy,
scheduling flexibility, supervisor’s support, relations with coworkers, fairness in the workplace,
job atmosphere, importance of job to patients, importance of job to the organization, and job satisfaction
in general.
Mean and standard deviation values for each index were calculated by gender and age group.
The analysis was conducted for each gender-age group cell as well as for both genders within each
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age group and all age groups within each gender. The disaggregation by gender and age group
took into consideration different values previously reported in the literature for male and female
pharmacists [43,44] as well as for practitioners of different ages [34,45]. The disaggregation for both
of these classifications is not commonly found for any other independent variable. As a general rule
and consistently with earlier work [16], overall average index values under 3.00 were considered low,
values ranging from 3.00 to 6.99 were considered moderate, and values 7.00 and above were considered
high. The cutoff point for statistical significance was p = 0.10. In addition, mean and standard
deviation values were calculated by gender and age group for the wages and salaries reported by the
pharmacists in the sample to compare actual earnings with the adequacy perceived by respondents in
the different categories.
4.2. Statistical Model
A two-way classification model with multiple replications was designed to probe the nature of
differences in indices related to job satisfaction. One classification consisted of both genders (i = 1, 2).
The other classification identified three age groups (j = 1, ..., 3): under 45 years old, 45–59 years old,
and 60 years or older. Within each gender-age group cell, nij replications were observed. This design
posed the advantage of allowing not only gender and age-group differences to be tested simultaneously
and independently of each other, but also testing a gender–age group interaction effect. The model has
been applied successfully in the analysis of variations in pharmacists’ earnings and other variables [17].
The linear additive model for each index was as follows:
Xijk = μ + γi + αj + (γα)ij + εijk (1)
where
Xijk was the index value reported by the kth pharmacist in the jth age group and the ith gender;
μ was the overall mean;
γi was the systematic effect of the ith gender;
αj was the systematic effect of the jth age group;
(γα)ij was the gender-age group interaction effect;
εijk was the stochastic disturbance (random error) term of the kth pharmacist in the jth age group and
the ith gender;
and where
i = 1 for men and i = 2 for women;
j = 1 for pharmacists under 45 years of age, j = 2 for 45–59 year-old pharmacists, and j = 3 for
pharmacists 60 years or older; and
nij was the number of pharmacists of the ith gender and the jth age group reporting their index value
for each index assessing satisfaction with key facets of their work.
4.3. Data
The survey data were gathered from responses to a questionnaire sent by the authors to 2400
pharmacists practicing throughout the United States. These pharmacists were selected by Medical
Marketing Services (MMS) using a simple random scheme. MMS is a leading provider of lists of
pharmacists and other healthcare professionals. Its data depository includes pharmacists from all
fields within the profession; approximately 90% of the estimated 281,560 U.S. registered pharmacists in
2012 [46] were included in the MMS data file.
The survey questionnaire, previously validated [16,17], was exclusively designed for this and
other pharmacist workforce studies. It was mailed in March 2012 and a reminder was sent two
weeks later. No major environmental or other factors affecting job satisfaction were anticipated since
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2012. The sample size was chosen according to Cochran’s formula developed for categorical and
other outcomes [47], with a 5% sampling error. The research effort was supported solely by internal
university funds, and institutional review board approval was secured to conduct the probe.
5. Results
Of the 2400 questionnaires mailed to potential participants, 139 packets were returned undelivered
for various reasons. A total of 701 pharmacists participated in the study by providing answers to all
relevant questions. The number of observations and the response rate (31.0%) compared favorably with
those reported by similar undertakings [2,48–51]. Out of the total respondents, 403 pharmacists (57.5%)
were men and 298 pharmacists (42.5%) were women; in terms of age, 27.0% were less than 45 years old,
45.6% were 45–59 years old, and 27.4% were 60 years or older. Reflecting the “womanization” of the
profession and the demographics of the population from which they were drawn, male pharmacists
were outnumbered by female pharmacists under 45 years of age, while the opposite occurred with
older pharmacists.
5.1. Indices
The means and standard deviations of the 18 assessment indicators reported by pharmacists are
presented in Table 1. All aggregate values, with the exception of perceived importance of job to patients,
were in the moderate range; perceived importance of job to patients was slightly higher. Importance
of job to patients, own capability as a pharmacist, and amount of workload were reported as the top
three aggregate index values; availability of advancement opportunities, perceived support from one’s
supervisor, and scheduling flexibility were ranked, in that order, at the bottom of the scale.
Table 1. Means and standard deviations (in parentheses) of indices related to pharmacists’ work by
gender and age group.
Index and Statistical Significance Age Group
Gender
Men (i = 1) Women (i = 2) Both Genders
Number of observations
Under 45 years old (j = 1) 71 (n11) 118 (n21) 189
45–59 years old (j = 2) 173 (n12) 147 (n22) 320
60 years or older (j = 3) 159 (n13) 33 (n21) 192
All age groups 403 298 701
Adequacy of earnings and benefits
Interaction effect (p = 0.038)
Under 45 years old (j = 1) 5.45 (3.12) 6.93 (2.60) 6.38 (2.88)
45–59 years old (j = 2) 5.64 (3.00) 6.37 (2.70) 5.97 (2.88)
60 years or older (j = 3) 7.27 (2.63) 6.29 (1.96) 7.08 (2.53)
All age groups 6.21 (2.99) 6.58 (2.58) 6.37 (2.82)
Importance of earnings and benefits
Between genders (p = 0.038)
Under 45 years old (j = 1) 6.03 (3.02) 7.11 (2.65) 6.70 (2.83)
45–59 years old (j = 2) 5.73 (3.00) 7.17 (2.37) 6.37 (2.82)
60 years or older (j = 3) 6.90 (2.83) 6.59 (2.37) 6.84 (2.74)
All age groups 6.21 (2.99) 7.08 (2.47) 6.58 (2.80)
Amount of workload
Between genders (p = 0.015)
Under 45 years old (j = 1) 6.01 (3.27) 7.03 (2.55) 6.65 (2.88)
45–59 years old (j = 2) 6.83 (2.51) 7.39 (2.06) 7.09 (2.33)
60 years or older (j = 3) 6.75 (2.37) 6.81 (2.25) 6.76 (2.34)
All age groups 5.86 (3.30) 7.18 (2.29) 6.88 (2.50)
Stress
Between genders (p ≤ 0.001)
Under 45 years old (j = 1) 5.86 (3.30) 6.96 (2.56) 6.54 (2.90)
45–59 years old (j = 2) 6.54 (2.74) 6.95 (2.50) 6.73 (2.64)
60 years or older (j = 3) 5.78 (3.14) 6.81 (2.62) 5.95 (3.08)
All age groups 6.12 (3.02) 6.94 (2.53) 6.47 (2.85)
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Table 1. Cont.
Index and Statistical Significance Age Group
Gender
Men (i = 1) Women (i = 2) Both Genders
Job security
Between genders (p = 0.043)
Under 45 years old (j = 1) 5.54 (2.99) 6.84 (2.44) 6.34 (2.73)
45–59 years old (j = 2) 5.70 (3.11) 6.13 (2.81) 5.90 (2.98)
60 years or older (j = 3) 6.09 (3.30) 5.97 (2.86) 6.07 (3.22)
All age groups 5.82 (3.16) 6.39 (2.69) 6.06 (2.98)
Availability of advancement opportunities
Under 45 years old (j = 1) 3.42 (2.68) 4.11 (3.15) 3.85 (2.99)
45–59 years old (j = 2) 3.34 (2.86) 3.37 (3.03) 3.35 (2.93)
60 years or older (j = 3) 3.10 (3.20) 3.61 (2.90) 3.19 (3.15)
All age groups 3.26 (2.97) 3.69 (3.07) 3.44 (3.02)
Autonomy
Under 45 years old (j = 1) 5.55 (2.78) 6.27 (2.37) 5.99 (2.55)
45–59 years old (j = 2) 5.80 (2.70) 6.14 (2.86) 5.96 (2.78)
60 years or older (j = 3) 5.93 (2.96) 5.59 (2.01) 5.87 (2.82)
All age groups 5.81 (2.82) 6.13 (2.60) 5.94 (2.73)
Scheduling flexibility
Between genders (p = 0.045)
Under 45 years old (j = 1) 5.11 (3.02) 6.15 (3.15) 5.76 (3.14)
45–59 years old (j = 2) 5.27 (3.22) 6.27 (3.09) 5.72 (3.20)
60 years or older (j = 3) 5.88 (3.27) 5.55 (2.86) 5.82 (3.20)
All age groups 5.48 (3.21) 6.14 (3.09) 5.76 (3.18)
Supervisor’s support
Between genders (p = 0.005)
Under 45 years old (j = 1) 5.07 (2.88) 6.00 (3.04) 5.65 (3.01)
45–59 years old (j = 2) 5.00 (3.25) 5.92 (3.32) 5.42 (3.31)
60 years or older (j = 3) 5.51 (3.62) 6.15 (2.68) 5.62 (3.48)
All age groups 5.21 (3.34) 5.98 (3.13) 5.54 (3.27)
Relations with coworkers
Between genders (p = 0.009)
Under 45 years old (j = 1) 6.01 (3.08) 7.27 (2.24) 6.79 (2.65)
45–59 years old (j = 2) 6.25 (2.90) 6.86 (2.56) 6.53 (2.76)
60 years or older (j = 3) 6.63 (2.92) 6.70 (2.67) 6.64 (2.87)
All age groups 6.36 (2.94) 7.00 (2.45) 6.63 (2.76)
Fairness in the workplace
Under 45 years old (j = 1) 6.13 (2.73) 6.38 (2.51) 6.29 (2.59)
45–59 years old (j = 2) 5.78 (2.88) 6.08 (2.88) 5.92 (2.88)
60 years or older (j = 3) 6.18 (3.36) 5.94 (2.68) 6.14 (3.25)
All age groups 6.00 (3.05) 6.19 (2.71) 6.08 (2.91)
Job atmosphere
Under 45 years old (j = 1) 5.92 (2.48) 6.53 (2.59) 6.30 (2.56)
45–59 years old (j = 2) 5.70 (2.95) 6.39 (2.72) 6.02 (2.86)
60 years or older (j = 3) 6.42 (3.07) 6.18 (2.40) 6.38 (2.96)
All age groups 6.02 (2.93) 6.42 (2.63) 6.19 (2.81)
Importance of job to patients
Between genders (p = 0.001)
Among age groups (p = 0.063)
Under 45 years old (j = 1) 5.70 (3.71) 7.42 (2.64) 6.77 (3.18)
45–59 years old (j = 2) 6.15 (3.49) 7.87 (2.54) 6.91 (3.21)
60 years or older (j = 3) 7.62 (2.86) 7.94 (0.97) 7.68 (2.60)
All age groups 6.62 (3.38) 7.70 (2.45) 7.08 (3.06)
Importance of job to the organization
Between genders (p = 0.016)
Interaction effect (p = 0.002)
Under 45 years old (j = 1) 5.15 (3.21) 7.64 (2.12) 6.70 (2.84)
45–59 years old (j = 2) 5.99 (3.22) 7.18 (2.67) 6.51 (3.04)
60 years or older (j = 3) 7.56 (2.81) 6.53 (2.72) 7.36 (2.80)
All age groups 6.42 (3.19) 7.28 (2.48) 6.78 (2.94)
Overall job satisfaction
Between genders (p = 0.024)
Under 45 years old (j = 1) 5.76 (2.91) 6.45 (2.48) 6.19 (2.66)
45–59 years old (j = 2) 5.60 (3.19) 6.60 (2.72) 6.06 (3.02)
60 years or older (j = 3) 6.14 (3.28) 6.24 (2.50) 6.16 (3.15)
All age groups 5.84 (3.18) 6.50 (2.60) 6.12 (2.96)
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Table 1. Cont.
Index and Statistical Significance Age Group
Gender
Men (i = 1) Women (i = 2) Both Genders
Professional satisfaction
Between genders (p ≤ 0.001)
Under 45 years old (j = 1) 5.73 (2.69) 7.19 (1.96) 6.64 (2.37)
45–59 years old (j = 2) 5.81 (3.00) 6.95 (2.76) 6.33 (2.94)
60 years or older (j = 3) 6.28 (3.19) 6.67 (2.34) 6.35 (3.06)
All age groups 5.98 (3.03) 7.01 (2.42) 6.42 (2.83)
Own capability as a pharmacist
Between genders (p = 0.093)
Under 45 years old (j = 1) 6.18 (3.46) 7.31 (3.19) 6.89 (3.32)
45–59 years old (j = 2) 6.22 (3.49) 7.72 (2.70) 6.88 (3.24)
60 years or older (j = 3) 7.37 (2.96) 6.76 (2.80) 7.25 (2.93)
All age groups 6.64 (3.33) 7.45 (2.91) 6.98 (3.18)
Own performance as a pharmacist
Between genders (p = 0.018)
Under 45 years old (j = 1) 5.91 (3.80) 7.35 (2.96) 6.81 (3.36)
45–59 years old (j = 2) 5.80 (3.75) 7.71 (3.01) 6.65 (3.56)
60 years or older (j = 3) 7.23 (3.33) 6.94 (2.79) 7.17 (3.22)
All age groups 6.35 (3.65) 7.48 (2.96) 6.83 (3.42)
The average index values of female pharmacists were consistently greater than the values reported
by their male counterparts, and the differences were statistically significant except for adequacy of
earnings and benefits, availability of advancement opportunities, autonomy, fairness in the workplace,
and job atmosphere. Significant differences among age groups were detected only for the amount
of workload and perceived job importance to patients, and the gender–age group interaction effect
was significant only for perceived adequacy of earnings and benefits and perceived job importance to
the organization.
5.2. Wages and Salaries
The empirical evidence showed significant differences in wages and salaries between genders
(see Table 2). On average, male pharmacists in the sample earned 11.2% higher wages and salaries than
their female counterparts for an estimated gap of 10.1%. This gender gap varied by age group: 10.8%
for pharmacists under 45 years old, 19.0% for pharmacists 45–59 years old, and –2.0% for pharmacists
60 years or older; in other words, female older pharmacists earned, on average, 2.0% higher wages
and salaries than their male peers. Yet the interaction effect was not statistically significant, nor were
differences among age groups.
Table 2. Estimated means and standard deviations (in parentheses) of pharmacists’ wages and salaries
by gender and age group.
Age Group
Gender
Men Women Both Genders
Under 45 years old 121,463 108,395 113,388
(31,896) (31,135) (31,978)
45–59 years old 126,350 102,330 115,055
(108,660) (33,390) (83,087)
60 years or older 104,798 106,914 105,143
(67,700) (20,238) (62,432)
All age groups 116,951 105,177 111,923
(84,131) (31,437) (67,126)
Differences between genders are statistically significant (p = 0.061).
20
Pharmacy 2019, 7, 46
6. Discussion
Several findings are worth noting in this analysis of U.S. pharmacists’ assessment of satisfaction
with key facets of their work. The first is that when age groups were controlled, female pharmacists
expressed overall higher levels of satisfaction with their job than male pharmacists; they also expressed
greater satisfaction with multiple specific facets as well as with the profession. These findings accorded
with those of other studies that did not account for variation in age [6,16,52,53]. Women’s relatively
greater overall job and professional satisfaction levels were observed in every age group, but the
differences were wider for younger than older practitioners.
Women also reported consistently greater satisfaction than men in every age group when assessing
the quality of their supervisor’s support, relations with coworkers, and perceived importance of job
to patients. These findings were in line with those of previous studies regarding women’s perceived
importance of supervision issues [54–56], interaction with fellow workers [57], and the nature of
tasks performed [15,53]. In four other job facets in which gender differences were statistically
significant—importance of earnings and benefits, job security, scheduling flexibility, and importance
of job to the organization—female pharmacists’ estimated response values were greater than the
values of male pharmacists, but women 60 years or older actually registered lower values than the
estimated values reported by men 60 years or older. Yet the gender–age group interaction effect was
not statistically significant for any of the four indices.
Despite the relatively greater satisfaction experienced by female pharmacists regarding different
facets of their work, they reported higher levels of workload and stress than male pharmacists, and the
inequalities were observed at all ages. Usually an excessive workload constitutes a major source of
dissatisfaction for pharmacists [1,2,6,10,14,15,51,58]. The incongruence was particularly confounding
in light of the finding of a previous study whereby female practitioners actually worked fewer hours
than male practitioners [16].
Another observed incongruence was the absence of a gender differential in perceived adequacy of
salaries and benefits, especially when men in the sample earned 11.2% higher wages and salaries than
women. This incongruence has been documented in the literature as the paradox of the contented
female worker [54,59–61]. Several plausible explanations for this paradox have been postulated [18].
One is that women feel less pressure to exceed at work than men because of the traditional division
of labor; men are primarily responsible for the household’s financial well-being and women are
primarily responsible for housework and childcare. Another plausible explanation may be that women
have lower labor outcomes expectations than men, so their goals are more easily fulfilled. A third
explanation suggests that additional earnings contribute more to the job satisfaction of men than to
women’s job satisfaction [62,63], which leads women to compensate for the foregone satisfaction of
less pay with social aspects such as interaction with patients, good supervisors, congenial coworkers,
and scheduling flexibility, all of which registered gender satisfaction differentials.
In any event, perceived adequacy of salaries and benefits exhibited a statistically significant
gender–age group interaction effect: relatively more women than men under 60 years of age thought
that their salaries and benefits were adequate, but the opposite was the case for practitioners 60 years
or older. Although the interaction effect of reported wages and salaries lacked statistical significance,
female practitioners under 60 years of age reported lower earnings than male pharmacists of the same
age groups, and the opposite was true for practitioners 60 years or older. Thus, the evidence observed
here points toward an even greater incongruence that may be more adequately termed “the paradox of
the contented male and female pharmacists.”
In general, pharmacists in the sample thought highly of their professional capability and
performance. In both instances women reported higher scores than men, and the differences were
significant. However, also in both instances, men 60 years or older reported higher satisfaction scores
than women in the same age group. Perhaps further research may shed some light into why the
satisfaction relationship between the genders is atypical for the 60 years or older group compared to
younger practitioners.
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Another important finding in this paper was the paucity of significant differences among age
groups or an interaction effect when pharmacists assessed their satisfaction with key facets of their
work. This paucity was contrary to commonly accepted platitudes found in the literature [18]. In the
only two indices that were statistically significant for age-group differences, pharmacists 45–59 years
old reported more dissatisfaction with their workload and gave higher ratings to the importance of their
jobs to patients than did younger or older pharmacists. Notwithstanding the absence of statistically
significant differences among age groups, a common pattern of women scoring higher values in the
less than 60 years age group, but lower values among older pharmacists, in seven indices should not
be ignored; it might not have occurred by chance alone.
7. Limitations
Job satisfaction is a subjective issue. Not only is it subject to different interpretations by different
people, even when they share a common background and professional outlook, but its assessment by
any one person may fluctuate over time, depending on the person’s emotions and feelings. It is virtually
impossible to fully standardize as a variable. This is the first constraint that limits the interpretation of
the findings presented in this paper. A second limitation is that the study rested on a cross-sectional
survey, so there was no measurement of whether or how practitioners’ satisfaction with key facets
of their work varied with time or was influenced by changing labor market conditions affecting the
pharmacist workforce or the ongoing revamping of the healthcare system. Self-reported data were
used, which opened the door to validity and reliability criticism even though the questionnaire was
tested prior to being mailed to participants.
The study was limited to analyzing the influence of gender and age group on reported satisfaction.
Other factors such as marital status, number of children, or the amount of outstanding student loans,
not considered here, may affect pharmacists’ satisfaction with key facets of their work independently of
gender or age, may be gender or age selective, or may contribute to the interaction effect. This limitation
may be addressed in a subsequent study.
Another limitation is that although the MMS data files utilized in configuring the sample were
broad-based and included about 90% of pharmacists practicing in 2012, the sample might not have
been representative of the other 10%. Furthermore, there was no way to ensure that the questionnaires
were received or completed by the intended respondents, which was another limitation. In addition,
some analysts might criticize the 31.0% response rate as relatively low. Information about earnings
and satisfaction with different facets of one’s work is considered by some people as of an intimate
nature, so some practitioners might have been reluctant to share it. No incentives such as monetary
remuneration or a chance to win a raffle prize were used to motivate participation, which might have
altered the number of respondents. In any event, the sample consisted of 701 observations, a sizable
data set whose volume compensated for a modest response rate.
8. Conclusions
Despite its limitations, this study was successful in estimating U.S. pharmacists’ levels of
satisfaction with various facets of their work, comparing simultaneously their levels of satisfaction
between genders and among age groups, and testing for the presence of a gender–age interaction
effect. It identified the facets in which practitioners scored highest and lowest satisfaction levels,
and found that when age was controlled, female pharmacists were consistently more satisfied with most
facets of their work than male pharmacists. Since men and women responded differently to multiple
facets, a uniform set of job-related rewards and incentives (or disincentives) offered by employers to
practitioners of both genders may not be adequate.
The seemingly atypical behavior exhibited by pharmacists 60 years or older (compared to younger
pharmacists), whereby men’s levels of satisfaction with several facets of their work were greater than
those of their female counterparts, should be analyzed more thoroughly. A potentially significant trend
along these lines, discovered in future research, might signal a need for further adjustment by employers
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in their efforts to keep their pharmacist employees happy and manage a diverse workforce more
effectively. Perhaps the age-group boundaries in this study were not specified properly, and practitioners
with heterogeneous needs and preferences were placed together, thereby weakening the statistical
outcomes of the age-group classification and the gender-age interaction effect. The specification of
different age groups might yield different results.
Finally, it is important to observe that while pharmacists’ satisfaction with their work remains
an elusive concept plagued with subjectivity, this study was successful in conceptualizing and applying
a methodological framework that produced concrete results. The empirical evidence obtained here,
and the conclusions derived from it, should be regarded as preliminary in nature, but, hopefully,
they will contribute to the development and refinement of rational criteria for increasing sources of
satisfaction in pharmacy settings.
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Abstract: The Community Pharmacy Foundation is a non-profit organization dedicated to the
advancement of community pharmacy practice and patient care delivery through grant funding
and resource sharing. Since 2002, CPF has awarded 191 grants and over $9,200,000 (US dollars) in
research and project grants. The purpose of this manuscript is to highlight the evolution of pharmacy
practice and pharmacy education in the United States through the presentation of exemplary cases
of Community Pharmacy Foundation funding that is aligned with new care delivery models and
approaches to the advancement of patient-centered pharmacy care. Pharmacy began in colonial
America as the United States of America was just beginning to form with apothecary shops and
druggists. Over time, the pharmacy industry would be revolutionized as America became urbanized,
and drug products became commercially produced. The role of the pharmacist and their education
evolved as direct patient care became a clear expectation of the general public. By the 1990s,
the pharmacy profession had carved out a new path that focused on pharmacist-led, patient-centered
pharmaceutical care and medication therapy management services. The Community Pharmacy
Foundation grant funding has aligned with this evolution since its founding in 2000, and multiple
exemplary grants are presented as support. As the role of pharmacists again transitions from a
fee-for-service model to a value-based model, the Community Pharmacy Foundation continues
to provide grant funding for research and projects that support the advancement of community
pharmacy practice, education, and expanded training of pharmacists.
Keywords: community pharmacy; pharmaceutical care; medication therapy management; pharmacy
practice; pharmacy education; grants
1. Introduction
The Community Pharmacy Foundation (CPF) is a non-profit organization founded in 2000 that is
dedicated to the advancement of community pharmacy practice and patient care delivery through
grant funding and resource sharing [1]. CPF was originally founded as part of a federal settlement
on behalf of community pharmacies in the United States (US) from class action litigation against
discriminatory drug pricing. As a result, CPF was originally governed by a court-appointed Board
of Directors (BOD) that consisted of four community pharmacists and a retired judge of the United
States District Court in Illinois. As part of the settlement, $18.6 million (US dollars) were awarded
to establish the CPF to advance the profession of community pharmacy. In the first two years after
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CPF was founded, the BOD established a formal process for the receipt, review, evaluation, awarding,
and monitoring of grant dollars based upon submission of grant application requests [1].
The primary goals of CPF grant funding are:
1. The development, processing, and use of findings that affirm the value of community pharmacy
practice in the healthcare delivery system.
2. The measurement, publication, and dissemination of findings documenting the value of
professional services delivered to patients by community pharmacists.
3. Efforts that measure the impact of pharmacist interventions in achieving the targeted therapeutic
goals set collaboratively by the patient, the pharmacist, and other members of the healthcare team.
4. Efforts that evaluate patient-specific outcomes with regard to the quality of care delivered by
community pharmacists.
In January of 2002, CPF received its first grant submissions, and awarded its first two grants
in May, 2002. Since 2002, CPF has awarded 191 grants and over $9,200,000 (US dollars) in research
and project grants for the advancement of community pharmacy practice and patient care delivery
improvement. The extent to which CPF grants have aligned with the primary goals of CPF has been
reviewed in detail elsewhere [2,3]. In general, CPF grants in the early years (2002–2008) primarily
focused on adding to the knowledge base of medical conditions and medications only, but have since
(2009–2019) moved toward studies that affect health outcomes and change pharmacy practices [2].
This evolution of grant funding is in line with changes in the scope of practice of American pharmacy
and pharmacists since its founding.
The purpose of this manuscript is to highlight the evolution of pharmacy practice and pharmacy
education in the United States through the presentation of exemplary cases of the Community Pharmacy
Foundation funding that is aligned with new care delivery models and approaches to the advancement
of patient-centered pharmacy care.
2. Colonial America: The Roots of Pharmacy Practice in the United States
In Colonial America, there were very few standalone pharmacies. The first documented
“pharmacist” was Bartholomew Browne of Salem in 1698 [4,5]. He operated a daily pharmacy
and traded produce and merchandise in exchange for services. Still, Mr. Browne’s pharmacy was
not the norm, as most physicians had their own apothecary shops and only utilized the druggist to
purchase the raw materials required for compounding medicines [4,5]. Similarly, the majority of drugs
utilized for compounding were imported from England. It was not until the Revolutionary war that
apothecaries became more common, due to a need for domestic sources of medicine [6]. The products
that apothecaries stocked also became more standardized, and typically included drugs, medicines,
surgical supplies, dyestuffs, essences, and chemicals [4].
Combined physician medical practice and apothecary shops had been widely debated in England
and were considered a conflict of interest [5]. However, the idea of separating physician and apothecary
practices in colonial American was not introduced until the late 18th century by John Morgan [5].
He proposed the idea after traveling to Europe where drug distribution and physician practices had
been separated to avoid conflicts of interest [5]. This concept was not popular and was widely rejected,
since drug distribution was a large part of physicians’ livelihoods, and patients did not want the extra
expense of seeing two practitioners [5]. It was not until the 19th century (after the war of 1812) that
the preparation of medicine became the pharmacist’s responsibility and physician drug shops were
phased out; however, very few physicians actually gave up their dispensing practice [5].
Pharmacy education was also evolving as American apothecary shops began to pop up across the
country. For example, the first diploma for apothecary practices was awarded in 1808 by the Legislature
of the territory of Orleans, and in 1818, South Carolina was the first state to require a pharmaceutical
examination before obtaining a pharmaceutical license [4]. In December of 1820, the first official
print of the Pharmacopoeia of the United States of America was published in English and Latin [4].
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Also, state-affiliated pharmacy schools were created, with the Philadelphia College of Pharmacy (1821)
and the Massachusetts College of Pharmacy (1823) being the first two in America [6]. Furthermore, these
state-affiliated colleges had legislative curriculum requirements to ensure quality [6].
In the 1840s, inferior drug products were being shipped from Europe that led to the Drug
Importation Act of 1848 [6]. This act led to drug examiners being stationed at points of entry to
verify the quality, purity, and fitness of drug products being imported to America. Due to political
cronyism, incompetent drug inspectors led to the failure of the Drug Importation Act and calls for
a national pharmacy organization began to grow [6]. As a result, a group of 21 pharmacists and
non-credentialed apothecaries met to form the American Pharmaceutical Association now called
the American Pharmacists Association (APhA) on 6 October 1852 [7]. By the 1880s, the practice
of pharmacy was recognized as an important public service, serving as the foundation for modern
pharmacy practice in the United States.
3. CPF Grant Funding Aligns with the Evolution of Pharmacy Practice in the United States
By the end of the 19th century, the practice of pharmacy was significantly changing. Parke, Davis, &
Company created the first standardized pharmaceutical extract (Liquor Erogtae Purificatus) in 1879 that
revolutionized the business of pharmacy [8]. Instead of pharmacists compounding medications,
a growing list of chemical companies began quickly expanding their research and development
programs to develop and commercialize standardized drug products and delivery systems. For example,
gelatin capsules became commercially available in 1875 followed by tablets and enteric coated tablets
in 1884 [8]. Therefore, the role of the pharmacist shifted from primarily being a medication preparer
to dispenser of commercially prepared medication. The 20th century would again bring further
changes as a result of several factors, including increased urbanization in America, expansion of the
manufacturing of drug products, and the emergence of new pharmacy business models (Figure 1).
 
Figure 1. The Evolution of Modern Pharmacy Practice in the United States [4]. AACP: American
Association of Colleges of Pharmacy; PhG: Pharmacy Graduate; B.S.: Bachelor of Science; COP: Colleges
of Pharmacy; ACPE: American College of Pharmacy Education; Am J Pharm Ed: American Journal
of Pharmacy Education; ASHP: American Society of Health System Pharmacists; PharmD: Doctor of
Pharmacy; FDCA: Federal Food, Drug & Cosmetic Act; APhA: American Pharmacists Association; BPS:
Board of Pharmacy Specialties; NAPLEX: National Association of Pharmacy Licensure Exam; OBRA:
Omnibus Budget Reconciliation Act; MTM: Medicare Therapy Management.
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As these changes were occurring, so too was the education of pharmacists within the United
States. In the 1950s, the entry-level degree for pharmacists transitioned to a professional degree, which
has been the standard since 2000 [4]. Furthermore, as the scope of practice for pharmacists began to
evolve, so did the training required to meet those demands when pharmacists graduated and entered
into practice. As such, the development of post-graduate hospital training programs was created in the
early 1960s by the American Society of Health System Pharmacists (ASHP) [9]. Then in 1973, APhA
established the Board of Pharmacy Specialties (BPS) which helped pave the way for post-graduate
residency training in specialized practice areas [9]. For the next 20 years, hospital-based residencies
with specific accreditation standards were implemented in health systems across the United States.
By the 1980s calls began to grow for the creation of community pharmacy residency programs to
improve clinical skills and prepare pharmacists for pharmacy ownership. In 1986, APhA created the
pharmacy residency program initiative starting the process for developing community pharmacy
post-graduate training programs [10]. By 1988, 200 ASHP residency programs had been accredited with
124 being in hospital pharmacy, 39 in clinical pharmacy, and 37 in specialty areas such as psychiatry
and hospital administration. Furthermore, over 5800 residents had successfully graduated from an
accredited ASHP residency program [9].
3.1. The Pharmaceutical Care Era
The term “pharmaceutical care” was first used in 1975, referring to the care a given patient requires
and receives which assures safe and rational drug use [11,12]. The term manifested in response to
renewed interest in shifting back to care for patients as opposed to the drug product, and coincided with
the establishment of the clinical pharmacy era which recognized the value of pharmacists for their expert
drug therapy knowledge [11]. The path of clinical pharmacy would be further developed in 1990 after
a landmark article by Hepler and Strand was published outlining the patient care responsibilities of
pharmacists that went beyond the traditional role of dispensing [13]. As a result, a new professional
practice emerged that required a definition to aid in moving the idea from theory into application [11].
Thus, a pharmaceutical care practice is one in which the practitioner takes responsibility for all of a
patient’s drug-related needs and is also accountable for this commitment [11,13]. However, at the time,
there was not an overall consensus for the best way to accomplish this expanded role of the pharmacist.
Therefore, initial demonstration projects and pilot programs were conducted to help add to the
knowledge base of pharmacists as healthcare providers. For example, CPF awarded its very first grant
in May of 2002 for a program that sought to evaluate the effectiveness of a community pharmacist-based
home blood pressure monitoring program [14]. The study included 125 patients from 12 different
community pharmacies. Patients were randomized to receive a high-intensity or low-intensity blood
pressure intervention to determine differences in systolic and diastolic blood pressure from baseline to
follow-up between the high-intensity and low-intensity patients. The results showed the high-intensity
intervention achieved a lower diastolic blood pressure (p = 0.03) and could serve as a strategy for
future patients with hypertension [14].
Another early study funded by CPF in 2002 examined pharmacy participation in the Wisconsin
Medicaid Pharmaceutical Care Program (WMPCP) [15]. Pharmacies who participated in this program
were provided an enhanced dispensing fee for pharmaceutical care actions. This study retrospectively
reviewed administrative claims paid between 1997–2003 to investigate characteristics of claims
submitted to WMPCP and claims paid for pharmaceutical care services. There were 359 pharmacies
who participated in WMPCP for seven years. The claims per pharmacy ranged from 9.41–64.37, with
an increasing volume trend observed at the end of the study period. The results showed that patient
behavior, pharmacists resolving problems with patients, and patient response were the most common
claims. Furthermore, some of the pharmacies had incorporated the program into their practice routinely.
Also, pharmacists focused on drug therapy problems related to patient behavior, and worked directly
with the patient to resolve these problems through education [15].
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As more evidence became available about the value of pharmacists in helping improve patient
outcomes expanded care delivery models began to be created. For example, CPF funded a study grant
that was completed in 2006 and evaluated the effects of an extended diabetes care program compared
to regular care on primary clinical outcomes such as hemoglobin A1c, low-density lipoprotein (LDL)
cholesterol, and blood pressure [16]. The extended care diabetes program was provided by trained
community pharmacists over 12-months with quarterly visits. The extended care program consisted
of drug-therapy evaluation, patient education, and drug-therapy recommendations to the patient’s
physician as needed. Twelve pharmacists and eight community pharmacies participated in the
program. A total of 67 subjects completed the study. The results showed pharmacist intervention
helped to decrease LDL cholesterol levels significantly and resulted in a significant improvement in
aggregate patient self-management of diabetes. There was no significant impact observed for blood
glucose control or blood pressure levels. However, the overall program results were positive and
helped to decrease the cardiovascular risks of the enrolled patients [16]. Additional CPF grants were
awarded during the pharmaceutical care era that focused on pharmacy operations and furthering our
understanding of the pharmacists’ impact on disease state management [17–21].
At the same time, pharmacy education was also evolving to keep up with the changes in pharmacy
practice. In 1997, APhA updated their post-graduate year-one (PGY1) community pharmacy residency
program guidelines to reflect the new focus on pharmaceutical patient care [10]. These revised guidelines
were then used to develop the first APhA-ASHP community pharmacy residency accreditation
standards that were adopted in 1999. The adoption of the accreditation standards was an important
step in the evolution of community pharmacy and for the development of community pharmacy
residency programs. Further, accreditation standards increased program development, increased the
perceived value of community pharmacy residencies, and allowed eligible student pharmacists to
participate in the Residency Match Program [10].
3.2. Relationship of Medication Therapy Management to the Practice of Pharmaceutical Care
Medication therapy management (MTM) was the next development in the evolution of pharmacy
practice. Origins of the term Medication Therapy Management can be traced to legislation proposed in
the mid-1990s intended to reimburse pharmacists for pharmaceutical care services [22]. Then in 2002,
the Medicare Payment Advisory Commission (MedPAC) prepared a report for Congress on Medicare
payment for nonphysician providers describing medication management as an evolving approach in
which drug therapy decisions are coordinated collaboratively by physicians, pharmacists, and other care
providers together with the patient [23]. Shortly after this MedPAC Report was published, there were
several noteworthy events that clarified MTM as a service provided within the practice of pharmaceutical
care. A coalition of national pharmacy organizations collaborated with the American Medical Association’s
Current Procedural Terminology (CPT®) Editorial Panel in preparation of a proposal establishing reporting
and billing codes for pharmacists’ clinical services. In official health reporting nomenclature of CPT®,
Medication Therapy Management Services (MTMS) is described as face-to-face assessment and intervention
as appropriate, by a pharmacist, to optimize the response to medications or to manage treatment-related
medication interactions or complications [24]. Furthermore, the comprehensiveness of MTMS in official
health reporting nomenclature was further clarified as an assessment to identify, resolve and prevent
drug therapy problems, formulating a medication treatment plan to achieve patients’ goals of therapy,
and follow-up monitoring and evaluation of patient outcomes [24,25]. CPF also supported a grant to
develop educational tools to advance MTMS [26].
MTM service has also been characterized by the Centers for Disease Control and Prevention (CDC) as
“a distinct service or group of services provided by healthcare providers, including pharmacists, to ensure
the best therapeutic outcomes for patients. MTM includes five core elements: medication therapy review,
a personal medication record, a medication-related action plan, intervention or referral, and documentation
and follow-up” [27]. In addition, this service was also recognized in the Medicare Modernization Act of
2003 (MMA), which established the Medicare Part D drug benefit and requirements for controlling costs,
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quality improvement, and MTM programs [28]. As part of the MMA, broad goals were established to
optimize therapeutic outcomes (e.g., reducing adverse events) for targeted beneficiaries. Afterward, several
pilot programs were carried out across the US to increase knowledge of MTM (e.g., Asheville Project,
Diabetes Ten City Challenge) [28]. These early pilot programs were essential in the process of creating a
profession-wide-consensus about the process of MTM [29].
CPF’s grant funding during this time also went through an evolution process by moving towards
the funding of projects that were more outcomes based. A study by Isetts et al. compared the impact
of CPF funding between the initial years and recent years of the foundation utilizing the AHRQ
Impact Factor Framework (Table 1). Their study found a trend of more recently completed grants
having a higher AHRQ impact level compared to those in the initial years. For example, 53% of
projects completed in the initial years had an AHRQ impact of level 1 compared to 36% in recent years.
Furthermore, grants completed more recently were more likely to have a higher impact at levels 2, 3,
and 4 (36%, 26%, 3%, respectively) [2].
Table 1. The Four AHRQ Impact Factor Levels [2].
AHRQ Level AHRQ Level Description
1 Studies that add to the knowledge base only and do not represent direct change in policy or practice
2 Studies that may lead to a policy or program change as a direct result of the research
3 Studies that may cause a potential change in what clinicians or patients do, or result in a change in acare pattern
4 Studies that may change actual health outcomes (clinical, economic quality of life, and/or patientsatisfaction), or profoundly change practice
CPF grants during the early years of MTM also helped to contribute to a professional consensus
about the viability of MTM. For example, CPF funded a grant that was completed in 2008 that evaluated
the effect of implementing MTM services (pharmaceutical case management [PCM]) conducted by
community pharmacists for a private health plan [30]. The PCM model had already demonstrated
success with Iowa Medicaid beneficiaries and was an innovative model of care when initiated in
2000. Therefore, an 18-month pilot study was conducted with CPF support to assess the benefits of
implementing the PCM model in a private sector health plan. The same PCM model used for Iowa
Medicaid Beneficiaries was adopted; however, only pharmacists could be reimbursed in this program
(including collaboration with some case managers and disease managers) [30].
The objectives of the PCM pilot program were to evaluate the effect of PCM on medication
appropriateness, characterize drug-therapy problems identified by PCM pharmacists, compare healthcare
utilization among patients eligible for PCM services, assess the impact of PCM on patient’s self-reported
health, and assess pharmacist barriers to providing PCM services [30]. The pilot program showed on
average almost three drug-therapy problems were identified per patient over the study period, and 89.3%
were resolved by the pharmacist. This early pilot program identified significant barriers such as the higher
health status of private sector patients which may have led to a perception that they did not need the PCM
service, and 50% of pharmacies had less than five eligible patients. Overall, PCM services were considered
an opportunity to reduce overall healthcare costs and utilization; and served as a launching pad for future
MTM studies conducted in the community pharmacy setting [30].
Another CPF grant awardee showed it was possible to set up a network of 135 pharmacists across
seven states of the upper Midwest to provide MTM services to older adults [31]. As a result, the grantee
was able to create a tool, called TIMER (Tool to Improve Medications in the Elderly via Review), which
was shown to be helpful for pharmacists to provide MTM services to older adults [31]. There are
multiple other examples of CPF funded grants in the early MTM era which also contributed to the
knowledge base of pharmacists providing MTM services in the community pharmacy setting [32–36].
The funding of expanded MTM services with greater disease state complexity became
commonplace after the viability of pharmacist-led MTM programs was established based upon
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CPF grant funding. For example, a grant completed in 2009 implemented a pharmacist-led rapid strep
test service in the community pharmacy setting [37]. Furthermore, the participating pharmacists also
obtained prescriptive authority via collaborative practice agreements in order to provide antibiotic
treatment after a positive rapid strep test. In total, 85 rapid strep tests were performed and showed
pharmacists could conduct rapid strep tests, identify the presence or absence of group A Streptococcus,
and whether or not antibacterial therapy should be initiated [37].
Similarly, a 2014 pilot project evaluated whether or not community pharmacists could identify
patients at risk of worsening heart failure through the use of a clinical decision tool called the One
Minute Clinic for Heart Failure (TOM-C HF) [38]. TOM-C HF was a simple six-item screening tool
that would be used during routine patient encounters. Results showed application of the screening
tool took about 1 to 5 min in over 80% of the patient interactions. Furthermore, of the 121 patients
evaluated, 62% had one or more symptoms of worsening heart failure. The most common symptoms
identified were edema (39%) and increased shortness of breath (17%). Also, self-reported weight
gain (>5 lbs) was also found in 19% of patients. This study showed that pharmacists can help screen
and identify patients for heart failure decompensation and may be an important link in disease state
management of heart failure to help lower hospital readmission rates [38].
The establishment of community pharmacy residency programs also began to grow rapidly during
this time, with the number of programs almost tripling between 1999 and 2001 [10]. This growth has
been attributed to an increase in clinical services being offered in the community setting, increased
buy-in from colleges of pharmacy, and significant funding for PGY1 residency programs by the Institute
for the Advancement of Community Pharmacy (IACP). IACP provided over $900,000 (US dollars) and
led to the establishment of 45 community pharmacy residency positions over six years [10]. CPF grant
funding was also in line with the trend of increased focus on the value of community pharmacy
residencies during the MTM era and in 2004, CPF partnered with the APhA Foundation to co-fund
community pharmacy resident incentive grants to cultivate innovative research projects of pharmacy
residents (https://www.aphafoundation.org/incentive-grants) [39].
In 2010, CPF funded a grant that surveyed the perceived value of providing community
pharmacy residency training from the perspective of the colleges of pharmacy and pharmacy provider
organizations [40]. Survey findings revealed the most common value responses were altruistic (e.g.,
pharmacy profession development and pharmacy education development). In addition, barriers to
offering residency programs included operational issues and challenges related to accreditation [39].
In 2014, CPF also funded a project that created an implementation guide for PGY1 community pharmacy
residency programs to support the growth and expansion of these programs and to contribute to
the advancement of community pharmacy [41]. As a result of this grant, the “implementation guide
provided critical resources and materials to assist organizational entities, community pharmacies,
and colleges of pharmacy in their development, implementation, and accreditation of new community
pharmacy residency programs” [41].
3.3. The Value-Based Care Era
Pharmacists are considered the most accessible healthcare provider, and are uniquely qualified
to provide patient-centered care that engages patients in proper medication use and chronic disease
state management [42]. The provision of MTM services within the practice of pharmaceutical care
forever changed the way pharmacists would be involved in the care of patients with expanded roles
such as patient assessment, identification of therapeutic interventions, medication synchronization,
immunizations, point-of-care testing, chronic disease state management, and therapeutic monitoring
and follow-up. As such, the trend in the healthcare industry has seen a movement from a fee-for-service
care model to one that is value-based where patient outcomes result in pay-for-performance as opposed
to the volume of services rendered [42]. Pharmacists have begun to take on even more responsibility in
the care of patients concerning medication optimization, clinical status, patient satisfaction, and chronic
disease state outcomes. As a result, there are expanded opportunities for pharmacists to partner
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with physicians, payers, and other healthcare stakeholders more than ever before to improve health
outcomes, enhance the patient experience, and reduce the total cost of care.
Approximately 60% of the grants awarded by CPF are direct-patient care focused. For example,
a CPF grant completed in 2017 evaluated the effects of individualized patient care services by
pharmacists on total costs of care, an adherence measure, and the use of high-risk medications by older
patients [43]. To accomplish this, the grantee setup a separate pharmacy-based medical clinic that was
staffed by healthcare providers who were recognized by payers to bill for services. The pharmacists,
in collaboration with the rendering providers, were able to increase the number of patients seen,
the quality of patient clinical outcomes, and the number of clinical services the pharmacy offers.
The clinic saw 309 patients between September 2014–December 2015. An A1c drop of −1.29 was
observed (average 8.72 to 7.43), and the patient’s body mass index dropped −3.28 (35.68–32.4) after six
months of the intervention. As a result of the demonstrated value for services, the clinic pharmacy was
able to establish a limited provider status with a large healthcare payer leading to direct pharmacist
billing and payment (vs. incident-to-billing) [43].
Another CPF grant completed in 2017 utilized targeted medication reviews by pharmacists to
deliver pre-conception care as a public health demonstration project [44]. Community pharmacists
were provided an American College of Pharmacy Education (ACPE) accredited continuing education
program on addressing pre-conception care needs of patients via the framework of MTM. The targeted
medication reviews (TMRs) included women 15 to 45 years enrolled in an Ohio managed care plan and
focused on medications that could cause fetal harm, folic acid use, and immunizations. TMRs were
generated and assigned to pharmacies where the eligible patients filled prescriptions. Any pharmacy
in Ohio that participated in the commercially available MTM platform received a TMR notification.
Pharmacists then provided the service, documented, and billed for the service through the MTM
platform. Results showed 1149 pharmacists from 818 pharmacies completed at least 1 TMR (n = 6602).
The TMRs had a 33% completion rate with a 65% (n = 4266) success rate. This demonstration project
showed new service programs could be rapidly implemented into existing MTM service processes
over hundreds of pharmacies in Ohio. Furthermore, it also provides data demonstrating the value
of pharmacists and can serve as justification for additional payers to reimburse for similar services.
Finally, pharmacists may be able to assist with other similar preventative care services and utilize this
model to improve patient health outcomes as well as obtain reimbursement for their service [44].
Value-based services will require the collaboration of multiple healthcare providers including
pharmacists to help patients achieve the best health outcomes. To better understand this requirement,
a CPF grant completed in 2017 was conducted to increase knowledge about collaborative working
relationships between pharmacists and other healthcare providers throughout multiple practice
settings [45]. The study sample included 16 community pharmacists, nine prescribers, and five care
managers. There was an agreement between all participants for the need to have face-to-face meetings
with other healthcare team members to determine shared goals. Prescribers and care managers
identified that community pharmacists providing education on medications was very helpful and
also helped them reinforce the education each time they saw a patient. Also, medication adherence
packaging provided by community pharmacists was also stated as helpful in improving adherence to
chronic medications per prescribers and case managers. Community pharmacists from the project felt
personally responsible for a patient’s medication regimen. Also, prescribers and care managers felt
they had additional time to focus on other, non-medication related issues when they worked with a
community pharmacist to manage the patient’s medication regimen. As a result, this demonstration
project showed that including community pharmacists into team-based care can potentially improve
patient care and outcomes [45].
CPF grants supporting pharmacists in patient-centered medical homes (PCMH) are important for the
understanding of community pharmacist roles and responsibilities in alternate payment models [46–49].
The collaboration of pharmacists with other interprofessional care teams has further expanded during the
value-based care era with the creation of alternative payment models in both commercial and government
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health insurance programs, such as accountable care organizations (ACOs). An ACO according to the
Centers for Medicare and Medicaid Services (CMS) is a “group of doctors, hospitals, and other healthcare
providers who come together voluntarily to deliver coordinated high-quality care to Medicare patients” [50].
This coordinated care helps reduce healthcare costs and ensure patients are receiving proper care while
preventing unnecessary duplication of services and preventing medical errors. Further, when ACOs are
successful in providing coordinated care for chronic disease states while simultaneously lowering costs
they share in the savings they achieve for the Medicare program [50].
CPF grant funding has also been awarded to projects that seek to evaluate and establish the role
of community pharmacists in an ACO. For example, a grant completed in 2016 assessed the feasibility
of integrating MTM services provided by community pharmacists into the clinical care teams and the
health information technology (HIT) infrastructure for a Minnesota Medicaid ACO [51]. The study
included 15 community pharmacies who were all integrated into the HIT infrastructure via Direct
Secure Messaging. There were 32 recipients who received MTM services resulting from ACO referral
at 5 out of the 15 community pharmacies over one year. The project was able to set up an electronic
MTM referral system successfully, and there was consideration given to the community pharmacists
providing MTM in future ACO shared savings agreements [51].
Pharmacy education has also continued to evolve as pharmacists take on more advanced patient
care roles. Since June of 2013, 34,824 pharmacists have graduated from ASHP accredited residency
programs [9]. Also, BPS now recognizes twelve distinct specialties and more than 41,000 pharmacists,
national and internationally, are board certified [52]. CPF continues to fund grants that support
pharmacy education and the expansion of community pharmacy practice. For example, a 2016 CPF
grant supported the development of a vision and strategic action plan for the future of community-based
residency training [53]. This funding is directly aligned with the further evolution of pharmacy practice
and the goals of achieving provider status and expanding access to care. The strategic action plan will
help ensure the future needs of community-based pharmacist practitioners are met [53].
4. Conclusions
In summary, the Community Pharmacy Foundation is a non-profit organization whose mission is
to support the advancement of community pharmacy practice and patient care delivery through grant
funding and resource sharing. The history of pharmacy within the United States dates back to the
beginning of the colonies, when physicians, druggists, and apothecaries were essential to providing
health care in the new world. As America became urbanized and continued to grow in population,
the necessity for domestic sources of drugs and pre-manufactured medications drastically changed the
business of pharmacy, placing the pharmacist in a dispensing role. However, the pharmacist’s extensive
drug therapy knowledge would create an environment to shift the focus back onto the patient and
create new pharmacy care service models that have been the backbone of modern pharmacy practice
in the United States. Since its founding, CPF has actively supported grants that are aligned with the
evolution of pharmacy practice and CPFs mission. In the early years of the foundation, the majority of
grants focused on building the pharmacy knowledge base, but have since shifted towards impacting
the health outcomes of patients. In addition, the CPF grants awarded have also helped contribute to
establishing reimbursement models for pharmacies and pharmacists who participate in advanced
patient care and the advancement of the profession through education and training.
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Abstract: Community-based pharmacy practice is evolving from a focus on product preparation
and dispensing to becoming a health care destination within the four walls of the traditional
community-based pharmacy. Furthermore, community-based pharmacy practice is expanding
beyond the four walls of the traditional community-based pharmacy to provide care to patients
where they need it. Pharmacists involved in this transition are community-based pharmacist
practitioners who are primarily involved in leading and advancing team-based patient care services
in communities to improve the patient health. This paper will review community-based pharmacy
practice innovations and the role of the community-based pharmacist practitioner in the United States.
Keywords: community-based pharmacy; community-based pharmacist practitioners
1. Introduction
1.1. An Overview of Health Care and the Role of Community-Based Pharmacists
There are substantial challenges related to public health including issues associated with health
care inequalities, aging populations, increasing levels of chronic disease and urbanization [1]. There
is a need to increase access to primary care services, control costs, and improve outcomes in health
care for patients especially in the management of chronic conditions which puts a strain on health
care systems worldwide [2]. Addressing these issues is critical for improving the health of patients
in communities. To fully address these issues, all types of health care providers with the necessary
knowledge, skills, abilities, and required competencies must be utilized whenever possible to provide
needed care.
From a global perspective, community-based pharmacists represent the third largest health care
professional group outnumbered only by physicians and nurses [2]. Community-based pharmacists
are an underutilized health care provider who can improve access to care when and where patients
want to receive it. Fortunately, a trend is emerging for community-based pharmacists to function
as care extenders to counter primary care provider shortages and address the substantial problems
and associated costs due to the inappropriate use of medication [2]. While the types of patient care
services that community-based pharmacists are providing are extremely variable by country or even
by provincial or state jurisdiction, more and more pharmacists are providing important emergency
medication refills, renewals/extensions of prescriptions, changes to doses or formulations, therapeutic
substitution, prescribing for minor ailments, initiation of prescription drug therapy, ordering and
interpreting laboratory tests, and administering drugs by injection [2].
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In the United States, the challenges to the health care system continue to mount. Despite changes
to health care laws and coverage intended to insure more individuals and decrease costs, a substantial
portion of the population remains without insurance coverage. Additionally, health care cost continues
to be a significant portion of the gross domestic product in the United States (US) and is projected
to grow by 5.5% from 2018–2027 [3]. Prescription drug costs are expected to increase an average of
6.1% per year during the same time due to the introduction of new drugs and a focused effort for
patients with chronic disease to adhere to their medication regimen [3]. Pharmacists, who practice
in community-based settings are key to improving adherence to prescribed medications. As the US
health care system continues to evolve, a primary focus is on outcomes and quality as ways to manage
costs effectively and efficiently [4].
Currently, there are shortages of health care providers with increasing shortages in primary care
predicted for the future [4]. Specifically for physicians, it is predicted there will be a shortage of at least
43,000 primary care physicians and 140,000 total physicians in the US by 2030 [5]. Community-based
pharmacists, however, can help to address this problem. The US Bureau of Labor Statistics estimates
that there are more than 186,000 community-based pharmacists in the United States [6]. Increasingly,
the pharmacists’ role is being recognized as an important as the US health care environment changes
and in initiatives to reform healthcare [7].
1.2. Defining Community-Based Pharmacist Practitioners
Community-based pharmacy settings positively impact patient care as a result of their convenience
and as supported by the frequency of access by patients. One study revealed patients visited a
community-based pharmacy 35 times per year compared with a primary care physician only four
times per year [8]. Additionally, pharmacists are available in these settings with 58% of employed
pharmacists in traditional community-based pharmacy settings (pharmacy, supermarket or general
merchandise) [6]. Other community-based pharmacies include health-systems, Federally-Qualified
Healthcare Centers, clinics, and specialty. Pharmacists are also in community-based settings beyond
the traditional “four walls” of a pharmacy including physician offices, patient homes, churches, and
work places [9,10].
Pharmacists practicing in community-based settings are health care providers who offer either
generalist or specialist ambulatory care services to patients in the communities they serve [9].
The primary goal of a community-based pharmacist practitioner is to keep patients healthy [10].
Community-based pharmacist practitioners create, advance, and influence team-based care; strive
to enhance management of community-based pharmacy practices to focus on the delivery of patient
care services; serve as leaders within community-based pharmacy settings, local communities, and
the profession of pharmacy; and provide direct patient care to meet the healthcare needs of the
communities that they serve [9]. Regardless of the actual physical practice setting location, the focus of
the community-based pharmacist practitioner is providing patients with the care they need, when and
where they need it.
Community-based pharmacist practitioners provide a wide range of services including educational
consultations, medication management and other medication optimization services, chronic condition
management, patient empowerment, care coordination, health and wellness services, and other
services that help to improve the lives of patients in the community [9]. Community-based pharmacist
practitioners are essential health care professionals who provide direct patient care, advance team-based
care, manage services that focus on the patient, and serve as leaders within their communities and the
profession [9]. As a greater focus is placed on the importance of chronic disease management, wellness,
and medication management the opportunities for community-based pharmacist practitioners are
expected to continue to grow [11].
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1.3. Challenges Facing Community-Based Pharmacist Practitioners in the United States
The underlying issues surrounding the expansion of community-based pharmacists’ role in
patient care no matter the country requires dedicated remuneration, primary care integration, and
multidisciplinary education [2]. In traditional community-based pharmacies, there are multiple
challenges for community-based pharmacist practitioners implementing innovative patient care
services. The physical layout of the traditional community-based pharmacy does not facilitate patient
care services. Many community-based pharmacist practitioners are adding semi-private counseling
areas, private counseling rooms, exam rooms, and conference rooms for innovative patient care service
delivery. The workflow process in community-based pharmacies can also be a challenge. The process
for dispensing of prescription medications usually requires the pharmacist as the person responsible for
drug utilization review and the verification of the prescription. The number of support staff can greatly
impact the pharmacist’s ability to be involved with other patient care services along with dispensing
of product. Several methods have been used to overcome the issue of time for the pharmacist to
provide patient care services including adding more support staff, pharmacist overlap (i.e., more than
one pharmacist working at a time) and using a technician checking technician, if allowed by state
law [12,13].
It is essential to change, update, and redesign the business model in community-based pharmacy
practice. The focus of community-based pharmacist practitioner activities need to be on patient-centered
care to maximize their impact in the communities they serve. Schommer and colleagues state that
you must “create payment and business models for community-based pharmacy practice, advance
pharmacy technician practice, expand community-based pharmacy residency programs, and begin
seeing transformations through the patient’s eyes” [14]. This fundamental paradigm shift to the
business model of community-based pharmacy practices will establish the pharmacy practice location
as a heath care access point where the practice is reimbursed for the public health services they are
providing [14]. The redesign of community pharmacy practices as settings of care is essential including
changing the business model, implementing strategies such as medication synchronization, integrating
technology and maximizing technicians [15].
Another challenge for community-based pharmacist practitioners is integrating technology in
community-based practices. Currently, the majority of community-based pharmacies use a dispensing
system with or without the capability to document patient care services, limiting the ability to
document services. Furthermore, the pharmacy systems usually do not integrate with the electronic
health care record (EHR). Several recent articles have been published documenting the value of EHR
integration [16,17]. There is also a movement for documentation and patient care services through
the use of a pharmacist e-care plan [18]. New systems enabling standards and technology systems
will hopefully help to address these issues primarily focusing on consistent electronic documentation
methods and strategies for consistently coding and documenting care provided to patients [19].
Additionally, the location of community-based pharmacy practices can be a barrier to the provision
of team-based care and integration [20]. However, as the community-based pharmacist practitioner
expands beyond the four walls of the traditional based-community pharmacy it will become easier
to engage in team-based care. Furthermore, the profession does not have a referral process that is
similar to other health care providers. There needs to be process for referrals between pharmacists
and other healthcare providers as well as other pharmacists. Integration of technology may help with
team-based care and the referral process.
Expanding the role of pharmacists where they are practicing at the “top of their license” to
improve care and drug therapy outcomes is essential to the activities of a community-based pharmacist
practitioner and has been promoted by the World Health Organization [7,20]. In 2007, Canada enacted
laws that enabled expanded scope in some provinces through the Additional Prescribing Authorization
(APA) [20]. In the United States, the practice of pharmacy is regulated by individual state boards
of pharmacy and scope of practice and authority varies greatly from state to state. States such as
Oregon, California, Idaho, and Washington have begun to expand the scope of practice and authority
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for pharmacists to prescribe medications, perform point of care diagnostic tests, initiate hormonal
contraception, and administer injectable medications [21]. However, continued expansion of changes
remains a challenge in many states, but important to allow community-based pharmacist practitioners
to provide the needed patient care services in the communities they serve.
A major obstacle for community-based pharmacists in the United States is that pharmacists lack
formal designation as providers in the federal Medicare program. Specifically, pharmacists are not
recognized as providers under Section 1861(s) (2) of the Social Security Act, as such pharmacists are not
paid by the Federal government for health care services under the Medicare Part B program. To address
this important barrier, professional associations, and other stakeholders have advocated for decades
that action be taken through the US legislative process to include pharmacists and enable a payment
mechanism for the services that pharmacists can provide to patients. It is important because other
payers in the US typically follow Medicare payment policies, thus limiting the ability of pharmacists
from receiving payment from these other public, private and commercial entities. The reason that
recognition in the Federal Medicare program is viewed by many as the key to the establishment
of successful payment models nationwide. However, it is important to note that many states have
designated pharmacists as providers, however, this recognition may or may not guarantee payment
for service. Pharmacist services need recognition as being valuable by patients and other payers [7].
While the overall number of potential community-based pharmacist practitioners is large; engaging
and developing them as providers of care remains a challenge. There is a need for these individuals
to undergo continuing professional development and training with a focus as on patient-centered,
team-oriented, evidence-based care providers of care [22]. Additionally, there are needs for the
credentialing and privileging of community-based pharmacist practitioners which facilitates provision
of care and payment for service. Finally, there is an inherent difficulty in establishing value and
attributing the outcomes to the pharmacist-provided patient care services [19]. What are the innovative
community-based pharmacy services in the United States and the role of the community-based
pharmacist practitioner?
2. Methods
This review was developed based on the author’s knowledge of community-based pharmacy
practice. The authors define the service delivery model and innovative services and provide support
from the literature where available. The authors have developed a system for organizing the types
of community-based pharmacy innovative patient care services characterizing all of the patient care
services in six different categories. All of the types of innovative patient care services are incorporated
in one of the six categories. Additionally, the authors describe the services with a focus on the role of
the community-based pharmacist practitioner [9].
3. Findings
The findings include a description of community-based pharmacy practice innovations and the
role of the community-based pharmacist practitioner in the United States. First, the service models are
described to provide insight on the framework for the delivery of the patient care in community-based
pharmacy practice. Then the types of the innovative patient care services are described with detail
under the six categories. It is important to note that all of the types and categories of patient care
services may be offered within the different service delivery models. Most of the innovative patient
care services are supported by recent literature. Furthermore, a brief global context is offered about the
impact of innovations in the US.
3.1. Models of Community-Based Patient Care Service Delivery
Traditionally, around the world, community pharmacists have been viewed as a distributor of
medications [1]. This, however, is shifting as now with the public viewing pharmacists as health
care providers. To support this, research has been published that indicates patient and pharmacist
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preferences for care provided in community-based pharmacies [23]. Published in this research, patients
report that from their perspective, the optimal service model includes options for appointments with
a health care provider in the pharmacy, having access to the full medical record, providing a point
of care diagnostic testing, offering preventive health screening, limited physical examinations, and
prescribing of medications [23]. As the profession of pharmacy continues to evolve to focus on patient
care, a shift is occurring from product centered to a patient-centered model of care [14]. In the US,
patient’s medication experience includes both a social and personal experience [14]. Responding to
these changes, the pharmacy profession has entered a new “patient-centered medication experience”
era and pharmacy practices are employing principles of “collaboration theory” to implement new
systems of care [14]. To address these changes, community-based pharmacist practitioners spend time
and make connections to the community being visible, increasing health awareness and meeting the
needs of the patients in the communities they serve [10].
The service model develops from the traditional community-based pharmacy or four walls
and expands beyond to the community (Figure 1). Additionally, the four walls of the traditional
community-based pharmacy are changing, becoming health care destinations which even include
health care classes such as yoga. Community-based pharmacist practitioners are participating in
outreach events in the communities, churches, workplaces, shopping malls, etc. Community-based
pharmacist practitioners are conducting home visits form traditional community-based pharmacies.
Community-based pharmacist practitioners are also being placed in physician offices to provide
care. These patient care services are on a part-time basis where the community-based pharmacist
practitioner spends some portion of their time in the physician office or the community-based
pharmacist practitioner is embedded in the office on a full-time basis, but employed by the traditional
community-based pharmacy. This article will focus on innovative community-based pharmacy services
that are encompassed within this service delivery model.
Figure 1. Community-based pharmacist practitioner service model.
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3.2. Community-Based Pharmacy Services
Community-based pharmacist practitioners in community-based settings are providing innovative
patient care services beyond preparing and dispensing prescription products. These services are
categorized into the following areas: medication optimization, wellness and prevention, chronic care
management, acute care management, patient education, and other services (Table 1). This manuscript
will review those services and supporting literature, if available.

















































































































BHRT—biodentical hormone replacement therapy.
3.2.1. Medication Optimization
Medication optimization is defined as a patient-centered, collaborative approach to managing
medication therapy that is applied consistently and holistically across care settings to improve patient
care and reduce overall health care costs [24]. Medication optimization services are comprehensive
and include services directly related to the medication including medication packaging and home
delivery and other services such appointment-based medication synchronization, other adherence
programs, comprehensive and targeted medication management, and deprescribing.
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Community-based pharmacists are also making an impact on adherence through
appointment-based medication synchronization. This process has been shown to increase adherence
and improve chronic health conditions, as well as reduce overall cost [25,26]. Although synchronization
can help remind patients, provide updates on their progress, simplify the process, and make refilling a
prescription more convenient, nonadherence can be multifactorial. The monthly appointments with
the pharmacist are critically important, because it allows the pharmacist to educate, engage, and
solve problems [26]. However, some community-based pharmacist practitioners may provide only
medication synchronization without the appointment with the pharmacist as a way to just align refills
and avoid trips to the pharmacy. Other adherence programs include counseling and education by
pharmacists and automatic refills [27]. Community-based pharmacist practitioners are helping through
medication packing and home delivery. Medication packing helps patients to take their medications
correctly and know if they have missed a dose. Community-based pharmacist practitioners package
patient medications according to days of the week or time of day. Another mechanism for improving
patient adherence is through community-based pharmacist practitioner administration of medications
such as long-acting injectables (e.g., antipsychotics, contraceptives) and vitamin B-12 [28]. Home
delivery of medications has increased patient access to their medications by taking away the barriers
of transportation and proximity to a pharmacy.
Medication reconciliation is the process of creating the most accurate medication list to increase
patient safety, decrease medication related problems, and improve health outcomes [29,30]. One of the
barriers to maintaining an accurate medication list happens when the patient is discharged from a
healthcare facility to another facility because there is loss to follow up. The Affordable Care Act in 2012
launched measurement of hospitals on performance with the Hospital Readmission Reduction Program.
This program is administered by the Centers for Medicare and Medicaid Services (CMS) and penalizes
hospitals with excess readmissions within 30 days of discharges for certain chronic diseases [31].
Community-based pharmacist practitioners are emerging in the transitions of care area to help decrease
readmissions rates and emergency room visits and increase healthcare cost savings [32,33]. Physicians
in multiple settings believe that community-based pharmacists should be a part of the transitions of
care process because of their medication knowledge and access to patients [34,35].
Medication management services also contribute to medication optimization. Medication
management services are a spectrum of patient-centered, pharmacist-provided, collaborative services
that focus on medication appropriateness, effectiveness, safety, and adherence with the goal of
improving health outcomes [36]. Typically, in practice there are two different distinct services; either
comprehensive medication management or targeted medication review. Comprehensive medication
management is defined as the standard of care that ensures each patient’s medications (whether they
are prescription, nonprescription, alternative, traditional, vitamins, or nutritional supplements) are
individually assessed to determine that each medication is appropriate for the patient, effective for
the medical condition, safe given the comorbidities and other medications being taken, and able to
be taken by the patient as intended [37]. Several studies have documented the positive impact of
community-based pharmacist practitioner engaged in comprehensive medication management [38–40].
Targeted medication review (TMR) assesses medication use, monitors whether any unresolved issues
need attention, new drug therapy problems have arisen, or if there has been a transition in care. TMRs
are also used when a potential medication therapy problem is identified and the community-based
pharmacist practitioner verifies whether or not there is an actual problem and if a problem exists, an
attempt is made to resolve it. Medication optimization also includes efforts by community-based
pharmacist practitioners to be involved with deprescribing medications.
3.2.2. Wellness and Prevention
Community-based pharmacist practitioners have been involved in wellness and prevention
services through point-of-care testing (POCT) for years, including blood glucose, cholesterol, and
A1c. Many states allow pharmacists to perform these laboratory tests through the state’s pharmacy
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practice act or by establishing a collaborative practice agreement with a provider. These services can be
provided by a pharmacist once the pharmacy obtains and maintains Clinical Laboratory Improvement
Amendments (CLIA) Certificate of Waiver through Centers for Medicare & Medicaid Services (CMS).
The pharmacy must follow ‘good laboratory practice’ when performing tests, which address issues of
proper physical environment and recording of test results with patient information in a retrievable file.
The pharmacy also needs to follow Occupational Safety and Health Administration (OSHA) standards
to provide a safe and healthy environment [41]. As of 2015, community pharmacies are the fourth
highest-ranking entity of CLIA-waived laboratories, accounting for 5.4% of all CLIA-waived laboratory
facilities [42,43]. More recently, community-based pharmacist practitioners have become involved in
POCT for infectious diseases like Human Immunodeficiency Virus (HIV), Hepatitis C, streptococcus,
and influenza [44,45]. As pharmacogenomics develops, POCT devices that measure drug metabolism
are becoming available and community-based pharmacist practitioners with their drug expertise are a
good choice to provide this service [46]. This would prevent someone from taking a medication that
they cannot process and avoid having to try multiple medications to find the right one. For those
states that do not allow pharmacists to provide these services, risk assessments can be provided to
patients. These can determine the patient’s risk of developing or assessing the severity of conditions
like depression, asthma, and cardiovascular risks. These services have been performed by pharmacists
as health screenings in patients who are undiagnosed and for monitoring a patient’s chronic disease
state [40].
One of the most successful services in wellness and prevention that community-based practitioners
offer is immunizations [47]. Pharmacist-provided immunization services began with the administration
of the influenza and pneumococcal vaccine. From there, services expanded to pharmacists administering
routine adult immunizations. Pharmacist involvement with administering immunizations has increased
vaccinations rates [47,48]. In 2000, pre-travel health services began to be offered to patients by
community-based pharmacist practitioners [49,50]. These services not only include immunizations
needed for international travel but also education, treatment, and prevention of non-vaccine preventable
disease. Studies have shown that the pharmacist run pre-travel health clinics have an overall high
patient satisfaction rate and recommendations are accepted by providers [51,52].
Community-based pharmacist practitioners provide tobacco cessation services and new scope
of practice changes in individual state jurisdictions are facilitating the role by allowing pharmacists
to prescribe medication [53,54]. Another service facilitated by practice change is the prescribing
of contraceptive therapy for women [55]. Due to the increase in patient deaths from the opioid
epidemic, a new role in most states is for community-based pharmacist practitioners to be involved
with the dispensing and administering of naloxone. It has been shown that pharmacist involvement
in the dispensing of naloxone had significant reductions in fatal opioid overdoses as opposed to just
improving access [56]. Other wellness and prevention services include weight management, fluoride
treatments, falls prevention, pharmacogenomics, sleep assessment, drug take back, nutraceuticals,
and bioidentical hormone replacement [57–62]. Lastly, community-based pharmacist practitioners are
involved in providing Medicare Annual Wellness Visits in physician offices [63].
3.2.3. Chronic Care Management
Chronic care management (CCM) is defined as services aim to deliver quality patient centered
care, which can assist providers in improving patient outcomes and quality metrics [64,65]. CCM aims
to increase non-face-to-face interactions with patient which helps to improve the coordination of care
between provider office visits. Pharmacists are able to partner with qualified health professionals to
provide CCM services under general supervision of providers, including those located in federally
qualified health centers (FQHCs) or rural health centers (RHCs). Studies have shown community-based
pharmacist practitioners are involved with CCM visits which make an impact on health indicators, like
adherence and medication safety [66,67]. In another study, pharmacists proved that they could reduce
the overall drug cost and increase the quality of care through medication management [68].
45
Pharmacy 2019, 7, 106
Community-based pharmacist practitioners also offer chronic care management sometimes known
as disease management for chronic disease such as diabetes, hypertension, hyperlipidemia, heart
failure, asthma, or hepatitis C [69]. Additionally, community-based pharmacists offer anticoagulation
services. These chronic care management services may or may not be offered under collaborative
practice agreements [21]. Some of these services may even be offered outside of the four walls of
the community pharmacy in places such as barbershops [70]. Furthermore, the community-based
pharmacist practitioner can use CLIA-waived tests for monitoring chronic disease states or these tests
may be offered in the pharmacy without any association management services. These tests may include
pharmacogenomics tests for ensuring patients are taking appropriate therapy. Community-based
pharmacists are using saliva testing for biodentical hormone replacement therapy services.
3.2.4. Acute Care Management
Antibiotic resistance is one of the largest global health problems leading to extended inpatient
hospitals stays, higher medical costs, and increased mortality [71]. Community-based pharmacist
practitioners are well positioned to serve as gatekeepers for antibiotic prescribing due to their
considerable training and knowledge of infectious disease pathophysiology, antibiotic indication,
dosing, and appropriate length of treatment [72]. In addition to being competent antimicrobial stewards,
community-based pharmacist practitioners’ role in curbing antimicrobial resistance is expanding to
increase patient access to care through physician-led collaborative practice agreements and CLIA
waived POCT [73]. In community pharmacy-based CLIA-waived testing facilities, community-based
pharmacist practitioners can screen for and treat acute infectious diseases, such as influenza A/B, Group
A streptococcus (GAS) and Helicobacter pylori, decreasing time to therapy for patients [74].
It has been reported that patients who present with influenza-like symptoms and are not tested
for influenza are twice as likely to be prescribed antiviral therapy [75]. The increasing prevalence of
CLIA-waived POCT and rapid diagnostic testing (RDT) in community pharmacies can help mitigate
unnecessary antimicrobial prescribing. A report on midwestern pharmacies offering influenza testing
showed that of the 121 patients who presented to a community-pharmacy with influenza-like symptoms
and screened for influenza, 75 patients were tested, with 8 tests yielding positive results. Seven of the
eight patients who tested positive received a prescription for oseltamivir and six of these seven patients
reported feeling better during 24–48-h follow-up call [76]. Initiation of appropriate antiviral therapy
for patients infected with influenza is time sensitive. Community-based pharmacist practitioners
offer extended hours and patients can access appropriate antiviral medications quicker by seeing a
pharmacist for diagnosis and treatment than when a patient is referred to another provider [77].
Analogous to influenza POCT in community-based pharmacies is group A streptococcus (GAS)
POCT, which has also grown as a community-based pharmacist provided service. Community-based
pharmacist practitioners need to be conscientious antimicrobial stewards because adult pharyngitis is
most commonly viral, yet it has been shown that up to 75% of patients are prescribed antibiotics [78].
Streptococcus pyogenes is the most common bacterial cause of adult pharyngitis, accounting for
up to 15% of cases, indicating that antibiotics are only warranted for roughly 15% these adult
pharyngitis cases [78]. GAS POCT can be implemented alongside influenza POCT within the same
community-based pharmacies using a similar collaborative care model for managing patients that was
used in several midwestern pharmacies [79]. Community pharmacy-based GAS POCT was found to
be more cost effective for the diagnosis and treatment than physician-based diagnosis and treatment,
in addition to being more convenient for patients. [80].
Community-based pharmacist practitioners are capable of managing and prescribing for other
common acute diseases such as uncomplicated urinary tract infections (UTIs) [81]. Evidence is lacking in
the US, but in a prospective trial in 39 community pharmacies in Canada, community pharmacists were
able to achieve symptom resolution in 88.9% of patients who presented to the pharmacy with symptoms
of a UTI, with high patient satisfaction [82]. In the United Kingdom, community pharmacists were
able to screen patients for UTIs and provide trimethoprim to 73% patients, with the remaining patients
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receiving symptomatic management. Outcomes of this study suggest that community pharmacists can
provide appropriate treatment for patients with uncomplicated UTIs and increase patient access to
care [83].
3.2.5. Education
Community-based pharmacist practitioners are well prepared to educate patients about
medications, wellness, and prevention and medical conditions. Community-based pharmacist
practitioners are playing an even larger role within their community by promoting health and wellness
programs. Pharmacists are coaching on healthy eating habits, assisting with smoking cessation, and
combating sedentary lifestyles [84]. The Centers for Disease Control and Prevention (CDC) recognize
community pharmacists’ role in preventive health care and have even called upon them to facilitate
the National Diabetes Prevention Program (DPP) throughout the country [85]. Community-based
pharmacist practitioners are also providing accredited diabetes education programs through either the
American Diabetes Association or American Association of Diabetes Educators [86].
3.2.6. Other Services
Community-based pharmacist practitioners are serving as transitions-of-care (TOC) champions
when patients are discharged from inpatient settings to help minimize gaps in care, reduce hospital
readmissions, and resolve medication-related problems. When community pharmacies provided
medication management services within one week of hospital discharge to patients with congestive
heart failure, chronic obstructive pulmonary disease, or pneumonia, the 30-day readmission rate was
13.1% less in patients compared to patients who did not receive the service [87]. Through community
pharmacy-based TOC programs, patients’ risk of readmission can be decreased by 28% and 31.9% at
30 and 180 days, respectively, when pharmacists are involved in discharge counseling, medication
reconciliation, and telephone follow-up [88]. Through the utilization of pharmacists during health care
setting transitions for patients, community-based pharmacist practitioners are capable of improving
patient outcomes and reducing hospital readmission rates.
Teleheath is rapidly advancing, which provides increasing opportunities for community-based
pharmacist practitioners to be involved in remote pharmacy operations and patient care. Virtual
pharmacist services is a new innovative practice model that has been shown to improve patient
outcomes and minimize costs [65,67,89]. When patients at risk for medication-related problems were
referred to a telepharmacist for chronic care management at an outpatient family medicine clinic,
pharmacists generated 200 interventions over a 6-month period. The physicians accepted 37.5% of the
pharmacist’s recommendations, over half of which were related to medication safety [65]. Pharmacists
have also been able to show effective management of hypertension and diabetes through telepharmacy
by providing medication management and lifestyle modification recommendations with medication
adjustments [90,91].
Community-based pharmacist practitioners collaborate with local associations and public health
agencies to provide education and serve as a resource during public health emergencies. In fact,
community-based pharmacist practitioners are well positioned to respond to emergencies due to
their wide distribution across urban, suburban, and rural settings, and their easy access for patients.
Proposed disaster-readiness roles of pharmacists include “clinical” and “other”, with the clinical
category referring to ambulatory care, community-based or outpatient clinic pharmacists with strong
pharmacotherapy backgrounds, working in a variety of settings during a disaster such as a shelter,
hospital, clinic, or outreach site [92]. In an evaluation of community healthcare providers ability to
respond to emergencies resulting from bioterrorist attacks, pharmacists scored higher (78.5%) than
physicians (71.3%) and nurses (66.5%) in their ability to demonstrate creative problem solving and
flexible thinking to unusual situations [93].
Some community-based pharmacist practitioners have started a new patient care service that is
involves administering an intradermal injection; tuberculin skin testing. The first report of pharmacists
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conducting tuberculin skin testing was in 2008 in a national grocery chain pharmacy where 18 tuberculin
skin tests were administered over 11 months by two pharmacists and 17 of the 18 patients returned
within the allotted time for their reading. The pharmacists felt that this service was relatively simple to
integrate into workflow, with each test taking less than 10 min per patient and that it was an important
public service opportunity [94]. In 2011, New Mexico pharmacists became authorized to prescribe,
administer, and read tuberculin skin tests. Trained pharmacists in rural and urban New Mexico
administered 606 tuberculin skin tests with 578 patients having appropriate follow-up to read the test.
The authors attributed the high follow-up rates at the community pharmacies to convenience and
accessible locations [95].
4. Innovation in the US and Global Impact
It is beyond the scope of this paper to provide a comprehensive review of global innovative
community-based pharmacy practice. However, it is important to note that there is a global shift
in community-based pharmacy from a dispensing retail to a health care provider practice [2]. No
country has been able to transform community-based pharmacy practice completely as a sustainable
health care destination without the product driving the business model. However, some countries
like the US have made substantial progress in certain innovations. This provides an opportunity for
community-based pharmacists practitioners to learn from practice innovations in other countries.
In 2016, the International Pharmaceutical Federation published a report on the global impact of
pharmacy-based immunization [96]. Pharmacists in Australia, Canada, England, Netherlands, and
Scotland have made substantial progress in expanding the role of the community-based pharmacist [2].
Examples of services related to medication optimization include providing emergency refills,
renewing or extending prescriptions, changing drug dosage or formulation, and making therapeutic
substitution [2]. Furthermore, in Canada and the United Kingdom, community-based pharmacists are
offering comprehensive minor ailment services [97,98]. New Zealand has an opportunity to expand
community-based pharmacy services through a new funding model [99]. Changes to qualifications
of pharmacists in South Africa which will include prescriptive authority will facilitate expansion of
community-based pharmacy services [100]. The United Arab Emirates is implementing initiatives to
allow expansion of the role of the community pharmacist; however, other countries in the Middle East
continue to struggle with practice expansion [101]. The expansion of the role of the community-based
pharmacist has been inconsistent in Asia, but emerging with health assessment, health promotion and
medication use reviews [102]. The Pharmaceutical Group of European Union (PGEU) issued a 2030
vision for community-based pharmacy in Europe including expanding pharmacy services to increase
access and optimize medication use as part of collaborating primary care team, integrating digital
health solutions in practice, showing leadership in personalized medicine, reducing the burden of
chronic disease through wellness and prevention and education, identifying public health threats,
and providing innovative and effective services to reduce the burden on other services [103]. These
components of practice expansion are similar to innovations reported in this manuscript for the US
community-based pharmacy practice.
5. Conclusions
Community-based pharmacist practitioners in the US are developing and delivering services
that meet the needs of patients within the communities they serve. However, there are challenges to
overcome but which may be accomplished through policy change, education and training, collaboration,
and technology. Through the engagement of community-based pharmacist practitioners, patients will
have additional access to more than 180,000 community-based pharmacists, substantially increasing
provider capacity, improving care, and reducing overall health care costs to the US health care system.
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Abstract: Background: Applying the principles of service design can help pharmacists manage both
the quality and patient perceptions of the services they provide. Service blueprints are a widely
used service design tool that are rare in the healthcare literature. They can be used to design new
services or revisit the design of established services. This paper describes service blueprints and
their uses, and illustrates how to build one using an example. Methods: A blueprint is built for
appointment-based medication synchronization services to illustrate the tool. Conclusions: Service
blueprints permit pharmacists to better see and understand service processes. They clarify the
process of service delivery and the roles of customers, service providers, and supporting services.
They provide a way of depicting complex services in a concise visual way that communicates details
at a glance. Pharmacists who utilize service blueprints can improve the consistency and quality of
services provided, and they can increase the chance that every interaction with patients sends a
positive message about the value of pharmacist services.
Keywords: serviced marketing; design thinking; medication synchronization; community
pharmacists; innovation science; adherence; competitive advantage
1. Introduction
Pharmacy is a service profession. Although pharmacy practice revolves around the provision
of a tangible product, the value of pharmacists lies in the intangible acts delivered along multiple
touchpoints of the service experience. Yet, the public stills sees pharmacists as a dispenser of drugs
due to the distinct nature of services [1–4].
When compared to tangible products, services are much harder to promote due to four distinct
attributes they have known as the 4I’s [5]. The first “I” is intangibility, which characterizes services as
intangible actions or events. Services are intangible because they cannot be seen, held, or touched.
Thus, their quality cannot be measured, tested, or verified in advance of the sale to ensure excellence.
The second “I” is inconsistency in that no two service performances are identical—meaning that they
vary from person to person, transaction to transaction, and even time to time. Service quality cannot be
easily standardized because of the variations among interactions between buyer and seller. The third
characteristic is inseparability—referring to the fact that the service provider, customers, and service
itself are inseparable because the service is co-created by both the provider and the customer. Each
participates in and determines the quality of the service experience. In pharmacy practice, the more
engaged the patient, the more likely that better outcomes will occur. The fourth and final characteristic
is inventory, which describes how face-to-face services cannot be put into inventory or on a shelf for
later use. With online and mobile services, this characteristic is less applicable because technology
now allows us to store many services electronically. The fourth “I” only applies to person-to-person
services that are provided in a real-time, synchronous manner. When added up, the “4I’s” of services
present special challenges in marketing the value of pharmacists [5].
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2. Challenges in Marketing Pharmacy Services
It is a challenge for pharmacists to get customers to appreciate and desire an intangible product
they cannot see or touch. The intangible nature of pharmacist services makes it hard for consumers to
mentally appreciate what pharmacists do. It is much easier for people to grasp the purpose of a drug
than to comprehend the pharmacist services associated with that drug.
Intangible services are hard for consumers to assess. Although some aspects of pharmacy services
are easy to evaluate (e.g., fast, friendly, inexpensive), the clinical and technical aspects of the service
experience are difficult to evaluate even with extensive experience. For instance, consumers cannot
typically tell if a pharmacist omits critical drug-related information during patient counseling, fails
to screen for drug interactions, or misses a chance to intervene in avoiding a drug-related problem.
Instead, patients tend to rely on variables that they can assess, such as how a pharmacist looks and
acts [6].
The variability of pharmacist services also makes them a challenge to provide and assess.
Pharmacists and pharmacy technicians are imperfect human beings whose service performances can
vary from minute-to-minute with changing service conditions. Each service experience can be affected
by a host of factors including the atmospherics of the work environment, the engagement of patients,
the characteristics of individual pharmacists and technicians, and the workload. Demand for service
varies throughout the day and week; there are times when business is relatively slow and other times
when it gets quite hectic. It is a problem to synchronize customers’ demand for services with the
availability of pharmacy personnel to serve them. When combined with the fact that most pharmacist
services are performed behind the scenes out of view of the customer, patients have an uneven and
unclear understanding of the value of what a pharmacist does.
Applying the principles of service design can help pharmacists manage both the quality and patient
perceptions of the service provided [7,8]. Service design is the process of planning and organizing
the customer service experience using a number of methods and tools derived from disciplines as
diverse as ethnography, systems engineering, management science, and informatics. Service design
tools and methods typically attempt to portray services visually, using flow diagrams of the customers,
front-facing service providers, and supporting individuals and processes. An established service
design tool that would benefit pharmacists is the service blueprint [9].
3. Service Blueprints
Service blueprints are pictures or maps of service processes intended to help providers and service
marketers to design, deliver, and manage new and established service offerings [10]. They depict
the service process and the roles of consumers, service providers, and supporting services involved.
These visual depictions help improve the delivery of pharmacy services by identifying gaps and
potential points of failure in processes. They are able to improve communications between consumers,
pharmacists, support staff, and backstage services by mapping out the various points of contact
throughout the service process. Service blueprints can visually communicate complex service processes
to stakeholders more clearly and efficiently than verbal descriptions of the services.
Although widely used and accepted by service designers in many industries, evidence of the
use of service blueprints is lacking in pharmacy. Holdford and Kennedy [9] used service blueprints
in describing the dispensing process for a new prescription and for a smoking cessation program.
Other than that single instance, no other mention of service blueprints can be found in the pharmacy
literature. This paper will describe how to build service blueprints and discuss how they can be used
by pharmacists and when.
4. Uses of Service Blueprints
Service blueprints can be used whenever there is interest in improving a service experience.
It can be used to design new services or revisit the design of established services. A major benefit of
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developing a service blueprint is that it forces pharmacists to conduct a detailed analysis of each step
in the service process. It challenges pharmacists to question the value of each step and clarify the roles
of everyone involved. Pharmacists who utilize service blueprints can improve the consistency and
quality of services provided, and they can increase the chance that every interaction with patients
sends a positive message about the value of pharmacist services.
Blueprints can be used in research to provide explicit details of interventions. A clearly written
blueprint can be used in implementation science to allow comparisons at a glance of the exact nature of
service innovations in comparison to the status quo. They are also helpful in describing the competitive
advantage of one innovation over another, allowing pharmacists to develop service offerings that are
sustainable over time [11].
Service blueprints are especially useful in designing complex services that might include multiple
people, processes, and channels of communication. The greater the complexity, the increased likelihood
of miscommunication, fumbled handoffs between individuals, and lack of accountability between
people. A blueprint can clarify problems and coordinate complicated processes.
Finally, blueprints can be used to promote a positive image of pharmacists [7,9]. Because customers
often have difficulty evaluating pharmacist services due to the intangible nature of services, they look
for tangible clues to quality. Tangible clues are things such as signs, parking, landscaping, cleanliness,
advertising, pharmacy layout, and how service personnel are dressed. Service blueprints can be used
to identify these visual and physical aspects of services that customers often use as tangible cues
of quality. By seeing services from the customer’s perspective, pharmacists can ensure that these
tangible cues send the same positive message of professionalism delivered by other touchpoints of the
service experience.
5. Components of a Service Blueprint
There are no concrete rules for designing service blueprints allowing for a lot of flexibility in their
purpose and use. However, most service blueprints have the following key components [12]: customer
actions, “frontstage” contact employee actions, “backstage” contact employee actions, and support
processes—as explained below and illustrated in Figure 1.
Customer actions. These are actions performed by the customer when interacting with a service
provider. “Customers” can be any recipient of the service including patients, family caregivers,
physicians, and nurses, depending on the process. Customer actions associated with a pharmacy visit
can be contacting the pharmacy website prior to the visit, driving to the pharmacy, dropping off a
prescription, providing information to the pharmacist, waiting, receiving the prescription along with
counseling, and leaving the pharmacy. Each customer action is a touchpoint or moment-of-truth where
customers judge the quality of pharmacy services and make decisions about whether to continue
visiting the pharmacy in the future. The number of customer actions and the level of detail about each
depends on the depth of the analysis desired.
Frontstage actions. These are the service actions that are directly visible to the customer. They
can be actions between the customer and service personnel or with technology, such as a website
or mobile app. Frontstage actions associated with a pharmacy visit could include interfacing with
the pharmacy website prior to the visit, talking to pharmacy personnel throughout the steps of the
dispensing process, and a follow-up phone call to help resolve any concerns the patient has about their
medications. Frontstage actions do not always match every customer action. Some customer actions,
like waiting for a prescription to be filled, are things that the customer does alone.
Backstage actions. These are any actions done for the customer that are not visible. Backstage
actions in a pharmacy might include professional decisions made by pharmacists (e.g., checking
the patient profile for drug allergies, interactions, and duplicate medications), consultations with
physicians about therapy, resolving insurance claims, and remote filling of prescriptions.
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Figure 1. Basic components of a service blueprint.
Support processes. Support processes are any actions that support frontstage and backstage
actions in service delivery. For pharmacists, these might include computer support services, billing,
prescription claims adjudication, web design, and inventory control.
In service blueprints, key components of the blueprint are separated by three horizontal lines:
the line of interaction, the line of visibility, and the line of internal interaction (Figure 1). The line of
interaction is where customers and providers interact. Service encounters occur wherever a vertical
line crosses the line of interaction. The line of visibility separates frontstage contact employee actions
and backstage employee actions. Actions below this line are invisible to the customer. This line is
critical because patients’ image of a pharmacist is determined to a great extent by what they see the
pharmacist do. If the patient’s primary view is of the pharmacist counting and pouring, then the image
of pharmacists will be consistent with that view. The line of internal interaction separates frontline
employees from supporting individuals. Any action that crosses this line indicates a process that
supports the frontline employee.
Optional Components of Service Blueprints
Additional components can be added to service blueprints depending on the purpose and goals
of completing one. These components include physical evidence, arrows, and time.
Physical evidence. This describes the tangible features of each step in the service process that
might influence a customer’s perception of the service experience and service firm. Physical evidence
includes the dress of service employees, the signage in the pharmacy, location, advertising, website
design, delivery vehicles, and pharmacy layout. These and other forms of tangible evidence set
expectations of service and influence evaluation of service quality. Clarifying the physical evidence of
services can help ensure a consistent message across all elements of the service experience.
Arrows. Arrows are used to visualize relationships between key components of the blueprints.
Arrows are used to indicate dependent relationships between customer and service provider
actions. Single arrows indicate linear one-way relationships and double arrows signify collaborative
two-way relationships.
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Time. Time can be added to service blueprints to map out the amount of time needed for the total
service experience or elements of it. This can be useful in estimating personnel costs in providing
services and estimating the cost effectiveness of each step in the process.
6. Building a Blueprint
Building a service blueprint starts by developing an intimate understanding of the customers’
service experience as well as a clear delineation of all of the people, processes, and systems involved.
Whether the pharmacy service experience is face-to-face, online, via an app, over the phone, or via
multiple service channels, a service blueprint can be used to map out the process.
Service blueprints can be developed using a provider-centered or a customer-centered perspective.
Provider-centered perspectives start by mapping out the details of the service delivery process and
then seeing where customers interact with this process. Provider-centered perspectives might be taken
when analyzing an established service for gaps, redundancies, and other inefficiencies in delivery.
A customer-centered approach starts by mapping out the service experience from the customer’s
perspective. It begins by outlining the points of contact between customers and the service—customer
experiences with the pharmacy parking lot, the pharmacy building itself, signage, website, phone
calls, printed bag, self-service machines, and contact with frontline employees like clerks, technicians,
and pharmacists. Each time a customer interacts with a touchpoint, they have a service encounter
that is mapped on the blueprint. The following description of building a service blueprint will use a
customer-centered perspective.
The process of building a customer-centered service blueprint commences by asking what the
customer hopes to achieve by interacting with a pharmacy service. The blueprint will vary depending
on whether the visit is to fill a prescription, ask advice, enroll in a smoking cessation program, seek
a nonprescription medication, or some other reason. Another question to be asked is the breadth
and level of detail desired in mapping the service. An entire service process (e.g., dispensing) can
be mapped, or the focus can be on a specific component of the process (e.g., patient counseling).
Once these decisions are made, the blueprint is built through the following steps [12], which will be
illustrated using the service blueprint illustrating an appointment-based medication synchronization
program shown in Figure 2 [13].
1. Draw a template similar to the one in Figure 1 delineating the components of the service blueprint
including lines of interaction and any optional components like physical evidence and time.
Note that arrows can only be added as the actions are added.
2. Map the customer’s journey through the service experience. From the customer’s perspective,
chart each action and choice made by the customer and place them sequentially in the customer
actions of the blueprint template. For the appointment-based medication synchronization
program in Figure 2, customer actions are patient learns details of the program, signs a contract,
brings in prescriptions to the pharmacy to choose synch date, participates in establishing an
appointment and adherence plan, receives a monthly call prior to picking up the medications,
and receives the medications and discusses any issues with adherence or therapy.
3. Map frontstage actions. List all of the visible points of contact between the customer and specific
service personnel, technologies (e.g., website), or processes. They should generally match the
temporal sequence of the customer’s journey throughout the service process although there
may not always be a matching frontstage action with each customer action. For the program in
Figure 2, frontstage actions are a discussion of the program with patients, having the patient sign
the contract, the pharmacist conducting a comprehensive medication review, the cocreation of a
treatment plan, a reminder call, and the interaction with the patient when they visit the pharmacy.
4. Map backstage actions. List all of the service actions which are invisible to customers. In many
cases, these are actions in support of frontstage actions but sometimes they involve interactions
with other healthcare professionals, healthcare insurers, and other stakeholders.
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5. Map internal support activities. Support activities may serve either frontstage or backstage actions.
In Figure 2, internal support activities serve both frontstage and backstage actions and consist of
support from information technology, marketing, website design, and the business office.
6. Add additional details as needed including physical evidence, arrows, and time. The blueprint in
Figure 2 has single arrows to illustrate one-way relationships (e.g., patient signs the ABMS contract
and gives it to a technician or pharmacist). Double arrows illustrate two-way relationships where
both customer and provider collaborate in the task (e.g., establishing a patient appointment and
adherence plan). Note that some arrows may cross more than one line of interaction.
Figure 2. Service blueprint of an appointment-based medication synchronization (ABMS) program.
7. Managerial Uses of Service Blueprints
The process of completing service blueprints requires pharmacists to clarify each step of the
service experience. This process often leads to obvious opportunities for improving service delivery.
Blueprints might suggest a need for minor improvements or a complete overhaul of the service system.
The following is a list of actions that might be taken in response to an analysis of a service blueprint:
• Standardize service delivery by ensuring every frontstage, backstage, and support action is
consistently provided. Time-and-motion studies and quality improvement cycles can assist in
this standardization.
• Identify added service steps that might appeal to other customer segments. For instance, some
segments might benefit from comprehensive medication reviews in appointment-based medication
synchronization while others may not need or want it.
• Incorporate physical evidence into marketing communications plans. Although some pharmacists
only see marketing communications in terms of paid advertising, every touchpoint in the service
delivery process is a way of communicating a message of quality to patients. Therefore, cues to
quality should be identified within the service experience and changed if needed to provide the
messaging desired.
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• Simplify service delivery. Look at every step of the process and remove any that do not add value.
• Identify those moments of truth that drive customer perceptions of the service process. There
may only be a few touchpoints that drive loyalty to a pharmacy. Make certain that delivery at
those touchpoints exceeds customer expectations.
8. Conclusions
Service blueprints permit pharmacists to better see and understand service processes. It clarifies
the process of service delivery and the roles of customers, service providers, and supporting services.
It breaks down the service into components and arranges them according to their purpose.
Service blueprints are rare in healthcare although they can be used in implementation research,
interprofessional service delivery, business modeling, quality improvement interventions, and outcomes
studies. They provide a way of depicting complex services in a concise visual way that communicates
details at a glance. Services blueprints also use a customer-centered approach to design in which each
customer action is matched to service providers and processes. When combined with physical cues to
quality, pharmacists can send a consistent positive message to customers.
Service blueprints force a careful analysis of each step in the service process and help communicate
that information to people such as the frontline employees who help determine its success.
When everyone in the service process engages in the development of blueprints, they can understand
each step in the process, probe for difficulties, and identify problem areas.
Finally, blueprints can facilitate the analysis of cost–benefit tradeoffs in providing services.
They provide a template for quantifying the value of each patient contact, customer touchpoint,
and support process. In some cases, some frontstage and backstage actions may be added if they
add value to the service experience. In other cases, low value activities may be deleted without any
impact on perceived value. Service blueprints allow pharmacists to be more strategic in the design and
delivery of their services.
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Abstract: Value-added pharmacy services encompass traditional and emerging services provided
by pharmacists to individual and entire populations of persons increasingly under the auspices of a
public health mandate. The success of value-added pharmacy services is enhanced when they are
carried out and assessed using appropriate theory-based paradigms. Many of the more important
management theories for pharmacy services consider the “servicescape” of these services recognizing
the uniqueness of each patient and service encounter that vary based upon health needs and myriad
other factors. In addition, implementation science principles help ensure the financial viability and
sustainability of these services. This commentary reviews some of the foundational management
theories and provides a number of examples of these theories that have been applied successfully
resulting in a greater prevalence and scope of value-added services being offered.
Keywords: pharmacist; services marketing; management; value-added services
1. Introduction
Pharmacists have always been in a service industry, including those in the community sector selling
medicines and other health products, specifically for the delivery of health and medication-related
services. The role of the pharmacist has evolved over the years, from compounding remedies from
raw materials; to dispensing pre-manufactured dosage forms; to educating, advising, managing,
and monitoring the outcomes of drug therapy for both patients and populations. All of these services
add value to medication and patient care outcomes. Additionally, pharmacists have continued to
develop services that add value to the medication use process and encompass a variety of individual
and public health services. The more “traditional” and newly emerging services can be regarded
as “value-added” services, or those that are likely to positively impact medication outcomes [1].
These services are especially salient for certain populations of vulnerable or high-risk persons, such as
those with multiple comorbidities, younger and older patients, those with diminished access to care,
those with marginal or low health literacy, and the medically underserved, to name a few. As such,
value-added services aim to contribute toward and improve public health and health outcomes across
diverse settings. Among the more common value-added services of pharmacists and pharmacy
personnel under the aegis of public health is the provision of immunizations for various infectious
diseases, such as for influenza, herpes zoster and pneumococcal [2] as well as provision of education
and advocacy related to vaccinations [3,4]. Pharmacists are also increasing their roles in public health
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issues such as health literacy [5,6] opioid misuse and naloxone training and education [7–10], emergency
preparedness planning [11] and safe medication disposal [12,13]. Pharmacists are also members of
health care teams in ambulatory care settings and provide medication and disease management for
chronic conditions such as diabetes, hypertension, and congestive heart failure [14–17]. In the hospital
setting, pharmacists have roles in antibiotic stewardship [18,19], medication reconciliation [20,21] and
therapeutic drug monitoring [22,23].
2. Business Planning for Successful Implementation of Pharmacist Services
Careful planning and management is needed to evaluate whether a value-added pharmacist
service should be pursued or not. Thus, the creation of a business plan is a foundational step in
beginning a new service. A business plan helps stakeholders (e.g., administrators, investors, payers,
other health care professionals) decide whether to devote resources and energy to a new service.
The first step of a business plan is to identify how a value-added service aligns with an organization’s
strategic plan, mission statement, and current priority areas. For example, an organization that
is focused on improving diabetes outcomes will likely not be interested in a service that focuses
on asthma [24]. Next, input from stakeholders such as pharmacists, technicians, physicians and
other health professionals, and patients should be sought to refine ideas and tailor a new service to
stakeholders’ needs. Given that pharmacists have an established track record of implementing services
ranging from medication therapy management to chronic disease management to immunization
programs, it is likely that a review of the primary literature and pharmacy organization websites would
provide guidance and examples of successful models that could be replicated [24].
It is also worthwhile to consider the flexibility level of the pharmacy organization when deciding
what type of value-added service to pursue. Feletto has described four states of flexibility that a
pharmacy organization may be in when transitioning to provision of value-based services. These include
steady-state, operational, structural, and strategic flexibility [25]. A pharmacy in steady-state does not
offer services beyond traditional dispensing activities. Operational flexibility occurs when a pharmacy
is beginning to expand offerings to increase the number of customers but not providing a value-based
service. A pharmacy that has developed at least one value-based service and begun to implement
internal infrastructure to support the service is exhibiting structural flexibility, although at this point
there is not a plan for long-term success. Strategic flexibility occurs when a pharmacy has successfully
implemented value-based services and has infrastructure and processes in place for sustainability [25].
A pharmacy in a steady-state may venture into value-based services by offering immunization services
whereas a pharmacy in strategic flexibility may be in a position to partner with providers for a diabetes
management service.
3. The Market for Pharmacist Services
No matter how valuable the service might be in the mind of the pharmacist and no matter how
well executed, if that service does not fulfill a perceived or actual need by its target market, it will likely
fail. Thus, it is essential to consider the target market for the service. Collaboration with other health
care professionals is usually needed for a successful pharmacist service [24,26]. Building relationships
with health care professionals who could benefit from a pharmacist service is important to facilitate
patient referrals, medical information exchange, and billing for pharmacist services. Pharmacists and
health care providers are likely aware of each other in a community but that does not automatically
translate to meaningful collaboration. Thus, pharmacists will need to spend some effort increasing
interactions with local providers to develop successful services. Once a provider recognizes that a
pharmacist can provide nondispensing services, a pharmacist can begin to build trust and rapport
to lead to sharing of patient information, referrals, etc. To build rapport it is important to be able to
clearly articulate the purpose of the service and how it benefits a health care professional, such as
a physician. For example, a pharmacist seeking referrals for medication therapy management in a
community setting may highlight benefits such as improved medication adherence which can in turn
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lead to a decrease in use of acute services such as hospitalization. Physicians are under increasing
pressure to meet quality metrics such as controlling high blood pressure in their patients, and this
creates opportunities to align value-based pharmacist services with blood pressure monitoring and
medication therapy management [24].
Payment for services should always be considered when thinking about a new pharmacist service.
Thus, health care payers are another stakeholder to consider when marketing a new service. Pharmacists
have had some success with payers reimbursing for nondispensing services such as medication therapy
management (MTM) and diabetes management [27,28]. However, the fact that pharmacists are not
recognized as providers by most payers can present challenges to pharmacists negotiating service
payment. It is important that pharmacist services align with priorities of payers, which often means
reducing high-cost expenditures such as emergency department visits or hospitalizations for chronic
conditions. The “value-add” of a service for a payer often means decreasing costs while improving
patient outcomes [29,30]. Effective management would entail understanding of various reimbursement
mechanisms and leveraging them not only for the success of the pharmacy, but perhaps even a larger
organization. For example, Wu et al. used monies acquired for participating in the 340B drug discount
program to create a financially viable and more clinically relevant hospital discharge service associated
with improved patient outcomes, such as a reduction in 30-day readmissions [31].
A market evaluation should also consider the competition for services. Depending upon the
type of service being provided, competitors could include physicians, nurse practitioners, and even
other pharmacists/pharmacies [24,32]. In addition to pharmacists, diabetes education can be provided
by physicians, nurse practitioners, and other health professionals. A payer would want to know
why a pharmacist versus other qualified health professional should provide diabetes education to
its beneficiaries. In a community pharmacy, perhaps the value-add is the convenience of providing
the service on a walk-in basis with little to no waiting whereas in a patient-centered medical home,
the value-add could be increasing physician time to focus on other patients or services. To effectively
mitigate the impact of competitors, a pharmacist should be able to describe how a service is unique
from similar services [24,33].
The viability of a pharmacist service is also impacted by the volume of potential consumers (i.e.,
patients) in its service area. Internal and external data can be used to help assess market size for a
pharmacist service. Internal data, such as patient profiles, purchasing, and financial records can help
examine the number of potentially eligible patients within the organization. Often, a new service has a
goal of attracting new patients. In this case, local information about desired health outcomes can be
obtained from interviews of other health care professionals in the pharmacy’s market area or a review
of the local health department website to identify indications and prevalence of the area’s major health
burdens. A market research study could also be undertaken to collect feedback and perceptions about
a service from potential patients [24,34,35].
Although market research may indicate patient interest in a particular service, ultimately patients
may not be willing to pay for a service if they cannot afford it or if they do not perceive value in the
service [24,29]. This may be especially true if a service is not covered by insurance and a patient would
have to pay out-of-pocket. Although Medicare recognizes pharmacists as a provider for MTM provided
to Medicare Part D beneficiaries and some state Medicaid programs and commercial payers will pay
for pharmacist services, most payers do not pay for pharmacist services in the United States [29].
Government sponsorship helps cover costs for other services in other countries such as U.K.’s minor
ailment service [36] and Australia’s Home Medicines Review program [37].
4. Patient Engagement and Participation in Services Delivery
Consumers’ willingness to pay and even their impressions and experiences with a service will
likely be enhanced if they are engaged and participatory in the service encounter [38]. For example,
if a pharmacist has effectively engaged a patient in a lipid management service, the patient will likely
be more successful in the endeavor to maintain control, or keep their lipid levels below target goal.
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Further, if the pharmacist is able to get that same patient to relay successes and strategies for how they
are succeeding and engage them in provocative discussion, then the patient will enjoy the entirety
of the service to a greater degree. This behooves the pharmacist to ascertain the degree that patients
might want to engage, thus tailoring strategies of service delivery to reflect patient desires. As such,
any service designed must be flexible, and pharmacists and support personnel providing the service
must be adaptive to the situation. With this in mind, research has demonstrated that the transtheoretical
model (TTM), health belief model, and theory of planned behavior can be useful guides for pharmacists
in designing and implementing value-added services [39]. This extends toward contemporary patient
needs and public issues, such as that with the opioid crisis. Fleming et al. effectively employed the
theory of planned behavior to identify challenges to overcome in pharmacists’ engagement of patients
in an attempt to curb their misuse of drug substances [40].
5. Meeting Patient Needs
Assuming that there is a consumer need and a market for a particular value-added pharmacist
service, business planners must ascertain whether the service is meeting a need. One way to discern
this is through a SWOT (i.e., strengths, weaknesses, opportunities, and threats) analysis [24]. In a SWOT
analysis, internal opportunities and weaknesses and external opportunities and threats are examined.
Generally, internal opportunities and weaknesses are easier to control than external opportunities and
threats. Internally, resources such as personnel, training requirements for pharmacists and staff, space,
equipment (e.g., computers and software) and supplies (e.g., medical and office supplies) needed to
deliver a service should be determined. This can help decide the amount of working capital necessary
to support development of a new service. Initially, an organization may leverage existing resources,
such as reallocation of pharmacist time to include a percentage of time to deliver MTM, before investing
large amounts of capital into a service. At a minimum, resources for equipment, supplies, and market
are often needed [24]. Administrative support and buy-in for a new service is critical to getting
support for resources needed for the service. Evaluating the culture is also part of the homework that
needs to be done. Organizational culture has shown to be the primary driver in the success of many
value-added pharmacy services. The organization’s culture might or might not be receptive to new
ideas, might infer a preference as to who or what types of persons approach upper administration with
ideas, and also how to couch, or frame the discussion when pitching the idea [41].
Externally, a number of factors, such as demographic trends of patients and providers, state scope
of practice laws and regulations, and the number and type of competitors in a market, can represent
opportunities or threats for a value-added pharmacist service. For example, an aging population
might represent an opportunity for disease management, but a threat in lack of time to devote to
non-dispensing activities. If a pharmacist has identified the potential opportunities or threats to a
service, they can apply some of the management principles described above to manage the impact.
Patients often understand their own needs, but in some cases, might not perceive a need for a
particular service or even see its relevance unless they have been properly engaged. While some patients
are undertreated, many patients with comorbid disease states are on too many medications that may
result in untoward outcomes, even idiosyncratic conditions. Historically referred to as “polypharmacy”,
the term “deprescribing” refers to systematic and evidence-based practices to deprescribe, or streamline
a patient’s therapeutic regiment to maximize outcomes. Trenament et al. described a service in which
they engaged patients in a deprescribing program to promote those patients’ buy-in, have greater
confidence in and thus better adherence to their new medication regimen [42].
6. Managing the Servicescape
The ability of pharmacists to manage internal and even some external factors in service deliveries
provides them great opportunities in what has been referred to as the “servicescape” [43]. It refers
to physical and other constructs wherein a service is performed, delivered, and consumed [44].
There are objective stimuli generated during the performance and consumption/use of a service that
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are measurable and controllable to enhance employee/patient interactions. The servicescape influences
the patient’s experience and thus their satisfaction with service experience. For example, the layout
and structural design of the pharmacy, along with job descriptions and workflow, will determine
where a patient drops off their prescription, how long it is they might have to wait before being greeted,
who takes responsibility for greeting them and for initial medication history-taking and other services,
and the extent to which privacy can be offered and even the types or array of services that could
potentially be offered for each patient. In the background, various “physical” attributes ranging from
such phenomena even as the type [or lack] of music playing in the background of the pharmacy has an
impact on the overall sensory experience of the patient. Design of the servicescape can be informed by
any number of questions such as:
How can the servicescape be designed to attract the most profitable customer/patient segments to
the service?
How can the servicescape be designed to maximize customer satisfaction and retention?
How much money and resources should be invested into the servicescape? These questions get to
the core business mission, vision, and values of the organization and thus translate into consideration
of which service, or services might be offered from an array of possibilities.
7. Array of Value-Added Pharmacist Services
Value-added pharmacist services range from focused, one-time interventions to resolve medication
issues identified during the dispensing process to nondispensing direct patient care services that focus
on comprehensive and longitudinal management of medications for chronic conditions. Prevention
and wellness services are another type of pharmacist service [24].
Recently, there has been a focus on creating opportunities in the community pharmacy setting
for increased engagement between pharmacists and patients and to enhance clinical services [44].
Continuous medication monitoring (CoMM) is one approach to that has been gaining momentum [45].
In CoMM, “pharmacists systematically review the patients' medication record and monitor every
medication being dispensed to prevent, identify, and resolve drug therapy problems or obstacles to
optimal therapy during the dispensing process” [45]. Traditional MTM, especially for Medicare Part
D beneficiaries whereby pharmacists can be reimbursed, remains a clinical service offered in many
pharmacies. MTM generally includes five key steps, including comprehensive medication review,
medication action plan, personalized medication record, intervention and referral, and documentation
and follow-up [46].
Value-added services, such as appointment-based models (ABM), may be integrated with existing
services such as CoMM or MTM. The goal of ABM is to increase medication adherence and efficiency
for pharmacies and patients [47]. ABM is comprised of three components: medication synchronization
which includes refilling all medications on the same day each month, monthly phone call to patient to
confirm refill order and identify any medication-related issues, and scheduled monthly appointment
to pick up the medications [48]. At the monthly appointment, additional services such as MTM may
be provided to address medication-related problems.
Whereas MTM is a holistic approach to managing all medications, disease state management is a
more focused type of service that pharmacists provide. In disease management, pharmacists educate
and monitor medication therapy to achieve therapy goals over a period of time, make recommendations
about drug therapy to providers, and may be able to directly initiate or change therapy under
a collaborative practice agreement (depending upon each state’s scope of practice). Examples
of conditions that pharmacists commonly manage include hypertension [49], heart failure [50],
diabetes [51,52], and asthma [53,54].
Finally, pharmacists have an established history of delivering monitoring/screening services
and wellness/health-promotion programs. Examples include anticoagulation services [54–57],
travel health [55,58], hormonal contraception prescribing [59], naloxone dispensing and education [60],
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smoking cessation counseling [61], osteoporosis screenings [62], and lipid screenings [63]. Point-of-care
testing for conditions such as influenza, strep throat, and hepatitis C is also increasing [64,65].
8. The Aesthetics of Services Delivery and Consumption
There are various idioms referring to the importance of making a good first impression, or a
good impression, overall. Service companies depend on front-line service workers to control and
communicate a certain image that consumers/patients will associate with the business and with the
service [66]. In community practice, technicians have been referred to by pharmacists as the “face” of
the pharmacy [67]. Image control demands that service workers act according to scripts that diverge
from their actual preferences and capacities. Additionally, service recipients are also acting on social
norms, as well as to gauge the intent of the service provider and to potentially acquire a higher level of
service or enhance their own experiences. Given the acting of both parties, a number of conflicts arise
regarding the truthfulness of sincerity regarding service performance. The expected set of behaviors
each actor in the process plays out are often referred to as roles; and thus role theory might be helpful
in determining proper training for pharmacy staff and for the expectations one might have of patients.
The aesthetic appeal of services is thus under significant control and can be managed effectively by
the pharmacy. This includes ascribing proper roles to workers, training patients on the roles they
might assume in receiving services, and strategizing to optimize the impression by patients of the
service. The impression of those using or experiencing the service will go a long way toward successful
marketing of the service, particularly in an age where reviews of experiences are proliferated so
quickly on web-based ratings platforms. It is important, then, to manage not only the entirety or
“gestalt” of the service but also its individual components. A recent study of both “traditional” and
emerging pharmacist services found that visual appeal of the pharmacy and its aesthetics, including the
image projected by service personnel (pharmacists and technicians) impacts the relationship between
perceived quality of the service and thus customer loyalty [68].
9. Components of A Value-Added Pharmacist Service
Once the decision is made to implement a new service, patient eligibility criteria for the service
needs to be established and roles and responsibilities of the pharmacist and other supporting staff
need to be defined and agreed upon by all stakeholders [69,70]. Patient eligibility will vary depending
upon the service but may include patients who are not meeting goals for a particular chronic disease,
patients with multiple chronic conditions, or patients taking multiple chronic medications [66]. Also,
workflow for delivery of the intervention and processes such as identification of eligible patients,
data collection, and documentation, needs to be developed. A detailed workflow can help guide next
steps needed for implementation such as reallocation of existing pharmacist resources to deliver the
service or engaging information technology personnel to create a flag in an electronic health record to
identify eligible patients [71].
9.1. Patient Data Collection
A well-developed data collection plan is important to ensure that relevant baseline and monitoring
variables are systematically recorded when the service is provided. A pharmacy management system
or electronic health record may need to be modified in order to collect the desired data [24]. This process
should begin early because it can be time-intensive as it often involves additional organizational
approvals and may depend upon availability of personnel from nonpharmacy departments such as
information technology [72]. A data collection plan should also include details about security of data
and compliance with rules and regulations such as the Health Insurance Portability and Accountability
Act of 1996 HIPAA [24].
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9.2. Pharmacy-Based Laboratory
While laboratory data are often obtained from external sources, it may be advantageous or
even necessary to conduct laboratory monitoring/screening as part of a broader service. Thus,
some pharmacists have equipment and supplies available to measure blood glucose, A1C, international
normalization ratio, lipids, or bone mineral density at the point-of-care. Any pharmacy performing
tests that involve collecting blood or saliva must follow guidelines according to the Clinical Laboratory
Improvement Amendments of 1988. Other considerations include being familiar with the Occupational
Safety and Health Act (OSHA) and having a plan in place for blood-borne pathogen exposure [24].
In some U.S. states, pharmacists are permitted to order laboratory tests when needed to assess and
monitor medication-related problems [73].
9.3. Medication Management Protocols/Collaborative Practice Agreements
A protocol or collaborative practice agreement (CPA) is useful to provide a framework for consistent
delivery and guide treatment decisions for a medication or disease management service, which typically
includes a comprehensive assessment of medications for appropriateness and whether or not treatment
goals are being reached, identification and resolution of medication-related problems, development of a
medication care plan and follow-up and monitoring [74,75]. Protocols or CPAs formalize collaborations
between pharmacists and providers and “define certain patient care functions that a pharmacist
can autonomously provide under specified situations and conditions” [76].Treatment pathways in
protocols or CPAs should adhere to national guidelines and evidence-based recommendations and
reflect input and feedback from collaborating providers, such as physicians and nurse practitioners.
The roles and responsibilities of each team member should also be clearly defined. While a protocol or
CPA is typically not required for pharmacist services, it is advantageous to outline a process to support
decision-making. Further, a protocol or CPA improves efficiency of a pharmacist being able to directly
implement therapy recommendations rather than wait for provider approval [24].
CPAs, or as they are otherwise known as collaborative practice agreements (CPAs), can become
so commonplace and so successful as to eventually actuate or serve as a foundation for changes in
scope of practice. For example, Farris et al. utilized a CPA to extend pharmacists’ roles in providing
oral contraceptive medications and other related services [77]. This and other programs like it,
along with regulatory and societal attitude evolutions about oral contraception, have resulted in more
commonplace pharmacist involvement in such services [78].
9.4. Patient Education
Patient education is commonly included as part of a value-added pharmacist service although
the extent of education varies by the type of service being delivered. Patient education may be brief
such as discussing benefits/risks of immunizations for an immunization service or providing one-time
education about how a medication works and expected outcomes from taking a medication [24].
Pharmacists are increasingly expanding their roles in managing patient education services, such as is
the case with nutrition education [79] and in engaging patients in successful weight loss programs using
individualized and group education, as well as other tailored interventions [80]. More comprehensive
education may be provided over time for disease management services. For example, in diabetes
management pharmacists may spend time training a patient on how to use a blood glucose monitor
and/or insulin injections and providing education about healthy eating, signs and symptoms of
hypoglycemia, and assessing patient goals for treatment over multiple visits. For education services,
it is important for a pharmacist to consider literacy levels and needs of local populations, such as
availability of educational materials in English and Spanish, when applicable [24].
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10. Outcome Measurements
Pharmacists need to think about which outcomes should be assessed to determine the effectiveness
and value of services. It is a good practice to obtain feedback from key stakeholders about outcomes
as well. For example, pharmacists often focus on clinical outcomes whereas an administrator may
be primarily focused on economic outcomes. A combination of process, clinical, and economic
outcomes are useful to be able to have a full picture of the impact of a service. Process measures
may include the number and type of medication-related problems identified and resolved. Examples
of clinic measures include systolic and diastolic blood pressure, A1C, and lipid levels. Economic
outcomes can range from total health care costs to costs of medications, hospitalizations or emergency
department visits. Some stakeholders may also be interested in the return-on-investment for a particular
service [24]. Pharmacists should determine if desired outcome data is easily available in a pharmacy
management system or electronic health record. Often, a pharmacist has to work with information
technology personnel to develop templates to systematically collect and document outcomes for
reporting purposes [72,81]. Humanistic outcomes, such as patient satisfaction, often require collecting
data from patients with a tool such as a survey. For some outcomes, such as cost data, partnering with
payers for claims data may be necessary. Thus, it is important to create an evaluation plan early to
have the necessary infrastructure in place for successful outcome reporting.
Outcomes are not necessarily mutually exclusive to one another. More often than not,
when exemplary clinical and humanistic outcomes are being achieved, financial outcomes are in
lock-step with them. As mentioned previously, pharmacies develop services in agreement with their
mission and to advance the profession and to diversify their revenue streams. Relying solely on product
distribution or even hanging one’s hat on one particular service can be especially problematic in an
environment of shrinking profit margins. It is healthy and wise to consider concomitant services that
leverage one another in use of resources and in marketing, while also focusing on a comprehensive set
of operations management strategies that seek to optimize concurrent and various types of outcomes.
It has been suggested that pharmacies develop and succeed in distinctive competencies, ranging from
unique services delivery, to distribution efficiency, and marketing efforts to maximize the likelihood of
clinical and economic success [82].
11. Pharmacist and Staff Training
For a service to be successful and attractive to payers, the service needs to be consistently and
systematically delivered to all patients [83]. To ensure this, pharmacists and staff should be trained
and proficient in delivering the service. The type and extent of training varies according to the type of
service being provided. For services such as MTM, pharmacists may adopt national programs such as
the American Pharmacists Association MTM Certificate program [84]. A component of training should
also focus on documentation and outcome reporting procedures. It also useful to provide scripts
or workflow diagrams (may be electronic or on paper) as part of the training to guide pharmacists
in consistent delivery of an intervention. Adequate training of support personnel is demonstrated
repeatedly for successful expansion of pharmacist services, such as when technicians accept medication
histories of patients being admitted into the hospital, thus affording pharmacists the ability to effectively
work with prescribers on medication care planning [85]. Annual booster trainings should also be
considered to maintain quality [83]. Technicians and support personnel involved in record-keeping,
coordination, and assistance with data retrieval as a component of the service process should receive
training as well as the overall goals of the service, how the service fits with the organization’s mission,
and what value they (as support staff) bring to the table in executing the service [24].
12. Management and Marketing Services—The Services as Theatre Paradigm
There are many ways one can conceptualize services so as to proffer management and marketing
best practices for their development and implementation. Grove et al. envisage service as a human
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drama depicting the service experience [77]. Those performing the service are actors aiming to create a
desired impression before the audience on the “front stage” [86]. The “rehearsal” for the performance
takes place “backstage” away from the audience and where strategies for design and implementation
are laid out. In drama, the service is carried out not in the absence, but rather, with the audience’s
input. Similarly, a performance of a service often requires stakeholder (i.e., patients, physicians and
other health professionals, and payers) participation in the process. Like theatrical performances,
services delivery can be tenuous and fragile as processes can be disrupted by minor mishaps. As such,
both service provision and drama performance employ strategies to create a desirable impression.
This includes avoidance of service mistakes, of which things like poor service design are obvious (e.g.,
not aligning a service with organizational needs), but also avoidance of “simple” errors like misspelling
a patient’s name on a communication that might connote laziness or apathy. Organizations that are
skillful in their management of stakeholder expectations and interactions with them can improve the
value of the service from the view of those stakeholders.
Much of this metaphor would suggest the performance of the actors in delivery. However,
the scenery cannot be ignored. Just like an audience might be favorably impressed with superior
stage setting, design, and props, the health care service delivery must be provided in a place that is
clean, professional, and connotes the appropriate atmosphere. To that end, to be successful, service
performance is about managing the expectations and meeting the needs of stakeholders. In one
particular interdisciplinary collaborative, pharmacists worked with other healthcare professionals to
manage the expectations of kidney transplants patients during medical and education services, as well
as with self-monitoring activities, to better regulate their expectations and elevate their experiences
throughout the process [87].
13. Monitoring and Sustaining Value-Added Pharmacist Services Through
Implementation Science
Although there are many steps involved in getting a new service started, part of implementation
activities also includes thinking about what needs to be achieved for sustainability (or not) [88].
Additionally, in the spirit of public health discussed previously, pharmacy organizations will advance
the profession and best serve the community and its vulnerable populations when it develops
sustainable services that treat and monitor patient progress for positive outcomes over the long haul.
When approaching the value-added services concept, a useful paradigm to consider is implementation
science, which is defined as the “scientific study of methods to promote the systematic uptake of
research findings and other evidence-based practices into routine practice, and, hence, to improve the
quality and effectiveness of health services” [89]. As pharmacy, continues to work towards advancing
practice, implementation science offers a key to promote the systematic uptake of newer evidence-based
practices and a frame on how to improve the quality and effectiveness of existing services, such as
MTM [90].
Within implementation science, a useful approach for the implementation of value-added
pharmacy services is the Consolidated Framework for Implementation Research (CFIR) model [91].
The model has designers of services consider the following to help ensure service longevity: evidence
strength and quality advantage; adaptability; trialability; complexity; design quality and packaging;
and cost. The CFIR and similar implementation science frameworks have demonstrated success
in service design and monitoring. The aforementioned appointment-based model (ABM) can have
an even more positive impact on the pharmacy and its patients when designed using a CFIR
approach [44]. Use of an implementation model approach was associated with greater longevity
for an pharmacist-driven asthma service in the community setting [92]. This type of framework
might be especially valuable for other “non-routine” or “outside the box” types of pharmacy services,
such as those associated with assisting breastfeeding mothers with their particular medication-taking
needs [93] and mental health services [94]. In one study, success rates of MTM services (defined as
completed and reimbursable claims) rose from 42.9% to 64% of attempts following the adoption of a
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CFIR framework [95]. Again, the adoption of CFIR and other implementation science frameworks
approaches service design and implementation from many aspects, but principle among them is the
mindset of ongoing evaluation and the need to ensure program quality.
The CFIR provides an excellent framework for executing services that promote positive
outcomes for all stakeholders, thus potentiating its success well after its initial design. However,
there are still additional considerations for ensuring long-term sustainability of a service even
well after its implementation. Lennox et al. reviewed the implementation literature for
successful program sustainability and produced a comprehensive model that involves patients/clients,
infrastructure, staff training and support, maintaining organizational readiness, continuously raising
the organization’s profile, and keep attuned to socioeconomic and political changes in force [96]. Shelton
and Cooper concurred, emphasizing the dynamic nature of sustainability and thus the organization’s
ability to adapt to change [97].
14. Receiving Payment for Value-Added Services
Ultimately, for a value-added service to be successful, payment must be received for it. This can be
complex for value-added pharmacist services because traditionally payment for pharmacist dispensing
services has been tied to a medication and pharmacists are not recognized as providers by most payers.
A first step is to set a price for the service. In order to do this, one must determine all of the costs (e.g.,
personnel, equipment and supplies, space) related to delivery of the service. One paradigm that has
been used is that a service should result in revenue that is two to three times a pharmacist’s salary [24].
Assuming that a pharmacist earns $60/hour, this may mean charging $2.00 to $3.00 per minute for a
value-added pharmacy service [98]. It also important to remember that setting a price for a service
does not mean that a payer (or patient) is willing to pay that price [24].
Next, various pricing methodologies should be reviewed to determine which one aligns best with
the service. Fee-for-service pricing, which charges a set rate based on time or a specific intervention,
is a common approach. However, it might not maximize revenue for the provider or might create
disadvantages for promoting the service to patients. This strategy does not consider external factors,
such as competitors’ prices and could also overestimate or underestimate its value to clients. Another
pricing method is based on the resources used, or resource-based relative-value scale (RBRVS) used
commonly in the U.S.24 There are available pharmacy-specific Current Procedural Technology (CPT)
codes that might be accepted by Medicare carriers and other payers, including [99]:
99605: An initial encounter service performed face-to-face with a patient in a time increment of
up to 15 min.
99606: For use for a subsequent or follow-up encounter with the same patient in a time increment
of up to 15 min.
99607: An add-on code that may be used to bill for additional increments of 15 min of time to
either of the above codes.
CPT code 99211 is another code which has been used by pharmacists providing patient care
incident to a physician [99]. There are various codes for specific procedures such as for fasting lipid
panel, finger stick, and others. In partnership with providers, pharmacists may also be able to use
codes such as CPT code 99490 for chronic care management [99].
As mentioned previously, the use of implementation science and CFIR frameworks can assist not
only in sustainability, but also with quality assurance and reimbursement for services. Increasingly,
payers are looking for value; that is, payment for services that will save money for the insurer and its
patients in the long term, when considering all medical costs. Alternative payment models reward
performance, sustainment, and quality metrics. Therefore, it makes sense to identify and resolve
medication-related problems “upstream” at the point-of-care to avoid clinical inertia, medication errors,
and prevent more costly “downstream” care such as hospitalizations, readmissions, or emergency
room visits [100]. This inertia, or momentum, often tempts pharmacy managers to focus on quantity
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(volume) and efficiency, which is important; however, reimbursement is often attained at higher levels
and at higher rates when the goals of design and implementation focus on quality.
15. Conclusions
There are numerous opportunities for pharmacists to engage in the provision of valued-added
services. Successful implementation of value-added services requires careful planning, evaluation and
monitoring. The use of business and management principles as well as theory-based frameworks can
facilitate a path to financial viability and sustainability of value-based pharmacist services.
Author Contributions: S.P.D., D.P.Z., and L.R.M. conceptualized this commentary. A.B.C. and K.H. provided
valuable updates and recent literature, along with additional editing.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Marcrom, R.E.; Horton, R.M.; Shepherd, M.D. Creating value-added services to meet patient needs: Use these
practical suggestions to help tailor your services to various market segments and expand your practice.
J. Am. Pharm. Assoc. 1992, 32, 48–57.
2. Westrick, S.C. College/school of pharmacy affiliation and community pharmacies’ involvement in public
health activities. Am. Assoc. Coll. Pharm. Annu. Meet. 2009, 73, 123. [CrossRef]
3. Queeno, B.V. Evaluation of inpatient influenza and pneumococcal vaccination acceptance rates with
pharmacist education. J. Pharm. Pract. 2017, 30, 202–208. [CrossRef]
4. Gonzalvo, J.D.; Lantaff, W.M. CDE pharmacists in the United States. Diabetes Educ. 2018, 44, 278–292.
[CrossRef]
5. Vargas, J.; Dang, C.; Subramaniam, V. Public health approaches in ethnically diverse populations. Drug Top.
2011, 155, 4.
6. Gerber, B.S.; Cano, A.I.; Caceres, M.L.; Smith, D.E.; Wilken, L.A.; Michaud, J.B.; Ruggiero, L.A.; Sharp, L.K.
A pharmacist and health promoter team to improve medication adherence among Latinos with diabetes.
Ann. Pharmacother. 2010, 44, 70–79. [CrossRef]
7. Cochran, G.; Hruschak, V.; De Fosse, B.; Hohmeier, K.C. Prescription opioid abuse: pharmacists’ perspective
and response. Integr. Pharm. Res. Pract. 2016, 5, 65–73. [CrossRef]
8. Strand, M.A.; Eukel, H.; Burck, S. Moving opioid misuse prevention upstream: A pilot study of community
pharmacists screening for opioid risk. Res. Soc. Adm. Pharm. 2019, 15, 1032–1036. [CrossRef]
9. Hill, L.G.; Sanchez, J.P.; Laguado, S.A.; Lawson, K.A. Operation naloxone: Overdose prevention service
learning for student pharmacists. Curr. Pharm. Teach. Learn. 2018, 10, 1348–1353. [CrossRef]
10. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for the Application of
Prevention Technologies. Preventing the Consequences of Opioid Overdose: Understanding Naloxone
Access Laws. 2018. Available online: https://www.samhsa.gov/capt/sites/default/files/resources/naloxone-
access-laws-tool.pdf (accessed on 12 January 2019).
11. Fitzgerald, T.J.; Kang, Y.; Bridges, C.B.; Talbert, T.; Vagi, S.J.; Lamont, B.; Graitcer, S.B. Integrating pharmacies
into public health program planning for pandemic influenza vaccine response. Vaccine 2016, 34, 5643–5648.
[CrossRef]
12. Athern, K.M.; Linnebur, S.A.; Fabisiak, G. Proper disposal of unused household medications: The role of the
pharmacist. Consult. Pharm. 2016, 31, 261–266. [CrossRef]
13. Eerry, L.A.; Shinn, B.W.; Stanovich, J. Quantification of an ongoing community-based medication take-back
program. J. Am. Pharm. Assoc. 2014, 54, 275–279.
14. Benedict, A.W.; Spence, M.M.; Sie, J.L.; Chin, H.A.; Ngo, C.D.; Salmingo, J.F.; Vidaurreta, A.T.; Rashid, N.
Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated
Health Care System. J. Manag. Care Spec. Pharm. 2018, 24, 114–122. [CrossRef]
15. Choe, H.M.; Farris, K.B.; Stevenson, J.G.; Townsend, K.; Diez, H.L.; Remington, T.L.; Rockafellow, S.;
Shimp, L.A.; Sy, A.; Wells, T.; et al. Patient-centered medical home: Developing, expanding, and sustaining a
role for pharmacists. Am. J. Health Syst. Pharm. 2012, 69, 1063–1071. [CrossRef]
73
Pharmacy 2019, 7, 99
16. Moczygemba, L.R.; Goode, J.V.; Gatewood, S.B.; Osborn, R.D.; Alexander, A.J.; Kennedy, A.K.; Stevens, L.P.;
Matzke, G.R. Integration of collaborative medication therapy management in a safety net patient-centered
medical home. J. Am. Pharm. Assoc. 2011, 51, 167–172. [CrossRef]
17. Hirsch, J.D.; Steers, N.; Adler, D.S.; Kuo, G.M.; Morello, C.M.; Lang, M.; Singh, R.F.; Wood, Y.; Kaplan, R.M.;
Mangione, C.M. Primary-care based, pharmacist-physician collaborative medication-therapy management
of hypertension: A randomized, pragmatic trial. Clin. Ther. 2014, 36, 1244–1254. [CrossRef]
18. Parente, D.M.; Morton, J. Role of the pharmacist in antimicrobial stewardship. Med. Clin. N. Am. 2018, 102,
929–936. [CrossRef]
19. Baker, S.N.; Acquisto, N.M.; Ashley, E.D.; Fairbanks, R.J.; Beamish, S.E.; Haas, C.E. Pharmacist-managed
antimicrobial stewardship program for patients discharged from the emergency department. J. Pharm. Pract.
2011, 25, 190–194. [CrossRef]
20. Patel, E.; Pevnick, J.M.; Kennelty, K.A. Pharmacists and medication reconciliation: A review of recent
literature. Integr. Pharm. Res. Pract. 2019, 8, 39–45. [CrossRef]
21. Splawski, J.; Minger, H. Value of the pharmacist in the medication reconciliation process. Pharm. Ther. 2016,
41, 176–178.
22. Balch, A.H.; Constance, J.E.; Thorell, E.A.; Stockmann, C.; Korgenski, E.K.; Campbell, S.C.; Spigarelli, M.G.;
Sherwin, C.M. Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.
J. Clin. Pharmacol. 2015, 55, 212–220. [CrossRef]
23. Wong, K.R.; Nelson, L.A.; Elliott, E.S.; Liu, Y.; Sommi, R.W.; Winans, E.A. Utilization of antipsychotic
therapeutic drug monitoring at a state psychiatric hospital. Ment. Health Clin. 2016, 6, 1–7. [CrossRef]
24. Zgarrick, D.; Moczygemba, L.R.; Alston, G.L.; Desselle, S.P. Pharmacy Management: Essentials for All Practice
Settings, 5th ed.; McGraw-Hill: New York, NY, USA, 2016.
25. Feletto, E.; Wilson, L.K.; Roberts, A.S.; Benrimoj, S.I. Building capacity to implement cognitive pharmaceutical
services: Quantifying the needs of community pharmacies. Res. Soc. Adm. Pharm. 2010, 6, 163–173. [CrossRef]
26. Kennedy, A.G.; Biddle, M.A. Practical Strategies for Pharmacist Integration with Primary Care:
A Workbook. Available online: http://contentmanager.med.uvm.edu/docs/default-source/ahec-documents/
practicalstrategiesforpharmacistintegrationwithprimarycare-workbook_000.pdf?sfvrsn=2 (accessed on
13 January 2019).
27. Cowart, K.; Olson, K. Impact of pharmacist care provision in value-based care settings: How are we
measuring value-added services? J. Am. Pharm. Assoc. 2019, 59, 125–128. [CrossRef]
28. McAdam-Marx, C.; Dahal, A.; Jennings, B.; Singhal, M.; Gunning, K. The effect of a diabetes collaborative
care management program on clinical and economic outcomes in patients with type 2 diabetes. J. Manag.
Care Spec. Pharm. 2015, 21, 452–468. [CrossRef]
29. American Pharmacists Association (APhA). Pharmacists’ Patient Care Services Digest. Building Momentum.
Increasing Access. 2016. Available online: http://media.pharmacist.com/documents/APhA_Digest.pdf
(accessed on 13 January 2019).
30. Smith, M.; Cannon-Breland, M.L.; Spiggle, S. Consumer, physician and payer perspectives on primary care
medication management services with a shared resource pharmacists network. Res. Soc. Adm. Pharm. 2014,
10, 539–553. [CrossRef]
31. Wu, T.; Williams, C.; Vranek, K.; Mattingly, T.J. Using 340B discounts to provide a financially stable medication
discharge service. Res. Soc. Adm. Pharm. 2019, 15, 114–116. [CrossRef]
32. Zrebiec, J. A national study of the certified diabetes educator: Implications for future certification examinations.
Diabetes Educ. 2014, 40, 470–475. [CrossRef]
33. Doucette, W.R.; McDonough, R.P. Beyond the 4 P’s: Using relationship marketing to build value and demand
for pharmacy services. J. Am. Pharm. Assoc. 2002, 42, 183–194.
34. Feehan, M.; Walsh, M.; Godin, J.; Sundwall, D.; Munger, M.A. Patient preferences for healthcare delivery
through community pharmacy settings in the USA: A discrete choice study. J. Clin. Pharm. Ther. 2017, 42,
738–749. [CrossRef]
35. Painter, J.T.; Gressler, L.; Kathe, N.; Slabaugh, L.; Blumenschein, K. Consumer willingness to pay for pharmacy
services: An updated review of the literature. Res. Soc. Adm. Pharm. 2018, 14, 1091–1105. [CrossRef]
36. Nazar, H.; Nazar, Z. Community pharmacy minor ailment services: Pharmacy stakeholder perspectives on
the factors affecting sustainability. Res. Soc. Adm. Pharm. 2019, 15, 292–302. [CrossRef]
74
Pharmacy 2019, 7, 99
37. White, L.; Klinner, C.; Carter, S. Consumer perspectives of the Australia Home Medicines Review Program:
Benefits and barriers. Res. Soc. Adm. Pharm. 2012, 8, 4–16. [CrossRef]
38. Dabholkar, P.A. How to improve perceived service quality by increasing customer participation. In Proceedings
of the 1990 Academy of Marketing Science (AMS) Annual Conference. Developments in Marketing Science: Proceedings
of the Academy of Marketing Science; Dunlap, B., Ed.; Springer: Cham, Switzerland, 2015.
39. Patwardhan, P.D.; Amin, M.E.; Chewning, B.A. Intervention research to enhance community pharmacists’
cognitive services: A systematic review. Res. Soc. Adm. Pharm. 2014, 10, 475–493. [CrossRef]
40. Fleming, M.L.; Bapat, S.S.; Varisco, T.J. Using the theory of planned behavior to investigate community
pharmacists’ beliefs regarding engaging patients about prescription drug misuse. Res. Soc. Adm. Pharm.
2019, 15, 992–999. [CrossRef]
41. Holiday-Goodman, M. Entrepreneurship, resource management, organizational culture and other “business”
factors influencing pharmacy practice change. Res. Soc. Adm. Pharm. 2012, 8, 269–271. [CrossRef]
42. Treneman, S.; Willison, M.; Robinson, B.; Andrew, M. A collaborative intervention for deprescribing: The role
of stakeholder and patient engagement. Res. Soc. Adm. Pharm. 2019, 15. [CrossRef]
43. Bitner, M.J. The servicescape. In Handbook of Services Marketing; Swartz, T.A., Iacobucii, D., Eds.; Sage:
Thousand Oaks, CA, USA, 2000; pp. 37–50.
44. Zeithaml, V.; Bitner, M.J. Services Marketing; McGraw-Hill: New York, NY, USA, 1996.
45. Goedken, A.M.; Butler, C.M.; McDonough, R.P.; Deninger, M.J.; Doucette, W.R. Continuous medication
monitoring (CoMM): A foundational model to support the clinical work of community pharmacists. Res. Soc.
Adm. Pharm. 2018, 14, 106–111. [CrossRef]
46. Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model, Version
2.0. American Pharmacists Association and National Association of Chain Drug Stores Foundation. 2008.
Available online: https://www.pharmacist.com/sites/default/files/files/core_elements_of_an_mtm_practice.
pdf (accessed on 6 June 2019).
47. Patterson, J.; Holdford, D. Understanding the dissemination of appointment-based synchronization models
using the CFIR framework. Res. Soc. Adm. Pharm. 2017, 13, 914–921. [CrossRef]
48. Watson, L.L.; Bluml, B.M. Pharmacy’s Appointment Based Model: Implementation Guide for Pharmacy
Practices. APhA Foundation. 2013. Available online: https://www.aphafoundation.org/sites/default/files/
ckeditor/files/ABMImplementationGuide-FINAL-20130923.pdf (accessed on 3 June 2019).
49. Khazan, E.; Anastasia, E.; Hough, A.; Parra, D. Pharmacist-managed ambulatory blood pressure monitoring
service. Am. J. Health Syst. Pharm. 2017, 74, 190–195. [CrossRef]
50. Milfred-LaForest, S.K.; Gee, J.A.; Pugacz, A.M.; Pina, I.L.; Hoover, D.M.; Wenzell, R.C.; Felton, A.;
Guttenberg, E.; Ortiz, J. Heart failure transitions of care: A pharmacist-led post-discharge pilot experience.
Prog. Cardiovasc. Dis. 2017, 60, 249–258. [CrossRef]
51. Halalau, A.; Shelden, D.; Keeney, S.; Hehar, J. Pharm-MD; an open-label, randomized controlled, phase II
study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients study
protocol for a randomized controlled trial. Trials 2018, 19, 458. [CrossRef]
52. Schultz, J.L.; Horner, K.E.; McDanel, D.L.; Miller, M.L.; Beranek, R.L.; Jacobsen, R.B.; Sly, N.J.;
Miller, A.C.; Mascardo, L.A. Comparing clinical outcomes of a pharmacist-managed diabetes clinic to
usual physician-based care. J. Pharm. Pract. 2018, 31, 268–271. [CrossRef]
53. Pett, R.G.; Nye, S. Evaluation of a pharmacist-managed asthma clinic in an Indian Health Service clinic. J.
Am. Pharm. Assoc. 2016, 56, 237–241. [CrossRef]
54. Hale, A.; Merlo, G.; Nissen, L.; Coombes, I.; Graves, N. Cost-effectiveness analysis of doctor-pharmacist
collaborative prescribing for venous thromboembolism in high risk surgical patients. BMC Health Serv. Res.
2018, 18, 749. [CrossRef]
55. Lee, J.C.; Horner, K.E.; Krummel, M.L.; McDanel, D.L. Clinical and financial outcomes evaluation of
multimodal pharmacist warfarin management of a statewide urban and rural population. J. Pharm. Pract.
2018, 31, 150–156. [CrossRef]
56. Manzoor, B.S.; Cheng, W.H.; Lee, J.C.; Uppuluri, E.M.; Nutescu, E.A. Quality of pharmacist-managed
anticoagulation therapy in long-term ambulatory settings: A systematic review. Ann. Pharmacother. 2017, 51,
1122–1137. [CrossRef]
75
Pharmacy 2019, 7, 99
57. Durham, M.J.; Goad, J.A.; Neinstien, L.S.; Lou, M.A. A comparison of pharmacist travel-health specialists’
versus primary care providers’ recommendations for travel-related medications, vaccination, and patient
compliance in a college health setting. J. Travel Med. 2011, 18, 20–25. [CrossRef]
58. Hess, K.M.; Dai, C.W.; Garner, B.; Law, A.V. Measuring outcomes of a pharmacist-run travel health clinic
located within an independent community pharmacy. J. Am. Pharm. Assoc. 2010, 50, 174–180. [CrossRef]
59. Manchikanti Gomez, A. Availability of pharmacist-prescribed contraception in California. J. Am. Med. Assoc.
2017, 318, 2253–2254. [CrossRef]
60. Puzantian, T.; Gasper, J.J. Provision of naloxone without a prescription by California pharmacists 2 years
after legislation implementation. J. Am. Med. Assoc. 2018, 320, 1933–1934. [CrossRef]
61. Smalls, T.D.; Broughton, A.D.; Hylick, E.V.; Woodard, T.J. Providing medication therapy management for
smoking cessation patients. J. Pharm. Pract. 2015, 28, 21–25. [CrossRef]
62. Salvig, B.E.; Gulum, A.H.; Walters, S.A.; Edwards, L.B.; Fourakre, T.N.; Marvin, S.C.; McKenzie, M.S.;
Moseley, M.V.; Ansari, I.J. Pharmacist screening for risk of osteoporosis in elderly veterans. Consult. Pharm.
2016, 31, 440–449. [CrossRef]
63. Smith, M.C.; Boldt, A.S.; Waston, C.M.; Zillich, A.J. Effectiveness of a pharmacy care management program
for veterans with dyslipidemia. Pharmacotherapy 2013, 33, 736–743. [CrossRef]
64. Isho, N.Y.; Kachlic, M.D.; Marcelo, J.C.; Martin, M.T. Pharmacist-initiated hepatitis C virus screening in a
community pharmacy to increase awareness and link to care at the medical center. J. Am. Pharm. Assoc. 2017,
57, S259–S264. [CrossRef]
65. Klepser, D.G.; Klepser, M.E.; Smith, J.K.; Dering-Anderson, A.M.; Nelson, M.; Pohren, L.E. Utilization of
influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting.
Res. Soc. Adm. Pharm. 2017, 14, 356–359. [CrossRef]
66. Grayson, G.; Shulman, D. Impression management in services marketing. In Handbook of Services Marketing;
SwartZ, T.A., Iacobucci, D., Eds.; Sage: Thousand Oaks, CA, USA, 2000; pp. 51–68.
67. Guhl, D.; Blankart, K.E.; Stargardt, T. Service quality and perceived customer value in community pharmacies.
Health Serv. Manag. Res. 2018, 32, 36–48. [CrossRef]
68. Desselle, S.P. An in-depth examination of pharmacy technician worklife through an organizational behaviour
framework. Res. Soc. Adm. Pharm. 2016, 12, 722–732. [CrossRef]
69. Ghorob, A.; Bodenheimer, T. Building teams in primary care: A practical guide. Fam. Syst. Health 2015, 33,
182–192. [CrossRef]
70. Brummel, A.; Lustig, A.; Westrich, K.; Evans, M.A.; Plank, G.S.; Penso, J.; Dubois, R.W. Best practices:
Improving patient outcomes and costs in an ACO through comprehensive medication therapy management.
J. Manag. Care Pharm. 2014, 20, 1152–1158. [CrossRef]
71. MacKeigan, L.D.; Ljaz, N.; Bojarski, E.A.; Dolovich, L. Implementation of a reimbursed medication review
program: Corporate and pharmacy level strategies. Res. Soc. Adm. Pharm. 2017, 13, 947–958. [CrossRef]
72. Musselman, K.T.; Moczygemba, L.R.; Pierce, A.L.; Plum, M.B.; Brokaw, D.K.; Kelly, D.L. Development and
implementation of clinical pharmacist services within an integrated medical group. J. Pharm. Pract. 2017, 30,
75–81. [CrossRef]
73. American Pharmacists Association. Pharmacist Scope of Services. Available online: https://www.
pharmacist.com/sites/default/files/files/APhA%20-%20PAPCC%20Scope%20of%20Services.pdf (accessed on
1 January 2019).
74. Collaborative Practice Agreements and Pharmacists’ Patient Care Services: A Resource for Pharmacists.
National Center for Chronic Disease Prevention and Health Promotion. Available online: https://www.cdc.
gov/dhdsp/pubs/docs/Translational_Tools_Pharmacists.pdf (accessed on 6 June 2019).
75. Collaborative Practice Agreements: Resources and More. NASPA. Available online: https://naspa.us/
resource/cpa/ (accessed on 6 June 2019).
76. Collaborative Practice Agreements (CPA) and Pharmacists’ Patient Care Services. APhA Foundation.
Available online: https://www.aphafoundation.org/collaborative-practice-agreements (accessed on
6 June 2019).
77. Farris, K.B.; Ashwood, D.; McIntosh, J.; DiPietro, N.A.; Maderas, N.M.; Landau, S.C.; Swegle, J.; Solemani, O.
Preventing unintended pregnancy. Pharmacists’ roles in practice and policy via partnerships. J. Am. Pharm.
Assoc. 2010, 50, 604–612. [CrossRef]
76
Pharmacy 2019, 7, 99
78. Beal, J.L.; Plake, K.S.I. Social and legislative shaping of access to to contraceptives and the pharmacist’s role:
A literature review. Res. Soc. Adm. Pharm. 2019. [CrossRef]
79. Parsai, S. Nutrition education improves patient care. J. Am. Pharm. Assoc. 2016, 56, 225–226. [CrossRef]
80. Harmon, M.; Pogge, B.; Boomershine, V. Evaluation of a pharmacist-led, 6-month weight loss program for
obese patients. J. Am. Pharm. Assoc. 2014, 54, 302–307. [CrossRef]
81. Matzke, G.R.; Czar, M.J.; Lee, W.T.; Moczygemba, L.R.; Harlow, L.D. Improving health of at risk rural patients:
A collaborative care model. Am. J. Health Syst. Pharm. 2016, 73, e583–e591. [CrossRef]
82. McGee, J.E.; Love, J.G.; Festervand, T.A. Competitive advantage and the independent retail pharmacy:
The role of distinctive competencies. J. Pharm. Mark. Manag. 2000, 13, 31–46. [CrossRef]
83. Planas, L.G. Intervention design, implementation, and evaluation. Am. J. Health Syst. Pharm. 2008, 65,
1854–1863. [CrossRef]
84. Delivering Medication Therapy Management Services. American Pharmacists Association. Available
online: https://www.pharmacist.com/education/advanced-training-programs/delivering-medication-
therapy-management-services?is_sso_called=1 (accessed on 6 June 2019).
85. Jobin, J.; Irwin, A.N.; Pimentel, J.; Turner, M.C. Accuracy of medication histories collected by pharmacy
technicians during hospital admission. Res. Soc. Adm. Pharm. 2018, 14, 695–699. [CrossRef]
86. Grove, S.J.; Fisk, R.P.; John, J. Services as theatre: Guidelines and implications. In Handbook of Services
Marketing and Management; Swartz, T.A., Iacobucci, D., Eds.; Sage: Thousand Oaks, CA, USA, 2000; pp. 2–36.
87. Crawford, C.; Low, J.K.; Manias, E.; Williams, A. Healthcare professionals can assist patients with managing
post kidney transplant expectations. Res. Soc. Adm. Pharm. 2017, 13, 1204–1207. [CrossRef]
88. Crespo-Gonzalez, C.; Garcia-Cardenas, V.; Benrimoj, S.I. The next phase in professional services research:
From implementation to sustainability. Res. Soc. Adm. Pharm. 2017, 13, 896–901. [CrossRef]
89. Eccles, M.P.; Mittman, B.S. Welcome to implementation science. Implement. Sci. 2006, 1, 1. [CrossRef]
90. Curran, G.M.; Shoemaker, S.J. Advancing pharmacy practice through implementation science. Res. Soc.
Adm. Pharm. 2017, 13, 889–891. [CrossRef]
91. Shoemaker, S.J.; Curran, G.M.; Swan, H.; Teeter, B.S.; Thomas, J. Application of the Consolidated Framework
for implementation research to community pharmacy: A framework for implementation research on
pharmacy services. Res. Soc. Adm. Pharm. 2017, 13, 905–913. [CrossRef]
92. Fuller, J.M.; Saini, B.; Bosnic-Anticevich, S.; Cardenas, V.G.; Benrimoj, S.I.; Armour, C. Testing evidence
routine practice: Using an implementation framework to embed a clinically proven asthma service in
Australian community pharmacy. Res. Soc. Adm. Pharm. 2017, 13, 989–996. [CrossRef]
93. Sim, T.F.; Hattingh, H.L.; Sherriff, J.; Tee, L.B.G. Towards the implementation of breastfeeding-related health
services in community pharmacies: Pharmacists’ perspectives. Res. Soc. Adm. Pharm. 2017, 13, 980–988.
[CrossRef]
94. Hattingh, H.L.; Kelly, F.; Fowler, J.; Wheeler, A.J. Implementation of a mental health medication management
intervention in Australian community pharmacies: Facilitators and challenges. Res. Soc. Adm. Pharm. 2017,
13, 969–979. [CrossRef]
95. Stafford, R.; Thomas, J.; Payakachat, N.; Diemer, T.; Lang, M.; Kordsmeier, B.; Curran, G. Using an array of
implementation strategies to improve success rates of pharmacist-initiated medication therapy management
services in community pharmacies. Res. Soc. Adm. Pharm. 2017, 13, 98–946. [CrossRef]
96. Lennox, L.; Maher, L.; Reed, J. Navigating the sustainability landscape: A systematic review of sustainability
approaches in healthcare. Implement. Sci. 2018, 13, 27. [CrossRef]
97. Shelton, R.C.; Cooper, B.R.; Stirman, S.W. The Sustainability of Evidence-Based Interventions and Practices
in Public Health and Health Care. Annu. Rev. Public Health 2018, 39, 55–76. [CrossRef]
98. DaVanzo, J.; Dobson, A.; Koenig, L.; Book, R. Medication Therapy Management Services: A Critical Review.
2005. Available online: https://www.acccp.com/docs/positions/commentarties/memts/pdf (accessed on
6 June 2019).
77
Pharmacy 2019, 7, 99
99. Payment Methods in Outpatient Team-Based Clinical Pharmacy Practice, Part 1. ACCP Practice Advancement
Issue Brief. 2018. Available online: https://www.accp.com/docs/positions/misc/IB1PaymentPart1-
ACCPPracticeAdvancement.pdf (accessed on 6 June 2019).
100. Smith, M.A. Implementing primary care pharmacist services: Go upstream in the world of value-based
payment models. Res. Soc. Adm. Pharm. 2017, 13, 892–895. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Co-located Retail Clinics and Pharmacies:
An Opportunity to Provide More Primary Care
Katherine Knapp 1,*, Keith Yoshizuka 1, Debra Sasaki-Hill 1 and Rory Caygill-Walsh 2
1 College of Pharmacy, Touro University California, 1310 Club Drive, Vallejo, CA 94592, USA
2 Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94702, USA
* Correspondence: Katherine.knapp@tu.edu
Received: 10 April 2019; Accepted: 18 June 2019; Published: 26 June 2019
	

Abstract: This paper proposes that co-located retail clinics (RCs) and community pharmacies
can increase opportunities to provide more accessible, affordable, and patient-friendly primary
care services in the United States. RCs are small businesses of about 150–250 square feet with
a clientele of about 10–30 patients each day and most frequently staffed by nurse practitioners
(NPs). Community pharmacies in the U.S. at ~67,000 far outnumber RCs at ~2800, thereby opening
substantial opportunity for growth. Community pharmacies and pharmacists have been working
to increase on-site clinical services, but progress has been slowed by the relative isolation from
other practitioners. An ideal merged facility based on an integrated platform is proposed. NPs and
pharmacists could share functions that fulfill documented consumer preferences and still maintain
separate practice domains. Potential benefits include a broader inventory of clinical services including
laboratory tests, immunizations, patient education, and physical assessment, as well as better patient
access, interprofessional training opportunities, and economies related to the use of resources,
day-to-day operations, and performance metrics. Challenges include the availability of sufficient,
appropriately trained staff; limitations imposed by scope of practice and other laws; forging of
collaborative relationships between NPs and pharmacists; and evidence that the merged operations
provide economic benefits beyond those of separate enterprises.
Keywords: community pharmacy; retail clinics; pharmacists; nurse practitioners; interprofessional
training; primary care; healthcare access
1. Purpose
We propose that the growing presence of co-located retail clinics (RCs) and pharmacies in the United
States provides an opportunity to improve the delivery of accessible, affordable, and patient-friendly
primary care services in the United States. In this paper, we present the case for the gains that
could be made and the challenges that could reduce benefits and/or stand in the way of continued,
successful implementation.
2. Methods
A three-person team with practice and research experience searched PubMed, Google Scholar,
and Google for articles and papers about retail clinics, community pharmacy practice trends,
training and clinical activities of nurse practitioners and pharmacists, primary care delivery trends,
and approaches to merging business operations. Search terms included community pharmacy, retail
clinics, pharmacist, nurse, and primary care. Previously collected resources were added to relevant
articles. Based on the importance of legal issues, we only considered papers from the United States.
The resource articles and follow-up discussions were used to identify benefits and challenges in
establishing a successful, merged operation in co-located RCs and community pharmacies.
Pharmacy 2019, 7, 74; doi:10.3390/pharmacy7030074 www.mdpi.com/journal/pharmacy79
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3. Background
3.1. Retail Clinics
The retail clinic (RC) is a relatively new site for providing primary healthcare services. These
ambulatory sites render preventive and therapeutic services and are generally staffed by nurse
practitioners (NPs) or physician assistants (PAs) [1–3]. In 2018, RC numbers in the U.S. were estimated
at 2800, and the numbers continue to grow [4]. The potential value of RCs was explored in a landmark
2009 study that provided evidence that the cost of a typical RC visit ($110) was significantly less than
similar visits to physician offices ($166), urgent care centers ($156), or emergency departments ($570),
while the quality of care was equivalent or better [5]. The RCs are generally co-located with pharmacies.
To date, CVS and Walgreens have sponsored the greatest numbers of RCs. Also sponsoring RCs, either
directly or by contract, are mass merchandise corporations such as Target and Walmart and some
grocery operations [2]. Here also, co-location with pharmacies is generally the rule. To give an idea
of the potential for expansion, in 2015, <3% of the approximate 67,000 pharmacies in the U.S. had
co-located RCs [6].
A 2015 report described RCs as small businesses of about 150–250 square feet with a clientele of
about 10–30 patients each day [7]. It is hard to imagine RCs flourishing as independent, stand-alone
entities; indeed, the business model pairing them with pharmacies has many potential advantages,
a number of which we explore in this paper. With cost a critical issue for sustainability and expansion,
it seems that co-located RCs and pharmacies should explore all reasonable economies by virtue
of co-location.
3.2. Nurse Practitioners
NPs are generally preferred over PAs to lead RC operations. This is because scope of practice laws,
which are generated at the state level, have allowed NPs in most states to have more autonomy from
physician oversight. Given the small percentage of pharmacies co-located with RCs, a basic question
for potential RC growth is the availability of sufficient numbers of appropriately prepared NPs.
Advanced Practice Registered Nurses (APRNs) provide diagnostic and therapeutic services for
acute, episodic, or chronic illnesses [8,9]. APRNs include three cohorts, with NPs representing about
76% by number and nurse midwives and nurse anesthetists representing the rest. (Clinical nurse
specialists are a fourth cohort of APRNs. This group is not currently represented in Bureau of Labor
Statistics (BLS) data.) Bureau of Labor Statistics (BLS) data for 2017 report 166,280 employed NPs in
the U.S. with mean annual wages of $107,480 [9]. There are several specialty areas for NPs based on the
patient populations they are trained to care for. Some examples are pediatrics, acute care, psychiatry,
and family care [10]. Family NPs (FNPs) are the only group licensed to treat both adults and children.
This is an important consideration given that RCs treat both adult and pediatric patients, and it makes
the FNP the best candidate for RC positions.
Requirements for licensure as an NP vary by state. Most states require RN status, completion of
a Master’s degree or higher with emphasis on nursing skills from an accredited institution, and national
certification from either the American Association of Nurse Practitioners or the American Nurses
Credentialing Center [11]. Achieving NP status takes about two years beyond RN status. Nationally,
there is a trend toward common licensure requirements for NPs. While every state would still require
NP licensure to practice in that state, common licensure requirements could benefit RCs expanding
across state lines by allowing NPs to gain licensure in another state more easily.
Health-related services that NPs can offer are determined by state-based scope of practice laws,
a circumstance which has implications for RCs. Practice activities of NPs in California, for example,
must meet the requirements for “standardized procedures” (SPs), meaning that only procedures
that have been developed, reviewed, and approved by an interdisciplinary team can be legally
performed [12]. Standardized procedures apply to diagnostic and treatment activities. One such
procedure is the ability to prescribe medications under protocol. (In California, the term “furnish”
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is used in legal language regarding prescribing activities for both NPs and pharmacists.) For RCs,
a particular advantage of co-location with pharmacies is this authority—an approved practice activity
which is generally broader than allowed for pharmacists. The ability to obtain prescriptions which
can potentially be filled under the same roof has been cited as a preference by patients [13]. There are,
however, limitations on prescribing activities which are discussed below. A new direction related to
services that can be offered is reflected in a bill that has been introduced in the California legislature that
would allow NPs and physician assistants to practice independent of a supervising physician [14,15].
3.3. Pharmacists
By way of comparison with NPs, pharmacists are greater in number. According to the BLS [16],
309,330 pharmacists were employed in the United States in 2017. Their mean annual wage was
$121,710. To become a pharmacist, one must earn a Doctor of Pharmacy (PharmD) through a program
accredited by the Accreditation Council of Pharmacy Education (ACPE). The PharmD program requires
four years, sometimes three years, depending on the curriculum of the institution. Once graduated,
two sets of exams must be passed to obtain licensure: the North American National Pharmacist
Licensure Examination (NAPLEX) and the Multistate Pharmacy Jurisprudence Examination (MJPE)
or a state-specific law exam. Some pharmacists will continue training by completing a residency or
fellowship. Some will pursue board certification in a specialty area by passing an examination. Currently,
there are 41,000 [17] pharmacists worldwide that are Board of Pharmacy Specialties (BPS)-certified in
11 specialty areas such as pharmacotherapy, geriatrics, ambulatory care, and cardiology.
Pharmacists have been working professionally and politically to increase clinical involvement in
patient care, especially in areas that relate to primary care. Through education and training, as well as
expansion of scope of practice laws, progress has occurred. Indeed, pharmacists have been identified
as part of the solution to reducing the shortage of primary care providers in this country [18,19]. Some
states have passed laws allowing qualified pharmacists to expand their scope of practice and a pathway
has been created to support another level of licensure: Advanced Practice Pharmacist (APP). California,
North Carolina, Minnesota, New Mexico, Oregon, and Washington now support APP licensure.
However, despite these advances, community pharmacies’ physical locations, somewhat isolated from
other healthcare providers, have slowed this progress. The prospect of pharmacists partnering with
NPs whose practice privileges overlap—but usually extend beyond those of pharmacists—opens the
door to expanding services as a merged, joint operation.
3.4. Pharmacies
Health services offered in pharmacies have been expanding since the early 2000s when
immunizations started being offered widely at pharmacies. More recently, but only in some
states, pharmacies became able to prescribe naloxone for opioid overdose, hormonal contraceptives,
and medications recommended for international travel. Pharmacies are providing smoking cessation
programs, and there has recently been a proposal for pharmacists to prescribe medications to prevent
the transmission of HIV [20–22]. Ohio recently passed SB 265 to provide reimbursement to pharmacists
for clinical services by the state Medicaid program [23]. This trend toward expanding health services
in community pharmacies has continued with both CVS and Walgreens recently launching initiatives.
For example, CVS has opened three concept stores in the Houston area featuring “HealthHUBs” that
offer assistance with durable medical equipment, yoga classes, blood tests, and nutritional advice in
addition to their RCs (MinuteClinics) and pharmacies. CVS also announced the availability of telehealth
services through its MinuteClinics [24]. Additionally, Walgreens renovated a store in Deerfield, Illinois
to house a “Health Corner” offering such services as vision care, lab tests, and hearing services [25].
These initiatives by pharmacy industry giants may be an indication of the future direction of community
pharmacies. Most recently, health insurer Aliera signed an agreement with CVS’s MinuteClinics to
provide their members “with access to MinuteClinic services at no cost and with no applicable co-pays
or deductibles” [26].
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Besides these new ventures by pharmacy corporations, there is evidence that customers/patients
are looking for an expanded service package when they go to a pharmacy. Table 1 combines results
from three studies about consumer preferences for pharmacy-based health services. The first of these is
a 2017 study of over 9000 people ≥18 years of age [27]. The second is a 2018 study of >1000 U.S. adults
≥40 years of age [13]. The third is a 2018 study that showed agreement among pharmacists, physicians,
and patients that “minor ailments” could be well treated in rural community pharmacy settings by
pharmacists, NPs, and/or PAs [28]. In these studies, participants identified preferred services they
would like to see in community pharmacies. Table 1 suggests that, under the right circumstances, NPs
and pharmacists could share several of these functions and still maintain separate practice domains.
The shared services could allow for flexibility depending on the demand for services in either the RC
or the pharmacy. This topic is explored further in a later section.
Table 1. Customer/Patient preferences from three studies.






Access by appointment or
walk-in
Ability to make an appointment














common infections including flu,
strep, hepatitis, tuberculosis, HIV
and chemistry tests (urine, saliva,
and blood)
Yes Yes, in CA with SPs
(Quick) OTC treatments
and/or recommendations
Allergies, skin rashes, cough and
cold, gastro-intestinal issues,
feminine issues, sleeping aids, first
aid, eye and ear problems,
analgesics
Yes Yes, in CA with SPs
Patient education














Keep records on medications,




Blood pressure, heart rate,
breathing rate, extremities Yes Yes
Medication services
New prescriptions, refill
reminders, delivery, counseling Yes Yes, in CA with SPs
Immunizations
Vaccinations: flu, pneumonia,
zoster, travel medications Yes Yes, in CA with SPs
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Table 1. Cont.








cessation, adjustment of dose Yes *** Yes, in CA with SPs
Advice and monitoring
Weight loss, diabetes, cholesterol,
blood pressure Yes Yes
* Some screenings may be performed by the pharmacist, while others require specialized equipment not available
in the pharmacy. ** In most cases, a patient’s electronic health record is not readily available to the pharmacist,
and a patient’s electronic health record is not readily available to the NP. However, in some pharmacies affiliated
with a medical care system, this information can be available to both parties. *** Pharmacist prescribing is dependent
upon the setting (a provider who contracts with a licensed health care service plan with regard to the care or services
provided to the enrollees of that health care service plan [29]) or the level of license of the pharmacist (Advanced
Practice Pharmacist (APP)).
4. An Ideal Co-located Facility
4.1. Advantages of an Integrated Platform
Imagine for a moment that RCs and pharmacies could develop an integrated platform for
delivering health services that are both preventive and therapeutic and that could also address
customer preferences. What might it look like? The preferences in Table 1 indicate that customers
and patients want their access to health care to be uncomplicated, quick, and convenient. In our ideal
facility, for example, a patient could use a single access point—electronic, telephonic, or otherwise—to
make an appointment for an immunization or blood pressure check, to get answers to questions about
medication interactions, and/or to schedule a diabetic foot examination. Both NPs and pharmacists
are trained to offer these services, although NPs perform diagnostic procedures more frequently.
So, depending on the issue and overall workload, the patient’s appointment could be with either
an NP or a pharmacist or both. In an ideal situation, staff could be cross-trained in areas that do not
require specialized licenses or certificates to fill in for the other service area to prevent delaying or
denying services to the patient. For situations requiring prescription medications, patients would
have the option of filling their prescription and receiving counseling a few steps away, although
there are caveats about getting prescriptions filled that are discussed below. In short, an integrated
RC/pharmacy platform could mimic, on a smaller scale, a well-established and reputable health
maintenance organization where a patient could receive several different healthcare services under
one roof.
4.2. Clinical Laboratory Tests
Regarding customer preferences around clinical tests, the Clinical Laboratory Improvement
Amendments 1988 (CLIA) describe quality standards for testing in clinical laboratories. For >1400
test systems that are non-technical and unlikely to provide erroneous results, CLIA requirements
have been waived. These include, for example, blood glucose testing, cholesterol and hemoglobin
A1c measurement, and testing for the presence of HIV-1 and HIV-2. Both pharmacies and RCs can
offer diagnostic tests that are CLIA-waived after obtaining a CLIA Certificate of Waiver (COW).
An integrated operation under the same roof and address could allow a single COW for the facility—a
valuable efficiency saving time and money. In like fashion, inventories of vaccines could serve both the
pharmacy and the RC.
4.3. Interprofessional Training Opportunities
Both pharmacist and NP training programs struggle with meeting mandates for interprofessional
training as part of their programs. Such training is now mandated by accreditation agencies for most
health professions [30,31]. An integrated, co-located RC and pharmacy could provide an ideal site
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for NP and pharmacy students to work with other health professionals—and one another—as part of
providing care and being part of a care team. From a training perspective, these sites could help schools
achieve accreditation requirements. From an economic perspective, students could augment the
amount of service that can be offered to patients. From a student perspective, there is the opportunity
for concrete experience working as a team in a primary care arena. One caveat would be that it is
probably optimal that a site used for training be “mature” in the sense that integration is operational
and the staff are experienced in working as a team.
4.4. Other Advantages
Some other advantages that could be realized with an integrated platform include providing more
flexibility with hours of operation, providing more and richer patient education, creating in-house
consultation on clinical issues, and expanding the service list that a single facility can offer.
5. Challenges
5.1. NP Supply
Despite the several clinical, financial, and convenience advantages cited above, there are barriers
to consider and overcome. First, adequate numbers of appropriately trained NPs are needed to staff
RCs. As noted earlier, only Family NPs (FNPs) are licensed to provide care for children and adults and
would therefore be preferred to staff RCs. Approximately 67% of the NP cohort are FNPs [32], which,
using BLS data, would be about 110,000 persons, an attractive pool for RC recruitment. Moreover,
the BLS projects the number of NPs to grow by 31% between 2016 and 2026, a growth rate which is
“much faster than average” [9]. However, given that NPs must provide evidence of registered nurse
(RN) status to qualify for NP licensure, a shortage of RNs in the U.S., reported as recently as 2019, is
relevant to the issue of sustained supply [33]. The same report lists reasons for the RN shortage to
include a shortage of faculty that limits enrollment, an aging population of RNs, workplace stress,
and difficulties finding appropriate training sites [34]. Based on the relationship between RN and NP
supply, sustained RN growth will be an important factor in having sufficient FNPs to staff RCs.
5.2. Collaborative Practice Agreements
This paper discusses the topic of RCs located within a pharmacy on a national basis. There are still
a handful of states where collaborative practice for pharmacists is severely restricted (such as the state
of New York, where pharmacist collaborative practice agreements are restricted to teaching hospitals).
Even in those states that allow collaborative practice agreements, some are so restrictive that a separate
agreement must be established for each patient. The strategy of inserting the NP as the provider in
RCs definitely has advantages, but state legal restrictions could limit the applicability of this strategy.
5.3. Antitrust and Stark Laws
The management of prescription medications is another issue that is potentially challenging.
While it may seem logical that a prescription generated by a RC co-located with a pharmacy be filled
at that pharmacy, the patient always has the choice of where to get that prescription filled. Limiting
that choice may possibly violate antitrust laws [35] and the Stark laws [34] regarding illegal referrals.
The prescriber may not direct the patient to use a particular pharmacy, nor can a lease agreement
contain any requirements or incentives regarding the number of prescriptions generated. The Stark
law specifically states in 42 USC §1395nn(a)(1)(A) “ . . . the physician may not make a referral to the
entity (where there is a financial arrangement) for the furnishing of designated health services for
which payment otherwise may be made under this subchapter”, and the definition of health services
specifically lists outpatient prescription drugs [36].
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5.4. Pharmacist Reimbursement
Reimbursement for clinical services provided by pharmacists could be an impediment to the
business success of co-located RCs and pharmacies. While pharmacists may bill Medicare for certain
services as “incident-to” a visit [37], efforts to pass legislation for direct reimbursement to pharmacists
under Medicare Part B have failed to make it out of committee in Congress [36,38]. There are some
signs of progress; however, these are not without complications. For example, in California, a bill
passed both houses and was signed by the governor in 2016 authorizing payment to pharmacists
by MediCal (Medicaid) for clinical services allowed by SB 493 [39]. However, it has taken MediCal
three years to issue billing codes to allow pharmacists to bill for such services. On the positive side,
Washington State was successful in passing a bill in 2015 requiring commercial health plans to enroll
pharmacists as providers and pay for services permitted within their scope of practice [40], and,
as noted earlier, the Ohio legislature recently passed a bill to provide reimbursement to pharmacists
for clinical services by the state Medicaid program [23]. Some commercial health plans have taken the
initiative to recognize and reimburse pharmacists for clinical services, but this is more the exception
than the rule.
One area where pharmacists have found success is by contracting with Accountable Care
Organizations (ACOs) created by the Patient Protection and Affordable Care Act [41] to work within
their scope of practice to improve the quality of care, improve accessibility, and reduce costs. The ACO
is based upon population management as opposed to fee-for-service, so there is incentive to provide
improved-quality care while reducing costs. Overall, these fragmented and state-based approaches to
pharmacy/pharmacist reimbursement for clinical services have not made a major breakthrough and
can still obstruct efforts to expand services in pharmacies whether or not they are co-located with RCs.
5.5. Business Relationship between the RC and Pharmacy
The last challenge we present is based on the financial and operational arrangements between
the RC and pharmacy. Current models may not allow crossover in financial areas including payroll,
reimbursements, and cost of supplies. This practice effectively places the pharmacy in competition
with the RC. We would propose that the best chance for the success of co-located facilities to be greater
than the individual successes of each entity is to establish an integrated platform that merges the
use of resources, the inventory of clinical services, rules for day-to-day operations, and performance
metrics while paying attention to customer preferences. This merging will be no easy task and will rely
heavily on the development and use of skills and methods involving collaboration. To the best of our
knowledge, there is currently no model that achieves a sustainable, merged organization, but a recent
study outlines the characteristics of such a model and actions that can build the needed collaborative
relationships [42]. With the continued deficit in primary care access and affordability in the United
States and the potential to use existing facilities to a broader extent, it seems reasonable to explore,
experimentally implement, and assess a merged operation. We hope that the information and ideas
presented here can promote efforts toward a model that capitalizes on the advantages of co-locating
RCs and community pharmacies.
6. Summary
Retail clinics (RC) co-located with pharmacies have the potential to increase the delivery of
primary care in the United States. The advantages in merging the two operations include the ability to
address customer preferences, to expand clinical services, to achieve efficiencies in managing supplies
and materials, and to create more interprofessional training sites. Challenges to achieving a successful
merged operation include the limitations imposed by scope of practice and other laws, difficulties
with pharmacist reimbursement for clinical services, a possible shortage of family nurse practitioners,
and the development of a practice model that achieves these goals while being financially successful.
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At this point, while the concept of co-located RCs and pharmacies is young, it is recommended to
develop, implement, and assess a model or models based on merged, integrated operations.
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Abstract: There is an imminent need to identify and develop new ambulatory care practice sites
with the increase in the number of colleges of pharmacy across the nation. This manuscript provides
recommendations to help clinical faculty determine whether a potential pharmacy practice site will
be able to provide adequate resources and support to establish a successful practice. This may
be challenging to pharmacy practice faculty in settings where clinical pharmacy services have
never been utilized. Topics include the pre-work needed prior to approaching a new practice site,
assessing the need for physical requirements, meeting key personnel, marketing clinical skills and
services, implementing, and evaluating practice site. Preparation includes having a clear vision of
the pharmacist services, ensuring that stakeholders have an understanding of the pharmacy services
inquiring the site support and resources for the pharmacist, and regularly communicating.
Keywords: ambulatory care; pharmacy practice faculty; pharmacy learners; clinical practice;
pharmacist services
1. Purpose
The Accreditation Council for Pharmacy Education (ACPE) Standards 2016 requires all colleges
of pharmacy across the United States to provide ambulatory care practice experiences to pharmacy
students as a requirement for graduation [1]. With the increase in the number of colleges of pharmacy
across the nation, there is an imminent need to identify and develop new ambulatory care practice
sites [2,3]. This provides unique challenges for pharmacy practice faculty, as well as colleges of
pharmacy, to establish a rewarding clinical practice while also providing opportunities for learners,
including pharmacy students and residents. Additionally, faculty may be working with providers who
may be unfamiliar with the clinical services ambulatory care pharmacists can provide [4]. Since many
of these new programs are being established in areas where ambulatory care clinical pharmacy services
are relatively novel, pharmacy practice faculty often find themselves describing the utility of an
ambulatory care pharmacist.
Previous publications have focused on the establishment of a practice site that will exhibit clear
evidence of outcome improvement and create financial incentives for clinics to thrive and justify
salary requirements [5–10]. Pharmacy practice faculty have a different priority when establishing new
ambulatory care clinic sites. Thus, it is imperative that the pharmacy practice faculty and academic
unit closely evaluate the practice site for suitability towards their purpose. This purpose includes a
collaborative learning environment to foster development of learners and building a practice site in
his or her area of expertise. Literature is lacking for faculty hopeful in establishing a new practice
site that will fulfill their goals and objectives. Based on experience establishing new ambulatory care
practice at sites which have not previously had a pharmacy practice faculty, the authors have identified
various factors to consider in order to create a successful practice model. These experiences include
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creating disease-state specific clinics, initiating interprofessional patient health programs, improving
meaningful use and quality metrics as part of accountable care organizations, and coordinating
activities at multiple clinics within an organization. The authors have also had experience with
establishing practice initiatives that did not thrive to their full potential, allowing for reflection on
the key issues that lead to unsuccessful implementation and identification of strategies to improve
future forays.
Evaluation of the practice site is a multifaceted process and the importance of each section below
needs to be weighed determine if the site will fit the needs of the pharmacist and the college of
pharmacy. As a result, a formulaic approach is unlikely to be successful as each situation will require a
nuanced understanding of various factors. The recommendations below are not in a sequential order
and may need to be adapted to circumstances and preliminary conversations with the practice site.
2. Summary
2.1. Preparation
Prior to a meeting with individuals at the practice site, the first discussion that will occur will
be between the pharmacy practice faculty and the college leadership, such as the dean of the college
of pharmacy, clinical department chair or experiential director. This conversation will be focused on
various responsibilities of the pharmacy practice faculty, related to expectations for both didactic and
experiential teaching, service to the college and the profession, as well as scholarly activities. It’s critical
for the faculty and the college leadership to establish expectations related to how much time will be
devoted to each of the faculty’s roles, and specifically the time devoted to the practice site. Additional
consideration should be given if the faculty position is split funded, with the clinic or health system
providing some salary offset, either directly to the pharmacist or though remuneration to the school.
In these situations, the clinic may have higher expectations regarding how much time the faculty
member should be providing services at the site. Thus, clear delineation of roles and responsibilities is
crucial during initial conversations between the college and the practice site leadership. As successful
implementation of a new practice site may take up to 6–12 months, additional time may be devoted
to the practice site during that period, with limited focus on other faculty responsibilities. The time
commitment of the pharmacy practice faculty to the practice site will need to be discussed again in
collaboration with the clinic leadership to establish clear expectations.
A practice protocol may help pharmacy practice faculty interested in pursuing a new practice
site. The protocol can describe proposed clinical services and how the service may fit patients’ needs,
outlines key components of the practice flow, and includes the goals and the vision for the pharmacy
services. The goals and vision may include conducting comprehensive medication reviews, identifying
and solving complex drug-related problems, ensuring evidence-based and cost-effective therapies,
and educating patients about appropriate medication use. Faculty also need to identify which disease
states they would like to address, the types of collaborative drug therapy management that would be
offered, and the scope of practice desired. Although it’s essential to have a vision for services based
upon the faculty’s practice interest, it’s important to keep in mind that the actual services provided
at the site may be modified based upon a needs assessment of the patients seen at the practice site.
However, the services may be extended after a period of time to also include some of the faculty’s
practice interest.
The description should include information such as hours of operation of the clinical services,
how patients will be referred, what will be accomplished during the appointment with the patient,
how interactions with patients will be documented, changes to therapy communicated to providers,
what follow-up will look like, and how providers will be able to contact the pharmacist. Beyond the
clinical components of practice, faculty also need to consider how the environment will foster teaching
and learning, including opportunities for interprofessional education. Writing these components into
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a practice protocol will help define the pharmacist’s role in patient care, but may need to be revised
after discussions with key clinic personnel.
Faculty should consider gathering some evidence demonstrating that pharmacy services can help
improve patient care in various practice settings as part of the preparation [11–14]. The pharmacist
should also have an updated curriculum vitae (CV) that includes his or her training and experiences
in implementing pharmacy services to help key clinic personnel to gain an understanding of role of
the pharmacist.
Laws regarding the scope of practice and collaborative drug therapy management (CDTM) play
a large role in delineating what is achievable in a new practice. This may be especially important in
areas where ambulatory care clinical pharmacy services have not been fully established and widely
adopted. Enhancing the scope of pharmacy practice may be difficult as it requires buy-in from
several different stakeholders. While there are collaborative practice laws in nearly every American
jurisdiction, the level of practicality written into these regulations varies widely across the nation and
dictates limitations to the practice culture [15]. These laws must be considered in order to develop the
clinical practice site. Consider preparing a collaborative practice agreement (CPA) or modify one that
has been previously created taking state laws into consideration [16]. This may serve useful during
conversations with the medical director to help develop a mutual understanding of the pharmacist’s
scope of practice.
One barrier encountered involves unfamiliarity with the role of the pharmacy practice faculty in
an ambulatory care practice. Resolution of this issue may require education about the pharmacist’s role
in direct patient care prior to discussions regarding the model of practice at the clinic. It’s important
to emphasize that the pharmacist’s role is to augment the productivity of the clinic and optimize
patient outcomes in collaboration with other healthcare providers (HCPs) and does not replace the
other providers’ patient encounters [3,4]. The Pharmacist Patient Care Process model (PPCP) has been
created to assist with succinctly explaining the role of a pharmacist in patient care, and may prove
useful for discussions with providers and other clinic staff [17].
Other issues that may arise and limit the full implementation of the original practice vision may be
the patient population, reimbursement constraints, or access to health resources. Careful consideration
of potential barriers must be taken and the original practice protocol revised as necessary to create a
plan that can be implemented within the required boundaries.
2.2. Physical Requirements
Consideration of physical requirements including space, access, and equipment are important to
successfully establish pharmacy services. The discussion regarding these essentials will likely need to
occur in collaboration with college and clinic leadership as the finances related to any physical space
modifications, electronic health record (EHR) access, supplies and equipment for the faculty as well as
the students will need to be delineated.
2.2.1. Space
Many clinic managers may be unfamiliar with the role of an ambulatory care pharmacist or
have little insight as to the physical space and access requirements that a pharmacy practice faculty
might need. Request adequate space for the number of patients that will be seen and the number of
learners who will be on rotation at one time. There will be a need for an exam room or private space if
direct patient care is offered. In the authors’ experiences, two exam rooms are optimal if patients are
scheduled back-to-back (every 30 or 45 min), as this allows for the rooming of one patient while the
pharmacist is seeing another patient, improving efficiency.
Another key consideration for a successful practice is office space. Consideration regarding where
documentation of encounters will be completed and where learners will look up information and
prepare to interview patients is important. Determine the need for desks, chairs, work terminals,
and storage space for educational materials. Having a dedicated workstation for the pharmacist and
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one workstation per learner is optimal. The pharmacist should also consider the space needed to have
discussions with learners about work related to patient care or other assignments required for the
rotation. Having access to a conference room, if available, provides adequate space to better facilitate
topic discussions, and journal article presentations.
2.2.2. Access and Equipment
Electronic health record (EHR) access is key to any successful ambulatory care practice, and is
becoming more prevalent even in community [18,19]. The clinic site must ensure that, as a HCP,
the pharmacist will have access to the full medical record, as well as the ability to document in the
EHR. The ability to modify medication orders will vary between locations based on local collaborative
practice laws and practice culture. The pharmacist should advocate to practice at the top of his or
her license and promote themselves as an integral part of the healthcare team. It may be appropriate
for the pharmacist to initially attain limited authority to establish rapport with the providers until
providers are comfortable with the pharmacist’s clinical decision making.
The pharmacist should consider the resources that are available for scheduling and seeing patients
in addition to EHR access and permissions. Considerations may include equipment needed for practice.
These resources can include a blood pressure machine or point of care testing devices, availability of a
medical assistant to help with scheduling and taking vitals for patients, and a phone for contacting
and following-up with patients.
2.3. Meeting Key Personnel
2.3.1. Finding a Niche
One of the first meetings that will likely occur is with the medical director and the manager of the
clinic to assess their interest in clinical pharmacy services. The medical director will be an essential
partner to advocate for the clinical pharmacy services to other providers as they oversee all the HCPs
at the site. The clinic manager will be a key asset during day-to-day operations as the pharmacist is
learning to practice in a new environment. Other key personnel, such as a compliance officer, other
medical leaders, human resources, or chief financial officer, may also be present during one of the first
meetings to provide additional perspectives.
Pharmacy practice faculty must inquire about the patient population seen at the clinic and the
needs of the patients from the medical director and clinic manager. Knowing basic information such as
patient age, literacy, ethnicity, and socioeconomic status will help to tailor services to meet patients’
needs. Ask the medical director about any current needs of the clinic or any gaps in care that the
providers are hoping to improve. Identifying these will aid in matching the skill-set of the pharmacist
with the needs of the site, creating a symbiotic relationship.
Faculty should provide a draft of the practice protocol for overview, which details a description of
proposed clinical services and outlines key components of the flow of the practice. This will allow the
medical director and the clinic manager to have a sound understanding of the day-to-day operations
and how the patients will benefit from the pharmacist consultations. Some processes will likely change
depending on the needs assessed during the discussion as well as the limitations of the clinic.
2.3.2. Marketing Your Skills and Services to the Medical Director and Clinic Manager
The pharmacist should describe the importance of the program, and the vision of progression of
services, including both short and long-term goals during the meeting. Goals could include expanding
the scope of the disease states managed, initiating group patient education classes, or regularly
planning a short presentation with providers at the clinic for continuing education. General goals of
the service should include delivery of comprehensive, integrated, and patient-centered care to improve
patient health and reduce costs. As the climate regarding medical service reimbursement shifts from
fee-for-service towards improving quality metrics, the efforts of the pharmacist can be focused to ensure
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that compensation is maximized. Within certain value-based reimbursement initiatives, achieving
population health goals, such as a certain percentage of cardiovascular disease (CVD) patients receiving
an appropriately dosed statin, can increase the rate of reimbursement to the clinic. Myriad examples
of pharmacist-led initiatives in quality improvement exist, and it is recommended that the faculty
member become familiar with current quality-based reimbursement models prior to meeting with
the medical director and clinic manager [11,13,14]. In the authors’ experience, improving just a few
quality measures for the clinic often opens doors to a broader practice scope as the clinic management
observes the positive impact the pharmacist has on patient care.
The faculty can consider discussing how pharmacists can help improve care by reducing
medication errors, decreasing number of medications by discontinuing inappropriate medications,
optimizing therapy to meet therapeutic goals, improving patient outcomes, improving patient
satisfaction, increasing medication adherence, enhancing patient understanding, reducing patient and
health-system costs, and decreasing hospitalizations [20–28]. The authors have found the Ambulatory
Care Pharmacist’s Survival guide to be a useful resource which highlights successful pharmacy
practice initiatives, along with networking through national organizations, including the American
Association of Colleges of Pharmacy (AACP), the American College of Clinical Pharmacy (ACCP),
and the American Society of Health-Systems Pharmacists (ASHP) [6]. These organizations, and others
like them, hold national and international meetings in which presenters highlight their practice
initiatives and provide a platform for networking and establishing mentoring relationships with
other practice faculty. Seeking out these mentoring relationships is recommended and can provide an
excellent resource for academic pharmacists establishing ambulatory care practice sites.
2.3.3. Other Points of Discussion
Billing for pharmacy services may not be a requirement as a pharmacy practice faculty. However,
inquiring about the billing structure may be important to consider if the site is amenable to billing
patients for pharmacist services. Clinics participating in a split-funded faculty position may have
a greater stake in ensuring revenue is generated from the pharmacy services. This revenue can aid
the clinic in recuperating some of the cost of the pharmacist’s salary, or can be used to provide more
resources for the pharmacist to improve patient care. Although a discussion regarding billing practices
are beyond the scope of this manuscript, many resources are available to practicing pharmacists
regarding billing for clinical services [9,29–31]. Knowing the most common types of insurances that
will be encountered at the site will also help to determine what medications are normally covered by
insurance versus those that are unlikely to be covered.
The pharmacist should discuss the implementation of a collaborative practice agreement (CPA) in
an effort to gain autonomy in decision making. As most providers may not be familiar with a CPA,
providing a copy of one that was developed by the pharmacist or a sample copy that is available
through resources may be helpful [6,7,20]. A collaborative practice may have a narrow or broad scope
which will depend on state laws, as well as the comfort level of providers to allow a pharmacist to make
clinical decisions regarding patient care. Discussion should focus on the benefits of a collaborative
practice agreement [32–35]. In the authors’ experiences, this includes easing care burden of providers,
avoiding provider workflow interruptions to inquire about a patient, and improving the timeliness of
patient care.
2.3.4. Keeping Faculty Responsibilities in Mind
A pharmacy practice faculty is likely required to precept pharmacy students and perhaps residents
at the practice site; thus, it is important to discuss this role with the medical director and clinic manager.
Explain that the learners, especially pharmacy residents, will operate as an extension of the pharmacist
and will be able to closely monitor patients seen at the clinic under supervision. Learners can help
coordinate in-services for providers, as well as complete projects that will improve care for patients
and help to improve clinic functions [36,37]. Assess the clinic for opportunities where learners would
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be able to learn about, from, and with other healthcare professional learners [38]. Discuss how
interprofessional education can allow for effective collaboration and allow all those involved to have
a better understanding of their respective roles and responsibilities, develop a mutual respect for
interprofessional practice, improve communication, and function more cohesively as a team to improve
patient care. This has been identified as an essential component in maintaining ACPE accreditation
and improving patient care [1,39].
An additional pharmacy practice faculty responsibility will likely be an expectation of research
in an area of expertise. Clinical practice aligns with clinical research and provides an environment
where new ideas may develop based upon scenarios in patient care. Inquire about the feasibility of
research at the practice site, including the ability to collect patient information, availability of resources
to help with data collection, the internal or external institutional review board (IRB) requirements at
the site. Identifying opportunities early will help the pharmacist initiate research endeavors and plan
for known obstacles.
2.4. Implementation
2.4.1. Recommendations for Starting Out
The pharmacist should request to attend provider meetings prior to starting services at the site
even though he or he will have met with the medical director and the clinic manager. The pharmacist
should provide an introduction, his or her integration and role within the healthcare team, and the
services that can be provided. Additionally, determining areas where the HCPs feel that a pharmacist
can provide value to the patients may help the HCPs buy into the new services, as it may directly help
the patients.
The pharmacist should also consider attending staff meetings temporarily as they are getting
started to become acquainted with the staff and help them understand the role of the pharmacist.
Speaking with the staff may provide insight of the current systems and processes in place, and can
also identify barriers and opportunities where the pharmacist might be able to help.
2.4.2. Evaluation
The pharmacist should regularly evaluate the success of current methods in achieving short
and long-terms goals once clinical services have been established. Ask for feedback from either the
medical director or HCPs at the site to determine if any changes need to be made to improve the
integration of pharmacy services into the clinical workflow. Prior to starting services, it is important
to identify some metrics which will define success for the ambulatory care pharmacist. These could
include decrease in A1c, or blood pressure. Identify key personnel, such as an individual in the field of
pharmacy informatics or information technology, who may be able to help navigate tracking data and
designing reports with the desired outcomes. Learners can be helpful with tracking the clinical impact
and sorting through data, which may be especially important for pharmacy practice faculty in their
evaluations to achieve promotion and tenure. Showing the number of interventions the pharmacist
and learners have made, care improvements that have occurred, and even estimating cost savings
are all excellent ways to show that the contributions at the clinic are leading to positive outcomes
for patients. This data can also be used for formalized research projects to be synergistic with the
pharmacy practice faculty’s goals and aspirations towards promotion.
3. Conclusions
Implementing a new clinical service at an ambulatory care site as a pharmacy practice faculty
may be overwhelming but can also be exciting. Being aware of the appropriate information to gather
prior to committing to a practice site is crucial in creating a valuable learning site. The pharmacist
should ensure that an overview of the services that will be offered to the patients at the clinic has
been provided, and inquire regarding the support and resources that can be expected from the site.
94
Pharmacy 2018, 6, 111
Open communication can increase the likelihood of success at the practice site and provide a great
opportunity to showcase the importance of interprofessional practice in ambulatory care clinics without
previous pharmacist services. Successful implementation will be essential to the education of our
future pharmacists.
Key Considerations
• Have a clear vision of the pharmacist services at the practice site
• Be prepared prior to discussions with the medical director, other healthcare providers, and clinic
manager, and anticipate questions that may arise
• Ensure that the key stakeholders have a clear understanding of the services that the pharmacist will
provide to the patients at the clinic, and inquire regarding the support and resources that the pharmacist
can expect from the site
• Prior to committing to a practice site, gather information regarding the feasibility of a successful clinic
and seek mutually beneficial goals that will provide benefit and value to pharmacy students and
residents, providers, patients, and to the pharmacy practice faculty
• Regular communication with the providers and staff will help identify barriers and help set up a thriving
clinical practice site
• Recognize that establishing a new practice is a difficult process, and it may take a considerable amount of
time for the pharmacist to become fully integrated into the clinic
• Determine needs versus wants and be prepared to negotiate to establish a successful
learning environment
• Be flexible, but if a site is unable to accommodate basic needs to set up a successful practice,
consider moving on to identify other sites
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Abstract: Adherence to renin angiotensin system antagonists (RASA), non-insulin diabetes
medications (NIDM) and statins has been included in the Medicare Star Ratings program since
2012. The long-term use of these measures emphasizes adherence to a limited number of chronic
medications and may present opportunities for Part D plan sponsors to misuse the measures to
influence their Medicare Part D Star Rating. It also does not capture the adherence needs of high-risk
patients with multiple chronic conditions. The objective of this study was to describe the development
of a new measure to capture adherence to multiple medications for chronic conditions (MMCC).
The MMCC measure captures adherence to 71 different therapeutic categories of medication and was
constructed using North Carolina Medicaid prescription claims data from 2015 to 2017. This measure
was validated against the existing RASA, NIDM and statin adherence measures. This new measure
was highly correlated with Star Rating measures, captured a greater number of eligible patients than
these existing measures and had a lower proportion of patients meet the adherence threshold than
the existing Star Ratings adherence measures. There is an opportunity to develop new measures,
which include adherence to multiple medications in populations with multiple chronic conditions.
Keywords: medication adherence; quality measurement/benchmarking; multiple chronic conditions;
CMS Star rating
1. Introduction
1.1. Medication Adherence and Multiple Chronic Conditions
Multiple chronic conditions (MCC), defined as the presence of two or more concurrent chronic
conditions, presents a significant burden to the U.S. health care system. It is estimated that 50% of
older adults have three or more concurrent chronic medical conditions [1]. The burden of MCC is felt
by the health care system through increased health service utilization and expenditures. It is estimated
that 66% of total U.S. health care spending is directly attributable to a disproportionally small number
of approximately 27% of American’s with MCC [2]. This burden is felt not only by the health care
system, but also by patients through higher morbidity and mortality as well as reductions in patient
reported quality of life [3] (p. 15).
The primary treatment modality for most chronic conditions comes in the form of prescription
medication treatments. It is estimated that 60% of elderly patients are prescribed with three or more
medications [4]. In reports from the U.S. Centers for Disease Control and Prevention (CDC), some 37%
of older Americans are reported to use five or more prescription medications concurrently with this
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prevalence doubling since 1999 [5]. As the number of medications used by a patient to manage chronic
conditions increases, so too does the risk of inappropriate medication use and adverse drug events [6,7].
Ensuring medications are used appropriately is imperative to reducing the burden of MCC.
However, estimates of non-adherence to medications are reported to be as high as 50% for many
chronic conditions [8,9]. Medication non-adherence is responsible for an estimated 33–69% of
medication-related hospitalizations [10] and may result in an additional $300 billion in direct health
care spending in the U.S annually [11]. Further evidence provided by the CDC suggests medication
non-adherence is tied to approximately 50% of treatment failures in chronically ill patients and
corresponds to approximately 125,000 deaths per year [12].
1.2. Adherence and Star Ratings
Given the importance of medication adherence to the quality of care provided to patients,
a number of initiatives have been taken to improve rates of adherence to medications for chronic
medical conditions. One initiative adopted by the Centers for Medicaid and Medicare Services (CMS) is
to tie health plan payments and performance ratings to their population’s medication adherence rates
for a select number of chronic health conditions using the CMS Star Ratings program. Beginning in 2007,
the Star Ratings program was implemented as a means for CMS and Medicare beneficiaries to assess
and compare plans on their performance with a broad array of measures associated with the quality of
care provided to patients. For standalone prescription drug plans (PDPs), these performance metrics
provide a benchmark for patients to select health plans on the basis of the quality of care provided. For
Medicare Advantage plans offering health and prescription drug benefits, these performance metrics
have additional importance and have been tied to per member per month (PMPM) quality bonus
payment rates since 2012 [13].
The metrics used to measure plan performance change from year to year with the 2018 Medicare
Star Ratings including 48 different quality and performance measures, of which 14 involve ratings
of prescription drug plan indicators [14]. Three of the 14 prescription drug plan indicators in the
Star Ratings program measure medication adherence using a prescription claims-based measure of
adherence termed the proportion of days covered (PDC). Under the Star Ratings program, patients are
considered adherent to treatment if they have a PDC of 80% or higher and fill two or more prescriptions
in a year for any of the following three chronic medication therapeutic categories: Renin angiotensin
receptor antagonists (RASA) for hypertension, non-insulin diabetes medications (NIDM) and/or statin
medications for hyperlipidemia. Each of these three medication adherence ratings is triple weighted in
the Star Ratings program demonstrating their importance to achieving a summary Star Rating for the
health plan, which can range anywhere from one to five Stars per plan year [15].
Although different metrics under the Star Ratings program churn over time, the three medication
adherence measures used to evaluate plan performance have been in place in one form or another
since 2012 [16]. The consistency of these measures in the Star Ratings program, as well as the heavy
weights placed on these outcomes, leads to a heavy emphasis by health plans in achieving adherence
targets. As a result, the trend in adherence to these medication therapeutic categories has increased
significantly over time. From 2017 to 2019, an MAPD plan receiving five Star status for NIDM, RASA
and statin medications saw an increase from 83% to 85%, 83% to 88% and 82% to 87% respectively [17].
Over the same time-period, a four star MAPD plan’s targets increased for these same medication
categories from 79% to 81%, 79% to 86% and 77% to 83% respectively.
1.3. Limitations of Star Ratings Adherence Measures
Improvements in medication adherence rates reported through the Medicare Star Ratings program
are encouraging, but also raise a number of important questions. The trend in rates of adherence now
exceeds what is commonly accepted as the true rate of medication adherence in the clinical literature.
A recent study of more than 200,000 diabetic patients showed that only 69% or oral diabetes medication
users are 80% or more adherent to their medication when measured using the medication possession
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ratio (MPR), which is a more liberal measure of adherence than the Star Ratings’ PDC. [18]; another
recent study, which including 238,372 patients using different oral anti-diabetes medications, suggested
that 47.3%, 41.2% and 36.7% of patients were adherent to DPP4 inhibitors, sulfonylurea medications
and thiazolidinedione therapies respectively when measured as a PDC of 80% or higher during a one
year follow up period [19]. Similar findings are present when looking at other medication classes.
Even in a large population of high-risk Medicare beneficiaries with a previous myocardial infarction
(MI), the rate of adherence to statin medications as measured by a PDC of 80% or higher one year
after their MI was only 59% at six months and 42% at two years in patients 66 to 75 years of age [20].
Combined, our review of the clinical literature suggest that the true rate of medication adherence to
therapeutic classes included in the Star Ratings program is lower than that reported by CMS.
The discrepancy in Star Ratings-reported adherence rates and the rates commonly found in the
clinical literature raise a number of important questions. The first question relates to the validity of
the PDC as a measure of adherence when applied to performance-based value incentive models for
payment. It is important to remember that the PDC measure does not measure actual consumption
of medication by patients, but instead measures patterns of refills using prescription claims data.
In essence, gaps between an actual fill date and an expected fill date, which is based on days supply
from a prior fill, are counted as “uncovered” days in the PDC measurement. These gaps in coverage are
compared to the length of time a person is observed to account for the proportion of days covered on
treatment. Although the PDC has been validated against other commonly used measures of medication
adherence such as patient self-report and medication electronic monitoring systems (MEMS) [21,22],
they do not measure actual consumption of medication by patients and are imperfect metrics of
actual adherence.
In addition, claims based adherence metrics may be subject to gaming by health plans attempting to
improve Star Ratings and quality bonus payments. The use of automatic refill programs is one example
of an early strategy employed by health plans to potentially gain higher PDC rates. Sending a refill to
patients without their need to authorize the next fill reduces the risk that a patient will not fill their next
medication from the pharmacy, but does not actually ensure in any way that once a patient receives their
medication they will continue to use it. To reduce waste associated with shipping unneeded medication
to patients, CMS implemented policies limiting this practice in 2013 [23,24] (p. 133).
The use of mail order programs and 90-day fills are other potential strategies to improve PDC
rates even if not directly associated with improvements in patient medication consumption. Since the
PDC relies on the need to identify gaps between fills to identify periods of non-adherence, reducing
the number of potential gaps over a measurement period may artificially inflate PDC rates [25]. Over
a 12-month period, the number of potential gaps is three with 90-day fills compared to eleven with
30-day fills. The use of 90 day fills, which are common in mail order programs, may result in artificial
improvements in adherence that are not reflective of actual improvements in medication consumption
patterns by patients.
Even if one assumes the PDC rates reported in the Star Ratings program reflects a valid rate of
medication adherence in patients, the very high rates of adherence reported by health plans still raise
concerns. First, the consistent use of the same measures over time means that health plans adopting
programs to improve medication use in Medicare are focusing clinical efforts on a limited number
of chronic conditions. As previously mentioned, it is estimated that 50% of older adults have three
or more concurrent chronic conditions at any given time [1]. Focusing on a select number of these
conditions does not address the entire scope of medical conditions a patient may have and may resulted
in siloed clinical offerings by health plans in an attempt to improve plan ratings. In addition, the rates of
adherence in four and five Star Plans are approaching the ceiling of the PDC measurement, which caps
at 100%. This reduces the ability to differentiate high performing plans from low performing plans.
Given the potential limitations of the current medication adherence measures in the CMS Star
Ratings program, opportunities to develop and validate new measures of medication adherence may
be useful. The objective of this study is to describe the development of a measure of medication
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adherence for patients using multiple medications for chronic conditions. This measure was developed
to incentivize payment to community pharmacies to improve medication adherence for a broad range
of chronic conditions through the development and delivery of enhanced pharmacy services [26,27].
2. Materials and Methods
2.1. Setting
The development of a new measure designed to capture adherence to multiple medications for
chronic conditions (MMCC) was used to support payment incentives under an alternative payment
model (APM) in a network of community pharmacies providing enhanced services to Medicaid
recipients in North Carolina. This program was supported by a CMS Innovations Award provided
to Community Care of North Carolina, which serves as the primary care-based medical home for
the state’s Medicaid population. The specific aspects of this APM are described elsewhere [28].
In brief, the APM model included four different medication adherence metrics (RASA, NIDM, statin
and MMCC) as well as three health service utilization measures (emergency department utilization,
inpatient hospital visits and total cost of care) to measure the performance of each pharmacy relative
to their peers. The MMCC measure described herein is one of the four adherence measures used to
incentivize pharmacy performance.
2.2. Data
We constructed our measure of MMCC using North Carolina Medicaid prescription claims data
from 2015 through 2017. As part of the APM, the measure was constructed on a quarterly basis
with a rolling 12-month look back period to facilitate payment. Additional Medicaid claims data for
outpatient and inpatient services as well as beneficiary enrollment data were also used to attribute
patients to the network and facilitate payment. This study was not considered as human subjects
research and was exempted from Institutional Review Board approval.
2.3. Sample
To be considered for inclusion into the MMCC measure, patients must first meet attribution
criteria to the APM. Eligibility criteria included continuous Medicaid program enrollment for the entire
calendar year (2015, 2016 or 2017). We further required that patients not be dually enrolled into the
Medicare program to ensure we were able to fully capture all prescription drug claims. Finally, we
limited the analysis to patients 18–64 years of age.
2.4. Medication Adherence Measurement
We used a list of 71 different therapeutic categories constructed by CCNC to identify therapeutic
categories for inclusion in the MMCC measure. These categories were constructed by CCNC to
identify high-risk chronic conditions effecting the Medicaid population. As seen in Table 1, the chronic
conditions included in our measure spanned a wide variety of different therapeutic areas including
chronic infectious conditions (e.g., hepatitis and HIV), diabetes, hypertension, additional cardiovascular
conditions (e.g., diuretics, angina, anticoagulation), mental health conditions (depression, schizophrenia,
bipolar disorder), osteoporosis, seizures and a number of other chronic conditions. This measure
is much more inclusive of overall types of conditions patients might present with than the three
Star Ratings adherence measures currently in use. Given that this list was constructed for purposes
other than simply the construction of the MMCC adherence measure and applies specifically to a
Medicaid population, which may require care management services, this study represents primarily a
proof-of-concept exercise.
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Table 1. Therapeutic categories included in initial multiple medications for chronic conditions (MMCC)
adherence measurement.
Indication Therapeutic Categories
Asthma Anti-IgE Monoclonal Antibodies, Inhaled Corticosteroids, Leukotriene Modulators
Diabetes Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas,Thiazolidinediones
Hepatitis B Hepatitis B agents
Hepatitis C Inceivek, Interferon, Simeprevir, Ribavarin, Sofosbuvir, Boceprevir
HIV
Antiretrovirals (Entry inhibitors, integrase inhibitors, protease inhibitors, ritonavir) Antiretroviral
Reverse Transcriptase Inhibitors (RTI) Non-nucleoside analogues, Antiretroviral RTI Nucleoside
analogues (purine, pyrimidines, thymidines) Antiretroviral Nucleotide Analogues, Antiretroviral CMV
agents, Cobicistat, Antiretroviral combination products
Hyperlipidemia Antihyperlipidemics, Antihyperlipidemics-Bile Acid Sequestrants
Cardiovascular conditions Antiadrenergic agents, Antianginal agents (non-nitrates), Antiarrhythmics, Antiplatelets
Hypertension ACE Inhibitor, Alpha-beta blockers, Angiotensin II receptor antagonists, Beta-blockers, Calcium channelblockers, Renin inhibitors, Selective aldosterone receptor antagonists
Diuresis Thiazide diuretics, Potassium sparing diuretics, Loop diuretics
ADHD ADHD stimulants, ADHD miscellaneous
Dementia Acetylcholinesterase inhibitors, NMDA receptor antagonists
Antidepressants
Alpha-2 Receptor Antagonists, Antidepressants-Combo, Antidepressants-Modified Cyclics,
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs),
Selective Serotonin Reuptake Inhibitors (SSRIs)
Other Mental Health Antipsychotics-Second Generation, Antipsychotic-First Generation, Antimanic Agents,Antiparkinson Agents
Seizures Anticonvulsants misc.
Osteoporosis Bone density Regulators-Bisphosphonates and Calcitonins, Bone density Regulators-ParathyroidHormone, Vitamin D, Selective Estrogen Receptor Modulators
Contraception Contraceptives misc.
Digestive Aids Digestive enzymes misc.
Gout Gout agents misc.
Thyroid Disorder Hyperparathyroid Treatment-Vitamin D Analogs, Hypothyroid agents
Prostatic hypertrophy Prostatic Hypertrophy Agents
Peptic ulcer Peptic ulcer agents misc.
We measured adherence using PDC. A specific PDC was calculated for each of the 71 therapeutic
categories of medications and followed the Star Ratings technical specifications. Hospitalized days
were accounted for by crediting the patient for a medication believed to be given in the hospital if
the patient was covered by the medication on the day they were admitted [29]. To be eligible for the
MMCC measure, patients were required to use four or more of the 71 chronic therapeutic categories of
medication from Table 1 over the 12 month calendar year period. In addition to the MMCC measure,
we also constructed annual medication adherence rates for the three Star Ratings adherence measures
(RASA, NIDM and statins) to evaluate correlations between the new measure and these established
metrics. Patients were deemed adherent to the Star Ratings measures if their PDC was 80% or higher.
To be considered adherent to the MMCC measure, we required patients to have a PDC of 80% or
higher for at least 75% of the therapeutic categories used. For example, a patient using four specific
therapeutic categories would be deemed adherent if they had a PDC of 80% or higher for at least three
of the four therapeutic categories.
2.5. Criterion Validity Testing
We examined the potential criterion validity of the newly developed MMCC measure by correlating
the measure with the three existing Star Ratings measures, which have gone through prior validation.
This validity testing process assumes that adherence to Star Rating adherence measures and the MMCC
measure are positively correlated. Given that the MMCC measure is constructed within each year
(2015, 2016 and 2017) we first correlated the MMCC measure with each of the three Star Ratings
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measures using chi-square testing within the year of analysis. The chi-square comparison examines
whether or not patients who were adherent to the MMCC measure (>75% of chronic medications
used had a PDC ≥ 80%) were also categorized as adherent to the Star Ratings measure of interest
(PDC ≥ 80%) Next, we assessed the correlation between MMCC and Star Ratings measures by running
generalized estimating equations (GEE) models, which controlled for repeated observations for patients
contributing adherence information across more than one single year of data to control for within
subject variation. The GEE model specifies a binomial distribution with a log link. Data are converted
to odds-ratios and are presented with corresponding 95% confidence intervals. All statistical analyses
were deemed significant at α = 0.05 and the analyses were run in SAS Version 9.4 (Cary, North Carolina,
USA).
3. Results
Across the three-year period, more than 40,000 patients per year were eligible for the MMCC
measure (Table 2). The number of patients eligible for the MMCC measure exceeded the approximate
10,000 patients a year eligible for the NIDM measure and more than 20,000 patients eligible per year
for RASA and statin measures. The mean number of MMCC-eligible therapeutic categories was six
with a range from four to 22. In 2017, the percent of patients eligible for adherence measures for NIDM,
RASA and Statin medications that were adherent to treatment as defined by a PDC ≥ 80% (51.3%,
44.0% and 51.2%) was higher than the percent of patients adherent to the MMCC measure (34.6%).
This trend was consistent across all years.
Table 2. Descriptive statistics of adherence measurement for full sample and MMCC 1 eligible patients.
2015 2016 2017
Full Sample Eligible Population N = 93,857 N = 96,824 N = 83,711
Eligible for NIDM 2
Adherence Measure
9681 (10.3%) 10,669 (11.0%) 9394 (11.2%)
Eligible for RASA 3
Adherence Measure
27,495 (29.3%) 28,853 (29.8%) 23,244 (27.8%)
Eligible for Statin Adherence Measure 23,201 (24.7%) 25,044 (25.9%) 21,565 (25.8%)
Adherent (≥ 80% PDC) NIDM Users 5101 (52.7%) 5988 (56.0%) 4821 (51.3%)
Adherent (≥ 80% PDC) RASA Users 15,030 (54.7%) 15,844 (54.9%) 10,242 (44.0%)
Adherent (≥ 80% PDC) Statin Users 12,996 (56.0%) 13,573 (54.2%) 11,030 (51.2%)
MMCC 1 Eligible Population N = 43,712 N = 46,813 N = 40,001
Therapeutic Categories
Defining Eligibility
4 therapeutic categories 12,021 (27.5%) 12,520 (26.7%) 11,197 (28.0%)
5 therapeutic categories 9564 (21.9%) 10,194 (21.8%) 8899 (22.3%)
6 therapeutic categories 7192 (16.5%) 7747 (16.6%) 6680 (16/7%)
7 therapeutic categories 5353 (12.3%) 5849 (12.5%) 4787 (12.0%)
8 or more therapeutic categories 9582 (21.9%) 10,503 (22.4%) 8438 (21.1%)
Mean Count of Therapeutic
Categories (SD) 6.1 (2.1) 6.1 (2.2) 6.1 (2.1)
Range of Therapeutic Categories (4,21) (4,22) (4,21)
Also Eligible for Star Rating
Adherence Measure 29,032 (66.4%) 31,343 (67.0%) 26,487 (66.2%)
Also Eligible for NIDM 2
Adherence Measure
8068 (18.5%) 8912 (19.0%) 7754 (19.4%)
Also Eligible for RASA 3
Adherence Measure
20,371 (46.6%) 21,651 (46.3%) 17,464 (43.7%)
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Table 2. Cont.
2015 2016 2017
Also Eligible for Statin
Adherence Measure 19,460 (44.5%) 21,154 (45.2%) 18,063 (45.2%)
Adherent MMCC Users 4 15,114 (34.6%) 15,133 (32.3%) 11,679 (29.2%)
MMCC Users Adherent to NIDM 2
(≥ 80% PDC) 4525 (56.1%) 5287 (59.3%) 4229 (54.9%)
MMCC Users Adherent to RASA 3
(≥ 80% PDC) 11,679 (57.3%) 12,387 (57.2%) 7998 (46.0%)
MMCC Users Adherent to Statin
(≥ 80% PDC) 11,190 (57.5%) 11,722 (55.4%) 9515 (52.7%)
1 MMCC = Multiple Medications for Chronic Conditions; 2 NIDM = Non-Insulin Diabetes Medications;
3 RASA = Renin Angiotensin System Antagonists; 4 MMCC Adherence Rate is defined as ≥ 75% of medications
with ≥ 80% PDC.
Although unique from existing adherence measures, the three categories of medication that deem
a patient eligible for inclusion into the Star Ratings program (RASA, NIDM and statins) were also
common in patients eligible for the MMCC measure. Within each year, more than 66% of patients
eligible for the MMCC measure were also eligible for inclusion into one or more of the Star Ratings
adherence measurements. In 2017, 19.4%, 43.7% and 45.2% of patients eligible for MMCC measurement
were also eligible for measurement of NIDM RASA, and statin medication adherence measures in the
Star Ratings program respectively.
We hypothesized that among patients attributed to the MMCC measure who were also eligible for
any of the three Star Ratings measures, adherence to the previously validated Star Ratings adherence
measure would correlate with adherence to the new MMCC measure. Table 3 presents bivariate
chi-square comparisons between each Star Ratings adherence measure and the MMCC measure.
Overall, this correlation shows that among patients adherent to MMCC there is a higher likelihood of
adherence to the three Star Ratings measures and similarly, among non-adherent MMCC patients there
is a higher likelihood of non-adherence to Star Ratings measures. If a patient is not adherent to a Star
Ratings PDC measure, they are unlikely to be adherent to the MMCC measure. For example, in 2017,
only 6.9% of non-adherent NIDA users, 7.5% of non-adherent RASA users and 6.2% of non-adherent
statin users were considered adherent for the MMCC measure. However, there were a significant
number of patients deemed adherent to the Star ratings measures, which were not deemed adherent
to the MMCC measure for each of the Star Ratings measures across each year. To illustrate, 50.7% of
adherent NIDA users, 48.8% of adherent RASA users and 44.5% of adherent statin users were deemed
not adherent to MMCC respectively in 2017.
Accounting for multiple observations across the three years, we further exaimine the relationship
between adherence to the three existing Star Ratings measures and the probability of adherence to
MMCC using GEE. Table 3 describes the odds-ratios and corresponding confidence intervals resulting
from those tests. The odds ratio associated with MMCC adherence in adherent NIDA (Odds Ratio
(OR) = 13.64: 95% CI: 12.6, 14.8), RASA (OR = 16.69: 95% CI: 15.8, 17.6) and Statin (OR = 21.32: 95% CI:
20.2, 22.6) users suggests a very strong correlation between the measures.
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4. Discussion
Given the limitations associated with the three existing Star Ratings measures, we explored the
implementation of a new MMCC measure of medication adherence. This measure captures more of
the overall adherence needs of a patient by considering adherence to 71 different therapeutic categories
of medication. This new measure has less opportunity for potential gaming by health plans, which
are currently only required to emphasize adherence for a limited number of health conditions. As a
more patient centered measure of medication adherence, the MMCC measure emphasizes more than a
single chronic condition and is more reflective of the overall health needs of a patient. In addition,
the focus on patients with multiple chronic conditions with the MMCC targets a high-risk population
of patients with MCC who have higher than average health expenditures. Emphasizing adherence
in this population is likely to pay greater dividends to actual health improvement than emphasizing
adherence in patients with a single condition, some of which may be otherwise healthy.
The MMCC measures included more patients than any of the Star Ratings measures individually,
and more than the total number across all Star Ratings measures combined. Additionally, there were
many patients who were included in the traditional PDC measures who were not included in the
MMCC measure. This suggests that the MMCC measure may target a different population than the
traditional measures, and, because of larger denominators, be a more statistically reliable measure of
medication adherence. Furthermore, the proportion of patients who met the adherence threshold for
MMCC measure was substantially lower than the proportion of patients categorized as adherent to the
traditional adherence measure. If confirmed in a Medicare population, this measure would solve some
of the ceiling problems, which have been observed for four and five star plans.
To examine the criterion validity of this measure to previously validated adherence measurements,
we correlated the MMCC measure with these three Star Ratings measures and found a very high
correlation between them. However, we also found evidence that the criteria, which defined adherence
to this new MMCC measure was more difficult to meet than the current criteria for NIDA, RASA or
statin medication adherence. This suggests that the new measure may have less ceiling effect and
provide better discriminative ability.
The results of this study should be interpreted in light of a number of important limitations.
In many ways, this study represents a proof of concept investigation into the possibility of using
an MMCC measure to capture medication adherence more broadly than that observed with limited
therapeutic categories for single conditions. The therapeutic categories included in the measure were
selected to support the needs of the state Medicaid program. This led to the inclusion of therapeutic
categories that represent high-risk populations (e.g., HIV and Hepatitis) that might not represent the
needs of commercially insured or Medicare plans to the same extent. For this measure to be accepted
more broadly as a measure of plan performance, it is important to obtain the perspective of clinicians,
patients and plans in the process of identifying which drug classes to include in an eventual MMCC
measure. It should also undergo a formal validation process required of any new measure prior to
implementation [30,31]. Finally, the proof of criterion validity in this study included the three Star
Ratings measures, which we identified as having significant limitations in this article.
5. Conclusions
Given existing concerns associated with the use of medication adherence measures for limited
therapeutic categories as part of the Star Ratings program in Medicare, opportunities for the
development of new adherence performance measures exist. This proof of concept study shows
the potential benefits associated with the development of a performance metric designed to capture
adherence in patients with multiple chronic conditions. This measure correlated well with other
validated adherence measures. Opportunities to develop and implement new quality metrics of
medication adherence such as the MMCC should be explored.
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Abstract: The high costs associated with pharmaceuticals and the accompanying stakeholders are
being closely evaluated in the search for solutions. As a major stakeholder in the U.S. pharmaceutical
market, the practices of pharmacy benefit manager (PBM) organizations have been under increased
scrutiny. Examples of controversial practices have included incentives driving formulary status
and prohibiting pharmacists from disclosing information on lower-cost prescription alternatives.
Ethical investigations have been largely omitted within the debate on the responsibilities of these
organizations in the health care system. Ethical analysis of organizational practices is justified based
on the potential impact during health care delivery. The objective of this study was to analyze
several specific PBM practices using multiple ethical decision-making models to determine their
ethical nature. This study systematically applied multiple ethical decision-making models and
codes of ethics to a variety of practices associated with PBM-related dilemmas encountered in the
pharmaceutical environment. The assessed scenarios resulted in mixed outcomes. PBM practices
were both ethical and unethical depending on the applied ethical model. Despite variation across
applied models, some practices were predominately ethical or unethical. The point of sale rebates
were consistently determined as ethical, whereas market consolidation, gag clauses, and fluctuation
of pharmacy reimbursements were all predominantly determined as unethical. The application of
using provider codes of ethics created additional comparison and also contained mixed findings.
This study provided a unique assessment of PBM practices and provides context from a variety of
ethical perspectives. To the knowledge of the authors, these perspectives have not been previously
applied to PBM practices in the literature. The application of ethical decision-making models offers
a unique context to current health care dilemmas. It is important to analyze health care dilemmas
using ethics-based frameworks to contribute solutions addressing complexities and values of all
stakeholders in the health care environment.
Keywords: pharmacy benefit manager (PBM); ethics; pharmaceutical regulation; health care policy;
decision-making; organizations; ethical models; code of ethics; pharmacist
1. Introduction
The costs of pharmaceuticals as a portion of health care spending has continued to vex the United
States (U.S.) as well as the rest of the world for several decades [1]. This issue has prompted vigorous
discussion from a variety of stakeholders in the attempt to find agreeable solutions to a seemingly
insolvable problem [2]. Discussions with experts and stakeholders have included government payers,
health insurance organizations and pharmaceutical manufacturers. The most common frameworks
considered in solutions are economic and legal rationales [3]. Economic defense of high costs
often point towards the capitalistic free market and hence, theory of supply and demand. Further,
legal considerations rely on explanations related to intellectual property rights, patents, proprietary
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information, obligations to shareholders, as well as complexities of government policies, regulation and
oversight [1,2]. As an example of legal complexities, the United States health care practices (including
health insurance law) are regulated at the state level (e.g., New York will differ from California),
in contrast to uniformity at a national level [4]. This results in a variety of co-existing regulations
depending on the regional location of the organization, the care provider, or the patient. Even beyond
the U.S., legally sanctioned intellectual property rights and patent laws for pharmaceuticals are not
always consistent across countries, resulting in complexities in the world-wide market [5].
In the U.S., the fiduciary issue of high spending on pharmaceuticals is one that involves specific
interrelated stakeholder organizations including manufacturers, wholesalers, pharmacies, pharmacy
benefit managers (PBMs), and plan sponsors (i.e., health insurance organizations) [6,7]. Briefly,
these organizations and their relationships include the following: Pharmaceuticals are developed and
made by manufacturers, delivered to pharmacies by wholesale distributors, obtained by patients at
pharmacies where there is often reduced pricing according to coverage by plan sponsors [6,7]. PBMs
are organizations that developed to provide added value and reduced costs by specifically managing
the pharmaceutical benefit on behalf of a plan sponsor. In addition to using formularies and utilization
requirements to control cost and incentivize cost-effective medication use, PBMs also negotiate lower
prices from manufacturers [8]. This practice is commonly known as rebating. Although ideally a
cost-saving tool, rebate levels are confidential and the actual cost savings is unknown. Under normal
market conditions this would not be problematic, however, there is evidence to suggest that the
most cost-effective pharmaceuticals are not being incentivized due to how PBMs sometimes place
higher-priced pharmaceuticals as the preferred status on formularies and patients may spend more
than they would for lower cost, equally effective alternatives [8]. Recently, PBM business practices such
as rebating have begun to receive public scrutiny as the U.S. looks for solutions to the problem of high
costs of pharmaceuticals [9–13]. Additional business practices undergoing scrutiny include exclusion
lists, gag clauses, rapid fluctuation in pharmacy reimbursement rates, market consolidation and point
of sale rebates [14]. In brief, exclusion lists are a way to specify non-coverage of certain medications,
that is, it is a list of prescription medications that are excluded from any plan sponsor coverage. It has
been noted that these exclusion lists are growing longer, in particular, for new or more expensive
prescription medications [15]. A lesser-known policy referred to as gag clauses are in reference to a
commercial contract between a PBM and pharmacies prohibiting a pharmacist’s ability to inform a
patient whether or not a prescription has alternative purchasing options [16]. Another concern with
PBMs has been the fluctuation of reimbursements through the use of redirect and indirect remuneration
(DIR) fees assessed to pharmacies, retrospectively, dependent upon pharmacy performance or upon
changes in market prices [17]. The practice known as point of sale rebates refers to PBM contracts with
a discount program to offer cash-paying consumers an ability to purchase prescription medications
at prices lower than a pharmacy’s list price of the medication [18] and circumvents the effectiveness
of utilization incentives towards lower cost alternatives. Finally, as in many industries, the market
consolidation of PBMs with other types of organization in the form of vertical integration challenge the
intent of legal anti-trust statutes [7] (pp. 30–32), further attracting public scrutiny.
Health providers often find themselves as reluctant mediators between patients and high cost
pharmaceuticals. Generally, provider involvement includes prescribing, educating, dispensing, and
even administration of pharmaceuticals pursuant to laws regulating the scope of practice for various
types of health professions. Specific to physicians, it has been argued that “physicians often neglect,
or are simply unaware of, their role as economic agents for patients. Physicians play a crucial role
in controlling prices and enabling patients to access affordable therapies” [19] (p. 9). In contrast,
many community pharmacists are well versed in advocating for patient access to medications in the
commercial environment of high costs [20].
It is pertinent that the experts and researchers continue work to find agreeable solutions to the
problem of high costs of pharmaceuticals. To frame these discussions, an ethical framework would
stand in contrast to the use of an economic or legal framework. Although there are a number of ethical
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theories worthy of consideration, in comparison to other frameworks, the ethical dialog uses concepts
such as avoiding harm, duty to patients, virtues, justice, or the common good. Interestingly, stakeholder
organizations and their corresponding practices described above, have remained largely uncriticized
in the ethical literature, with the only exception being pharmaceutical manufacturers [19,21]. However,
PBMs have been showing signs of increased scrutiny by private nonprofit health foundations [8], the U.S.
government [7,14], professional pharmacy organizations [20,22] and in the economic literature [23,24].
The increased scrutiny directed toward PBMs has resulted from shielded business practices that
may raise ethical concerns. For example, the literature has debated whether the reduced prices for
some result in increased prices for others [13,19]. More specifically, PBMs may be causing a form
of price-shifting between stakeholders, resulting in increased profits for manufacturers and PBMs,
reduced revenues for pharmacies, reduced prices for some patients and plan sponsors, and increased
prices for other patients and plan sponsors [23].
An ethical-oriented framework is one that is easily relatable to the case-based decisions of health
care providers (e.g., pharmacists or physicians) [25]. Ethical principles are used in health care to
provide a moral grounding for the day to day work of providers. The study of ethics remains an
important part of education and culture for nearly all care providers charged with supporting the
health of individuals in society [26,27]. Codes of ethics exist for clinical health professionals, and are
intended to guide decision-making in the face of competing interests, social dilemmas, or conflicts
encountered during the provision of care [28]. Although the study and application of ethics remain
at the core of health professionals’ conduct, some have begun to question the degree to which the
application of ethical principles may be in conflict with daily work requirements within the health
care system, especially when balancing fiscal considerations [29]. Some base a growing concern for
physician burnout and failing mental health on a kind of moral crisis [30]. Further, an application of a
concept previously used for combat veterans known as moral injury has been used in the context of
health care and posited as resulting from providers feeling as if their work is dissonant with their own
moral and ethical principles [31].
Although there is an abundance of literature in the application of ethics in health care related
to the provider-patient interactions, there has been substantially less attention on how health care
organizations impact providers during the delivery of care [32]. In fact, organizational ethics is
considered as an adjacent field to more typical bioethics applications in health care. However,
some ethical theory work has shown new approaches using contextual differences to shape discussion
when a dilemma includes both clinical and organizationally ethical standpoints [33]. As the dilemma
of the high costs of pharmaceuticals is situated most prominently at an organizational level, it has
been rarely considered through the more common bioethical (i.e., provider-patient focused) lens in the
health care literature. Arguments to address this gap have used organizational ethics to demonstrate
that stakeholder organizations can make decisions from a moral point of view in cooperation with the
broader health care environment [21]. In addition, some have discussed a need for a cross-over between
ethics and other fields, such as economics, to avoid economic-based solutions that inadvertently
compound ethical concerns [19].
Specific to the field of pharmacy, a comprehensive review of the theory of pharmacy ethics
found the existence of very little formal literature on philosophical values or frameworks specific
to pharmacy [34]. Rather, this review found application of traditional medically-based bioethical
concepts to pharmacy-oriented practice scenarios, as well as the application of professional codes to
direct the behavior of pharmacists. Therefore, research on pharmacy ethics presents an area ripe for
investigation due to the constant balance of the clinical aspects of patient care with commercial aspects
of practice, especially in the community pharmacy settings [34]. Some limited theory-based research in
this area found health care organizations do shape the ethical decision-making of pharmacists [35].
For example, some research has found that professional hierarchies, closeness (or distance) from patient
care, or daily gatekeeping (i.e., roles balancing clinical care with fiscal responsibility) can require a great
deal of provider moral contemplation [36]. Further, this literature has discussed that intensification of
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commercial pressures in the profession of pharmacy are resulting in pharmacists feeling pressure to
make unethical decisions that may be in conflict with their moral values [36]. This evidence only serves
to strengthen the argument of growing moral injury distress in health care providers. With the growing
concern over the moral crisis faced by providers, the authors were interested in how questionable
practices by key organizations undergoing public scrutiny would stand through a framework more
commonly aligned with the decision-making of providers, that of an ethical analysis.
When considering potential economic and legal solutions, an ethical analysis would provide a
novel and grounded framework for understanding the potential ethical considerations by providers as
well as broader context for stakeholders. Moreover, there exists a gap in the literature relating to how
such organizational practices in health care, and those of PBMs in particular, might fare under ethical
examination. Therefore, as a first step towards bridging this gap, this study sought to investigate the
ethical nature of PBM practices using ethical decision-making models.
Ethical issues in health care, including pharmacy, are commonly discussed using four core
bioethical principles of beneficence, non-maleficence, autonomy and justice [37,38] as well as with
professional codes of ethics [34]. In addition, some pharmacy specific texts have included fidelity
and truthfulness as newer ethical principles with application and relevance [39]. However, work by
Cooper et. al. described that much previous empirical ethical work in pharmacy commonly used
these principles solely due to normative consideration rather than because these values are reported
by pharmacists themselves. These authors observed pharmacists used a range of ethical values
during the reasoning process, and that various ethical approaches may have relevance to pharmacy
dilemmas. Moreover, research has found that even when provided a four-stage process guideline,
pharmacists displayed limited abilities in ethical reasoning [39]. Cooper and colleagues’ open-ended
empirical approach hoped to capture the complexity and nuance in pharmacist decision-making,
however, it was found that pharmacists frequently reasoned dilemmas in legal terms and lacked ethical
awareness. Therefore, given the overall lack of literature on ethical theory in pharmacy combined with
the possibility of criticism on the application of normative ethical theory (i.e., the four major bioethical
principles), it is prudent to take a comprehensive approach.
There is some ethical theory literature which proposes the use of multiple frameworks to compare
contextual differences from a clinical versus an organizational standpoint [28,33]. Further, this work
argues complexities of health care rarely allow one model to capture value differences among all
stakeholders. Thus, it would be of interest to use multiple ethical models in order to compare potential
value differences encased in various ethical scenarios. The literature suggests that pharmacists may
need additional guidance for ethical decision-making in practice [39] and that there have been calls for
integration of novel ethical schemas for grappling with complex and especially commercial aspects of
health care [34]. As a result, the authors chose to use established decision-making models based upon
a diversity of ethical theories and principles.
Philosophical decision-making models assist with debate and identification of action steps given
an ethical issue. Work by Hammaker and Knadig, have summarized eight decision-making models
based on the major philosophers cited by the U.S. Supreme Court, the U.S. Court of Appeals, and the
state Supreme Courts since 2010 [40]. These models comprehensively cover teachings and writings of
philosophers that included: Kant, Rawls, Dworkin, Bentham, Mill, Confucius, Socrates/Plato/Aristotle,
Bradley, Epictetus, and Sartre [40] (p. 8). These decision-making models were appealing to use as a
framework in this study because they have been used extensively in the U.S. legal system, which the
literature has shown is important to pharmacists [39]. They include principles from deontology, teleology,
and utilitarianism as well as others. Regarding the eight accepted decision-making models, this study
chose six to use for analysis. After consideration, two models were excluded from the final analysis due
to inapplicability and ambiguity of context when attempting to create a consistent assessment. In place of
the two excluded decision-making models, the authors chose to examine how two professional codes of
ethics might assess each of the issues. Provider codes of ethics are also referenced in the literature as ways
health care providers are taught and therefore utilize ethical values in practice [19,34].
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In sum, because there has been a lack of ethically-based work surrounding organizations involved
in the high costs of drugs and that a gap remains in ethics-based pharmacy research, this study used
scrutinized PBM practices to comprehensively consider these issues within an ethical framework.
Therefore, the objective of this study was to systematically apply multiple ethical decision-making
models to specific PBM practices and determine their ethical nature.
2. Methods
2.1. Conceptualization
In this study, several types of controversial PBM practices were chosen for evaluation. PBM
practices were chosen based those receiving evaluation in U.S. government issued reports [7,14]. First,
this study identified if the practice was receiving scrutiny and a potential cause for increasing drug
pricing [14] (pp. 32–38). Second, the authors assessed if the practice could stimulate changes in the drug
supply chain [7] (pp. 26–32). And finally, the authors predicted if this practice or related changes in the
drug supply chain could present ethical concerns to providers. If a PBM practice was able to sufficiently
meet all elements for inclusion, it was evaluated using a systematic approach to determine its ethical
nature. This study was limited to a maximum of five ethical scenarios to ensure a thorough analysis.
The scenarios considered the market environment, including the purpose of the organization, typical
goals (i.e., cost-effectiveness and profit-maximization) and motivations of the involved stakeholders.
The scenarios considered in this study were purposely hypothetical and therefore did not use actual
cases, or details from any specific organization or company. The models have differences in value
considerations, yet all of which are considered a reputable means of determining an ethical decision
with health care and the legal systems [40]. This comprehensive approach provides a framework for
future work. The chosen ethical scenarios are detailed in Table 1.
Table 1. Ethical Scenarios.
Gag Clauses
A commercial contract between a pharmacy benefit manager and a network of pharmacies prohibiting
a pharmacist from informing a patient of alternative prescription purchasing options [16]
Fluctuation of Pharmacy
Reimbursement Rate
PBM determined redirect and indirect remuneration (DIR) fees assessed to pharmacies retrospectively
dependent upon incentive-based performance [17] (p. 33)
Exclusion Lists List of branded prescription medications to be excluded from insurance coverage [15]
Market Consolidation
Large mergers and acquisitions have been increasing between pharmacy benefit management
organizations and other organizations within health care [7] (pp. 30–32)
Point-of-Sale Rebates
A commercial contract between pharmacy benefit manager and discount card providers offering
cash-paying patients discounted prescription pricing [18]
2.2. Analytical Approach
This study used a systematic ethical analysis of PBM practices utilizing decision-making
models [40] (pp. 4–35) based upon a foundation of ethical philosophies. The six decision-making models
were applied to all five selected PBM practices in a detailed step-wise assessment. The foundational
ethical philosophies that comprise the six models are fully described in chapter one of the Hammaker
and Knadig text [40]. These were the utility model (utilitarianism), exceptions model, choices model,
justice model, common good model, and virtue model. In the utility model, maximizing good and
minimizing harm are the foci of this ethical determination. The exceptions model is a unique framework
to consider the ethical nature if an individual exception became the standard or norm for all. The choices
model places a focus on how decisions are made, with an emphasis being placed on moral respect for
individual choices. The justice model, commonly applied in health care, involves the consideration of
the distribution of limited resources. The common good model is similar to the utility model, but rather
than focus on benefits to individuals, it asks to focus on how a decision might benefit everyone. Finally, the
virtue model focuses on core values aspired to by the decider, and determinations whether a given scenario
helps or hinders one towards reaching these values. Examples of core values of health professionals
may include characteristics of compassion, honesty, or self-control. Complete descriptions of the specific
step-wise framework for application of the models were included in Table S1A–F, in the Supplemental
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Materials. More specific details about the foundational ethical theory and foundational philosophies for
each of the models can be found the Hammaker and Knadig text.
To demonstrate reproducibility, the following outlines an example of how a step-wise application
of each ethical model would be conducted. These steps and application responses were applied to
the five chosen ethical scenarios. They were determined by the authors separately, and then together
through detailed discussion until a consensus for each scenario was reached. In this application,
the steps outlined for the justice model (Table S1D, Supplementary Materials) were applied to the PBM
practice known as exclusion lists.
The justice model contains five steps: (Step 1) Define the distribution of resources by determining
who is getting the benefits and burdens in the situation. Should those who get benefits also share burdens?
(Application Response 1) The purpose of the PBM’s formulary cost structure is to fairly distribute
prescription benefits and burdens (i.e., costs) across all plan members, assuming reasons for any inequality
are fair and just. (Step 2) Once the distribution is known, establish which criterion for distribution would
be the fairest and justify why it would be most fair in the situation. (Application Response 2) The fairest
distribution is typically through PBM authorized prescription cost structures based on medication
tiering and copayment agreements with plan members. The use of these structures and formularies
allows for fair distribution based on principles of cost-effectiveness medication use. (Step 3) Select a
framework to decide what is fair if disagreement persists over which outcome is fair or over which
criterion for inequality is best in the situation, then choose a framework to decide what is fair. (Application
Response 3) The framework used to determine fairness has been built into the PBM authorized formulary
structure and plan sponsor pricing. Factors such as employment, premiums, maximum out-of-pocket
expenses, exclusion lists, etc. all have a role in pricing and payment. Following agreed upon terms of the
authorized formulary will most consistently produce a fair outcome. (Step 4) Make an ethical decision.
Decide whether an action will produce a fair distribution and why. (Application Response 4) This practice
is deemed ethical. Exclusion lists are applied to prevent inconsistencies within authorized cost structures
to maximize cost-effectiveness for plan members. (Step 5) Monitor and reassess when applicable.
Ethical scenarios were also assessed using the Pharmacist Code of Ethics and the Physician Code
of Ethics [41,42]. These two professional codes of ethics were chosen because of the potential impact
of these health care providers as fiduciary advocates in the pharmaceutical market. For the analysis
with the professional codes, the authors added the total number of sections (i.e., Section I, Section II.)
finding the practice as ethical, to the total number finding the practice as unethical, to calculate the
overall ethical determination. In other words, the authors assessed whether each section would call
the practice ethical or unethical. Inclusion of other health provider’s codes of ethics was beyond the
scope of the study’s objective. There was no weighting assigned to these assessments, each model or
code section stood on its own merits. Once an ethical nature was determined using each model and an
individual code of ethics, the resulting ethical determinations were totaled.
3. Results
The PBM practice that was most likely to be found ethical by the models included point of sale
rebates. Exclusion lists were equally found to be both ethical and unethical, depending on the model
applied. In contrast, a clear majority of ethical models found market consolidation and gag clauses to
be unethical. Additionally, all ethical models unanimously found that the fluctuation of pharmacy
reimbursement rates to be unethical.
The ethical models found different results for each PBM practice, with the exception of the
common good and choices models, which made identical ethical assessments. Further, the codes of
ethics applied also found differing assessments. The Physician Code of Ethics aligned most closely
with the utility and the justice models. In contrast, the Pharmacist Code of Ethics aligned most closely
with the choices and common good models.
A complete summary and cross-tabulation of ethical assessments for the models and codes of
ethics can be found in Table 2, below.
114














































































































































































































































































































































































































































































































Pharmacy 2019, 7, 65
4. Discussion
This study systematically applied multiple ethical decision-making models to a variety of PBM
practices. The results showed a novel assessment of ethically questionable PBM practices with mixed
findings on their ethical nature. The PBM practices were determined to be simultaneously ethical and
unethical depending on the varied considerations for each applied model. The application of the codes
of ethics of pharmacists or physicians further created comparisons for these results.
In consideration of the PBM practices, exclusion lists produced the most varied findings when the
ethical models were applied. More consistent results were established with all other PBM practices,
which were predominately deemed unethical. Point-of-sale rebates were the only PBM practice
with a consistent ethical determination. This practice has been more recently scrutinized and more
information will develop with changes in the market that could change results [43]. Future assessment
is warranted for this ethically questionable scenario.
The majority of PBM practices resulted in an unethical determination. These results can be
attributed, in part, to the ethical philosophies in which the decision-making models are based. Generally,
philosophical renderings consist strictly of a two-sided pendulum, one beneficence (i.e., ensuring
welfare) and the other maleficence (i.e., opposes welfare). When applying the theories or models,
a decision must be made with little acceptance or consideration of an ethical spectrum. However,
the context does matter and could change the decision. It has also been noted that vagueness of
ethical codes is also a cause of conflict for a consensus of interpretation [19] (pp. 4–35). Many PBM
actions were simultaneously ethical and unethical dependent on the applied philosophical model.
However, unethical results are more prevalent because greater significance tends to be placed on
acts of beneficence or maleficence with a direct effect on individuals rather than societies. Whereas,
the objective of PBM organizations is the cost-effective management of medication use for an entire
covered group of people, or a population, and therefore more closely align with the needs of a broader
society than an individual.
More specifically, the common good model and the choices model produced identical ethical
determinations for all PBM practices under ethical assessment. The models, although different in
structure and application, produced identical results due to a shared emphasis on the individual within
a society. The common good model determines ethical nature through the distribution of benefits and
burdens of individuals within a society, as well as the sustainability of the distribution. The choices
model requires individuals to be given an individualized determination of their life outcome via specific
choices and values. The choices model and the common good model both ethically assess society
through an individualized perception. The two models strongly favor an unethical determination of
recently scrutinized PBM practices.
The utility model and common good model produced the most contradicting results among
the ethical models. Regarding the five practices assessed, three showed disagreement. The utility
model and the common good model are nearly identical in their structure and application, however
found different results. The models assess foreseeable benefits and burdens resulting from an action.
Then, the models determine the most beneficial option available as an ethical decision. However,
the important distinction is the utility model only considers those immediately affected by an action,
whereas the common good model considers the benefit and burden to all of society and also accounts
for unintentional and non-immediate benefits and burdens. The subtle difference is significant when
determining results. An example of such disagreement is also demonstrated when assessing gag clauses.
The utility model determines gag clauses to be justified and therefore ethical because they produce
the best overall outcome and the greatest long-term benefit to those affected. The common good
model determines gag clauses to conflict with the pharmacist’s ethical obligation, which prioritizes the
importance of maintaining a beneficial and truthful relationship with patients. The ideologies upheld
by a pharmacist’s ability to communicate transparently to patients contribute more common good to
society than any common good deriving from the PBM’s gag clause. In this scenario, the common good
is the general condition that all patients have equal access to a quality relationship with their pharmacist.
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The differences among the models for the ethical scenario of market consolidation further
demonstrate how subtle philosophical orientation can provide context to an ethical determination.
Both the utility model and virtue model supported market consolidation but for different reasons.
For example, the utility model supported market consolidation as ethical because of the potential
effect on the distribution of benefits and burdens of those immediately affected by the action.
Those immediately affected are likely to already hold a prescription benefit plan within the established
system. The consolidation of entities within the pre-established market will further benefit plan holders
due to increased access to affordable care through plan participation. Those who do not hold plans
within the system will not have any direct benefit and are likely burdened by a decreased supply within
the market upon entry. However, the utility model does not take those individuals into consideration
when making an ethical determination due to a lack of immediate effect. The virtue model focuses
primarily on the aspirations of a professional and secondarily on the action itself. More specifically,
the virtue model emphasizes a health care professional’s ability to deliver high-quality and equitable
care to the patient population. This emphasis on delivery of care supports the consolidation of the
market. Consolidation allows for near universal availability, coverage, and access to prescription
benefits, which benefits both the health care professionals and patients financially and clinically.
However, the patient must have sufficient resources to gain access to the market in order to experience
the added benefits consolidation offers. The common good and choices models place emphasis
on individual assessment. In general, consolidation usually places importance on the benefit to a
population or society rather than an individual perception.
The Physician’s Code of Ethics, virtue model, justice model, and exceptions model produced
mixed results. In contrast, the utility model, choices model, common good model and Pharmacist’s
Code of Ethics were more consistent. An interesting finding was a lack of alignment between the
Pharmacist’s Code of Ethics and the Physician’s Code of Ethics. This could be due to specificities within
each code of ethics. The physician’s code appears to have a broadened perspective, emphasizing the
value of societal health as well as the individual patient. For example, Sections VII and IX (Table S2B,
Supplementary Materials) are both pointing towards the broader community and societal issues of
health care access to all and to public health. Whereas, the pharmacist’s code has an emphasis focused
more specifically on individual patients. For example, the only mention of broader society is in
Section VIII (Table S2A) and this section speaks of a balance towards the broader societal distribution
of resources with individual patients. The similar but differing ethical values could be viewed as
a system of checks and balances between types of care providers or could be viewed as a way to
better understand the foundational values of each unique profession. It would be of further interest to
compare ethical codes for additional health professions.
The future success of quality care relies on providers who are willing to actively assess the
changing landscape of the health care system and confront potentially unethical practices. Grass-roots
advocacy by health providers have had, and continue to have, the potential to make changes in health
care both from a regulatory and organizational standpoint. Therefore, it is critical for providers to be
knowledgeable about current practices impacting foundational values that guide their work. Despite
the multiplicity of theory-based ethical models as well as ethical codes among the health professions,
it is important that providers are supported when complex problems in health care infringe on their
moral values. Further, ethical models and professional codes can assist in guidance, but should be used
cautiously if applied singularly or in a simplified dichotomous (i.e., ethical/unethical) or authoritative
way. Therefore, this study provides an example of how to use theory-based models and multiple
professional codes to deepen the understanding of current ethical problems in practice. Finally, in
pharmacy as in other health professions, ethical standards can have important legal implications and
thus, make practical application essential.
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5. Limitations
The limitations of this study can be categorized into a few areas. Despite a structured step-wise
process, there remains subjectivity in decision-making application and the rationales for determinations.
Others following a similar assessment may or may not have greater insight and exposure to the actions
and therefore may conclude alternative findings compared to those found in this study. Second,
there is an inherent lack of certainty in organizational assumptions based on cost-effectiveness
information and actuarial analysis as to whether or not a specific practice brings greater benefits or
burdens to a population. The authors propose the assessment in this study to be value-neutral but
remains hypothetical, nonetheless. For example, many of these determinations were made under
the assumption that both PBMs and plan sponsor organizations value efforts to lower the cost of
health care delivery in the U.S. while maintaining profit expectations of both employees and investors.
These assumed values are an area of ambiguity, differ between organizations, and may undergo
fluctuation based on environmental factors in the marketplace. For example, exclusion lists were
initially expected to decrease pharmaceutical expenditures by limiting market availability to drug
manufactures. However, further market development revealed exclusion lists do not always produce
decreased expenditures [15].
Additionally, fundamental assumptions were made of both PBMs and the closely linked
organization of plan sponsors. A fundamental concept of PBM organizations is to increase purchasing
power when negotiating with manufacturers to provide discounted drug pricing. This discount
is passed to the plan sponsor via rebates. PBMs can, therefore, produce savings on behalf of the
plan sponsor from these negotiated rebates. In theory, the plan sponsor uses the rebates to reduce
the costs to all of the plan members. However, some PBMs have openly claimed all rebates are
retained, with no distribution to plan members in any way [44] (p. 12). Rebates are assumed to be
retrospectively applied to future pricing. However, it is possible that these rebates are not accounted
for in pricing models. The potential for organizational variations must be considered when assessing
the ethical nature of organizational practices [23]. Recent policy proposals in the U.S.’s Centers for
Medicare and Medicaid Services (CMS) have furthered market uncertainty. Recent analyses have been
unable to accurately predict potential financial outcomes of developed regulations due to irregular
responses from manufacturers, plan sponsors, and PBMs [45]. However, supply chain transparency
and point-of-sale rebates are considered market trends that could benefit the overall population.
6. Conclusions
This analysis fills a gap in the literature to use ethically-based frameworks to assess organizations
involved in the high costs of pharmaceuticals. To the knowledge of the authors, an ethical perspective
has not been previously applied to scrutinized organizational PBM practices. Theory-based ethical
decision-making models provided a variety of perspectives that offer practical context to current
dilemmas in health care. Depending on the applied model, the assessed scenarios resulted in a mix
of ethical and unethical determinations. Despite variation across applied models, some practices
were predominately ethical or unethical. Point of sale rebates were consistently determined as ethical,
whereas market consolidation, gag clauses, and fluctuation of pharmacy reimbursements were all
predominantly determined as unethical. The application using provider codes of ethics created
additional and diverse comparison for the analysis. The codes of ethics were different in their overall
assessment for ethical determination with the physician’s code aligning more closely with values of
societal benefit, whereas the pharmacist’s code aligned more closely with patient-centric values.
This approach can be applied across many areas of health care as a mechanism allowing for the
productive analysis and open-minded deliberations of health care issues. The systematic assessment of
ethical dilemmas help guide providers towards grounds for concrete argumentation when applied with
a fundamental understanding of involved stakeholders and realistic solutions. It remains imperative
that health care professionals retain accountability towards addressing difficult ethical questions
in practice. Moreover, given the potential moral distress encountered as professionals closely tied
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with both the clinical and fiduciary aspects of medication use, it is essential that pharmacists remain
committed to ethical reasoning amidst a rapidly evolving pharmaceutical market.
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Abstract: Cystic fibrosis (CF) is one of the most common life-threatening, genetic conditions. People
with CF follow complex, time-consuming treatment regimens to manage their chronic condition. Due
to the complexity of the disease, multidisciplinary care from CF Foundation (CFF)-accredited centers
is recommended for people with CF. These centers include several types of healthcare professionals
specializing in CF; however, pharmacists are not required members. The purpose of this study was to
identify the outpatient care needs of people living with CF that pharmacists could address to improve
their quality of care. Healthcare members from a CFF accredited center and pharmacists were recruited
to participate in semi-structured, audio-recorded interviews. Prevalent codes were identified and
data analysis was conducted, guided by the systems engineering initiative for patient safety (SEIPS)
model. The objective was to understand the medication and pharmacy-related needs of patients
with CF and care team perspectives on pharmacists providing support for these patients. From the
themes that emerged, pharmacists can provide support for people living with CF (medication burden,
medication access, medication education) and the CF care team (drug monitoring and adherence, prior
authorizations and insurance coverage, refill history). Pharmacists are well-positioned to address
these difficulties to improve quality of care for people living with cystic fibrosis.
Keywords: cystic fibrosis; pharmacists; pharmacy services, medication management; medication
use burden
1. Introduction
Cystic fibrosis (CF) is one of the most prevalent chronic and fatal genetic diseases, affecting
approximately 70,000 people worldwide and 30,000 in the United States alone [1,2]. CF is a progressive,
multisystem disease that primarily affects the respiratory and digestive systems as well as the pancreas,
liver, and reproductive system [1]. CF is an incurable autosomal recessive disorder caused by mutations
in the CF transmembrane conductance regulator (CFTR) [3]. The CFTR transports chloride and sodium
ions in and out of epithelial cells which controls the movement of water in tissues of the body [4].
Mutations in the CFTR cause thick secretions of mucus to line several organs in the body such as
the lungs, pancreas, digestive system, and reproductive system [4]. Consequently, the thick mucus
production puts patients with CF at risk of developing bacterial infections in the lungs [1]. Although
advances in treatment and knowledge of CF have extended the median predicted survival age to 47.7
years for individuals born in 2016 (compared to age 42.7 years for those born between 2012 and 2016),
patients manage complex, time-consuming, and lifelong treatment regimens [1,5].
Medication management with CF is challenging and burdensome. Patients often use eight or
more medications daily with lengthy treatments, such as inhaled antibiotics, that can range 1–3 h
each day [1]. CF medications include CFTR modulators, mucus thinners, bronchodilators, antibiotics,
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anti-inflammatories, and pancreatic enzymes [6]. Patients with CF also need to perform airway
clearance techniques which may include the use of a vest and nebulizer treatments [6]. Vest treatment is
a high-frequency chest wall compression therapy that loosens mucus in the lungs and can be performed
in 30-min sessions two to four times per day. Treatment of comorbidities such as depression, anxiety,
and diabetes further complicate CF management [4]. Consequently, CF medication adherence can be
as low as 50%, particularly among children and adolescents [1,7]. Poor adherence can lead to negative
health outcomes such as exacerbations, hospitalizations, and increased healthcare costs [7].
The complexity of managing CF warrants a multidisciplinary healthcare team. The CF Foundation
(CFF) recommends that patients visit accredited centers with specialized healthcare professionals
at least four times annually [8]. The CFF requires accredited centers to include healthcare team
members such as physicians, nurses, respiratory therapists, dietitians, social workers, and program
coordinators [9]. Pharmacists are only listed as recommended healthcare team members [9]. However,
CF standards of care in countries such as Australia and Britain consider pharmacists to be vital
healthcare team members [10–13]. There has been limited research exploring how pharmacists in
outpatient settings can support people living with CF, which is a missed opportunity to improve the
care of these patients. There is an urgent need to increase access to pharmacist-provided outpatient
care for people with CF to improve their treatment adherence, medication self-management, and
overall health-related quality of life. This study aims to describe works system characteristics for the
pharmacists’ role in caring for patients with cystic fibrosis.
2. Materials and Methods
2.1. Theoretical Framework
The systems engineering initiative for patient safety (SEIPS) 2.0 Model was applied to guide our
understanding of medication management and interactions between pharmacists and other members of
CF healthcare team [14]. The SEIPS model is the most widely used systems engineering framework for
patient and healthcare research and embraces three important principles: (1) A holistic systems-based
approach, (2) person-centeredness, and (3) design-driven improvement needs to be person-centered
to enhance and improve outcomes. The framework proposes the following components of the work
system: Person, organization, tools and technology, environment, and tasks. To explore a collaborative
process in which patients, pharmacists, and other members of the CF healthcare team can actively
engage in medication discussions, it is necessary to understand the activities (or “work”) that each of
these individuals carries out with regard to CF medications.
In the SEIPS framework, person(s) are professional or non-professional individuals and
characteristics of those individuals, like age and expertise. Tasks are specific actions within larger
work processes, with characteristics such as difficulty, complexity, variety, ambiguity, and sequence.
Organizations, in the SEIPS framework, are thought of as structures external to a person put in place by
people that organize time, space, resources, and activity. Tools and technologies are objects that people
use to do work or that assist people in doing work, and is described by usability, accessibility, familiarity,
etc. The SEIPS framework separates environment into two factors: The internal environment (the
physical environment—lighting, noise, temperature, etc.,) and the external environment, which are
economic, ecological, and policy factors outside an organization.
2.2. Setting, Sample, and Recruitment
CF healthcare team member participants were recruited from a CFF-accredited center in an urban
city hospital in Western Pennsylvania. Pharmacists were purposefully recruited from independent,
inpatient, outpatient, and small-chain pharmacies in an urban city in Western Pennsylvania. The
research team worked with the center director to identify study participants. CF healthcare member
participants declined compensation and pharmacist participants received a $50 incentive. Verbal
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consent was obtained from study participants. This study was approved by the University of Pittsburgh
Institutional Review Board.
2.3. Data Collection
We conducted key informant interviews with stakeholders integral to the CF medication
management process. The research team developed semi-structured interview guides using open-ended
questions to understand the medication and pharmacy-related issues for people living with CF. Two
members of the research team assessed the interview guides and provided feedback to ensure content
validity. Appendix A contains the guides used to conduct study interviews with pharmacists and
other healthcare team members (such as physicians, nurses, dieticians). A research assistant conducted
20-min, in-person, and audio-recorded interviews with study participants from July to September 2016.
Participant demographic characteristics such as age, sex, ethnicity, and race were collected. Interviews
were conducted until data saturation was achieved. All interviews were professionally transcribed
verbatim. To ensure study rigor and trustworthiness, pilot-tested interview guides were used, and
reflective journaling and peer debriefing were completed after each interview.
2.4. Data Analysis
The research team reviewed the transcripts for accuracy. Interview transcripts were analyzed to
develop a list of codes that represented the main conceptual categories within the data. An initial draft
of the codebook was developed by members of the research team. The codebook was later simplified
and refined based on the results of the first two rounds of coding. Coding was carried out using
NVivo10 (QSR International, Melbourne, Australia), a qualitative data analysis software program
that enables multi-coder projects. Interviews were coded by at least one of the coders, with the two
coders overlapping on 12 of the interviews. Disagreements in coding were adjudicated jointly by the
principal investigator and coders. The interview transcripts were coded to identify prevalent themes.
Bi-weekly coding meetings were held to review all codes and resolve any discrepancies. Two coders
coded the interviews to ensure interrater reliability and had an average Kappa score of 0.60. After
the initial coding process, AM conducted deductive content analysis using the categories described
in the work system components of the SEIPS 2.0 theoretical framework. Interview transcripts were
reviewed using the SEIPS 2.0 Model by searching for key words, such as “pharmacist”, “benefit”,
“patient”, “medication”, or “management”. Responses were classified according to the corresponding
work system components of the SEIPS 2.0 model. Within those components, similar topics and ideas
were aggregated into constructs. OA reviewed the application of the SEIPS 2.0 model to the data to
validate the coding. Any discrepancies or differences in opinion were resolved and consensus was
researched before final results were obtained.
3. Results
A total of 22 participants were interviewed, including 8 pharmacists, 6 pulmonologists, 6 nurses,
and 2 dietitians. Of the 22 participants, 12 (55%) were female, 12 (55%) were aged 50 years or older,
21 (95%) were non-Hispanic and White, 7 (32%) had worked 0–10 years, and 7 (32%) had worked
21–30 years (Table 1). The predominant themes that emerged from this study are discussed within
each of the work system components of the SEIPS 2.0 model [14]. Additional verbatim quotes from
study participants which elaborate on each construct beyond what is provided in the results section is
available in Appendix B.
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Table 1. Participant Demographics (n = 22).





<30 years 3 (14 1)
30–49 years 7 (32 1)
≥50 years 12 (55 1)
Race
White/Caucasian, Non-Hispanic 21 (95)
White, Hispanic 1 (5)
Role
Nurse 6 (27 1)
Pulmonologist 6 (27 1)
Registered Dietician 2 (9 1)
Pharmacist 8 (36 1)
Years Worked
0–10 years 7 (32)
11–20 years 4 (18)
21–30 years 7 (32)
30+ years 4 (18)
1 Because of rounding, percentage may not total 100.
3.1. Person
Most members of the CF healthcare team have thorough experience working with people with CF.
Pharmacists have variable levels of expertise in CF and in providing services for people with CF. There
is also variation in the setting in which these pharmacists had experience providing service to people
with CF.
Experience and Expertise Caring for People with CF
Pharmacists experience with CF varied: Two pharmacists described providing pharmacy services
to only one to two patients with CF, while three pharmacists reported working with patients with CF
for many years. As pharmacists’ experience working with CF varied, so did their understanding of the
disease. All pharmacists understood healthcare services for patients with CF to be complex, robust,
and requiring of multidisciplinary care, no matter the amount of experience they reported.
“I’ve dealt with [CF] for like 30 years . . . From the medication standpoint I think I know pretty
much a lot of what their needs are, for the medications they need, and also the insurance coverage and
everything that I try to do.”—Pharmacist 8
3.2. Tasks
Tasks that participants identified for pharmacists to perform include medication management,
medication education, and medication access.
3.2.1. Medication Management Burden
Any tasks that must be done by patients, members of the CF care team, or pharmacists to
maintain patient compliance to their individual medication regimen or treatment plan are considered in
medication management. All members of the healthcare team and most pharmacists identified a high
treatment burden in people with CF, describing medication management as complex, time-demanding,
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confusing, and difficult for the patients in their care. Nurses and pharmacists described additional
medication management burden for the pediatric CF population.
“I think adherence, treatment burden. I mean, our patients can have like an hour and a half of inhale
antibiotics twice to three times a day. Plus, enzymes with each meal and every snack.”—Nurse 1
“I think a lot of them struggle because they have so many meds to take. I think sometimes it can be
difficult for them to necessarily be motivated to take all their medications.”—Dietician 1
3.2.2. Medication Education
All healthcare professionals rely on and advocate for verbal education between a patient with CF
and each member of the care team. Pharmacists highlight the importance of specialized, one-on-one
counseling, but the frequency by which they believe this counseling should occur and the topics
that should be covered by pharmacists varied. Physicians verbally educate people with CF, but
primarily rely on nurse educators to supplement initial educational conversations. Nurses educate
verbally and provide written materials for people with CF, but describe CF education as a team effort,
including dieticians and respiratory therapists as educators. Nurse educators do not rely on community
pharmacist involvement to educate patients with CF on their medicines. Members of the existing CF
healthcare team highlighted additional educational efforts that needed to be in place for transition
from child to adult care.
“great benefit comes from one on one counseling. We will, as pharmacists here, we will actually get to
a patient’s home, counsel them on how to actually use their medication.”—Pharmacist 3
“we, the [doctors] may introduce the medication to the patient . . . but then that gets followed up by our
nurse educators . . . I think they sort of try to reinforce our initial educational efforts.”—Physician 3
Many physicians stated they were aware that patients and their families want to hear information
from the doctor, not other members of the healthcare team. Nurses also felt that patients wanted to
hear information from the physician.
“Parents and patients—I think, want to hear it from the doc, but I think giving them a different
perspective from somebody else has some real power.”—Physician 2
There was unanimous agreement amongst the healthcare providers that verbal counseling should
be supplemented by additional education materials. There was a split opinion about the effectiveness
of this material, as this content was currently offered as written paper pamphlets. Dieticians also
employ pre- and post-testing material during verbal counseling.
“I think that combined with some of the technology and certainly as I said, the handouts, the pamphlets,
paperwork, things like that. Something tangible.”—Pharmacist 5
“I think most of the pamphlets go in the garbage.”—Nurse 5
3.2.3. Medication Access and Insurance Challenges
All healthcare professionals discussed the challenges people with CF face regarding insurance.
Prior authorizations were described as a major challenge by the healthcare team, and nurses and
pharmacists identified this was something in which pharmacist could assist.
“definitely access. A lot of the times, patients struggle with getting prior authorization or letters of
medical necessity, which oftentimes can delay therapy. Or even maybe as simple as their insurance
will only cover the medication if it’s coming from a specialty pharmacy”—Pharmacist 1
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“If we could get more of a pharmacist, we would . . . I would love for some of the higher-level prior
authorizations to be taken over, too, by the pharmacist.”—Nurse 2
Physicians and nurses also discussed financial burden for people with CF because of the high
cost of medications. Pharmacists also identified medication access challenges regarding the need
for one patient with CF to rely on multiple pharmacies (including specialty pharmacy) to obtain all
their medications.
“I think they have challenges in terms of expense, they have challenges in terms of getting them through
their insurance, and they have challenges just keeping up with the compliance intake.”—Physician 6
3.3. Organization
The organizational impact on pharmacist involvement in the CF care team was highlighted by
study participants.
3.3.1. Awareness of Pharmacy Services
Physicians unanimously reported that they rarely interacted with community pharmacies, and
many physicians identified that nurses were the primary point of contact with pharmacists. Most
nurses reported they communicate with outpatient pharmacies daily via telephone conversations.
Dieticians also report working with pharmacists daily, primarily to overcome insurance barriers.
“I don’t always necessarily think their knowledge of CF is as vast as it could be, I mean I know it’s a
very specialized disease. But most of the time, if you provide them with an explanation, they’re willing
to work with you . . . I’d say I deal with them pretty regularly though. Daily.”—Dietician 1
Existing communication between the CF care team and pharmacists was described as minimal
by physicians. The healthcare team members had some ideas by which this communication could be
improved, such as including pharmacists on rounds.
“It isn’t much. I mean, I’m not going to be judgmental and say the communication is poor. I would
just say that there tends not to be much.”—Physician 5
“I think it’s not even the pharmacists that we need to improve communication with, but the layers
that exist before the pharmacist . . . when you finally get to that pharmacist, they understand, they
know what you’re talking about and it’s a little easier.”—Nurse 4
3.3.2. Benefits and Drawbacks of Pharmacist Involvement
Pharmacists identified several areas in which they could be helpful, including medication education
and discharge counseling, relieving other care team members’ workload by handling drug-related
issues, and providing private counseling in community pharmacies to improve adherence.
“we can provide a different aspect of monitoring care that the physicians then don’t need to do. So
all the drug level monitoring, some of the compliance monitoring, some of trying to figure out how
to make things taste better, or how to fit them down a G-tube, or how to avoid drug interactions by
spacing certain meds away from each other.”—Pharmacist 6
“I think the most important benefit is—would be number one, education.”—Pharmacist 3
The healthcare team members identified several ways in which pharmacists could contribute to
overall care for patients with CF, including insurance coverage and drug acquisition, refill history,
medication safety, and patient education.
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“It would be particularly useful if there were pharmacists always available who could be doing the
tracking and the, making sure that the flow of medications continues through the paperwork and other
hurdles.”—Physician 6
“As the medication regimens are getting more and more complex, we need the expertise of a pharmacist
to help do some of those higher prior authorizations that require a little more knowledge and data to
defend”—Nurse 3
Pharmacists anticipated only a few drawbacks of being a member of the healthcare team that
cares for people with CF. The primary concern discussed by several pharmacists was care coordination
and the increased complexity required to uphold good communication practices between the care
team. Pharmacists also mentioned increased costs for the healthcare system, as pharmacists were not
included in the hospital’s existing financial model.
“I think bringing all parties together so that we’re all working cohesively is probably the biggest
challenge.”—Pharmacist 4
“If you don’t have robust communication with the nursing staff as well as the physician or collaboration
between the three of them, then that can create a serious issue . . . ”—Pharmacist 3
“So not any drawbacks that I can think of other than, possibly, I guess, increased cost of the health
care system. But in the hopes of the program, or the hopes of the CF pharmacist is to reduce costs
elsewhere.”—Pharmacist 1
Members of the CF care team also identified increased financial burden on the hospital to support
pharmacists providing care but were primarily concerned with patients feeling overwhelmed by
having to visit with another member of the healthcare team. The care team was also concerned that
community pharmacists’ knowledge about CF may be limited to properly support people with CF.
“Our patients meet with four or five team members in every visit, so inserting yet another person that
extends their hours long visit, they just might get tired of seeing so many people.”—Physician 6
“The barriers will include, education. Not every pharmacist is trained in CF . . . and so, there’s issues
around patient populations, and disease frequency”—Physician 5
“Predominantly money . . . Resources, limited resources! Space and money. Yeah, and time”—Nurse 3
3.4. Tools and Technologies
Participants discussed the potential for a mobile application to be used as a tool to improve
medication adherence for people with CF. Pharmacists also identified the use of social media as a tool
to communicate with people with CF.
Technologies That Influence Adherence and Prescribing
All healthcare professionals perceived benefit to offering a mobile application for use by people
with CF, though there were differing opinions about the content and purpose of the app. In general,
pharmacists described the app as a tool to support existing medication management techniques.
Physicians thought an app could be helpful for self-management or compliance.
“I always feel that some sort of knowledge center with that has a wealth of videos, a video library that
would be able to, number one show people how to use their medication. Number two, go through the
clinical aspects of the medication. Side effects, storage, and stability.”—Pharmacist 3
“I think it could be very helpful for, perhaps, keeping them on track for when they’re supposed to take
them . . . as a reminder function, I think it could be very valuable.”—Physician 3
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“We’ve had different nutrition apps and we’ve asked people to go home and look at things and that
doesn’t really happen.”—Dietician 1
There were some concerns to offering a mobile application, including effectiveness of a mobile
app as an educational tool, and how the app could be safely offered in clinic, using a communal device.
“Well, in the clinic setting that’s hard to do on a pad because it has to be sterilized between patients.
And so, we think it’s easier to hand out papers.”—Nurse 2
“In terms of whether they would take the time to actually learn the details of the medicines through an
app, I’m a little skeptical but it might work.”—Physician 6
Participants were also concerned that a mobile application may not be appropriate for all ages of
people with CF. Pharmacists believe medication education is only successful if patients were reached
in their environment, providing education through blog posts or social media, or preparing them to
explain CF in their own way.
“I think that is targeted—it would definitely be for adolescents, and not necessarily our older
patients.”—Physician 4
“I mean if I’m looking at how old the average patient is, you know, we gotta look where they are.
So you would use the data to suggest, ‘Hey they’re probably on Facebook’ . . . you scroll and you’re
watching and it’s like, everything is in a video. It’s all video digesting content.”—Pharmacist 2
In terms of other medication adherence tools, there was interest among physicians to implement
compliance-tracking devices to install on the patient’s vest.
“We are now instituting a way of determining whether patients are using their vest. There are some
devices that you can plug the vest into, and so you can tell from the electrical current use whether the
device has been turned on or not.”—Physician 5
3.5. Environment
Participants solely discussed external environment factors, including collaborative practice
agreements for pharmacists and issues with care team access to complete refill histories.
3.5.1. Collaborative Practice Agreements
Pharmacist participants advocated for their CF care team involvement as decision-makers through
collaborative practice agreements. Pharmacists had several ideas about what the partnership between
pharmacists and other healthcare professionals could look like, and identified many reasons this would
be beneficial to improve health care for people with CF.
“I think that pharmacists have an opportunity to even go further and be—take part in collaborative
practice agreements . . . where pharmacists could change the therapy without having direct physician
oversight.”—Pharmacist 1
“We would be a physician extender. So the physician is billing for the services that the pharmacist
provides . . . we touch these patients multiple times a month.”—Pharmacist 2
3.5.2. Refill History Access
All members of the CF care team rely on refill and dispense histories as their primary method to
tracking medication adherence, and supplement refill history knowledge by discussing medication
adherence with the patient. Physicians also evaluated lung function tests to supplement refill history
and improve their understanding of patient compliance.
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“No, not one particular method . . . you often can tell by their nonverbals, by the look on their face
when you ask them a question . . . and we have patient fill histories that we can look at.”—Nurse 3
“I always discuss it with the patient to see what barriers there are between them adhering to the
medication and non-adherence . . . I think it’s very individual.”—Dietician 1
4. Discussion
Despite the benefits that inpatient pharmacists have made in the care of patients with CF,
pharmacists are not required members of the healthcare team at CFF-accredited centers [15–17]. The
perceptions of CF care team participants about where pharmacists could contribute were reported
within the components of the SEIPS model (person, tasks, organization, tools and technologies,
and environment) [14]. This study identified specific opportunities for pharmacists to assist with
medication challenges experienced by people living with CF, including poor medication adherence,
medication counseling, and limited medication access because of barriers such as prior authorizations
or insurance coverage. Though pharmacists can provide benefit to CF patient care, members of the CF
care team may not fully appreciate the value and contributions pharmacists can provide. Establishing
a team of pharmacists with advanced CF expertise may improve care coordination with the CF care
team and eliminate some of the issues people with CF face regarding medication management and
treatment burden.
Medication adherence due to high medication burden is a serious concern for all members of the
CF care team. Study findings identified several medication challenges for people with CF, with the CF
care team and pharmacists describing treatment management as burdensome, time-consuming, and
complex. The typical medication regimen requires multiple medications in different forms (i.e., inhaled,
oral, intravenous) to be taken two to three times each day [1,4,6]. Consequently, medication adherence
can be difficult, which has been shown in other studies [1,7]. A recent study found that recognizing the
importance of CF medications is a predominant barrier to patient adherence to treatment regimens [18].
The pediatric and adolescent population is especially vulnerable. Previous research has shown that
adolescents with CF in particular have low adherence rates which can be attributed to forgetfulness,
being too busy, feeling that treatments give them less freedom, and believing that skipping treatment is
acceptable [19,20]. To monitor adherence, members of the CF care team frequently consult a patient’s
medication refill history, a log that community pharmacists are responsible for maintaining. Results
show the CF care team is aware of pharmacist involvement in refill history maintenance.
Further complicating medication adherence, medication access is a significant issue experienced
by people with CF; study findings show members of the CF care team are burdened by tasks to improve
access for patients in their care. Some insurance providers will only cover medications from specialty
pharmacies, which do not always stock CF medications. Insurance companies may also only cover
specific medications causing patients with CF to not receive the medications they were prescribed. In
addition, medication cost was an identified concern. Participants stated that some CF medications
from specialty pharmacies cost thousands of dollars and even those covered by insurance have high
copays. The high cost of these medications (i.e., Orkambi®, Kalydeco®) limits access to patients with
CF [21]. In handling medication access challenges, study participants explained that issues with prior
authorizations were time consuming and caused delays in patients receiving their CF medications. A
previous study found that insurance prominently impacts the health of patients with CF, where patients
who had Medicaid or public insurance had a higher risk of death while waiting for a lung transplant
than those who had private or Medicare insurance [22]. A previous study shows pharmacists are
well-positioned to address prior authorization and insurance coverage challenges that burden existing
CF care team workload [23]. Study findings show the CF care team identified pharmacist assistance
with this task as a perceived benefit to the organization.
The study identified challenges in care coordination and transitions of care for patients with CF.
Pharmacist participants revealed that they are often not included by other healthcare members in
the care of patients with CF even though they see the patients more frequently. The coordination of
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care is often difficult due to the many pharmacies that patients with CF use for their medications.
CF care team participants reported they do not expect community pharmacists to have the level of
expertise required to properly educate people with CF, knowing that many community pharmacists
have little contact or opportunity to experience providing care for a patient with CF. This suggests a
community pharmacist’s level of expertise and interaction with nurses and dieticians impacts CF care
team awareness of pharmacy services they can provide. Consequently, as shown in a previous study,
medication reconciliation needs to be prioritized [24]. Pharmacists are easily accessible medication
experts that can provide clinical services to people with chronic conditions such as CF more frequently
than other healthcare professionals [25–27].
Pharmacists are in the community and can provide counseling and education to people living
with CF about their medications or address any barriers. Previous research has shown that pharmacists
involved in CF care have provided patient education on medications and treatment management,
monitored drug-drug interactions, and detected appropriate medication dosing [15]. Other benefits of
pharmacists included in CF care in the inpatient setting include improving medication monitoring,
communication with the multidisciplinary healthcare team, and efficient use of resources when caring
for patients [16,17]. Due to the complexity of CF treatment regimens, participants recommended that it
would be beneficial for the pharmacist to create medication schedules for patients with CF to avoid
drug interactions. Participants also stated that pharmacists could assess adherence in people with
CF by reviewing their medication list and addressing any issues that arise. In addition, participants
recommended that pharmacists address insurance issues encountered by patients with CF. Outpatient
pharmacists within CFF-accredited centers will be well-positioned to assist patients to navigate
insurance issues with prior authorizations, medication access, and cost. Consequently, this would
relieve the burden from the healthcare members at the CFF accredited center and patients with CF.
Pharmacists can also provide medication education to CF patients. Results from this study suggest
that CF patients prefer online learning materials or interactive technology such as tablets or mobile
applications. Previous studies have used smartphone applications and telehealth to improve adherence
in patients with CF and were shown to be feasible and acceptable [28,29]. Consequently, innovative
methods using technology should be implemented to deliver education to patients with CF.
Limitations
Healthcare members were recruited from one CFF-accredited center, so the results may not
generalizable to all regions. Pharmacists who were knowledgeable about CF were also recruited to
participate in interviews which creates selection bias and cannot be generalizable to all pharmacists.
5. Conclusions
People living with CF experience many medication and pharmacy-related challenges such as high
medication burden, medication access, cost, insurance coverage, and care coordination. Although
pharmacists are not required members of the healthcare team for CFF accredited centers, this study
identified many benefits of having outpatient pharmacists support patients with CF. Pharmacists
can help relieve the medication burden for patients with CF by creating schedules that avoid drug
interactions. Additionally, pharmacists can assist with assessing drug monitoring and adherence, and
assist with insurance issues.
Author Contributions: Conceptualization, O.A.; methodology, O.A.; validation, O.A.; formal analysis, O.A. and
A.M.; investigation, O.A.; resources, O.A.; data curation, O.A.; writing—original draft preparation, O.A. and A.M.;
writing—review and editing, O.A. and A.M.; visualization, O.A.; supervision, O.A.; project administration, O.A.
Funding: This research received no external funding.
Acknowledgments: Daniel Weiner for helping to facilitate data collection and Alison Feathers for assisting in
data collection and analysis.
Conflicts of Interest: The authors declare no conflict of interest.
131
Pharmacy 2019, 7, 34
Appendix A
Appendix A.1 Pharmacist Interview Guide
A. Introductory Questions about Cystic Fibrosis (CF)
1. Can you describe what do you know about CF?
2. What do you know about the healthcare services needed for patients with CF?
3. Have you had experiences providing pharmacy services for patients with CF?
If Yes:
a. Please describe the pharmacy services that were provided.
b. Were there specific medication use challenges that these patients experienced?
c. Were there specific pharmacy-related problems they experienced? (i.e., access to medication,
insurance, etc.)
d. Were these able to be addressed?
If No:
a. Describe the pharmacy-related needs or problems of CF patients. (May probe for issues
related to access to medications, insurance issues, etc.)
b. What recommendations do you have for addressing these pharmacy-related issues?
4. What do you think are the benefits or drawbacks of pharmacist involvement in the care of patients
with CF?
5. Can you describe how pharmacists could potentially partner with other healthcare professionals
to improve care for patients with CF?
B. Support for People Living with CF
We would like to know more about how pharmacists can support people living with CF.
1. From your experience, what common difficulties do patients have when taking medications for
chronic conditions?
2. Can you describe possible ways pharmacists could assist patients with CF?
(How do you think pharmacists could be equipped to support patients with CF?)
a. Do you think pharmacists can support people living with CF? If so, how?
In what ways can community pharmacists uniquely support people with CF?
C. Preferences for Medication Education
We would like to know more about how you think people living with CF should be educated
about their medications.
1. How do you think a patient using medication for CF should be educated on his/her condition
and medication regimen?
a. How often do you think a patient using medication for CF should be educated about taking
his/her medications correctly?
2. If you have provided medication education for patients with CF, what types of educational
materials have you used?
If No: What types of education materials have you used with patients with other types of
chronic conditions?
132
Pharmacy 2019, 7, 34
3. What types of education materials do you think would be most helpful for providing medication
education for patients with CF?
4. Assuming patients want information about their medications, how do you think patients prefer
to receive education about their medications?
Probe for different educational methods (one-on-one counseling with the pharmacist, written
materials/pamphlets, interactive technology like on an iPad, videos on the Internet or TV, using
an app on a smartphone or tablet)
5. Do you think patients with CF would be interested in using an app, like on a smartphone or
tablet, to learn about his/her medicines and self-management? If so, why?
If Yes:
a. How do you think an app could help patients with CF to learn about their medicines
and self-management?
b. What features and content do you think would be beneficial to the app design?
6. Of the methods we discussed, which do you believe is the most effective method for delivering
education to patients at a community pharmacy?
D. Pharmacist Counseling
We will now ask you about providing medication counseling for people living with CF.
1. How do you feel about talking to patients with CF about their medications?
2. Can you describe potential ways that pharmacists could be better equipped to provide medication
counseling for people living with CF?
3. How do the elements of the pharmacy (waiting area, space) facilitate or impede counseling to
patients with CF?
(If not discussed) Please describe any changes you believe would help.
4. Can you describe other ways to engage younger CF patients in medication use discussions?
Do you have anything you’d like to add before we end?
Appendix A.2 Other Healthcare Team Members Interview Guide
A. Introductory Questions
1. Tell me about what you do in your CF care center.
2. Describe the pharmacy-related needs or problems of CF patients. (May probe for issues related to
access to medications, insurance issues, etc.)
3. What kinds of challenges do you think that CF patients face regarding the use of CF medications?
4. What types of medications or treatments seem to be especially hard for CF patients to administer
or adhere to correctly?
5. What method(s) do you use to assess if patients are adhering to their medication regimens?
6. What recommendations do you have for addressing these medication or pharmacy-related issues?
B. Medication Education
We would like to ask you about providing adolescent or young adults (AYA) with CF information
about their medicines.
1. Have you provided any form of medication education to patients with CF?
a. If Yes: Please describe what information was provided (i.e., drug information, dosing, side
effects, etc.) and how often you provided medication education.
b. What steps do you take to make sure the patient with CF has understood the medication
information you provided?
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2. How well do you think that patients with CF are educated on their medications?
a. How can their knowledge about medicines be improved?
3. Who do you think should be educating patients with CF on their medications? (Probe for doctor,
pharmacist, nurse, etc.)
4. Assuming patients want to learn about their medications, how do you think patients with
CF prefer to learn about their medications? (Probe for one-on-one counseling with the
pharmacist/doctor/nurse, written materials/pamphlets, interactive technology like on an iPad,
videos on the Internet or TV, using an app on a smartphone or tablet)
5. Do you think patients with CF would be interested in using an app, like on a smartphone or
tablet, to learn about his/her medicines and self-management? If so, why?
a. If Yes: How do you think an app could help patients with CF to learn about their medicines
and self-management?
b. What features and content do you think would be beneficial to the app design?
6. Are there any other ways that you can think of that would be helpful for patients with CF to learn
about their medicines?
C. Experiences with Outpatient, Specialty, and Community Pharmacists
We would now like to ask you some questions about your experiences with outpatient and
community pharmacists.
1. How often and in what practice setting (i.e., in-patient, outpatient, community pharmacies such
as Giant Eagle, Rite Aid, CVS, Walgreen’s, etc.) do you interact with pharmacists involved in the
care of patients with CF?
2. How would you describe the communication between pharmacists and other CF healthcare
team members?
3. Can you describe any possible ways to improve communication between the healthcare team
members and pharmacists?
4. How do you think pharmacists can support the other members of the healthcare team providing
care for people with CF?
5. What challenges with treatment and medications do you think pharmacists could possibly address
for patients with CF?
6. Do you think there are any barriers to pharmacist involvement in the care of patients with CF?
a. If so, what kinds of barriers?
7. Do you think there would be any benefits by implementing outpatient pharmacy services in your
CF center?
a. If so, what benefits?
8. Do you think there are there any barriers to implementing outpatient pharmacy services?
a. If so, what kinds of barriers?
9. Do you think community pharmacists can uniquely support patients with CF? (Pharmacists
practicing at Giant Eagle, Rite Aid, CVS, Walgreen’s, etc.) If so, how?
Do you have anything you’d like to add before we end?
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“CF is an autosomal recessive disorder essentially where, in a nutshell, you have these CFTR
mutations where secretions in different mutli-organ systems become thick . . . oftentimes leading to
lung transplant later on down the road. But it also affects the liver, pancreas, and then also male
reproductive systems. So it’s multi-organ disease.”—Pharmacist 1
“I’ve been able to provide probably only to about two patients that we’ve had with CF—well actually,
one with CF”—Pharmacist 3
“I do cover the pulmonology service on the floors. I do all their pharmacokinetics for all their levels, I
help them pick the antibiotics, I make sure all their meds are right, I help with their prescriptions,
writing them and whatever, if they ever need me to go in and talk to them about something, I




“the challenging administration options for the administration options for the medications as most
of them are inhaled, oftentimes have to do them 3 times a day—to 2 times a day . . . so it takes up a
large portion of these patients’ time”—Pharmacist 1
“I think Cayston® . . . but it’s a three time a day medication. So, I think even though it only takes
three minutes to nebulize, it’s three times a day. I find that patients don’t do medications three times
a day. Tobi tends to take between twenty minutes and a half an hour to nebulize . . . even though it’s
only every other month, they tend to struggle in those months because it’s an added medication to
their day. They seem to be able to get Pulmozyme® in, although when they travel it’s hard because
it’s a refrigerated medication. And then HyperSal® is twice a day and it makes you cough, so—and
it tastes bad, so some of the patients don’t want to use the Hyper-Sal because it makes you
cough.”—Nurse 4
“I think that one of the main difficulties is just remembering to take the medication . . . a lot of times
patients can get busy and forget to take those dosing of the medications. I think sometimes too,
particularly with antibiotics, patients start feeling really well and they decide not to take their
medications after they start feeling well. And then on the flip side of things, you can also have
patients feel not so well, and they think that their medications are contributing to their poor state
and decide not to take their medications.”—Pharmacist 1
“I know that there are medication use challenges that they do experience because they are children.
They are not as familiar with how to use a nebulizer. It can be challenging to them.”—Pharmacist 3
Medication Education
“We don’t necessarily expect any local pharmacy, brick and mortar I’m referring to, to do patient
teaching for their meds. It’s too complex, too specialized.”—Nurse 3
“I think most people learn best from one on one counseling. If you give someone written materials,
it’s more likely than not that they will not be read . . . we’re very careful about education in our
clinic. And we have a dedicated person call a nurse educator . . . and they tend to meet with the
families and go over the finer points about the medications.”—Physician 5
“For our end, with the kind of quiz that we’re doing, that’s actually geared more towards our




“So, the pharmacy said the medication was denied, then we have to reach out to the insurance
company and do a prior auth . . . if the auth is denied, then we do the appeal . . . if we can’t get the
appeal, then we have to have our physician reach out. We don’t handle the enzyme authorizations or
the supplements. We have a dietician that does those.”—Nurse 1
“The drugs can be astonishingly expensive. Some as much as $306,000 a year for Kalydeco for
example.”—Physician 5
“coordinating all the prescriptions, right? There’s a lot of fragmentation, right? They’re going to






“They can help with anti-microbial management looking at past cultures and . . . helping physicians
and nurses decide which anti-microbial regiments would be best for the patient to—as to not limit
our options for future use based on antimicrobial resistance.”—Pharmacist 1
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“It’s just infuriating to find out that we think we gave a patient an antibiotic, which was prescribed,
and find out eight days later that they haven’t gotten it yet because of insurance hoops, prior
authorizations . . . They’re little snags, but they result in devastating consequences. So, those are all
things that a pharmacist can help us with.”—Nurse 3
“more education, maybe more safety for the patients, better outcomes for the patient.”—Dietician 2
“Sometimes we go in and we review their medications when they first come into clinic and we go
over what they’re taking. I think if there was a more in-depth conversation.”—Nurse 1
“I think that our nutritionist would like him [the pharmacist] to help in . . . helping with patients





“we used to call all the pharmacists and order them, so we had more interaction than we do now.
Now with the electronic medical record and electronic e-prescribing, we have much less interaction.
And I find that we probably have, maybe some or more delays to patients getting their meds because
of that.”—Nurse 2
“I think that video presentations with graphics followed by a quiz is probably the best way to do it so
that they learn and then have to self-reflect and then spit out what the answers are.”—Physician 1
“I think—specifically for young people, videos, apps . . . some sort of content like that, they can
watch it at their own time, rewatch to understand a missing point. And then make notes and reach
out to us like, ‘Hey I watched this, and these are the questions I have.’”—Pharmacist 4
“I think that we have a lot online now and we have iPads . . . that’s what kids really like. They want




“I think that we can help them to streamline some of their therapies, or make adjustments, additions
and subtractions, like discontinuations of things as they progress through.”—Pharmacist 7
Refill History Access
“Well a lot of the pharmacies are set up, especially with the expensive drugs, it seems they try to
track them more because they have a vested interest to do so. So, we’ll get reminder calls.”—Nurse 2
“[the pharmacists] call us—I think that’s a generous—you know, for refills, they’ll call us, or fax for
refills and I think that helps families. Some of the pharmacists call for medication lists because they
are kind of keeping an eye on what the family is getting and sending automatic refills to the
family.”—Nurse 4
“The most effective test we have right now is lung function testing. And lung function testing is
kind of the final common pathway for all therapies. To say if your lungs are good then you must be
doing the right thing.”—Physician 5
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Abstract: Background. An essential way to ensure patient safety in the hospital is by applying
pharmacy services in emergency units. This strategy was implemented in Indonesia several years
ago, with the aim of ensuring that adequate pharmacy services are given to patients in hospitals. To
achieve this, pharmacists are required to cooperate with other health workers via inter-professional
teamwork. This study intended to identify the perceptions and expectations of health workers with
respect to pharmacy services in emergency units. Methods. This was a qualitative study, using a
phenomenological approach with a semi-structured interview technique to obtain data. This study
was performed at the Prof. Dr. W.Z. Johannes Hospital Kupang from June to September 2018. The
results of the interviews were thematically analyzed using QSR NVivo software 11. Results. The
themes identified in this study included: (1) The positive impact of pharmacists in service; (2) Badan
Penyelenggara Jaminan Sosial (BPJS) influence; (3) Acceptance of health workers; (4) Medication
administration information; and (5) Expectations of health workers. Various perceptions were
conveyed by participants regarding the emergency unit services in the hospital’s pharmaceutical
department. Data obtained proved that the existence of a pharmacist increased the efficiency of
time for services and prevented human error. Conclusion. Pharmacists and policy-makers play a
significant role in providing appropriate pharmaceutical services in emergency units. Pharmacists
also need to improve their quality of practice in accordance with their competence. They must review
the patient medical history and physician’s prescriptions, educate the patients and other health
workers, so that the workload and service time will be reduced.
Keywords: pharmacy; emergency unit; health workers
1. Introduction
One essential way to ensure patient safety in hospitals is by ensuring the presence of pharmacists
in emergency rooms. One measure, based on the decision of Accreditation Commission for Hospital
(KARS: Komisi Akreditasi Rumah Sakit) in 2012 and 2016 Number 72, aims at ensuring that adequate
pharmacy services are given to patients in hospitals. To ensure adequate patient safety in hospitals,
pharmacists collaborate with other health workers via inter-professional teamwork. Unfortunately, the
relationship between pharmacists and other health personals in developing and developed countries
is not cordial [1]. For instance, one study conducted in Canada revealed that a main obstacle to
pharmacists in working in hospitals is inadequate support from other health workers [2].
Studies about health workers’ perceptions of the role of pharmacists in emergency units have
not been conducted in Indonesia. Clinical pharmacist development in Indonesia is still in its infancy.
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However, problems in emergency units related to medications are increasing, and these can result in
medication error. This study aims at identifying the perceptions and expectations of health workers
with respect to the emergency pharmacy units in hospitals located in the city of Kupang.
2. Methods
2.1. Study Design
Qualitative research was undertaken, with a phenomenological approach using a semi-structured
interview technique to obtain data. The research was conducted at the Regional General Hospital Prof.
Dr. W.Z. Johannes Kupang between June and September 2018.
2.2. Guidelines of the Interview
The questions, which were designed during the study, followed the open-ended question rule.
Open-ended questions were purposed to explore the perception of health providers about the pharmacy
service in emergency units. The interview guide followed previous studies [3]. However, some
questions were designed with the purpose of understanding the impact of pharmacist services on
patients’ safety, the cost control, the behavior of health professionals toward pharmacists with respect to
high-alert medications, and health professional’s expectations toward pharmacy services in the ward.
2.3. Recruitment Strategy
We used purposive and convenience sampling technique with variations of age, profession, and
employment duration. The researcher found information on the participants by contacting a key
informant working in the hospital. The researcher directly met the participants at the emergency unit.
An informed consent process was conducted by the researcher. Anonymity was used to maintain
confidentiality. The interview was conducted directly and recorded based on the permission of the
participants. There were two groups of participants: physicians and nurses. Health workers who were
willing to take part in the study filled out a form stating their willingness to participate. The researcher
ensured that confidentiality was maintained. A face-to-face interview method was conducted using a
purposive sampling technique. The interview was held in a closed emergency unit area within the
participants’ working hours.
2.4. Data Analysis
Data was analyzed using the QSR NVivo 11 software. The examined data were theoretical, which
enabled the researcher to determine pre-themes from the research questions. The code was developed
from information that was specific or relevant to the research question.
The interview transcript was analyzed by NVivo 11 codebook. The themes were designed based
on theoretical thematic analysis, where the codes associated with the research questions were arranged.
The themes were arranged based on the Standard of Pharmacy services and the interview. We used
open coding without pre-setting and we did not use code from every list; however, we modified the
codes during the coding process.
2.5. Ethical Consideration
This research received approval from the Research Ethics Commission of the Ahmad Dahlan
University (N: 011803044, ED 19.07.2019).
2.6. Trustworthiness
This study conducted by researchers with the expertise of lecturers, practitioners, and master’s
students. The pharmacy services disclosed in this study were based on the perspectives of physicians
and nurses. To minimize study bias, we involved hospital workers to check the data interpretation. An
endeavor was made to achieve transferability by explaining the study in more detail. Confirmability
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was conducted by reflexivity, involving an explanation of the motive, background, perspective, and
study finding implications. The themes were designed by LS and reviewed by DA and one external
reviewer. Data credibility was guaranteed using member check with transferability used to give a
detailed description [4].
3. Results
We present our study results according to themes, using narratives and tables with examples of
direct quotes from the participants. The narratives of the quotes from physicians and nurses are presented
according to the themes. Some narratives are separated with respect to physicians and nurses because
of the different perspectives between them, especially in terms of the theme of acceptability of the
pharmacist’s role among other health workers. We encoded the physician as “P” and the nurse as “N”.
Participant:
A total of eight participants consisting of medical practitioners and nurses participated in the
research. The participants’ characteristics are shown in Table 1. The themes identified in this study are
presented in Table 2.










General physician 4 50
Nurse 4 50
Working (Mean 7.4 years)
<10 years 4 50
>10 years 4 50
Table 2. Theme classifications and participant quotes.
Major Themes Examples
Positive impact of pharmacists in service
When a pharmacist comes across a problem associated with wrong dosage, he will review
it. Luckily for me, mine was very careful, we could not just take medicine without his
assistance—N1.
Effect of National Insurance (Badan
Penyelenggara Jaminan Sosial:BPJS)
We are more flexible with BPJS patients because certainty is guaranteed, but in the case of
accident victims, we sometimes ask them to pay upfront, most times they ask us to treat
them with the guarantee of paying up later. However, sometimes they do not redeem these
bills. So it’s wrong too—P4
Acceptance of health workers It’s just a matter of language, if communication is good, ok, if for example thecommunication is insistent, it doesn’t depend on the doctor—P4
Drug information Same is applicable with medicine. All who understand the medicine are pharmacists. Itnever goes down to the patient—P2.
Expectations of health workers
If we had the slightest idea that this drug would be finishing soonest, we would have made
adequate provision for it. Since it hasn’t been replaced till now, we are assuming it must
have run out of production—N2.
It is expected that more drugs are purchased, especially if there is an emergency—N4.
It is not only about the pharmacist. Pharmacists are all good, and they ensure the
availability of medicine in hospitals—P1.
Pharmacists must understand that the drugs are fast moving, so they can do the planning
of the procurement better—N2.
Pharmacists have to increase their effort in planning the procurement of drug in the
emergency unit—P4.
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3.1. Positive Impact of Pharmacists on Services
3.1.1. Time Efficiency
The presence of pharmacists in emergency units has a positive impact on patients and health
workers and it is an essential contextual factor for health workers. The efficient of pharmacy services
can improve the time efficiency. With the presence of the pharmacist, faster service is provided
to patients.
For example: a patient with heart failure, will need furosemide to lower their breathing rate. But what
will happen a situation where there is no pharmacist to prescribe the drug, will the patient be left to
die?-P1
We have to wait for a moment, when we have to get the medicine from the pharmacy—N3.
3.1.2. Medication Error Prevention
Installing an emergency medical system is essential in order to prevent human errors associated
with medication. Pharmacist has competency in reviewing the prescription, including to recalculate
the dosage based on the patients’ condition. This competency is expected by the nurse to be applied in
the Emergency unit.
Giving the wrong prescription, can endanger the lives of patients, and the effect can be very fatal—N2
Participants realized that they could make a medication error both in the prescription and
administration phases. Participants opined that the presence of pharmacists in the emergency
department influences patient’s safety as they tend to review and re-check a prescription to ensure the
drugs received are safe and appropriate for consumption.
In my opinion, pharmacists have a huge influence on drug prescription, because drugs need to be
properly checked and given with the right prescription—P2
Patient safety at the emergency department is crucial. Human error can occur and it is possible
for the pharmacist to make mistakes. Therefore, it is important to crosscheck all prescriptions given to
avoid human error.
I tried digging it again, by asking him if he was sure the prescription was ok—P3
We are already accustomed to double checking our prescriptions. Whenever I give out prescription it
is cross checked by the pharmacist and if ok, given to the nurse, who also checks and issues according
to instructions. Hence, it must be safe—P4
3.2. Effect of National Health Insurance
3.2.1. Drug Supply Limitation
In this research the participants expressed the influence of the health financing system on medicine
management and the availability of medication in hospitals. There tend to be many issues related to
the unavailability of drugs, especially those guaranteed by insurance. Participants stated that one of
the administrative barriers which was related to pharmacist work was insurance. When the patients
visit the hospital, the pharmacist checks the insurance of the patients as a guarantee. After that, the
medicine is delivered to the patients. According to the participants, this situation can hold up service.
Thus, insurance is a barrier to services.
Usually the BPJS drugs sometimes run out in government hospitals. That’s the problem, so we ask
them first—P1
Sometimes, when the drugs are not available, we have to buy the drugs outside of the hospital—N2
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3.2.2. Dilemma
BPJS can influence the service system in the emergency unit. Before delivering the medicine to
the patients, the pharmacist should make sure that the patients is under the guarantee of BPJS. This
situation should not become the obstacle in the delivery of medicine.
Actually it doesn’t violate the standard operating procedure (SOP) defined by BPJS, however, in the
most of the patient’s times, they opt for payment immediately they step into a medical facility. So these
conditions has been shown to prevent such actions—P3
In contrast to this perception, this system is more of a dilemma for other participants where they
cannot sue the pharmacist. This is because most times after the drug is given, the guarantee requested
is not available and the patient fails to pay. This can be detrimental to the hospital. According to one
respondent, services can be more flexible for patients with insurance because health workers do not
need to think about their patient’s medication costs.
With respect to costs, one of the roles of pharmacists is to ensure that patients make full payment
at the hospital; however, this research reveals the existence of a BPJS (national insurance) system,
in which participants fail to notice any form of reduction in health costs owing to the presence of a
pharmacist in the emergency unit.
In terms of costs, the pharmacist controls the hospital, but this research revealed that with the
existence of a BPJS system, participants failed to witness a reduction in health costs. By using BPJS,
patients paid nothing, so the reduction of the costs due to the pharmacist’ role was not clear.
If it’s here because the general hospital costs are usually not too big, then the patient can afford for
the costs—N1
Most of the patients are BPJS members, so money is not the problem for them, because everything is
free?—N1
3.3. Acceptance of Health Workers
In terms of therapy selection, the data showed the diverse behavior between doctors and
pharmacists. One participant revealed that there was a communication hierarchy which made the
pharmacist’s advice difficult to accept. Pharmacist intervention is expected with the expectation that
the service can run smoothly without any form of dispute.
In the emergency room, we also collided with hierarchy of the health professional. Sometimes the
specialists ask for particular medicines. The pharmacist can discuss with the doctor for a change in
medication if he runs out of medicine—P1.
Meanwhile, other participants could accept the pharmacist’s intervention as long as it was under
the pharmacist’s confirmation, especially for narcotics with serious adverse drug reactions. Pharmacists
have also confirmed that drugs that contain narcotics have side effects capable of endangering the life
of patients.
I often get angry when someone changes medicine without confirmation if the drugs have some side
effects that can endanger them—P2
In addition, other participants stated that the doctor was the decision maker and the person
responsible for patient therapy. All decisions regarding therapy need to be properly communicated.
It’s just a matter of language, if communication is good, ok, if for example the communication is
unclear, it doesn’t depend on the doctor—P4
In terms of medicine information services, one of the participants who happened to be a doctor
stated that patients rarely asked them questions because they felt more comfortable asking someone
who had similar knowledge and professional experience.
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It was not a problem I did not bother asking them because I had a friend with similar
professional knowledge—P3
3.4. Drug Information
The action of giving the drug information by pharmacists in emergency units is still limited. This
is still often performed by other nurses and doctors and considered to be a waste of time, creating
a greater workload. Pharmacists are still passive in dealing directly with patients. According to the
participants, pharmacists are the most appropriate health workers and are competent with respect to
drug information.
Actually, the activity of counseling, education and information to patients is suboptimal. The problem
is that we ordered medication, which means that we are in the emergency unit and no pharmacists
here. Clarifying prescriptions to patients will mean doubling the effort, so it will be better for me to
give the medicine already explained by the pharmacy—P4.
So far communication is usually between pharmacists and nurses, and sometimes with patients which
is most times rare—N2.
3.5. Expectations of Health Workers
3.5.1. Drug Availability
Health workers expect pharmacists to do the drug procurement, thus avoiding shortages
of medicine.
Other participants stated that drug supply was not the responsibility of other hospital personnel
but rather that of the pharmacy. Other participant said that the drug supply is not only the responsibility
of the pharmacist, but also other staff. Participants expected pharmacists to perform optimal drug
planning, avoiding the unavailability of drugs. There are some techniques for the drug procurement,
such as epidemiologic, consumption and the combination of epidemiologic-consumption. Pharmacists
have competencies in this area, so that the other health professionals expect the best effort for the
drug procurement.
3.5.2. Drug Utilization Review
Overall, pharmacy services are also expected to be applied at the emergency department.
According to participants, pharmacists do not only manage medicines and medical devices but
also ensure the safety of patients. The pharmacy service should be in the emergency unit, especially
when taking into account drug management, information, and patient safety. Collaboration with other
health workers is expected to be focused on patient safety. It is also important that the pharmacist
is given the responsibility of keeping track of a patient’s medical history. This will support inter
professional communication between doctors and pharmacists. In giving therapeutic advice, one
doctor stated that the pharmacist also needs to know the history of the drug so as to give the right
advice that fits the needs of the individual.
The history of the treatment should be known to the pharmacist. So he can have an idea of the patients’
eligibility to take the drug. Yes, those are things that I think are necessary for adequate collaboration
between doctors and pharmacists. Not all of the cases in the emergency unit are new—P2.
Pharmacist can remind us about the patient’s history, such as drug allergy—P4
Some doctors revealed that a detailed medical history can provide a good understanding of the
patient’s condition and treatment. Not only is it beneficial, but it can also reduce workload and save
service time.
We need it, maybe the pharmacists are more active in directing services to patients, and those who
must be served. It is not right with us. Direct service means medicament delivery—P2.
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3.5.3. Drug Information and Education
Drug information was expected to be delivered to the patients. This activity can decrease
the workload of other health professionals, since currently, they also have to give information and
education to the patients.
We need the pharmacist to give direct service to the patients, such as information and education—N2
Just give the drug information and education to the patients—P4
On the other hand, the nurses also expected the pharmacist to give the education about drug
admixture. The nurses need more education about the incompatibility of drugs in the case of admixture.
Sometimes, we do not understand about how to admixture the drugs. In the past, we also did not
learn about it—N2.
Training on how to admixture the drugs is given; however, it is necessary to increase the frequency
and carry out routine checkups.
A few months ago there was but lately there is no such training—N4
The working environment and the large number of patients should be considered in order to
reduce medication errors.
This means that many patients come into the emergency room, sometimes we also can’t blame human
error because it can be tiring—P4
If the patients are few, it’s ok. But if there are many patients coming to ask for this, we get
confused. Hassle—N3
4. Discussion
Medical information needs to be given in the emergency unit, covering a wide range of aspects
including medicine selection, dosage and administration, medicine reactions that harm intravenous
compatibility, drug interactions, and identification of unknown medicines. Pharmacists stationed at
the emergency unit must ensure that appropriate access is provided at the primary, secondary, and
tertiary levels to ensure the smooth and prompt respond to medical requests [5]. Simone et al. reported
that almost 66% of nurses expected a protocol or informative brochure in the emergency room on
how to admixture intravenous drugs [6]. Inadequate pharmacological knowledge and fatigue caused
by high workload for nurses are some of the managerial and human factors that lead to medication
error [7]. Another qualitative study revealed that the main factors that contribute in reducing drug
safety problems include sustainable education for health workers, the development of a culture that
encourages awareness for reporting medication errors, the use of technology, and the promotion and
implementation of policies related to patient safety [8].
One of the impacts associated with the implementation of national health insurance is regulation
and medical supply, which ultimately affect the availability of drugs. Lack of medication is mostly
caused by high demand for certain types of needs such as cancer treatment and dialysis. The budgets
for the purchase of medicines are routinely being siphoned to meet the shortage of cancer drugs [9].
According to Prabowo, one of the factors that influences the availability of medicine in the BPJS era
is the inability of the pharmacist to procure adequate medicine [10]. A method to anticipate drug
unavailability is substitution of drugs with other trade names that meet the criteria. More factors must
be involved by the pharmacist in the drug procurement process, so that drug unavailability could
be avoided.
A study about implementing a comprehensive pharmacist program in emergency unit, the
department pharmacist program revealed an increase in cost efficiency, with 76.7% of respondents
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stating that the role of pharmacists could reduce the cost of healthcare [3,11]. According to a recent
study, with pharmacy program in emergency unit, cost of efficiency reached 74.03%. This type of
intervention can be said to be quite significant in terms of cost-saving. In that study, the health costs
were not a concern for participants, and no significant cost savings were made by the pharmacists [12].
According to other research, the opportunity for cost savings in many countries is limited where the
average cost for each patient per treatment represents only a small part of the total cost. Thus, it is
difficult to justify the result [13].
In a study conducted by Keller et al. using a qualitative research approach, one participant
stated hierarchy as one of the obstacles between doctors and nurses, and expressed relief that they
could communicate outside the hospital with ease [14]. A similar study revealed that doctors might
think that making prescriptions and ensuring the patient follows the instructions or orders is better
than participating in decision-making. Differences in the educational level and knowledge between
professions can impact members’ ability to exchange ideas and interpret patient health problems,
thereby affecting the quality of treatment provided. This level of education and knowledge gap
will hinder the process of effective communication [15]. A qualitative study conducted by Pun et al.
revealed one of the problems of inter professional communication in the emergency unit as being the
transfer of medical information to inadequate staff. Owing to the fact that patients often enter the
emergency unit without medical records, a comprehensive understanding of the patient’s condition
and treatment history should be made to support quality health services [16]. A drug utilization review
should be conducted precisely in the emergency unit because of the inconsistency in the patient’s
medical records. The pharmacist has the competence to perform drug reconciliation and to prevent
medication errors during patient visits to the emergency unit [17,18].
Some pharmacy services can be developed at the emergency unit and this service involves
creditors, regulators, and administrators of health care facilities [5]. For the clinical pharmacy practice
in the hospital ward, normally one pharmacist must undertake prescription review, monitoring of
treatment, giving of drug information, and education and counseling for 30 patients. For outpatient
services, one pharmacist must perform prescription screening and drug administration, and provide
information, education, and counseling for 50 patients [19]. According to this situation, ideally, one
pharmacist must be placed in the emergency unit.
For clinical practice, the pharmacy service in the emergency unit is still related to drug supply
management. The national standard should be developed to increase the quality of the pharmacist
services. The interprofessional relationship concept should be accepted and applied by all health
professionals. This concept must be introduced in undergraduate education.
Health workers’ perceptions of the pharmacist’s role in the emergency unit include not only
services but also the patients’ safety in the emergency unit. This perception brings up expectations
about patient safety. On the other hand, the national health insurance system may influence perceptions
and expectations. To the best of our knowledge, this study is the first qualitative study conducted
in Indonesia on the topic of health workers’ perceptions of the pharmacist’s role in emergency units.
Currently there is no national standard for the pharmacy services in emergency units. Our findings
can be used as a consideration to develop the standard of the pharmacist’s role in the emergency
unit. Physicians and nurses perceive that delivering the drug information is an important job of
the pharmacist in the emergency unit. However, the pharmacist’s role can be limited by national
health insurance due to the limited medications available in the emergency unit. During emergency
situations, the physician and the nurse need medications appropriate to the patients’ conditions. The
pharmacist is responsible for the availability of the medications.
This study has the limitation due to the use of only one method, which was the semi structured
interview method. Thus, we cannot generalize the results. The results of study were more focused
on drug supply management and drug information. In these cases, the small number of participants
can support the validity of the study findings. Furthermore, data analysis was only carried out by the
researcher to clarify the efficiency of the data obtained.
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5. Conclusions
Various perceptions are conveyed by participants regarding the pharmacy service in emergency
units. The existence of a pharmacist may increase the efficiency of service time and prevent human
error. The national health insurance service is in charge of the role played by health workers and
pharmacists. Communication, information, and adequate medical education are still insufficient in
emergency units. Participants expect that pharmacists and policy makers make adequate provisions for
drugs in the emergency units. Pharmacists need to enhance the quality of practice in accordance with
their competence, especially in tracking the patient’s drug history and in terms of drug education for
both patients and health workers. These expectations are intended reduce the workload of participants,
save time, and improve the quality of communication among medical personnel.
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Abstract: As value-based payments become more common in healthcare, providers can develop
collaborative relationships to support performance. A medical clinic and community pharmacy
worked together to deliver collaborative medication management services to targeted patients in
an accountable care organization. The community pharmacy was paid by the clinic to conduct
comprehensive medication reviews (CMRs) for 116 patients. The CMRs initially were delivered to
patients taking at least 10 medications and to patients rated as high cost/risk by the clinic. The most
common medication-related problem types were Needs additional therapy (38.8%) and Suboptimal
therapy (19.0%). The most common pharmacist actions were to Change medication (18.1%) and
Initiate new therapy (13.8%). Financial analyses showed net savings in annual patient out-of-pocket
expenses just over $15,000 for the cohort of patients, and net annual direct cost savings from a
payer perspective of about $70,000. This innovative partnership between a medical clinic system
and a regional pharmacy chain built upon initial discussions and planning. The partners were
able to address problems that arose with their collaboration, changing their approach as needed.
The outcomes were positive for the clinic and pharmacy, their patients and the payer(s). Interested
providers are encouraged to pursue similar collaborations, which could be key to success in today’s
healthcare environment.
Keywords: comprehensive medication review; community pharmacy; collaboration
1. Introduction
The current healthcare environment has made value-based payments a popular approach [1,2].
Under such programs, providers often can benefit from closer coordination with each other across
the continuum of care. An important provider dyad, especially for managing chronic conditions,
is the medical clinic–community pharmacy. Both of these providers are involved with helping patients
achieve positive outcomes from medication therapy while working to limit total costs of care [2,3].
Though some clinic–pharmacy coordination is occurring, few detailed descriptions have been
published about successful collaboration between clinics and community pharmacies under the
evolving value-based payment environment [4,5]. Over the past five years, the Iowa Department of
Public Health has worked with a team at the University of Iowa College of Pharmacy to foster team care
among clinic–community pharmacy partners to improve management of hypertension and diabetes.
This work has stimulated some clinic–community pharmacy collaboration. The objective of this case
report is to describe the development, operations, and outcomes of an innovative clinic–community
pharmacy collaborative care model for providers facing value-based payments.
McFarland Clinic has been a leading multispecialty clinic organization in Iowa for over 70 years.
It is Iowa’s largest physician-owned multispecialty clinic. The McFarland Clinic provider network
serves patients through about 20 locations in central Iowa, delivering over 1 million patient visits
annually, involving more than 280 providers and 1000 staff members. McFarland Clinic embraces
innovation which enables excellence in clinical practice. Given the presence of value-based payment
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programs by accountable care organizations (ACOs), McFarland Clinic leaders were considering ways
to successfully apply a population health management model to support their value-based performance.
NuCara Pharmacy is a full-service regional pharmacy chain with more than 20 locations in four
states. NuCara strives to provide the best products, the best service, and latest innovations to benefit
their patients and customers. Their pharmacists work with patients and other providers to optimize
medication therapy, in addition to delivering a range of pharmacy services. Their services include
compounding custom prescription medications, medication management, immunizations, medication
synchronization, medication packaging, infusion services, and sales of home medical equipment.
They participate in a value-based pharmacy program operated by a large payer, which made closer
coordination with clinics of interest to them.
2. Materials and Methods
To gather data about this case study, a key informant from both the participating clinic and
the participating pharmacy was interviewed, using semi-structured questions. The set of interview
questions was developed from an initial description of the clinic-community pharmacy joint activities
by a participating pharmacist. The questions asked about having the pharmacy conduct comprehensive
medication reviews for patients using a lot of medications, a pharmacy medication management
service for high risk/high cost patients, and the start of medication adherence management service
provided by the pharmacy. The interviews were audiotaped, transcribed verbatim, and then analyzed.
The responses were coded for the topics describing how the partners developed their joint activities,
as well as how they operated. In addition, some documents describing the partnership were shared
with the investigator.
In addition, a financial analysis was conducted by the pharmacy to estimate the net benefit
associated with the joint activities. A conservative approach was followed, focusing on cost savings
resulting from changes in medication therapy made in response to the CMRs, primarily from brand
or non-formulary medications to generic formulary medications. Such savings were estimated for
12 months, from a payer perspective and for patient out-of-pocket expenses. Medication costs were
calculated using insurance payment formulas for the insurance the patients had, or a cash formula
used for that medication. Estimated actual acquisition costs for the pharmacy were used for product
costs. No related cost estimates for reduced clinic visits, ER visits or hospitalizations were included in
the financial analysis.
3. Results
Initial Teamwork: Both of these providers have locations in Ames, Iowa that participated in an
initial effort at team management of patients with diabetes, working with a team at the University
of Iowa. For this first effort, representatives of the McFarland Clinic and NuCara Pharmacy met
with personnel from the University of Iowa and the Iowa Department of Public Health to discuss
how the team approach could work between their organizations. Though these providers worked
to collaborate, this initial effort was limited by having few targeted patients not meeting diabetes
goals (e.g., hemoglobin a1c target, BP target). Thus, this coordinated work on team management of
medications for patients with diabetes did not persist. However, it did lay the groundwork for later
collaboration, as the providers were able to better understand each other’s practices, appreciate their
respective expertise and establish a working rapport.
Medication Management for High Medication Use Patients: One approach pursued by the clinic
to try to improve ACO performance metrics was to optimize medication therapy for their patients
who were taking at least ten different medications and were covered by an insurer’s ACO program.
The clinic approached NuCara Pharmacy in Ames about providing a comprehensive medication review
(CMR) service for a panel of patients with high medication use. The primary discussions occurred
between the physician and pharmacist who had worked together in the initial team management for
patients with diabetes. After a mutually agreeable plan had been outlined, each provider worked with
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their own organization’s leadership to get support to proceed. The pharmacy was willing to provide a
comprehensive medication management service, for which the clinic paid the pharmacy using a fee for
service approach. The physician leader talked with the clinic’s providers about the program to gain
their support and feedback. No formal agreement was signed initially, to allow flexibility to adjust the
collaboration, though one was signed later.
To begin the service, the clinic identified a list of about 200 patients in the Ames area to receive
a comprehensive medication review (CMR) by one of the pharmacy’s pharmacists. These patients
were taking at least ten different medications, which was considered high medication use. Some of
these patients got their medications dispensed from the participating pharmacy, while most did not.
The clinic sent an initial letter to each patient that described the program and encouraged them to work
with the pharmacy to receive a CMR. After the letters were sent out, the pharmacy phoned the patients
on the list to determine their willingness to participate in the program and to schedule CMRs for
interested patients. There was a low response rate from patients initially. To address this issue, the clinic
revised the patient letter and added the patient’s provider’s signature. Also, the NuCara pharmacist
tweaked the telephone contact script. Together, these changes improved the patient participation in
this CMR program. The pharmacy provided collaborative comprehensive medication management
services to 85 patients in this first phase.
Most of the CMRs were conducted over the telephone, though some were completed in the
pharmacy. The pharmacist first gathered patient information from the available patient records
(either from the pharmacy or from the clinic EMR) to get an initial view of the patient’s medication
regimen and labs. Then, the pharmacist talked with the patient to collect additional information about
how the medications were being taken, and if likely adverse effects were present. While on the call with
the patient the pharmacist discussed a medication plan to address any identified problems. The plan
was implemented by working with the patient and/or the involved provider(s). Communication with
providers used multiple modes, including secure text through the EMR, faxing the clinic, and phoning
the clinic.
Another obstacle was limited responses by clinic providers to clinical notes sent by the pharmacist.
It was typical that the pharmacist identified either a question or a potential medication-related problem
when reviewing a patient’s medications. In such instances the pharmacist sent a note to the involved
provider(s) asking them to clarify the situation or to adjust medication therapy. Unfortunately, since
this was the first time many of the clinic providers were collaborating closely with a community
pharmacist on medication management, the providers hesitated to respond to pharmacist notes/queries.
The pharmacist and physician leader discussed this situation, and the physician leader communicated
with the clinic providers to clarify the objectives of the collaboration, asking them to be responsive to
the pharmacist’s notes/queries.
The pharmacist worked with the patients’ dispensing pharmacies to get their medication lists
and/or dispensing records, which were used for the CMRs. It required considerable effort to get other
pharmacies to provide medication information, but some did eventually provide patient medication
information requested by the pharmacist. To get more complete clinical information about the
listed patients, the pharmacist worked with the clinic to get access to the clinic’s EMR. The EMR
provided the pharmacist with clinical information that allowed more efficient and effective CMRs
to be conducted. In addition, the pharmacist was able to use a secure texting feature in the EMR.
However, its effectiveness in communicating with the clinic providers was variable because not all of
them used it.
Medication Management for High Risk Patients: After the success of the initial teamwork to
address patients with high medication use, the clinic and pharmacy developed another joint effort
focused on patients with high risk and/or high cost. From a list of high risk patients from the clinic,
31 patients received comprehensive medication review services from the pharmacy in the second
phase of this collaboration. The clinic continued to pay the pharmacy to provide the collaborative
CMR service. As with the previous teamwork, the clinic notified the patients that the pharmacy would
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be contacting them about the CMR service. The same collaborative CMR service was delivered to
this second group of patients, who typically had multiple chronic conditions or were taking high
cost medications. As with the first group, not many of these patients were getting their medications
dispensed at NuCara Pharmacy. Though the communication processes were smoother than during
the initial phase, some patients declined to have the CMR service. Similarly, the responsiveness of
providers was somewhat better with this second group, after having the processes improved during
the work with the first group of patients.
The partners conducted an aggregate evaluation of the collaborative comprehensive medication
review services for the two groups. This work provided CMRs for a total of 116 patients. One component
of their assessment was to characterize the medication-related problems identified by the pharmacist
when conducting the CMRs. The most frequent types of medication-related problems were “Needs
additional therapy” (38.8% of patients) and “Suboptimal therapy” (19.0%) (Table S1).
In addition, the pharmacist’s actions were summarized. The most common pharmacist action was
to work with the provider and patient to change a medication (18.1%) (Table S2). The pharmacist also
worked to initiate new drug therapy (13.8%) and helped to discontinue unnecessary or problematic
medications (12.9%). The pharmacist also educated patients to improve their medication administration
technique (e.g., use of inhaler) (11.2%).
For the financial analysis, the net cost savings associated with pharmacist services under the
partnership were calculated from a patient perspective and a payer perspective. The estimated 12-month
direct cost savings for the 116 patients totaled $15,483. Also, direct cost savings on medications for a
payer were estimated to be $70,513.74 over 12 months. Based on a variable fee amount for the different
patient groups, the cost to the clinic for paying the pharmacist to conduct the CMRs totaled $13,150.
Current State of Collaborative Medication Management: The partners have built on the success
of the comprehensive medication review service by implementing a service targeted at improving
medication adherence, which is a common challenge for chronic medication therapy. This step was
an initiative raised by the pharmacy to work together to improve medication adherence for shared
patients: Adherence Services Referral Program. The adherence program can help the pharmacy
perform well on metrics in a value-based pharmacy program in which it is participating. For this
adherence program NuCara Pharmacy worked together with Medicap, another regional pharmacy
chain who also has a pharmacy in Ames and others in central Iowa. Together these pharmacies are
working with McFarland Clinics in their communities to identify and address medication nonadherence
for only their own dispensing patients. Building on the success of the collaborative CMRs with one
NuCara Pharmacy, McFarland Clinics is working with over a dozen pharmacies between NuCara and
Medicap pharmacies–with all of the pharmacies participating in a value-based pharmacy program that
includes adherence-based metrics. A progressive aspect of this newer program is that McFarland has
allowed these pharmacy partners to access their EMRs through the web-based EpicCare Links. Such a
connection creates efficiencies for the pharmacists caring for mutual patients of McFarland Clinics,
while eliminating some phone calls to the clinic. Though it is too early to evaluate this adherence
program, it is promising.
4. Discussion
This case report describes collaboration that occurred primarily over about 18 months between
McFarland Clinic and NuCara Pharmacy. These partners built on an initial team-based project to
implement collaborative comprehensive medication review services, delivered by a pharmacist working
with clinic providers and patients. There were several innovative components of this collaboration,
including: a clinic paying a community pharmacy to improve patient care under an ACO model, the
clinic actively engaging patients and providers to participate with the pharmacy services, and the clinic
connecting with the pharmacy via its EMR. Given the widespread presence of ACOs, and the many
clinics that do not employ pharmacists, this model could be useful to a large number of providers.
Progressive clinics and pharmacies that want to succeed under the value-based payment programs
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being used more commonly today should explore the feasibility of implementing a similar approach in
their communities [6].
Facilitators and obstacles of this collaborative approach can be identified. An important facilitator
is having a trusted, motivated partner [7–9]. In this case, the partners gained familiarity by working
on a small project facilitated by the Iowa Department of Public Health and the University of Iowa.
Other prospective partners can identify opportunities to work together to address a problem in their
community or among mutual patients. Perhaps it is finding a way to improve medication adherence,
or in coordinating to better manage a key chronic condition, such as diabetes or hypertension,
represented in performance metrics. Working together will give the partners an opportunity to get to
know each other better, which is a starting point for developing a working rapport and trust [10].
A related facilitator for establishing successful clinic-pharmacy collaboration is to start small [10].
Both of the key practitioners from the clinic and pharmacy partners in this case identified starting in
a limited way as an important factor in their progress. The clinic approached the pharmacy about
providing some type of service that could help with their patients who were the highest medication
users. The pharmacy had some experience with providing comprehensive medication reviews,
and offered that as a viable option. Upon discussion, the partners agreed that the clinic would send
a list of patients using at least ten medications, who became the targets for the first phase of the
medication review service. This relatively narrow focus allowed the clinic and pharmacy to work
through issues that arose as the new program was implemented, including communications with
patients, responsiveness of clinic providers to pharmacist notes and pharmacy access to the clinic
EMR. Potential partners seeking to pursue a similar collaborative model would benefit from discussing
patient groups or issues to get their collaboration started. Then, spend time clarifying roles of the
parties involved, including what services are to be performed, how communication will be conducted,
and details for any payments or revenue sharing. Starting small, but with a clear plan, should support
positive results on innovative collaboration for pharmacy services.
A third factor that can contribute to a successful collaborative working relationship is to collect
data that track performance on key variables or metrics [6]. In this case, the parties tracked the
number and type of medication-related problems identified and managed through the comprehensive
medication review service. In addition, they examined finances associated with the program. It takes
some planning and effort to determine which data to collect, how it will be collected, and then how
it will be analyzed. Each of these partners had some resources and experience in evaluating new
services or programs, which helped them make a feasible evaluation plan for their collaboration.
In addition, they worked with Telligen, the CMS quality improvement organization (QIO) that serves
Iowa. While Telligen did not have data for the commercial ACO, they did have data for the small
number of Medicare beneficiaries who received a CMR. Partners should prospectively plan for some
type of evaluation of their efforts at collaboration. Such an assessment can be used internally to build
support for the program (e.g., among providers), as well as externally (e.g., to talk with payers or other
potential partners).
An obstacle encountered by these partners was limited responsiveness by clinic providers to
pharmacist notes sent either by fax or via the clinic EMR. This likely occurred since many of the
providers were not used to receiving clinical notes from pharmacists. Rather, their communications
with pharmacists tended to focus on renewing prescription orders or clarifying questions on new orders.
For the CMR service, the pharmacist had to communicate with the providers about potential problems
with the medications, sometimes with suggested changes in therapy. Again, the clinic providers may
not have wanted to receive such feedback at first and ignored it. The lead clinic physician spent
more time communicating with his colleagues about the collaboration, and the responsiveness of the
providers improved. Prospective partners, especially within a clinic or system, should have discussions
beforehand about what types of communications they could receive and how they should respond to
them. Having clear expectations about communication should smooth out some of the progress when
implementing a new collaborative program.
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Patient acceptance was a challenge for the collaborative comprehensive medication review service
delivered to the two patients groups identified at the clinic. This mostly arose because not all of the
patients were regular patients at the partner pharmacy. Rather, the pharmacy was serving as the
provider for the CMR services for the clinic’s patients. Though the clinic sent letters to the patients
before the pharmacy telephoned them, over half of the patients initially declined the CMR service.
An adjustment in the letter from the clinic, incorporating their physician’s agreement, helped the
providers and patients both have more confidence in that particular patient receiving the CMR service.
The pharmacy also made helpful changes in their phone script when contacting the patients. The latest
service, focused on medication adherence, is directed only at current patients of the clinic and pharmacy.
Thus, the difficulty of not having a relationship with the patient will not be present for the pharmacy.
Prospective partners can address this issue by limiting their collaboration to only mutual patients.
In addition, having an announcement about any collaborative program initiated by the clinic would be
vital to informing patients about a new service opportunity.
5. Conclusions
In conclusion, this case report describes an innovative partnership between a medical clinic
system and a regional pharmacy chain. Both organizations are innovative, and were willing to work
together. Their collaboration built upon initial discussions and planning. They were able to continue
to communicate to address problems that arose with their collaborative program. The outcomes
were positive for both the clinic and pharmacy, their patients and the payer(s). The clinic improved
performance associated with ACO metrics and received helpful clinical input from a pharmacist.
The pharmacy expanded its services and generated new revenue. Patients received more coordinated
care, which supported some cost savings for the patients and payers. Interested clinics, health systems
and pharmacies are encouraged to pursue similar collaborations, which could be key to success in
today’s healthcare environment.
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Abstract: Interprofessional care for chronic kidney disease facilitates the delivery of high quality,
comprehensive care to a complex, at-risk population. Interprofessional care is resource intensive and
requires a value proposition. Joint Commission certification is a voluntary process that improves
patient outcomes, provides external validity to hospital administration and enhances visibility to
patients and referring providers. This is a single-center, retrospective study describing quality
assurance and performance improvement in chronic kidney disease, Joint Commission certification
and quality outcomes. A total of 440 patients were included in the analysis. Thirteen quality indicators
consisting of clinical and process of care indicators were developed and measured for a period of
two years from 2009–2017. Significant improvements or at least persistently high performance were
noted for key quality indicators such as blood pressure control (85%), estimation of cardiovascular
risk (100%), measurement of hemoglobin A1c (98%), vaccination (93%), referrals for vascular access
and transplantation (100%), placement of permanent dialysis access (61%), discussion of advanced
directives (94%), online patient education (71%) and completion of office visit documentation (100%).
High patient satisfaction scores (94–96%) are consistent with excellent quality of care provided.
Keywords: chronic kidney disease; interprofessional care; quality assurance
1. Introduction
Interprofessional (IP) care for chronic kidney disease (CKD) facilitates the delivery of
comprehensive care to a complex, at-risk population. Evidence based strategies for slowing progression
of CKD are well described but not consistently applied to the individual patient. Interprofessional
teams focus on implementing evidenced based care to slow down the progression of CKD, educating
patients about their disease and streamlining the transition to end stage renal disease (ESRD).
This comprehensive care has been shown to reduce hospitalizations [1–6] lower mortality [1,3,4,7–9],
slow the progression of CKD [1–3,10,11] and prepare patients for transitions in care [4,7,8]. Despite
these benefits, IP CKD programs are difficult to implement because of resources. Advocates of IP care
should provide evidence of value to justify the additional cost since CKD consumes a disproportionate
share of healthcare funding globally [12,13]. The Joint Commission (TJC) certification is a voluntary
process that can improve patient outcomes, provides external validity to hospital administration and
enhances visibility to patients and referring providers. In this paper, we describe the development of
an IP CKD program and the pathway to TJC disease specific certification in CKD care.
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2. Materials and Methods
This is a retrospective, single center study of all adult patients receiving care in the IP CKD
Program from July 2011–2016. We included all adult patients with CKD receiving IP care. Patients
with less than 3 months of follow up in the program were excluded from the analysis. Clinical data
including patient demographics, comorbidities, laboratory results, vital signs measured during clinic
visits, medications, process of care measures as well as outcomes of dialysis initiation, transplantation
or death were extracted from the electronic health record (EHR). To analyze patient demographics
and performance measures for each recertification cycle, we used descriptive statistics including mean
and standard deviation (SD) or median and range for continuous data when appropriate, frequency
counts and percentage for categorical data. Descriptive statistics were calculated using R version (3.4.2).
The institutional review board (IRB) for human subjects approved this study with a waiver of consent.
2.1. Program Description
The pharmacist wrote the proposal for the IP CKD Program and obtained funding from the health
system. This program was set up as its own cost center and the pharmacist funding is supported by the
health system for direct patient care and administration of the CKD program. The nephrologist and
pharmacist created the infrastructure for the program including a mission statement, clinic schedules,
job descriptions, template notes and standard orders. Our institutional IP CKD Program opened in
2007 and provides comprehensive care to patients with CKD stage 2 through 5. Patients are referred for
IP care by a nephrologist or through direct referral from other disciplines. The program does not have
specific referring criteria; rather any patient who the referring physician feels would benefit from IP
CKD care is eligible. The program consists of two half-day clinics, which operate in the same physical
space as other nephrology clinics. Patients are seen every 1 to 6 months depending on disease severity.
Visits are approximately 90 and 45 min for new and return patients, respectively. The core IP team
consists of a nephrologist/medical director, pharmacist/program administrator, nurse, dietitian, social
worker and patient education coordinator. Interprofessional care is provided based on institutional
CKD guidelines and documented in the EHR. Chronic kidney disease guidelines were developed
using Kidney Disease Improving Global Outcomes (KDIGO) guidelines, Kidney Disease Outcomes
Quality Initiative (KDOQI), Joint National Commission hypertension guidelines, American Diabetes
Association diabetes care guidelines, American Heart Association guidelines as well primary and
tertiary references [14–69]. These were approved by our institutional Pharmacy and Therapeutics
Committee and updated annually.
Patients receive many services in addition to the traditional nephrology care such as cardiovascular
risk assessment, dietary counseling on CKD diet, weight loss, vaccinations, smoking cessation,
medication reconciliation and management, personalized medication schedules, assistance with
insurance and transportation issues as well as assistance with transition of care to transplant, dialysis or
hospice (Appendix A). Patient education is provided during each visit on an individual basis, through
online educational videos (https://www.youtube.com/playlist?list=PLp5o_4MxOoYRJ_zYObvWzC-
O0VE7wFqaG) and in a classroom setting. Educational topics include introduction to CKD, medications
and CKD, diet, social support networks, renal replacement modalities and transplantation.
Each team member has defined roles and responsibilities to optimize patient care. All members
of the IP team receive orientation to the program and institutional CKD guidelines. Team members
are evaluated for competency initially and must demonstrate continuing competency and education
annually. Competency is assessed verbally and through the demonstration of skills where appropriate.
Team members answer questions about mini case scenarios to test their knowledge of CKD staging,
overall goals of care based on CKD stage, laboratory parameters and foods high in phosphorus and
potassium. Skills such as blood pressure measurement or administration of medications are evaluated
by demonstration. Contemporary topics in CKD care are reviewed during a mandatory monthly
journal club. The Medical Director and Program Administrator conduct annual performance reviews
for all team members incorporating 360-degree feedback from team members.
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2.2. Design of Quality Assessment and Performance Improvement Program (QAPI) and CKD Registry
The IP team determined appropriate quality indicators consisting of clinical, process and financial
measures such as blood pressure (BP) control, prevalence of permanent vascular access at dialysis
initiation, vaccination rates, patient education among others (Table 1). These measures were chosen on
the basis of their importance for delaying CKD progression, streamlining transitions in care, improving
patient experience and applicability to the majority of the program population. Each quality indicator
was defined, baseline and targets established and strategies were developed to achieve target goals.
For example, we defined BP control as the percentage of patients achieving the target BP per Joint
National Committee guidelines. We established our baseline rate of control and set a target for
improvement. Strategies to achieve the target included medical assistant education on performing
a BP measurement, providing home BP monitors and logs to patients for home monitoring, patient
education and nursing telephone follow up for patients with uncontrolled hypertension.
We developed a CKD registry in the EHR enabling the automated reporting of CKD outcomes.
Data is electronically extracted and presented in a QAPI dashboard, which is reviewed on a monthly
basis by the IP team and submitted to TJC. All outliers are reviewed in detail during the monthly team
meeting and new strategies to achieve targets are developed on an as needed basis.
Table 1. Summary of performance measures.
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Table 1. Cont.
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access and/or
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Not all patients are
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(i.e., age less than 70 years,
no active cancer in the past
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decline dialysis and/or
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Nephrologists caring for CKD patients
are in a position to discuss transitions in
care and patient preferences.
2011–2013
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Process of Care/All new
patients receiving
education on CKD within
3 months of entering
the program.
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Patient education can increase
knowledge of CKD progression and








patients with DM and
CKD stage 2–5 with
HgA1c tested in last
6 months.
90%
Tight control of glucose is associated
with a reduction of microvascular and
macrovascular complications. Patients
with controlled diabetes should have
HgA1c checked every 6 months and if
uncontrolled every 3 months [61].
2015–2017
Access to care Process of Care/Mediandays to first appointment. Negative trend
Two half day clinics limits the number
of visits. Patients experienced long










Cardiovascular disease is the leading
cause of death in patients with CKD.
The ASCVD risk calculator provides an
estimate of a patient’s risk for a
cardiovascular event with the goal of






office visits cancelled by
patients.
Negative trend
Patients with CKD have numerous
barriers to their access to care.
Evaluating the clinic cancellation rate
and reasons may improve the






office visit encounters with
complete documentation
within 48 h.
Positive trend Complete encounter documentation isrequired to effectively bill for services. 2013–2015
BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure, CKD = chronic kidney
disease, AVF = arteriovenous fistula, CVC = central venous catheter, eGFR = estimated glomerular filtration rate,
DM = diabetes mellitus, ASCVD = atherosclerotic cardiovascular disease.
3. Results
A total of 440 patients currently receive care in the IP CKD program. The demographics are
summarized in Table 2.
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Table 2. Patient demographics.
Characteristic n = 440
Age, years (mean ± SD) 64.2 ± 14.5
Gender, Male (%) 55










The mean age of the population is 64.2 ± 14.5 years, 55% are male and the majority are White with
24% Hispanic patients as the second largest ethnicity. The majority of patients are in CKD stage 3 (51%)
followed by stage 4 (24%) and stage 5 (17%). Approximately half of the patients have diabetes and 92%
have hypertension.
Prior to the first certification in 2010, we chose the following quality indicators: (1) blood pressure
control (median systolic and diastolic blood pressure, percent of patients with SBP ≤ 130 mmHg,
percent of patients with SBP ≤ 140 mmHg), (2) median hemoglobin, (3) screening for appropriate
patient referrals to vascular surgery and transplant and (4) percent of patients with education about
CKD within 3 months of clinic enrollment (Table 3).
Table 3. Performance measurement report: 2009–2011.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 190 219 198 199 191 199 208 216
Median SBP (mmHg) 136 137 135 132 127 131 133 131
Median DBP (mmHg) 73 74 74 70 70 72 73 72
Median Hemoglobin (g/dL) 11 11 12 11 12 11 11 11
Patients with Referral to Vascular Surgery (%) 96 100 96 100 100 100 91 100
Patients with Referral to Transplant Program (%) 88 100 100 100 100 100 81 100
Patients Attending Patient Education Classes (%) 29 33 50 50 100 100 100 100
CKD = chronic kidney disease; DBP = diastolic blood pressure; SBP = systolic blood pressure.
We collected 6 months of data on those measures for the initial certification. The range of median
systolic blood pressure was 127–137 mmHg, 36–44% of patients had SBP ≤ 130 mmHg, and 56–76%
of patients had SBP ≤ 140 mmHg. Eighty-eight to 100% of patients had an appropriate referral to
vascular surgery or transplantation. The percentage of patients who received in classroom CKD
education within the first 3 months of joining the clinic steadily rose from 33% to 50%. We received
Disease Specific Certification for CKD with no findings for improvement and were noted to be the
first program in the United States with this designation. After receiving our certification, our surveyor
invited us to present our program outcomes to the Quality Net Conference for the Centers for Medicare
and Medicaid.
In the first recertification cycle 2011–2013, we chose the following indicators: (1) SBP ≤ 130 mmHg
(2) pneumococcal vaccination rate (3) discussion of advanced directives (4) office visit cancellation rate
(Table 4).
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Table 4. Program performance measurement report: 2011–2013.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 209 210 223 227 228 214 211 225
Patients with SBP ≤ 130 mmHg (%) 57 54 51 51 45 47 49 58
Patients with SBP ≤ 140 mmHg (%) 79 88 79 85 75 74 79 82
Patients with Pneumococcal Vaccine (%) 49 61 69 84 88 89 93 93
Patients with Advanced Directive Addressed (%) 29 75 94 93 94 93 93 89
Office Visit Cancellation Rate (%) - 28 25 19 23 22 25 21
SBP = systolic blood pressure.
Tight control of SBP ≤ 130 mmHg was achieved in 47–58% of patients and SBP ≤ 140mmHg was
obtained in 74–85% of patients. Pneumococcal vaccination included Prevnar 13 and Pneumovax 23
and the rate rapidly rose from 49% in the first quarter to 93% in the last quarter of the cycle, as did the
percentage of patients who discussed advanced directives with our social worker, from 29% to 94%
over a two-year period. We were not able to sustain a decrease in the rate of cancellation of office visits
after an initial drop from 28% to 19%.
In the second recertification cycle 2013–2015, we chose the following quality indicators: (1) SBP ≤ 130
and 140 mmHg (2) percentage of patients starting hemodialysis (HD) with AVF or arteriovenous graft
(AVG), (3) median days from referral to first appointment in CKD clinic and (4) percent of office notes
closed in EHR within 48 h (Table 5).
Table 5. Performance measurement report: 2013–2015.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 240 234 241 156 256 259 223 136
Patients w/SBP ≤ 130 mm Hg (%) 53 56 55 55 - - - -
Patients w/SBP ≤ 140 mm Hg (%) 81 84 82 85 85 79 82 83
Patients w/AVF or Graft at Dialysis Start (%) 100 100 100 100 60 25 75 50
Median Days from Referral to First Appointment 17 13 7 7 9 37 12 14
Notes Closed within 48 h (%) 45 98 96 99 92 95 98 100
AVF = arteriovenous fistula, SBP = systolic blood pressure.
In December 2013, the Joint National Commission released new guidelines recommending a blood
pressure goal of ≤140 mmHg and we decided to stop tracking the SBP goal ≤130 mmHg. We achieved
SBP control to ≤140 mmHg in 79–85% of patients. The percentage of patients starting dialysis with
AVF or AVG varied from 25 to 100% in different quarters with overall average of 77%. The median
wait time from referral to first CKD clinic appointment varied from 7 to 37 days. The percentage of
note closure within 48 h improved from 45% to 100%.
In the third recertification cycle 2015–2017, the following quality indicators were chosen: (1) patient
viewing of online education videos, (2) continuation of permanent dialysis access indicator, (3) ordering
of hemoglobin A1c every 6 months for patients with diabetes and (4) estimation and documentation of
atherosclerotic cardiovascular disease (ASCVD) risk (Table 6).
Table 6. Performance measurement report: 2015–2017.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 216 252 219 247 224 225 212 243
% Patients w/AVF or Graft at Dialysis Start 100 89 50 100 0 44 56 50
% Patients w/Online Patient Education 0 10 25 35 48 55 64 71
% Patients w/DM and HgA1c Order within 6 mo 90 94 90 93 89 91 97 98
% Patients w/ASCVD Risk Documentation 82 100 99 100 98 99 100 100
ASCVD=atherosclerotic cardiovascular disease; AV= arteriovenous fistula, DM=diabetes mellitus, HgA1c= glycated
hemoglobin, mo =months.
Fifteen patient education videos were created to improve treatment adherence, self-care,
and clinical outcomes for CKD patients. CKD team members, including the nephrologist, pharmacist,
dietitian, and social worker, each created several 5–15 min videos on specific topics related to CKD
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patient care that were peer reviewed by all team members. The videos were filmed in English at
a production studio located on the main university campus. The entire process of video planning
and filming took three months. After production of videos was complete, a CKD playlist of videos
was created and published on YouTube (https://www.youtube.com/playlist?list=PLp5o_4MxOoYRJ_
zYObvWzC-O0VE7wFqaG). A link to the videos was shared through e-mail, EHR patient messaging
and posted on the CKD program website. A brochure advertising the videos was created and
distributed to patients in clinic and through mail. For patients without computers, internet access,
or mobile phones, a DVD was distributed in clinic or the video was played for the patient on clinic
computers. Each patient was asked about video views during the office visit and this was documented
in the EHR using smart fields for electronic data extraction. There was a steep and consistent increase in
the percentage of patients viewing our online education videos from 0 to 71%. The 15 videos received
a total of 284,808 views and the total number of views per videos ranged from 276 to 132,710 far
surpassing our patient population. Videos with the highest views included content on: (1) symptoms
of kidney disease (132,710 views), (2) stages of kidney disease (91,265 views), and (3) laboratory values
of kidney disease (18,615 views).
For the other quality indicators, the percentage of permanent dialysis access at dialysis initiation
was 0–100% (median 61%), and, the number of patients starting dialysis was low ranging from 0–3 per
month. Hemoglobin A1c testing was high at baseline at 90% and remained consistently high with a
range of 89–98%. ASCVD risk was not routinely documented in office visit notes at baseline. After
implementation of an automated ASCVD risk estimate calculator in the EHR, we demonstrated an
immediate increase in documentation to 82% in the first quarter of implementation and subsequent
increase to 100% documentation. We received re-certification with no findings for improvement and
positive feedback on the successful development of online education for patients with CKD.
Patient satisfaction was measured using The Consumer Assessment of Health Providers and
Systems surveys administered by Press Ganey and collected for each certification and recertification
cycle. From 2012 to present, the percentage of surveys where patients reported “yes, definitely” on a
3-point scale for their likelihood to recommend the program and the physician communication domain
were approximately 94% and 96%, respectively.
4. Discussion
In this study, we demonstrated that IP care for CKD could be implemented and sustained over a
long time period at an academic institution. The process of obtaining TJC certification is educational
and rewarding. It provides opportunity to examine program performance and identify gaps in care.
TJC certification ensures an ongoing process of quality measure development, implementation of
interventions to achieve program goals and measurement of outcomes. In contrast to other regulatory
agencies, TJC certification provides flexibility for programs to determine their own meaningful measures
of performance. Over the past eight years, we have defined and measured 13 quality indicators for
CKD care. Overall, we were able to improve performance on the majority of quality indicators or at
least maintain the high performance. Most indicators were retired at the end of the recertification cycle.
Some were considered critical to CKD care and were continued in additional cycles.
4.1. Blood Pressure Control
Blood pressure control remained a performance measure for 3 cycles of recertification since it is
essential to preventing CKD progression and we found opportunity for performance improvement.
On average, blood pressure control was achieved in 81% of patients. When we targeted a more
stringent goal (<130/80 mmHg), between 53–67% of our patients were able to achieve that target.
Despite a drop in control with implementation of more stringent targets, we still achieved higher
rates of control compared to the literature. Thanamayooran and colleagues demonstrated that 40% of
patients achieved a target blood pressure of <130/80 mmHg when receiving IP CKD care [75]. Surveys
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of the general population have demonstrated that 13.2–37% of patients with CKD achieve a target
blood pressure [76,77].
Achieving a target clinic blood pressure proved to be challenging. To improve blood pressure
control, the entire IP team was engaged in numerous aspects. Our medical assistants have yearly
competency evaluation on accurate blood pressure measurement and ensure elevated blood pressure
measurements are repeated and recorded. The dietitian counsels on dietary sodium restriction and
educates patients on how to read food labels. The pharmacist assesses medication adherence, adverse
effects of antihypertensives and optimizes therapy. Nurses perform routine telephone follow up on
home blood pressure measurements for patients whose clinic measurements are not at goal. The social
worker assesses financial resources and addresses barriers to medication access and provides a free
blood pressure monitor to patients in need. The physician reviews the team recommendations,
summarizes a plan that optimizes the antihypertensive regimen and includes principles of healthy
lifestyle (regular exercise, low sodium diet, limiting alcohol intake, etc.). Over 90% of our patients
monitor and log home blood pressure, which facilitates medication adjustment based on home
readings. A significant number of patients have a white coat hypertension, so the use of clinic readings
underestimates true blood pressure control [28,70]. With the implementation of and increased patient
engagement in the EHR, it may become possible to report performance based on home readings.
Future initiatives for blood pressure control include having patients enter their home readings into
the MyChart portal of the EPIC EHR using their mobile device or laptop so values are recorded and
actionable. We have not yet implemented this blood pressure initiative due to a lack of educational
materials and resources to educate patients on this electronic reporting.
4.2. Education
Education on CKD is critical in empowering patients to be active participants in their care and
has been associated with decrease in hospitalizations and mortality [1,3–5,7,8,11]. In a prospective,
randomized, controlled trial of an IP CKD educational intervention, the IP care group showed a
significant delay in initiation of dialysis therapy compared to the usual care group (p < 0.0001) [78].
Pre-dialysis education is important in assuring a smooth transition to dialysis including placement
of permanent access and/or transition to transplantation [79]. Peritoneal dialysis (PD) and home
hemodialysis (HD) are underutilized in the United States with ~90% of patients receiving in-center
HD [80]. We believe that extensive education provided to our patients was the reason for a relatively
high percent of our patients starting renal replacement therapy with PD (30%) compared to in-center
HD (70%). This is consistent with other studies that showed that CKD education is associated with
increased selection of home HD and PD modalities as opposed to in center HD [81]. In a survey of
practicing nephrologists, over 90% of the nephrologists would choose home dialysis for themselves,
yet few CKD patients are on home dialysis therapy [82]. Clinicians should apply the same standards
for taking care of patients that they would desire for themselves or family members, should they
develop ESRD. Various medical programs are increasingly adopting technology solutions to support
self-management practices [83,84]. We were able to educate many more patients with online videos
than group classes (70% vs. 33% respectively). Online education provides the solution to several
barriers faced with in-person education including transportation to the facility, scheduling, learning
pace (i.e., patients can watch videos at their convenience and pace), and frequent physician visits or
hospitalization. One major limitation is the production of videos in different languages. Due to limited
resources, we did not translate the education videos into Spanish; consequently, not every patient
benefited from the videos.
4.3. Vascular Access
Timely permanent access creation for chronic dialysis is complicated by numerous clinical and
psychosocial factors making this an important but challenging quality metric. Use of AVF for HD is
associated with improved mortality and morbidity and lower cost compared to the use of a central
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venous catheter [10,72,85]. Over the last decade, the rate of AVF use in prevalent dialysis patients has
improved significantly from approximately 35% to 65% [80]. However, at dialysis initiation, AVF use
continues to be very low with over 80% of patients initiating dialysis using a tunneled catheter [80].
Emergent start of dialysis continues to be too common and likely contributes to high mortality and
morbidity in the first 6 months of starting dialysis, especially in patients over 65 years of age [80].
Early in our program development, we experienced significant delays from patient referral to
vascular surgery to the actual visit and/or placement of permanent vascular access. In order to
address this problem, we created a joint CKD-vascular surgery clinic, scheduled once a month, where
patients who had advanced CKD could see the nephrologist and surgeon during the same visit.
This coordination of care resulted in timely vascular access evaluation and surgery. On average,
77% of patients started HD with a functional AVF in the first 2-year cycle and 61% in the second
cycle. One challenge we encountered with this quality indicator is the small number of patients who
transition from CKD stage 5 to HD making it difficult to compare and trend month-to-month data
or to demonstrate significant improvement. Our results are similar to other studies demonstrating
higher AVF rates of 45.2–68.4% in patients receiving IP CKD care compared to 4.8–58.8% in the usual
care groups [1,4,86,87]. Despite receiving comprehensive education and IP care, there are patients
who will start HD with a tunneled catheter for multiple reasons including: (1) late referral of patients
with advanced CKD and low socioeconomic status, (2) emergent dialysis for acute kidney injury in
patients who previously had moderate (not advanced) CKD at baseline and (3) patients who initially
choose peritoneal dialysis, yet start with HD due to unforeseen acute deterioration in health. We are
developing and implementing a protocol for urgent start PD (within 24–48 h after placement of PD
catheter) to address the latter problem.
4.4. Transplantation
Survival rates for patients with ESRD are much better for those undergoing kidney transplantation
compared to those receiving chronic dialysis [80]. Our program ensures timely referral of appropriate
candidates to the transplant program once the GFR approaches 20 mL/min/1.73 m2. Our experience is
that patients from our CKD IP program have better health related outcomes (i.e., health maintenance,
self-monitoring of health outcomes and medication adherence) and experience a higher likelihood of
placement on the transplant waiting list (not reported). However, we have not measured and compared
our referral to listing ratios to that of usual nephrology care. Some patients receive preemptive kidney
transplantation while others start accruing waiting time prior to initiation of dialysis (i.e., once the
GFR is below 20 mL/min/1.73 m2). To facilitate transplant referral, we have worked with the transplant
program and informatics team to enable the clear and visible display of transplant listing status in each
patient’s EHR.
4.5. Vaccinations
Vaccinations are one of the most beneficial health prevention strategies to reduce morbidity and
mortality associated with communicable infections. Patients with CKD should receive an annual
influenza vaccine, pneumococcal and hepatitis B vaccinations [71]. We focused on pneumococcal
rather than hepatitis B vaccination since our baseline rate for hepatitis B vaccination was high whereas
there was an opportunity for improvement in pneumococcal vaccination rate. To improve this measure,
we ensured accurate documentation of vaccination history by the pharmacist for every patient and
we streamlined the vaccination ordering process. We experienced a robust increase in pneumococcal
vaccine administrations from a baseline of less than 50% to over 90% patients at the end of the
reporting cycle.
4.6. Advanced Directives
During the re-certification process, there is opportunity to discuss the retirement of measures
and adoption of new quality measures. Our Joint Commission surveyor felt that providers in IP CKD
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clinic are in a unique position to discuss transitions in care and patient preferences and suggested
we start tracking discussions about advanced directives with our patients. Discussion of advanced
directives can be uncomfortable especially in an ambulatory care setting and with younger patients.
Our social worker felt best prepared and positioned to lead the discussions with patients. Despite
our perceived concerns around this measure, we were able to initiate conversations about advanced
directives in 90% patients, which was a significant improvement from a baseline value of less than 30%.
In 2015, Medicare spending exceeded $64 billion for beneficiaries with CKD and $34 billion for ESRD
costs totaling over $98 billion [80]. The cost is disproportionally high for dialysis patients in the last
year of their life. Discussing advanced directives with pre-dialysis and dialysis patients is critical to
select medical interventions that are aligned with patient preferences, while reducing unnecessary cost
to society.
4.7. Cardiovascular Disease Risk
Cardiovascular disease (CVD) remains the leading cause of death in the United States and most
other developed countries [88]. Among patients with CKD, death from CVD is far more common
than progression to ESRD. CKD has been identified as an independent risk factor for CVD, even after
adjustment for usual comorbid conditions [74]. The risk for CVD increases as GFR declines [80,89].
Assessing the risk is critical given high prevalence and poorer prognosis after a CV event in patients
with CKD compared to general population (i.e., adjusted two-year survival of patients with acute
myocardial infarction is 81% in general population, compared to 56% for CKD Stage 4–5 [80]. Estimating
risk for CVD in patients with CKD is complicated due to the presence of traditional and non-traditional
cardiac risk factors. Online and smart phone risk calculators have been developed by the American
College of Cardiology, available: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/
(Last Accessed: 6/25/18). We worked with the informatics team to implement an electronic ASCVD
risk calculator in the EHR, resulting in a quick and steep increase in documentation of this important
risk from zero to 100% by the end of the reporting cycle. Patients with high ASCVD risk receive
additional attention in terms of education on the importance of lifestyle modifications, appropriate
medical management and referrals to cardiology.
4.8. Other Indicators
For other indicators, we were successful in improving the rate of completion of office visit
documentation in the EHR within 48 h of the office visit from below 50% to approximately 100%.
We ensured that over 90% of diabetic patients had HgA1C checked at least every 6 months. We did not
make much improvement in some process measures like clinic cancellation rate or access to care due to
numerous factors outside of our control.
4.9. Challenges
Upfront cost of an IP team is the biggest challenge to implementing and maintaining IP CKD care.
The standard fee-for-service model in the United States does not reimburse many team members other
than physicians or advanced practice professionals (physician extenders). Dieticians are reimbursed by
Medicare for evaluating patients with CKD stage 4, though we encountered logistical challenges with
scheduling patients for two separate visits (with the physician and dietician) during the same CKD
visit, obtaining insurance authorization for each visit with the dietitian and placing a physician referral
to the dietician for each subsequent visit. Medicare provides reimbursement for 6 educational sessions
on dialysis modalities, but these sessions must be of at least 30 minutes duration and provided by a
physician or physician extender. Medication therapy management services provided by the pharmacist
are not reimbursable under the current Medicare structure since the CKD visit is done in conjunction
with the physician. Social worker services are not reimbursable unless counseling is provided for a
mental health condition. However, IP CKD programs have a potential for creating downstream or
indirect revenues by increase in outpatients starts of dialysis, more patients starting dialysis with a
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permanent access, more PD utilization, improved referrals for living kidney donor transplantation and
in turn higher rates of transplantation. All of those help to offset the cost of IP care or even make IP
CKD programs cost effective.
In 2015, Medicare ESRD expenditure/person/year was $88,750 for a HD patient, $75,140 for a PD
patient and $34,084 for a transplant patient [80]. Patients who receive dialysis with AVF have a lower
total cost/member/year compared to those with HD catheters [80]. More recently, Lin and colleagues
evaluated the cost-effectiveness of a theoretical IP CKD program compared to usual CKD care in U.S.
Medicare beneficiaries with stage 3 and 4 CKD between the age of 45 and 84 years. The results of the
model showed that a Medicare-funded IP CKD program could be cost effective by decreasing the need
for RRT and prolonging life [13].
Space may also pose a challenge when developing a new program. We initially secured space by
sharing the same clinic space and time allocation as the general nephrology clinics. This was not as
challenging compared to securing new space as part of our goals to expand the program. We struggle
with obtaining new space to add additional clinics in other geographic locations to better serve our
diverse patient population.
4.10. Limitations of Our Study
There are several limitations to our study. This is an observational, descriptive study evaluating
the impact of Joint Commission certification and recertification on clinical and process of care outcomes
for patients with CKD. Since there was no control group in this study, it is possible that clinical
outcomes achieved in this program could be achieved in a physician-based clinic. However, various
team members led many of the quality improvement projects (i.e., vaccination rates by pharmacist,
advanced directives by social worker, permanent dialysis access by a nephrologist) and it is unlikely
that one team member alone could do all of it. This shared approach was critical to our success and
this degree of quality improvement would not likely be sustained over a long period of time in a
physician-based clinic. Secondly, some of the patients referred to our program received care in the
general nephrology clinic prior to referral and it is possible the previous care had impacted their
outcomes, but this bias may have been in both directions for the outcomes of interest. Lastly, the results
may not be generalizable to non-academic programs given differences in the informatics resources,
patient population and IP team members. Additional research is needed to compare the outcomes and
cost-effectiveness of IP care to usual CKD care and to evaluate the feasibility of disseminating this
model of care to other institutions.
5. Conclusions
Joint Commission certification requires the development and implementation of robust quality
assurance and performance improvement plans. CKD care delivery involves a set complex processes
and improvement in outcome measures are best achieved using a team-based approach where high
quality care is a priority for all IP team members. Achieving certification is not a simple task, it requires
strong leadership, dedication, time commitment and institutional support with the reward of nationally
recognized, external validation of the excellence in care to the patients we serve.
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Appendix A




3. Orders for encounter (lab tests, referrals, medications, follow-up)
4. Documentation of visit in EPIC
5. Supervises nephrology fellow and medical residents
6. Supervises interprofessional team
7. Plan and present classes on kidney disease
8. Oversees medical management for CKD population
9. Strategic planning with respect to program growth, outcomes
10. Participate in staff evaluations




1. Medication history and medication reconciliation
2. Medication therapy management (evaluate doses for renal function, etc.)
3. Assist with orders for encounter (lab tests, referrals, medications, follow-up)
4. Counsel patient on new medications, medication changes and provide a current list
of their medications
5. Documentation of visit in EPIC
6. Supervises pharmacy residents and students
7. Supervises interprofessional team
8. Plan and present classes on kidney disease
9. Responsible for analyzing and presenting program outcomes
10. Staff recruitment and performance appraisal
11. Lead team meetings
12. Strategic planning with respect to program growth, outcomes
13. Prepare budget annually
Dietitian
1. Evaluate nutritionally relevant information
2. Assess diet and make recommendations for changes in diet or dietary supplements
3. Document assessment, care plan and education in EPIC
4. Plan and present classes in nutrition
5. Create meal plans for individual needs
6. Monitor dietary change and provide feedback
7. Attend CKD team meetings
Case Manager
1. Brief psychosocial assessment on all new patients and document in EPIC
2. Assess for changes on return visits
3. Address any insurance and community resource needs with patients as appropriate
4. For patients in CKD IV or higher, begin discussing dialysis plans, preference for PD
versus HD and location
5. Assist in teaching Modalities (Kidney Treatment Options) class to new patients and
document their attendance and preference in EPIC progress notes
6. Refer patients anticipated to need dialysis for insurance verification
7. Assisting with transition to dialysis
8. Assist with placement in long term facilities or communication with
outside facilities
9. Facilitate communication between patients, CKD team members and other
medicine/surgical disciplines (example vascular access, interventional radiology)
10. For any unfunded or partially funded patients; notify dialysis administrator and
clinical service chief and request temporary acceptance until funding is secured
11. Attend CKD team meetings
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Table A1. Cont.
Nurse
1. Schedules patients into the CKD clinic
2. Triages new referrals to CKD clinic
3. Reviews clinic schedule every week to ensure appropriate numbers of patients
4. Prints out the after visit summary and discharges patient from the visit
5. Reviews next appointment, lab work needed for appointment, procedures, referrals
and medication changes/prescriptions
6. Confirms patients understanding of care plan
7. Administers erythropoietin stimulating agents in clinic when prescribed
8. Administers vaccinations in clinic when prescribed
9. Documents in EPIC
10. Receives patient calls and requests for refills from call center and triages these to
appropriate individuals
11. Attend CKD team meetings
Medical Assistant
1. Takes vital signs on patient (blood pressure, pulse height and weight)
2. Puts the patient into the rooms
3. Notifies CKD team of patient arrival





1. Schedule team meetings, create agendas and attend meeting
2. Maintain SharePoint site for communications
3. Coordinates all aspects of patient education classes (mailings, patient outreach,
coordinate logistics for rooms, audio-visual, and refreshments, speakers, handouts)
4. Maintains database of all clinic patients
5. Prepare and mail new patient education packets
6. Collect patient data for quality indicators database
7. Maintain office and educational material supplies
8. Program coordinator for 10-week Wellness Program. Responsible for brochure,
mailings, patient outreach, scheduling logistics for rooms, audio-visual, and
refreshments, speakers, handouts
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Abstract: Pharmacy practice is changing to accommodate the need for pharmacists to be better team
members in newly emerging collaborative care and integrated health systems. Pharmacy schools
could lead this change by educating students to be effective participants in these relatively new
models of care. Schools are encouraged to follow the approach outlined in the recent guidance
published by the Health Professions Accreditors Collaborative (HPAC) for interprofessional practice
and education (“the new IPE”). This approach includes articulating an IPE plan, establishing goals,
assessing student achievement of the necessary IPE competencies, developing educational plans
that are multi-faceted and longitudinal, and modifying the existing assessment/evaluation process
to ensure the quality of the IPE effort. These curricular decisions should be based on existing and
new research on the effectiveness of IPE on student’s attitudes, knowledge, skills, and behavior.
A key decision is how to create effective interactions between pharmacy students and those of
other professions. Educational emphasis should be directed toward team building skills, not just
individual competencies. The pharmacy faculty probably need to enhance their teaching abilities
to accommodate this change, such as learning new technology (e.g., simulations, managing online
exchanges) and demonstrating a willingness to teach students from other professions.
Keywords: pharmacists; pharmacy education; interprofessional practice and education
1. Introduction
An integrative/collaborative approach to health care services is needed to create a more efficient
workforce and positive health outcomes [1,2]. Collaborative care is defined as occurring “when multiple
health workers from different professional backgrounds provide comprehensive services by working
with patients, their families, and communities to deliver the highest quality of care across settings.”
Integrative Health Care is described as “bringing together inputs, delivery, management and
organization of services related to diagnosis, treatment, care, rehabilitation and health promotion.
Integration is a means to improve services in relation to access, quality, user satisfaction and efficiency.”
Both approaches require enhanced cooperation among all levels of caregivers to ensure optimal
service [1,3].
The call for more cooperation is not new and neither is the potential role of pharmacists in this
effort [4,5]. Despite those historical appeals, there was limited local, national, and international effort to
vigorously promote this approach for many years. That apathy began to change with the publication
of the Institute of Medicine (IOM) report in 1999 entitled To Err Is Human [6]. This report suggested
that as many as 98,000 hospital deaths per year were due to medical errors. A key finding of the report
was the observation that these deaths likely arose “from the decentralized and fragmented nature of
the health care delivery system—or “non-system,” to some observers.”
The 1999 IOM report created a more concentrated effort of health professional collaboration,
particularly around patient safety. However, other problems of the health care system, such as
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fragmented care, poor access, suboptimal patient outcomes, dissatisfied patients, and a frustrated work
force, were still present. These issues were later highlighted in two key reports. The World Health
Organization (WHO) noted in a 2010 report entitled that interprofessional collaboration connected
with shared education would strengthen health care delivery and improve outcomes [1]. At the same
time, an international commission of professional and academic leaders published a report in the
Lancet calling for a new direction in health professional workforce education that emphasizes more
interprofessional education and collaboration [7].
The result of these calls for action is an international movement toward reform of health
professional education and practice [8–10]. This effort presents a great opportunity for pharmacy,
which is recognized by many health professionals for its expertise in drug products and medication
management [11–13]. However, pharmacy suffers the same barriers to team practice as other professions:
a fractionated health system, scope of practice restrictions, hierarchical order of decision-making,
and an insufficient educational focus on the skills needed to be an effective multi-professional team
member or leader [14,15]. The purpose of this paper is to address the lack of educational focus and offer
suggestions for curricular changes that support greater implementation of interprofessional practice
and education (known as the “new IPE” [10]) principles in pharmacy education.
2. Approach
Pharmacy education traditionally focused on the “shaping” of student learners to become
pharmacists. That identity revolves around teaching the skills needed to become drug product and
medication management experts [16]. Like all health professions education, this “uni-professional”
approach can be a barrier to preparing learners to function effectively in collaborative/integrative care
practice settings, which could prevent them from providing high quality care to patients. Instead,
a multi-professonial approach is needed with a shift toward inclusion of more interprofessional
experiences, resulting in the development of a dual identity as both a pharmacist and as a key
participant of collaborative care teams or as members of integrated health systems [9,17].
The idea of the dual or multi-professional approach of educating students to become pharmacists
and effective members of the health care team has been discussed extensively in the past few
years. The 2004 report on Educational Outcomes by the Center for the Advancement of Pharmacy
Education (CAPE) mentions the need to educate pharmacy students to become effective members of
interprofessional health care teams [18]. This focus was expanded in the 2013 CAPE guidelines which
identified the “collaborator” role of pharmacy [19]. The 2013 report suggested that learning objectives
for pharmacy students should include establishing a climate of shared values, defining clear roles and
responsibilities, communicating effectively with other professions, and promoting joint problem solving.
The 2013 CAPE report generated a number of research papers on desirable approaches to promoting
IPE in pharmacy education in such areas as Integrative Health Education [20], Advanced Pharmacy
Practice Experiences [21], and Entrustable Professional Activities [22].
The CAPE guidelines identified the need for IPE in pharmacy curricula and subsequent research
identified possible strategies. These efforts were the basis for the Accreditation Council for Pharmacy
Education (ACPE) Standard 11, which identifies key elements desired in a pharmacy curriculum to
prepare students to become contributing members of an interprofessional team [23].
None of the efforts to date have provided a universally accepted plan for appropriate integration
of IPE in pharmacy curricula. Fortunately, a recent guidance published by the Health Professions
Accreditors Collaborative (HPAC), which is a collaboration among at least 25 of the accrediting agencies
(including pharmacy), offers a template for developing that approach [9]. It suggests that every
educational plan include the following characteristics:
A. Rationale: Articulate a vision, framework, and justification for the IPE plan.
B. Outcome-based Goals: State in terms that will allow the assessment of students’ achievement of
objectives and interprofessional competencies for collaborative practice.
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C. Deliberate Design: Intentionally design and sequence a series of classroom, extracurricular,
and clinical learning activities integrated into the existing professional curriculum that are
longitudinal in nature, spanning the entire length of the program and including content and
instructional formats appropriate to the level of the learner and to the outcome-based goals.
D. Assessment and Evaluation: Use methods to assess individual learners’ mastery of
interprofessional competencies and to evaluate the IPE plan for quality improvement purposes;
and if appropriate, education and practice outcomes, research and scholarship.
These are general guidelines for all health professions educational programs. The specifics for
each health profession have not been developed yet. However, possible applications to pharmacy
education are offered in the following paragraphs:
Rationale. Pharmacy educators have a solid rationale for the development of pharmacists as drug
product and medication therapy experts, especially applied to areas such as improved therapeutic
outcomes, patient adherence, drug safety, and transitions of care [24–26]. The expansion of this
professional role to becoming effective participants in collaborative/integrative care is not as clear.
The HPAC guidelines suggest that a conceptual model is needed to provide an overview of how
collaborative activities are linked to better health outcomes. The example in the guidance is the
Institute of Medicine Interprofessional Learning Continuum Model that illustrates the continuum
of IPE through all levels of learners (undergraduate, graduate, and current practitioners) and how
the learning process is affected by factors such as culture and the availability of needed resources [2].
Another useful model is the one developed by WHO, which suggests a positive relationship between
IPE, collaborative care, and positive health outcomes [1].
These models imply that the pharmacist’s expert knowledge of drug products and medication
management would be a necessary but not a sufficient factor in ensuring better health outcomes.
To be more effective contributors, pharmacy education would need to go beyond teaching drug
product/medication expertise to a more expansive instruction on factors such as the social determinants
of health, the principles of human behavior, and non-medication strategies to improve health [19,27–30].
Outcome-based goals. Pharmacy educational programs already have a clear set of learning
outcomes identified through the standards set ACPE and promoted by CAPE [19,23]. These outcomes
include a strong foundational knowledge in the sciences, understanding of the principles of pharmacy
practice, demonstration of the skills needed to manage medication therapy and medication use systems,
and awareness of the best pathways to promoting health wellness in improving population-based care.
The HPAC guidance suggests that a related but broader set of competencies are needed to
effectively cooperate with other health professionals. The competencies created by the Interprofessional
Education Collaborative (IPEC) [31] was the suggested starting point for dual interprofessional
development of students. They are:
Competency 1, Values/Ethics for Interprofessional Practice: Work with individuals of other
professions to maintain a climate of mutual respect and shared values.
Competency 2, Roles/Responsibilities: Use the knowledge of one’s own role and those of other
professions to appropriately assess and address the health care needs of patients and to promote and
advance the health of populations.
Competency 3, Interprofessional Communication: Communicate with patients, families,
communities, and professionals in health and other fields in a responsive and responsible manner
that supports a team approach to the promotion and maintenance of health and the prevention and
treatment of disease.
Competency 4, Teams and Teamwork: Apply relationship-building values and principles
of team dynamics to perform effectively in different team roles to plan, deliver, and evaluate
patient/population-centered care and population health programs and policies that are safe, timely,
efficient, effective, and equitable.
ACPE has already addressed some of these competencies under its interprofessional education
standard (standard 11). This standard focuses on demonstrating competence in three key elements:
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Interprofessional team dynamics, interprofessional team education, and interprofessional team
practice [23]. The newness of the standard means that there are very few examples of successful
strategies performed by Colleges of Pharmacy to meet those criteria.
Deliberate Design. Pharmacy education programs already need to be intentionally designed and
sequenced to meet accreditation [23] and licensing standards [32]. The design for IPE preparation
would emphasize the same approach but would focus on a progression based, multifaceted,
longitudinal integration of the IPEC interprofessional competencies into the full length of the existing
pharmacy curriculum [31].
A key aspect of an IPE educational program is the focus on pharmacy students learning about,
from, and with students from other professions regarding how to collaborate and improve health
outcomes, which is consistent with the WHO definition of IPE [1]. In order to achieve this goal,
traditional methods of teaching pharmacy students (e.g., lecture or classroom discussions) need
to change.
Approaches need to be multifaceted and include student-to-student IPE learning activities that go
beyond courses, such as one-time gatherings of many different professions to address an issue (e.g.,
disaster preparedness events), online exchanges, and IPE simulations. Formally designed team based
learning exercises with students from other professions need to be emphasized. Clinical rotations that
highlight multi-professional teamwork supervised by faculty from multiple professions are needed to
demonstrate the full value of collaborative care [28,33–35].
Assessment and Evaluation. Pharmacy accreditation already focuses on the key elements of
student assessment, the quality of the mentoring process, and the value of the strategic educational
plan [23]. IPE assessment builds on that foundation by focusing on student abilities to function as
effective team members; emphasizing supervision and mentoring by a multi-professional faculty
in team care environments; and strategic planning that includes the dual process of professional
and interprofessional socialization. Assessment of the pharmacy student should include measures
of changes in perceptions and knowledge of the capabilities of other professions, understanding of
teamwork, and the demonstration/performance of collaborative behaviors in simulations and health
practice settings [2,9,31].
3. Discussion
Pharmacy faculty are always confronted with challenges to update the curriculum to prepare
students for the constantly changing health care environment. Moving toward a more interprofessional
focus is especially challenging because of the need to engage other professional schools in the process.
Here are some useful suggestions, based on my long time experience as a pharmacy educator (and
Dean) and as a Director of a University-wide Interprofessional Center, that may assist in ensuring that
the IPE curricular goals are met.
A. The curricular decisions on IPE should be based on research that identifies the best educational
strategies. This information is lacking in many areas because the IPE movement is still new,
which means that more scholarship is required in this area. Many questions need to be resolved
through thoughtful research and vigorous assessment of the various efforts. For example,
what will be the typical practice models in the future and what would be the key roles of
the various health professions? What are the specific skills needed to become an effective
team member? Who are the important individuals that pharmacists need to interact with in
the collaborative/integrative care environment? Does the nature of the pharmacist team role
change in different practice settings (e.g., institutions vs ambulatory care)? What are the proper
links between learner education, effective collaborative/integrative practice, and positive health
outcomes? Resolution of these questions are needed before a valued based IPE curriculum can
be successfully implemented.
B. Despite our knowledge gaps, a crucial ingredient to any IPE curriculum is the level of discourse
with students from other professions. The WHO definition of IPE emphasizes intense interaction
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of learners from different professions directed toward joint problem solving exercises [1].
The key for pharmacy curricular planners is deciding the priority of formal contact with a
multitude of professions given the inherent logistical challenges. ACPE’s standard 11 states
that the “curriculum prepares all students to provide entry-level, patient-centered care in a
variety of practice settings as a contributing member of an interprofessional team. In the
aggregate, team exposure includes prescribers as well as other healthcare professionals” [23].
This standard is helpful because it recognizes the medication management focus of pharmacy
practice. However, it does not address the value of interactions with professionals who are not
prescribers e.g., social work). These interactions should be based on their value to enhancing
the perspective/knowledge of pharmacy students, not simply their educational accessibility.
Co-location of these schools on the same campus is desirable but not necessary; it is appropriate
to meet with students from other professions through specific collaborating institutions or
through regional networks [9,36,37].
C. The IPE emphasis should be on team building skills not just individual competencies [38].
The models used to support the rationale for interprofessional education emphasize the value of
health professional teamwork in creating positive health outcomes [1,2,27]. Thus, popular team
building techniques such as TeamSTepps [39] or the Interprofessional Collaborator Assessment
Rubric (ICAR) [40] should be used extensively in the teaching process in order to emphasize
group development. The focus is on educating pharmacy students to engage in shared decision
making, joint accountability for patient care and population health [41].
D. Pharmacy educators need to accept, endorse, and participate in a multi-professional approach
to teaching their students. These actions may consist of acquiring a new set of teaching skills.
These skills include effective facilitation of formal team based learning, use of technology such
as simulations, or creating/managing online multi-professional forums. There also must be a
willingness to teach non-pharmacy learners and to encourage other professionals to instruct
pharmacy students [28,31,35,41,42].
4. Conclusions
Pharmacists are moving toward more active participation in collaborative/integrative models
of care. This involvement emphasizes teamwork skills, more extensive interaction with other health
professionals, and a broader understanding of the patient’s health needs. Implementing IPE in
pharmacy education is necessary in order for students to be successful in this new practice model.
The approach to implementation of IPE discussed in this paper is endorsed and supported in the HPAC
Guidance [9]. However, implementation will only be effective if it is not viewed as a supplemental
addition but rather a full integration into the curriculum. There are many examples of productive
new attempts at curricular implementation in pharmacy schools [43–47]. These strategies are likely to
expand in the future.
The focus of this paper is on the implementation of IPE in the United States, but these academic and
practice issues are prevalent throughout the world [48]. In fact, the WHO report promoting IPE viewed
the movement as an important strategy to mitigate the global workforce crises [1]. The International
Pharmaceutical Federation (FIP), the major international pharmacy organization, has promoted
interprofessional education and practice for many years. Its 2016 report entitled: “Global Vision for
Education and Workforce” emphasizes that pharmacy must develop a care model that is based on
collaboration with other health professionals [49].
The need for pharmacists to be educated to be more collaborative is universal but the strategies
are more likely to vary by country due to different pharmacy educational requirements, regulation of
the scope of pharmacy practice, payer systems, and the availability of other health professionals [50,51].
Nevertheless, examples of successful implementation of IPE within pharmacy education and practice
exist outside the United States, many of which set the standard for the whole world [52–57].
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Successful integration globally of IPE principles into pharmacy curricula is extensive and will
continue to grow in the future. These efforts will increase the educational shift necessary to ensure
pharmacists are essential members of the future collaborative teams and full participants in the
integrative health approaches needed to ensure better health outcomes to the patients we serve.
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Abstract: Introduction: The scope of pharmacy practice has evolved over the last few decades
to focus on the optimization of medication therapy. Despite this positive impact, the lack of
reimbursement remains a significant barrier to the implementation of innovative pharmacist
practice models. Summary: We describe the successful development, implementation and
outcomes of three types of pharmacist collaborative care models: (1) a pharmacist with physician
oversight, (2) pharmacist–interprofessional teams and (3) physician–pharmacist teams. The outcome
measurement of these pharmacist care models varied from the design phase to patient volume
measurement and to comprehensive quality dashboards. All of these practice models have been
successfully funded by affiliated health systems or grants. Conclusions: The expansion of pharmacist
services delivered by clinical faculty has several benefits to affiliated health systems: (1) significant
improvements in patient care quality, (2) access to experts in specialty areas, and (3) the dissemination
of outcomes with national and international recognition, increasing the visibility of the health system.
Keywords: collaborative practice; clinical pharmacy; advanced practice pharmacist provider
1. Introduction
Collaborative care between pharmacists and physicians has been recognized to improve
pharmacotherapeutic outcomes and provide increased value and efficiency to the health care system [1].
Models for collaborative drug therapy management have been designed with a focus on the most
studied chronic diseases including hypertension (HTN) and type 2 diabetes (T2D). Numerous studies
have demonstrated the positive impact that physician–pharmacist collaborative management can
have on blood pressure and glycosylated hemoglobin (A1C) among patients with HTN and DM [2–4].
Additionally, this positive impact has been demonstrated for other chronic diseases [5,6]. More recently,
Matzke and colleagues demonstrated that pharmacists integrated in a patient-centered medical
home reduce hospitalizations by 23.4%, resulting in estimated cost savings of $2619 per patient [7].
Despite the overwhelmingly positive impact of pharmacist services on patient outcomes, the integration
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of pharmacists in ambulatory care programs is not widespread. A survey conducted by Hattingh and
colleagues identified three major themes as factors that impacted the provision of pharmacist services:
(1) pharmacist characteristics, (2) local needs, structures and support, and (3) an enabling practice
framework [8,9]. In this paper, we describe the program development, successful implementation and
outcomes of pharmacist collaborative care models provided by the University of California, San Diego
Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) faculty in two affiliated academic
health systems.
Setting
For decades, the scope of pharmacy practice in the United States (US) has expanded to optimize
medication use to achieve patient health-related goals. More recently, the passage of California
Senate Bill 493 allows all pharmacists to administer drugs and biologics when ordered by a prescriber,
furnish oral contraceptives, travel medications and nicotine replacement products for smoking
cessation, as well as administer vaccinations. This bill established an Advanced Practice Pharmacist
(APP) recognition and authorizes APPs to perform patient assessments, order and interpret drug
therapy–related tests, refer patients to other health care providers, initiate, adjust, and discontinue
drug therapy upon referral from a patient’s treating prescriber and in accordance with established
protocols, and participate in the evaluation and management of diseases and health conditions in
collaboration with other health care providers. The APP recognition requires a separate APh licensure
application, review and approval from the California Board of Pharmacy.
At UC San Diego Health (UCSDH) and the Veteran’s Affairs San Diego Healthcare System
(VASDHS), comprehensive collaborations were developed in which pharmacists provide patient
care under collaborative practice agreements (CPA) in the inpatient and ambulatory care settings.
The positive impact of pharmacist services has been established using various models of care for
chronic disease management [10–12]. However, recognition of pharmacists as providers has been
challenged, and reimbursement for services has been limited. The lack of reimbursement for services
creates a barrier to the implementation of new pharmacist care models in health systems [13].
2. Health System Overview
UCSDH is a comprehensive health system with an average daily census of approximately
600 patients and over 580,000 ambulatory care visits per year. Approximately 12 faculty from
SSPPS provide collaborative care within the health system. Since 2010, the UCSDH pharmacy
department developed a program expanding the role of the pharmacist in inpatient and ambulatory
care and affiliated clinic settings. VASDHS provides care to more than 249,594 Veterans in the San
Diego and Imperial Valley counties. In addition to the main facility in San Diego, VASDHS has six
community-based outpatient clinics. Two faculty from SSPPS provide patient care within VASDHS.
Faculty partner with staff pharmacists within each affiliated health system to develop new services.
CPAs were developed and implemented for practice areas including chronic kidney disease (CKD),
diabetes, family medicine, heart failure (HF), oncology, pain and palliative care, psychiatry, solid organ
transplantation (SOT), and transitions of care (TOC). Collaborative care is delivered using three main
care models: (1) pharmacists with physician oversight, (2) pharmacist–interprofessional teams, and (3)
physician–pharmacist teams.
2.1. Needs Assessment and Proposal Development
Each program arose from a clinical need identified by the health system or through a needs
assessment conducted by individual faculty with subspecialty expertise. Some needs were based
on regulatory requirements (e.g., solid organ transplant), gaps identified by a physician champion,
or grant funding available for novel clinical services. Initial steps include proposal development,
identified gaps in care, proposed outcome measures, and a business case for return on investment.
All pharmacist practices were successfully funded by affiliated health systems or grants.
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2.2. Implementation
A multi-professional, collaborative approach involving pharmacists, physicians, nurses and
administration personnel was required to establish and streamline the patient care process for the target
population. Clinical program development included creating a scope of practice and credentialing,
clinical guidelines or protocols, clinic schedules and space, referral criteria and documentation templates
in the electronic health record (EHR). In each affiliated practice setting, the pharmacist–physician team
determined the pharmacist scope of practice. Within the scope of practice, prescribing authorities were
defined for specific diseases or conditions. These authorities include the initiation, adjustment and
discontinuation of medications according to program-specific clinical guidelines or health system
policies, where appropriate. Pharmacists have the authority to order medication-related tests
(i.e., laboratory, pharmacogenomic and radiographic tests) to monitor therapy outcomes and make
referrals to other providers. The CPA is not limited to specific medications (with the exception of
controlled substances, where this is required by the Drug Enforcement Agency), providing prescribing
flexibility. All pharmacists who wished to establish a CPA with a physician must have been licensed
in California and demonstrate experience and competence treating patients within their specialty in
order to be credentialed through their respective health system.
2.3. Outcome Measurement
EHRs enable the measurement of patient care clinical and process outcomes. Each program is
responsible for defining, measuring and reporting care outcomes. Collaborative practice outcome
measurements are in different phases, with some at the design phase and others using comprehensive
dashboards. Dashboards are useful tools for tracking outcome measures and identifying areas for
performance improvement. However, this approach is largely retrospective and dependent on the
frequency of outcome trending. EHR disease registries are used to capture, manage and provide
access to condition-specific information for a specified group of patients to support organized clinical
care [14,15]. Registries enable point of care integration with clinical practice guidelines, outreach to
patients between visits to address care gaps and periodic evaluation of aggregate data and performance
to manage a population [16]. Several registries have been developed at UCSDH and VASDHS for
patients with conditions such as CKD, T2D and thrombotic disorders.
3. Collaborative Care Models
3.1. Pharmacist with Physician Oversight Care Model
3.1.1. VASDHS Diabetes Intense Medical Management “Tune Up” Clinic
In 2009, a needs assessment identified over 9600 Veteran patients had a diabetes diagnosis and
A1C values> 9% (per internal VASDHS VISN 22 Registry Data). In May 2009, the Diabetes Intense Medical
Management (DIMM) “Tune Up” Clinic was created as a collaborative pharmacist–endocrinologist
clinic to manage complex T2D patients and help them achieve clinical goals (e.g., A1C, blood pressure,
lipid, weight goals) within 6 months. The clinical pharmacist specialist employs a short-term model
that couples personalized clinical care with patient-specific diabetes education during an average of
three 60 min visits over 6 months. After achieving goals, patients are referred back to their primary care
provider (PCP). This allows a collaborative effort between the PCP and the pharmacist, frees up time
during PCP visits to address other patient disorders, and provides patients with lifelong skills to manage
their T2D and related metabolic disorders. The intended outcomes were to help PCPs and the medical
center to achieve performance measures, avoid health system costs to treat diabetes complications,
and prevent or delay patients from experiencing costly long-term complications of diabetes. Prior to
implementation, the DIMM “Tune Up” clinic was reviewed, approved, and supported by key decision
makers at the medical center: the Chief of Pharmacy, the Chief of Endocrinology, and the Chief of Internal
Medicine, representing the PCPs.
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Clinical issues, comorbidities, complications, socioeconomic and behavioral issues are integrated
and assessed using the MTM Spider Web©, a visual tool developed for systematically creating a
patient-centered clinical care plan [17]. The comprehensive nature of the tool helps ensure completeness
and accuracy, as well as aiding patients to participate in shared decision-making while improving
awareness and knowledge to assist in self-advocacy in their care. Strong emphasis is placed on
adherence and educating and empowering patients to take control of their own diabetes without
hypoglycemic events. Patients receive an individualized action plan and a personal medication record
at each visit.
DIMM clinic outcomes demonstrate a 2.4% reduction in A1C compared to 0.8% in a PCP control
group within 6 months, and glycemic control was achieved without significantly impacting medication
regimen complexity [18,19]. A pharmacoeconomic analysis demonstrated that DIMM Clinic care
resulted in $5287 savings per patient compared to usual PCP care, translating to a $9 to $1 return on
investment [20]. Cost savings to the institution and reimbursement from insurance, as well as the
strong metabolic outcomes, have justified continued clinic funding.
3.1.2. UCSDH Diabetes Self-Management
The Diabetes Self-Management Program is an ambulatory care clinic providing diabetes
self-management education for up to 350 patients annually with pre-diabetes or T2D. This program
was developed, implemented and led by two pharmacists and a physician champion. Subsequently,
it was accredited by the Diabetes Education Accreditation Program enabling insurance billing.
The pharmacists are funded by the medical group and provide care following a CPA. Patients are
referred by their UCSDH provider for group classes or individual visits at four different UCSDH
outpatient clinics. The group education classes consist of two core, two-hour classes, each 1–2
weeks apart, covering seven diabetes self-management topics. For patients with cognitive deficits,
hearing or visual impairment, a language barrier, or those requiring insulin initiation, individual
60 min visits are preferred. Services provided include medication reconciliation and the assessment of
adherence, nutrition habits, and glucose meter results, with education tailored to patient’s specific
needs. All patients set specific behavioral goals for themselves. Pharmacist recommendations are
electronically sent to the referring provider after the visit. Telephone follow-up occurs 1–2 weeks
following the classes or visits.
Annually, the program has over 500 office visits and 300 telephone follow ups. For group
education, 45.8% patients attended one or two group meetings, and 13.2% attended three or four
group meetings; the remaining patients were seen individually [21]. The mean decrease in A1C at
6 months was −0.6% compared to usual care −0.2%, p < 0.001, with no significant change in body mass
index [21]. The program has also demonstrated a reduction in the number of patients with A1C > 8%,
resulting in 55% achieving A1C <8% after 3 months and improved screening for A1C, with 57% of
patients receiving two or more screenings per year. The outcomes have enabled continued funding of
the program and the addition of a dietician (0.1 FTE) and scheduler (0.2 FTE).
3.1.3. VASDHS Heart Failure Medication Management Clinic
Established in 2012, the HF medication management clinic objective was to reduce HF readmissions
and improve outcomes in collaboration with the VA Advanced HF Team comprising cardiologists,
nurse practitioners and nurses. The pharmacists’ scope of practice includes prescribing HF-related
medications and ordering relevant laboratory and diagnostic studies. The advanced HF team establishes
a diagnosis and initiates treatment, then referring patients for 30 to 60 min visits focused on medication
management and follow-up. The pharmacist evaluates volume overload and worsening signs of
congestion, titrates neurohormonal blockade to target doses, adjusts diuretics, assesses medication
adherence and adverse effects. Typical medication titration visits can occur every 2–4 weeks,
whereas patients requiring frequent diuretic adjustment may be seen weekly. The pharmacist works
with the VASDHS quality improvement team to improve HF care and reduce hospital readmissions.
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3.1.4. SSPPS Partners in Medication Therapy (PMT)
PMT was established to provide medication therapy management services to self-insured
employers, medical groups, and health plans. Services include optimizing medications and patient
education on medication therapy for chronic diseases such as T2D, asthma, and cardiovascular disease.
Partnerships with large third-party health plans generated opportunities for SSPPS APPs to work
with different PCPs in Independent Practice Associations to provide telehealth visits. Patients were
identified and referred to the APP based on gaps in therapy, adherence problems, or lack of treatment
goal attainment detected by the health plan pharmacy claims data or the EHR. Clinical protocols
were developed for chronic conditions such as HTN and T2D as well as therapeutic interchange to
reduce drug costs. Under a CPA, APPs were authorized to initiate, modify, substitute, or discontinue
agreed-upon medications according to the protocol and to authorize refills.
Using individual medical group EHR remote access, four APPs performed one-hour phone
sessions to provide comprehensive medication management, order labs, document recommendations
and communicate with PCP as needed. Each patient received an updated medication list and action
plan. Follow up frequency was determined by patient-specific needs. Patients were discharged after
goal attainment or failure to have detectable improvement after 6 to 12 months. In an initial four-month
pilot program with St. Joseph Heritage Healthcare (Orange County, CA, USA), 756 patients were
referred and screened with 61 resulting appointments.
3.2. Interprofessional (IP) Care Model
3.2.1. UCSDH Chronic Kidney Disease (CKD)
In 2007, the CKD program was developed as an ambulatory clinic providing evidence-based IP
care to delay CKD progression for approximately 400 patients with CKD Stages 2–5. UCSDHS funded
the program as a separate cost center allowing financial outcomes including office visit volumes,
medication revenue and expenses to be measured. The team consists of a nephrologist, pharmacist,
nurse, dietitian and social worker. Patients see all team members at each visit, with new visits lasting
approximately 90 min and return visits 60 min.
Under a CPA, the pharmacist conducts medication reconciliation, adherence assessment,
and comprehensive medication management, facilitates access to medications, and provides patient
education on changes to the medication therapy plan as well as the patient’s progress towards their
health-related outcomes. The pharmacist optimizes medication therapy for hypertension, diabetes,
proteinuria, hyperlipidemia, anemia, bone disease, hyperkalemia, metabolic acidosis and vaccinations.
The pharmacist estimates kidney function and adjusts the doses of medications. The pharmacist orders
prescriptions to the community pharmacy, medications to be administered in clinic, vaccinations and
medications to be administered in the infusion centers. Patients receive one-on-one education during
their clinic visit, are provided links to online education videos (developed by the CKD Program),
and can attend a group class on dialysis modalities and kidney transplantation.
Implementation barriers included the expense of an IP team and low insurance reimbursement
rates. Additionally, the pharmacist, social worker, and dietitian could not bill the insurers for their
individual services, and the physician could not bill more complex office visits for services provided
by the team. To minimize facility overhead expenses, the CKD program operates clinics in the same
physical space as general nephrology clinics. Clinic volumes are at capacity, and the expansion of
the program has been limited due to cost and available space. Despite challenges with expansion,
this program has been sustained with a steady stream of new referrals.
This program was the first in the US to receive disease-specific certification in CKD from the Joint
Commission, demonstrating high-quality care to patients [22]. Clinical and process outcomes routinely
measured include but are not limited to blood pressure control, non-steroidal anti-inflammatory drug
(NSAID) usage and counseling on avoidance, sick day management with angiotensin converting
enzyme inhibitors or angiotensin receptor blockers, and referral for vascular access and transplantation
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as well as vaccination rates. With over 1000 office visits per year, the team achieved systolic blood
pressure control in 58% of patients, with 0% of patients prescribed NSAIDs, 98% counselled to avoid
NSAID products, and 64% viewing online CKD educational videos [23].
3.2.2. UCSDH Oncology
Moores Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer
Center in San Diego, provides over 56,000 cancer patient visits annually including approximately
200 autologous and allogeneic hematopoietic stem cell transplants.
In 2014, the clinical pharmacy program was developed and implemented by a pharmacist in
collaboration with a physician champion. Funding was provided by the cancer center for clinical
services for two full days per week. The pharmacist initially developed a clinical practice in the
thoracic medical oncology and the blood and marrow transplant departments. After one year of
practicing, the pharmacist collaborated with leadership to expand the clinical pharmacy program by
one full-time equivalent clinical pharmacy specialist in the head and neck/thoracic medical oncology
ambulatory clinics.
The IP teams consist of oncologists, pharmacists, nurse case managers, mid-level providers
(nurse practitioners and physician assistants), and medical assistants with the support of a social
worker and a nutritionist on an as-needed basis. Clinical services provided by the pharmacist include
medication management under a CPA, conducting medication reconciliation, oral chemotherapy
adherence assessment, symptom management, immunization screening and ordering, therapeutic
drug monitoring, oncology stewardship, and chemotherapy order preparation. The pharmacist
provides literature support for the off-label utilization of cancer treatments. In addition, patients
receive one-on-one education with the pharmacist or attend a group class focused on Chemotherapy
and Immunotherapy Treatment that was developed and implemented by the pharmacist.
3.2.3. UCSDH Pain and Palliative Care
The ambulatory and inpatient palliative care IP consult team is comprised of physicians,
pharmacists, social workers, nurse practitioners and a chaplain. A description of the CPA development
has been previously published [24]. In accordance with California code 4052, UCSDH palliative care
pharmacists have independent prescriptive authority, with Drug Enforcement Agency (DEA) licensure
and National Provider Index (NPI) status. Reasons for pharmacist consultation included physical
symptom management, including but not limited to cancer-related pain, constipation, nausea and
vomiting, fatigue, and insomnia.
Initial studies evaluating palliative care pharmacist contributions in the ambulatory care and
inpatient settings have been positive [25–27]. Patients seen in clinic by a palliative care pharmacist
versus patients who received standard of care showed trends for better pain control and health-related
quality of life and function [26]. Medication prescribing changes by palliative care pharmacists
commonly include a change in dose and/or the initiation of a new medication [27]. Positive trends were
observed in pain control for patients with cancer over subsequent clinic visits [27]. Analgesic efficacy
was improved by 17% and non-adherence was reduced by 13% [27].
Additionally, in the inpatient setting, the palliative care pharmacist provides opioid stewardship
and guideline development for safe and effective analgesia. Prescribing trends are evaluated for
safety and efficacy. Areas of focus include but are not limited to the prescription of fentanyl
patches, patient-controlled analgesia, gabapentinoids, ketamine oral and intravenous infusion,
lidocaine intravenous infusion, mexiletine, methadone, and naloxone [23,28–36]. Guidelines for
the appropriate use of end-of-life opioids were developed [37]. Early access to the inpatient palliative
care pharmacist resulted in a shortened length of stay, shortened length from admission to palliative
care consult, and a positive impact on time from consult to discharge or death [25].
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3.2.4. UCSDH Solid Organ Transplantation
The Solid Organ Transplant program is a comprehensive IP center that provides evidenced-based,
full-spectrum care from pre-transplant evaluation to post-transplant management for patients needing
a kidney, pancreas, liver, lung, or heart transplant. The teams consist of transplant physician
specialists (i.e., nephrologist, hepatologist, cardiologist, etc.), transplant surgeons, pharmacists, nurses,
dietitians, and social workers. In 2004, the bylaws of the United Network for Organ Sharing were
amended to include pharmacists as necessary providers on the transplant team [38]. There are eight
dedicated transplant pharmacists, including two faculty pharmacists who each devote 15% effort to
ambulatory patient care and receive salary support from the UCSDHS Center for Transplantation.
Revenue generated by improving patient utilization of discharge and ambulatory UCSDH pharmacies
has led to expansion and continued salary support for transplant pharmacists.
Similar to other services in the health system, transplant pharmacists initiate, discontinue,
change, and monitor drug therapy under a CPA. Working closely with transplant physicians and
surgeons, pharmacists manage a patient’s immunosuppressive therapies, as well as treatments for
complications of immunosuppression, other associated medical conditions, and preventative therapies.
The pharmacists conduct medication reconciliation, adherence assessment, a focused assessment
of immunosuppression, MTM for various complications of transplantation, order laboratory tests,
immunizations, facilitate access to medications and provide comprehensive patient education. In 2018,
approximately 95 kidney, 41 liver, 56 heart, and 23 lung transplants were performed, and long-term
follow-up was provided.
3.2.5. UCSDH Transitions of Care (TOC)
The TOC program aims to optimize care and reduce hospital readmissions by providing hospital
and ambulatory care continuity services for approximately 7800 high-risk patients within UCSDH.
Funding support for the TOC program was initially driven by Medicare incentive programs such
as Delivery System Reform Incentive Payment (DSRIP) and the Community-Based Care Transitions
Program (CCTP) to improve care transitions for high-risk patients. The TOC pilot program was
implemented by a pharmacist to target patients with advanced stages of HF. Following the conclusion
of the DSRIP and CCTP projects, funding from UCSDH was justified with documented interventions
from the pilot programs. The TOC pharmacist service has since expanded to include other populations
(e.g., HIV) and select groups of managed care patients. An SSPPS faculty member joined the TOC
program with UCSDH funding support of 40% in an effort to assist with the increased breadth of
patient services.
TOC pharmacists work under a CPA with prescribing authority to initiate, adjust, monitor,
or discontinue medication therapy for HF and related conditions in hospital and ambulatory
clinics. Inpatient TOC pharmacists make rounds daily with an IP team, conduct admission and
discharge medication reconciliation, assess adherence, collaborate with the medical team on medication
therapy, facilitate access to medications, and provide comprehensive patient education. Ambulatory
TOC pharmacists perform phone-call follow-up and focus on post-discharge patients in-clinic to
conduct medication reconciliation, assess adherence, perform MTM for HF and related conditions,
facilitate medication access, and provide patient education.
Given the expense of pharmacist salaries and the inability to bill insurers for pharmacist services,
funding remains the primary barrier to expanding the TOC program. Funding for pharmacy technicians
and longitudinal TOC introductory pharmacy practice experiences for pharmacy students have been
implemented to maximize budget resources. Approximately 70% of patients require a pharmacist
intervention, with an average of two interventions per patient.
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3.3. Pharmacist-Physician Team Care Model
3.3.1. UCSDH Family Medicine Clinics
The UCSDH Family Medicine Clinics provide services at three locations throughout San Diego
County to patients from pre-conception to end-of-life care. Since 2010, two clinical pharmacists
have provided chronic disease management under a CPA. Patients are identified by the PCP and
are referred for a “shared” collaborative visit with a pharmacist and a family medicine physician.
During each visit, the pharmacist conducts medication reconciliation and reviews the patient’s past
medical history, relevant family and social histories, risk factors, allergies, medications, and lab
results. Pharmacists manage anticoagulation, diabetes, HTN, hyperlipidemia, tobacco cessation,
and immunizations. A care plan is developed with the patient that includes treatment goals and
education. The plan is communicated with the physician, who also meets with the patient to address
any further questions or health problems. Based on the complexity of the visit, insurance is billed with
the physician signing off on the care plan. The PCP is also notified of the care plan. Patients are seen in
30 min appointments with regular follow-up, accounting for over 1000 annual office visits.
Ongoing and regular physician referrals remain a challenge. Patients may also be identified
through EHR registries or dashboards and then scheduled for a pharmacist visit, although patients
are more likely to attend visits when suggested by their PCP. Additionally, since the physician paired
with each pharmacist is different at each session, it is not always guaranteed that a patients’ own
PCP will be the physician during their shared visit. The physician sees his/her own limited set of
patients for the session, and so challenges arise with respect to timing and visit duration, impacting the
patient and provider experience. While these types of visits do increase IP collaboration and allow for
more complex visits and reimbursement, there have been discussions about moving toward a more
independent-pharmacist model within the clinics.
Clinical outcome measures being implemented include improved A1C, anticoagulation time in the
therapeutic range, the achievement of goal blood pressure, and the primary and secondary prevention
of coronary artery disease and stroke. This particular program was selected as one of three in 2018 by
the Centers for Disease Control and Prevention for an evaluability assessment site visit as a program
routinely using innovative strategies in hypertension care [39].
3.3.2. Geriatric Community Partnerships
In 2015, UCSDH was awarded a grant from the federal Health Resources Services Administration
Geriatrics Workforce Enhancement Program (GWEP) of the Department of Health and Human Services
to train and research novel approaches to providing older adult care. One particular focus of this
proposal was the incorporation of a clinical pharmacist in a primary care clinic to provide direct-patient
care for underserved populations via a partnership with the Medicare–Medicaid-funded Program
of All-Inclusive Care for the Elderly (PACE) Clinic in San Ysidro, CA, and to train and embed a
pharmacist fellow in the clinic to perform comprehensive medication management under a CPA [40].
The funding also supported a part-time student pharmacist to assist with clinic provider education
on potentially inappropriate medications, polypharmacy, medication regimen complexity, program
development, and participation in required rapid-cycle quality improvement projects [41]. The patient
population was 90% percent Spanish-speaking, with limited health literacy and, as Medicaid qualifiers,
they were low-income patients with an average of 14 medications per patient. The pharmacist conducts
transitions of care medication reconciliation, manages anticoagulant dosing, initiates immunizations,
reduces the use of inappropriate medication and high-cost medications, and provides medication
usage recommendations to center management [42]. The clinic has continued its funding of a full-time
clinical pharmacist.
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3.3.3. UCSDH Psychiatry
UCSDH Outpatient Psychiatry Services include general psychiatry and specialty clinics in mental
health such as college mental health, child and teen psychiatry, addiction treatment, treatment-resistant
depression, women’s reproductive mental health, sexual health, early psychosis, and senior behavioral
health. The clinics employ numerous health professionals to provide a full range of outpatient
psychiatric services, including intakes, individual and group psychotherapy, pharmacotherapy,
and psychoeducation. Established in 2008 [43], the pharmacist clinic has experienced between
approximately 150–300 annual office visits [43]. The patient population varies from county-funded
patients with severe mental illness to public and private funding for mood disorders, anxiety disorders,
PTSD, and ADHD. The Department of Psychiatry provides funding for 10% work for the psychiatric
pharmacist’s clinic time.
During each visit, the psychiatric pharmacist spends approximately 30–45 min providing
psychotropic medication management under a CPA. The pharmacist conducts medication reconciliation,
assesses medication adherence and adverse effects, evaluates medication dosing, assists with refills
and insurance authorizations, and makes referrals to other services. The pharmacist and attending
psychiatrist develop the therapeutic plan and then discuss the plan with the patient. The pharmacist
has a DEA license, which allows the initiation and modification of controlled and non-controlled
medications. Recently, the pharmacist coordinated the initiation of a new, long-acting, injectable
antipsychotic program to improve patient access and continuity of care.
Implementation challenges include funding for the pharmacist’s work, insurance billing,
shared visit scheduling, and regulatory requirements for documentation. Program outcomes include
patient encounter volumes, top patient diagnosis, and pharmacist interventions. Future program
outcomes will include symptom improvement using standard rating scales and required medication
monitoring documentation.
4. Discussion
In this paper, we describe collaborative pharmacist–physician practice models that provide clinical
care to patients with complex disease states. The pharmacists not only focus on the optimization
of care for their respective specialties but also provide comprehensive care for comorbid conditions
and complications. Notably, the pharmacists provide a large scope of services which encompass
medication therapy management, including but not limited to medication reconciliation, initiating and
adjusting medications, the ordering and monitoring of laboratory tests, performing physical
examination, assessing and optimizing adherence, promoting healthy lifestyles, and providing
education. These services were delivered using different care models integrating the pharmacist within
IP teams or partnering with physicians.
The type of practice model chosen was based on the disease state, patient complexity,
needs assessment, strategic goals, and financial viability. We summarized the advantages and
disadvantages for the described care models (Table 1). For example, the DIMM clinic model is a
pharmacist with physician oversight model since evidence-based medication optimization to improve
glycemic control could be most efficiently delivered by the pharmacist provider. However, in psychiatry,
the pharmacist–physician team care model was chosen due to patient complexity and the need for an
individualized approach to management that considers numerous patient factors.
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Table 1. Advantages and disadvantages of different pharmacist care models.
Care Model Advantages Disadvantages
Pharmacist with
physician oversight
Autonomy in clinical decision making.
Efficient model for optimizing medication
management using evidence-based guidelines.
Improves public recognition of advanced
pharmacist provider roles.
Can only be applied to patients with established
diagnosis who mainly require optimization of
medications.
Complex patients requiring additional diagnostic
testing may not be appropriate.
Pharmacist may feel a disconnect from physician
collaborator.
Dependent on referrals from physician
collaborators.
Low reimbursement on visits in the United States.
Interprofessional
Best suited for complex disease states or
patients with numerous comorbidities.
Patient convenience-comprehensive care
delivered in one single office visit.
Greater ability to achieve target clinical
outcomes with multi-prong management (e.g.,
lifestyle modification, medications, social
interventions)
Higher reimbursement since physician
provider bills for visits.
Requires greater coordination of team members
during visits to ensure efficiency.
Less time for each health professional to spend
with patient.
Longer visit duration for patients.
Longer visits may result in lower patient volumes.
Interprofessional team is resource intensive.
Pharmacist-Physician
Team
Can manage established and newly diagnosed
patients who may require additional diagnostic
testing.
Enhances care provided in physician only visits
due to optimization of drug therapy.
Easier to coordinate team members.
Higher reimbursement since physician
provider bills for visits.
Less pharmacist autonomy
Longer visits
Dependent on referrals for patient volume.
Importantly, the majority of these care models have been funded by the affiliated health systems,
and a few are funded by grant mechanisms. This was made possible by creating goals that align with
the health system priority initiatives and recruiting faculty whose expertise could help to achieve these
goals. A business case was developed by reviewing published literature, identifying potential quality
outcomes and direct and indirect financial metrics. Several studies have been published demonstrating
the financial benefit of pharmacist care services in a variety of care environments from community
pharmacy to ambulatory care clinics and to hospital acute care environments. In a study examining the
impact of the community pharmacist-initiated management of uncomplicated urinary tract infections,
pharmacist care was associated with lower costs ($72.47) when compared to family ($141.53) and
emergency ($368.16) physician-initiated care, estimated to result in significant long-term net total
savings of $51 million [44]. Ourth and colleagues conducted a cost-effectiveness study of clinical
pharmacists managing diabetes and found a negative cost per quality of life adjusted years after 3 years,
suggesting that it is cost-effective to incorporate pharmacists into diabetes care teams [45]. Similarly,
studies of transitions of care programs have demonstrated significant cost savings. Ni and colleagues
documented average cost savings of $2139 in the first 180 days after discharge [46].
The practices described in this paper proved to be sustainable with continued funding for
long periods of time despite cessation of grant funding. Moore and colleagues found that after
initially funding pharmacist services through grant mechanisms and demonstrating quality care,
the services could be continued and expanded through funding by accountable care organizations [47].
We demonstrate that clinical faculty can effectively provide comprehensive pharmacist services to
a large breadth of complex patient populations across multiple practice settings in affiliated health
systems. Our programs position pharmacists to obtain APP status in the future given their collaborative
practice meets necessary criteria for APh licensure.
We stated that the outcome measurement of these pharmacist care models varies with some
practices in the design phase and others measuring patient volume to robust clinical and process
outcome dashboards. Successful programs measure meaningful outcomes that demonstrate the
return on investment for the health system. Many of our programs have developed significant
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improvements in clinical and process outcomes. We demonstrated that pharmacist-delivered diabetes
care resulted in A1c reductions of 2.4%, compared to 0.8% for standard of care, with significant cost
savings. The pharmacist within the IP CKD care team focused on reducing the number of patients
prescribed an NSAID to 0% and counseling over 98% patients on NSAID avoidance. In palliative
care, pharmacist interventions resulted in 17% improved medication efficacy and a reduction in
non-adherence by 13%. Transitions of care pharmacists demonstrated a significant reduction in hospital
readmissions with cost savings to the institution. These clinical and process outcomes have been
revised as needed for continuous quality improvement, with the retirement of outcomes at goal and
new outcomes identified. In some instances, new outcomes or strategies were developed for financial
sustainability. These results have been disseminated at national and international IP conferences,
or published in journals with broad readership. This dissemination is critical to allow for these care
models to be easily replicated at other institutions.
The value of pharmacist services we described has received notable recognition from government
agencies, accreditation bodies, and professional societies. From these various models of pharmacist
services, we identified some common facilitators. These included a gap in care that could be met
with pharmacist services, a linkage between clinical and financial outcomes, a physician champion
to support proposals, and the strategic recruitment of faculty with expertise in these growth areas at
affiliated health systems.
Program design and implementation always comes with challenges; space and funding are
well-recognized resource barriers. However, our collective approach has been to share our faculty
experiences and to brainstorm funding mechanisms and develop successful space propositions such as
colocation. The colocation of interprofessional team members in a shared work space and elimination
of private physician work offices has been shown to improve team communication, cohesiveness,
and team primacy [48]. An important facilitator of funding challenges is the joint appointment of the
UCSDH Chief Pharmacy Officer as a clinical faculty member that provides a critical advantage for the
development of new clinical services at UCSDH. Our future directions include the development of new
clinical faculty practice settings in geriatrics and infectious disease within the affiliated health systems.
5. Conclusions
In conclusion, the expansion of pharmacist services delivered by clinical faculty has several
benefits to affiliated health systems: (1) significant improvements in patient care quality, (2) access
to experts in specialty areas, and (3) the dissemination of outcomes and national and international
recognition, increasing the visibility of the health system.
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Abstract: Purpose: To describe a unique pharmacy intern program in a group of federally qualified
health center (FQHC) outpatient primary care provider clinics. Summary: A pharmacy intern
program was created at the North Central Nursing Clinics in Indiana, a group of four FQHC
outpatient primary care provider facilities. Intern-performed tasks included: Prior authorization (PA)
requests, medication assistance program (MAP) applications, sample procurement and inventory,
and contraceptive devices for implantation inventory management. Interns interacted with clinic
administration, nurse practitioners, and medical staff to complete their assigned responsibilities.
Over a one-year period, the interns completed documentation on more than 2000 charts during a
combined 12 h a week. Interns identified the interprofessional interactions as the most beneficial
experience, while providers acknowledged no difference in the processing of paperwork during
the transition of duties from pharmacy fellow to intern. Conclusion: This unique pharmacy intern
program was successfully created and implemented in a primary care provider office, resulting in
learning opportunities for pharmacy interns, as well as operational efficiencies to fellows, providers,
and the organization.
Keywords: pharmacy intern; student pharmacist; primary care; interprofessional; federally qualified
health center
1. Introduction
Pharmacy interns have a variety of different roles and responsibilities and typically work in
community and hospital pharmacy environments [1–6]. Student pharmacists, serving as interns,
contribute to their educational process and professional development as they gain practical experiences
related to the pharmacy curriculum. While there is evidence of student pharmacist involvement in
direct patient care activities through student-run free clinics, these students operate on a volunteer
basis or are participating as part of a required pharmacy practice experience, compared to intern
positions that are paid [7–10]. Currently, there are no descriptions of the role of pharmacy interns in
the literature beyond those in hospital or community pharmacy settings. In this manuscript, a unique
pharmacy intern program in a rural outpatient primary care facility is described.
The North Central Nursing Clinics (NCNC) in Indiana consist of four primary care provider
offices in rural communities. Affiliated with the Purdue University School of Nursing and College
of Pharmacy, the clinics are led by nurse practitioners whose specialties include pediatrics, family
medicine, and women’s health. Other integral members of the healthcare team include support staff
(e.g., front office personnel, billing, insurance navigators), social workers, medical assistants, and
nurses. The clinics are federally qualified health centers (FQHC), and all four sites are considered
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Level 2 Patient-Centered Medical Homes. As part of the FQHC requirements, no patient is denied care
based on their ability to pay for healthcare services. The patient population served at each of the clinics
varies, with 42–45% of patients enrolled in Medicaid and/or Medicare and 22–23% of patients being
uninsured. Roughly 10% of the clinics’ patients are native Spanish speakers, requiring translational
and interpretive services.
Pharmacy fellows are licensed pharmacists who serve as the sole provider of clinical pharmacy
services at the clinics as part of the Purdue University College of Pharmacy Academia and Ambulatory
Care Fellowship program. Fellows spend approximately 50% of their time in clinic and perform multiple
roles in the clinics, including: conducting patient visits for chronic diseases under collaborative practice
agreements (CPAs), precepting student pharmacists on advanced pharmacy practice experiences
(APPEs), and providing cost-effective medication recommendations. Fellows are also responsible for
completing prior authorizations (PAs), assisting patients in obtaining medication through medication
assistance programs (MAPs), and drug inventory management. Completion of a postgraduate year
one residency is a prerequisite for the fellowship program, as the fellows are required to operate
independently at these clinics. Two of the clinics serve as the fellows’ primary practice sites, with one
fellow based at each clinic. In addition, each fellow provides remote pharmacy services for the clinics
not staffed by the fellowship program.
2. Pharmacy Internship Program Description and Review
In August 2016, pharmacy services expanded, which resulted in increased direct patient care
activities and the need for assistance with administrative tasks. As a response to this need, the
pharmacy internship program was created. Two interns were hired for a total of 12 h per week.
Described duties included completing PAs, coordinating MAP applications, and tracking contraceptive
device prescription processing for each of the four clinics, as well as managing inventory of medication
samples at the main clinic. It was decided by all involved parties that students recruited for the intern
positions would have completed at least their first year of the professional program. Both interns
are supervised by the on-site fellow and communicate any issues or questions to them. The interns
each work primarily out of one clinic site location, but assist with administrative responsibilities for
patients from all of the clinics. All documentation by the interns is submitted to both the responsible
provider and the fellow for review. Interns also perform follow-up phone calls with the patient and the
pharmacy as necessary to ensure timely processing of medications and expedite patient care. When
processing PAs, if an adjustment can be made due to a formulary requirement or therapeutically
equivalent medication, the fellow is authorized to change the medication order, either through a CPA
or with verbal authorization from the provider.
From October 2017 to October 2018, pharmacy interns completed in excess of 2000 documented
tasks (Table 1). Interns initially worked a combined 12 h a week at the clinic. For quality assessment,
interns were instructed to document their daily workload processes, recording the number of PAs,
MAPs, contraceptive devices, inventory and other assorted tasks not covered under these categories.
As a result of significant work volume, intern hours were expanded to a combined 16 hours a week
in May 2018. The documented tasks may be slightly underestimated due to some brief gaps in data
recording. In addition to the routine activities outlined previously, examples of some unique intern
tasks include working with a pharmaceutical company to complete an adverse event report in response
to a vaccine and clarifying dosing discrepancies on prescriptions with community pharmacies.
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Table 1. Pharmacy intern completed tasks.
October 2017–October 2018
Assigned Tasks Volume Completed
PAs 1582
MAP applications 208
Appeals to PA rejections 21
Contraceptive device procurement 3
Inventory 4
Other tasks completed 252
Total tasks completed 2070
MAP =medication assistance program; PA = prior authorization.
3. Benefits of the Pharmacy Internship Program to Pharmacy Interns
The Fink Model of Significant Learning (FMSL) was applied in the development of the internship.
In this model, Fink outlined six main categories of learning that create significant learning experiences
for students. These six categories are: (1) foundational knowledge, (2) application, (3) integration,
(4) human dimension, (5) caring, and (6) learning how to learn. Interns experienced each of these
categories as a part of the internship program. The interns are utilizing their foundational knowledge
of medication use from the didactic curriculum and integrating specific patient needs as part of the PA
and MAP processes. Through their interaction with providers and patients, they are learning about the
human dimension of patient care, as well as caring and advocating for others. Interns regularly inquire,
or learn how to learn, to resolve drug-related problems and issues related to medication access [11].
Pharmacy interns participated in semi-structured interviews upon completion of their term.
The pharmacy interns describe this position as rewarding for several reasons. Primarily, it offers
an opportunity to work with vulnerable and underserved populations, a unique experience not
always provided through traditional internships (FMSL categories: caring and human dimension).
The diverse patient population requires multi-faceted approaches to obtaining medications that are
often expensive. Interns regularly review pharmaceutical companies’ MAPs, community pharmacy
discount medication programs, discount medication cards, and websites (FMSL categories: Learning
how to learn and application). Interns are also offered opportunities to shadow providers on their own
unpaid time, if desired, to potentially gain a greater understanding of interprofessional relationships
and comprehensive patient care that occurs in an ambulatory care setting. Additionally, interns
participate in scholarly opportunities related to their work, resulting in two poster presentations and
two manuscript preparation opportunities to date (FMSL categories: Learning how to learn, integration,
and application). Finally, interns educate other student pharmacists who are completing curricular
requirements, such as a rotation or service-learning activity about the intern responsibilities at the
clinic (FMSL categories: Integration and human dimension).
Prescriber management of PAs is often unseen by student pharmacists. Both interns previously
completed an introductory pharmacy practice experience (IPPE) in the community setting and observed
the PA process in that setting. As processing PAs is the primary function of the intern position, it
exposes interns to the challenges faced when working with a variety of insurance companies, while also
ensuring patients receive their necessary prescribed medications. In processing PAs, interns critically
review patient profiles and determine the patient-specific factors that are relevant in the selection
of a medication (FMSL categories: foundational knowledge, application, and integration). Interns
further advocate for patients with insurance companies by communicating the provider’s rationale
and decision-making process in prescribing the requested medication (FMSL categories: Caring,
human dimension, and integration). Interns take part in an essential component of the prescribing
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process, leading to a better understanding of preferred medications, insurance formularies, and prior
authorization approval criteria of prescription medications.
Additionally, the interns valued learning about the financial barriers experienced by some of the
NCNC patient population (FMSL category: caring). Patients, especially those who are vulnerable or
underserved, often see costs associated with their care as burdensome, and will periodically go without
care, leading to poor health outcomes and increased healthcare costs [12]. Interns helped address these
barriers by coordinating between providers and patients to complete MAP applications, resulting in
increased medication access for patients and potentially improved patient outcomes (FMSL categories:
Foundational knowledge, application, and integration). Interns identified barriers which slowed or
complicated the MAP process, including the patient’s motivation to provide and complete the required
documentation, as well as provider understanding of application requirements. Solutions to these
identified barriers were implemented as a result of intern observations, including provider education
on the application processes, prefilled applications with provider information already completed,
highlighted patient requirements on the applications, and increased availability of applications to
providers and patients.
Skills learned by the interns in the pharmacy curriculum were applied and practiced through the
internship program. Areas of emphasis include appropriate written communication and thorough
documentation, interprofessional collaboration with providers to address insurance and/or patient
barriers, and dissemination of key clinical information to insurance companies to justify a medication’s
necessity. Additionally, interns apply and integrate many of the tools and skills learned in the didactic
portion of their pharmacy curriculum (i.e., foundational knowledge). Their role in the clinic allows
them to practice skills prior to becoming pharmacists, when they will be expected to make clinical
recommendations based on a variety of patient-specific factors.
4. Benefits of Pharmacy Internship Program to the FQHC Clinics
Pharmacist Fellows—Primarily, the pharmacy intern program allowed pharmacist fellows to
explore and expand clinical pharmacy services, including an increase in direct patient care activities as
a result of decreased time addressing PAs and MAPs. Subsequently, the fellows have implemented
CPAs with the providers to manage multiple chronic disease states. The number of patients receiving
anticoagulation management services has more than doubled, an event that has been aided by the
transfer of administrative responsibilities. Providers are able to refer patients with diabetes to a
pharmacist-directed telephone consult program designed to facilitate insulin management. Finally, in
supervising the interns, the fellows gain additional management experience that will prove vital in
their future careers as clinical faculty and preceptors.
Providers—The pharmacy interns provide on-site coverage for administrative paperwork four
days a week, and are able to interact with providers, should the need arise. Interns facilitate MAP
applications, obtain provider signatures for PAs, address any inventory issues, and communicate
needed changes in a timely and efficient manner. Providers receive education on common prescribing
issues with insurance formularies (e.g., prescribing omeprazole instead of Prilosec OTC®) and modify
their prescribing habits to avoid these issues. Providers and their patients have also directly benefitted
from the expansion of pharmacy services, including expanded direct patient care services, medication
adjustment and monitoring through the CPAs, and clinical medication profile reviews for optimal
chronic disease management.
Providers are regularly asked for feedback on the intern program and have not described any
concerns with the transition of responsibilities from pharmacist to intern. Several providers have
expressed appreciation for having the interns available on-site to answer insurance-related questions
when the pharmacist is not at the clinic. Periodically, a patient will tell the provider during their office
visit that they cannot afford the medication, or the insurance requires some action before approval.
The interns have served as a valuable resource and are able to smoothly rectify the situation for the
patient and the provider, deferring to the pharmacist when necessary.
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Clinic—Implementation of the pharmacy internship program assisted in developing cost-effective
pharmacy strategies for both the patient and the clinic. Prior to the fellowship program, other staff
members (e.g., medical assistants, staff nurses, or support staff) would need to complete patient
paperwork. A 2011 article estimated US physician and administrator costs related to time spent
interacting with payers to be almost $83,000 annually [13]. The estimated cost of hiring the interns to
manage these interactions with payers and other administrative responsibilities is approximately $10,800
annually, more than a seven-fold cost differential. Reduction in the burden of these administrative
processes for providers, clinic staff and pharmacy fellows has increased efficiency in other areas and
provides more time to deliver optimized patient-centered care.
Student pharmacist learners—Prior to the pharmacy internship program, APPE students at the
clinics spent considerable time on PAs and MAP applications, resulting in few direct patient care
activities. With the pharmacy internship program in place, APPE students engage in more hands-on
patient interaction experiences, such as independently leading anticoagulation management visits,
organizing medication and disease consult appointments, providing clinical recommendations to nurse
practitioners through chart review, conducting in-service education to the interprofessional staff, and
leading educational sessions with patients. APPE students also have the opportunity to participate in
scholarly activities with the fellows and the institutions.
5. Challenges in Implementing the Pharmacy Internship Program
There were challenges in the implementation of the pharmacy internship program. First, there
was an initial learning curve for the interns in identifying the best ways to contact insurance companies
and communicating the information to successfully complete a PA or MAP application. This led to
some trial and error in the beginning and resulted in some general delays with completing the daily
assigned tasks. To reduce the transitional burden, one intern is recruited annually upon completion
of their first professional year in the pharmacy program to fill the place of the intern advancing to
the fourth year of the curriculum, while the other intern remains in place, providing stability and
consistency during each period of transition. The “senior” intern serves as a resource and assists in
orienting and training the “junior” intern. Further, semi-structured interviews occur at the end of
each intern’s time in the role to identify areas of improvement or difficulties that can be addressed
by the fellows or the organization. Second, the position was originally approved for 12 h a week,
which was often evenly split by the interns. This allowed for coverage three to four days a week,
however, the clinics are open up to 12 h a day. As such, there was only a brief amount of time for
the interns to complete paperwork for all four clinics, and the volume of patients cared for by the
providers outpaced what the interns could provide. Requests would sometimes take several days to
be processed, especially during holidays and weekends. The program expanded its hour limit to 16,
which offset some of these delays and helped ensure timely processing of all responsibilities. Third, as
part of their education, the pharmacy interns had academic requirements that periodically kept them
from being able to work at the clinic, such as final exams or IPPEs. This challenge was managed by
using a flexible schedule approach, requiring the interns to identify when their external responsibilities
would be heaviest. The interns were able to adequately balance their academic and co-curricular needs
through open communication with the pharmacist fellow, and no significant delays in service occurred.
6. Conclusions
This pharmacy internship program in an outpatient primary care organization is a unique learning
and employment opportunity for student pharmacists. It provides them with a valuable experience
while simultaneously benefitting the clinics, providers, and patients. From the intern perspective,
working with the medically underserved was considered the most beneficial aspect of the program.
Further, the interns utilized their acquired skills and experiences from the internship program during
their APPEs. This experience also encouraged them to explore opportunities to work with underserved
patient populations. The program demonstrates improvement in provider efficiency by spending less
199
Pharmacy 2019, 7, 36
time on administrative paperwork and creates opportunities for the provision of direct patient care.
Additional benefits are seen for the organization and student learners on required learning rotations.
Primary care facilities may benefit from implementation and expansion of the pharmacy intern role to
other basic clinical pharmacy needs.
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Abstract: Nearly 44 million Americans are affected by mental illness every year. Many individuals,
however, are not diagnosed and/or do not receive treatment. The present manuscript reviews the
incidence of mental illness, the continuum from mental wellness to mental illness, and the role of
the pharmacy staff in helping individuals manage different mental health needs. In particular, there
is discussion of stigma of mental illness that those with mental health needs experience by those
around them including health professionals such as pharmacy staff. One way to resolve such stigma
is through training such as Mental Health First Aid (MHFA). The paper reviews key aspects of MHFA,
the evidence supporting MHFA, and how MHFA relates specifically to pharmacy practice and services.
A conceptual framework for MHFA and its relationship to individual factors, attitudes, behaviors, and
outcomes. Lastly, a discussion is presented that briefly compares MHFA to other similar approaches
to helping those in mental health crises, the limits of what is known about MHFA, and what future
research might explore to better understand the outcomes of pharmacy staff providing mental health
education, support, and referral to care.
Keywords: mental health care; pharmacy staff; mental health first aid; mental illness; pharmacist roles
1. Background
There are at least 43.8 million individuals in the US affected by mental illness every year [1]. There
are several more millions of individuals, undertreated, who would be diagnosed and properly treated
for mental illnesses who are not in the system [2]. In addition, there are numerous other individuals
who do not meet the criteria for a diagnosis of mental illness or require treatment but experience
episodes where they are unable to optimally cope or manage their temporary thoughts, feelings, and
behaviors. For a variety of reasons, whether for those already diagnosed with mental illness, needing
to be diagnosed and/or treated, or those with more transient/temporary mental health symptoms, these
groups of individuals face significant challenges in obtaining resources to help them initiate and/or
remain consistently engaged with a support system that can provide the needed support to help them
resolve their temporary or long- term difficulties. Key reasons why these groups of individuals struggle
to initially reach out for support or consistently engage in support include (1) the stigma experienced
by all these groups that are afflicted with different levels of mental health challenges face, and (2) the
lack of access to individuals trained to provide temporary supportive management of specific mental
health crises and know when and what types of additional support is needed for such individuals [3].
The National Alliance on Mental Illness (NAMI) and many other mental health advocacy groups
and organizations have promoted anti-stigma campaigns to target the first of these two reasons [4].
Clearly, there is still much work to do to make individuals with a variety of mental health symptoms
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feel more comfortable reaching out and having someone help them through their symptoms. There are
many efforts that continue to focus on facilitating cultures at work places, health care environments,
and other areas of the community that avoid judgement and distance away from the individual
suffering from ongoing or temporary mental health symptoms [5]. One common example is using
“person first” language that avoids labeling individuals by their illness such as “schizophrenics” and
rather referring to these individuals as those with lived experience of schizophrenia or “individuals
with schizophrenia.” Rather, the focus of this anti-stigma work is to help bring the affected individual
together with a community resource and together support the individual towards improved mental
health management. As valued, trusted members of the community, pharmacists are at the frontlines
of primary health care and thus regularly interact with individuals who may have mental illness and
mental health crises. If pharmacists were equipped with tools that enhanced their engagement of
individuals with mental health needs, it is possible pharmacists could help adults in need of mental
health services seek mental health care. Mental illnesses are so prevalent throughout society, yet they
are also some of the most severely undertreated. While 1 in 5 adults in the US is afflicted by mental
health conditions in a given year, only 41% of those adults received mental health services [1]. Among
adults with a serious mental illness, 62.9% received mental health services in the past [1]. Additionally,
just over half (50.6%) of children with a mental health condition aged 8–15 received mental health
services in the previous year [1]. Such disparities contribute to significant costs to the individuals with
mental health symptoms and the healthcare system as a whole. Not only are individuals unable to
optimally function that affects their quality of life, but they are actually also at greater risk for many
comorbid conditions. On average, adults in the US living with mental illness die 25 years earlier than
others, largely due to treatable medical conditions [1]. Suicide is also the 10th leading cause of death
in the US, the 3rd leading cause of death for people aged 10–14, and the 2nd leading cause of death
for people aged 15–24 [1]. Not only does mental illnesses severely impact individual lives, it has also
contributed to $193.2 billion in economic losses per year [1].
Identifying mental health concerns and illness can be thought of on a continuum from what
is considered mental wellness to mental illness (Table 1). The model presented in Table 1 is based
on the definition and concepts in the Mental Health Continuum Model [6]. On the mental wellness
end of the spectrum, we would expect healthy reactions including predictable mood fluctuations,
general acceptance of challenges, sense of humor, high performance, average sleep patterns, moderate
to high level of energy, and avoidance of excessive use of substances and engagement in addictive
behaviors. Moving to the middle of continuum, an observer might start noticing the following: more
unpredictable mood fluctuations, difficulty managing life challenges, diminishing sense of humor,
reduced performance, poor sleep patterns, and moderate to low energy, more anxiousness about
different activities, and gradual engagement in unhealthy behavior patterns. At the ill end of the
spectrum, an individual will be observed to have: angry outbursts that are more significant and
frequent, very labile moods with very low and/or low moods, significant anxiety, presence of unusual
thoughts and behaviors, poor sleep, significant difficulties performing in daily activities and work,
excessive substance use and risky and/or addictive behaviors, and thoughts of harming the self and
others. Individuals presenting at different stages within this continuum are in need of different levels
of support and professional help. Thus, awareness of the mental health continuum acts as a useful
resource and context to clarify the severity of impairment of those suffering from mental health crises
and illnesses, and what resources such individuals may need. Although Table 1 depicts a list of signs
and symptoms under each aspect of the continuum from mental wellness to mental illness, this should
not be interpreted that an individual needs to have all the signs and symptoms listed at one time to be
considered mentally well or mentally ill. An individual may present with signs and symptoms from
different parts of the continuum.
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Predictable mood fluctuations Unpredictable mood fluctuations Frequent & significant outbursts
General acceptance of challenges Difficulty managing life challenges Labile moods
Sense of humor Diminishing sense of humor Significant anger and/or anxiety
High performance Reduced performance Unusual thoughts and behaviors
Average sleep patterns Irregular sleep patterns Consistently poor sleep patterns
Moderate to high level of energy Moderate to low energy Significant dysfunction in daily
Avoidance of excessive use of substances Anxiousness about activities activities and work
Avoidance of addictive behaviors Gradual engagement in unhealthy
behavior patterns
Excessive substance use &/or addictive
behaviors
Thoughts of harm to self/others
While poor mental health can lead to poor physical health and mental illness, it is possible to have
poor mental health temporarily and not lead to a diagnosed mental illness. For example, a person
going through a hard life experience may have poor mental health during this time period without
necessarily having a mental illness. Thus, feeling miserable or isolated may be red flags that your
mental health requires attention and improvement. In these cases, it is important to utilize support
from friends/families/other groups, focus on healthy lifestyle habits such as eating regularly and
appropriate sleep hygiene, and even seeking support from a therapist can be beneficial. Poor mental
health not leading to mental illness can be due to difficult life transitions, environmental challenges,
and the lack of needed resources. It is also important to note that poor mental health may not lead to
poor health and that an individual with mental illness may be in good physical health.
Diagnosed mental illnesses, however, are often associated with physiological alterations in
the brain due to genetic predisposition, chemical changes, traumatic experiences, and/or major
developmental challenges leading to significant changes in mood, thinking, and behavior that cannot
be easily managed with self-help strategies or non-professional support systems. These individuals
often require referrals to their primary care doctor, a psychologist, a psychiatrist, and occasionally
a social worker for management of the various aspects of treatment. Some more severe cases may
require hospitalization, or treatment programs with more intensive interventions and monitoring.
2. Role of the Pharmacy Staff
Pharmacists are considered the most accessible health care professionals, and see a large volume of
patients in community pharmacies every day. The College of Psychiatric and Neurological Pharmacy
(CPNP) and National Alliance on Mental Illness (NAMI) collaborated on a 2012 national survey and
assessed the opinions of 1031 individuals with mental health concerns, or their caregivers, regarding
their relationship with their pharmacist. Ninety-one percent felt very comfortable going to their
community pharmacy, and 83% felt like the pharmacist respected them [7].
Pharmacists are involved in many services including: counseling, monitoring, and reducing
side effects, assessing serum concentrations, identifying interactions, assisting in treatment plans,
and developing ways to increase medication adherence. Pharmacists have also been repeatedly shown
to enhance patients’ knowledge, beliefs, and sense of treatment progress related to psychotropics
such as antidepressants [8]. These findings illustrate the impact that pharmacists can have on the
treatment, attitudes, and perceptions of their patients with mental illnesses. Such impact can help
improve patient medication adherence. Pharmacy staff already have access to a large segment of this
population. If pharmacy staff have the appropriate mental health skills, they can help to reshape the
negative perceptions individuals with mental health needs and illness have about themselves and
their illnesses. Such pharmacy support can remove a significant barrier to care, to be discussed in
greater detail in next section [9]. In addition, pharmacy staff knowledgeable in the signs and symptoms
of mental illnesses can also help identify individuals that may need to be referred to a clinician for
follow-up and support. Pharmacy staff also can be excellent resources of information about mental
health conditions and encourage various self-help and other strategies.
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3. Barriers to Care: Presence of Stigma
A significant barrier to care for those individuals with mental illness is the stigmatization of their
illness by others. Stigma has been developed and supported by a combination of media incorrectly
portraying mental illness, and a lack of training/education regarding mental health awareness. With
movies like Friday the 13th—A New Beginning (1985), Psycho III (1986), Misery (1990), and Silence of the
Lambs (1991), many people have grown up with the misconceptions that mental illness disenables a
person from logical thinking and makes them difficult to reason with, and even dangerous [10].
Stigma persists throughout all areas of the community, and healthcare is no exception [9,11].
In general, some healthcare professionals may view individuals with mental illness as incompetent,
unpredictable, dangerous, difficult to communicate with, and require too much time to provide service.
Even insurance companies have been shown to offer greater coverage for physical illness over mental
illness [12]. Studies generally show that pharmacists have a positive view of people with mental illness,
but are often uncomfortable with them [9,13–16]. Upon survey, pharmacists reported being more
willing to counsel on a physical disorder (i.e., asthma) than a mental disorder [16].
In the 2012 national survey by CPNP and NAMI mentioned previously, a little over half of those
sampled reported having a strong professional relationship with the pharmacist [7]. Approximately
40% of those in this latter sample actually reported no relationship with their pharmacist and 75%
reported not receiving effectiveness and/or safety monitoring assistance from the pharmacist [7].
This illustrates a need for greater education focusing on how pharmacy staff can feel more comfortable
in communicating with individuals with mental health needs and illnesses. Such greater comfort
in communication will foster a stronger relationship between individuals with mental health needs,
mental illnesses, and pharmacy staff. Through these stronger relationships, pharmacy staff can provide
much needed education and motivational resource for individuals with mental health needs that may
otherwise be overlooked by their system of care. Pharmacists need more training and skills to help
improve their comfort in communication and build relationships with individuals with mental health
needs. Such mental health training opportunities will be discussed in the next section.
4. Mental Health First Aid
Mental Health First Aid (MHFA) is a training program offered to the general public aiming
to increase mental health literacy, and impart the participant with the skills required to provide an
immediate response to a person experiencing an acute mental health crisis [17]. MHFA also helps train
the participant to understand the signs and symptoms of different mental illnesses so they can help
someone seek the appropriate support especially in the earlier stages of developing a mental health
disorder or problem. The program originated in Australia in 2001 and was designed by Kitchener, a
nurse specializing in health education, and Jorm, a mental health literacy professor. The program can
be given as a one 8-hour day, two 4-hour days, or four 2-hour days. Programs delivered over the course
of multiple days should not occur more than two weeks a part. During this time, participants obtain
the skill set necessary to not only intervene in a mental health crisis, but to identify those at risk and/or
having symptoms of mental illness, and direct them to the help they need. In both the participant
and MHFA instructor manuals, MHFA is presented as being like first aid needed for cardiovascular
support (American Red Cross’ CPR program) but for mental health crises.
The program focuses on depression and other mood disorders, anxiety disorders, trauma,
psychosis, and substance use disorders. Participants in the training learn the program’s “Mental Health
First Aid Action Plan,” and are taught to apply the action plan to many different scenarios—specifically
guiding interactions with others experiencing suicidal thoughts or behaviors, panic attacks, non-suicidal
self-injury, overdose or withdrawal from substance use, and reaction to a traumatic event. The action
plan consists of five steps:
1. Assess for risk of suicide or harm
2. Listen non-judgmentally
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3. Give reassurance and information
4. Encourage appropriate professional help
5. Encourage self-help and other support strategies
The first letter of each step forms the acronym ALGEE. Throughout the training, instructors
frequently refer to ALGEE and reinforce the ALGEE action plan.
There are no requirements for the training; it is available to the general public. The National
Council for Behavioral Health (NCBH) that accredits the training programs strongly encourages
professionals to participate who have frequent contact with those at risk or experiencing mental
illness/crisis. Specific examples listed on the MHFA website include police officers, human resources
workers, primary health care workers, schools, community faith organizations, and friends and family
of someone experiencing mental illness or mental health crises. The Community Pharmacy Foundation
supported a project by the National Community Pharmacist Association (NCPA) to develop and
provide 8-hour of continuing education credits for pharmacists and technicians who participate in the
8-hour MHFA courses. This project also supported the creation of specific pharmacy-related cases that
MHFA instructors can use when presenting topharmacists and pharmacy technicians. These cases are
available to certified MHFA instructors who complete several days of NCBH training for certification.
To use these NCPA cases, there is no additional training beyond needing to be certified to train others
in MHFA.
There is a small but growing literature on MHFA in general and its application to pharmacy.
A meta-analysis was performed estimating the effects of the MHFA program in participants of any
occupation, both for adults and young people, based on results published up to March 2014 [18]. MHFA
was found to be effective in increasing knowledge regarding mental health problems, and effectively
decreasing negative attitudes toward individuals suffering from mental health problems. The program
was also shown to increase help-providing behavior. Another publication reviewed three published
trials, and found improved concordance with health professionals about treatments, improved helping
behavior, greater confidence in providing help to others, and decreased social distance from people
with mental disorders [19].
In Sweden, researchers conducted a randomized controlled trial involving a group of staff from
various agencies who randomly received MHFA training and those who did not [20]. Results showed
that the MHFA group had significantly greater knowledge and confidence in helping others with
mental health disorders than the control group [20]. Such MHFA effects were shown to be maintained
to a great extent after a two-year follow-up period [20]. The collective data reviewed in this section
reinforces the central finding that taking a course in MHFA can significantly improve a participant’s
knowledge of mental health and mental health disorders, confidence in helping an individual manage
a mental health crisis, decrease stigma, and sets the participant up for a more successful interaction
when reaching out to those with mental illnesses.
In addition to the general literature regarding MHFA’s impact on trainee outcomes, there is specific
growing literature on MHFA’s impact on pharmacists and pharmacy students. One study took place
in eight rural Australian community pharmacies and entailed a survey assessing barriers to MHFA
training and applications of the training to pharmacy [21]. Pharmacists identified and supported the
need for MHFA, and had low confidence in their ability to handle an acute mental health crisis without
the additional training [21]. The majority (72%) of pharmacists agreed they have a role to provide
MHFA, but less than half (48%) were comfortable in providing this support. [21]. Most participants
stated that they would be prepared to undertake this training. About a third of the sample thought the
training should be administered during their intern year, 24% thought training should be administered
during their pharmacist years, and the majority (76%) preferred administration of training as a one-day
course with an online component [21]. The major barriers identified by pharmacists included time,
geographic location, and resources [21]. These results show that pharmacists have both identified the
need for and are willing to undertake MHFA training in order to improve access to mental health
support in individuals at risk for or experiencing mental health crises and illnesses.
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A controlled trial was conducted assessing 60 third year pharmacy students at the University of
Sydney randomly chosen to complete one of two 12-hour sessions of MHFA and complete a follow
up survey [22]. The survey (administered before and after the training) evaluated mental health
literacy, the 7-item social distance scale, and 16 items related to self-reported behavior. Survey results
showed that MHFA training reduced the pharmacy students’ stigma towards individuals with mental
illness, improved recognition of mental disorders and improved confidence in providing services to
individuals with mental illnesses in a pharmacy setting [22].
Another randomized controlled study of 262 members of the Australian public demonstrated that
students (pharmacy and other programs) who participated in an online MHFA course responded better
to measures of stigma reduction compared to those that used a written manual [23]. This indicates
that completing a training program such as the MHFA is more valuable than just offering educational
materials to students. While pharmacy programs often provide clinical background on mental illnesses
and evidence-based treatments to target these illnesses, they are typically less focused on helping
students manage crises that might occur in their pharmacies. An additional study, taking place at
University of Sydney, evaluated the differences in confidence and attitudes of their pharmacy students
towards suicidal crisis in three groups of students: the first group simply completed MHFA training,
the second group completed MHFA training and observed a simulation of a patient and pharmacist
interaction with a person undergoing suicidal crisis, and the third completed the MHFA training and
participated in the live simulated interaction [24]. Results displayed a statistically significant increase in
confidence in all students who participated in the MHFA training. In particular, the greatest increases
in confidence were among pharmacy students participating in the live interaction. Such data suggests
that participating in a live simulation is critical to the MHFA training experience. This combined
literature shows the clear value and impact of MHFA on learner attitudes and behaviors toward those
at risk for mental health crises and/or experiencing mental illness.
These findings are likely supported by an underlying conceptual framework for how MHFA
relates to individual factors, attitudes, behaviors, and outcomes. The authors depict this conceptual
framework in Figure 1 as it specifically relates to MHFA by pharmacy staff and its effects on both the
pharmacy staff and the outcomes of individuals experiencing mental health concerns and illnesses.
Moving from left to right, the framework starts with the concept that background factors of both the
individual with lived experience of mental health concerns and illness and the pharmacy staff affect the
extent to which stigma of mental illness exists for both the individual and the pharmacy staff. From past
extensive research on stigma of mental illness, it is well known that culture, education on mental
illness, personal contact with individuals with mental health needs and illness, and demographics all
impact the extent to which stigma towards mental illness develops [9,16,25,26]. In addition, there is
a robust literature and framework development supporting the role of these background factors on
pharmacy staff perceptions of counseling, relationships with patients, and the willingness to provide
care and related counseling services to those with mental illnesses [16,27].
In the middle of Figure 1, MHFA can be seen as a variable with bi-directional impact on (1) stigma
involving pharmacy staff and that of individuals with mental health needs, (2) attitudes of individuals
with mental health needs and pharmacy staff towards each other, and (3) services provided by pharmacy
staff to those with mental health needs. The research reviewed in this section supports MHFA’s direct
impact on these aspects of pharmacy practice [21,22]. Although not examined specifically, it is likely
that the stigma changes and practice changes from MHFA would likely change the willingness to adopt
and implement MHFA (reflected by the arrows going from stigma back to MHFA and practice-related
perceptions and services back to MHFA).
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The arrows from pharmacy stigma, stigma of those with mental health needs, practice-related
perceptions and services, and outcomes are all supported by decades of stigma and pharmacy practice
research on these topics [25,27]. Many of the non-pharmacy literature reviewed also support how
MHFA changes knowledge, willingness to help, negative attitudes toward those with mental health
needs, and other process outcomes [18–20].
As for the right part of the Figure 1 linking MHFA to outcomes, there needs to be more research
demonstrating the links between MHFA and various patient and health system outcomes such as
mental and physical health of individuals helped by MHFA, cost of care and improved treatment [28].
Feedback models, such as Figure 1, often suggest that outcomes or outputs of the model will affect
model inputs such as background characteristics. If MHFA improves mental and physical health,
it is expected that one’s background and experience would also change as well, and subsequently
other relationships in the conceptual framework. One suggested research approach to testing the
relationships in Figure 1 is through the secret shopper methodology whereby trained actors go into
pharmacies showing signs of being in a mental health crisis and see how those trained in MHFA
react differently from those not trained in MHFA and how the actor felt differently with a trained and
untrained MHFA person. It would be useful to also conduct randomized controlled trials to see if
practicing pharmacists trained in MHFA respond differently to individuals with mental health needs
and illnesses than those not trained in MHFA.
5. Additional Considerations
MHFA is designed for administration to the general public. As noted by Chowdhary and
colleagues, it may be prudent to give healthcare professionals a different program tailored to their
education, training and experiences [28]. These programs should also highlight that pharmacists are
not being trained in psychotherapy and other treatments. Rather, pharmacists being trained in MHFA
need to remove their clinical intervention hats and focus on the ALGEE action plan to manage a mental
health crisis.
MHFA is not the only program available to train participants on how to deal with mental health
crisis and communicate effectively with those suffering. Other programs include options such as
Psychological First Aid (PFA) and Emotional CPR (eCPR). PFA usually focuses more on protocol
following a disaster. MHFA is more general than PFA by focusing on any mental health crisis [29].
eCPR, however, is another training geared toward the general public to assist a person experiencing an
emotional crisis using three components [30].
1. C = Connecting with Compassion and Concern to Communicate
2. P = emPowerment to experience Passion, Purpose and Planning
3. R = Revitalize through Re-establishing Relationships, Routines and Rhythms in the community
eCPR is believed to involve consumers with lived experience of mental illness more actively in
the trainings and, therefore, the voices of those with mental illnesses are heard first hand throughout
the trainings. With no head to head studies comparing the different available training methods,
it remains uncertain that MHFA is superior to these other programs in preparing the general public and
pharmacy staff for these crisis-based interventions. MHFA, however, is gaining significant momentum
throughout the country and recently Walgreens has announced its plan to train their pharmacists
in MHFA [31]. Pharmacists are becoming certified train-the-trainers and offering MHFA sessions to
pharmacy students and practicing pharmacists.
6. Conclusions
Although there is not yet enough evidence to support that MHFA improves patient outcomes,
there is considerable support that it decreases existing stigma regarding mental illness (a leading
barrier to individuals seeking care and pharmacy staff providing care). There is also evidence that
MHFA increases pharmacist and pharmacy student confidence in identifying, approaching, interacting
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with an individual who is undergoing a mental health crisis, and helping them seek appropriate care.
These are significant steps in improving access to needed help for individuals with mental illness or
experiencing a mental health crisis. However, with no head to head studies comparing MHFA to
other programs, it is still unclear which of the available programs are superior in creating sustainable
changes in pharmacy staff confidence and engagement of individuals with mental health needs.
With the pharmacist being one of the most accessible and most frequently visited healthcare
professionals, community pharmacists are well positioned to bridge the gap between those with a
mental health crisis and/or illness and access to the treatment and support they need to begin the
healing process. Community pharmacists clearly need to augment their knowledge regarding how to
identify and respond to a mental health crisis. Training programs, like MHFA, are well designed to
reduce stigma of mental illness, increase knowledge and confidence on how to manage mental health
crises and support mental illnesses. By having more community pharmacists trained in MHFA or
other similar programs, community pharmacists can meet a critical public health problem by being
able to identify the urgent needs of someone in a mental health crisis, offer non- judgmental support,
and provide critical information that allows the individual with mental health needs to quickly access
the appropriate resources to help the individual achieve greater mental and physical wellness.
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Abstract: In December 2016, pharmacists in Ontario, Canada with authorization to administer
injections saw an expansion in their scope from a restriction to the influenza vaccination only to
now including an additional 13 vaccine-preventable diseases, largely those related to travel. It was
uncertain whether this change in scope would see sufficient uptake, or translate to a corresponding
expansion in other travel health service offerings from community pharmacies. In October/November
2017 a survey was conducted of all licensed community pharmacists in Ontario, followed by
semi-structured interviews with 6 survey respondents in June 2018. A web-based survey of members
of the public from a single region of the province was also conducted in September 2018 to assess
uptake of expanded vaccination services. Broad variability in uptake of these services was noted,
ranging from the dispensing of travel-related medications and vaccinations only through to vaccine
administration and prescribing under medical directive; however, uptake was generally at the lower
end of this spectrum. This was evidenced by 94% of pharmacists reporting administering fewer than
10 travel vaccinations per month, fewer than 10% of patients reporting receiving a travel vaccine
administered by a pharmacist, and a maximum of 30 pharmacies (of nearly 6000 in the province)
designated to provide yellow fever vaccinations. Fewer than 1 in 3 pharmacists reported performing
some form of pre-travel consultation in their practice, often limited to low-risk cases only. Barriers
and facilitators reported were similar for these services as they were for other non-dispensing services,
including insufficient time to integrate the service into their workload, perceived lack of knowledge
and confidence in travel health, and low patient awareness of these new services available to them
through community pharmacies.
Keywords: travel; immunization; vaccination; pharmacist; community pharmacy
1. Introduction
In 2012, pharmacists in Ontario, Canada, were authorized to administer the influenza vaccine to
patients age 5 years and older following the successful completion of an immunization training
program, and obtaining valid certification in cardiopulmonary resuscitation and first aid [1].
In December 2016, amendments were made to the Pharmacy Act to permit injection-trained pharmacists,
pharmacy students, and interns to administer vaccines to patients for 13 travel and travel-related
vaccine-preventable diseases [2], listed in Table 1. Of note, this legislation only authorizes the
administration of each vaccine, with some still requiring a prescription as indicated in the table [3].
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Pharmacists in Ontario currently do not have broad prescribing authorization for vaccines, although
pharmacists can pursue medical directives from physicians or nurse practitioners to prescribe these
vaccines under delegation [4]. Vaccines currently on Ontario’s routine immunization schedule [5] can
be obtained at no charge from a physician office or public health clinic; however, any of these vaccines
received in a pharmacy must be paid for by the patient, as well as any administration fee that may
be charged by the pharmacy. Some patients may be eligible for coverage through private insurance,
although this varies by insurer and by vaccine.
Table 1. Vaccines that can currently be administered by authorized pharmacists in Ontario.
Vaccine Prescription Required
Bacillus Calmette-Guérin Yes




Typhoid /Hepatitis A Combination Yes
Hepatitis A Yes
Hepatitis B Yes







This expansion in scope may have a positive impact on the health of travellers by offering
additional points of access to vaccinations and other travel-related care. Indeed, the convenience of
pharmacist-administered vaccinations has been cited as a key factor influencing patients’ decisions
to be vaccinated at a pharmacy [6]. One study reported that 30% of vaccinations administered by a
U.S. pharmacy chain were administered outside of usual physician office hours, including weekday
evenings, weekends, and national holidays [7]. However, vaccinations are only one component of
travel-related risk reduction, with infectious diseases representing less than 2% of deaths among
travelers [8]. However, seeking necessary vaccinations can be a driver for travelers to seek pre-travel
healthcare advice. This creates the opportunity for clinicians to assess patient-, itinerary-, and
destination-specific risks, as well as prophylactic drug therapy and education on non-drug health and
safety measures [9].
There is evidence on the potential positive impact that pharmacists can have on patients’ travel
health care. With respect to vaccinations, previous studies have reported higher vaccination rates against
seasonal influenza in jurisdictions that authorize pharmacists to administer vaccinations [10,11]. It is
uncertain whether a similar trend is observed with travel vaccines. There is also evidence on the clinical
outcomes achievable from pharmacist-performed travel consultations, including high acceptance
rates of recommended vaccinations and medications, low incidence of illness while travelling, and
patient confidence in their ability to self-manage illness abroad [12,13]. Finally, pharmacist-provided
services were observed to lead to significant cost savings in one study as a result of lower use of
unnecessary vaccinations and medicines when compared to consultations performed in a nurse-based
travel service. This study also reported that pharmacists were able to identify and order missing
vaccinations that were indicated for patients outside of just travel vaccinations (e.g., pneumococcal
vaccine) [14]. Many of these studies were conducted among pharmacists with a specialized practice and
additional training in travel health; moreover, other work has suggested that the general population of
community pharmacists lack confidence in their ability to perform pre-travel consultations and assess
the appropriateness of prescribed travel vaccines [15,16].
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It is unknown whether an expansion in pharmacists’ scope to include the administration of
vaccines for travel-related purposes would translate to expanded offerings of multifaceted travel health
services in community pharmacies, or if pharmacists would embrace this new scope in addition to their
existing workload. The objective of this study is to examine data available to date on the landscape of
travel health services in Ontario community pharmacies following this change in scope, pharmacists’
perceptions of their ability to provide these services in practice, and patients’ self-reported receipt of
these additional vaccines by pharmacists, to determine the initial impact of this legislative change on
pharmacy practice and patient care.
2. Materials and Methods
Triangulation of quantitative and qualitative data from four sources was performed:
2.1. Pharmacist Survey
Following a literature review, an online survey consisting of 38 questions was developed in
consultation with a pharmacy practice researcher and an individual with expertise in health policy,
and pilot tested for understandability and functionality among a sample of five third-year pharmacy
students. The complete list of survey items is available in Appendix A. Questions sought basic
demographic information about respondents, and explored the respondents’ current travel health
service offerings, changes around service offerings since the expansion in scope of December 2016,
barriers and facilitators to service implementation, and further educational needs. Inclusion criteria
for the survey were: (1) Current practice in a community pharmacy; and (2) Part A (active practice)
licensure through the Ontario College of Pharmacists. The survey was administered using QualtricsTM
software (Qualtrics, Provo, UT, USA) and disseminated through the following methods: the Ontario
Pharmacists Association’s weekly email bulletins, social media, direct contact with known pharmacists,
and through email to all Part A pharmacists in Ontario who provided permission to the Ontario
College of Pharmacists to have their contact information utilized for research. Descriptive statistics
were performed using IBM SPSS Statistics for Mac, Version 25 (Armonk, NY, USA). Ethics approval
was received from the University of Waterloo Research Ethics Committee (ORE #22510) and Ryerson
University’s Research Ethics Board (REB 2018-282).
2.2. Pharmacist Interviews
At the conclusion of the pharmacist survey described above, respondents were asked to express
interest in being contacted for a follow-up interview to gain deeper insight into reasons contributing to
variable uptake across pharmacists and pharmacies, and to identify potential strategies to provide
necessary support to pharmacists who wish to expand their patient care services in this area.
Interested individuals were contacted and asked to participate in a telephone interview at a mutually
agreeable time. A semi-structured interview guide was developed and is available in Appendix B.
No compensation was provided for participants. Interviews were performed until data saturation
was achieved, based on the perspective of the interviewer (JPS) and the principal investigator (SH).
Interviews were audio-recorded and transcribed verbatim, with qualitative content analysis performed
independently by two team members (ZRY and HF) for the first three transcripts to identify and
summarize themes, and any disagreements resolved by consensus. The remaining transcripts were
coded by one team member (HF). Analysis was performed using Microsoft Excel for Mac, version 15.33.
Ethics approval was received from the University of Waterloo Research Ethics Committee (ORE #31442)
and the Ryerson University Research Ethics Board (REB 2018–282).
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2.3. Public Survey
Annually, the Survey Research Centre at the University of Waterloo conducts a Waterloo Regional
Area Web Panel Survey. This omnibus survey allows researchers to pool resources for surveying the
general public residing in the Waterloo region of Ontario, Canada. As such, the survey addresses a
variety of topics of relevance to the general public. Members of the panel were identified through
random digit dialing using both landline and cellular telephone numbers, followed by random selection
of one member of the household for inclusion. Participants were then asked if they would be willing to
be contacted by email to complete a web survey. Those who consent were invited by email to complete
the survey, with two reminder emails at weekly intervals. Ethics approval for the survey was received
from the University of Waterloo Research Ethics Committee (ORE #23309).
The 2018 survey included demographic questions such as employment status, household income,
level of education, household size, and marital status, as well as a series of questions about receipt of
pharmacist-administered vaccinations. Specifically, respondents were asked to indicate which (if any)
vaccines they had ever received from a pharmacist. Each vaccine currently within the scope of practice
for Ontario pharmacists was included. Web survey questions are provided in Appendix C.
Survey results were first analyzed descriptively using IBM SPSS Statistics for Mac, Version 25
(Armonk, NY, USA). Binary logistic regression was then performed to identify any associations between
each demographic variable as independent variables and the receipt of any vaccine from a pharmacist,
as well as each vaccine individually as the dependent variable. Statistical significance was defined a
priori as p < 0.05.
2.4. Designated Yellow Fever Vaccination Centres
In Canada, the yellow fever vaccine is only distributed to healthcare facilities with current status
as a Designated Yellow Fever Vaccination Centre through the Public Health Agency of Canada [17].
Pharmacies can obtain this designation, provided that they have either a pharmacist with authorization
to prescribe the vaccine or have identified an individual with prescribing authority for the vaccine
to serve as the site’s nominated healthcare practitioner. This individual is responsible for overseeing
operations to ensure compliance with designated site requirements. As yellow fever is not endemic
in Canada [18], the use of its vaccine here is limited to international travellers. Additionally, given
the complexity related to its use and other travel health risks associated with travel to yellow fever
endemic countries, it can be assumed that only those sites providing pre-travel consultations and travel
vaccinations on a regular basis would apply for designation. As such, the number of Designated Yellow
Fever Vaccination Centers over time can serve as a proxy for the provision of travel health services.
All sites with this designation are publicly listed online, and searchable by province; however,
the Public Health Agency of Canada does not retain historical records on the number and type of
sites. To identify changes in the number of designated sites in Ontario over time, lists of all designated
sites in the province of Ontario [19] were generated at 3-month intervals, beginning with March 2017.
Pharmacies on this list were identified by cross-referencing pharmacy names and addresses with the
list of licensed pharmacies maintained by the Ontario College of Pharmacists [20]. All other sites were
coded as one of the following: travel clinic, medical clinic (includes interdisciplinary Family Health
Teams and urgent care centers), public health unit, corporate or occupational health clinic, or other.
Facilities whose categorization were uncertain based on their name alone were identified by performing
an internet search to visit the website of the organization and determining the most applicable category.
In the event that a facility was listed as a ‘medical and travel clinic’ it was coded as a travel clinic
with the assumption that travel consultations performed here would be more representative of those
performed at a specialized travel clinic than a general medicine practice.
As this analysis uses publicly available data, research ethics approval is not required. Descriptive
statistics were performed using IBM SPSS Statistics for Mac, Version 25 (Armonk, NY, USA).
214
Pharmacy 2019, 7, 35
3. Results
3.1. Pharmacist Survey
Of the 222 respondents initiating the survey, 17 were excluded for failing to provide consent to
participate (n = 5), not currently working in a community pharmacy (n = 11), or not currently holding
Part A licensure (n = 1). The demographic characteristics of the 205 respondents completing the survey
is provided in Table 2.








Mass merchandiser 15 (7.3%)
Grocery store 10 (4.9%)
Not specified 1 (0.5%)
Role in pharmacy
Staff pharmacist 93 (45.4%)
Owner 47 (22.9%)
Manager 46 (22.6%)
Relief pharmacist 18 (8.8%)
Not specified 1 (0.5%)
Years in a community pharmacy practice





More than 30 32 (15.6%)
Not specified 2 (1.0%)
Average number of hours worked per week





More than 40 51 (24.9%)




Gender variant / non-conforming 1 (0.5%)
Not specified 5 (2.4%)
Authorized to administer injections
Yes 178 (86.8%)
No 21 (10.2%)
Not specified 6 (2.9%)
Most (n = 178, 87%) respondents had authorization to administer vaccines in Ontario; of these, 78%
reported that they personally administer travel vaccines at their pharmacy (defined as any vaccines
currently within their scope other than influenza). The most common way this service was offered
was anytime by walk-in (69%), followed by appointment (24%) and during set days or hours such
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as a clinic day (6%); however, approximately half (54%) stated that appointment was their preferred
method, with walk-in preferred by only 17% of respondents. Among the 137 individuals providing
information on fees charged, 120 (88%) reported that their pharmacy charged patients a fee for this
service, with CAD$20 per injection being most common (mean $18.32, SD $5.70, range $10–50). Uptake
of this service appears to be low, as 94% of respondents reported administering fewer than 10 of these
vaccines per month in total. Vaccines that respondents indicated they have personally administered
since the expansion in scope are presented in Figure 1. Very few indicated administering any other
vaccines under delegation, consisting of tetanus/diphtheria/pertussis (n = 3), measles/mumps/rubella
(n = 2), and polio (n = 1).












Haemophilus influenzae type B




Figure 1. Pharmacist respondents’ self-report of vaccinations they have personally administered to
patients since December 2016.
Approximately 1 in 5 respondents (n = 56, 27%) reported that their pharmacy offers pre-travel
consultation services, with walk-in being the most common model (55%) followed by an appointment
basis (40%) and during clinic days (5%). By appointment is the preferred model by 62% of respondents,
with only 16% preferring walk-in. Fees are charged by 35% of respondents offering this service,
averaging CAD $34.17 (SD $12.81, range $20–50). As with vaccinations, pre-travel consultations are
also infrequently performed, with 71% reporting performing fewer than 5 per month.
As illustrated in Figure 2, increases were noted in the number of respondents whose pharmacy
offered a number of travel-related services following the expansion in scope, most notably an increase
in pharmacies prescribing travel vaccines under delegation (relative increase of 50%) and offering
pre-travel consultation services (relative increase of 33%). After vaccine administration, offering
pre-travel consultations was the most frequent service, followed by the prescribing of oral medications
under delegation and vaccine administration under delegation for vaccines currently outside of scope.
In terms of future plans, 71% of respondents indicated an interest in receiving their Certificate in Travel
Health designation from the International Society of Travel Medicine [19] within the next 5 years, and
77% expressed an interest in either implementing or further expanding their pharmacy’s travel-related
services. However, the stage of implementation was highly variable, with 38% stating they have a plan
in place that they are working towards, while the remaining 62% have not established a plan.
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Figure 2. Travel-related services offered by respondents’ practice site before and after scope expansion.
Asterisk indicates activities requiring delegation or medical directive from a physician or other
healthcare professional. Note: * indicates activities requiring a medical directive.
Respondents reported a number of barriers impacting uptake of these services by their pharmacy
and by patients as indicated in Figure 3, and actual or potential facilitators as indicated in Figure 4. Taking
both reported barriers and facilitators into account, education in travel health and the authorization to
prescribe appear to be key priorities to better support this service in community pharmacy practice,
followed by supports related to integrating these services into existing workflow. When asked if
offering these services was revenue generating for the pharmacy, responses were split, with 50.6%
feeling it was revenue generating and 49.4% feeling it was not. Revenue was primarily earned through
service fees charged to patients (n = 69) followed by sale of non-prescription drugs for travel purposes
(n = 43), the dispensing of prescriptions for travel purposes (n = 31), and new patient recruitment as a
result of offering the service (n = 26).
0 20 40 60 80 100 120
Pharmacy owner unwilling to offer service
Discomfort with administering injections
Liability associated with vaccination
Lack of training in administering injections
Risk of anaphylaxis or adverse reaction to vaccine
Lack of prescribing authorization
Patient hesitation to have pharmacists vaccinate
Desire to avoid interprofessional conflict
Lack of private space
Similar services already available nearby
Access to resources/materials
Unsure how to implement services into existing workflow
Lack of demand from patients
Lack of support staff
Lack of remuneration, patient willingness to pay
Lack of patient awareness of pharmacist scope
Lack of training in travel medicine
Time to provide services
Frequency
Figure 3. Barriers impacting ability to offer travel-related services.
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Full use of pharmacy technicians' scope of practice
Designated pharmacist to perform travel services
Increased support staff
Collaboration with other health professionals or travel clinics
Increased patient awareness of pharmacist scope
Revenue generation for the pharmacy
Increased patient demand
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Additional training in travel medicine
Frequency
Figure 4. Facilitators (actual or potential) impacting ability to offer travel-related services.
3.2. Pharmacist Interviews
A total of six pharmacists (4 male, 2 female) from the above survey consented to participate
in a semi-structured interview to further investigate pharmacy practice since the 2016 regulation
change. Chain and independent practices were equally represented, as were staff pharmacists versus
managers/owners. Years in practice ranged from 8–34, with one pharmacist reporting holding their
Certificate in Travel Health from the International Society of Travel Medicine [21].
3.2.1. Confidence with New Scope
While all of the pharmacists were confident in administering influenza vaccinations, pharmacists
experienced varying confidence levels and fewer number of patients accessing the pharmacy for
administration of the other 13 vaccines within their scope. A number of factors appeared to influence
the confidence level expressed:
• Lower demand for non-influenza vaccinations. The proportion of pharmacy patients who had
an indication for influenza vaccine (the universal immunization program in Ontario advocates for
all residents without contraindications to be vaccinated) versus the other vaccines means there are
fewer opportunities to exercise the expanded scope.
• Confidence is directly related to level of exposure. Lower exposure to administration of the new
vaccinations impacted pharmacists’ confidence with both administering the vaccine and verifying
its clinical appropriateness for a patient. One pharmacist practicing with a medical directive
to administer non-influenza vaccinations since 2012 reported high confidence, while the others
reported varying confidence based on the vaccine (e.g., more confident with herpes zoster than
travel vaccines).
• Duration of available scope. Influenza vaccination by pharmacists in Ontario has been permitted
since 2012, while additional vaccination authority was only initiated in December 2016. As such,
there has been more time to gain experience with influenza vaccination, including administration
and monitoring. For example, pharmacists are highly familiar with the volume, route, and adverse
effects of influenza vaccination, but would need to look this information up for other vaccines.
It was recognized that comfort and familiarity with the 13 new vaccines would likely increase
with time as it did with influenza.
Pharmacists reported comfort with recognizing when a patient may need referral to another
healthcare professional, such as last-minute travellers, those requiring yellow fever vaccination, and
pediatric patients. For example, one respondent commented, “I may . . . refer them [the patient] to
some place like . . . Travel Clinic because of their experience; they’re going to know which things to
get onboard right away, if there’s alternative regimens that they might be able to use that I’m not
comfortable suggesting” (Pharmacist 1).
218
Pharmacy 2019, 7, 35
Low-risk cases were considered to largely consist of healthy patients travelling to all-inclusive
resorts in the Caribbean, and of those pharmacists that reported performing pre-travel consultations,
most limited their practices to these low-risk cases.
3.2.2. Patient Identification and Interprofessional Collaboration
Patients requiring travel advice and other vaccinations were identified in one of three ways:
(1) Patients self-identifying as needing advice; (2) Referral from other healthcare professionals;
and (3) Pharmacist identification based on travel-related prescriptions presented for dispensing.
Self-identified patients appeared motivated to present by an advertisement of the service or through
an existing relationship with the pharmacist. Some pharmacists had collaborative relationships with
other healthcare professionals who were aware of the regulation change and supported it. For example,
one pharmacist described a relationship with a local nurse practitioner, saying “she has been sending a
lot of her clients to us for the recommendation and then she provides a prescription“ (Pharmacist 1).
However, others reported pushback from other healthcare professionals who identified this expanded
scope as overlapping or competing with their services. Pharmacist 2 found this differed with physician
age, stating “Some of the newer physicians were keener to utilize the pharmacist whereas some of the
ones that have been around for a bit longer were more reluctant.” Pharmacist 3 similarly observed
great variation, saying “Some doctors consider us as an equal and part of their practice. But some
other doctors, they won’t consider or they don’t even take our recommendation.”
3.2.3. Barriers and Facilitators
Barriers emerging from the interviews generally mirrored those of the broader survey, with the
exception that inability to prescribe was a more frequently cited barrier among those interviewed
than among survey respondents. As one respondent noted, “Right now our biggest barrier would
be prescribing of course . . . So we’ll gather all the information and we’ll first communicate directly
with the patient, tell them what our recommendations are and whichever ones they approve or they
agree with then we go through their primary care practitioner to try and get a prescription for those
products” (Pharmacist 1).
1. Awareness of Pharmacists Scope: Depending on the pharmacy and its location (e.g., co-located
with a medical clinic vs. standalone), lack of awareness of the regulatory change to pharmacists’
scope was recognized among both patients and physicians, despite it being in effect for over a
year at the time of the interviews. One pharmacist reported, “I don’t think [regulation change]
had a big change. I don’t know if the patients are even aware about it or if it’s advertised”
(Pharmacist 3).
2. Clinical Knowledge: Travel health is a clinical area that is not routinely used daily in pharmacy
practice, nor emphasized in university curricula. Pharmacists have to take it upon themselves
to learn its extensive body of knowledge in order to become an expert in the field. In addition
to the breadth and depth of clinical knowledge, it is also an ever-changing practice. Travel
advisories, epidemics, and recommendations can change much quicker than other clinical areas
(e.g., diabetes), which adds another difficulty for pharmacists to uptake travel health services.
This distinction between travel health and other clinical areas was described by Pharmacist 1 as
“[it’s] kind of like you need to go above and beyond what is out there to make sure you have the
background information . . . .it’s not like every day practice.”
3. Inability to Prescribe: Pharmacists not being able to prescribe medications or vaccinations is a
significant limitation to their provision of travel health services. Unlike receiving a consultation
from a travel clinic, where a patient can receive their assessment, immunizations, education, and
prescriptions in one appointment, patients that receive a consultation from a pharmacist must
bear an additional wait time of a prescription being sent to the pharmacy from another health
professional with prescribing ability. Many pharmacists expressed frustration at this limitation,
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with Pharmacist 1 stating “I think our profession really needs to push towards having prescribing
rights for those immunizations . . . There is no harm in immunizing somebody, so I can’t imagine
what the barrier is to getting those prescribing rights.”
4. Remuneration: The inability to prescribe also complicates remuneration for services, since
pharmacists without medical directives to prescribe rely heavily on physicians to provide
prescriptions for travelling patients. Some physicians may be hesitant to do so if they offer
their own pre-travel consultations for a fee or could otherwise charge for a related office visit.
It is perceived that they are contributing to the consultation but without receiving a fee like the
pharmacist can, which may negatively impact collaboration. One pharmacist (Pharmacist 4)
noted that this can also be confusing for patients, as “the doctors want to get paid for their service
for writing a prescription, in which case [my consultation is] kind of redundant. Why is the
patient paying [the pharmacist] as well?”
A strong facilitator of the service mentioned by all pharmacists was the added convenience that
pharmacist-provided services offers for patients. Pharmacist 5 commented “We’re open eight to eight
Monday to Friday and we’re open on weekends. We close three days a year, right, so finding a time to
come in and get their vaccine or whatever is not an issue for them.” While some patients were hesitant
to pay an administration fee to receive the injection at a pharmacy versus at no charge from their
physician’s office, Pharmacist 1 explained the return on investment as: “You can wait and go to your
doctor, if you like, go book an appointment, take another day off work . . . . Or you can get them right
here, right now and maybe wait for five minutes or ten minutes for me.”
3.3. Public Survey
Surveys were completed by 248 respondents (response rate 38.5%) with a mean age of 59.1 years
(SD 14.0), of which 42.7%, 56.9%, and 0.4% identified as male, female, or transgendered, respectively.
In total, 122 (49.2%) reported having never received a vaccine that was injected by a pharmacist.
Vaccines received by a pharmacist, and the number and proportion of respondents reporting receiving
each vaccine, are listed in Table 3. As influenza vaccination by pharmacists in Ontario has been in
place since 2012, it is not surprising that it remains the most commonly-received vaccine by injection
from a pharmacist. Interestingly, uptake of vaccines most commonly indicated for exposure related to
travel were all administered by pharmacists to fewer than 5% of respondents, with the only exception
being the hepatitis A&B combination vaccine at 5.6%.
Table 3. Vaccines reported by survey respondents as being received by injection from a pharmacist.
Vaccine
Frequency (%)
(n = 248 Respondents)
Influenza 117 (47.2%)
Herpes zoster 16 (6.5%)
Pneumococcal 15 (6.0%)
Hepatitis A&B combination 14 (5.6%)




Hepatitis B (monovalent) 6 (2.4%)
Hepatitis A (monovalent) 5 (2.0%)
Rabies 3 (1.2%)
Yellow fever 3 (1.2%)
Haemophilus influenzae type B 2 (0.8%)
Human papillomavirus 1 (0.4%)
Japanese encephalitis 1 (0.4%)
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Binary logistic regression did not detect any statistically significant relationships between
vaccination or non-vaccination by a pharmacist and the independent variables of age, employment
status, household income, level of education, number of individuals in the household, and marital
status, with the following exceptions:
• Negative relationship between increasing age and receipt of meningococcal (OR 0.847, p = 0.03),
hepatitis B (OR 0.866, p = 0.004), and rabies (OR 0.839, p = 0.036) vaccines
• Positive association between increasing age and receipt of the herpes zoster vaccine (OR 1.05,
p = 0.048)
3.4. Yellow Fever Vaccination Centres in Ontario
Prior to the expansion in pharmacist scope in December 2016, there were 220 Designated Yellow
Fever Vaccination Centres in Ontario; unfortunately, data on the name of each site at this time could
not be accessed; therefore, centres could not be categorized as of that date. At the first date of
complete data availability, there were 227 designated centres with travel clinics and medical clinics
comprising over 80% of all centres (Figure 5), followed in frequency by pharmacies and public health
units, occupational health clinics, and a single nursing clinic. Small increasing trends in the number
of designated sites were observed across travel clinics and general medical clinics over time, with
pharmacies experiencing a near doubling between March 2017 and June 2018; however, this was
immediately followed by a drop from 30 pharmacies to only 13 by September 2018 which remained
consistent through December 2018. While reasons for this reduction in the number of pharmacies with
designation are unavailable from the Public Health Agency of Canada, cross-referencing all pharmacies
with discontinued designation against the register of licensed pharmacies in Ontario identified that all
but two of these pharmacies remained licensed to operate, indicating that closure of the pharmacy was
not the reason for discontinued designation status.
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Figure 5. Designated Yellow Fever Vaccination Centres in Ontario, by category and date.
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4. Discussion
Through the triangulation of multiple data sources, this study identified that the uptake of
travel-related services by community pharmacies in Ontario has been generally slow, with some
variation by activity and by pharmacist, since an expansion in scope to allow for the administration of
travel-related vaccines in December 2016. Key challenges identified included lack of time to provide the
service within existing workflow, knowledge needs related to making clinical recommendations and/or
confirming the appropriateness of vaccines and prescribed drugs, and lack of prescribing authorization.
While triangulation of results from four different types of datasets was performed, limitations
remain with these conclusions due to methodological design and data availability. With the
pharmacist survey, the low response rate must be noted (n = 205, of over 16,000 pharmacists
currently licensed in Ontario) [22], as well as under-representation of pharmacists practicing in
independently-owned community pharmacies (24.9% of respondents, versus 52% of pharmacies in
Ontario being independently owned), and over-representation of pharmacists with authorization
to administer injections (86.8% of respondents vs. 46.8% of pharmacists in Ontario with injection
administration authorization) [22,23]. Pharmacist interviews were also conducted with a small sample;
however, it was felt that saturation was achieved with the responses obtained. Respondents from the
public survey represented a 38.5% response rate among those contacted, but may not be representative
of the overall population as the individuals invited to participate were those who had previously
completed a telephone survey conducted by the Survey Research Centre at the University of Waterloo
and opted-in to an online follow-up survey. Participants for the telephone survey were identified
through random-digit dialing of both landline and cellular telephone numbers within the region, so
individuals without access to a telephone, and individuals without internet access or comfort with
internet technology, were likely excluded. Finally, as all facilities that administer the yellow fever
vaccine must be registered as a Designated Yellow Fever Vaccination Centre, data on designated sites
is complete; however, a worldwide shortage of yellow fever vaccine since November 2016 [24] may
have negatively influenced the number of sites seeking this designation at this time.
The findings of this study are consistent with the literature on pharmacists’ uptake of new
services and pharmacists’ perception of their ability to provide travel-related care. Slow uptake of new
services by pharmacists in Canada was observed for activities including prescribing for medication
renewals or adaptations and initial prescribing [25], prescribing for smoking cessation specifically [26],
and medication reviews [27,28]. Similar trends have been observed internationally, even when
remuneration is offered for the new service without having to request payment from patients [29].
Barriers and facilitators identified were consistent with those reported by pharmacists across other
disease areas [30–33], in travel health specifically [14], and even by pharmacists in Ontario prior to
the legislative change expanding their scope in December 2016 [16], including lack of confidence in
their knowledge and skills, concerns with integrating new services into existing workflow, patient
awareness of new services, and a desire for acceptance of (or enhanced collaboration with) physicians
and other health professionals. We hypothesize that the clinical knowledge barrier may be more
pronounced for travel health than other clinical areas due to minimal training received by many health
professionals in travel health in their professional degree [34]; however, it was outside of the scope of
this study to evaluate this assumption.
5. Conclusions
Similarities across barriers and facilitators with previous work in travel health and other services
suggest that there are systemic changes that can be made to pharmacy practice to support non-dispensing
services. A movement towards appointment-based patient care models when possible, pharmacy
space layout modifications to provide adequate space and privacy for consultations, investment in
continuing professional development and clinical software to aid with clinical decision-making and
confidence with those decisions, and advocacy efforts targeting the public to increase awareness of
pharmacists’ expertise and scope will support all aspects of non-dispensing services performed in
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community pharmacies, with applicability to travel health and management of other clinical issues.
Efforts to increase education in travel health in pharmacy curricula and the development of toolkits or
standardized approaches to patient evaluation and risk management may also have a positive impact
on reducing the broad variability observed related to pharmacist practice in travel health.
Author Contributions: Conceptualization, S.K.D.H.; Data curation, S.K.D.H., K.K., and Z.R.-Y.; Formal analysis,
S.K.D.H., K.K., H.V.J.F., Z.R.-Y.; Funding acquisition, S.K.D.H. and Z.R.-Y.; Investigation, S.K.D.H.; Methodology,
S.K.D.H., K.K., and Z.R.-Y.; Project administration, S.K.D.H.; Supervision, S.K.D.H.; Writing—original draft,
S.K.D.H.; Writing—review and editing, S.K.D.H., K.K., H.V.J.F., Z.R.-Y.
Funding: Portions of this research were funded through an Applied Health Research Question submitted by the
Ontario Pharmacists Association to the Ontario Pharmacy Evidence Network (OPEN). OPEN is funded by a grant
from the Government of Ontario.
Acknowledgments: The authors wish to acknowledge the Ontario Pharmacy Evidence Network (www.open-
pharmacy-research.ca) for their support allowing us to email Ontario pharmacists who consented to be contacted
for research. We also wish to acknowledge the contribution of Jane Pearson-Sharpe for conducting the telephone
interviews, and the Survey Research Centre at the University of Waterloo (https://uwaterloo.ca/survey-research-
centre/) for conducting the Waterloo Regional Area Web Panel Survey.
Conflicts of Interest: Houle has received unrestricted research support from Valneva Canada, Inc. and unrestricted
education grants from Merck and GSK. The remaining authors declare no conflict of interest. The funders had no
role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript,
or in the decision to publish the results.
Appendix A
Table A1. Pharmacist survey questions.
Question Answer Options
Screening




Do you currently have an Ontario Part A license to




Which type of community pharmacy practice setting
do you primarily work in?
• Independent community pharmacy
• Community pharmacy associated with a chain
• Community pharmacy associated with a banner
• Community pharmacy associated with a grocery store
• Community pharmacy associated with a mass merchandiser
• Other (please specify)
What is your role in the community pharmacy
practice setting you work in?
• Community pharmacy owner
• Community pharmacy manager
• Community pharmacy staff pharmacist
• Community pharmacy relief pharmacist









How many years have you worked in a community
pharmacy practice setting?
• Less than 1
• 1 to 5
• 6 to 10
• 11 to 20
• 21 to 30
• More than 30
On average, how many hours per week do you work
in a community pharmacy practice setting?
• Less than 8
• 8 to 16
• 17 to 24
• 25 to 32
• 33 to 40
• More than 40
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Table A1. Cont.
Question Answer Options









Do you currently administer travel or travel-related
vaccinations at your pharmacy?
• Yes
• No
When and how do you currently offer travel or
travel-related vaccinations at your pharmacy? Select
all that apply.
• Anytime by walk-in
• During set days/hours by walk-in (e.g., clinic days)
• By appointment
What would be your preferred method for offering
travel or travel-related vaccinations at your
pharmacy?
• Anytime by walk-in
• During set days/hours by walk-in (e.g., clinic days)
• By appointment
• No preference
Does your pharmacy charge a fee to patients to
administer travel or travel-related vaccinations?
• Yes (please specify the fee amount)
• No
Which of the following travel or travel-related
vaccines have you personally administered since the
expansion of Ontario pharmacists’ scope in December
2016? Select all that apply.
• Bacille Calmette-Guérin (BCG) (for tuberculosis)
• Haemophilus influenza type b (Hib)
• Hepatitis A
• Hepatitis B
• Combined hepatitis a and b
• Herpes zoster (shingles)






• Combined typhoid and hepatitis A
• Varicella zoster (chickenpox)
• Yellow Fever
• None of the above
Which other vaccines have you personally
administered under delegation or a medical directive?
Select all that apply.
• Diphtheria
• IPV (poliomyelitis)
• Measles, mumps, rubella (MMR)
• Pertussis
• Tetanus
• Other (please specify)
• None of the above
On average, how many travel or travel-related
vaccinations do you administer in a month?
• Less than 5
• 5 to 10
• 11 to 15
• 16 to 20
• More than 20
Travel Consultations




When and how do you currently offer travel
consultations at your pharmacy? Select all that apply.
• Anytime by walk-in
• During set days/hours by walk-in
• By appointment
What would be your preferred method for offering
travel consultations at your pharmacy?
• Anytime by walk-in
• During set days/hours by walk-in
• By appointment
• No preference
Does your pharmacy charge a fee to patients to
receive a travel consultation?
• Yes (please specify the fee amount)
• No
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Question Answer Options
On average, how many travel consultations do you
complete in a month?
• Less than 5
• 5 to 10
• 11 to 15
• 16 to 20
• More than 20
Practice Changes Related to Regulatory Expansion
Which travel medicine services did you offer prior to
the regulatory change? Select all that apply.
• Individual travel consultations
• Prescribing of travel or travel-related vaccines
under delegation
• Prescribing of other drugs for travel purposes (e.g., travellers’
diarrhea, altitude sickness, malaria) under delegation
• Travel or travel-related vaccine administration
under delegation
• MedsCheck prior to travel
• Travel medicine clinic days/events
• Other (please specify)
• Not applicable—I was not offering travel medicine services
prior to the regulatory change
Which travel medicine services do you currently
offer? Select all that apply.
• Individual travel consultations
• Prescribing of travel or travel-related vaccines
under delegation
• Prescribing of other drugs for travel purposes (e.g., travellers’
diarrhea, altitude sickness, malaria) under delegation
• Travel or travel-related vaccine administration under
expanded scope
• Travel or travel-related vaccine administration
under delegation
• MedsCheck prior to travel
• Travel medicine clinic days/events
• Other (please specify)
• Not applicable—I am not currently offering travel
medicine services
Please choose one of the following statements that
best describes how your pharmacy practice has
changed since the regulatory expansion with respect
to the number of travel medicine services you
complete on a monthly basis. (Consider all travel
medicine services you offer.)
• I am completing a higher number of services
• I am completing a lower number of services
• I am completing about the same number of services
How does your pharmacy promote your
travel-related services (vaccinations, consultations,
and other related services) to patients? Select all
that apply.
• In-store posters




• Social media (e.g., Facebook, Twitter)
• Word of mouth
• Audio ads over pharmacy's intercom system
• Audio ads while patients are on hold on the phone with
the pharmacy
• Other (please specify)
Practice Barriers and Facilitators
What have been, or would you consider to be, the
primary barrier(s) to implementing travel medicine
services in your community pharmacy practice?
Select all that apply.
• Lack of injection training
• Lack of travel medicine training
• Lack of knowledge of/access to resources/materials
• Lack of time to dedicate to travel medicine services
• Insufficient availability of support staff (e.g., pharmacy
technicians, assistants)
• Lack of demand from patients
• Lack of patient awareness of pharmacists’ expanded scope
• Patients unwilling to have pharmacist vaccinate
• Lack of remuneration
• Unsure how to incorporate processes into daily work flow
• Travel medicine services are already available near my place
of practice
• I am uncomfortable with administering injections
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Question Answer Options
Practice Barriers and Facilitators
What have been, or would you consider to be, the
primary barrier(s) to implementing travel medicine
services in your community pharmacy practice?
Select all that apply.
• Religious beliefs
• I want to avoid conflict with other professionals who
can vaccinate
• I do not want to be professionally responsible for the act
of vaccination
• I do not feel prepared to handle allergic or adverse reactions
in my pharmacy
• Lack of private space
• Other (please specify)
Of the options you selected in the previous question,
please select the ONE that you consider to be the
PRIMARY barrier to implementing travel medicine
services in your community pharmacy practice.
• Lack of injection training
• Lack of travel medicine training
• Lack of knowledge of/access to resources/materials
• Lack of time to dedicate to travel medicine services
• Insufficient availability of support staff (e.g., pharmacy
technicians, assistants)
• Lack of demand from patients
• Lack of patient awareness of pharmacists’ expanded scope
• Patients unwilling to have pharmacist vaccinate
• Lack of remuneration
• Unsure how to incorporate processes into daily work flow
• Travel medicine services are already available near my place
of practice
• I am uncomfortable with administering injections
• Religious beliefs
• I want to avoid conflict with other professionals who
can vaccinate
• I do not want to be professionally responsible for the act
of vaccination
• I do not feel prepared to handle allergic or adverse reactions
in my pharmacy
• Lack of private space
• Other (please specify)
What have been, or would you consider to be, the
primary facilitator(s) for the implementation of travel
medicine services in your community pharmacy
practice? Select all that apply.
• Completion of additional training in immunization or
travel medicine
• Collaboration with other healthcare professionals or
health clinics
• Increased patient demand
• Increased awareness of pharmacists’ expanded scope
• Increased support staff hours
• Increased use of pharmacy technicians’ scope of practice
• Designated travel medicine services pharmacist
• Pharmacists’ ability to prescribe travel vaccines or
travel-related medicine
• Revenue generation
• Other (please specify)
Of the options you selected in the previous question,
please select the ONE that you consider to be the
PRIMARY facilitator to implementing travel medicine
services in your community pharmacy practice.
• Completion of additional training in immunization or
travel medicine
• Collaboration with other healthcare professionals or
health clinics
• Increased patient demand
• Increased awareness of pharmacists’ expanded scope
• Increased support staff hours
• Increased use of pharmacy technicians’ scope of practice
• Designated travel medicine services pharmacist
• Pharmacists’ ability to prescribe travel vaccines or
travel-related medicine
• Revenue generation
• Other (please specify)
Do you find your pharmacy’s travel medicine
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What do you feel primarily contributes to the
profitability of your service(s). Select all that apply.
• A fee-for-service is charged to patients
• More people are becoming patients at my pharmacy because
of the travel medicine services I/we offer
• More travel-related OTC sales after counselling are occurring
• More patients are bringing in their travel-related
prescriptions because of the travel medicine service I/we offer
• Efficiencies (through optimal use of staff, materials/resources
used, implementation of processes, etc.) have been created as
a result of implementing travel medicine services
• Not applicable—a business evaluation of this service has not
yet been conducted by our pharmacy
• Other (please specify)
Education Needs and Preferences
Which areas of additional travel medicine-related
education would facilitate the implementation or
improve the quality of pharmacist-led travel
medicine services in your community pharmacy?
Select all that apply.
• Processes for completing a pre-travel assessment
• Pre-travel assessment knowledge based on geographical
location(s) during travel
• Pre-travel assessment knowledge based on activity/activities
during travel
• Pre-travel assessment knowledge based on patients’ health
status, comorbidities, and special patient populations
• Travel-related diseases
• Travel-related vaccines
• Travel-related prescription medication use
• Travel-related self-care and non-prescription drug measures
• Other travel health risks
• Other (please specify)
• Not applicable—I feel confident in my travel
medicine-related knowledge and training background
With respect to acquiring further travel
medicine-related education, which forms of
education would be most appealing to you? Select up
to 5 options.
• Self-directed online continuing education course of
<2 h duration
• Self-directed online continuing education course of
2+ h duration
• Webinar
• In-person or live continuing education course (half day)
• In-person or live continuing education course (full day)
• Downloadable clinical practice guidelines on travel
medicine topics
• Downloadable or printable educational materials
(e.g., booklets)
• Mobile app or online resources
• Self-assessment tools
• Diploma/certificate level training in travel medicine
• Other (please specify)
Would you be interested in pursuing a Certificate in
Travel Health designation from the International




Future Plans and Advocacy
Which of the following statements best describes your
future plans with respect to offering travel medicine
services in your pharmacy?
• Already implementing, and not currently working on a plan
to further expand
• Already implementing, and wanting/working on a plan to
further expand
• Intend to implement, and currently working on a plan
• Interested in implementing, but not currently working on
a plan
• No intention to implement in the near future
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Question Answer Options
In addition to allowing additional vaccines to be
administered, the regulatory changes under the
Pharmacy Act also now allow for injection trained
pharmacy students and interns to administer the
same vaccines. Which of the following statements
best describes how your pharmacy practice has
changed since the regulatory change with respect to
pharmacy students and interns
administering vaccines?
• My pharmacy now has pharmacy students and/or interns
administering vaccines
• My pharmacy does not have pharmacy students or interns
administering vaccines and does not intend to have them
administering vaccines
• My pharmacy does not have pharmacy students or interns
administering vaccines but is considering having them
administer vaccines in the future
• Unsure
• Not applicable—vaccines are not administered at
my pharmacy
Would you want OPA to advocate for pharmacists’




Would you want OPA to advocate for pharmacists’
ability to prescribe travel-related drugs (e.g.,




OPA, Ontario Pharmacists Association; OTC, over-the-counter.
Appendix B
Semi-structured interview guide for pharmacists.
Let’s start with some questions about your current practice:
• Please describe your pharmacy’s patient population (Prompt if needed: for example, age, socioeconomic
status, health conditions)
• Please describe your relationships with other healthcare providers in your community and their
perception of your role as a patient care provider.
• Is there a travel clinic or another health professional that currently provides travel health services
in your community? Does this effect the types of services you offer?
• Can you explain your experience, if any, with administering influenza vaccines in your pharmacy?
(Prompt if needed: How long have you been doing this? How many patients have you administered to?
What is your comfort level with this?)
• Can you explain your experience, if any, with administering other vaccines that are generally not
used for travel, such as pneumococcal, zoster, or HPV vaccine? (Prompt if needed: How long have
you been doing this? How many patients have you administered to? What is your comfort level with this?)
Tell me about your experiences with travel health services in your practice? (Prompt if needed
to discuss both administering travel vaccines and performing consultations. A consultation is an
individualized assessment of a person’s health risks while travelling, considering patient-specific,
destination-specific, and activity-specific factors).
What impact, if any, has the regulatory change to expand the list of vaccinations that pharmacists
can administer had on your services? Why?
IF they have experience with administering travel vaccines in their pharmacy:
Regarding administering travel vaccines, such as those for hepatitis A or B, typhoid, Japanese
encephalitis, or yellow fever:
• Describe your process for administering these vaccines and how it fits within your workflow.
• How do you identify eligible patients?
• Are there any clinical or non-clinical circumstances where you would not administer travel
vaccinations to a patient who requested it? (Prompt if needed: What are these, and why?)
• Describe your process for documentation. (Prompt if needed: Do you inform the patient’s primary care
provider that you administered these vaccines?)
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• Do you provide patients with any written educational materials about these vaccines? If so, which
resources do you provide? (Prompt if needed: Information from website online, pamphlet provided by
vaccine manufacturer, written information developed in-house)
• Tell me about your rationale for either charging, or not charging, a fee for administering these
vaccines. IF a fee is charged: How have your patients responded to being asked to pay for
this service?
IF they have experience with performing travel consultations in their pharmacy:
Regarding providing travel consultations:
• Describe your process for providing this service and how it fits within your workflow.
• How do you identify eligible patients?
• Are there any clinical or non-clinical circumstances where you would refer a patient to another
healthcare professional for a consultation? (Prompt if needed: What are these, and why?)
• Describe your process for documentation. (Prompt if needed: Do you inform the patient’s primary care
provider that you performed this consultation?)
• Do you provide patients with any written educational materials about travel health? If so, which
resources do you provide? (Prompt if needed: Information from website online, pamphlet provided by
vaccine manufacturer, written information developed in-house)
• Tell me about your rationale for either charging, or not charging, a fee for this consultation? IF a
fee is charged: How have your patients responded to being asked to pay for this service?
For any pharmacists with experience with either or both of the activities above:
Let’s talk about your overall experience as a travel health care provider:
• Tell me about facilitators and barriers you have experienced in delivering travel health services
to your patients? What strategies have you tried to make it easier for you to provide this care
in practice?
• Please describe for me your level of confidence with providing travel health services?
• What feedback, if any, have you received from your patients?
• What feedback, if any, have your received from other healthcare providers in your community?
For pharmacists that report NOT administering travel vaccines and NOT providing travel
consultations:
• Under what clinical circumstances would you consider providing your patients with:
◦ Travel vaccine administration?
◦ Travel consultations and education?
• What are some reasons why you have not offered these services in your pharmacy? (Prompt if
needed: Some examples might be staffing, management support, need for more training or confidence, or do
you feel this is outside of the scope of practice for pharmacists?)
• What are some supports that would help you to offer these types of services?
• If your pharmacy were to start providing travel health services, would you charge a fee for
administering vaccines or providing travel consultations? Why or why not?
Appendix C
Waterloo Region Area Survey questions.
Demographic Questions:
Please select your gender:
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• Other (Please specify: _____________)
What is your current household income before taxes? (SELECT ONE ONLY)
• Less than $20,000
• $20,000 to less than $50,000
• $50,000 to less than $80,000
• $80,000 to less than $100,000
• $100,000 or more
What is the highest level of formal education that you have completed? (SELECT ONE ONLY)
• Grade school
• High school
• College or trade apprenticeship
• University degree
• Other (Please specify: _____________)
Not including yourself, how many people live in your household? Please include all adults, other
than yourself, and any children that live with you all or most of the time.
At present, are you married, living with a partner, widowed, divorced, separated, or have you
never been married? (SELECT ONE ONLY)
• Married
• Living with partner/common-law
• Widowed
• Divorced or separated
• Never married
Pharmacist-Administered Vaccines Question:
Please indicate which vaccines, if any, you have ever received by injection by a pharmacist:
(Please select all that apply)
• Influenza (flu) vaccine
• Bacille Calmette-Guérin (tuberculosis) vaccine
• Haemophilus Influenzae type b (Hib) vaccine
• Meningococcal (meningitis) vaccine
• Pneumococcal (pneumonia) vaccine
• Typhoid vaccine
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• Hepatitis A vaccine
• Hepatitis B vaccine
• Hepatitis A and B combined vaccines (e.g., Twinrix®)
• Herpes Zoster (shingles) vaccine
• Human Papillomavirus (HPV, cervical cancer) vaccine
• Japanese Encephalitis vaccine
• Rabies vaccine
• Varicella (chickenpox) vaccine
• Yellow Fever vaccine
• I have never received a vaccine that was injected by a pharmacist.
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Abstract: Introduction: Pharmacist roles promoting safe opioid use are recognized in literature and
practice. Pharmacists can offer services such as counseling on opioid risks, naloxone dispensing,
education on opioid storage and disposal, prescription drug monitoring program (PDMP) utilization,
opioid deprescribing, and providing resources for addiction treatment to help mitigate the opioid
crisis. Objective: This commentary seeks to describe current and potential roles for pharmacists to
combat the United States opioid crisis and identify key factors affecting service provision. Methods:
The paper summarizes evidence-based studies describing current pharmacist roles and services,
factors affecting service implementation, and strategies to further improve pharmacist roles and
services related to promoting safe opioid use for patients. Results: Pharmacists recognize their roles
and responsibilities to counsel patients on opioid risks, dispense naloxone, educate on opioid storage
and disposal, utilize prescription drug monitoring programs (PDMPs), offer opioid deprescribing,
and provide resources for addiction treatment. However, pharmacists express low confidence, time,
and training as barriers to service provision. This suggests a need for structured training, resources,
and organizational support for pharmacists to improve confidence and participation in such services.
Conclusions: Although pharmacists are aware of roles and responsibilities to help reduce the opioid
crisis, more training, education, organizational support and resources are needed to increase their
ability to embody these roles.
Keywords: pharmacist services; opioid; communication; naloxone; misuse; disposal;
safety; counseling
1. Introduction
Opioid medications have the potential to cause dependence characterized by a strong desire
to take opioids, persistent opioid use despite harmful consequences, increased tolerance, a physical
withdrawal reaction when opioids are discontinued, and potential fatal overdose [1]. In 2016, 34 million
people globally reported using opioids consistently and about 19 million people used opioids at
least once [2]. Deaths attributed to opioid overdose contribute up to half of all drug-related deaths
globally [2]. There are effective treatments for opioid use disorders, and yet less than 10% of people
who would benefit from treatment are receiving it [2].
In the United States (U.S.), prescription opioids specifically contribute largely to the current opioid
crisis, with more than 40% of all opioid overdose deaths in 2016 involving a prescription opioid,
and more than 46 people dying every day from overdoses involving prescription opioids [3]. From
1999–2016, more than 200,000 people died from overdose related to prescription opioids alone [4].
Approximately 1000 individuals are treated in emergency departments (ED) each day for prescription
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opioid misuse [5]. Deaths related to opioid overdose have increased exponentially and will likely
continue to grow, making this an important national issue in the U.S. and the focus of this commentary.
Although many individuals and organizations are involved in combating the opioid crisis
nationwide, healthcare professionals are primarily responsible for appropriate opioid prescribing and
promoting safe opioid use [6]. Pharmacists are especially well-positioned to contribute to safe opioid
use due to their role dispensing opioid prescriptions and accessibility to patients [7,8]. Pharmacists
utilize prescription drug monitoring programs (PDMP) to help prevent diversion of opioids and detect
inappropriate prescribing, and can monitor and recognize signs of opioid misuse [8]. PDMP is a
state-based electronic database accessed by prescribers and pharmacists to track controlled substance
prescribing and dispensing [9]. Specific information collected from the pharmacy includes what
controlled substances were dispensed, how much, to whom, and by whom [9]. Pharmacists can
extend patient counseling responsibilities by educating patients on risks associated with opioid use,
proper storage and disposal of medication, and the consequences of sharing medications with another
person [10]. Additionally, many pharmacists can distribute naloxone, an opioid antagonist effective
in reversing respiratory depression from opioid use, enabling a family member, friend, or potential
bystander to prevent death associated with opioid overdose [11]. Pharmacists are knowledgeable
about addiction treatment options and can connect patients to resources within the community [8].
Although pharmacists are equipped to provide these services to help mitigate the opioid crises, current
literature documents that pharmacists’ breadth of opportunities for services is far from fully realized.
Underlying factors need to be considered to help pharmacist meet their potential to provide services
related to opioid use.
2. Objectives
This commentary seeks to describe current and potential roles for pharmacists to reduce the
opioid crisis, identify key factors affecting service provision, and suggest strategies for improvement.
3. Methods
An exhaustive search of PubMed and Cinhal databases was conducted to identify evidence-based
studies describing current pharmacist roles and services, factors affecting service implementation, and
strategies to further pharmacist roles and services related to promoting safe opioid use for patients.
The following search terms and combinations were used: opioids, pharmacy, pharmacist, safety,
counseling, disposal, naloxone, PDMP, and deprescribing. Only studies conducted in the United States
were included. The available evidence was summarized into six main categories based on pharmacist
roles: counseling on opioid risks, naloxone dispensing, opioid storage and disposal, PDMP utilization,
opioid deprescribing, and addiction treatment resources.
4. Results
4.1. Counseling on Opioid Risks and Safety
A nationally distributed case vignette survey of primary care physicians (PCPs), pain specialists,
and pharmacists, along with nested chart reviews and surveys of patients with chronic pain revealed
that prescribers and pharmacists often omit key messages during patient counseling regarding safe
opioid use [12]. Among pharmacists, safety counseling is generally limited to informing patients of
potential side effects [12]. The omission of information provided may be due to limited self-efficacy
among pharmacists in communicating with patients regarding prescription drug abuse and misuse.
Pharmacists cited common barriers to communication as lack of confidence, training, and time [13].
Barriers to discussing opioid therapy were similar to those cited for discussing drug abuse and pain with
patients, including lack of confidence, training and inadequate access to health information [7]. These
barriers are compounded by uncertainty among pharmacists and patients regarding pharmacists’ roles
in opioid safety. Patients and pharmacists perceived pharmacists to be responsible for medication safety,
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yet the majority of pharmacists were uncomfortable dispensing opioids and felt they were “policing”
opioid prescriptions [14]. Overall, there is a paucity of literature describing current counseling
practices pharmacists use to educate patients about opioid risks, such as dependence and overdose, or
mechanisms to promote safe opioid use.
4.2. Naloxone Dispensing
Increased state and national legislative and regulatory initiatives are partly due to greater
recognition and acceptance of naloxone use by the general public, people who use drugs (PWUD),
and healthcare professionals such as pharmacists. About half of states have increased funding to
expand patient access to naloxone, pharmacologic treatment options for PWUD, and guidelines for
safe opioid prescribing [15]. Standing orders have been implemented on a national level, and allow
for naloxone dispensing by pharmacists or other healthcare professionals without a patient-specific
prescription [16]. Pharmacists have successfully utilized standing orders to increase patient access
to and distribution of naloxone in many pharmacy settings [17]. State and national policies have
facilitated the expansion of pharmacist roles, enabling pharmacist to be a key resource in opioid
overdose prevention [18]. Pharmacists utilize these policies and standing orders to identify patients
who are at risk of overdose and would benefit from naloxone given their medication regimens, medical
history, and comorbidities [11,19,20].
In two surveys about pharmacist roles in naloxone dispensing and education, simultaneously
administered to patients receiving treatment for substance use disorders and pharmacists in Ohio,
patients expressed interest in naloxone-based interventions [21]. Meanwhile, many pharmacists were
opposed to facilitating naloxone-based interventions [21]. Some of the same concerns were raised
for naloxone consultations as had been identified for consultation with patients about opioid safety
and risks. Pharmacists identified barriers to delivering these interventions or services as a lack of
training to identify eligible patients, and challenges communicating with patients about the need
for naloxone. Pharmacists also identified lack of time, reimbursement, and lack of support from
management as barriers to implementing naloxone services [22,23]. Institution-specific guidelines and
protocols addressing pharmacist roles, criteria for screening for eligibility, and flowcharts for education
and dissemination of naloxone have facilitated identification of patients at risk of overdose, and serve
as important resources for pharmacists and other healthcare professionals [24,25]. These resources
along with structured programs regarding naloxone use have helped pharmacists successfully dispense
naloxone to patients at risk of overdose [18,24,25].
4.3. Opioid Storage and Disposal
Pharmacists have a unique opportunity to educate patients on the importance of proper medication
disposal and storage and disposal programs available in the community [8,26,27]. Student pharmacists
can partner with community officials and businesses to provide safe and appropriate medication
disposal [28]. While it is widely understood that medications such as opioids and other controlled
substances contribute to environmental pollution when improperly disposed, it has proven hazardous
to the population and community health as well [28]. Drug take-back programs have been popular
across schools and pharmacies in the country and drug take-back days are helpful in facilitating these
activities. Some community pharmacy chains, such as CVS, have installed drug take-back boxes in the
pharmacies for patients to dispose of unused or expired prescription medications [29].
4.4. PDMP Utilization
Statewide prescription drug monitoring programs (PDMP) are a useful tool for healthcare
professionals to track and monitor controlled substance prescriptions [9]. Specific legislative initiatives
that support safe opioid prescribing and naloxone use include the 2016 21st Century Cures Act, which
awarded funding to improve state PDMPs [30]. The PDMP can serve as a resource for pharmacists to
identify patients that might be misusing opioids or those at risk of overdose. Additionally, the 2018
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SUPPORT for Patients and Communities Act requires checking the PDMP for Medicare beneficiaries
prior to controlled substance prescription. This may prompt further conversations with patients
regarding opioid safety [31]. States have varying requirements for PDMP use among pharmacists and
prescribers, ranging from voluntary to mandated use [9]. The majority of pharmacists have viewed
the PDMP as an objective resource to support clinical decisions, make professional judgements, and
prevent diversion and drug abuse [9,32–34]. Pharmacists also felt the PDMP helped support patient
and prescriber communication regarding suspected drug abuse and helped provide patient education
about opioid-specific risks and controlled substance abuse [9,32,35]. While the majority of pharmacists
agreed that the PDMP was important in the prescribing and dispensing process, some pharmacists
reported barriers to using the PDMP [36]. Pharmacists were less likely to use the PDMP if use was
not mandated, if they were unfamiliar with it, didn’t like the user interface, or if no training was
provided on using the PDMP platform [9,36]. Some pharmacists also reported challenges in working
with prescribers or patients in response to PDMP reports [9]. Factors that facilitated regular use of the
PDMP included providing training and education on PDMP use. Integrating the PDMP interface into
dispensing software and electronic health records was shown to be particularly powerful, along with
mandating use for pharmacists and prescribers at the point of prescribing and dispensing, and the
ability to contact the prescriber directly through the PDMP [9,32,36].
4.5. Opioid Deprescribing
Deprescribing is a necessary mechanism to reduce the use of inappropriate medications, including
medications that cause patient harm or unnecessary adverse effects, medications not providing
benefit, or medications with no indication [37]. Deprescribing programs initiated by pharmacists, or
that included pharmacists in a multidisciplinary team, have measured successful outcomes such as
decreased pill burden or decreased use of inappropriate medications [38–43]. However, few guidelines
have been developed to guide healthcare professionals in a systematic process to deprescribe or
taper inappropriate medications. Systematic processes for deprescribing or tapering inappropriate
medications are limited to a few specific classes of medications, and no guidelines exist for opioid
discontinuation or tapering [44–48]. Further barriers exist to deprescribing practices in general.
Prescribers cite barriers related to lack of time, limited resources to support deprescribing, patient
fear, patient withdrawal symptoms, or patient criticism among deprescribing programs involving
pharmacists [49,50]. Pharmacists report barriers related to pressures to focus on productivity, rather
than clinical interactions or decision-making with patients. Other barriers identified by pharmacists
and prescribers include challenges working with patients and caregivers, lack of policies or guidelines
specific to deprescribing, and difficulty partnering inter-professionally across health care settings due
to lack of shared health information and patients visiting multiple pharmacies [50]. Factors cited
by pharmacists and prescribers that would facilitate deprescribing include further involvement of
patients and caregivers, staff education, financial incentives, and involvement in initiatives that expand
evidence supporting deprescribing practices [50].
4.6. Providing Resources for Opioid Misuse and Addiction Treatment
Pharmacists play a key role in recognizing opioid toxicity and preventing diversion of opioids [26].
Compared to prescriber colleagues, pharmacists perceived a larger percentage of patients to be
abusing opioids (17% prescribers and 41% pharmacists, respectively) [51]. Pharmacists understand
the importance of providing appropriate counseling and resources to such patients but believed that
engaging with patients potentially abusing opioids may cause loss of customers. Pharmacists identified
regulatory agencies and patients’ family or friends as most likely to influence their willingness to refer
patients to resources for opioid misuse [20]. As with the earlier topics, pharmacists cited many of the
same barriers to effectively communicating with patients such as lack of confidence, training, and time.
Time required for counseling was found to be the most commonly cited control belief [51]. Pharmacists
who had greater amounts of addiction-specific education had a higher likelihood of substance abuse
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counseling and felt more confident about counseling; however, the majority of pharmacists received
no addiction education [52]. This suggests that the neurobiological basis for addiction, standards of
care, and pain management guidelines are likely not understood by a subset of pharmacists.
5. Discussion
Pharmacists are considered gatekeepers for dispensing opioid medications by other health
care professionals and in the literature [53]. They are well positioned to facilitate safe opioid use
through counseling patients on opioid risks, educating about safe storage and disposal, providing
naloxone, participating in deprescribing initiatives, utilizing the PDMP, and connecting patients to
resources for addiction treatment [8]. Although these roles for pharmacist services exist, there are
opportunities for broader implementation. Pharmacists are interested in providing these services and
have identified mechanisms to support safe opioid use among patients as well as barriers to service
implementation. Lack of confidence, training and resources, structured guidelines, and limited time
were the most commonly cited barriers by pharmacists for providing all the services addressed in this
commentary [7,9,14,22–25,32,50,51,54].
5.1. Counseling on Opioid Risks and Safety
Although pharmacists are expected by the Centers For Disease Control and Prevention (CDC) to
communicate dependency, overdose, and other opioid risks during patient counseling, pharmacists
reported barriers such as lack of confidence, training, and time [7,14,55] * (*The Centers for Disease
Control and Prevention (CDC) is a federal agency that conducts and supports health promotion,
prevention, and preparedness activities in the United States.). Pharmacists would benefit from
additional training and resources in pharmacy school curricula and in practice to facilitate effective
counseling for opioid medications. Due to the paucity of research and few initiatives focusing on
pharmacist communication for opioid medications, additional research is needed to inform effective
training strategies.
5.2. Naloxone Dispensing
Pharmacists are recognized as stewards of naloxone dispensing and often stock naloxone in the
outpatient setting, but do not necessarily dispense naloxone regularly [22]. Pharmacists expressed a
lack of training and confidence to detect patients who would benefit from naloxone and to provide
education about the necessity and use of naloxone [22,56]. Targeted training and resources about
naloxone dispensing and communication techniques will facilitate further pharmacist involvement in
naloxone dispensing and education [18,24].
5.3. Education on Opioid Storage and Disposal
Pharmacists recognize their role in informing patients about safe storage and disposal of opioids,
yet few initiatives have measured pharmacist improvement, facilitators and barriers to providing
such services [27]. There is a need for more evidence-based intervention research about how to help
pharmacists offer services to promote safe disposal of opioids [29].
5.4. Guidelines and Protocols for PDMP Use and Opioid Deprescribing
Most pharmacists agreed that PDMP was a useful tool, especially when linked to the electronic
health record and utilized as a platform to contact prescribers. However, pharmacists also reported
challenges when working with patients and prescribers about issues detected in PDMP reports [9,32,36].
Policies and procedures highlighting pharmacists’ roles within the PDMP can help promote more
frequent PDMP use and help involve pharmacists in the monitoring process. Beyond the monitoring
of prescribed opioids, pharmacists also play an important role in eliminating unnecessary medication
when it is inappropriate or no longer needed. Specific algorithms and guidelines would facilitate
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opioid deprescribing practices in a variety of pharmacy settings. Integrating these into electronic
health records would strengthen the intervention even further.
5.5. Providing Resources for Addiction Treatment
Pharmacists recognized and valued their role in detecting and communicating with patients
potentially misusing prescription opioids [51]. They also expressed lacking confidence and time when
talking to patients about opioid abuse [13,51]. Training and resources about addiction treatment
should be offered by schools of pharmacy and continuing education programs to facilitate better
understanding and identification of resources available to patients in the community.
Overall, training, education, and guidelines for pharmacist roles specific to increasing their
readiness to deliver services regarding prescription opioids is warranted for ensuring that pharmacists
participate in services that promote safe opioid use among patients. This commentary summarizes
services that pharmacists currently offer, assesses factors that affect pharmacists providing these services,
suggests strategies for improvement, including areas that should be augmented with education or
advocacy in order to ensure enhanced pharmacist services that promote safe opioid use. This
commentary has limitations to acknowledge. The scope of this commentary focuses on the opioid crisis
and pharmacist services within the U.S., reducing generalizability to other countries. The methodology
does not follow a rigorous data extraction and data analysis procedure, but rather includes articles
which the authors deemed most applicable and appropriate to include. This paper points to a lack of
evidence demonstrating that pharmacist services are directly impacting patient outcomes. All of these
services in theory have beneficial effects but it is difficult to find evidence of direct effect of pharmacist
services in the literature. Thus, there is need for future research about the impact of pharmacist services
in mitigating the opioid crisis.
6. Conclusions
This commentary paper is one of its kind to describe current practices and roles of pharmacists
and factors that affect pharmacists’ behaviors and attitudes dispensing these services. Pharmacists
successfully recognize the importance of their involvement in services to promote safe opioid use.
While pharmacists are expected to participate in service provision to mitigate the opioid crisis, it is
evident that pharmacists need more targeted training, education, resources, and structured guidelines
to increase confidence and self-efficacy in delivering such services.
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Abstract: Community pharmacists are viewed by the public as convenient and trustworthy sources
of healthcare and pharmacists likely can play a larger role in addressing the major public health
issue of the opioid epidemic affecting Wisconsin residents. Approved medications, including
long-acting injectable naltrexone, can transform the treatment of individuals with opioid use
disorder (OUD). Due to shortages of behavioral health providers in the U.S., and pharmacists’
knowledge about the safe use of medications, pharmacists can be a significant access point for
treating OUD with naltrexone. Wisconsin’s pharmacy practice laws authorize pharmacists to
administer medications via injection, and a small number of pharmacists currently are using this
authority to provide a naltrexone injection service. This exploratory study had two objectives:
(1) describe the pharmacist injection service process and identify barriers and facilitators to that
service and (2) analyze the legislative/regulatory environment to ascertain support for expanding
naltrexone injection service. Semi-structured pharmacist interviews (n = 4), and an analysis of
Wisconsin statutes/regulations governing public health and social services, were undertaken to
explore the objectives. Findings suggest that the service process requires considerable coordination
and communication with practitioners, patients, and pharmacy staff, but many opportunities exist to
broaden and sustain the service throughout Wisconsin.
Keywords: naltrexone; opioid use disorder; implementation; service process; regulatory; community
pharmacy
1. Introduction
The current opioid epidemic, including prescription opioid misuse or abuse and associated
overdose deaths, represents a major public health issue in the United States [1–3]. The impact of
opioid-related harms, including overdoses, is significant. Nationally, the opioid epidemic has resulted
in an increase in inpatient stays and emergency department visits [4–9]. The rate of opioid related
deaths also increased by 345% from 2001 to 2016 with the percent of deaths attributable to opioids
increasing from 0.4% to 1.5%, a 292% increase over the same time period [10]. The increase in deaths
has led to a decline in life expectancy for the third consecutive year due in part to opioid use disorder
(OUD) [11]. An OUD represents a chronic relapsing condition similar to diabetes or hypertension,
where individuals will experience patterns of treatment and abstinence from opioid use followed by a
resumption of opioid use and relapse [12–14].
Wisconsin has not evaded this public health crisis. From 2006 to 2016, the number of Wisconsinites
with an OUD tripled from 5828 to 20,590 [15]. During the same time, the number of inpatient hospital
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discharges per 100,000 residents associated with OUD increased 93% as compared to a 308% increase in
OUD-related emergency department discharges [16]. Mortality associated with OUD for Wisconsinites
is also increasing. Over a 15-year period (2001 to 2016), opioid-related deaths have increased by
529%, an increase primarily influenced by prescription opioids deaths [17]. The rate of change in
opioid-related deaths experienced in Wisconsin from 2001 to 2016 is 53% higher than the national
average [17].
1.1. Medication for Opioid Use Disorder
Potential access to FDA-approved medications is transforming how treatment is delivered
to individuals with OUD. Medication for OUD (MOUD) includes methadone (an opioid agonist),
buprenorphine (a partial opioid agonist) in all forms (sublingual, injectable or implantable), or oral
naltrexone (tablet) or extended-release naltrexone (an injectable opioid antagonist, also known as
Vivitrol®). The medications can be used to manage symptoms of opioid withdrawal or maintenance
(methadone or buprenorphine) or abstinence from opioids (naltrexone) [14]. Managing OUD with
medications has been shown to be more effective than treatment as usual [12,18,19]. For example,
patients who receive oral naltrexone experienced reduced time in inpatient substance abuse and mental
health treatment [20] or reduced opioid use [21]. More importantly, individuals who received six
naltrexone injections experienced improvements in employment, mental health and psychosocial
functioning, and reduced opioid craving and drug use [22]. Improving MOUD access is broadly
considered a crucial public health strategy in confronting the opioid epidemic [23–26].
Despite demonstrated effectiveness as a treatment for OUD and federal agencies’ calls for
increased access, MOUD is underused in the United States [27,28]. Current delivery models for MOUD
rely on patients accessing MOUD in primary care physician’s offices or through a local addiction
treatment provider. However, problems exist with current delivery models for MOUD, such as there
not being enough practitioners who are registered (i.e., DATA-waived) with the Drug Enforcement
Administration (DEA) to prescribe buprenorphine for office based opioid addiction treatment, negative
practitioner attitudes about becoming DATA-waived, concerns about diversion of methadone and
buprenorphine, insufficient infrastructure in practitioner offices/clinics to provide injections while
maintaining patient anonymity, and lack of knowledge about naltrexone as a viable treatment modality
for OUD [29–40]. This final issue is especially problematic, given that naltrexone is not a controlled
substance. As a result, unlike both methadone and buprenorphine, any licensed physician can prescribe
naltrexone without requiring an additional registration. Thus, new approaches are needed to improve
access to and underutilization of MOUD.
1.2. Pharmacist Involvement in Patient Access to MOUD
Approaches to the treatment of individuals with OUD have largely eschewed pharmacists’
involvement despite calls that specifically suggest that pharmacists be involved in such efforts [41–43].
Pharmacists can especially facilitate provision of MOUD because pharmacists commonly are one of
the most accessible health care providers in communities [44,45], they provide a myriad of patient
care services that contribute to public health [46,47], and patients are very accepting of the services
provided by pharmacists [46–48]. In Wisconsin, an emerging pharmacist service is naltrexone injections
for patients with OUD.
Pharmacists licensed in Wisconsin have legal authority to become an active partner in the care
team for treating patients with OUD. The authority for pharmacists to provide patient care services,
which can include naltrexone injections, is codified in Wisconsin law governing both medical and
pharmacy practice (see Table 1), and represents a significant facilitating factor for pharmacists to
be involved in OUD treatment. Beginning in March 2016 (2015 WI Act 290), pharmacists have had
the legal authority to administer non-vaccine medications via injection provided they comply with
training and reporting requirements. Additionally, Wisconsin’s medical practice laws provide statutory
authority for physicians to use a collaborative practice agreement to delegate patient care services to
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a pharmacist. Interpretation of the laws suggest that activities allowed under collaborative practice
agreements between physicians and pharmacists would include the management of patients with
OUD, including administering drugs via injection and/or administering oral drugs.
Table 1. Wisconsin State Statutes and Regulations Related to Pharmacist Authority to Provide Patient
Care Services.
Wisconsin State Law Section Intended Purpose of Cited Section of Wisconsin State Law
Wisconsin statute for Medical Practices
[Section 448.03(2)]
Authorizes physicians to delegate patient care services to other
health care providers through a collaborative practice agreement
between physicians and pharmacists.
Wisconsin statute for Pharmacy
Practice [(Section 450.033)]
Provides statutory authority for pharmacists to perform any patient
care service delegated to a pharmacist by a physician
Wisconsin statute for Pharmacy
Practice [(Section 450.035 (1r)]
Provides statutory authority for pharmacists to administer
non-vaccine drugs via injection after completing specific training
Wisconsin statute for Pharmacy
Practice [(Section 450.035 (1t))]
Provides statutory authority for pharmacist interns to administer
non-vaccine drugs via injection after completing specific training
Wisconsin Pharmacy Examining Board
(in Chap Phar 7 Section 7.10)
Establishes additional requirements for pharmacists and pharmacist
interns who are administering non-vaccine drugs via injection
As Table 1 suggests, state legislatures, agencies, and regulatory boards play an important role
in facilitating access to care for patients with OUD by creating and passing statutes and interpreting
statutory language in regulations that have the potential to affect OUD treatment. As an employer,
a provider of social services, and a payer of health care services, state government can influence
greatly whether pharmacists can have an accepted role in the treatment process for patients with OUD,
as well as the extent to which pharmacists are expected to be involved in such treatment. As such,
the broad analysis of state statutes and regulations related to requirements for public health and human
services can identify the potential demand for a pharmacist-provided naltrexone injection service.
Understanding where and how pharmacists potentially can fit into the treatment processes for patients
with OUD established by states is an important step in expanding the injection service across the state
and/or the U.S.
Objectives
Pharmacists providing naltrexone injections to patients with OUD is a new service and a limited
number of Wisconsin pharmacists currently are providing naltrexone injections to patients with OUD.
The first objective of this exploratory study was to describe how pharmacists are currently providing the
injection service, the processes used by pharmacists to provide the injection service, and barriers and
facilitators for the injection service. Exploring the process and implementation barriers and facilitators
will provide areas of future research and provide strategies to expand the service to other pharmacists.
The second objective of this exploratory study was to examine the legislative and regulatory
environments in Wisconsin that can influence pharmacist involvement in treatment for patients with
OUD. The review of both statutes and regulations governing a variety of healthcare practices and state
social health or welfare agencies was meant to highlight a number of provisions that could potentially
facilitate or impede the expansion of pharmacist-provided naltrexone treatment services for patients
with OUD. Exploring provisions currently in state law will provide suggestions for ways to expand
pharmacist service for naltrexone injections to treat OUD.
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2. Materials and Methods
2.1. Objective 1—Service Process and Implementation
2.1.1. Interview Guide
Since the naltrexone injection service has been emerging in Wisconsin since 2016, qualitative
research methods, including interviews, were used to collect and analyze data about the process and
implementation strategies developed and used by pharmacists providing the service. We constructed
a semi-structured interview guide for the interviews. The interview guide was developed to obtain
descriptive information from pharmacists about how the service was being provided. The interview
guide included questions about topics such as how patients were referred to the pharmacy, the
process developed by the pharmacist to provide the service, costs to the pharmacy for itemized inputs
needed for the service process, system, prescriber, patient, and pharmacy barriers and facilitators to
accessing and implementing the service, and a question related to any miscellaneous items related to
the development, implementation, and experience with providing the service. Question probes were
included to obtain more details about various aspects of the service.
2.1.2. Sample
A snowball sampling technique was used to identify and sample pharmacists who were providing
the injection service to interview. Initially, we obtained the names and contact information for two
pharmacists providing the service from staffmembers at the Pharmacy Society of Wisconsin. When
we contacted the initial pharmacists, we obtained the names of additional pharmacists providing the
service by asking those pharmacists for names of other pharmacists that were providing naltrexone
injections in their community.
2.1.3. Data Collection
We conducted four interviews with a purposeful sample of five pharmacists. Four of the five
pharmacists were currently providing naltrexone injections in community pharmacy environments
and the other pharmacist was planning the development of the service within a health system.
All interviews took place between April and June 2018. Four pharmacists were practicing in urban
areas and one pharmacist was practicing in a rural area of Wisconsin. One interview included two
pharmacists providing the service and was conducted via telephone. The other three interviews were
conducted in person, two were conducted in a private room at the University of Wisconsin School of
Pharmacy and one was conducted at the pharmacy site. In the interviews with pharmacists, which
were conducted conversationally, we asked about the naltrexone injection process at the community
pharmacy with additional questions intended to seek clarification or learn more about specific process
steps (e.g., interaction with behavioral health provider or actual injection process). The interviews
were not recorded; however, each author took extensive notes during the interviews. Since this was
neither conceptualized nor viewed by the IRB as research, a systematic data collection procedure was
not necessary to meet the purpose of a quality improvement investigation.
2.1.4. Data Analysis
The notes from the interviews were reviewed to identify specific points and themes related to
the naltrexone injection process at each community pharmacy. Authors analyzed the content of the
interviews separately and then met to achieve consensus about their interpretation of identified content,
and to discuss and negotiate the classification and naming of the processes and thematic domains
related to the naltrexone injection process derived from the interview data.
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2.2. Objective 2—Analysis of Wisconsin Statutes and Regulations
The purpose of the legislative and regulatory analyses was to identify requirements in state law
that have the potential to either facilitate, allow, or impede pharmacist services to provide treatment
to patients with OUD throughout Wisconsin. A synopsis of all identified policy requirements was
created, as well as the implication of those requirements on pharmacists’ roles in countering the current
shortage of treatment services for patients with OUD in local communities.
2.2.1. Identification of Wisconsin Laws
All potentially relevant statutes and regulations were identified using Lexis® Academic,
an electronic legal database available to all faculty, staff, and students at the University of
Wisconsin—Madison. Identification of applicable language in all statutes and regulations involved
two phases: (1) a keyword search of electronic text, and (2) manual review of potentially-relevant
sections or subsections of laws. Relevant legislative statutes, as well as related regulations, which serve
as the “sample” for this study objective, are listed in Table 2 and demonstrate the state agencies that
are most central to the clinical issue of drug abuse treatment. For professional practice regulation and
licensing laws, this search was confined to physicians, advanced practice nurses, and pharmacists, who
are authorized to prescribe, dispense, or administer medications for chronic diseases or conditions. In
addition to the specific laws in Table 2, an effort was made to determine applicable provisions that
relate to the ability of practitioners to engage in telehealth (i.e., using electronic communication for
exchanging health information to facilitate patient care) around OUD-related issues.
Table 2. Reviewed Statutes and Regulations that can Influence Pharmacist-Provided
Medication-Assisted Treatment with Naltrexone.
Legislation Regulations
Veterans Chapter 45 Department of Veterans Affairs
Social Services Chapter 46
State Alcohol Drug Abuse, Developmental
Disabilities, and Mental Health Act Chapter 51
Chapter 150 Regulation of Health Services,
Subchapter IV Department of Health Services
Corrections Chapter 301 Department of Corrections
Regulation and Licensing
Chapter 440 for prescribers
Chapter 450 for pharmacists
Department of Regulation and Licensing
Department of Children and Families
2.2.2. Policy Analysis
All content of the policies contained in Table 2 was collected, downloaded, and reviewed to
select provisions that could be related to treatment with naltrexone. Regulation and Licensing laws,
specifically pharmacy practice statutes and regulations, were examined first since they provide the
legal authority for pharmacists’ involvement in treatment of patients with OUD (see Table 1). The other
areas of legislation and regulations identified in Table 2 were then analyzed to determine the other
areas in law that likely impact pharmacists’ roles in treatment of patients with OUD. Since state statutes
provide the authority for state agencies to engage in certain activities, and regulations implement the
statutory authority by defining the process for engaging in those activities, whenever possible related
statutes and regulations (e.g., pharmacy practice act and pharmacy board regulations) were described
together to reduce redundancy. All policy provisions identified for this analysis were current as of
30 September 2018.
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3. Results
3.1. Objective 1—Service Process and Implementation
3.1.1. Pharmacy Infrastructure
Prior to offering naltrexone injections, the pharmacies had to create the service infrastructure.
Infrastructure development comprised: (a) completing training on how to provide injectable medications
in general; (b) working with Alkermes (manufacturer of injectable naltrexone) or other nurse educators
to complete naltrexone injection training; (c) obtaining a Clinical Laboratory Improvement Amendment
waiver to administer the rapid urine drug screen; and (d) establishing policies and procedures
(e.g., urine drug screen testing, naltrexone procurement). Pharmacists also discussed setting aside a
private consultation room or area to provide the injections that was located away from the prescription
counter and other pharmacy and customer activities.
3.1.2. Summary of How Patients are Referred to the Pharmacist
All of the pharmacists providing the service reported that they had established collaborative
practice agreements with a behavioral health practitioner or physician prescriber in accordance with
Wisconsin statutes and regulations outlined in Table 1; although prescribing practitioners can refer
patients to a pharmacy for naltrexone injections without a collaborative practice agreement, using such
a document better assures coordination of care, especially for the provision of long-term care. One
pharmacist said that 80% of their patients receiving the injections were from provider referrals, but that
20% of patients were walk-ins. These unscheduled patient walk-ins require immediate pharmacy staff
attention creating a coordination burden for the pharmacist and patient, which may conflict with their
ongoing counseling and dispensing responsibilities. The pharmacist planning the service said that a
referral process from primary care providers whose clinics could not provide the injections would
need to be established to bring patients with OUD to the pharmacy for the injections.
3.1.3. Development of a “Straw Model”
Results of the analysis of the data collected from the semi-structured pharmacist interviews were
used to develop a “straw-model” (see Figure 1) of the pharmacist-provided naltrexone injection service.
The term “straw-model” provides an initial representation of a process that is then utilized to generate
discussion and revision [49,50]. The “straw-model” we developed for the naltrexone injection service
starts with access and acceptability barriers that may prevent a patient with OUD from using, or their
practitioner from referring the patient to, a pharmacist for the naltrexone injection service. The next
three steps of the “straw-model” focus on the activities that occur prior to (e.g., scheduling), during
(e.g., urine drug screen, injection) and after the actual service encounter (e.g., scheduling follow-up
appointment) with the pharmacist.
 
Figure 1. Community Pharmacy Medication Assisted Treatment with Naltrexone “Straw-Model”.
Access and Acceptability Barriers. The interviews with pharmacists providing the naltrexone
injection service identified perceived access and acceptability barriers (Table 3) from both the patient
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and the pharmacist perspectives. Pharmacists shared comments they heard from patients about barriers
to medication and treatment for OUD in general and to naltrexone injections. Access barriers, broadly
defined, related to the infrastructure and access issues. Acceptability barriers included issues related
to prescribers’ perceptions about treating OUD, and patients’ perceptions about OUD. There was
consensus that pharmacists thought patients feel less stigma receiving OUD treatment in the pharmacy
since other customers remain unaware of the reasons for the patient presence in the pharmacy.
Table 3. Access and Acceptability Barriers to Pharmacist-provided Naltrexone Injection Service.
Access Barriers Acceptability Barriers
Infrastructure
- Lack of clinic infrastructure to support
providing injections
- Prescriber unaware of naltrexone
- Naltrexone covered as a Specialty
Medication—limited pharmacy access
Prescriber Perceptions about Treating OUD
- Patients with OUD are difficult to manage
- Prescriber concerns about the use and potential
diversion of medications
Access
- Lack of transportation to prescriber and/or
pharmacy (especially in rural areas)
- Poor Access to prescribers (especially
rural areas)
- Access to naltrexone Injections
Patient perceptions
- Stigma associated with MAT
- Patient knowledge and fear about medication
Injection Service Process Steps. During the interviews, pharmacists outlined the sequence of steps
involved in the injection service and provided details about each step, in response to the interviewer’s
prompts. Prior to providing a naltrexone injection, the pharmacist must work with the prescriber
and/or patient to schedule the appointment, and obtain the naltrexone injection after receiving the
order from the prescriber. In some circumstances the drug can be ordered directly from the drug
wholesaler. If the naltrexone injection is covered by a private prescription drug insurance plan that
places the drug in a specialty drug tier, the pharmacist needs to make arrangements to obtain the drug
from the specialty pharmacy.
Pharmacists described a general process involved in providing the injections for a patient that
is seeing a psychiatry provider via tele-psychiatry at the pharmacy. Once the patient arrives at the
pharmacy, to initiate the visit, the provider sends a code to the pharmacist to start the tele-psychiatry
service session that includes just the patient and the provider using an i-pad in a private room in the
pharmacy. At the end of the session, the psychiatry provider asks the patient if the injection can be
provided to the patient today while the patient is in the pharmacy. If the patient responds affirmatively,
the psychiatry provider asks the patient to go and get the pharmacist. Once the pharmacist is in the
room, they engage in a three-way conversation between the pharmacist, provider and the patient
to tailor the dose for the patient and also communicate with the provider/pharmacist about the
dosing. After approval is given for the injection, the pharmacist collects relevant patient demographic
information (e.g., age, gender) and conducts a rapid urine drug screen. The purpose of the drug screen
is to ensure that a patient is opioid free. After preparing the naltrexone injection, the pharmacist
administers the injection and monitors the patient (approximately 30 min) for any adverse reactions to
the medication. Typically, the patient remains in the private area of the pharmacy until the monitoring
is completed. During their visit to the pharmacy, the patient may receive behavioral health counseling
from a counselor prior to receiving the injection or during the post-injection observation period
via telemedicine.
After the appointment is completed, the pharmacist will schedule a follow-up appointment with
the patient, bill for the service, and communicate the administration of the drug and monitoring
feedback to the prescriber. Billing for services for Medicaid patients typically occurred under Healthcare
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Common Procedure Coding System (HCPCS) code Q-3014 (Telehealth originating site facility fee).
One pharmacist indicated that they could charge the patient an injection administration fee if the
patient provided the naltrexone medication. Under this scenario, the patient picked up the medication
from a specialty pharmacy as required by their private insurer and then transported the medication to
the local pharmacy who administered the medication and the patient then paid the administration
injection fee directly to the community pharmacy.
3.1.4. Perceived Facilitators and Barriers
Pharmacists identified facilitators as well as internal and external barriers to providing naltrexone
injections in the community pharmacy (Table 4). Internal barriers were categorized as those barriers that
related to aspects of the pharmacy or pharmacists that were providing the injection. External barriers
were categorized as those that occurred outside of the pharmacy and related to patient, community, and
health system factors. Since community pharmacies are more convenient for the patient and reduce
patient perceptions about stigma, pharmacists in one pharmacy expressed a belief that physicians
actually prefer that pharmacies provide the naltrexone injections because it facilitates access to care.
However, these same pharmacists believe that insurance drives the locations where naltrexone can be
administered, thus limiting patient access to the injections. Internal barriers reflect concerns expressed
by the pharmacist about the viability of providing naltrexone injections (e.g., fixed cost investment,
liability risks and inadequate reimbursement); and inexperience in providing naltrexone injections or
process concerns (e.g., time to coordinate activities, lack of experience and training on how to schedule
patients and manage no-shows).
Table 4. Naltrexone Administration: Preliminary Facilitators and Barriers in Community Pharmacies.
Facilitators Internal Barriers External Barriers
Motivated pharmacists and
pharmacy ownership structure
Frontend fixed costs associated
with staff, training, remodeling,
on-site drug testing and billing.
Lack of adequate patient
transportation and care
coordination with prescriber,
caseworker and other entities
leads to poor adherence
Patient trust in the community
pharmacist
Lack of a business case including
insufficient reimbursement for
drug administration and testing
Lack of supportive wraparound
services (e.g., behavioral health)
Pharmacists’ and behavioral
health providers’ knowledge of
telemedicine and its role in
proving health care.
Time to coordinate activities
associated with administration
including prior authorization,
patient scheduling & managing
appointment no-shows
Lack of awareness on ability to
refer patients to pharmacies via
collaborative practice agreement.
Flexible scheduling: community
pharmacy vs. physician office to
provide injections
Liability risks associated with
providing MAT in the pharmacy
Misperceptions: pharmacists do
not provide patient services/not
treatment team member
Availability of training courses
that allow pharmacist to meet
regulations regarding injections
Pharmacists’ lack of training and
experience in MAT injections and
induction.
Patient reluctance to pay drug
co-pays or pharmacy injection fees
Willingness of pharmacists already
engaged in practice to share
knowledge with others
Pharmacy seen as a retail
establishment versus clinic service
provider
The external barriers generally differ from the access and acceptability barriers described previously
in Table 4. Identified external barriers focus on issues such as the absence of resources in the community
to support care coordination or to provide wrap-around services that are needed by the patient to
adequately manage their chronic disease related to OUD. For example, one pharmacist mentioned a
desire to connect patients with a recovery coach in the community to support the patient and improve
the likelihood that the patient will return for subsequent naltrexone injections. The final set of external
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barriers focus on provider and patient misperceptions about their community pharmacy and the
available services. For example, residents in the community may believe that the local community
pharmacy primarily fills prescriptions in a retail capacity and does not offer clinical services, including
naltrexone injections for persons with an OUD.
3.2. Objective 2—Analysis of Wisconsin Statutes and Regulations
The content of identified provisions and their implications, as well as the accompanying legal
citations, are detailed in Table 5 for each state agency that has relevant activities involving drug abuse
treatment and control.











Department of Children and
Families)
Applicants for work experience
programs require substance abuse
screening, testing, and referrals
treatment (Wis. Adm. Code DCF
105.01), and a positive test requires
treatment participation (Wis. Adm.
Code DCF 105.06)
Requirements could increase







Prisoners are provided drug abuse
assessment and treatment at each
facility within the corrections system,
while parolees or people on extended
supervision also are to receive drug
testing (Wis. Stat. § 301.03). For
healthcare services, a prescription
drug formulary is used (Wis. Stat.
§ 301.103), but covered medications
are not specified
If naltrexone is included on the
drug formulary, it conceivably
could be offered through
pharmacist service as a viable
modality if positive assessments
lead to treatment
Substance abuse treatment also can
seem to be a component of a variety of
correctional programs and services,
including:
• for inmates selected for the
challenge incarceration program
(Wis. Stat. § 302.045; Wis. Adm.
Code DOC 302.38(3)(e))
• for inmates transferred from
state prisons (Wis. Stat. § 302.05)
• those in an earned release
program (Wis. Adm. Code DOC
302.39(3)(c))
• for those on-site or in hospitals
using crisis intervention services
(Wis. Stat. § 302.365)
• when transferring a prisoner to a
hospital or an approved
treatment facility (Wis. Stat.
§ 302.38)
• within residential, outpatient,
and aftercare settings, as a means
to reduce recidivism (Wis. Stat.
§ 301.068)
There are a variety of
opportunities throughout the
corrections system for identifying
inmates as needing substance
abuse treatment, and to potentially
engage pharmacists to provide
naltrexone injections either
directly through the corrections
facility or through their
community pharmacies
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Description of Identified Provisions
Implication for Pharmacist
Service
• when in intensive sanctions
program, as an alternative to
incarceration (Wis. Adm. Code
DOC 333.01(3) & (4))
• when transferring to the
Wisconsin resource center (a
specialized treatment program
for inmates in need of mental
health services) (Wis. Stat.
§ 302.055)
• for those in jail using a prisoner
classification system to provide
services and programs based on
medical/mental health needs
(Wis. Stat. § 302.36; Wis. Adm.
Code DOC 302.02)
• for those in municipal lockup
facilities and jails using a health
screening form to identify drug
abuse problems (Wis. Adm.
Code DOC 349.03(9) & (17); Wis.
Adm. Code DOC 350.03(12) and
policies and procedures to
provide drug abuse treatment
services (Wis. Adm. Code DOC
349.16(1)(b); Wis. Adm. Code
DOC 350.13(1) & (2))
Under certain circumstances, the DOC
must notify local law enforcement
before releasing a person into
extended supervision (Wis. Stat.
§ 302.113) and can facilitate inmate
release (Wis. Adm. Code DOC
302.34(5)(e) & (7)(g); Wis. Adm. Code
DOC 302.35(3)(e)(2)) and can even
expedite a risk reduction sentence
(Wis. Adm. Code DOC 302.40(3)(e))
Such notification offers an
opportunity to coordinate
substance abuse treatment needs
within the community, which
could involve pharmacist
naltrexone injection services if
pharmacists are identified as a
viable community resource
Wisconsin counties must provide
emergency mental health services
(Wis. Adm. Code DHS 34.01), for
conditions contained in the American
Psychiatric Association’s Diagnostic




Statistical Manual includes an
OUD diagnosis, providing a clear
context for pharmacists’
naltrexone injection service
A number of specific health services
programs and services permit SUD
treatment, including:
• outpatient mental health clinic
services (Wis. Adm. Code DHS
35.17(1)(b)(4))
• comprehensive community
services programs (Wis. Adm.
Code DHS 36.02)
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• treatment alternative program
(TAP) for people involved in the
criminal justice system, as a
means to avoid imprisonment
(Wis. Adm. Code DHS 66.01(1))
• for applicants of certain
employment and training
programs (Wis. Adm. Code DHS
38.06(1) & (2))
• for people with an SUD
diagnosis who have a functional
impairment that interferes with
major life activities (Wis. Adm.
Code DHS 36.14(1) & (2))
• community support programs
(Wis. Adm. Code DHS 63.08(1)
• community substance abuse
prevention and treatment
services (Wis. Adm. Code DHS
75.01(1))
• prevention services and
strategies to reduce the risk of
substance abuse (Wis. Adm.
Code DHS 75.04)
• emergency outpatient service
(Wis. Adm. Code DHS 75.05(1))
• medically-managed inpatient
treatment service (Wis. Adm.
Code DHS 75.10(1))
• individual and group counseling
(Wis. Adm. Code DHS
75.10(6)(f))
• day treatment service (Wis. Adm.
Code DHS 75.12(1))
• outpatient treatment service (Wis.
Adm. Code DHS 75.13(1))
• transitional residential treatment
service (Wis. Adm. Code DHS
75.14(1) & (6)(b))
There are a variety of
opportunities throughout the
Health Services system for
identifying people as needing
substance abuse treatment, all of
which could be used to coordinate
naltrexone treatment with
community pharmacists
• opioid treatment service for OUD
providing methadone or other
FDA-approved medications, as
well as other medical or
psychological services,
counseling, or social services
(Wis. Adm. Code DHS 75.15(1))
• intervention services that
includes case management (Wis.
Adm. Code DHS 75.16(1))
This provision provides a direct
role for pharmacists and their
authorization to provide
naltrexone injections for the
treatment of OUD
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Healthcare examining boards can
establish practice standards (Wis. Stat.
§ 450.02)
Practice standards could include
pharmacist services in providing
naltrexone injections
Advisory committees can be convened
to address behavioral health issues
(Wis. Stat. § 440.043)
An advisory committee could be
convened to address pharmacist
services for OUD prevention and
treatment
Any licensed physician can use
telemedicine as a patient engagement
tool, after documenting a patient
evaluation (Wis. Adm. Code Med
24.07)
Telemedicine authorization does
not involve pharmacists, and it is
unclear how this provision
extends to pharmacists who are






Agencies; Chapter 46. Social
Services)
(Regulations—none)
DHS has established a drug abuse
program that creates the foundation
for education, diagnosis, and
treatment (Wis. Stat. § 46.973), and
county-level DHS offices are
developed to address, in part, drug
abuse issues (Wis. Stat. § 46.23)
Through a variety of funding
mechanisms, community-based drug
abuse prevention and treatment can
focus on residential care, prisoner
reintegration into communities, urban
communities, and underserved
populations (Wis. Stat. § 46.48),
as well as to facilitate long-term care
transitions (Wis. Stat. § 46.2803),
for low-income Hispanics and Black
Americans in urban areas, the Native
American population, and women
(Wis. Stat. § 46.975), and for inmates
in the criminal justice system as an




funding could increase demand
for naltrexone injection service,
especially when DHS efforts




State Alcohol, Drug Abuse,
Developmental Disabilities




Agencies; Chapter 51. State
Alcohol, Drug Abuse,
Developmental Disabilities
and Mental Health Act)
(Regulations—none)
This statute addresses a broad range
of AODA prevention and treatment
services and is designed to assure
continuity of care for such treatment
(Wis. Stat. § 51.001), which reinforces
DHS’s authority to establish a
comprehensive and coordinated drug
abuse program for education,
diagnosis, and treatment (Wis. Stat.
§ 51.45)
Pharmacist-provided drug abuse
treatment services could be a
regular component of DHS
coordinated care efforts
Methadone treatment programs
include the provision of methadone,
buprenorphine, and naltrexone (Wis.
Stat. § 51.4223)
The provisions for methadone
treatment programs could allow
pharmacist services for naltrexone
injections
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Healthcare assistance from a variety of
health care providers is available to all
needy veterans (Wis. Stat. § 45.40)
Under this section, the definition
of “health care provider” does not
include pharmacists
Substance abuse treatment programs
approved by the U.S. Department of
Veteran’s Affairs (USDVA) or
Wisconsin-certified AODA programs
are available for needy veterans (Wis.
Adm. Code VA 2.01), and treatment in
such programs can facilitate
subsistence aid when veterans lose
income due to drug abuse (Wis. Adm.
Code VA 2.01(3)(b))
Given the description of
AODA-related programs in
Wisconsin’s Health Services and
Social Services regulations, as well
as in the State Alcohol, Drug
Abuse, Developmental Disabilities
and Mental Health Act, it is likely
that such treatment could involve
injection naltrexone
Federal grant to counties can be issued
to improve services to veterans (Wis.
Stat. § 45.82), and the Tribal veterans’
service office can apply for American
Indian grants (Wis. Adm. Code VA
15.02(1))
Veteran-related funding may
potentially be applied to drug
abuse issues, but pharmacist
involvement in providing such
services may be limited due to
their not being a recognized
“health care provider”
A systematic analysis of Wisconsin statutes and regulations identified a variety of provisions that
could facilitate a pharmacist service for providing naltrexone injections to treat patients with OUD.
Requirements contained in Correction laws and in Health Services regulations provide ample chances,
under a variety of situations, for pharmacists to be a member of the patient care team for OUD. This
role is further strengthened by DHS’s authority to maintain treatment coordination for people with
drug abuse problems (Wis. Stat. § 51.45). Treatment continuity would be especially important for
people transitioning within the corrections, health services, and social services systems, or for inmates
who are released into the community. Despite these opportunities, there are instances of legal language
that could impede pharmacists providing the injection service. For example, healthcare assistance to
needy veterans does not seem to involve pharmacists, even though drug abuse issues can be a problem
with which needy veterans are struggling. In addition, telemedicine authorization is not contained in
pharmacy practice laws, although it is permitted for physicians. As a result, it is ambiguous whether
a pharmacist could be involved in distance consultations with a physician even as a function of a
collaborative practice agreement between the two healthcare professionals.
4. Discussion
The results of this study suggest that a pharmacist-provided naltrexone injection service can be an
access point for the treatment of patients with OUD. Additionally, the legislative and regulatory analysis
documented numerous opportunities for the service to be incorporated into the current infrastructure
for public health and social services in Wisconsin. Given the shortage of behavioral health providers
in Wisconsin, and that pharmacies are more accessible to patients, a pharmacist-provided naltrexone
injection service can broaden patients’ treatment options. A pharmacist-provided naltrexone injection
service has the potential to be a “game changer” for OUD treatment [51]. The study identified five key
factors that explain why MOUD from pharmacists is not widely available: transportation; awareness
and acceptance; inter-organizational coordination of care; reimbursement and funding; and service
infrastructure including telemedicine.
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Transportation to and from the pharmacy for patients needing MOUD is a critical issue that needs
to be addressed. Community pharmacists have a long history of offering delivery service to patients
to facilitate prescription drug access. Perhaps pharmacists can use their experience with delivery
service to develop a cost-effective method to convey patients to and from the pharmacy for naltrexone
injections. Another model that could be considered is pharmacists making monthly trips to treatment
facilities and providing the injections to groups of patients. Further research is required to understand
the needs of patients with OUD to access the injection service and to study the costs and effectiveness
of different methods to access the service.
Similar to other pharmacist services, increasing awareness about the service and promoting
acceptability are important for the spread of the service. According to the interview results, pharmacists
said that patients were universally accepting of the service since it reduced the stigma of treating OUD.
However, additional research needs to determine the generalizability of these interview findings, and
more broadly assess the perceptions and attitudes of patients with OUD about receiving naltrexone
injections from a pharmacist. Learning which aspects of the service—before, during, and after the
injection—are most beneficial to patients could help pharmacists to better promote the service and
generate better adherence outcomes.
Increasing prescriber acceptance of the service is integral to more widespread adoption and
sustainability of the service. A strategy to promote practitioners’ acceptance of the service is informed
by the process illustrated by the interviewed pharmacists to provide the naltrexone injections, as well
as described in a previous study [52]: (1) establishing and following a protocol that is used in clinics
when treating patients with OUD and (2) meeting quality benchmarks to show that the process and
service is of high quality. Approaches to promote the acceptability of the service to prescribers could
focus on advantages of naltrexone (i.e., it is not a controlled substance, and prescribers do not have to
be DATA-waived) and how pharmacists can facilitate access to naltrexone and can provide the injection
and post-injection monitoring. As also suggested by our analysis of legislative and regulatory language,
public health and social services administrators and affiliated prescribing practitioners need to be
accepting of the service as well. Importantly, understanding practitioners’ attitudes and perceptions
about pharmacists’ involvement in OUD treatment, including providing naltrexone injections, would
be a useful gauge for the viability of the service. Attitudes and perceptions could be used to develop
approaches and messaging to increase acceptability of the service. Additionally, researchers and
pharmacists are encouraged to propose comparative effectiveness trials of pharmacist-provided
naltrexone injections to study the relative advantages of the service. Dissemination of the results could
be used to promote acceptance of the service.
One implication of the injection service process is that it requires extensive engagement,
communication, and coordination to get the patient into the pharmacy for the first injection, as well
as additional coordination to assure their return for follow-up. The finding that coordination and
communication is a key component of successful OUD treatment is consistent with research about OUD
treatment in clinics [53]. The pharmacists we interviewed had spent significant time working with the
behavioral health provider to be part of the patient care team, including mechanisms for communication.
Although telemedicine with a behavioral health provider was a component of the injection service
described by the interviewed pharmacists, OUD treatment with naltrexone can be initiated by local
primary care providers. Pharmacists interested in starting a naltrexone injection service should be
aware of OUD treatment providers and access issues in their immediate and surrounding communities.
Such efforts should focus on the connection with community resources to promote awareness and
acceptance of community pharmacy provided naltrexone injections by non-prescribers.
Interviewed pharmacists reported that reimbursement for costs associated with the administration
of the naltrexone injection is not widely available. One pharmacist even provided an itemized list
of naltrexone administration costs, and it was estimated that each administered injection resulted
in approximately $102 of unreimbursed cost. It should not be surprising that the non-remunerated
cost of providing the service can be a substantial barrier impacting the initial decision to provide the
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service and for the sustainability of the service in a community. Although the analysis of state laws did
not involve reimbursement laws due to their complexity, it did identify conceivable opportunities for
payment for the injection administration service through separate funding from the public health and
social services areas.
As mentioned, there are many additional sources of state-level funding that possibly could help
expand pharmacists’ role in OUD treatment across the state, and pharmacists may put themselves in a
beneficial position by learning whether possibilities for payment for the injection administration, or other
mechanisms for payment, are available through these sources. In fact, an entire statute (Charitable,
Curative, Reformatory and Penal Institutions and Agencies, Chapter 46) is devoted to preventing
substance abuse, and providing community-based services for people experiencing difficulties with
substance abuse issues, primarily through the establishment of program funding opportunities. Table 5
also identifies additional funding opportunities available through DHS-distributed grants, specific
drug abuse treatment funds, and veterans’ service grants. Each of these potential funding sources
presumably creates the prospect of expanding MOUD around the state. As pharmacist-provided
naltrexone injections become increasingly normalized as a convenient and reliable avenue for OUD
treatment within the community, it is likely that such funding would broaden the availability of that
essential service.
In addition to legally-sanctioned funding opportunities, it is clear from the analysis of statutes and
regulations that Wisconsin law provides broad legal capacity, through a variety of government agencies,
for the treatment of people with an OUD—even though demand often outstrips available resources.
Infrastructures for OUD treatment seem especially robust for the areas of corrections, health service,
and social services, as well as through the State Alcohol, Drug Abuse, Developmental Disabilities and
Mental Health Act. Although considerable systems exist by law for people needing AODA treatment,
the role of pharmacists and their ability to administer injectable naltrexone is currently either undefined
or underutilized. The extensive legal foundation for comprehensive AODA assessment and treatment
in Wisconsin is still advantageous, because, as this pharmacy service develops and spreads, statutes
and regulations could more clearly define the role of pharmacists and facilitate demand for the service.
While Wisconsin law permits pharmacists to give naltrexone injections either pursuant to or
without a collaborative practice agreement with a physician, little additional guidance is provided
to pharmacists about engaging in such treatment. However, it would be possible for the pharmacy
board to develop practice standards for pharmacist-involved OUD treatment, including with injectable
naltrexone. Such a standard, potentially coupled with an appointed committee’s advisory statement
about OUD-related behavioral health issues, would offer important clarification about the extent of
pharmacists’ potential contributions to treatment with naltrexone. In addition, the State Alcohol,
Drug Abuse, Developmental Disabilities and Mental Health Act identifies “methadone maintenance
programs” as including the use of naltrexone; although there are no legislative notes to provide
information about the contributions that pharmacy service can make to these programs, agency policies
and procedures could be modified to specifically describe the role of pharmacists providing treatment
in methadone maintenance programs. As such results suggest, clarifying these standards could
contribute to promoting awareness of the pharmacist service, as well as better assure that health and
social services administrators and practitioners are more accepting of the service.
In relation to general healthcare practice, physicians can engage in telemedicine to facilitate
distance treatment. When pharmacists and physicians collaborate to conduct a visit via telemedicine,
as done by the pharmacists we interviewed, it offers a new location (i.e., community pharmacy) for the
provider-patient visit. The process then facilitates the pharmacist providing the naltrexone injection.
The lack of a parallel telemedicine provision in pharmacy practice laws, absent clarifying authoritative
statements, creates uncertainty about the legality of pharmacists’ involvement in physician or patient
interactions through telemedicine consults. To establish well-defined authority for pharmacists to
engage in telehealth, the pharmacy examining board could modify its regulations to permit such
practice. Such regulatory change, coupled with a communications strategy to its licensees about the
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change, has the potential to facilitate pharmacist service around naltrexone treatment for patients with
OUD and expand access to MOUD treatment.
Limitations
A few limitations characterize this initial analysis of state laws. First, it is possible that relevant
provisions were contained in either statutes or regulations but were overlooked or inappropriately
disregarded during the review. Second, due to the complexity of reimbursement-related laws (at the
Federal, state, and local levels, and either public or private sector), description of state insurance laws
were excluded for this project. Since the applicability of state insurance laws does not function in
isolation of other types of reimbursement laws, a more detailed discussion of these policies is necessary
for providing an accurate account of the coverage of pharmacy-provided naltrexone treatment, as well
as providing telemedicine services, which was outside the scope of this article. However, further
research is indeed necessary to examine the potential influence of the variety of reimbursement-related
laws affecting the use of injection naltrexone for OUD treatment.
Our understanding of the process of community pharmacists providing naltrexone injections was
based on a purposeful sample, and thus has a few limitations. First, it is possible that there are other
community pharmacists in Wisconsin who provide naltrexone injections and use service processes that
vary from the initial straw model we developed. Research to further describe the service process is
needed. Second, the perceived prescriber and patient acceptability barriers, as well as the identified
facilitators and barriers, may be understated, which in turn could impact the willingness to utilize
community pharmacists as a provider of naltrexone injections. Further research is needed to conduct
a broad environmental scan of community pharmacists, including if they are currently providing
(or would be willing to provide) naltrexone injections and identifying other perceived facilitators and
barriers to offering the service. Also, additional information is needed about the existing infrastructure
in community pharmacies offering naltrexone injections. The information could be used to develop
a toolkit for other community pharmacists and the toolkit’s effectiveness could be examined in a
comprehensive dissemination and implementation research study design.
5. Conclusions
The nascent growth of the partnership between community pharmacists, individuals with
an OUD and prescribers in Wisconsin to offer naltrexone injections highlights the potential for
community pharmacists to be active partners in addressing issues related to the growing opioid crisis.
However, barriers associated with transportation, service infrastructure, reimbursement, awareness
and acceptance by practitioners including communication and service coordination need to be studied
to facilitate implementation and sustainability of this service in community pharmacies. In addition, the
design, implementation and effectiveness of current naltrexone injection service delivery approaches by
community pharmacists are not well understood. Operating in a supportive legislative and regulatory
environment, community pharmacists, as an already trusted and acceptable provider of service
within their community, could provide individuals a significant access point for OUD treatment with
naltrexone injections.
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Abstract: MedsCheck (MC) is an annual medication review service delivered by community
pharmacists and funded by the government of Ontario since 2007 for residents taking three or
more medications for chronic conditions. In 2010, MC was expanded to include patients with
diabetes (MCD), home-bound patients (MCH), and residents of long-term care homes (MCLTC).
The Ontario government introduced an abrupt policy change effective 1 October 2016 that added
several components to all MC services, especially those completed in the community. We used
an interrupted time series design to examine the impact of the policy change (24 months pre- and
post-intervention) on the monthly number of MedsCheck services delivered. Immediate declines
in all services were identified, especially in the community (47%–64% drop MC, 71%–83% drop
MCD, 55% drop MCH, and 9%–14% drop MCLTC). Gradual increases were seen over 24 months
post-policy change, yet remained 21%–76% lower than predicted for MedsCheck services delivered in
the community, especially for MCD. In contrast, MCLTC services were similar or exceeded predicted
values by September 2018 (from 5.1% decrease to 3.5% increase). A more effective implementation of
health policy changes is needed to ensure the feasibility and sustainability of professional community
pharmacy services.
Keywords: community pharmacy services; health policy; interrupted time series analysis;
medication reconciliation
1. Introduction
Chronic medications are often critical to an individual’s ability to maintain and improve their
health [1]. However, drug therapy problems, such as unnecessary therapy, ineffective dosage, and
adverse drug reactions are common [2,3]. Effective strategies to identify and decrease drug therapy
problems are important to reduce the potential harms from medication [4]. Community pharmacists
are widely accessible and commonly maintain a comprehensive record of an individual’s prescription
medications [5]. Community pharmacists are thus well positioned to effectively identify drug therapy
problems and prevent adverse drug events [6,7]. Community-pharmacist medication review programs
are well-established and publicly funded in Australia, Denmark and the United Kingdom [8–10].
Canada has universal Medicare that covers all medically necessary physician services, and at minimum,
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partial coverage of medications listed on provincial formularies for seniors and specialized vulnerable
groups [11]. In April 2007, the government of Ontario launched the MedsCheck program as the first
publicly funded community-pharmacy delivered professional service outside of drug dispensation.
When it was originally introduced, the MedsCheck (MC) service was a one-on-one annual consultation
service in a community pharmacy that provided education and assessed adherence to therapy. The
program targeted Ontario residents taking three or more medications for chronic conditions, and
pharmacy reimbursement was limited to once every 12 months [12]. The opportunity for pharmacies to
be reimbursed for unlimited follow-up services was added in November 2007. In September 2010, the
MedsCheck program was expanded to include people with diabetes (MCD), people unable to physically
attend a medication review service in a pharmacy due to physical or mental incapability (MedsCheck
at Home [MCH]), and residents in long-term care (MCLTC) [13,14]. In addition, unlimited follow-up
services within the year were included for MCD and quarterly services were included for MCLTC. MC
and MCD annuals and their respective follow-ups are completed in community pharmacies, whereas
MCH and MCLTC occur in a person’s place of residence. Pharmacies are reimbursed for these services
by submitting a claim to the Ontario Drug Benefit program. Of interest is the fact that all long-term care
(LTC) homes are required by legislation to ensure pharmacist participation in quarterly and annual
medication reviews with each patient [13].
The Ontario government announced changes to MedsCheck service delivery in July 2016 that
were implemented on 1 October 2016. The mandatory changes added several components to each
service, including follow-up services, such as requiring written patient consent, structured pharmacist
documentation, and the provision of summary information and recommendations to physicians
(Table 1) [15]. MCD included an extra set of assessment parameters related to diabetes education
and goal-setting, and new requirements that pharmacists have either a certified diabetes educator
designation or have gained adequate diabetes management knowledge through a professional
continuing education program approved by the Canadian Council on Continuing Education in
Pharmacy [13,16]. However, MCD follow-up services were less rigorous, intended for education and
did not require a complete medication review. The objective of this study was to estimate the change
in the monthly number of MedsCheck services delivered following the 2016 policy change.
We hypothesized that the increased workload accompanying the policy change and added
documentation and training requirements for MCD delivery would impact the feasibility of community
services, and thus, an immediate decline in the number of services would be identified. However, given
that regular medication reviews are required in LTC, we hypothesized that pharmacies would leverage
the MCLTC program to meet medication review requirements and thus, changes to the program would
have minimal impact on the frequency of MCLTC services.
2. Materials and Methods
2.1. Study Design
We used an interrupted time-series segmented regression design to study trends in the monthly
services delivered [17–19]. Interrupted time series is a robust, quasi-experimental approach for
evaluating the effects of policy and public health interventions [17,20]. This method models changes in
the level (immediate impact) and trend (slope) after a policy change; in our case, we examined the
change in monthly MedsCheck services following the 1 October 2016 policy change.
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Table 1. MedsCheck documentation requirement pre- and post-October 2016 policy change.
Before October 2016 Since October 2016 Policy Change
Patient Assessment Summary with Pharmacist’s
Signature and Date 1. MedsCheck Patient Acknowledgement of Professional Pharmacy Service *
• Completed annually for all community MedsCheck services (not
required for MCLTC)
2. Pharmacists Worksheet * for professional notes, 4 pages
3. Personal Medication Record, 1 or more pages (not required for MCLTC)
• Signed and dated by the pharmacist indicating the date of
the consultation
• Documentation with assurance that the record is an accurate
assessment of the patient’s prescription, non-prescription and natural
health product usage
• Table format for: what, why, how and comments for each product
• Includes evidence that drug therapy problems have been followed-up
or have a plan for resolution
• Records if the optional patient take-home summary was provided
4. Healthcare Provider Notification of MedsCheck Services *, 1 page
• Mandatory summary provided to the primary prescriber that includes
the Personal Medication Record and lists follow-up issues identified for
resolution (not required for MCLTC)
5. MedsCheck Patient Take-Home Summary *, 1 or more pages (optional)
• Summary of discussion, patient goals, suggestions for how to achieve
goals, lists of resources, contacts and referrals
Specific to MedsCheck Diabetes annual services
6. Diabetes Education Checklist *, 4 pages
7. Diabetes Education Patient Take-Home Summary *, 1 or more pages
• Summary of discussion, patient goals, suggestions for how to achieve
goals, lists of resources, contacts and referrals
• Unlike other community MedsCheck services, the take-home summary
is required for patients receiving MedsCheck Diabetes services
Specific to MCH
Medicine Cabinet Review:
Review of the medicine storage areas
Expired or unused medications itemized removed
from the home with signed consent for removal
Specific to MCLTC
Name of designate of long term care team with
whom results reviewed
* Standardized forms, available at http://www.forms.ssb.gov.on.ca/, accessed on 2 May 2019 [15]; MCH: MedsCheck
at Home, MCLTC: MedsCheck Long-Term Care.
2.2. Data Sources
We identified all MedsCheck services from October 2014 to September 2018 based on the product
identification number submitted to the Ontario Drug Benefit program (Table 2). Age and sex were
identified from the Registered Persons Database. These data were linked using unique encoded
identifiers and analyzed at ICES. Records with errors (death date prior to first service date, age <0,
missing age or missing sex) were excluded, and duplicate claims in the same month were deleted. The
total number of claims over the study period and the proportion of women and mean age of people
receiving each service were summarized by MedsCheck type (MC, MCD, MCH or MCLTC) based on
their first service date of each type.
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Table 2. MedsCheck service administrative codes and reimbursement fees as of October 2016.
Service PIN Fee
MedsCheck (MC) 1
MC annual 93899979 $60 1
MC follow-up
• Hospital discharge ≤ 2 weeks 93899981
• Pharmacist decision 93899982 $25
• Physician or nurse practitioner referral 93899983
• Planned hospital admission 93899984
MedsCheck Diabetes (MCD) 2
MCD annual 93899988 $75
MCD follow-up 93899989 $25
MedsCheck at Home (MCH) 3
MCH annual 93899987 $150
MedsCheck Long Term Care (MCLTC) 4
MCLTC annual 93899985 $90
MCLTC quarterly 93899986 $50
1 $50 before October 2016, eligible for residents with valid Ontario health card taking 3 or more chronic
medications.2 eligible for residents with diabetes and a valid Ontario health card. 3 eligible for residents with a valid
Ontario health card and with diabetes or taking 3 or more chronic medications and unable to attend community
pharmacy to have a MedsCheck service. 4 eligible for residents of licensed long-term care (LTC) homes with valid
Ontario health card and taking 3 or more chronic medications. Pharmacist participation in annual and quarterly
medication review services in LTC are required by legislation [13]. PIN: Product Identification Number.
2.3. Analytical Approach
The primary outcome was the monthly number of MedsCheck claims by MedsCheck service type
(MC annual or follow-up, MCD annual or follow-up, MCH, MCLTC annual or quarterly). We used
segmented regression to study trends in monthly service delivery, accounting for autocorrelation,
non-stationarity and seasonality. Autocorrelation was examined in the data using the Durbin-Watson
test [21] and autocorrelation plots, and stationarity was tested using the Dickey–Fuller test [22].
We specified our model to estimate level and trend changes in MedsCheck services in the 24-months
pre-implementation and 24-months post-implementation periods, while accounting for seasonality,
non-stationarity, and autocorrelation.
y = β0 + β1 × time + β2 × implementation + β3 × time after + e (1)
Equation (1) Generalized equation (autoregressive and moving average terms not included).
Equation (1) includes the generalized equation, where y was the number of MedsCheck services
delivered, β0 the number of MedsCheck services delivered in October 2014, β1 the monthly trend in
MedsCheck service delivery pre-implementation (October 2014–September 2016), β2 the immediate
(level) change in monthly MedsCheck services after implementation (October 2016), β3 monthly trend
in MedsCheck service delivery post-implementation (October 2016–September 2018), and e the random
error. The pre-intervention level and linear trends were plotted using model coefficients, and the level
and trend predicted values absent of the policy change were calculated for comparisons [23]. Analyses
were completed using R 3.5.2 (Vienna, Austria) leveraging the Companion to Applied Regression (car)
and Linear and Nonlinear Mixed Effects Models (nlme) packages [24].
3. Results
We identified 2,952,434 MC annual or follow-up services, 848,911 MCD annual or follow-up
services, 103,591 MCH services, and 1,084,410 MCLTC annual or quarterly services over the 48-month
study period, Table 3. The mean age at the first Medscheck service was lowest for MC (mean = 58.3,
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SD = 17.3) and highest for MCLTC (mean = 82.6, SD = 10.5). Besides MCD, a higher proportion of
MedsCheck service recipients were women.












Term Care (Annual or
Quarterly)
Number of recipients 647,740 209,060 57,583 95,191
Number of Service claims 2,952,434 848,911 103,591 1,084,410
Age, mean (SD) 58.3 (17.3) 60.6 (14.2) 74.4 (16.4) 82.6 (10.5)
Women, % 52.4 45.2 62.1 64.0
* Age and sex for each service type based on first service date for that service type. SD = Standard Deviation.
In the two years pre-intervention, there was a significant monthly increase for MCD annual and
MCH; yet, we observed a slight significant monthly decline for MCLTC annual (Table 4). A significant
immediate and large drop in the monthly number of MedsCheck community services was seen after
policy implementation (October 2016), ranging from 47% to 64% for MC (Figure 1), 71% to 83% for
MCD (Figure 2), and was 55% for MCH (Figure 3). In contrast, a considerable smaller decline was
seen for MCLTC, ranging from 9% to 14% (Figure 4). Gradual increases were seen over 24 months
post-intervention period, yet remained 21% to 76% lower than predicted for MedsCheck services
delivered in the community, particularly for MCD. In contrast, MCLTC services were similar to or
exceeded predicted values by September 2018 (from a 5.1% decrease to a 3.5% increase).
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Figure 1. Monthly number of MedsCheck claims relative to the implementation of the October 2016
policy change (vertical dashed line = intervention date). The solid lines show fitted values from the
interrupted time series model and the dashed lines show the predicted trend absent the policy change.
 
Figure 2. Monthly number of MedsCheck Diabetes claims relative to the implementation of the October
2016 policy change (vertical dashed line = intervention date). Solid lines show fitted values from the
interrupted time series model, and dashed lines show the predicted trend absent the policy change.
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Figure 3. Monthly number of MedsCheck at Home claims relative to the implementation of the October
2016 policy change (vertical dashed line = intervention date). The solid lines show fitted values from the
interrupted time series model and the dashed lines show the predicted trend absent the policy change.
 
Figure 4. Monthly number of MedsCheck Long Term Care claims relative to the implementation of
the October 2016 policy change (vertical dashed line = intervention date). The solid lines show fitted
values from the interrupted time series model and the dashed lines show the predicted trend absent
the policy change.
4. Discussion
MedsCheck was introduced in 2007 as a publicly funded medication review service for patients
in the community taking multiple medications, and expanded in 2010 to target other high-risk
groups (people with diabetes, home bound and residents of LTC homes) [12,13]. Despite the
rapid uptake of these services [14,25], some concerns were raised about quality resulting from the
lack of standard documentation or interprofessional coordination [26,27]. In response, the Ontario
government consulted the Pharmacy Council—a body that includes representation from the Ontario
Pharmacists Association and other stakeholders to provide advice and recommendations related to the
pharmacy profession on the development of standardized documentation for the suite of MedsCheck
services [28–30]. The added service components resulted in an immediate decline in the number
of MedsCheck services delivered in the community. The decreases were generally sustained over
the subsequent 2 years. However, there was minimal impact on the number of MedsCheck services
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delivered in LTC. Conceivably, the new requirements may have improved service quality. Future
mixed method studies that consider the relative quantity and quality of MedsCheck services pre- and
post-policy change are of high interest.
We found that MedsCheck follow-up services remained 61% (MC follow-up) to 76% (MCD
follow-up) below predicted 24 months after the policy change. This may partially be attributed to
pharmacies being ill-equipped to integrate routine follow-up services into their day-to-day workflow.
Reminder systems to identify patients that may benefit from follow-up services are not routine. In
addition, the use of part-time staffing and recent pharmacy funding cuts [31–34] may make it difficult
for pharmacists to step away from their dispensing duties and reach out to patients to conduct a
follow-up service [35]. Appointment-based pharmacy models are becoming more common in the
United States and research demonstrates that appointment-based models improve the number of
prescription fills, reduce the number of trips to the pharmacy, improve vaccination rates, and increase
the proportion of patients adherent to therapy [36]. The significant impact of the policy change on the
number of follow-up services in our study is concerning since monitoring and follow-up with patients
on a consistent basis allows for the evaluation of drug therapy effectiveness and adherence, as well as
identifying new drug therapy problems [37,38].
The impact on MCH is unexpected given the higher reimbursement ($150 MCH vs. $60 MC
annual and $75 MCD annual). However, increased documentation and reporting on top of travel time
and expense (i.e., fuel and parking) to visit a patient’s home, medicine cabinet reviews and the removal
of unused drugs for proper disposal at the pharmacy [39], may have made the service less feasible.
MCH serves an important role in the community as it provides medication review to homebound
individuals, typically frail and elderly or living in isolated settings. These patients are often more
vulnerable to medication related errors [32]. Managing medications in the home setting is a unique
challenge and MCH has the potential to educate patients and their families about medication therapy,
and thus ultimately contribute to improved health and quality of life.
Of interest is the fact that the number of monthly MCLTC services changed minimally after the
policy change and by 24 months after the policy change, services were above or close to the predicted
values. The legislative requirement for annual and quarterly medication reviews together with existing
infrastructure logically made MCLTC more feasible, i.e., much of the labour required in the community
was already automated in LTC. MCLTC serves an important role since seniors make up about 12% of
the Canadian population and 2.6% of all Canadian seniors reside in LTC [40].
Our study had a major strength by leveraging complete population-based level data submitted
for reimbursement. However, we were limited in the ability to adjust monthly claims by the number of
people eligible to receive MedsCheck services. Drug dispensation for chronic medication is increasing
in Ontario [33], therefore, we expect the number of eligible patients for MC and MCH services to
be increasing over time [41–43]. Similarly, the dispensation of diabetes medications is increasing,
indicating an increase in the number of patients eligible to receive MCD services. Finally, the number
of LTC beds increased by 2.5%, from 76,982 in 2016 to 78,872 in 2018 [40,44], thus, it is not surprising
that we found a 3.5% higher than projected number of MCLTC annual services by September 2018.
Despite our inability to adjust claims based on the number of eligible claimants, our results are
population-based and compelling given the negligible to slow increase in the number of MedsCheck
services over time.
Overall, the 2016 policy change that added several documentation and reporting requirements for
MedsCheck services was well-intended to help standardize service delivery yet was followed by a
substantive decline in the use of MedsCheck services. Although better standardization in program
delivery is desirable, better understanding and pilot testing for feasibility before rolling-out new
policies is encouraged. Indeed, leveraging a framework to optimize the design and implementation
of new programs has the potential to improve success, value and impact [45,46]. On 25 April 2019,
the Ontario Government announced a proposal to “modernize” the MedsCheck program with a sole
focus on transitions in care and LTC [47]. The proposed change will lead to the discontinuation of all
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community MedsCheck services outside of transitions in care. The details have yet to be announced,
yet we speculate that the termination of community-based MedsCheck programs relates to the keen
interest by the new government to reduce the deficit, coupled with the decline in service delivery
and lack of evidence of clinical benefit [48]. For example, the provincial budget notes that “Changing
the way pharmacy fees are paid, including a tiered framework for drug mark-up fees; fees paid for
filling prescriptions for long-term care home residents, and focusing the MedsCheck program on
patients transitioning between health care settings, [will result] in annual savings of over $140 million
by 2021–22” [49]. The decision to continue supporting MedsCheck services around transitions in
care may relate to evidence that supports the benefit of pharmacy-led medication review in reducing
readmission rates among patients discharged from hospital [6,49–51].
The impact of the cuts to MedsCheck services on the quality of the Ontario healthcare system is in
question, particularly related to the identification and resolution of drug therapy problems. A better
understanding of the impact of changes in service delivery on different subgroups of patients is
important. At minimum, we identified that patients with diabetes were possibly more impacted by the
policy-change with proportionally fewer MCD completed post-policy changes compared to MCH or
MC annual. However, it is also possible that pharmacies strategically switched from billing for MCD
annual to billing for MC annual among patients with diabetes taking three or more medications to
reduce some of the added paperwork specific to MCD. Further exploration of the use of MedsCheck
services among patients with diabetes is of interest. Community pharmacists are increasingly involved
in patient care through the conduct of regular medication review [52]. In particular, studies from
Australia, Canada, the United Kingdom, and the United States show that diabetes education and
support delivered through community pharmacies improves care and outcomes [53–55]. However,
direct clinical evidence of the various types of medication review programs is scarce. There is a need
for well-designed, rigorous studies with more sensitive and specific outcomes that consider the effect
of community pharmacists’ contributions to reviewing medications on improving health [52,56,57].
Our results provide compelling evidence of the immediate and sustained effects of policy decisions
on the level of publicly reimbursed professional community pharmacy-delivered services. In the
future, policy makers are encouraged to work closely with healthcare providers and fund research to
provide evidence of the best mechanisms for the implementation of new pharmacy services [45,46].
Funding research to consider the benefits and harms of programs is also important instead of abruptly
cancelling programs without considering how to better focus program delivery efforts.
Our research was limited in its ability to understand why the policy change had such a dramatic
impact on the number of services delivered, or if the changes impacted the quality of service delivery.
Future mixed-methods research is encouraged. Focus groups with community pharmacists will
provide a deeper understanding of the experience of delivering MedsCheck services pre- and post-2016
policy change, and thus help uncover the reasoning behind reduced levels of service delivery. Survey
research of MedsCheck program recipients may help to clarify the impact of changes on the quality
of service delivery, as well as patient satisfaction and possible concerns about the decision by the
Ontario government to cancel community services outside transitions in care. Finally, semi-structured
interviews with policy decision makers and Pharmacy Council may help clarify the rationale behind
the 2016 policy changes, as well as more recent changes to pharmacy practice in Ontario.
5. Conclusions
The Ontario government instituted a policy change October 2016 that abruptly changed
reporting and documentation requirements that was followed by a sharp and sustained decline in
community pharmacy MedsCheck services. Our findings highlight the importance of a well-executed
implementation strategy for health policy changes to ensure the feasibility and sustainability of
professional community pharmacy services. Despite consulting with pharmacy stakeholders through a
formal Pharmacy Council to develop a more standardized service, the comprehensive documentation
and interprofessional communication processes put in place were associated with a substantial
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reduction in the number of professional services delivered. The immediate and profound reduction in
service delivery speak to the importance and benefits of pilot studies that consider program feasibility
in a real-world setting. Better understanding of the impacts of the 2016 policy change on the quality of
MedsCheck services and outcomes, as well as potential harms from cancelling many of these services,
are needed to inform future policy-decision making.
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Abstract: Background: Patient counselling and addressing drug-related problems are the
pharmacist’s key activities to ensure the safe and effective use of medicines. This study aimed
to describe the dispensing practice of prescribed medicines in daily community pharmacy practice
and to identify factors influencing counselling provision; Methods: An observational study was
conducted in community pharmacies in Basel, Switzerland. One master student in pharmacy
performed non-participatory observations for one day at each of the participating community
pharmacies. Patient characteristics, counselling content, additional activities, and pharmaceutical
interventions were documented on a structured checklist; Results: 556 prescription encounters (PE) in
18 participating community pharmacies were observed (269 first prescriptions; 287 refill prescriptions).
Patients were regular customers (n = 523, 94.1%) and 53.8 ± 23.4 years old. Counselling was provided
to 367 (66.0%) customers on 2.9 ± 3.1 themes per PE. Factors influencing counselling were dispensing
by the pharmacist, new customer, customer who did not refuse counselling, customer with a first
prescription, with a prescription resulting in a pharmaceutical intervention, and a prescription filled
by carers. During 144 PEs, 203 interventions were documented. Pharmacists proposed few additional
activities and performed no cognitive pharmaceutical service; Conclusions: Our study quantified
counselling and additional services at the dispensing of prescribed medicines and identified
influencing factors on counselling provision at the patient, prescription, and pharmacy level.
Keywords: community pharmacy practice; dispensing; counselling; pharmaceutical intervention;
pharmaceutical care; observation
1. Introduction
The Pharmaceutical Care Network Europe defined “Pharmaceutical Care” as “the pharmacist’s
contribution to the care of individuals in order to optimize medicines use and improve health
outcomes provided” [1]. As part of pharmaceutical care, patient counselling and addressing
drug-related problems (DRPs) are the pharmacist’s key activities to ensure the safe and effective
use of medicines [2,3]. Dispensing includes all activities between the reception of the patient with
a prescription and the distribution of medicines to the patient with the provision of counselling [2].
During dispensing, community pharmacists help the patient to make the best use of prescribed
medicines by providing written and oral information, responding to the patients’ needs [4]. Patients
have the opportunity to receive counselling and education about their health problems and medicines
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in several care situations, especially in community pharmacies at the time of dispensing prescribed
medicines [5]. Patient counselling about their medicines (e.g., administration, risks and benefits)
has been shown to be effective in improving medicine adherence [6,7], and in identifying DRPs [8].
In contrast, insufficient information about medicines can lead to patient non-adherence to drug therapy,
and negative health outcomes [5].
The joint International Pharmaceutical Federation and World Health Organization (FIP/WHO)
guidelines on Good Pharmacy Practice (GPP) describes the pharmacist’s function of dispensing
medicines concerning counselling as “providing advice to ensure that the patient receives and
understands sufficient written and oral information to derive maximum benefit for the treatment” [3].
Prescription dispensing at the community pharmacy is an important contact point for patient
counselling [8]. Patients regularly pick up their prescribed medicines in community pharmacies [9],
hence pharmacy staff are usually one of the last healthcare providers who interact with patients prior
to medication intake that has the possibility to counsel them [10,11]. The joint FIP/WHO GPP also
suggests minimum national standards that should be established for this function.
In Switzerland, the Swiss Association of Pharmacists published standards for pharmaceutical
counselling [12]. A service–based remuneration system for community pharmacies has been
established since 2001 [13] and some cognitive pharmaceutical services are reimbursed by the health
insurance [14,15]. The counselling provided during dispensing of prescribed medicines is remunerated
by the ‘drug check’ (fixed fee for checking each dispensed item for dosage, interactions, risk factors,
contraindications, misuse and for patient counselling, choice of optimal package size, etc.) and ‘delivery
check’ (fixed fee for managing a patient record and checking medication history) [14]. In Switzerland,
prescribers can issue refill prescriptions for up to 12 months for patients with ongoing long-term
therapies, leaving responsibility for counselling and follow-up of therapy to the pharmacist.
The literature on counselling in community pharmacies described the communication between
patient and provider about the medicines use [16,17] and compared counselling practice to
guidelines [9,18]. A Swiss study described community staff-patient interactions with a focus on
adherence [19]. This study showed that only 6.7% of all patient interactions comprised adherence
counselling, and recommended an in-depth analysis of pharmacist-patient interaction. To the authors’
knowledge, the full pattern of the daily community pharmacy practice, with all activities and
interventions a prescription triggers at the time of dispensing in a setting with remuneration for
prescription validation and counselling, have not been described yet.
For this reason, the aim of the study was to describe the observed dispensing practice of prescribed
medicines at the counter in daily community pharmacy practice, focusing on counselling, pharmaceutical
interventions and further activities, and to define factors influencing counselling provision.
2. Materials and Methods
A non-participatory observational study was conducted in community pharmacies in Basel,
Switzerland to illustrate the observed dispensing practice of prescribed medicines. The Ethics
Committee of Northwest and Central Switzerland approved the study on 25.01.2016 (EKNZ BASEC
UBE-req. 16/00011).
2.1. Data Collection
Community pharmacies in Basel, Switzerland, were randomly invited for study participation,
according to a prior study [19]. One master student in pharmacy observed pharmacy staff-customer
interactions for one day at each participating community pharmacy in a non-participatory way
during March and April 2016. The observation method was based on ad-hoc manual recording of
exchanged information during a pharmacy staff-customer interaction and subsequent transcribing
into quantitative information. After a quick briefing about the study, the pharmacy staff were neither
actively involved in data collection, nor disturbed in their usual practice. At the dispensing of
prescribed medicines, counselling content (information exchanged over the counter between customer
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and pharmacy staff), patient characteristics (e.g., age), pharmaceutical interventions (e.g., dose
adjustment) and additional activities (offered and/or performed further activity/service) were
documented on a structured checklist for each prescription encounter (PE). The non-participatory
observer stood next to a pharmacy staff member and recorded a PE from the greeting of a customer
(patient or carer) filling a prescription in the community pharmacy to closing salutations; where after,
the next customer was observed. Customers were not informed about the study to avoid any influence
on the counselling activities. Only communication in German was assessed.
The checklist was modified from a previous study [20] and enabled ad hoc coding of nine
categories and 61 predefined themes: Patient characteristics (n = 4 themes), provider (pharmacy staff
involved, n = 1), prescription (n = 7), counselling (n = 34), intervention (n = 2), physician contact
(n = 2), situation (n = 6), and additional activities (n = 5). The category counselling, including 34
counselling themes that were considered as best practice, was derived from the ‘drug check’ of the
Swiss service–based remuneration system [13], the literature [9,21,22], the requirement of the Omnibus
Budget Reconciliation Act (OBRA, 1990) [23], the recommendations for internal audits of the Swiss
Pharmacists’ Association [24], and on expert discussions with five community pharmacists. Each
theme was defined in a data dictionary to standardize the observer judgement. The checklist enabled
to distinguish between the active and passive (e.g., asking and answering questions, respectively)
involvement of the pharmacy staff and the customer during the PEs. After piloting, the checklist was
refined and cases were discussed between the observer and two experienced community pharmacists
to ensure data quality. An anonymized copy of the prescription and list of medicines from refill
prescriptions of every observed patient were additionally collected and used to test the documentation
of the observed PEs on consistency and plausibility. Observation time and characteristics of the
pharmacies and their staff were recorded separately.
The systematic documentation of the pharmaceutical interventions, performed by pharmacists,
were accomplished with aid of the Pharmacists’ Documentation of Intervention in Seamless Care
(PharmDISC) system. This classified the pharmaceutical interventions in different categories (problem,
type of problem, cause, intervention, person involved, and the outcome of the intervention) [25].
At the end of the observation day, a semi-structured interview focusing the pharmacists’ opinion
on the counselling, triggers, facilitators, and barriers was conducted with one pharmacist per pharmacy.
The results of the interviews are reported separately [26].
The main outcome measures were the number and type of themes covered in counselling,
the factors influencing counselling provision, and number, frequency, and type of pharmaceutical
interventions and additional activities.
2.2. Data Analysis
All coded data were quantified and analyzed descriptively using IBM SPSS Statistics for Windows,
Version 24 (IBM Corp., Armonk, NY, USA). For the determination of factors influencing counselling
provision, counselling theme ratios (sum of each counselling theme counselled divided by the number
of medicines dispensed on one prescription) were expressed in percentage. A mean counselling theme
ratio of 100% represented the maximum of all 34 possible counselling themes counselled for each
dispensed medicine. A single factor variance–analysis, Chi-Square, Spearman, and Mann-Whitney U
tests were used to compare variables. A p-value < 0.05 was considered statistically significant.
3. Results
Forty-nine community pharmacies were invited and 18 (37%) took part in the study. Reasons for
participation refusal were no interest (n = 7), lack of staff resources (n = 4) or time (n = 4), holidays
(n = 2), or unknown (n = 14). All pharmacies were located in the urban area of Basel. Thirteen were
independent pharmacies (72.2%), while five belonged to a pharmacy chain (27.8%). They were on
average open for 10.25 ± 1.5 h per day, and were observed during 8 ± 0.6 h (covering 78.0% of opening
hours) per day, per pharmacy. The mean number of working staff per pharmacy at the observation
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day was 5.8 ± 2.6 (1.7 ± 0.9 pharmacists, 2.8 ± 1.7 pharmacy technicians, 1.0 ± 0.3 apprentices, and
0.2 ± 0.7 pharmacists in training).
During the total observation time of 145.5 h (18 observation days), 571 PEs (mean 31.2 ± 6.4 per
pharmacy, range 22–45) were documented. Fifteen PEs had to be excluded because no medicines were
dispensed (n = 9, e.g., drug not in stock), spoken language was foreign (n = 3), ordered medicines were
picked-up (n = 1), physician-ordered medication (n = 1), or no documentation about the dispensed
medicines was available (n = 1). A total of 556 PEs (269 first PEs and 287 refill PEs) constituted the
sample for statistical analysis (each PE involved one customer).
Table 1 illustrates the characteristics of the patient, prescription, and provider. The number of
medicines on a prescription varied from 1 to 25 (mean 3.2 ± 3.2).
Table 1. Patient, prescription, and provider characteristics.
Prescription Encounter
All First Refill
(n = 556) (n = 269) (n = 287)
Patient
Female n (%) 337 (60.6) 162 (60.2) 175 (61.0)
Mean age (years) ± SD 53.8 ± 23.4 45.6 ± 23.9 61.4 ± 20.2
Regular customer n (%) 523 (94.1) 242 (90.0) 281 (97.9)
Carer filled a prescription for a patient n (%) 105 (18.9) 62 (23.0) 43 (15.0)
Prescription
Ambulatory n (%) 468 (84.2) 212 (78.8) 256 (89.2)
Hospital discharge n (%) 88 (15.8) 57 (21.2) 31 (10.8)
Provider of counselling *
Pharmacist n (%) 149 (26.8) 70 (26.0) 79 (27.5)
Pharmacy technician n (%) 267 (48.0) 124 (46.1) 143 (49.8)
Apprentice n (%) 86 (15.5) 45 (16.7) 41 (14.3)
Pharmacist in training n (%) 13 (2.3) 8 (3.0) 5 (1.7)
Druggist n (%) 8 (1.4) 1 (0.4) 7 (2.4)
Combination of pharmacy staff n (%) 33 (5.9) 21 (7.8) 12 (4.2)
* Definition of the different counselling providers in Switzerland: Apprentice is a pharmacy technician in their
3-year training; pharmacist in training is a student in her/his last year of the master in pharmacy curriculum;
druggist accomplished a 4-year apprenticeship.
3.1. Counselling
The PEs lasted on average 4.5 ± 3.0 min (first 5.2 ± 3.1; refill 3.9 ± 2.7, p < 0.001), ranging from
1.0 to 23.0 min. In 106 PEs (19.1%), pharmacy staff offered counselling by asking if the patient already
knew about their medicines, or if they had any questions regarding the use of medicines (general
closed questions that were intended to verify patient need for counselling). During the 556 PEs,
counselling was provided to 367 (66.0%) customers, to 249 with first prescriptions and to 118 with
refill prescriptions (p < 0.001). Of the 367 customers, 68 (12.2%) received counselling on one theme (out
of the 34 counselling themes), 52 (9.4%) on two themes, 132 (36.0%) on three to five themes, and 115
(20.7%) on five to thirteen themes (Figure 1). Pharmacy staff did not provide any counselling in 169
refill PEs and in 20 first PEs. On average, customers were counselled on 2.9 ± 3.1 themes per PE (first
PEs 4.9 ± 3.0; refill PEs 1.0 ± 1.7, p < 0.001). Customers who refused counselling (148 PEs [26.6%]; 51
first PEs vs. 97 refill PEs, p < 0.001) were significantly more often approached for counselling at first
PEs than refill PEs (3.7 ± 2.9 theme vs. 1.7 ± 1.9, p < 0.001).
Table 2 presents the number of the counselling themes and their initiator. Pharmacy staff mainly
counselled on administration (at first PEs 465 times and at refill PEs 73 times), dose (188; 46), and use
(152; 36) and provided a label (189; 55). Of the 34 counselling themes, 8 were never addressed.
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Figure 1. Number of themes counselled by the pharmacy staff per prescription encounter (PE) during
first (n = 269) and refill PEs (n = 287).
3.1.1. Patient Involvement
The customer was actively involved in 193 (34.7%) of PEs by providing information (n = 149 PEs,
77.2%), asking questions (n = 25, 13.0%), or a combination of both (n = 19, 9.8%). During the first PEs,
the customer was more often actively involved than during refill PEs (48.7% vs. 21.6%, p < 0.001).
3.1.2. Factors Influencing Counselling Provision
Table 3 presents factors influencing counselling provision at the patient, prescription and provider
level. At patient level, new compared to regular customer received more counselling from the
pharmacy staff (11.9% vs. 5.0%, p < 0.001) (Table 3). The type of prescription also influenced the
rate of counselling. Significantly more counselling was provided with a first compared to a refill
prescription (mean theme counselling ratio 9.6% vs. 1.5%, p < 0.001), and with prescriptions requiring
a pharmaceutical intervention vs. no intervention (7.9% vs. 4.6%, p < 0.001). At the provider level,
pharmacists provided counselling on significantly more themes per PE than pharmacy technicians (3.5
vs. 2.6 themes, p < 0.05), druggists (3.5 vs. 1.9, p < 0.05), and apprentices (3.5 vs. 2.3, p < 0.05). However,
no significant difference between pharmacists and pharmacists in training (3.5 vs. 3.2, p = 0.849)
or between pharmacists and a combination of a pharmacist and another staff member (3.5 vs. 4.2,
p = 0.194) was seen.
The detection of factors influencing counselling provision allowed the illustration of counselling
patterns (Figure 2).
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3.2. Pharmaceutical Interventions
During all 18 observation days, 203 pharmaceutical interventions were documented at 144 PEs
(intervention rate 25.9%). Interventions occurred significantly more at first PEs (n = 103) vs. refill
PEs (n = 41; p < 0.001), with an average per prescription of 1.4 ± 0.7 (range 1–4). Pharmacists’
intervention mainly included drug substitution (n = 89, 43.8%), clarification of information (n = 64,
31.5%), and adjustment of the package size/quantity (n = 39, 19.2%). Table 4 represents the most
frequent pharmaceutical interventions. The cause was technical for 180 pharmaceutical interventions
(88.7%) and clinical for 23 pharmaceutical interventions (11.3%). Active interaction with the prescriber
was necessary in 11 (5.4%) pharmaceutical interventions, whereas the involvement of the patient was
observed in 127 (62.6%) pharmaceutical interventions and neither the prescriber nor the patient was
involved in 65 (32.0%) pharmaceutical interventions.
Table 4. The most frequently observed pharmaceutical interventions, their cause and type of problem
(documented with the PharmDISC system).
Intervention Cause of Intervention Type of Problem n (%)
Total interventions 203 (100.0)
Technical 180 (88.7)
Clarification/addition of information Incomplete/unclear prescription Manifest, reactive 55 (27.1)
Substitution (generic) Financial burden Manifest, reactive 49 (24.1)
Substitution Prescribed drug not available Manifest, reactive 31 (15.3)
Adjustment of package size/quantity Financial burden Manifest, reactive 18 (8.9)
Adjustment of package size/quantity Financial burden Manifest, reactive 9 (4.4)
Clinical 23 (11.3)
Adjustment of package size/quantity Concerns about the treatment Manifest, reactive 3 (1.5)
Substitution No concordance with guidelines,only suboptimal therapy possible Potential, preventive 2 (1)
Substitution Concerns about the treatment Manifest, reactive 2 (1)
Therapy stopped/no delivery Drug-drug interaction Potential, preventive 2 (1)
In-depth counselling of patient Drug-drug interaction Potential, preventive 2 (1)
The number of pharmaceutical interventions per PE increased with the frequency of counselled
themes per PE (correlation r = 0.270, p < 0.001) and with the frequency of dispensed medicines per PE
(r = 0.236, p < 0.001). The number of pharmaceutical interventions per PE did not increase with the age
of the patients (r = −0.018, p = 0.687) or the work experience of the pharmacy staff (r = 0.032, p = 0.470).
3.3. Additional Activities
Of all PEs, 10 PEs resulted in a phone call with the physician, five in a referral to the physician,
one PE in a consultation in a separate room, and one PE in a refusal of dispensing. The pharmacists
reconstituted seven suspensions, and offered three follow-ups. Non-pharmacological counselling
(e.g., balanced nutrition) was provided at 11 PEs (11 first, 0 refill, p < 0.001).
4. Discussion
This observation study allowed depicting the dispensing practice of prescribed medicines at the
counter of Swiss community pharmacies and analysing factors influencing counselling provision.
4.1. Counselling
Counselling was provided to 66.0% of the customers receiving prescribed medicines, which is
slightly more than in a previous observation study (57.3%) performed in Switzerland in 2010 [19].
A review of worldwide counselling practices on prescribed medicines reported counselling rates from
12% to 100%, when observational methods were used [17]. In this study, the customers were counselled
on up to 13 out of the 34 predefined counselling themes per PE. However, in real daily practice,
34 different themes cannot be counselled at one PE, as this would overload the patient. Staff members
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have to decide on priorities during the interaction with the patient. With refill prescriptions, additional
themes can be counselled at following visits. Written information in the form of an individualized
label to reinforce verbal communication was provided in 43% of the PEs.
A quarter of customers refused counselling and one-third of the customers did not receive any
counselling. The study design did not take into account the long-term relationship between the
pharmacy staff and the patient as a regular customer, with pre-existing counselling provided at a
prior PE, which could lead to PEs without observed counselling. This is in line with what was
observed previously: New customers received more counselling than regular customers. Nevertheless,
this study depicted how the patient received the counselling at the counter. The findings revealed
that pharmacists were involved in direct patient contact at the counter in only a quarter of all PEs.
Pharmacists’ activities, such as drug interaction-check and investigating medication history, have often
been done in the back office, and are neither visible, nor communicated to the customer. If pharmacy
staff were more transparent and better communicated their activities to the customer during dispensing,
this could improve trust and collaboration.
The themes of counselling were more product-centered (e.g., dose, administration) than
patient-centered (e.g., adherence, therapy benefit), similar to the findings of other studies [17,19,27].
Indeed, the counselling patterns of Figure 2 illustrate the gaps in patient-centered counselling.
Especially for patients refilling prescribed medicines, low counselling ratios were observed. Not
addressing the patient-centered counselling themes at refill might be interpreted as a missed
opportunity to improve patients’ adherence to their drug therapy. It is known that patients often stop
taking their newly prescribed medicines in the first months of therapy (medication non-persistence),
because of concerns (e.g., adverse effect) and lack of perceived need (e.g., poor understanding of
medicines/disease) [28,29]. To address adherence issues, remunerated cognitive pharmaceutical
services (e.g., ‘Polymedication check’, ‘Adherence fee’) were introduced in Switzerland since 2010 [14],
but during the observation, none of these services were performed.
Pharmacy staff–customer interactions have been observed before and the findings have been
similar internationally. Although countries and guidelines adopted pharmaceutical care as one
of the key roles for community pharmacist, they are reported to be delivered only in a limited
way [21,30–33]. Counselling rates are usually rather low, and the content is mostly about the
medication (product-centered) [16,17,19]. Patient-centered issues are seldom discussed in a pharmacy
staff-customer interaction and pharmaceutical care services are not provided to their full potential [32].
Our study confirms these results although in Switzerland, counselling about prescribed medicines and
certain pharmaceutical care services are remunerated by the health insurance. To our knowledge, this
is the first study observing the daily practice of dispensing prescribed medicines at the community
pharmacy under these conditions. Another possible barrier is the non-conformity of roles and
expectations between pharmacy staff and customers [34]. Educational interventions have shown
success in improving counselling by pharmacists [35].
4.1.1. Patient Involvement
This observational study showed that the pharmacy staff were the main initiators of discussion,
confirming the findings of another observational Dutch study, which videotaped their encounters [9].
A systematic review revealed a mainly passive role of the patient in conversations with healthcare
providers [36], even though guidelines encourage interactive communication [5]. This is in line with
this observational study; customers asked only a few questions, although these questions might give
the pharmacy staff the opportunity to tailor information on patients’ needs [4]. Lack of privacy at
the counter [37], lack of interest in pharmacy counselling [38–40], and patients’ underestimation of
pharmacists’ role in healthcare are possible reasons for patients’ barriers in asking questions [27,34,41].
Nevertheless, the patients’ initiative would be important, knowing that the outcome of a dialogue
depends on the person who initiates the discussion [42]. Indeed, in patient-centered care, the patient
always comes first, and their needs should drive the PE [43]. Therefore, the patient should be
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encouraged in PEs to be more active in the discussion. Furthermore, the findings revealed that
pharmacy staff sometimes offered counselling only by asking general closed questions (e.g., do you
know this medicine already?), limiting the counselling provision and the patient involvement, and
consequently not taking into account the patients’ needs. It has been shown that the counselling
provided to the patients does not fulfil their information needs [44]. A study exploring advice-giving
behavior in British community pharmacies reported that the counselling was mostly based on product
use, and that the customers wished information about the drug’s effectiveness, while the pharmacists
provided information on drug safety. The authors proposed a protocol to guide pharmacy staff,
including the customers’ perspective [27]. To meet patient needs, the pharmacists should better listen
to the patients’ problems and provide individualized counselling [45].
4.1.2. Factors Influencing Counselling Provision
Counselling was not equally provided, suggesting that pharmacy staff use different levels of
counselling at PEs. If extended counselling at each first and refill PE is not possible in daily practice,
pharmacy staff should target counselling for specific situations. However, it is important to notice that
each PE offers to the pharmacist an opportunity to interact with the patient and hence to detect DRPs
and patients’ concerns. The study findings highlight some factors influencing counselling provision at
the patient, prescription and provider level. These indicators could help in prioritizing prescriptions
needing in-depth counselling.
Patient level
• New customers were more likely to receive counselling from the pharmacy staff than regular
customers. The counselling patterns revealed that the pharmacy staff performed more likely an
anamnesis (medicine, diseases, and allergy) with the new customers, while the counselling
patterns of the other factors influencing counselling provision were comparable (Figure 2).
Similarly, to a review [17], the pharmacy staff mainly counselled on administration, dose and use.
• Customers who did not refuse counselling received more counselling. Refusing counselling did
not mean that the patient did not receive any counselling, but such refusal is known to be an
important barrier for the provision of counselling [19]. Lack of patient interest is a common
phenomenon during counselling in community pharmacy [38,39], up to 41–63% patients decline
a counselling offer [33,40], leading to low counselling ratios [40].
• Carers who filled a prescription for a patient received more information on the prescribed
medicines than the patients themselves. Possibly, the carer was not present at the consultation
with the prescriber and did not receive information on the patient’s drug therapy.
Prescription level
• Customers with a first prescription received more counselling than customers with a refill
prescription. In a first PE, it is important to ensure that the patient receives the knowledge
for using their medicines correctly [19]. Appropriate drug use is ensured by counselling on
therapy duration, dosage, and optimal timing of drug intake [46]. At refill PE, pharmacists could
suppose that patients with chronic medication were already informed about their use [47]. They
could also be regular customers needing less clarification. Previous studies showed that pharmacy
staff classified the communication with patients to be more difficult during refill PE than during
the first PE [48,49]. It has been shown that patients’ expectations towards counselling are different
in first and refill PEs. More interest by patients during a first PE may facilitate more extensive
counselling [40]. This is in line with the study findings: During the first PEs, patients showed
more interest in counselling than during refill PEs, as two thirds of the counselling refusals were
observed during refill PEs.
• Prescriptions that resulted in a pharmaceutical intervention required more counselling than
prescriptions without any intervention, because interventions imply to inform the patient about
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the DRP, and to involve him/her in solving it. Additionally, these prescriptions must involve the
pharmacist, who is known to give more counselling than other pharmacy staff member.
Provider level
• Pharmacists provided more counselling to customers than other pharmacy staff members. Other
studies reported this factor as well [19,47,50]. A reason could be that pharmacists have a larger
knowledge about drug therapy. Counselling should be driven by the patient and the prescription,
not by the randomly allocated pharmacy staff member.
Counselling quality can be improved by developing counselling skills through education
(e.g., role-play with standardized patients [51]), patient-centered communication (concordance of
provided care with patients’ preferences and needs) [52,53], the implementation of established guidelines
on Good Pharmacy Practice [3], and continuing evaluation with feedback (e.g., mystery shopper).
4.2. Pharmaceutical Interventions
The study findings confirm that the community pharmacists were effective in detecting,
preventing, and solving DRPs [4,54]. By intervening during dispensing, pharmacists contributed
to the safe, appropriate, and cost-effective use of drugs. Individual judgement and professional
knowledge of the pharmacists and collaboration with the patient, carer, or prescriber was needed
to respond satisfactorily to the patient needs. The rate of pharmaceutical interventions (25.9%) was
comparable to a German study describing DRPs at time of dispensing prescribed medicines, which
reported an intervention rate of 18.0% [54].
4.3. Additional Activities
Pharmacy staff proposed only a few additional activities during PE, missing the opportunity to
offer additional care and ensure continuity of care and optimize patient therapy and health outcomes.
Notably, each refill prescription is an opportunity for the pharmacists to offer follow-up and further
cognitive pharmaceutical services. Although such services are remunerated in Switzerland [14], none
of the pharmacists proposed a medication review (e.g., ‘polymedication check’) or an adherence
aid (e.g., ‘adherence fee’) to the customer during the observation time of 18 days. However, they
often performed ‘generic substitution’ for newly prescribed medicines. This limited practice of
pharmaceutical care in community pharmacies confirms the results of previous findings [33,50,55] and
indicates that the implementation of these cognitive pharmaceutical services is still challenging.
4.4. Strengths and Limitations
The approach of the study to describe the dispensing practice of prescribed medicines at the
counter was a non-participant observation, which is a useful way to study the quality of services
and consistency of care [56]. The full pattern of the real-life situation, with all of the activities and
interventions triggered by a prescription at the time of dispensing could be described, which forms a
basis to improve these processes. In general, observations allow the description of customers’ behavior
and practice in real daily life [57], avoiding consequently the biases of self-report methods [46].
The observation method used in this study was based on ad-hoc note-taking of exchanged information
and subsequent transcribing into quantitative information. This demonstrated that observation is
a feasible method to provide valuable insight into pharmacies’ activities. The documentation of
the observed PEs has been tested for consistency and plausibility. The data was collected in 18
randomly selected pharmacies; however, the study was restricted to one region in Switzerland.
The principal limitation was the presence of an observer, which could positively influence the
counselling performance of the pharmacy staff by triggering them to be more aware of their way of
approaching customers (the Hawthorne effect) [58]. To minimize this effect, the observer became
accustomed to the pharmacy staff prior data collection to make them feel comfortable. Moreover,
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the observation lasted a whole working day, which allowed observation of normal practice over time.
Simulated client methods, such as mystery shopping, could minimize observation bias, but present
limitations of their own. The extracted information corresponds to a small part (snapshot) of healthcare
practice only, and is therefore hard to generalize to other healthcare situations [59]. The observations
were not recorded and not reviewed by a second investigator, which might have limited the reliability
of the results.
5. Conclusions
The observation of the dispensing practice of prescribed medicines at community pharmacies
resulted in a picture about processes and activities triggered by a customer with a prescription in
an everyday practice setting. We identified factors influencing counselling provision at the patient,
prescription and provider level: Dispensing by the pharmacist, the customer with a first prescription,
customer with a prescription requiring a pharmaceutical intervention, carer filling the prescription
for a patient, new customer, and customer not refusing counselling. Counselling was not evenly
provided, indicating that pharmacy staff counsel different customers to different degrees. The themes
of counselling were more product-centered than patient-centered. With a more transparent practice
and patient-centered counselling, pharmacy staff could improve to address the patients’ needs on
medicines information. Pharmacists intervened frequently, however, only a few additional activities
and no further services (e.g., adherence support) were offered. Education of pharmacy staff should
focus more on patient-centered counselling and the customers should be informed about the role of
the pharmacist. Further research will analyze the pharmacists’ opinions gathered within this project.
Interventional studies could be used to investigate factors for enhancing pharmacy staff-customer
interactions overcoming known barriers.
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Abstract: Background: Studies suggest that the way pharmacy counselling takes place does not fully
support patients in obtaining optimal medicine use. To understand the basis of current challenges
in pharmacy counselling, we investigated which selected related cues, i.e., objects, sounds, or
circumstances in prescription encounters, patients, and pharmacy staff notice, and how they interpret
these cues. Pharmacy practice researchers’ cue orientation was also investigated to explore possible
differences to those of staff and patients. Methods: Twelve focus group interviews representing 5
community pharmacies (staff and patients) and 2 universities (researchers) were conducted during
2017–2018 in Denmark. A total of 20 patients, 22 pharmacy staff, and 6 pharmacy researchers
participated. A theoretical analysis based on cue orientation and social appraisal was conducted.
Results: Pharmacy staff, patients and researchers noticed different selected related cues in prescription
encounters. Staff particularly noticed ‘types of patients’. Patients were more divided and grouped
into three overall categories: ‘types of staff’, medical content, and the situation around the encounter.
Pharmacy researchers noticed multiple cues. Different emotions were integrated in the construction of
the cues. Conclusion: Differences in the cue orientation between all three groups were identified. The
identified types of cues and emotions can explain an underlying dissatisfaction with the encounters.
Patients lack, in particular, more personal contact. Staff need to consider these aspects to provide
relevant counselling.
Keywords: pharmacy communication; cue orientation; focus group interviews; Denmark
1. Introduction
Communication between pharmacy staff and patients at the pharmacy counter is important for
community pharmacies to fulfil their societal obligations of offering professional counselling to patients.
Medication counselling is a challenging process that should take the wishes and needs of the patient
into consideration, while at the same time performing quality dispensing and keeping waiting times to
a minimum.
Several aspects of medication counselling have been investigated, especially those regarding how
often staff provide information, what the information concerns, the duration of the encounters,
the quality of the counselling, and staff and patient characteristics with an influence on the
communication [1–8]. Studies suggest that the way pharmacy counselling takes place today does not
fully support patients in obtaining optimal medicine use. Identified problems include patient reliance
on doctors rather than pharmacy staff to provide relevant information [9], that staff do not activate
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patients in the encounters [10–13], and that patients do not always find information from the pharmacy
relevant [14]. However, the underlying reasons for the identified challenges remain unknown.
One important aspect in improving pharmacy counselling is to understand how counselling is
perceived by pharmacy staff and patients since the ways they approach and react to the encounters
are shaped by these perceptions. In any face-to-face encounter, there are, according to classic
communication theory, potentially many elements/cues i.e., objects, sounds, or circumstances to be
taken into consideration by participants in order for them to interpret what is taking place [15]. Cues
in a pharmacy could be the architecture, characteristics of the person at the counter, etc. Which cues
are selected for interpretation and how they are interpreted differ from preconceptions based on
cultural learning and personal experiences [15]. Hence, examining what cues pharmacy staff and
patients notice in pharmacy encounters, and which meanings and values they ascribe to them, will
help us understand their basic understanding of pharmacy encounters. The underlying perceptions of
pharmacy encounters could give valuable insight into why counselling challenges exist, especially in
the case of discrepancies between patients and staff.
One might assume that pharmacy practice researchers also develop certain perceptions of
pharmacy encounters that influence their research, both in terms of perspectives and interpretations. It
is important to find out what these are, especially since they may differ from those of both community
pharmacy staff and patients.
The aim of this study was, therefore, to investigate what cues in community pharmacy encounters
patients, staff and pharmacy practice researchers notice, and how they interpret these cues.
Due to identified differences in pharmacy patients’ interest in receiving over-the-counter versus
prescription counselling [14,16], the study was restricted to prescription encounters. This choice was
also made because prescription encounters, especially those involving refill prescriptions, appear to be
particularly challenging in terms of counselling [14,16].
2. Materials and Methods
To investigate pharmacy patients’, staffmembers’ and researchers’ cue orientation in prescription
encounters, focus group interviews were conducted. This method is ideal for stimulating discussion,
gaining insights and generating ideas of social issues under investigation [17].
2.1. Theoretical Framework
Only a small fraction of data from our surroundings is ever consciously perceived in any way
by an individual. Of this fraction, only a selected portion (cues) is in some sense chosen by the
individual. We further simplify the waves of incoming data by recording their contents into meaningful
‘summary codes’. The overall meaning we make of selected and usually related cues is influenced by
our ‘expectancy set’, which is described as: “One’s cultural belief system learned through socialization,
the sum of one’s experiences, and one’s currently salient roles” [15]. With regard to the selection of
incoming data, individuals tend to focus on cues that reinforce past or emerging interpretations [18].
In this study, the articulated focus of incoming data is defined as ‘selected related cues’ i.e., of all
the possible impressions in a pharmacy prescription encounter, what types of cues do the different
actors overall notice? The summary and interpretation of the ‘selected related cues’ i.e., which elements
do participants include in their description of ‘selected related cues’, are defined as ‘summary codes’.
Patients, pharmacy staff and researchers have individual knowledge and experiences but are expected
to share some cultural belief systems (in particular staff and researchers through education and
workplace socialization), which might create different patterns of cue orientation and summary codes
between the groups.
2.2. Design
To investigate selected related cues and summary codes, an exploratory study design was chosen
to cover participants’ untainted perceptions of and experiences with prescription encounters. The
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interview guide was thus kept short and open and consisted of only two major questions. The first
question was presented in three ways to stimulate as many reflections as possible:
- What types of encounters have you experienced at the pharmacy counter?
- What types of meetings have you experienced at the pharmacy counter?
- Which types of different (human) interactions have you experienced at the pharmacy counter?
The second question concerned participants’ opinions about the role of community pharmacies in
society, this was to explore if and how these views might influence the way participants react in the
pharmacy encounters.
To identify participants’ original cue orientation, they were first asked to write their immediate
thoughts about the first question for 5–10 minutes, and each participant was then asked to tell the
other participants about their notes. Participants then commented on each other’s remarks to generate
more reflections. By this design, both the individuals’ untainted cue orientation was identified along
with the benefit of the focus group participants discussing the cues with each other. By the end of the
interview, the second question was presented. Data collectors used probing questions when necessary.
The three types of interviewees were interviewed in separate focus groups to explore their perceptions
in depth. The interviews were recorded and transcribed verbatim.
2.3. Recruitment
Five community pharmacies in Denmark were approached for purposeful yet convenient sampling
ensuring heterogeneity between the pharmacies according to location (provincial/urban) and overall
socio-demographic background of inhabitants in the area. All agreed to participate. The pharmacies
were asked to recruit 4–6 staffmembers (both pharmacy technicians and pharmacists) and 4–6 patients
from the pharmacy for the interviews. Inclusion criteria for patients were adulthood, recipient of
prescription medicine and a variation in gender and age. Two groups of researchers from the University
of Copenhagen and from the University of Southern Denmark both engaged in pharmacy practice
research represented the views of pharmacy researchers.
The interviews took place at the five pharmacies and at the two universities. Four of the authors
(first, fifth, sixth and last author) conducted the interviews.
2.4. Analysis
Transcripts were read, and relevant citations were extracted and coded in NVivo12. Codes were
divided into whether the findings were from staff, patients or researchers. The codes and extracts were
theoretically interpreted according to the type of selected related cues (what items were mentioned when
participants were speaking of pharmacy encounters) and summary code (what different elements were
described by participants in relation to the selected related cues) [19]. All authors, individually, carried
out the initial stage of the analysis for three pharmacies (patient and staff focus groups). Selected
related cues and summary codes identified were then compared in consensus discussions. Based on
these discussions the first author undertook the analysis of the pharmacy researchers. This was as
three of the authors participated as interviewees in one university interview, and hence were not suited
for this.
Interviews at pharmacies (pharmacy staff and patients) were conducted in two more pharmacies
(by sixth and last author). Data saturation was then observed. The analysis indicated that emotions
were an integrated part of cue orientation and the development of summary codes, why (social)
appraisal theory was integrated into the analyses. Appraisal theory highlights how cognition and
emotions are interdependent in peoples’ appraisal and reactions to the events in which they take
part [20,21]. Hence, the same pharmacy meeting might arouse different feelings in staff and patients
and between different staff and patients based on their evaluation of what is going on in the situation.
Therefore, apart from registering selected related cues and summary codes as pure cognitive processes,
the analysis allowed the identification of emotional responses linked to the selected related cues and
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summary codes. Besides, it was registered whether an appraisal of a pharmacy meeting leading
to an emotional response appeared to be on an individual level or as a member of a social group,
i.e., pharmacy staff [21]. Two authors (first and third) carried out this supplementary analysis.
2.5. Ethics
Written information about the study was provided to patients and pharmacy staff at the time of
recruitment. Oral informed consent from all interviewees was further obtained at the beginning of the
interviews. The study was approved by the Danish Data Protection Agency (ref.no. 514-0310/19-3000).
The collected data were stored according to the EU rules of GDPR.
3. Results
Twelve focus group interviews were conducted during 2017 and 2018. Forty-eight persons
participated in the focus groups, including 20 patients, 22 pharmacy staffmembers and 6 pharmacy
researchers. Between 3 and 5 participants were included in each interview. Patient gender was equally
represented, but the majority of patients were over 50 years, whereas approximately 2/3 of the staff
participants were women and the majority were under 50 years of age. The majority of researchers
were women over 50 years of age. The interviews lasted between 55–95 minutes.
Quotes illustrating central elements of the identified ‘selected related cues’ and related ‘summary
codes’ are presented in Tables 1–3 for the three different groups.
3.1. Pharmacy Staff
3.1.1. Selected Related Cues
The predominant selected related cue noticed by staffwas the (type of) patient. Types of meetings
were mentioned by participants in especially one focus group. Further, many communication elements
were described, such as language barriers and power balance (please see Table 1).
Table 1. Examples of elements (transcript data) built into the summary codes of the selected related
cues noticed by pharmacy staff.
Selected Related Cues Elements in Summary Code
Type of patient
‘I have counseled those [ed. patients] who are open, that like to know more and who seek
insight into their own disease. That’s a good dialogue, I would say.’ (Pharmacy 1)
‘And then I have written a regular customer who is used to coming here and they are used
to us helping them and it is at our place that they look for advice and confirmation—and
we have to help them with all kind of things related to their treatment.’ (Pharmacy 1)
‘And then there are some who are a bit defiant who don’t want to listen because the doctor
knows best and we should not interfere . . . In those cases, I always try to plant a seed, so
perhaps they can think about it and then come back.’ (Pharmacy 2)
‘I experience that there is a bit of difference between customers, sometimes we have new
customers who are not well informed, who should have some counseling, in contrast to
people who have had it [ed. the medicine] for 20 years. There is a difference if they really
want to listen.’ (Pharmacy 4)
‘There is a big difference if you are speaking to a man or a woman because women like to
share and men don’t.’ (Pharmacy 4)
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Table 1. Cont.
Selected Related Cues Elements in Summary Code
Types of meetings
‘I think we have a lot of what I have called ‘the intimate meeting’, where the customer
opens up, where we get to talk about it, where we are allowed to get under their skin and
become intimate in our talk.’ (Pharmacy 3)
‘I have divided into a professional academic meeting where you are allowed to bring some
information to the customer which the customer was not aware of.’ (Pharmacy 3)
‘I have divided them into quick encounters without information. The customers knows
everything or they had the medicines for many years and think they know everything
about it . . . And then we have the in-depth encounters where you take into consideration
that the customer is a new user of the medicine and where the customer is interested in
receiving information.’ (Pharmacy 5)
Communication
elements
‘Cultures, high/ low status, habits of informing, those who know better, the busy ones, it all
have an influence on us in the interaction. It can be noise, a printer which is noisy, a
telephone that rings, somebody who wants you to answer the phone or who wants to ask
you something: ‘where can I find this product?’ There are so many things that influence
the encounter which makes it different for the customer.’ (Pharmacy 1)
‘And I have written the interactions in which the customer comes in with certain
expectations and then meets something else – and that can go both ways: ‘Thank you so
much’ or ‘Can’t we finish so I can get out of here?” (Pharmacy 2)
‘I agree that if you have a bad start of the encounter then it can influence the rest of the
meeting with this customer.’ (Pharmacy 3)
‘Person 2: Language barriers, I think we experience that with every second customer
Person 4: And it gives, as you said, impatient customers because if we have the language
barriers then it takes time.’ (Pharmacy 4)
3.1.2. Summary Codes
Various types of patients were described by staff, including positive patients with a general interest
in counselling and an interest in their own health, indifferent patients, busy patients, sensitive patients
needing discretion, insecure patients with many questions, and patients who sought information prior
to entering the pharmacy. The different types of patients were mainly perceived according to their
interest in receiving counselling from staff. This was often described as a personal trait of the patient
and, in fewer cases, as a consequence of other demographics, such as age, education, and language.
Pharmacy staff perceived that the type of patient impacted how the encounter developed. If
the patient was interested in a dialogue about medicines, the encounter often developed to address
the needs of the patient, whereas a meeting with a patient without interest would be rather short.
However, some participants in one pharmacy (pharmacy 2) described how they tried to develop the
patients’ interest in counselling by ‘planting seeds’.
A few staff participants, particularly in pharmacy 3, described different types of meetings that
differed according to the degree of empathy between the individuals, if the content was technical and
if staffmanaged to interest the patient in counselling. Short meetings (with no communication about
medicines) were mentioned in all pharmacies.
Several communication elements that were perceived to influence the meetings were described:
expectations, language barriers, a similar notion by both parties of what should take place, the power
balance, the importance of getting a good start to the encounter and staff feeling disturbed by phones.
A few staffmembers described how they themselves influenced the encounters. In these cases, the
way staff phrased their questions and their body language was perceived to influence the meetings,
but a few also added that it depended on whether they had a good day, whether they felt the topic
to be embarrassing and whether they were able to read the patient correctly. Variations were seen
between the focus groups in the different pharmacies in how many communication issues were
discussed, including if pharmacy staff’s own performance was perceived to influence the development
of the encounters.
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The emotions of staff linked to the described cues and summary codes were in many cases related
to the fact that staff felt dependant on the interest of the customer regarding whether or not they
could fulfil their perceived social role as medicine counsellors. Hence, different types of patients to a
large extent evoked the same types of feelings in staff. For example, those patients being interested in
counselling provoked positive emotions in staffwhereas those patients refusing counselling evoked
negative emotions in terms of disappointment.
3.2. Patients
3.2.1. Selected Related Cues
Patients were more varied than staff with regard to predominant selected related cues.
Approximately one-third of the patients noticed the type of staff they met at the pharmacy. Another
third noticed the content of the meeting. Finally, some patients emphasized the situation ‘around’ the
meetings, i.e., if it was a busy pharmacy day and if the requested medicine was in stock. Some patients
also described communication elements (please see Table 2).
Table 2. Examples of elements (transcript data) built into the summary codes of different selected
related cues noticed by patients.
Selected Related Cues Elements in Summary Code
Type of staff
‘Yes, then you get one of the staffwith whom you have special interaction.’ (Pharmacy 1)
‘I don’t mind [ed. getting information] but when I say: “Yes I’ve taken it for 25 years” they say:
“Yes, but you have to be aware of . . . ”—“But try to listen to what I’m telling you. I know it. I
discuss it with my doctor” and then they say: “Yes, yes but . . . ” and they keep on.’ (Pharmacy 1)
‘I just want more personal contact, something more personal than a conversation only about the
medicine or how expensive it is.’ (Pharmacy 5)
Content of meeting
‘They ask whether you have any questions regarding the medicine, if the medicine is new to you
or if you have any side effects, you would like to discuss.’ (Pharmacy 2)
‘I have experienced very professional encounters . . . It’s: “Do you know how to take it?” and the
dosage they focus on.’ (Pharmacy 4)
‘With regard to the counseling, I often feel that they advise you on how many tablets to take and
how often.’ (Pharmacy 5)
Situation around the
meeting
‘I think it’s quite nice to come to Copenhagen because they always have the products I need.’
(Pharmacy 3)
‘You could observe that there is some kind of stress from their (ed. the staff) side. I think some
times that if there is a long queue waiting then they perceive that it should be a bit quicker.’
(Pharmacy 4)
‘When they are very busy then they try to make it very short and concise – and then it’s out with
this guy and in with the next.’ (Pharmacy 5)
Communication
elements
‘I have lived in many different places and been a customer in many pharmacies. You sense if there
is a good spirit in the pharmacy. I haven’t yet sensed the spirit of the new owner down here.’
(Pharmacy 1)
‘Interviewer: have you ever experienced to be positively surprised?K3: Oh yes. It concerns all
aspects of life—also down here. Oh no not him and then it turns out well. And then it’s a good
experienceK2: basically it’s because your first judgment is wrong.’ (Pharmacy 1)
‘And it might be that there is another tone here in the counseling area after the new owner has
started . . . You feel it when you enter . . . .It has a positive influence on the staff.’ (Pharmacy 2)
‘I feel the quality can be different from pharmacy to pharmacy. It can be very different . . .
depending if you are in a big pharmacy or in a small branch and who is behind the counter.’
(Pharmacy 4)
3.2.2. Summary Codes
Patients who noticed staff discussed whether there was good personal chemistry between them
and staff and if they felt pharmacy staff listened to them. Some emphasized that having a personal
interaction with staffwas important. A few patients said they liked meetings where the two parties
had a laugh and did not necessarily talk about the medicine. A central element in the interpretation of
staffwas whether staffmembers were explaining too much and/or asking too many questions about
the medicine. This element was important because staff were perceived as sometimes overlooking that
the patient was not interested in the counselling, and staff thereby displayed a basic lack of interest
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in the patient. A few patients defended the routine of (over-) informing the patient since this was
perceived to be in the best interest of the patient and that staff were only fulfilling their healthcare role.
Other patients focused on the content of the encounter and how it proceeded. Examples of content
included how to take the medicine, correct dosage, possible adverse drug events, and drug-drug
interactions, and who initiated the discussion about the medicine.
Some communication elements influencing the meetings were also described; however, fewer than
by staff. The aspects mentioned were differences between pharmacies including how the pharmacy
owner influenced the atmosphere of the pharmacy also with regard to counselling. Patients who had
experienced management responsibilities themselves in their professional career seemed to notice this
aspect. A few patients described how they themselves influenced the meeting, for example, by being
too quick to judge (negatively) the staff.
Patient ascribed different emotions to pharmacy meetings with some being in general highly
content whereas others were more dissatisfied thereby clearly illustrating that patients bear different
meanings and emotional responses to the same type of events. There seemed to be a certain pattern
between emotions evoked by pharmacy encounters in relation to the cue orientation. Hence, patients
who were satisfied with the encounters appeared to focus on the content in their cue orientation,
whereas patients who were not always satisfied focused more on the staff ability to create a personal
meeting (or the situation around the encounter).
3.3. Pharmacy Researchers
3.3.1. Selected Related Cues
The pharmacy researchers described multiple selected related cues, i.e., more and different types
of cues than staff and patients. The selected related cues included content of the meetings, the
situation around the meeting, the length and outcome of meetings, the type of patient, and various
communication elements, for example, how the two parties were influencing each other (please see
Table 3).
Table 3. Examples of elements (transcript data) built into the summary codes of different selected
related cues noticed by pharmacy researchers.
Selected Related Cues Elements in Summary Code
Content
‘I have myself experienced what could be defined as generic substitution where we discuss





‘And then there are the problems when the doctor hasn’t sent the prescription and you [ed.
being the staff] talk a lot about that, problems with the doctor sending the wrong medicine.’
(University 1)
‘And the problems can be related to the people or due to IT-problems, it can be the
prescription-server, it can be something with the IT that doesn’t work, it can be
drug-shortages . . . ’ (Pharmacy 1)
‘And then there are very practical matters such as the customer complains because there
has been a mistake, or the customer can’t get the medicine due to drug shortages, the
customers finds the medicine expensive, the customer doesn’t speak Danish. So there are a
lot of meetings being event-dependent.’ (University 2)
Type of patient
‘And then I thought about some of the customers who are very worried about something or
that you received some new medicine or that you received a new diagnosis.’ (University 1)
‘There are many different kinds of meetings depending on what type of customer you have,
and that’s the way it should be.’ (University 2)
‘ . . . the customer is in a hurry, the customer doesn’t want to talk about something because
it’s a taboo, that the customer is emotionally affected . . . ’ (University 2)
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Table 3. Cont.





‘And then we have customers with misuse problems and the pharmacist knows this, and
then the customer thinks that the staffmember looks at him in a strange way and perhaps
the pharmacist does, but even so, the pharmacist doesn’t, you feel awkward as the
customer. But also, where the pharmacist doesn’t dare or care to make the effort because
it’s unpleasant.’ (Pharmacy 1)
‘I think in most cases that it is the customer who is a bit aggressive. They have been
waiting in the queue for a long time, they are aggressive, then you [ed. being the staff] turn
a bit aggressive because the other party, whoever that is, is influenced by it.’ (University 1)
’ . . . where the pharmacist or the pharmacy technician invites you for a talk about the
treatment or the drug counseling. Where the patient accepts – and other scenarios where
the pharmacist or the pharmacy technician invites for talk about drug advice where the
patient declines.’ (University 2)
‘There can be different parameters which have an influence such as age, language – is there
a language barrier which you often experience in the pharmacies and how it influences the
meeting.’ (Pharmacy 2)
3.3.2. Summary Codes
The content of a meeting that was influenced by a specific situation was specifically described by
the researchers. Examples included an encounter about the medicine being out of stock or discussions
about high prices, errors in the prescription, IT problems (electronic prescription not available), etc.
Hence, researchers, in contrast to staff and patients, gave specific examples of non-medical content
in the encounters. The researchers specifically made a distinction between whether the content was
about medicine or not, and noted if the staff took the initiative during the meetings to discuss the
medicine, and how the patients responded. Further, they described elements such as the length and
occurrence of a problem, for example, whether the problem was solved and the satisfaction with the
encounter of the involved parties.
Different types of patients were also described by the researchers; for example, some patients
were perceived as asking many questions, but patients were also perceived as emotional, complaining,
affected by a psychological disease, and getting the medicine for the first time – aspects that in some way
influenced the encounters. Researchers also stressed the challenges around obtaining fruitful meetings
and gave examples of how the two parties influenced each other, for example, on an emotional level.
One example of this was how an unpleasant situation might arise because the two parties repeatedly
reacted towards the other person’s stress. The staff skills to cope with such situations were discussed.
Otherwise, the researchers did not distinguish between types of staff as much as between types of
patients. In general, as part of the construction of summary codes, the researchers explicitly described
emotional aspects as an integral part of prescription encounters as compared to staff and patients who
were influenced by emotions but did not describe this specifically.
Researchers were in general reluctant to describe what they perceived to be the optimal pharmacy
encounter hence were hesitant to display their own emotions towards pharmacy meetings. However,
some criticism or dissatisfaction of pharmacy staffwas shown with regard to them not always being
able to assess adequately the needs of the patient. Researchers appeared aligned in their deliberate
lack of emotional response to pharmacy encounters perhaps thinking that displaying emotions is not
an acceptable social role of a pharmacy researcher or that they are looking at the encounters from a
distance and are hence not personally involved.
4. Discussion
Many and different types of selected related cues in prescription encounters were described by
pharmacy staff, patients and researchers. The three groups noticed different cues. Staff particularly
noticed patients whereas patients were more divided and grouped into three overall cues, including
staff, medical content, and the situation around the encounter. Pharmacy researchers noticed multiple
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cues. Different elements including emotions were included in the construction of the cues. For example,
patients’ interest in talking about the medicine or not was a central element in staff’s perception of
‘types of patients’ and influenced their emotional response towards the encounters, whereas staff skills
to create a personal meeting were included in patients’ descriptions of and satisfaction with ‘types of
staff’. Pharmacy staff and pharmacy researchers’ emotional responses involved in their perception of
pharmacy encounters were more univocal than those of patients.
4.1. Differences in Cue Orientation between Patients and Staff
Considerable difference as described above was found in the selected related cues noticed by
staff and patients and the meaning (summary codes) they ascribe to them. To our knowledge, this
is the first study to focus on cue and cue differentiation between community pharmacy staff and
patients; however, other researchers have previously identified differences between staff and patients,
for example, with regard to preferences of the roles of the community pharmacist [22,23]. In these
studies, staffmore than patients was shown to think that they should be involved in detecting and
solving patients’ drug-related problems. Such results were partly observed in our study, in particular,
in relation to some patients feeling content by having a casual talk rather than a talk about medicines;
in contrast to staffwho focused on whether a patient was interested in a dialogue about medicine or
not. Hence, staff and (some) patients do not agree on the items they appreciate being discussed in
prescription encounters. Yet patients in this study appeared to differ in this view as we also identified
a group of patients who were satisfied with staff asking questions about their use of medicines.
That staff primarily focused on types of patients and how they influenced the encounter, which
might be explained by staff aiming at fulfilling their perceived social role as medical counsellors. Hence,
pharmacists in many countries base their counselling on the individual patients, and trying to ‘read’
the patient is perceived as an integral part of good communication skills [24].
A reason for the identified differences in cue orientation between patients and staff could be
that when relationships do not work optimally the involved parties focus more on the underlying
relationship than the content [15]. In fact, the predominant type of cue of the majority of staff and
some patients pertained to the relationship i.e., a focus on the opposite person and how this person
influenced the meeting. In supplement, the patients who appeared satisfied with the counter meetings
focused primarily on the content. This result thus indicates that both patients and staff are dissatisfied
with prescription counselling today, yet for different reasons. Hence, the dissatisfaction is shown by
the aspects/cues they notice around pharmacy encounters and the meaning built into them. Assa-Eley
at al. (2005) noted the fact that disagreement between patients and staff of what ought to take place
during the encounters often goes unrecognized [23], which might explain why unsatisfactory practices
are being repeated.
4.2. Differences in Cue Orientation between Patients
We observed two overall types of patients: those who focused on the type of staff and those who
focused on content of the dialogue. A few patients noticed the situation around the encounter.
Renberg et al. (2011) investigated how patients differed according to their ideal prescription
pharmacy encounter and found two overall groups: those who focused on the ‘drug product’ and those
who focused on ‘personal support’ from staff [25]. Each overall group consisted of sub-groups/factors.
For example, ‘personal support’ included both the sub-group IV emphasizing a competent pharmacist
who should offer individual advice since the patient usually does not like to make health decisions
alone, as well as sub-group V emphasizing privacy and personal contact as some patients are not fond
of a traditional professional-client relationship [25].
When comparing our results to those of Renberg, the two predominant patient groups in this
study both pertain to the ‘personal support’ group but in different ways representing both sub-group
IV and V. Hence, in contrast to the study of Renberg, only a few of the patients in this study described
the pharmacy as a place that is only relevant for them in order to pick up medicine. However, this
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type of patient was described by staff in our study, which might have to do with how patients were
recruited and the willingness of patients to participate. The study by Renberg was conducted using
Q-methodology with a more overall perspective on pharmacy practice. Also, the study was conducted
in 2008 (in Sweden), which might explain some of the differences. Further, community pharmacies
worldwide have, for the last decade, attempted to embrace an expanded role in patient-centred
counselling, which some patients may now have started noticing and appreciating.
4.3. Practice Implications
Researchers described many types of selected related cues compared to pharmacy patients and
staff, which might be considered both appropriate and explainable considering the complexity of the
field [26]. Hence, researchers in the field of pharmacy communication seem to be open to studying
many different elements related to pharmacy encounters. However, for future pharmacy practice
research aiming to improve counselling, researchers and educators should consider paying special
attention to the issues of importance to staff and patients.
Another important aspect relates to the staff’s focus on the types of patients, i.e., the majority
of staff seem to perceive that the way the encounter develops is influenced by the type of patient
and not by themselves. This perception affected staff emotionally. Rather than trying to change the
situation many staff members appeared to accept it. Appraisal theory points to the phenomenon
of applying relevant adaptive emotions, i.e., a situation where emotions are selected based on the
individual’s evaluation of the situation comparing the capabilities and resources of the individual with
the requirements of the situation [20]. Hence, on one side disappointment as the emotional response to
lack of patient interest in pharmacy counselling is relevant in the sense that it conserves resources in a
situation that cannot be changed. However, this emotional response is at the same time unfortunate
since staff then prevents themselves from trying to develop the encounters further. Hence, being
aware of emotional responses in relation to pharmacy encounters might be one way of furthering
communication at the counter for pharmacy staff.
An indication of lack of satisfaction with prescription encounters of both patients and staffwas
identified. Patients, through their descriptions of prescription encounters, displayed the aspects
they appreciate and often lack in the encounters, in particular, more personal contact. As most staff
participants didn’t describe this aspect, a particular attention by staff in this area is warranted to
improve counselling.
4.4. Limitations
The results of this study might be influenced by selection bias. Contact persons in the five
pharmacies responsible for recruiting staff and patients might have (subconsciously) selected certain
kinds of participants, for example, those who are more in favour of pharmacy counselling. Social
desirability might also have played a role as the interviews with patients and staff took place in the
pharmacy. However, a group of patients who were not overly satisfied with pharmacy encounters was
also included in the sample.
Some of the discrepancies between staff and patients with regard to cue orientation might be
explained by the fact that the majority of patients were older than 50 years, whereas the majority of
staff were younger than 50 years. As cues and summary codes are influenced by both individual and
collective experiences, age is expected to play a role in forming expectations.
The enrolled researchers reflected on different kinds of experiences when contemplating pharmacy
encounters. Some of the researchers reflected on experiences as former community pharmacists, and
others reflected on their experiences as patients or insights gained through their research. These
different approaches might explain why researchers were particularly varied in their cue orientation.
That researchers noticed more selected related cues than staff and patients also illustrates how selective
the last two groups are in their cue orientation and, thus, how the theoretical approach of cue orientation
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is useful in investigating differences in cognitive (and emotional) elements constituted in underlying
perceptions of pharmacy encounters.
The perceptions and views of pharmacy encounters described by interviewees do not necessarily
reflect how the pharmacy counter meetings take place. To verify how meetings actually occur,
observational studies are needed. However, identified cues and summary codes are important tools
when trying to understand why pharmacy encounters today are not perceived as satisfactory by all
involved parties. This knowledge might be used as a basis for community pharmacy staff to further
develop their communication skills.
5. Conclusions
Cue orientation, summary codes, and related emotions in pharmacy prescription encounters
differ considerably between community pharmacy staff, patients, and pharmacy practice researchers.
These differences could constitute some of the identified challenges in pharmacy counselling today.
For example, some patients noticed aspects around a personal encounter whereas staff appeared more
oriented towards discussing the patient’s medicine. A group of patients, however, was content with
the current counselling practices of staff.
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Abstract: Training student pharmacists to administer vaccinations requires a substantial investment
in vaccines, supplies, and time. Few schools of pharmacy seek out or receive any reimbursement
for the provision of vaccines, despite the fact it is a covered service. This study sought to
implement, deliver, and demonstrate an innovative, financially sustainable curriculum-based
immunization program by trained pharmacy students as part of their experiential learning.
Thirty-nine community health clinics targeting Medicare beneficiaries were conducted throughout
Northern/Central California during Medicare’s fall open enrollment periods between 2014–2016.
American Pharmacists Association (APhA)-trained student pharmacists (under licensed pharmacist
supervision) administered 1777 vaccinations. Vaccines were billed via a secure Health Insurance
Portability and Accountability Act of 1996 (HIPAA)-compliant web-based portal. The total net income
was $11,905 and $8032 for 2015 and 2016, respectively. Return on investment was greatest for the
influenza vaccine > Tdap > pneumococcal. Pharmacy students are already being trained to provide
immunizations and can utilize their skills to deliver financially viable public health programs.
Keywords: immunization programs; mobile health units; experiential learning; billing; healthy
people 2020
1. Introduction
Vaccinations are a well-known, cost-effective, way to reduce morbidity and mortality. For each
group of individuals born in the same year (birth cohort) that is properly vaccinated, the following
could be prevented; 14 million cases of disease, 33,000 deaths, and almost $10 billion in direct health
care costs. However, approximately 42,000 adults in the United States still die from vaccine-preventable
diseases each year [1].
The Department of Health and Human Services initiated the Healthy People 2020 program with
the intent to promote the health of Americans by encouraging collaboration across communities,
empowering individuals, and measuring the impact of these interventions [1]. One notable goal is the
improvement of vaccination rates. Healthy People 2020 seeks a goal of at least 90% of adults 65 years
of age and older to be vaccinated against both influenza and pneumococcal disease [1]. In 2014, data
released by the Centers for Disease Control and Prevention (CDC) showed that approximately 70%
of seniors 65 years old and over were vaccinated against influenza and approximately 61% against
pneumococcal [2].
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Inadequate vaccination rates could be a result of multiple factors, including a lack of perceived
value, insufficient information and education, fear or opposition to vaccines, cost, accessibility, and
operational or systemic barriers [3]. Despite the fact that Medicare is the primary insurance for most
seniors, 36% to 71% of general internists and family physicians reported a lack of knowledge of
Medicare vaccine coverage [4].
Lower adult vaccination rates may also be due to the lack of immunization programs that support
and promote adult vaccinations. Vaccines for Children (VFC), a federally funded program through
the CDC, provides discounted vaccines to agencies that then distribute them to doctors’ offices and
public health clinics. The VFC program has proven successful in improving childhood vaccination
rates. Further contributing to the disparity in vaccination rates between children and seniors is the
fact that many older patients may be unaware of the importance of indicated vaccines, a pattern first
observed during adulthood [3]. The lack of proper education on immunizations remains an issue.
Studies that examined attitudes toward the influenza vaccine found that the main concern among
those eschewing the vaccine was the belief they would get influenza from the vaccination or experience
adverse effects [5]. Barriers to vaccination uptake among patients 65 years and older include a lack
of awareness of the need to get vaccinated and the perceived belief that they were unlikely to catch
“the flu” [5]. Interestingly, greater than half of unvaccinated patients studied did not know that the
entire cost of the influenza vaccine was a covered Medicare benefit [5]. Increased understanding of
this benefit should encourage greater uptake of the influenza vaccine by older patients. The study also
found that patients who were recommended immunizations by a healthcare professional were more
likely to be vaccinated. Immunization rates can be increased due to pharmacists’ easy accessibility and
their ability to dispel vaccine safety concerns and explain the risks of being unvaccinated. [5].
Expanding the provision of vaccines into non-traditional settings, such as worksites and
pharmacies, has been proven to be a cost-effective way to improve adult vaccination rates. Prosser
reported that the mean cost of providing vaccines was 40%–60% lower in non-traditional settings
when compared to traditional settings, such as physician offices [6]. Moreover, it was found that the
cost of preventing an episode of influenza was $90 in a pharmacy setting (e.g., when a pharmacist
provides the vaccine), $210 in a mass vaccination setting, and $870 in traditional settings. Providing
vaccines in non-traditional settings helps increase patient convenience, improves vaccination coverage
rates, and is cost-effective [6].
Since pharmacists can play a major part in increasing community vaccination rates, student
pharmacist training is crucial to preparing tomorrow’s pharmacists to take up this vital public health
role. As of June 2017, 67/135 schools of pharmacy throughout the United States are certified to provide
the American Pharmacists Association’s (APhA’s) Pharmacy-Based Immunization Delivery program to
their students [7]. The APhA’s Pharmacy-Based Immunization Delivery Program is a national training
certificate program employed to educate pharmacists on how to become vaccination providers [7].
After completion of this training, and subject to their state’s scope of practice laws, student pharmacists
are able to provide vaccinations to patients. Previous research by Turner and colleagues has shown that
the provision of vaccines by student pharmacists during introductory pharmacy practice experiences
can enhance students’ vaccine knowledge and increase students’ self-confidence in the administration
of vaccines [8]. Chou and colleagues showed that student pharmacist consultation can improve patient
perceptions and attitudes towards receiving vaccinations, further increasing adult vaccination uptake
and changing the public’s view of the pharmacist’s role in preventive health [9]. The provision of
vaccines by student pharmacists also helps schools of pharmacy satisfy accreditation standards for
disease prevention promotion set by the Center for the Advancement of Pharmacy Education [10].
While the majority of pharmacy schools across the county have pharmacy students provide
vaccinations to the community, few provide vaccines other than influenza, and even fewer bill for
provided vaccines. A previous study at The University of Oklahoma College of Pharmacy described
the integration of introductory and advanced pharmacy practice experiences within campus-based
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influenza clinics to provide vaccinations to faculty, staff, and their families [11]. They reported that
billing through their on-campus retail pharmacy generated a net income for their clinics [11].
Even though students from schools of pharmacy have been providing vaccinations for some time
now, little literature exists on the provision of any other vaccines besides influenza being provided
by student pharmacists. This may be due to the fact that the influenza vaccine is considerably less
expensive to provide than all other available vaccines, and thus more financially feasible given limited
school budgets.
This study details the creation and application of a curriculum-based, financially self-sustaining
pharmacy school program designed to increase vaccination rates in ambulatory Medicare beneficiaries
while providing an experiential learning environment.
2. Materials and Methods
During the fall Medicare open enrollment periods from 2014–2016, the University of the Pacific
School of Pharmacy & Health Sciences held thirty-nine Mobile Medicare Clinics in 10 different cities
throughout Northern/Central California. Beneficiaries at each clinic site were able to take advantage
of multiple health services/screenings, including: Medicare Part D plan reviews, Medication Therapy
Management (MTM), health screenings, and immunizations.
The following vaccines were available at each clinic location: influenza (TIV and/or QIV);
Pneumovax 23 (PPSV 23); Prevnar 13 (PCV13); and the tetanus, diphtheria, and pertussis vaccine
(Tdap). The influenza vaccine was both purchased by the School and also donated by multiple different
county public health departments. All other vaccines and supplies were purchased by the School.
During each MTM session, assisted beneficiaries were asked a series of questions so as to ascertain
their vaccination history. State vaccination registries and immunization providers were contacted
when patients were unsure of their vaccination history. To improve convenience, patients were able to
receive vaccinations at one of two locations at each clinic site: (1) a designated vaccination station or
(2) the table at which they were receiving the MTM intervention. Walk in patients not receiving MTM
services could also receive vaccinations.
Beneficiaries expressing interest in receiving any of the available vaccines provided personal
information (including their Medicare ID number) and were asked a series of standard APhA vaccine
screening questions, such as those relating to allergies, previous reactions to vaccines, pregnant or
could be pregnant, etc. All answers were reviewed by a licensed, immunization-certified pharmacist
and vaccine appropriateness was determined. School faculty and/or staff would verify beneficiary
eligibility and financial responsibility for Part B (influenza or pneumococcal vaccine) or Part D
(Tdap) vaccines using TransactRx, an internet-based billing and integrated claims processing platform.
TransactRx provides real-time patient eligibility and on-line billing and payment for all covered
Medicare Part B and D vaccines.
If the beneficiary was eligible for Part B billing of the influenza or pneumococcal vaccines,
there was no co-pay sharing. However, if the beneficiary was eligible for Part D billing of the
Tdap vaccine, the co-pay amount would be communicated to the patient and collected if they were
interested in receiving the vaccine. Co-pays were collected via cash, personal check, or credit card
using a University-approved PCI-compliant electronic payment system (CashNet). Vaccine doses
that could be successfully billed were drawn from the School’s purchased supply. The Public Health
influenza vaccine was used whenever an uninsured or unqualified beneficiary needed vaccination.
‘Vouchered vaccines’ were non-billable (e.g., Public Health donated vaccine, vaccines subsidized
through grant funds, or vaccines given away to the community) administered vaccines. Once vaccine
billing was initiated and an individual dose prepared, a certified student pharmacist administered the
vaccine under the supervision of a pharmacist preceptor and provided the beneficiary with necessary
paperwork (Vaccine Information Sheet (VIS) and proof of vaccination).
The number and type of vaccines provided at each mobile clinic were recorded. Return on
investment (ROI) was calculated as follows: ROI = [(Total revenue − Total Cost)/(Total Cost)] × 100.
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Along with ROI, net income was computed each season from TransactRx billing software reports.
Descriptive statistics (e.g., absolute frequency for types of vaccinations administered/billed and
average ROI for each vaccination type provided) were calculated and reported for these items.
Students received introductory pharmacy practice experiences (IPPE) credit as part of a required
health care outreach class that contributed approximately 8% of their total required hours. Vaccinations
were coordinated by a student group, Operation Immunization, and were responsible for bringing
supplies, set up, and other logistics necessary for a mobile health clinic. Additional students enrolled
in the outreach class signed up to participate in the vaccination or one of the other health screenings
being provided at the clinic. Students were not required to spend a specific amount of time per each
station, but were required to stay at the same station for which they signed up for the duration of
that event. Each event, on average, had two students from Operation Immunization and four to eight
students administering vaccines. Students participated in multiple health care outreach events to
acquire the required number of hours.
This study was approved by the University of the Pacific’s Institutional Review Board.
3. Results
A total of 4083 beneficiaries were served at our Mobile Medicare Clinics from 2014–2016. Senior
immunizations were a major part of the services provided. Overall, 1777 vaccines were administered
during the study time period. Table 1 identifies the type and number of vaccines administered and
billed at clinic sites from 2014–2016. As shown in Table 1, about two out of three of the vaccines
provided during the study period were for influenza. Of the 1777 administered vaccines, 1345 (75.7%)
were billed through TransactRx (Table 1); 832 (68.2%) influenza, 449 (99.6%) pneumococcal, and
64 (60.4%) Tdap. As shown in Table 1, 629 vaccines in 2014 were billed through an independent
partnering pharmacy as a proof of concept. In 2015 and 2016, 411 and 305 vaccines, respectively, were
billed directly using the TransactRx platform. A total of 432 vouchered vaccines were provided during
the study period; 388 (89.8%) of which were for influenza. Figure 1 highlights the ROI for each provided
vaccine in 2015 and 2016. The ROI was greatest for the influenza vaccine > Tdap > pneumococcal.
The total net income was $11,905 and $8032 for 2015 and 2016, respectively (data not shown).
Table 1. Number and Types of Vaccines Administered and Billed at Clinic Sites from 2014–2016.
Vaccination Type










administered 436 397 387 1220
billed 436 214 182 832
Pneumococcal
administered 138 191 122 451
billed 138 191 120 449
Tdap
administered 55 35 16 106
billed 55 6 3 64
Total
administered 629 623 525 1777
billed 629 411 305 1345
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Figure 1. Return on Investment for Each Vaccine from 2015–2016.
4. Discussion
The present study describes a new, fiscally self-sustainable vaccination program in which trained
student pharmacists provided vaccinations to Medicare beneficiaries in community settings as part
of their IPPE. Our study describes a program that utilizes a live-claim processing platform (e.g.,
TransactRx) for vaccines at community-based health clinics that can: (1) provide students with practical
experience of immunization administration, coverage, and billing; (2) help increase vaccination rates
of older adults and other Medicare beneficiaries; and (3) generate income for the provision of such
services by a school of pharmacy. The above criteria set up a true “win-win-win” proposition for the
target population, pharmacy students, and the school of pharmacy.
During the fall of 2015 and 2016, successful Medicare vaccine billing generated a total net income
of $19,937 for our School of Pharmacy. The generation of this net income was the first step in building
an effective community outreach program in which students delivered essential and needed services
in a budget-neutral way for our School. Profits from the program are used to purchase vaccines and
supplies for the next season. The vaccine billing model discussed here can be duplicated at other
schools of pharmacy throughout the country, with the ability to increase the types and numbers of
vaccines that students can provide to their communities.
While the majority of pharmacy schools across the county have pharmacy students providing
vaccinations to the community, few provide vaccines other than influenza, and even fewer bill
for provided vaccines. Our study adds to the current literature in that it describes the structure,
implementation, billing, and benefit of vaccination services in a mobile, community-based setting.
Utilization of a web-based claims processing platform (e.g., TransactRx) allows vaccine administration
and billing in areas outside of a traditional school/university’s campus or clinic. Using an on-line
claims billing service also allows patient eligibility to be checked and billed in real-time, virtually
eliminating billing denials and potential loss of revenue. Furthermore, implementation of such a
system can be used by any school of pharmacy across the country, regardless of whether they have an
on-site medical center or pharmacy.
Program models such as ours present schools of pharmacy a means to help fulfill the various
requirements of accrediting bodies and national objectives for improving public health. In 2011,
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the American Association of Colleges of Pharmacy, encouraged by the Healthy People 2020 curriculum
task force, instituted a new requirement in which core public health concepts were to be integrated into
every pharmacy school curricula (objective ECBP-17) [12]. Additionally, our program model also helps
to satisfy the Healthy People 2020’s Immunization and Infectious Diseases objective of increasing the
vaccination rates of adults 65 years of age and older (Objectives IID-12.7 and IID-13.1) [13].
The return on investment for the three vaccines we provided varied according to the type of
vaccine administered. The influenza vaccine was the highest, with about a 200% ROI. Of the three,
the influenza vaccine was the most inexpensive and had the highest margin. The influenza vaccine is
indicated to be administered annually and can be a continuous source of revenue for a school-based
immunization clinic. The other vaccines, pneumococcal and Tdap, had a lower ROI and are only
administered as a one-time dose or as a booster. The number of these vaccines declined notably after
the initial year because many of our clinics are held at the same locations and draw many of the same
patients every year. These vaccines did not function as a major source of revenue, but their availability
was essential to providing comprehensive vaccination services to an ambulatory Medicare population
with a vaccination rate below the goals of Healthy People 2020.
Some limitations of our study were that students at the time were not specifically trained to
counter vaccine hesitancy from patients and that cost/coverage was a main factor impacting patients’
acceptance of vaccination. Preparing students to better address vaccine myths and misinformation
could further improve vaccination rates and acceptance. Learning modules on vaccine hesitancy have
been developed and incorporated into didactic classes and vaccine clinics and are currently being
evaluated for their effectiveness. Another limitation is that the implementation of our program by other
schools will require a contract with Medicare to bill for Medicare covered services. The associated
application paperwork and administrative constraints can be lengthy, cumbersome, and require
considerable time for approval.
5. Conclusions
Vaccination billing through a web-based transaction platform provides schools of pharmacy with
a net income to boost the availability and variety of vaccinations administered by student pharmacists.
This incentivized and replicable vaccine billing model can be implemented by any school of pharmacy,
creating an economically sustainable, community-based vaccination program that provides students
with experiential training and addresses suboptimal vaccination rates of older adults and other
Medicare beneficiaries.
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Abstract: Human papillomavirus (HPV) vaccination coverage could be enhanced by community
pharmacies working with medical clinics to coordinate completion of the HPV vaccination series.
The objective for this study was to assess the feasibility of a coordinated model of HPV vaccine
delivery in which a clinic gives the first dose and refers patients to a partnering community pharmacy
to receive subsequent doses. A medical clinic-community pharmacy team was established in a
Midwestern state to develop and operate a coordinated care model for HPV vaccinations. Under the
coordinated model, the clinic identified patients needing HPV vaccination(s), administered the first
dose and described the option to complete the vaccination series at the pharmacy. Interested patients
then had an information sheet faxed and electronic prescriptions sent to the pharmacy. The pharmacy
contacted the patients to schedule administration of 2nd and 3rd doses of the HPV vaccine. Over a
12-month period, 51 patients were referred to the pharmacy by the clinic. Of these, 23 patients
received a total of 25 vaccinations. Clinic and pharmacy personnel mostly rated the coordinated
program favorably. An initial study of a coordinated HPV vaccination program between a medical
clinic and a community pharmacy supported patients getting HPV vaccinations.
Keywords: human papilloma virus; HPV vaccination; pharmacy; coordinated care
1. Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection, with 14 million
infections occurring in women and men in the United States (U.S.) annually [1]. HPV is responsible
for approximately 33,700 cases of cancer each year, including virtually all cases of cervical cancer [2].
The infection is most common among young adults in their early teens through late twenties, in which
it is transmitted sexually through contact with an infected person. The FDA approved the first vaccine
for HPV in 2006. The HPV vaccine is recommended for adolescents beginning at 11 years of age,
and consists of two doses administered over a course of six to twelve months, or three doses for those
ages 15 and over [3]. In the four years following the recommendation, HPV infections in teenage girls
decreased by 56% [4]. Despite the efficacy and safety of the vaccine, HPV vaccination rates have been
substandard. In 2017, only 48.6% of teens reported HPV vaccination series completed, showing HPV
vaccination rates are well below the Healthy People 2020 national goal of 80% [5].
Innovative strategies should be considered in order to improve the vaccination rates among at-risk
populations. In some countries, school-based approaches to delivering HPV vaccinations have been
successful [6,7]. However, due to limited availability and concerns about payment, such school-based
solutions are a challenge in the U.S. Pharmacists are healthcare professionals in a unique position to
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improve vaccine access and provide convenient administration of vaccines to patients, including the
HPV vaccine. The National Vaccine Advisory Committee recommended using pharmacies to raise
patient access to HPV vaccines [8]. Pharmacist involvement in vaccinations varies globally, with some
countries allowing pharmacists to administer vaccines. These countries include Argentina, Australia,
Philippines, South Africa, the UK and USA. These countries most commonly allow pharmacists to
administer influenza vaccines, though other vaccines are allowed. In the US, pharmacists typically
can administer influenza vaccines and other adult vaccines (e.g., for pneumococcus, or shingles) and
travel vaccines. Much less common is ability of pharmacists to administer the “childhood vaccines” [9].
Pharmacists have historically offered several immunizations (e.g., influenza and pneumococcal) in
the community setting and continually demonstrate their contribution to improved vaccination rates.
A recent study assessed a 10 year span and compared vaccination rates between states that permitted
pharmacy vaccination services and those that did not. The investigators found a significant increase in
influenza vaccination rates among the states permitting pharmacist vaccinations [10]. Community
pharmacies have collaborated with clinics to increase influenza vaccination rates [11]. Though such a
coordinated model could be effective for raising HPV vaccination rates, no descriptions of this approach
have been reported. It could be helpful to tap the potential of community pharmacists working in
coordination with a clinic to address HPV vaccine series completion rates. The objective for this study
was to assess the feasibility of a coordinated model of HPV vaccine delivery in which a clinic gives the
first dose and refers patients to a partnering community pharmacy to receive subsequent doses.
2. Materials and Methods
This study recruited one primary care medical clinic and one community pharmacy to develop
and evaluate a coordinated HPV vaccination program. To recruit a clinic-community pharmacy team,
based on an author’s experience (W.R.D.) several progressive community pharmacies were approached,
and interested pharmacists provided contact information for a clinician or clinic with which they
wished to partner with for HPV vaccine delivery. An independent pharmacy located in a micropolitan
area (population at least 10,000 but not more than 50,000) agreed to participate, along with a primary
care medical clinic. The pharmacy provided traditional dispensing services, immunizations, adherence
packaging services, medication management, and compounding services. The pharmacy employed
a total of five pharmacist full-time equivalents (FTEs), a community pharmacy resident, and five
technician FTEs. The two partners were located about two miles apart. The clinic is affiliated with a
university health system, and employs about 20 providers. Once a clinic-pharmacy team was identified,
the investigators contacted both providers and scheduled a 60 min face-to-face team building session
for the pharmacy-clinic team members, including providers, the clinic manager, other clinic staff and
pharmacy personnel. The team building session was facilitated by the research team, and consisted
of an explanation of the project objectives with team discussion of roles and responsibilities in a
coordinated HPV vaccination program.
In the USA, the credentialing of pharmacists to administer vaccinations varies by state. That is,
each state’s governing/licensing body for pharmacists sets the requirements for pharmacists to be able
to administer vaccines in that state. All 50 states have authorized pharmacists to administer vaccines
at some level. Three states did not allow pharmacists to administer HPV vaccines (in 2015). In Iowa,
the Board of Pharmacy allows pharmacists to administer HPV vaccines pursuant to a prescription order.
It requires that a licensed pharmacist must complete an approved program on vaccine administration
and complete training on basic life support for healthcare providers which includes hands-on training.
There are not specific requirements for pharmacies other than providing proper storage for vaccines.
Vaccinations typically are paid for by private insurance or through government program coverage,
such as Vaccines for Children or Medicare for older patients. The preferred workflow of the coordinated
program was determined by the clinic and pharmacy team members, including how patients would be
identified, communication with the patients and between providers, reporting of immunizations in the
state registry, and payment for the vaccinations. After the program was planned, practice changes and
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tools were made during a 4 month period, and then the coordinated program operated for a planned
12 month period. A brief online survey was used to collect feedback about the program from clinic
and pharmacy staff. The survey asked about overall performance of the coordinated approach using
a five-point scale (poor, fair, good, very good, excellent), challenges and benefits of the model using
checklists, and an open-ended question about suggested improvements to the coordinated model.
The Human Subjects Office at the University of Iowa approved this study.
The coordinated HPV vaccination program worked as follows. The clinic identified patients
in need of HPV vaccination during its established patient care processes for preventive care for
young patients. The first dose of the HPV series was administered within the participating clinic.
To incorporate the coordinated program, all patients then were offered a choice of receiving the
remainder of the HPV series vaccinations at the clinic or the pharmacy. For the patients who selected
the pharmacy, the clinic then used electronic order sets developed with their IT personnel for second
and third HPV vaccine doses and sent them to the participating pharmacy along with a patient
information sheet, which contained demographic and contact information. The pharmacy was then
responsible for working with the patient to schedule the remaining HPV vaccinations. During the
administration visit at the pharmacy, patients were offered educational materials available in English
and Spanish languages. The clinic and pharmacy served patients who spoke Spanish as their primary
language. The pharmacist recorded the vaccinations in the Iowa Immunization Registry Information
System (IRIS) and sent a clinical note in SOAP (Subjective, Objective, Assessment, Plan) format to the
clinic partner. The pharmacy submitted billing to private insurers or to the Vaccines for Children (VFC)
program for the doses administered there.
Prior to this study, the pharmacy had experience in administering vaccinations, including for
influenza, pneumococcus, herpes zoster, and others. The pharmacy staff participated in a provider
training session on the HPV vaccine provided by Merck. The patient education materials in English
and Spanish were obtained from the CDC and other sources. During the study period, the pharmacy
utilized a contact log to track communications with the patients, and used a texting service to remind
patients of scheduled vaccinations.
The primary outcome variable for the coordinated HPV vaccination program was the number of
HPV vaccinations delivered at the pharmacy. In addition, data were collected on the number of patients
referred to the pharmacy by the clinic and the number of patients receiving an HPV vaccination at the
pharmacy. Finally, changes in practice and tools developed for the program were collected from clinic
and pharmacy staff.
3. Results
Both practices made changes in their operations to be able to work together within the coordinated
HPV program. The clinic added electronic prescription order sets to be able to e-prescribe the second
and third doses of the HPV vaccine to the pharmacy. In addition, the clinic developed a patient
information sheet to fax to the pharmacy whenever they referred a patient for an HPV vaccine.
This information included patient name, date of birth, address, insurance coverage and numbers,
parent or guardian identification, and contact information. Finally, the clinic incorporated into their
workflow a discussion with eligible patients about the option of completing the HPV vaccination series
at the pharmacy. All providers participating at the clinic were physicians.
The pharmacy developed materials for patient communication, including a flyer about the HPV
vaccination service in English and in Spanish, as well as a script for pharmacists to use when calling
patients and/or their families about the HPV vaccination at the pharmacy. They also used “Oh Don’t
Forget” texting to send patients a reminder before a scheduled vaccination. The pharmacy already
routinely recorded vaccinations in Iowa’s Immunization Registry Information System (IRIS), and did
so with the HPV vaccinations. For communicating with the clinic, the pharmacy utilized a clinical
note template they already had in use that followed a SOAP format to inform the providers about
each HPV vaccination administered. They also sent to the clinic a quarterly summary of the patients
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receiving an HPV vaccination. This report listed the patients receiving an HPV vaccination during
that period, as well as the date of administration and the number of vaccine in the HPV series (e.g.,
2nd or 3rd). Other practice changes made by the pharmacy included establishing themselves as a
provider for the Vaccines for Children (VFC) program in Iowa, and developing a vaccination log to
track communications with patients. The Vaccines for Children is a federal program that pays for
vaccines for low income children.
During the 12 month study period, 51 patients were referred to the pharmacy by the clinic. Of these,
23 patients received a total of 25 vaccinations. All 23 patients completed their HPV series. Eighteen
(78.3%) of the patients were female, while the mean age was 13.4 years (SD = 1.4). The insurance
payments to the pharmacy were 13 (56.5%) commercial payers and 10 (43.5%) VFC. The other 28
patients either could not be reached by the pharmacy or declined to come to the pharmacy after
being contacted. Surveys were received from five people at the clinic (four physicians and the clinic
manager) and one from the pharmacy (pharmacist). Of the five respondents who rated the program’s
performance, two rated it as excellent, and one each as very good, fair and poor. Reported difficulties
in collaborating included having few interested patients, challenges with workflow, lack of staff time
and some language barriers with the patients. Reported benefits to the coordinated program were
that it made it easier for patients to complete the HPV vaccination series, increased opportunity for
pharmacists and improved communication between the providers and pharmacists. When asked
about changes to support such a team approach, having community pharmacist access to an electronic
health record was the most common suggestion.
4. Discussion
The coordinated delivery of the HPV vaccine using clinic-pharmacy partnerships is a promising
model for the improvement of HPV immunization rates through the use of alternative settings.
As reported by the participating providers, some patients appreciated the convenience of getting an
HPV vaccination at a pharmacy, which was open more hours than most clinics. This coordinated
model improved patient access to HPV vaccinations, similar to the enhanced access provided for other
vaccines, especially influenza. Previous work has shown that provider referrals are vital for pharmacies
seeking to administer vaccines [12]. The coordinated model builds in provider referrals from the
participating clinic. This study shows community pharmacies as a viable location for administration
of HPV vaccinations. Future research should be conducted to investigate how a coordinated model
could be implemented on a broader scale, perhaps involving a whole community instead of a single
clinic-pharmacy team.
Positive provider recommendations to patients are key in getting them to agree to receive
vaccinations, especially an HPV vaccine [13]. A strength of the coordinated program was that two
voices were used to inform and encourage parents and patients to complete the HPV vaccination series.
In addition to clinic personnel explaining the need for the HPV vaccine, a community pharmacist
also discussed the HPV vaccination series with the patients and parents/caretakers. Pharmacists have
been recognized as a trusted provider of medication and health information by patients [14], and can
serve in a public health role. In addition, most pharmacists have completed training in providing
immunizations, which supports their role in discussing HPV vaccinations with patients and/or their
parents [15]. Together, primary care providers and pharmacists can help overcome parental hesitancy
for HPV vaccinations [16]. This complementary communication can readily derive from a coordinated
care approach being followed by a clinic-pharmacy partnership.
Another facilitator of this coordinated HPV program was that the clinic and the pharmacy
exchanged patient information in a timely and usable manner. The patient information sheet sent by
the clinic to the pharmacy allowed the pharmacy to receive necessary patient information, and provided
successful patient hand-off communication [17]. The pharmacist was then able to contact the patient’s
caretaker to discuss and schedule the next dose of the HPV vaccine. Similarly, the clinical note sent by
the pharmacy to the clinic after vaccine administration let the clinic providers know that the patient
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had received another HPV vaccination. Another facilitator was the presence of HPV vaccination
champions in both the clinic and the pharmacy. These people, a registered nurse and a pharmacist,
helped assure that their respective organizations implemented the program and remained committed
to it during the 12 month follow-up period.
As reported by the FIP in 2016, four countries allowed pharmacists to administer HPV vaccinations:
Canada (some provinces), Portugal, the UK and USA [9]. It is hoped that the number of countries
giving pharmacists authority to administer HPV vaccines will increase as more experience is gained
with such services. A number of other countries allow pharmacists to administer influenza vaccines.
As flu shots become more expected at pharmacies, it could be that other vaccines will be added to
those that can be given by a pharmacist. Such changes likely would improve patient access to vaccines.
This study has several limitations. First is that only one clinic-community pharmacy team was
studied. This limits the variability in the practice characteristics involved with the coordinated care
model, including staff commitment, patient characteristics and community context. Having multiple
clinics and multiple pharmacies using a coordinated care model likely would uncover more obstacles
to be addressed in making the model work. This study showed that the coordinated care model
involving a clinic and community pharmacy can be successful. However, future research with multiple
clinic-pharmacy teams in a more rigorous design can address the limitation of just one team being
studied. Another limitation is that no patient feedback was collected about their experiences with the
coordinated care model. We do not know how satisfied they were with the vaccinations delivered at
the pharmacy. As community pharmacists deliver more HPV vaccinations, patient feedback could be
collected about their experiences with them.
5. Conclusions
An initial study of a coordinated HPV vaccination program between a medical clinic and a
community pharmacy supported patients getting HPV vaccinations. More research is needed to extend
and further test the effectiveness of this model.
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Abstract: Objectives: To determine the numbers of medication discrepancies and medication-related
problems (MRPs) identified and resolved when providing a transitions of care comprehensive
medication review (CMR) after hospital discharge within a community pharmacy; and to estimate the
cost-avoidance value of this service. Methods: Community pharmacists provided CMRs to covered
employees and dependents of a self-insured regional grocery store chain who were discharged from
the hospital. Data was collected prospectively over 4 months. Discrepancies were identified among
patients’ medication regimens by comparing the hospital discharge record, the pharmacy profile,
and what the patient reported taking. MRPs were categorized into ten categories, as defined by
the OutcomesMTM® Encounter Worksheet. Interventions were categorized using the severity scale
developed by OutcomesMTM®, a Cardinal Health company. Data were analyzed using descriptive
statistics and bivariate correlations. Results: Nineteen patients were enrolled in the program.
Pharmacists identified 34 MRPs and 81 medication discrepancies, 1.8 and 4.3 per patient, respectively.
The most common type of MRP was underuse of medication (70.6%). Significant positive correlations
were found between the number of scheduled prescription medications and the number of medications
with discrepancies (p ≤ 0.01; r = 0.825) and number of scheduled prescription medications and the
number of MRPs (p ≤ 0.01; r = 0.697). Most commonly, the severity levels associated with the MRPs
involved the prevention of physician office visits or addition of new prescription medications (n = 10
each); however, four emergency room visits and three hospitalizations were also avoided. The total
estimated cost avoidance was $92,143, or $4850 per patient. Extrapolated annual cost savings related
to this service would be $276,428. Conclusions: This transitions of care service was successful in
identifying and addressing MRPs and discrepancies for this patient population. By providing this
service, community pharmacists were able to prevent outcomes of various severities and to avoid
patient care costs.
Keywords: community pharmacy; medication therapy management; medication-related problems;
medication discrepancies; continuity of patient care; cost avoidance
1. Introduction
Medication errors resulted in an estimated 251,454 hospital deaths in 2013 [1]. It is estimated
that $17 to $29 billion is spent on preventable adverse events annually. In addition, up to 80% of
serious medical errors involve miscommunication among medical providers [2]. Given the high
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prevalence, morbidity, and cost of such errors, much attention has been drawn to discrepancies and
medication-related problems (MRPs) that occur during transitions of care, a time when patient care is
handed off among inpatient and outpatient providers.
Previous research has shown the value of pharmacist involvement in transitions of care. Inclusion
of a pharmacist has lowered rates of re-hospitalizations and emergency department visits, improved
patient satisfaction with care, and increased medication adherence [3,4]. Many hospitals and pharmacy
directors have also recognized the importance of involving pharmacists in transitions of care activities
for hospitalized patients [5].
Community pharmacists have aided in the transition process by calling patients within 2 to
7 days after discharge to reinforce the discharge plan, provide patient education, address any
medication-related issues, and review medications [6–9]. The extent to which pharmacists have been
involved has varied from a brief phone call to an extensive face-to-face visit with a pharmacist and
2-week follow-up [6–10]. For instance, in the study of TransitionRx, community pharmacists performed
face-to-face visits with patients admitted for congestive heart failure, chronic obstructive pulmonary
disease, and pneumonia [10]. These visits consisted of medication reconciliation, comprehensive
medication review (CMR), disease state education, patient counseling on new medications, and
self-management education. Patients were provided with a personal medication list (PML), medication
action plan (MAP), self-monitoring logs, and educational materials. Physicians were provided with
a summary of this face-to-face visit and any MRPs or discrepancies were resolved. There was a
readmission rate of 7% for patients who met with a pharmacist vs. 20% in the usual care group.
Kelling et al. described the implementation of medication therapy management (MTM)-based
transitions of care with a Medicaid population in a grocery store setting [11]. In the study, 17 Medicaid
patients met face-to-face with a pharmacist in either a supermarket chain pharmacy or a local federally
qualified health center. Patients were asked to bring all prescription and non-prescription medications
along with discharge paperwork. Pharmacists completed a medication reconciliation using the
discharge paperwork and resolved any MRPs or side effects via phone or fax. Patients were mailed a
PML and MAP. Reimbursement was provided through Medicaid, and additional payments for each
MRP were identified, resolved, and entered into the OutcomesMTM
®
Connect™ Platform. For these
17 patients, 50 pharmacologic recommendations and 36 behavior modification recommendations
were advised.
While these studies demonstrated that pharmacists could identify and resolve MRPs during
transitions of care, none provided an estimate of the cost avoidance of these interactions or examined
the severity of MRPs involved. Therefore, the objectives of this study were to determine the numbers of
medication discrepancies and MRPs identified and resolved when community pharmacists performed a
CMR for employees and dependents of a self-insured regional grocery store/pharmacy chain following
hospital discharge; and to associate each MRP with cost-avoidance to quantify the value of this service.
2. Service Description
Balls Food Stores (BFS) is a self-insured regional grocery store and pharmacy chain with
approximately 2600 covered lives under their health insurance plan. The company provides many
BFS pharmacist-led employee health programs and patient services, including one-on-one disease
state management visits for employees and dependents with uncontrolled hypertension, dyslipidemia,
diabetes mellitus, and history of myocardial infarction or stroke; tobacco cessation classes for employees
and dependents; immunizations including travel vaccine clinics; MTM services; and health screenings
are also conducted. BFS implemented a transitions of care service in the fall of 2013 to provide
transitions of care for covered employees and dependents. Three clinical pharmacists, employed by
BFS, performed this service.
Using information provided by BFS’ insurance plan administrator, pharmacists were able to
identify covered employees and dependents discharged from a hospital or long-term care facility.
Patients were eligible for this service if they were ≥18 years old, insured by BFS, and hospitalized
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for at least two consecutive days. Patients were not eligible for this service if hospitalized for
childbirth, suicidal attempts, or psychiatric conditions. Eligible patients were assigned to one of three
pharmacist providers who contacted these patients within 7 days of discharge to schedule a one-on-one
CMR. These providers were clinical pharmacists who had residency-training or were undergoing
residency training. Visits were completed as soon as the patient and pharmacist were available and
performed either in-person or via telephone. Pharmacists asked patients to provide discharge papers,
all prescription medications, over-the-counter products, herbal products, and supplements for the
CMR visit. If the patient did not have their discharge paperwork, the pharmacist requested a copy
from the medical records department of the discharging hospital. These visits were 30 to 60 min
long and were documented using a modified CMR worksheet and the OutcomesMTM
®
Encounter
Worksheet (see Supplementary Materials). Pharmacists compared the patient’s current medications
to the discharge orders and the active medications in the pharmacy dispensing profile. Pharmacists
were able to determine the number of MRPs detected and categorize them using the “drug therapy
problem detected” section of the OutcomesMTM
®
Encounter Worksheet. When an MRP was identified,
pharmacists took action to resolve it either directly with the patient or by communicating with the
patient’s health care provider.
Within 7 days of CMR completion, patients were mailed a PML, MAP, and cover letter with the
pharmacist’s hours of availability and contact information. Pharmacists completed documentation for
each MRP identified and followed up with each patient 1 week after mailing/delivering the medication
list to ensure that the patient received the letter and understood the action items required to resolve
the MRP.
3. Methods
For this research, data for all patients seen by this service from 1 December 2013 to 31 March
2014 were included for analysis. All MRPs and medication discrepancies were transcribed from the
patient care chart and recorded onto a master data collection sheet. Discrepancies were identified
by comparing the pharmacy dispensing profile, discharge paperwork, and patient interview. MRPs
were categorized into 10 categories, as defined by the OutcomesMTM
®
Encounter Worksheet and
discrepancies were assigned to one of three categories: Discrepancy between discharge instructions
and pharmacy medication profile, discrepancy between discharge instructions and patient self-report,
and discrepancy between pharmacy medication profile and patient self-report.
After completion of a premium subscription agreement and data use agreement with
OutcomesMTM
®
, encounters were entered into the OutcomesMTM
®
Connect™ Platform [12], and





administrative service company that allows pharmacists to bill for MTM services through their
electronic platform. This platform has been used primarily by community pharmacies to document
CMRs and targeted interventions (TIPs). OutcomesMTM
®
can also be used to identify cost savings
associated with pharmacist’s interventions to resolve therapy and adherence problems.
Each MRP was assigned a severity level and cost avoidance was assigned to each intervention
using the OutcomesMTM Actuarial Investment Model
®
[13]. All data were stored in accordance with
applicable federal privacy regulations. The methodology of OutcomesMTM
®
was used to document
severity level and cost savings associated with resolution of MRPs. MRPs included: Needs additional
drug therapy, unnecessary drug therapy, suboptimal drug, dose too low, adverse drug reaction,
drug interaction, dose too high, overuse of medication, underuse of medication, and inappropriate
administration or technique. Variables collected included patient demographics, types of discrepancies,
types of MRPs, severity levels, number of physicians per patient, and number of prescriptions. Data
were analyzed using descriptive statistics and bivariate correlations. A p value ≤ 0.05 was regarded as
statistically significant. This study was approved by the University of Missouri—Kansas City Adult
Health Sciences Institutional Review Board.
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4. Results
For the 4 months during which the transitions of care service was studied, 63 patients were
discharged from a hospital or intermediate care facility, and 40 met the inclusion criteria. Figure 1
represents the patients included and excluded from the service. Because of initial issues with reporting
from the insurance administrator, seven patients were not identified as eligible for this service until after
7 days post-discharge. These patients were not contacted for this service. Pharmacists attempted to
reach 13 patients three or more times regarding this service with no response; therefore, these patients
could not be included in the service. One eligible patient declined to participate. All 19 participating
patients received a CMR and either a complete or incomplete medication reconciliation. Sixteen
patients completed all aspects of the service (CMR, provision of discharge paper work, and medication
reconciliation). For three patients, pharmacists were unable to obtain discharge paperwork from the
hospital or the patient and thus had an incomplete medication reconciliation. For the 19 participating
patients, the majority were male (68%), and the mean age was 60 (range 46 to 70) years old. Patients took
an average of six (range 2 to 16) scheduled medications daily for their reported disease states (mean
4.4 range 1 to 16). Patients were hospitalized for a mean of 5 (range 2 to 12) days. This service was
primarily provided via phone versus face-to-face by request of the patient. Community pharmacists
identified and resolved 34 MRPs and 81 medication discrepancies after completing all aspects of
the service. On average, 4.3 discrepancies and 1.8 MRPs were identified per patient. The frequency
of MRPs is listed in Table 1. The most common type of MRP was underuse of medication (70.6%).
Medication discrepancies were similarly distributed among the three categories (31 discrepancies
between discharge paperwork and patient-self report, 25 discrepancies between discharge instructions
and pharmacy dispensing profile, and 25 discrepancies between pharmacy dispensing profile and
patient-self report), with a slightly higher percentage identified in the category of discrepancy between
discharge instructions and patient self-report.
 
Figure 1. Flowchart of patients included and excluded from the service.
Table 1. Types of medication-related problems (MRPs) identified during service.
MRP Frequency
Underuse of medication 24
Dose too low 2
Drug interaction 2
Dose too high 2
Inappropriate administration/technique 2
Needs additional drug therapy 1
Unnecessary drug therapy 1
Suboptimal drug 0
Adverse drug reaction 0
Overuse of medication 0
The two most commonly observed severity levels identified in the OutcomesMTM
®
platform
were “prevented physician visit” and “prevented additional prescription order”. Severity levels and
frequency for each MRP are listed in Table 2. In addition to interventions that prevented additional
prescription orders or physician visits, the pharmacists were able to prevent four emergency room
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visits and three hospital admissions. For example, during two medication reviews and consultations,
the pharmacists found that the patient was prescribed a phosphodiesterase inhibitor and nitroglycerin.
The pharmacist provided education to each of these patients about the risks of taking these medications
concurrently and was able to resolve this issue after consulting the patient’s primary care physician.
OutcomesMTM
®
staff determined that the pharmacist’s intervention in these visits prevented an
emergency room visit due to the risk for significant hypotension.
Table 2. Severity levels and frequencies (verified by OutcomesMTM
®
staff).
Severity Level Number of Events
Level 1: Adherence support 5
Level 2: Reduced drug costs 2
Level 3: Prevented a physician visit 10
Level 4: Prevented additional prescription order 10
Level 5: Prevented emergency room visit 4
Level 6: Prevented hospital admission 3
Level 7: Prevented a life-threatening situation 0
The OutcomesMTM Actuarial Investment Model
®
determined that the MRPs resolved by
pharmacists over the period of 4 months provided a total estimated cost avoidance of $92,143,
or $4850 per patient. If this rate of MRPs were to continue over a 12-month period, the annual cost
savings related to this service would have been $276,428.
There was a statistically significant positive correlation between the number of scheduled
prescription medications and the number of medications with discrepancies (p ≤ 0.01; r = 0.825); and
the number of scheduled prescription medications and the number of MRPs (p ≤ 0.01; r = 0.697)
(Table 3). In addition, statistically significant positive correlations were found between the following
variables: The number of scheduled medications and the number of disease states, the number of
medications with discrepancies and each of the following variables: Number of MRPs, inappropriate
adherence, needing an additional drug therapy, and the number of medications with each of the
following variables: Number of discrepancies, number of MRPs, and severity level determined by
OutcomesMTM
®
. There was a strong negative correlation between patients who had a medication
reconciliation completed in the hospital prior to discharge and the number of medications that were
found with discrepancies after discharge (p ≤ 0.01; r = −0.667).





Number of scheduled prescription medications 0.825 ** 0.697 **
Number of medications with discrepancies 1 0.701 **
Number of discrepancies between discharge paperwork and
pharmacy dispensing profile 0.854 ** 0.849 **
Number of discrepancies between discharge paperwork and
pharmacy dispensing profile 0.974 ** 0.610 *
Number of discrepancies between pharmacy dispensing
profile and patient reported medication list 0.422 0.531 *
Number of disease states 0.823 ** 0.7 **
Number of MRPs 0.701 ** 1
Medication reconciliation before discharge −0.667 ** −0.765 **
MRPs = medication-related problems. * Correlation is significant at the 0.05 level (2-tailed); ** Correlation is
significant at the 0.01 level (2-tailed).
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5. Discussion
BFS is a self-insured company that was interested to know whether this pilot program would
reduce costs associated with transitions of care for covered employees and dependents, and whether
this program should be continued. Previous research has shown positive benefits for transitions of care
services from the hospital setting, but limited research has been completed in the community setting.
Our study found a strong negative correlation between patients who received prior discharge
counseling in the hospital and the number of medications with discrepancies. This is consistent
with previous findings. For example, an urban, academic, safety-net hospital created a reengineered
discharge (RED) program that provided a package of services to decrease readmission rates [7]. This
program included six nurse discharge advocates (DA) and a clinical pharmacist. Nurse discharge
advocates were responsible for coordinating the discharge plan with the hospital team, creating an
after-hospital care plan (AHCP), and providing discharge counseling to patients using teach-back
methodology. The AHCP and discharge paperwork were faxed to the patient’s primary care physician.
Once a patient was discharged, a clinical pharmacist called the patient to reinforce the discharge plan,
review medications with the patient, and address MRPs. If MRPs were found, they were communicated
with the primary care provider or DA. Patients provided with this service had lower rates of hospital
utilization when compared with usual care.
Reported MRPs per patient ranged from 0.29 to 6.0 [9,11,14–17]. Our study found a similar number
of MRPs (1.8 per patient). By examining the medication discrepancies between the discharge orders,
the pharmacy profile, and the patient’s self-report of what they were actually taking, we discovered
many sources of potential MRPs. Discrepancies associated with the discharge orders involved use of
formulary medications in the same class as medications the patient had been using at home, incomplete
or different use instructions, changes in medication strength, missing medications, or continuation of
medications used inhouse that did not need to be continued on an outpatient basis. Discrepancies
associated with the pharmacy profile involved medications that had been discontinued during the
hospitalization that had not been communicated to the pharmacy, new medications that had been
started during the hospitalization for which the pharmacy had not yet received a prescription, and
changes in medication directions or strengths. Discrepancies associated with patient self-report
included not taking medications as directed, not starting new medications, not stopping discontinued
medications, and taking two medications from the same therapeutic class.
Although it is clear that community pharmacists are able to identify MRPs and discrepancies
post-discharge, the impact of this service has never been quantified in terms of cost avoidance. By using
the OutcomesMTM Actuarial Investment Model
®
, this pilot project demonstrates that the MRPs
resolved by pharmacists provided a total estimated cost avoidance of $92,142 for the 19 patients who
received this service, or $4850 per patient. Annualized, it is estimated that 57 BFS patients would be
seen, with an annual cost avoidance of $276,450. Based on this cost avoidance and the other findings
from this study, BFS has decided to continue this service for its own employees/dependents and to
expand this service to any BFS patient discharged from a local regional hospital in the Kansas City area.
Previous studies have identified several barriers to efficient transitions of care, including
communication between the hospital and the community pharmacist, identification of patients
discharged, contact with patients, lack of time to perform medication reconciliation, incomplete/missing
medication list, patient not present during consultation, patient use of multiple pharmacies, and
medication reconciliation with multiple providers. The barriers we discovered were lack of discharge
paperwork, lack of information about hospitalization (diagnoses), and inability to contact patients
who were recently discharged from the hospital. Our pharmacists tried to obtain discharge paperwork
either from the patient or requested it from the discharge hospital [6,11,16]. Many hospitals required
the completion of a consent form, and it was difficult to have the patient sign and return the form in a
timely manner. We also found that the insurance report for identifying patients who were discharged
from the hospital did not always include the most pertinent diagnosis. For example, if the patient was
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admitted to the hospital with pneumonia and had deep vein thrombosis while hospitalized, only the
admittance diagnosis would be listed on the report.
We utilized phone and face-to-face meetings at the pharmacy to complete this service. Although
the literature has shown that face-to-face interventions are more effective than those delivered via
phone [18], the majority of patients in this study preferred to complete this service via phone. The reason
for selecting this mode of service was not documented, but telehealth is shown to be a preferred
mode of communication for those who are unable to leave home [19]. To provide better quality care,
integration of telehealth services into a transitions of care program could be considered.
One limitation of this study was the relatively small sample size. We were able to provide this
service to about one half of potentially eligible patients. If this study was performed over a longer
period, we would have been able to enroll more patients and obtain a larger sample size. Because this
program is being continued, future research can include more patients. Another limitation is that there
were two patient outliers, one patient had 12 MRPs identified and resolved, eight of these MRPs were
due to adherence and an additional patient had nine MRPs, with eight resulting from non-adherence.
Both patients were on nine or more scheduled medications. The literature suggests a linear relationship
between the number of MRPs per patient and the number of medications that a patient is taking [20].
This relationship is seen not only in the hospital setting, but also in the ambulatory care and community
settings [21–23]. In addition, we did not collect data on whether physicians accepted recommendations
provided by the pharmacists, or how the pharmacists worked to resolve the MPRs. It would have
been meaningful to include data on how many recommendations made to physicians/providers by
pharmacists were actually implemented.
We chose residency trained pharmacists to provide this service. However, many other pharmacists
should be able to address MRPs and identify discrepancies as this is part of contemporary Doctor of
Pharmacy training.
Access to electronic health records would have allowed our pharmacists to address medication
discrepancies and MRPs in a timelier manner and may have allowed pharmacists to recognize other
MRPs that were not identified. This study shows that there is a need for health care providers
to work together to achieve positive health outcomes. Future research should focus on how
community pharmacists work with local health care systems to gain access to health records to
provide recommendations and counseling to patients.
6. Conclusions
Community pharmacists should be a part of the transitions of care team to help prevent medication
errors and discrepancies that can lead to increased health care spending. When provided with discharge
paperwork, community pharmacists are able to identify and resolve MRPs and discrepancies that
might not be recognized by health care providers in the hospital setting. Cost savings associated with
this service are sizable. Open communication of medical conditions and discharge paperwork between
health care providers is imperative in preventing rising health care costs associated with transitions
of care.
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Abstract: For years many pharmacists have been performing ‘brown bag’ medication reviews for
patients. While most pharmacists and student pharmacists are familiar with this process, it is
important to determine the value patients receive from this service. Over the course of this study the
authors attempted to modernize the medication reconciliation process and collect data on patient
prescription drug and over-the-counter drug use, along with quantifying the types of interventions
the pharmacy’s clinical staff performed for patients during this process. The pharmacy partnered
with a Quality Improvement Organization to trial their Blue Bag Intervention (BBI) program. The BBI
program offered several additional services to the traditional brown bag review. The BBI was instituted
as a follow-up tool in the pharmacy’s diabetes self-management education/training clinic to aid in
patient follow-up and help the clinical staff identify medication-related events such as medication
adherence issues and drug–drug interactions. The clinical staff identified approximately 2.2 events
per patient with over 50% being issues that affected patient safety.
Keywords: adverse drug events; brown bag; pharmacy; medication reconciliation; pharmacy
clinical services
1. Introduction
There are myriad potential clinical, humanistic, and pharmacoeconomic outcomes that a patient
may experience as a result of medication use. Healthcare practitioners utilize medications to improve
a patient’s medical condition(s); however, adverse events, ranging from minor adverse drug events
(ADEs) to patient death, may occur. Medication use, including both prescription and over-the-counter
(OTC) drugs, are common among older patients as well as those with complex and multiple medical
conditions. Polypharmacy, the concurrent use of multiple medications by the same patient at different
pharmacies, can place individuals at an increased risk for ADEs [1]. Building in a mechanism for
pharmacists to prevent and address these adverse events can lead to improved healthcare outcomes
while decreasing healthcare expenditure.
In a recent study of hospital discharges, patients who had discrepancies in their medication
reconciliation were twice as likely to experience a readmission within 30 days of discharge compared
to patients who had had an accurate medication reconciliation performed. In addition, a secondary
analysis of the data utilizing pharmacists’ medication reviews and patient interviews showed that 89%
of patients had at least one potential adverse drug event (pADE) [2]. Another study looked at the role of
incorporating a non-dispensing pharmacist into general practice. This study showed the impact that a
pharmacist-delivered medication reconciliation could have regarding tailored solutions for individual
patients, relieving interdisciplinary tensions of overlapping tasks, and the integration of more quality
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metrics into medication management [3]. Within a community pharmacy, pharmacists conducted
medication reviews to determine medication-related issues. However, this was not conducted in a
prospective way, such as by incorporating a patient interview with the medication review [4].
One successful strategy for reducing ADEs is to engage the patient in a comprehensive medication
review process with medication reconciliation, often referred to as a ‘brown bag’ medication review.
During a ‘brown bag’ medication review, patients will place all their medications, prescribed and taken
OTC, in a bag and bring them into a medical appointment with a healthcare professional.
Studies involving a ‘brown bag’ medication review have used various methodologies and designs
to determine patient medications, best practices, settings, outcomes, and effectiveness measures. Many
reviews included only prescription medications versus reviews that include additional OTC drugs,
vitamins, and herbal supplements. Another discrepancy arises from the fact that many reviews did not
define medication- or drug-related problems in the same manner [5].
It is estimated that 93% of the American population lives within 5 miles of a community pharmacy
and on average a patient will see their pharmacist 35 times a year [6]. This makes the pharmacist one
of the most accessible healthcare professionals available to the patient. Pharmacists, as a result of their
training, are in a unique position to help patients understand their medication regimen along with the
cause and effect between the medication(s) a patient takes and their intended or unintended effect(s).
The authors hypothesize that a structured, sustainable medication reconciliation program that
partners patients with a pharmacist with whom they have an established relationship and features
‘built-in’ medication safety measures will result in improved patient health outcomes. The aim of this
study was to define and classify medication therapy problems identified by a clinical pharmacist in
a community pharmacy setting. Moreover, the results may enable pharmacies to show the value of
their involvement to third-party insurance payers in order to justify expanding the role of pharmacist
billable services.
Numerous examples showing the impact of pharmacist-driven medication reconciliation programs
on improving health outcomes can be found in the literature [7–11]. The majority of studies involving
medication reconciliation programs have used multiple providers and varying program settings.
Previous studies tended to report the findings of ADEs in a retrospective manner, such as interventions
found during a chart review [12,13]. This study aimed to show a prospective approach to medication
reconciliation with pre-identified health outcome-related events during the patient’s medication
review. This study also sought to show the value of utilizing pharmacists practicing in a community
pharmacy setting.
2. Methods/Intervention
Apple Discount Drugs is a large, independent community pharmacy that has been operating on
the lower eastern shore of Maryland since 1971. Apple Discount Drugs’ pharmacy group consists
of four community pharmacy locations, a closed-door home infusion pharmacy, and Core Clinical
Care—a separate company that houses the pharmacy’s clinical programs. The pharmacy runs a
diabetes center and it is accredited by the American Association of Diabetes Educators. It is the only
pharmacy-based accredited diabetes center in the area and one of just a few such centers nationwide.
The pharmacy also provides extensive medication therapy management (MTM) services [14].
The objective of this study was to implement a structured pharmacist-driven comprehensive
medication review program and to identify both actual and potential ADEs among rural patients
referred to the pharmacy for diabetes self-management education and training (DSME/T) or for
comprehensive medication management. The medication-related problems that were identified by a
pharmacist were then categorized according to the type and severity of the event. Medication-related
problems included issues involving a possible risk to patient safety, issues surrounding medication
adherence, communication errors between the patient and prescriber, and duplicate medications.
This study was also designed to set a groundwork for future studies to determine the relationship
between proactive pharmacist intervention and specific patient health outcomes such as effects on
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blood pressure and hemoglobin A1C. The pharmacy used the Blue Bag Initiative (BBI) program,
developed by their Quality Improvement Organization (QIO), to provide a structured platform for
the pharmacy to conduct medication reconciliation and perform comprehensive medication reviews.
The BBI also assisted the pharmacy in capturing pharmacy-related outcomes related to pharmacist-led
clinical services.
The BBI intervention differs from the traditional ‘brown bag’ interview in a number of ways.
First, the BBI includes a data collection tool for pharmacists to record the number and types of ADEs,
pADEs, and interventions that were identified during the medication review (Table 1). The BBI also
ensures patient engagement by creating the expectation that the medication reconciliation process is an
ongoing activity—for instance, a reusable, blue drawstring medication bag and a patient appointment
card were provided to patients. The patient would be able to keep all medications in the medication
bag for easy transport to medical appointments or for safekeeping. The BBI allows for medications
that are active on the patient’s regimen to be separated from expired and discontinued medications by
including a separate white plastic bag.
Table 1. Blue Bag Initiative Event Classification.
Event Type
A possible risk to participant safety
Participant not taking medication as prescribed
Medication was correct, but dose was not
Participant stopped taking prescription meds without telling a clinician
Participant taking a new over-the-counter (OTC) med or supplement without telling a clinician
Drug–drug interactions could be possible
Participant failed to get medication(s) refilled
Expired medications
Participant had contraindication for one or more medications
Participant taking new prescription med (from another doctor) without telling clinician
Pill bottles brought in did not match the medication list in the patient’s medical record
Duplicate medications
Stopped taking an OTC med or supplement without telling a clinician
Participant changed to cheaper medication
The study was open to patients who had been referred to the pharmacy’s 10 (DSME/T), past
graduates of the program, and patients that were referred to the pharmacy’s MTM program for a
comprehensive medication review (CMR). Patients were excluded if they were only referred to the
pharmacy for a targeted medication review.
The diabetes education classes were taught by a pharmacist with a certified diabetes educator
credential. The prescriber could refer the patient for group classes, or if the patient had special needs
the prescriber could elect to have the classes taught one-on-one. The diabetes education cycle began
with a one-on-one meeting so the pharmacist could gauge the patient’s understanding of their disease,
followed by 3 h classes to teach the fundamentals of managing diabetes. A patient’s third-party
payer benefits for follow-up upon completion varied according to the payer. Many of the commercial
payers that the pharmacy contracts will allow for diabetes education follow-up on an as needed basis
according to the patient’s needs. Patients that have Medicare benefits are allowed 2 h of DSME/T
follow-up for each subsequent year following the completion of the class cycle. This lag time in benefits,
in many cases, can cause a care gap as many patients need medication management in the months
328
Pharmacy 2019, 7, 66
following the successful completion of a DSME/T class cycle, when the patient is able to begin making
lifestyle modifications.
The intervention was overseen by a pharmacist from the clinical team at Apple Discount Drugs.
The clinical team consisted of two pharmacists who also held Certified Diabetes Education credentials
and a licensed pharmacist completing a Community Pharmacy Residency program during their first
postgraduate year.
Reviews were standardized to the BBI to maintain a uniform distribution of pharmacy care.
Once the participants agreed to take part in the intervention, the pharmacist contacted their primary
care provider to send an updated medication list, progress notes, and requests for intervention when
necessary. Participants were instructed to put all their medications (including OTC medications,
vitamins, herbal supplements, and eye drops) into the blue bag and to bring it with them to the
pharmacy for their scheduled appointment. Apple Discount Drugs invited DSME/T class participants
referred to the pharmacy to sign up for the BBI intervention as an extra benefit to attending the class
sequence. Participants could choose to opt out of the Blue Bag comprehensive medication review with
a pharmacist and still take part in the DSME/T classes.
The pharmacist reviewed the medications at the conclusion of the interview, created an updated
medication list incorporating any medication changes, recorded patient outcome data into the QIO’s
BBI collection tool, and discussed the results with study participants. The pharmacist would also,
when necessary, secure outdated, discontinued, or contraindicated medications and instruct the patient
on how to safely discard medications.
3. Results
There were 110 patients who were offered the opportunity to participate and 73 patients agreed to
take part in the intervention (Table 2). Patients who were referred for targeted medication reviews or
patients who received telephonic MTM were excluded from participation. Over 50% of the patients in
this study were Medicare beneficiaries. There was an average of 8.5 medications (prescription and
OTC) per patient, with higher averages of 11 and 11.8 medications per patient in the age ranges of
86–90 years and 41–45 years, respectively. There was a similar number of medications per patient seen
amongst men (average 8.4) and women (average 8.6). For patient-identified ethnic groups, there was
an average of 7.6 medications per patient amongst Blacks/African-Americans and an average of 8.2
amongst Whites/Caucasians. The majority of patients seen were being treated for metabolic syndrome.
Of the patients taking part, 91.8% were treated for hypertension, 87.7% were treated for diabetes, and
63% were treated for hypercholesterolemia (Table 3).
Table 2. Patient demographics.





African American/Black 8 (11%)
Caucasian/White 46 (63%)






Patient preferred not to disclose 5 (6.8%)
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Table 3. Conditions/disease indication by patient count.












The majority of patients reported bringing all of their medications to their appointments with the
pharmacist (87.7%). Participants could also state what condition their medications were prescribed
for (82.2%). Less than half (49.3%) stated that any healthcare practitioner had inquired about their
medication list in the past 6 months (Table 4).
Table 4. Patient medication reconciliation survey responses.
Yes No No Response/Unsure
Did the participant say they brought in all their medications? 64 (87.7%) 8 (11%) 1 (1.3%)
Has anyone asked about the participant’s medications in the
last 6 months, not including today’s discussion? 36 (49.3%) 36 (49.3%) 1 (1.3%)
Could the patient state what each medication was for? 60 (82.2%) 9 (12.3%) 4 (5.5%)
Pharmacists identified potential and actual ADEs utilizing the Blue Bag Initiative (Table 5). There
was an average of 2.2 identified events per patient, with the highest number of ADEs (7 identified
events) found in three patients (Figure 1). Over 50% of pADEs identified were related to a possible harm
in patient safety. A 16% correlation was seen between an increased number of medications per patient
and the number of identified adverse drug events. A weaker correlation of 9% was seen between the
number of identified conditions per patient and the number of identified adverse drug events.
Table 5. Number of medication-related events identified.
Event Type Patient Count Percent
A possible risk to participant safety 41 56.20%
Participant not taking medication as prescribed 23 31.50%
Medication was correct, but dose was not 19 26.00%
Participant stopped taking prescription meds without telling a clinician 16 21.90%
Participant taking a new over-the-counter (OTC) med or supplement without telling a
clinician 13 17.80%
Drug–drug interactions could be possible 12 16.40%
Participant failed to get medication(s) refilled 12 16.40%
Expired medications 11 15.10%
Participant had contraindication for one or more medications 3 4.10%
Participant taking new prescription med (from another doctor) without telling clinician 3 4.10%
Pill bottles brought in did not match the medication list in the patient’s medical record 3 4.10%
Duplicate medications 2 2.70%
Stopped taking an OTC med or supplement without telling a clinician 2 2.70%
Participant changed to cheaper medication 2 2.70%
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Figure 1. Events per patient.
Out of the 674 medications reviewed, 162 were over-the-counter medications (24% of the total
medications reviewed). This was significant as many patients did not consider an OTC medication
to be part of their medication list and many did not inform their prescribers of OTC medication use.
There was a 23% correlation between patients who had OTC medications and an event occurring.
4. Limitations
This study was limited to the small number of patients that were referred to the pharmacy and
agreed to participate. The pharmacists performing the medication reviews relied on the patient for
an accurate accounting of medications added to the Blue Bag. The pADEs that were documented by
the pharmacists were subjective, especially when considering what constitutes a risk to patient safety,
which was the most common type of pADE reported. There is still a large variation in the literature as
to how these events are defined. The pharmacists participating in this study determined that a risk
to patient safety would include medication-related effects of the patient’s regimen outside of taking
one specific medication. Despite this initial training, the reporting of pADEs might have varied from
reviewer to reviewer. This means that training, implementation support, and periodic data collection
check-ins are recommended.
The low sample size prevented further assessment of the intervention’s impact on hospital
utilization, such as ED visits, admissions, readmissions, and observational stays. A systematic review
published in 2017 notes the importance of measuring factors such as medication therapy management
and patient-specific variables [15]. A further study investigating the effects of this intervention on the
abovementioned outcomes would be a recommended expansion of this initial study.
5. Discussion
Patient empowerment helped the investigators drive this study. Patients reported a better
understanding of the reasons why they were taking specific medications and how those medications
worked. This allowed patients to relate side effects to a particular medication, and empowered them to
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become more active participants in their healthcare. Research has shown that as patient empowerment
is improved there are increased levels of patient involvement and better patient behaviors such as
medication adherence [16].
Polypharmacy increases with the number of chronic conditions and prescribers. As the number
of medications goes up, so does the potential for medication-related problems. This is especially true
in older patient populations. A recent study performed in a geriatric patient population showed that
patients receiving a mean of 10 medications had the incidence of medication-related problems drop
from 86.6% to 56% when a pharmacist was involved in the medication reconciliation process [17].
In this study the need for medication reconciliation was shown when surveying the individuals, as
slightly less than half had not had their medications reviewed in the last 6 months. Retrospective
research has shown the risk of ADEs in ambulatory settings. Patients taking multiple medications,
such as non-opioid analgesics, anticoagulants, diuretics, and anti-seizure medications, have been
shown to be at an increased risk [18]. This was further exacerbated by the pharmacist finding 2.2
drug-related issues per medication review. Majority of the participants that completed this study
had an understanding of what their medications were for. Conversely, a third of the of patients were
not taking their medications as prescribed, ranking as the second-most identified event during the
medication review. The investigators also noted that many patients did not understand the associated
side effects of medications. After the interview with the pharmacist utilizing the Blue Bag review,
patients were able to identify the causes and effects of medication use. Cahn et al. looked at the
recognition of drug-related problems before and after pharmacist intervention. There was a significant
increase in identified problems seen when a pharmacist reviewed the patient’s medications, resulting
in increased clinical and compliance interventions [19].
There are a number of practical and innovative ways the BBI can assist in improving and
quantifying pharmacy workflow processes, many of which directly impact patient safety measures.
The BBI provides pharmacists with a mechanism to remove outdated and discontinued medications
from a patient’s medication regimen. Due to the expense of medications, often times a patient would
hesitate to discard a medication once it had been discontinued. The patient would want to have the
medication on hand in the event that the prescriber would restart the medication, so as to avoid an
additional copayment. Having a discontinued medication stored with other medications resulted
in patient confusion and a potential patient safety issue. Separating these medications from active
medications proved to be a valuable intervention to patient safety.
Studies have been published on medication discrepancies during medication reconciliation and
the effects of this on patients. In this study, the pharmacist found instances where the patient reported
medications of which the prescriber was unaware [20]. The likelihood of this occurring became
more common as the number of prescribers a patient saw increased. Each prescriber performed their
version of medication reconciliation at their practice site. Quite often, there would be discrepancies
among the medications a patient was prescribed from practice to practice. The BBI intervention
gave the pharmacist the ability to communicate current medications and medication changes to all
of the patient’s prescribers as well as alert prescribers to difficulties that a patient may experience
between visits.
There was a correlation between OTC medications and pADEs identified within the study; this
afforded the pharmacist with an opportunity to improve patient care. Many patients felt that OTC
medications were safe and effective for use without seeking treatment by a health professional. This
can be complicated by a patient’s use of other nonprescription and prescription medications, especially
as the amount of either increases. Pharmacists have an opportunity to encounter the patient and review
their medications to assess the harm of starting or stopping a nonprescription product and reporting
this information to other healthcare professionals.
As patients continue managing their various condition(s), their medication dose needs to be
considered for safety and efficacy. Often, medications need to be tapered up and titrated down.
Pharmacist are in a unique position to interview the patient and devise an appropriate medication
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plan for the patient by utilizing the Pharmacists’ Patient Care Process (JCPP) [21]. Pharmacists utilize
evidence-based medicine and patient-specific parameters to determine an appropriate medication
dose and frequency for a patient. Pharmacists play an integral role in providing patient counseling on
appropriate medication administration. This encompasses education not only on a specific medication,
but the patient’s entire medication regimen. Pharmacist guiding patients on various interactions
with supplements, herbal medications, and OTC products to avoid while taking their prescribed
medication regimen can circumvent potential adverse drug events. During the interview process,
many patients initially did not consider OTC and natural products to be a part of their medication
regimen. It was not until the pharmacist asked pointed questions or explained how OTC products
could impact a patient’s overall health that many patients understood the importance of complete
and accurate medication reconciliation. Several patients later reported taking their blue bags and
medication cards to doctor’s appointments with primary and specialty care. The BBI also helped
patients to understand the importance of communication with prescribers to alert them to changes to
their medication regimen.
Another area where the BBI can assist a pharmacy is in providing the pharmacy with a mechanism
to quantify interventions in a systematic format in order to track and share intervention data with
other healthcare professionals and insurers [22]. Many pharmacies that provide clinical services to
patients perform similar types of interventions as those noted by the study investigators. A study by
Tetuan et al. utilized a system where recently discharged inpatients were able to utilize the pharmacy’s
service in order to identify potential drug-related problems. By utilizing the BBI initiative as a marker
for cost avoidance, future studies on the resolution of drug-related problems will assist pharmacies
in sustaining initiatives with local health systems [23]. Without the ability to show the value of
these services to third-party payers, these pharmacist interventions become value-added services.
An intervention utilizing the BBI intervention showcased an average of $218 to $319 in potential
savings per completed medication review [24]. When pharmacists are able to quantify and assign a
value to these services, they are then able to market clinical interventions in the community pharmacy
setting and, in turn, use these programs to increase pharmacy revenue [25].
6. Conclusions
This study highlighted the impact of pharmacist-driven medication reconciliation and reviews.
The pharmacy’s implementation of the BBI demonstrated this program to be a viable way to
perform medication reconciliation and identify pADEs so as to improve health outcomes for patients.
By collecting specific data points from the patient and highlighting areas of correlation, pharmacists
will be equipped to display where their skills lie in medication management. Patients embraced the
interactive nature of the BBI and seemed to be willing to take a more active role in their healthcare as
a result.
Apple Discount Drugs is also expanding the use of the BBI to try to determine the cost savings
associated with the prevention of ADEs, and to use the outcomes from the BBI to expand the number
of billable services offered to pharmacies in coordination with third-party payers. The expansion
of the availability of this medication reconciliation program could have a great impact on the care
afforded to patients and could strengthen the implementation and data collection support offered
to healthcare providers. Additional studies on healthcare outcomes and control group comparisons
are recommended for future impact analyses of pharmacist-driven medication reconciliation in the
community pharmacy setting.
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Abstract: The high prevalence of chronic diseases and use of multiple medications identified in
Primary Health Care (PHC) suggest the need for the implementation of Comprehensive Medication
Management (CMM) services. This study aimed to evaluate the clinical results of CMM services in a
Brazilian PHC setting. A quasi-experimental study was performed with patients followed-up for two
years (n= 90). Factors associated with the detection of four drug therapy problems (DTP) or more in the
initial assessment were evaluated (univariate and multivariate analyses), as well as the clinical impact
observed in laboratory parameters (HbA1c, Blood Pressure, LDL- and HDL-covariance analysis).
A predominance of women (61.1%), a mean age of 65.5 years, and a prevalence of polypharmacy
(87.8%)—use of five or more drugs—were observed. A total of 441 DTP was identified, 252 required
interventions with the prescriber, 67.9% of which were accepted and 59.6% were solved. The main
DTP were ‘non-adherence’ (28.1%), ‘need for additional drug therapy’ (21.8%), and ‘low dose’ (19.5%).
Hypertension was positively associated with the identification of four DTP or more. A statistically
significant reduction was detected in all assessed laboratory parameters (p < 0.05). CMM services
contributed to the resolution of DTP and improved clinical outcomes.
Keywords: Comprehensive Medication Management; pharmaceutical care; primary health care;
chronic diseases; clinical results
1. Introduction
Primary Health Care (PHC) is the patient’s gateway to the public health system and has significant
participation in the management of chronic diseases and prevention of adverse health outcomes
through the integration of preventive and curative actions [1]. In Brazil, its organizational axis is the
Family Health Strategy (eSF—Equipe Saúde da Família), which, in turn, is supported by the Family
Health Support Team (NASF—Núcleo de Apoio à Saúde da Família). The NASF was established in
2008 by the Ministry of Health and consists of multidisciplinary teams (composed of pharmacists,
nutritionists, physical therapists, social workers, and others) that provide support to the work of the eSF
(composed mainly of a primary care physician and a nurse) [2]. The demands for a multidisciplinary
approach in primary health care is increasing, since a large part of the population followed in this
scenario has multiple health conditions, uses many medications, and is now composed of older adults,
representing about 12.6% of the Brazilian population [3].
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Patients treated in the PHC have a high prevalence of chronic diseases, such as diabetes mellitus
(DM), hypertension, and dyslipidemia and consequently use multiple medications. Therefore, adequate
drug therapy management becomes necessary, considering the complex drug therapy of this population.
Thus, the provision of Comprehensive Medication Management (CMM) services by a competent
clinical pharmacist inserted in the NASF can be an important strategy to enhance health outcomes and
the operationalization of PHC [4].
CMM is a clinical service grounded in the theoretical framework of Pharmaceutical Care Practice
that aims at the responsible provision of drug therapy to achieve tangible results that improve the
quality of life of the patients [5]. Thus, in CMM services, the pharmacist checks whether the medicines
used by the patient are the most appropriate, if they are effective, safe, and convenient for use in daily
living in order to optimize their drug therapy. Thus, when he/she detects a drug therapy problem
(DTP), defined as an event or circumstance linked to drug therapy that may actually or potentially
interfere with the expected treatment results, pharmacists intervene with the patient or the team to
solve it. It is worth emphasizing that patients are central to this practice and in partnership with the
pharmacist and other professionals define the best way to reach their therapeutic goals [6].
Studies have shown that CMM has a considerable impact on the enhancement of the treatment of
chronic diseases and contributes significantly to improve patients’ clinical results [7–10]. However, few
studies have shown the clinical impact of a CMM service in the Brazilian PHC and provided directly
by a NASF pharmacist. Therefore, this study aims to describe a CMM service in the primary care of
the Brazilian city of Belo Horizonte (MG) and to evaluate its clinical impact.
2. Materials and Methods
This study has a quasi-experimental longitudinal design, with a single group of patients that
received the CMM service. It should be emphasized that the World Health Organization encourages the
evaluation of the impact of the implementation of services through a quasi-experimental design, and
accordingly this study reflects this recommendation, which consists of a baseline and post-intervention
evaluation (uncontrolled before–after study type) [11,12].
2.1. Setting
The CMM service in question was provided by a single pharmacist in two community primary
care clinics of the municipality of Belo Horizonte, Minas Gerais. The populations assigned to these two
units were at the time of the study 22,000 and 15,023 users and were attended by, respectively, six and
four eSFs.
The pharmacist has a weekly workload of 40 h divided into 20 h for technical and managerial
activities (e.g., medicines inventory control and coordination of the drug dispensing activities) and 20
weekly hours for patient care activities (provision of CMM services, health education, and scheduled
meetings for discussion of cases referred to NASF professionals).
2.2. The Patient Care Process
CMM services as its theoretical underpinnings the practice of pharmaceutical care, whose patient
care process involves the use of a rational decision-making process called Pharmacotherapy Workup
(PW), as proposed by Cipolle et al. [13,14] Thus, the care process utilized in these services includes the
pharmacist’s assessment of all of a patient’s drug therapy, including over-the-counter, supplements
and prescribed medications, in order to identify, prevent, and resolve DTP that might be preventing
the patient to achieve his or her goals of therapy. Care plans are developed for each medical condition
and follow-up evaluations are carried out to determine actual outcomes.
2.3. Study Design and Data Collection
In order to assess the impact of the CMM service, the documentation of the CMM encounters
were analyzed retrospectively for the total number of patients (n = 90) followed-up by the pharmacist
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at the clinics over the two-year period (February 2015–February 2017). The following data were
collected: age (full years at the first visit), gender, place of care at the initial assessment (at home or
at the health service unit), number of health problems, number of medications used (prescribed and
non-prescribed), number of interventions (with the prescriber or the patient) and their acceptability
(intervention with the physician—accepted or not accepted), number of DTP identified and resolved,
as well as their types.
DTP were categorized according to the PW process meaning they were classified according to an
evaluation of the indication, effectiveness, safety, and convenience of each medication the patient was
taking [5,6]. DTP associated with the indication of a drug product include unnecessary drug therapy
(DTP1) or the need for additional drug therapy (DTP2). DTP related to effectiveness include ineffective
drug product (DTP3) or a dosage too low to be effective (DTP4). In the safety category, the patient can
have an adverse drug reaction (DTP5) or a dosage too high (DTP6). After evaluating the first three
categories, the pharmacist will assess the convenience of the drug product for that specific patient,
which might lead to the identification of a DTP of non-adherence (DTP7).
The Charlson Comorbidity Index (CCI) [15] was calculated for each patient enrolled in the service
and the following initial (detected at the first or second CMM visit) and final (detected at the last visit)
laboratory parameters were collected: glycosylated hemoglobin (HbA1c, in percentage), systolic blood
pressure (SBP, in mmHg), diastolic blood pressure (DBP, in mmHg), low-density lipoprotein-cholesterol
(LDLc, in mg/dL) and high-density lipoprotein-cholesterol (HDLc, in mg/dL).
2.4. Study Variables and Data Analysis
The data were first analyzed descriptively, measuring the absolute and relative frequencies of
the qualitative variables and the mean and standard deviation (SD) of the quantitative variables.
Then, univariate and multivariate analyses were performed to identify factors associated with the
identification of multiple DTP in the initial assessment (first and second consultations), and, therefore,
patients that should be prioritized to receive CMM services. For such purpose, the variable “number
of initial DTP” was dichotomized (0–3 DTP, ≥4 DTP) and the dependent variable, therefore, was
defined as the identification of four DTP or more. The independent variables defined were: age (22–69;
≥70 years), gender, number of health problems (0–2; ≥3), number of medications used (0–7; ≥8), the
presence of hypertension and DM. The quantitative variables (age, CCI, number of medications, and
number of DTP) were dichotomized according to their median.
Univariate analyses were performed using the Pearson’s chi-square test or Fisher’s exact test
when the expected value for one or more cells was equal to or less than five. Independent variables
with p < 0.20 in the univariate analysis were included in the multivariate model calculated by logistic
regression. A probability test was used to compare the models and the Hosmer–Lemeshow test was
run to evaluate the model’s quality of fit. Univariate and multivariate analyses were based on the odds
ratio (OR) and their respective 95% confidence intervals estimated by logistic regression. A level of
statistical significance of 5% was adopted to identify the characteristics independently associated with
the dependent variable.
The clinical impact of the CMM service was assessed by comparing the initial and final
clinical/laboratory parameters (HbA1c, SBP, DBP, LDLc, and HDLc). Only patients with more
than one visit (68 patients) were considered, and among these, only those with a measurement
of the specific clinical parameter at the initial and final visit. First, the normal distribution of the
clinical variables was verified with the Shapiro–Wilk test. As all variables had a normal distribution,
the difference between their initial and final values was assessed through covariance analysis with
repeated measures (ANCOVA) adjusted by the following covariates in their continuous format: CCI,
age, number of health problems, and number of medicines. Repeated measure designs facilitate the
measurement of the impact of the treatment on each subject rather than just comparing the means
between two groups. In this case, each subject serves as their control and the variability between
subjects can be isolated. Also, the ANCOVA analysis enables us to control the difference between
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the two measures by other covariates, increasing the test’s sensitivity. All statistical analyses were
performed by the Stata® statistical program, version 12.
2.5. Ethical Aspects
This study was approved by the ethics committee of the Federal University of Minas Gerais,
Report No. 25780314.4.0000.0149. Anonymity of the participants and confidentiality of the information
were guaranteed.
3. Results
A female majority (n= 55, 61.1%), with a mean age of 66.5± 13.4 years (minimum: 22, maximum: 89)
was observed among the patients followed up, revealing a predominance of elderly individuals with
60 years or more (n = 68; 75.6%). Table 1 shows the demographic, health and medication use profile of
the patients enrolled in the CMM service.
Table 1. Demographic, health and medication profile of patients enrolled in the Comprehensive














Number of drugs in initial assessment *
0–7 47 (52.2)
≥8 43 (47.8)
Number of DTP identified in initial visits *
0–3 45 (50.0)
≥4 45 (50.0)
* Initial assessment = 1st and 2nd CMM visits.
A total of 251 consultations was performed by the pharmacist (mean ± SD = 2.8 ± 1.6). In the
initial assessment, most patients were using five or more medications (n = 79; 87.8%), setting a mean
of 7.6 ± 2.7 medications (minimum: 2, maximum: 18). The patients had a mean of 3.23 ± 1.4 health
problems (minimum: 1, maximum: 7), with a mean CCI of 4.1 ± 0.2 (minimum = 0; maximum = 12).
The most prevalent diseases were hypertension (n = 74; 82.2%), dyslipidemia (n = 69; 76.6%) and
diabetes (n = 58; 64.4%).
A total of 346 DTP were identified in the initial assessment (mean = 3.8 ± 2.4; minimum = 0;
maximum = 10; median = 3.5), and 441 DTP in all consultations, and the most prevalent were related to:
‘non-adherence’ (DTP 7—n = 124; 28.1%); ‘need for additional drug therapy’ (DTP 2—n = 96; 21.8%);
and ‘low dose’ (DTP 4—n = 86; 19.5%). Table 2 describes the number of stratified DTP by type.
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Table 2. Absolute (n) and relative (%) frequency of drug-related problems (DTP) by category.
DTP Category n (%)
1. Unnecessary medication 42 (9.5)
2. Need for additional drug
therapy 96 (21.8)
3. Ineffective medication 19 (4.3)
4. Low dose 86 (19.5)
5. Adverse drug reaction 40 (9.1)
6. High dose 34 (7.7)
7. Non-adherence 124 (28.1)
Total 441 (100.0)
The main drugs associated with ‘non-adherence’ DTP were aspirin (n = 13; 10.5%) and simvastatin
(n = 12; 9.7%). The drug cholecalciferol—vitamin D (n = 14; 14.6%) was the main drug requiring
inclusion in drug therapy (‘need for additional therapy’ DTP). Regarding ‘low-dose’ DTP, the main
drug involved was NPH insulin (n = 32; 37.2%). Of the total DTP, 59.6% (n = 263) were resolved
(n = 263), 57.1% (n = 252) required interventions with the prescriber for resolution, and 67.9% (n = 171)
of these interventions were accepted. Also, 364 interventions were performed directly with the patient
(interventions performed vs. 82.5% of total DTP).
Table 3 shows the results of the univariate and multivariate analyses, which indicate that the
presence of hypertension was independently and positively associated with the dependent variable,
which was the identification of four DTP or more in the initial assessment, in a statistically significant
way (p = 0.031).
Table 3. Univariate and multivariate analysis of the characteristics associated with the dependent
variable—identification of four or more drug-related problems in the initial assessment. Belo
Horizonte. 2015–2017.
Variables
Univariate Analysis Multivariate Analysis
OR (95% CI) ** p-Value *** OR (95% CI) ** p-Value ****
Age (full years)
22–69 1.0
≥70 1.20 (0.52–2.75) 0.067 0.99 (0.41–2.44) 0.991
Gender
Female 1.0




≥3 2.47 (1.16–5.29) 0.020 1.67 (0.63–4.41) 0.300
Number of drugs
0–7 1.00 1.00
≥8 1.88 (0.76–4.66) 0.172 2.27 (0.93–5.55) 0.071
Hypertension
No 1.00 1.00
Yes 5.69 (1.49–21.66) 0.006 4.56 (1.14–18.19) 0.031
Diabetes Mellitus
No 1.00
Yes 1.48 (0.62–3.52) 0.378
Note: Number of DTP identified during the first and second visit; ** Odds ratio (95% CI) estimated by logistic
regression; *** Pearson’s chi-square; included in the multivariate model when p < 0.20; **** Logistic regression;
significant when p < 0.05.
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After multiple adjustments, a statistically significant difference was detected between the initial
and final values of HbA1c, SBP, DBP, LDLc, and HDLc (Table 4).
Table 4. Comparison of initial and final values of defined clinical and laboratory parameters.
Parameter (Unit/Number of Evaluated Patients) Median Initial Visit Median Final Visit p-Value **
HbA1c (%; n = 31) 8.4 7.8 <0.001
SBP (mmHg; n = 54) 136.5 132.2 0.020
DBP (mmHg; n = 54) 82.8 79.7 0.002
LDLc (mg/dL; n = 29) 119.7 109.1 <0.001
HDLc (mg/dL; n = 28) 45.3 50.4 <0.001
Note: HbA1c = glycosilated hemoglobin; SBP = Systolic blood pressure; DBP = Diastolic blood pressure;
LDLc = Low-density lipoprotein cholesterol; HDLc = High-density lipoprotein cholesterol; ** Estimated by
covariance analysis with repeated measures (ANCOVA) adjusted by the Charlson Comorbidity Index (ICC), age,
number of health problems, and number of drugs.
4. Discussion
The elderly majority among the patients assisted (75.6%) tended to increase the complexity of the
service described in this study. This population has a high number of chronic diseases, as a consequence
uses the health system more frequently, and usually consists of multiple-medication users [16], as
indicated by the high mean number of health problems (3.2 ± 1.4) and drugs used by patients enrolled
in the CMM service (7.6 ± 2.7). These findings reinforce the need to develop drug therapy qualification
strategies such as the implementation of CMM services since the use of drugs in the elderly is generally
associated with the occurrence of a more significant number of DTP [17].
With demographic and epidemiological transition, chronic and degenerative diseases have begun
to gain greater representativity [18]. This was reflected in the results of this study, where a high
prevalence of hypertension, DM, and dyslipidemia was detected, with a high number of patients
with three concomitant diseases (n = 44; 49.0%—a result not previously described). Such complexity
evidences the required action of the clinical pharmacist who is in charge of the drug therapy of
these patients.
Hypertension was the most prevalent (82.2%) chronic condition and was positively and
independently associated with the identification of four or more DTP in the initial assessment.
This result may be related to the fact that the PHC pharmacist has greater mastery and experience for
decision-making and identification of DTP related to hypertension since it is a chronic condition of high
national prevalence. Also, patients with cardiovascular diseases, such as hypertension, often prompt
the clinical pharmacist to evaluate the presence of DTP related to indication or appropriateness of drug
therapy that might lead to the inclusion of medications for adequate cardiovascular prevention [14].
This type of DTP was the second most frequently identified in the initial assessment of this study
(22.3%—results not described).
In a study that evaluated the clinical, economic, and humanistic outcomes of CMM services
provided over a ten-year period in the health system of Minnesota [19], the authors pointed out the
need for additional medication (accounting for 28.1% of total DTP), the use of low dose (26.1%), and
non-adherence to drug therapy (16.5%) as the most frequent DTP identified. This result is comparable
to the DTP frequency of this study. However, the reversed incidence was observed among DTP.
In the present study, the most frequent DTP was non-adherence (28.12%), followed by the need for
additional drug therapy (21.77%) and lastly the low dose, representing 19.50% of the total DTP. Another
study [20] with a sample of patients from South Australia also found that the most frequent DTP were
non-adherence to drug therapy (31.7%), followed by the need of additional medication (15.9%), and
then drug ineffectiveness (15.7%).
The leading causes of non-adherence DTP were forgetfulness and failing to understand the
instructions, which is consistent with the study population of mostly elderly, and therefore being more
susceptible to cognitive impairments. The high frequency of this type of DTP can contribute adversely
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to the clinical outcomes of this population since the understanding, acceptability, and continuity of
medication use are necessary conditions for the adequate management of chronic diseases. Thus,
interventions with the patient are essential in resolving these DTP and showed high frequency in this
study (performed to solve 82.5% of DTP). It should be noted that this type of intervention is deeply
rooted in the philosophy of pharmaceutical care practice, which aims for shared-decision making
between pharmacists and patients and to empower patients to get closely involved in the management
of their own care [13].
Patients’ non-adherence to drug therapy, especially among patients with chronic diseases and
with more complex treatments remains a challenge for health services [2]. Considering preventive
pharmacological measures, the difficulty of patients to understand the need for a medication may be the
main reason that aspirin and simvastatin were the most frequent drugs involved in the non-adherence
DTP. In Brazil, a study carried out in the city of Araucária-Paraná found that, among hypertensive
patients, non-adherence can reach 60% of users, and among the factors that contribute most are
schooling, failing to understand the disease, family history of cardiovascular disease, and the type of
drug combination used [21]. In Santa Catarina, a study showed that, among users of lipid-lowering
drugs, non-adherence increased in an average period of 19 months, after the onset of treatment [22].
Among diabetic patients, the low adherence to treatment was estimated at 50%, leading to poor
glycemic control [23]. Furthermore, among the elderly, self-reported rates of 62.9% of non-adherence
to treatment were found, and polypharmacy (use of five or more medications) is related to this
problem [24].
The second most prevalent DTP, the need for additional drug therapy, reinforces the need for
an expanded view of the pharmacist, who should focus not only on the drug therapy already in
place but also on the screening and identification of untreated health conditions. The drug that was
most frequently associated with this type of DTP, namely, Cholecalciferol (Vitamin D), is used against
hypovitaminosis, prevalent in the world, that has an even more significant representativeness and risk
among the elderly, who were the majority of the patients attended in this study [25,26].
For this reason, the Brazilian Society of Endocrinology and Metabology recommends
supplementation for individuals who are at risk of vitamin D deficiency, such as the elderly, patients
with osteoporosis, and those with a history of falls and fractures [25]. Thus, it is common practice for
the pharmacist to request the screening exam in the initial CMM assessment, since a high percentage of
the population is elderly. When a deficiency is detected, the propaedeutic procedure is to start therapy
and communicate the eSF during the matrix-based strategy meetings to guarantee continuity of care.
The third most prevalent DTP was too low a dosage, due to a sub-therapeutic dose, incorrect
administration, or use at inappropriate intervals, while NPH insulin was the primary drug associated
with this DTP. Several factors are considered as impediments in the treatment of DM, influencing
the achievement of patients’ therapeutic goals and increasing the frequency of DTP. This condition
requires complex treatment and involves the need for self-monitoring and frequent adjustments of
insulin dose in a large number of patients [27]. Besides, DM changes the life of the patient and is in
continuous clinical progression. The patients’ daily routine and non-pharmacological measures also
influence the effectiveness of insulin treatment. Thus, health professionals must be specifically trained
to care for patients in insulin therapy, as the therapeutic goals should be individualized according to
the characteristics of the patient and the stage of the disease [28].
In this study, most of the interventions were accepted by the prescribers (67.9%; n = 171), in a
proportion higher than that found in CMM services provided to patients with COPD (55.2% of the
accepted interventions) [8], with cancer (59.6%) [29], and with hypertension (42.7%) [30]. This may
have influenced the high number of DTP resolved (59.6%). This result reflects the strengthening of
the working relationship between the pharmacist and physicians, with a growing confidence in the
pharmacist’s clinical competence due to her participation in the workflows of the healthcare units.
By allowing discussions of patient cases directly with prescribers on a regular basis, the matrix-based
strategies (within or outside the fixed schedule) seem to favor the reassessment of the therapeutic
342
Pharmacy 2019, 7, 58
goals by the healthcare team and the shared construction of care plans. The necessary communication
between professionals rarely occurred through letters or phone calls, which were used only when the
pharmacist needed to contact professionals working outside her healthcare network.
A statistically significant decline was observed in all clinical and laboratory parameters (HbA1c,
SBP, DBP, LDL, and HDL) of the CMM patients at the end of the follow-up period. A quasi-experimental
longitudinal study conducted by Bunting (2008) [31] in Asheville also evaluated the clinical outcomes
of a CMM service. The service was provided to patients with hypertension and dyslipidemia for
six years, and the results also showed reduced SBP parameters (137.3–126.3 mmHg; p < 0.001); DBP
(82.6–77.8 mmHg; p < 0.001); LDL (127.2–108.3 mg/dL; p < 0.001); TC (211.4–184.3 mg/dL; p < 0.001)
and TG (192.8–154.4 mg/dL; p < 0.001).
Some limitations were found in this study. First, there was a single pharmacist providing CMM
who was still a novice at the implementation stage of the service. The pharmacist was still in the
process of learning the practice, the method of documentation, and all that is involved in the process
of transformation from a traditional pharmacist to a pharmaceutical care practitioner. The lack of
training and the fact that the service was provided by only one professional could have reduced the
quality and completeness of the documentation and, in consequence, hindered the evaluation of the
clinical impact in the present study. The process of documentation becomes perfected over time and
requires professional mastery and experience and, as highlighted by Ramalho de Oliveira (2011), it
directly affects the quality of the data collected, the care provided, and consequently the obtained and
evaluated results [6].
Another limitation was the difficulty of the other members of the health team to understand
the service provided, due to its non-institutionalization at the workplace pointed out by
Machado-Silva et al. (2018) in a study developed in the same health care unit [32]. In the Brazilian
context, the professional pharmacist acts with some constraints regarding drug therapy change when
he/she deems it necessary, always depending on the prescriber to accept and implement the suggested
changes [32,33]. Physicians generally do not expect pharmacists to have a clinical role in proposing
interventions [32,33]. Also, professional turnover requires that physicians always be updated regarding
the inclusion of a service that is new and, therefore, unknown, hampering the establishment of
partnerships [32]. This may be one of the factors explaining interventions that were not accepted
(n = 80; 31.8%).
We should also consider some factors such as the qualification of referrals. Many of the patients
were referred to the pharmacist because of problems of non-adherence. The pharmacist could only
make interventions or recommendations after receiving an update of the requested tests by the eSF, and
this caused some delay in the establishment of clinical conducts. As reported by Cipolle (2012) [13], it
is inconsistent to promote drug adherence without the evaluation of the indication, effectiveness, and
safety parameters. Also, the CMM service requires that pharmacists be trained and updated in their
clinical training to provide a quality and safe service for patients.
In addition, even though the present study demonstrated the significant impact that CMM services
had in the improvement of clinical parameters of non-communicable diseases, the reduced number of
patients limited these results to this particular setting and may not be applicable to a different patient
population or other primary health care setting. However, we highlight the importance of studies such
as the one hereby presented, since research describing and evaluating CMM services in the Brazilian
PHC, which is the gateway for the largest universal public health care system, is still scarce.
5. Conclusions
This study showed that the CMM service had a significant impact on the clinical outcomes of
patients. The clinical pharmacist was able to identify and propose interventions to solve and prevent
DTP. As a result, the streamlining of drug therapy improved the control of the most prevalent chronic
health conditions and proved to be a useful service in primary care. Thus, its incorporation into the
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PHC of the Brazilian health system should be considered a priority strategy for the control of prevalent
chronic diseases.
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Abstract: The study purpose was to use the theory of planned behavior to understand factors
influencing South Asian consumers’ intention to seek pharmacist-provided medication therapy
management services (MTMS). Specific objectives were to assess effects of attitude, subjective norm
(SN), perceived behavioral control (PBC), and socio-demographics on South Asian consumers’
intention to seek MTMS. Participants who were ≥18 years of age, of South Asian origin, with a
previous visit to a pharmacy in the US for a health-related reason, and with ability to read and
comprehend English were recruited from independent pharmacies in New York City. Responses were
obtained through a self-administered survey. Descriptive statistics were performed, and multiple
linear regression analysis was conducted to assess the study objective. SPSS was used for data
analyses. Out of 140 responses, 133 were usable. Mean scores (standard deviation) were 4.04 (0.97)
for attitude, 3.77 (0.91) for SN, 3.75 (0.93) for PBC, and 3.96 (0.94) for intention. The model explains
80.8% of variance and is a significant predictor of intention, F (14,118) = 35.488, p < 0.05. While
attitude (β = 0.723, p < 0.05) and PBC (β = 0.148, p < 0.05) were significant predictors of intention,
SN (β = 0.064, p = 0.395) was not. None of the socio-demographics were significant predictors of
intention. Strategies to make South Asians seek MTMS should focus on creating positive attitudes
and removing barriers in seeking MTMS.
Keywords: intention; medication therapy management; pharmacy services; South Asian; theory of
planned behavior.
1. Introduction
Drug-related problems (DRPs), such as adverse drug reactions, drug interactions, poor adherence etc.,
significantly affect morbidity and mortality rates and contribute to rising health care expenditures [1,2].
As healthcare professionals, pharmacists can identify, prevent, and resolve DRPs by helping patients
understand and self-manage their medications [3,4]. Emphasizing these professional roles of pharmacists,
the Centers for Medicare and Medicaid Services (CMS) recognized medication therapy management
services (MTMS) under the Medicare Modernization Act of 2003 [5,6]. Medication therapy management
(MTM) has been defined as a “distinct service or group of services that optimize therapeutic outcomes
for individual patients” [7]. MTM services (MTMS) typically include collecting medical and drug
histories from patients, patient education, comprehensive medication review, medication monitoring, and
provider outreach to convey recommendations for adjustments to drug therapy when necessary [8–10].
Pharmacist-provided MTMS helped improve clinical outcomes such as blood pressure, HbA1c, LDL
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cholesterol [11]; humanistic outcomes such as medication adherence, patient knowledge, patient
satisfaction [11,12]; and economic outcomes such as positive return on investment from MTMS [12].
Previous studies on MTMS mostly focused on healthcare professionals [13,14] and patients [13,15–26].
In the literature reviewed, patient-focused studies regarding pharmacist-provided MTMS explored patients’
awareness about MTM [15], attitude toward MTMS [16], perceptions and expectations about MTMS [17],
perception about pharmacists’ role [15], perceived medication-related needs [22], patient perceived
benefits/values [18], interest or willingness to receive MTMS [20], willingness to pay for MTMS [18],
satisfaction with MTMS [21], barriers in receiving MTMS [22], effective strategies for marketing MTM [22],
and impact of promotional strategies on patient acceptance of MTMS [24].
However, these patient-focused studies also had their own set of limitations, such as limited
sample size [15,21,24], lack of generalizability of study findings [15,17,18,22], low response rate [17,24],
and selection bias [21]. In addition, two major limitations are demographics of study participants and
lack of theoretical approach in study design. Respondents in previous patient-focused studies were
predominantly white [15,18,20]. Their responses might not truly represent opinions of the non-white
population, particularly the South Asian population. The South Asian population (people from India,
Pakistan, Bangladesh, Nepal, Sri Lanka, Bhutan, and the Maldives) is one of the fastest growing
immigrant communities in the United States (US). Members of this racial group have their own social
and cultural characteristics, such as language, religion, family ties etc., that may influence their health
behavior and healthcare decision making [27,28]. It has been reported that South Asians in the US
face various barriers including language, communication, and cultural barriers in accessing health
care services [28]. Effective delivery of culturally and linguistically appropriate services can help
pharmacists provide better services to this group. In order to design and deliver pharmacy services such
as MTMS in a culturally competent way, it is important to understand what influences the intention of
South Asians in the US to seek specialized pharmacy services like MTMS. The second major limitation
in past literature was the absence of a theoretical framework to explain factors influencing the intention
of patients to seek or receive MTMS. Understanding behavior change theories and using them skillfully
in research and practice can help design better interventions for patients [29]. This study used the
theory of planned behavior (TPB) as a theoretical framework which has been used extensively to
explain and predict behavioral intentions and health behaviors including health services utilization [30].
The purpose of this study was to use the theory of planned behavior (TPB) to understand factors
influencing intention of South Asian consumers to seek pharmacist-provided medication therapy
management (MTM) services. Based on the TPB model, specific study objectives were to assess
the influence of South Asian consumers’ (1) attitude on their intention to seek pharmacist-provided
MTM services, (2) subjective norm on their intention to seek pharmacist-provided MTM services,
(3) perceived behavioral control on their intention to seek pharmacist-provided MTM services, and
(4) external variables such as age, gender, income, education, number of medications etc. on their
intention to seek pharmacist-provided MTM services.
2. Background Literature and Theoretical Framework
The theory of planned behavior is an individual level health behavior theory which hypothesizes
that intention is a precursor of actual behavior. According to TPB, intention is influenced by attitude
towards performing a behavior, subjective norm associated with the behavior, and perceived control
over the behavior [30].
Attitude has been defined as an individual’s positive or negative feelings about performing a
behavior [31]. Past application of TPB found that attitude was a significant predictor of pharmacists’
intent to provide MTMS [31], community pharmacists’ intention to utilize a prescription drug
monitoring program [32], pharmacists’ intention to report serious adverse drug events (ADEs) to
the Food and Drug Administration (FDA) [33], and medical students’ intention to improve oral
hygiene [34]. Based on the research cited above, it was hypothesized that
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Hypothesis 1 (H1). South Asian consumers’ attitude toward seeking MTM services would be a significant
predictor of their intention to seek MTM services.
Subjective norm is an individual’s perception of whether people important to the individual think
the behavior should be performed [31]. Past TPB research found that subjective norm was a significant
predictor of intention in both pharmacists and consumers. Previous research on pharmacists found that
subjective norm was a significant predictor of pharmacists’ intention to provide MTMS [31], intention
to utilize a prescription drug monitoring program [32], and intention to report serious ADEs to the
FDA [33]. Previous research on consumers found that subjective norm was a significant predictor of
consumers’ intention to adopt Pharmacy Value Added Services (PVAS) [35]. Based on the research
cited above, the corresponding hypothesis was
Hypothesis 2 (H2). South Asian consumers’ subjective norm associated with seeking MTM services would be
a significant predictor of their intention to seek MTM services.
Perceived behavioral control reflects a person’s beliefs as to how easy or difficult it will be to
perform the behavior [36]. Like subjective norm, perceived behavioral control was also found to be a
significant predictor of intention in both pharmacists and consumers. Perceived behavioral control
was found to be a significant predictor of pharmacists’ intent to provide MTMS [31], pharmacists’
intention to utilize a prescription drug monitoring program [32], as well as consumers’ intention to
adopt Pharmacy Value Added Services (PVAS) [35]. In the study by Tan et al., perceived behavioral
control was found to be the most influential predictor among all TPB constructs in building intent of
consumers to adopt PVAS [35]. Based on the research cited above, it was hypothesized that
Hypothesis 3 (H3). South Asian consumers’ perceived behavioral control in seeking MTM services would be a
significant predictor of their intention to seek MTM services.
As per TPB, other external variables such as age, gender, type of disease etc., can influence attitude,
subjective norm, and perceived behavioral control, and in turn can influence intention to perform certain
behavior [30]. In a previous study, age and type of health problems were correlated with willingness
to pay for MTMS [18]; gender, income, education, number of health problems, and previous work
experience in the healthcare profession were associated with willingness to accept pharmacist-provided
MTMS [20]. Among individuals from different cultural groups, length of time in the United States
and socio-economic status influenced their beliefs about health, disease, and treatment [37]. Previous
research found that gender, education level, and race were significant predictors of the use of family,
friends, and co-workers as a source of health information by US adults [38]. Based on this literature, it
was hypothesized that
Hypothesis 4 (H4). South Asian consumers’ socio-demographic characteristics and other external variables
would be significant predictors of their intention to seek MTM services.
A summary of these hypotheses has been presented in Figure 1.
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Figure 1. Proposed model of the theory of planned behavior in predicting intention to seek medication
therapy management services (MTMS). Source: Modified from K. Glanz, B. K. Rimer, and K. Viswanath,
Health Behavior and Health Education: Theory, Research, and Practice. John Wiley & Sons, pp. 70, 2008.
3. Methods
3.1. Study Design
A cross-sectional, non-experimental, quantitative research design with a self-administered survey
approach was used in order to achieve the study objectives.
3.2. Target Population and Participant Recruitment
Study participants for survey research were recruited from neighborhoods in New York City. New
York City is one of the most diverse cities in the US with a population of different racial backgrounds
including South Asians [39]. Moreover, New York State has the second largest concentration of South
Asians in the US following California [28]. About 72% of South Asians in New York State resides in
New York City [28]. Participants were recruited from New York City neighborhoods of Jamaica Hills
and Jackson Heights in Queens, and Ozone Park in Brooklyn where the South Asian population was
the most prevalent during the study period. A non-probability convenient sampling was followed
for convenience and ease of access to participants. Upon approval from the human subjects review
committee, pharmacists in independent pharmacies located in Jackson Heights-Elmhurst, Jamaica
Hills, and Ozone Park in New York City were contacted by the primary researcher to inform them
about the study purpose and study design, and to seek permission to use their pharmacy premises as
the study setting for data collection. Three out of seven pharmacies which were contacted allowed the
researcher to use their premises as the study setting and for conducting surveys among consumers
visiting their pharmacies. Permissions from the interested pharmacies were taken through signed
consent letters.
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Study participants were South Asian consumers visiting these three pharmacies. Participants
were included in the study if they were of South Asian origin, were at least 18 years of age, had
previously visited a pharmacy in the United States for a health related issue, and were able to read
and comprehend English. The target sample size calculated for this study was 154 participants. This
target sample size was determined from past literature describing methods for sample size calculations
required for data analysis techniques (multiple linear regression and factor analysis) used in this
study [40–42].
3.3. Survey Development and Administration
A 28-item survey was developed for data collection. Survey items were developed to measure
attitude (five items), subjective norm (four items), perceived behavioral control (five items), and
intention (five items). These items were scored on a 5-point Likert scale with possible answers being
strongly disagree, disagree, neutral, agree, and strongly agree. Items related to socio-demographic
characteristics—age, gender, country of origin, highest level of education, annual household income,
marital status, duration of residency in the US, number of medications being taken, and work experience
as a health care professional (9 items)—were also included. No personal identifying information of
participants was collected to ensure anonymity of participants.
Items assessing attitude and intention were based on the core elements of MTMS (medication
therapy review, medication-related action plan, intervention and/or referral, and follow-up) as jointly
reported by the American Pharmacists Association (APhA) and the National Association of Chain Drug
Stores (NACDS) Foundation [7]. Items from a previous TPB study on pharmacist intention to provide
MTMS were modified to develop items assessing subjective norm in this study [31]. Items to assess the
perceived behavioral control were developed using past literature on TPB questionnaire construction
by Ajzen [43]. Patient-reported barriers to receive MTMS, such as inability to fix appointments due
to patients’ busy schedule; inaccessibility to pharmacist (location, parking) and time of day/week
reported in past literature were considered while developing items to assess perceived behavioral
control [13,22].
Face validity of the survey instrument was done with the help of graduate students and three
faculty members having expertise in research methods, survey methodology, and medication therapy
management services (MTMS). The survey was approved by the institutional review board.
Upon approval from the human subjects review committee, the survey was pilot tested on
a convenience sample of consumers visiting the selected pharmacies between October 2018 and
November 2018. The primary researcher approached consumers visiting respective pharmacies and
requested for their voluntary participation in the study. The study purpose, procedure of the study, and
voluntary nature of participation were explained to the consumers. Interested participants provided
their voluntary consent through a participant invitation letter and informed consent form. Consumers
who agreed to participate in the study were provided the study survey. A total of 30 surveys were
completed in the pilot study as recommended by Viechtbauer et al. [44]. It took approximately 6–10 min
for each participant to complete the survey.
Necessary changes were made to the original survey based on the findings from the pilot study.
After the pilot study, two items on the intention scale were merged into one item and one item from
demographic information was deleted to keep the survey concise. Items asking for previous work
experience in the health care profession were moved towards the end of the survey so that participants
who did not work in the health care profession did not feel offended in the middle of completing the
survey. Moreover, wording for some of the items was changed and examples were provided for some
items in the survey to make sure that participants understood the survey items easily. The revised
survey was submitted to the human subjects review committee as an amendment to the original
Institutional Review Board (IRB) application.
Upon getting the approval for the final survey from the human subjects review committee, data
was collected for the main study from mid November 2018 to the end of February 2019. It took
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approximately 4–8 min for each participant to respond to the survey questionnaire in the main study.
The response time for each participant for the main study (4–8 min) was less compared to the pilot study
(6–10 min) as the survey instrument for the main study was more easily understandable to participants
due to the reduction of the number of items, changes in wording, and addition of examples in the
revised survey instrument. To reduce the selection bias, every alternative consumer was requested for
participation in the study. A total of 140 consumers participated in this study.
3.4. Data Analysis
Prior to data analysis, completeness of survey responses was checked. Any missing data for study
variables of a respondent was replaced with an average score of other available items’ responses of
the scale within that respondent [45]. Construct validity for survey items was confirmed through
factor analysis using principal component analysis with varimax rotation. Items with factor loadings
less than 0.60 were considered for deletion. Following the factor analysis, the internal consistency of
measures was tested using Cronbach’s alpha. As suggested in the literature, a Cronbach’s alpha of 0.70
or higher was considered as an acceptable reliability coefficient [46].
Socio-demographic characteristics of the study sample were analyzed using descriptive statistical
methods. Multiple linear regression analysis was used to assess the influence of independent variables
on the dependent variable [47]. In multiple linear regression, attitude, subjective norm, perceived
behavioral, and socio-demographic variables were independent variables. Intention was the dependent
variable. Before running multiple regression, all of the socio-demographic variables were recoded as
dichotomous variables. If the p-value was <0.05, the independent variable(s) was considered significant
predictor(s) of the intention to seek MTMS. All statistical analyses were performed using IBM SPSS
Statistics Version 23.0 (IBM Corp., New York, NY, USA, 2015).
4. Results
Out of 140 surveys received, 133 surveys were usable for the study. Seven surveys were not
used as six of them had incomplete response to items related to TPB constructs and one did not have
demographic information.
4.1. Socio-Demographic Characteristics
The majority of the participants were male (71.4%), were 18–45 years old (72.9%), were married or
in a domestic relationship (62.4%), had a bachelor’s degree or higher (51.1%), had an annual income
less than $35,000 (54.9%), were living in the US for at least 5 years (63.9%), and had no experience in
the health care profession (88.0%), as shown in Table 1.
4.2. Validity and Reliability of Survey Items
Based on the findings from factor analysis, two items from the initial five items assessing attitude
and one item from the initial four items assessing subjective norm were deleted. One of the items for
the subjective norm scale was retained in spite of having a factor loading less than 0.60 (0.48) as it is
recommended to keep at least three items for each component [48]. No item was deleted from the
set of items assessing perceived behavioral control and intention. Finally, data analysis was done on
three items for the attitude scale, three items for the subjective norm scale, five items for the perceived
behavioral control scale, and five items for the intention scale, as shown in Table 2.
Cronbach’s alpha for the entire survey (excluding sociodemographic variables) was 0.96.
Cronbach’s alpha values for attitude, subjective norm, perceived behavioral control, and intention were
found to be 0.88, 0.88, 0.93, and 0.93, respectively, as shown in Table 2. Cronbach’s alpha values greater
than 0.70 for all of the constructs indicate attitude, subjective norm, perceived behavioral control, and
intention scales to be reliable multi-item measures.
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Table 1. Socio-demographic characteristics of the study sample (N = 133).
Characteristic Number Percent
Age
Between 18 and 30 years 51 38.3
Between 31 and 45 years 46 34.6
Between 46 and 65 years 27 20.3














Less than high school 13 9.8
High school or equivalent 33 24.8
Some college, no degree 10 7.5
Associate degree 9 6.8
Bachelor’s degree 29 21.8
Graduate degree 39 29.3
Household income
Less than $20,000 42 31.6
$20,000 to $34,999 31 23.3
$35,000 to $49,999 23 17.3
$50,000 to $74,999 14 10.5
$75,000 to $99,999 14 10.5
$100,000 or more 9 6.8
Marital status
Single (never married) 46 34.6





Duration of residency in the US
Less than 1 year 2 1.5
1 to 3 years 22 16.5
3 to 5 years 24 18.0
5 to 10 years 43 32.3
10 years or more 42 31.6





4 or more 25 18.8




Table 2. Theory of planned behavior scale constructs used to measure intention to seek MTMS
(N = 133).
Construct
No. of Items Retained












Attitude 3 (5) 4.04 0.97 1.00 5.00 0.88
Subjective norm 3 (4) 3.77 0.91 1.00 5.00 0.88
Perceived behavioral control 5 (5) 3.75 0.93 1.00 5.00 0.93
Intention 5 (5) 3.96 0.94 1.00 5.00 0.93
a. Individual items were measured on a Likert scale (1 = strongly disagree through 5 = strongly agree). Higher scores
signify more positive attitudes, more favorable subjective norm, more perceived behavioral control and stronger
intention to seek MTMS.
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4.3. Descriptive Statistics for TPB Constructs
Descriptive statistics for TPB constructs have been presented in Table 2. Participants had a mean
attitude score of 4.04 with a standard deviation of 0.97. A mean score of 3.77 was found for subjective
norm with a standard deviation of 0.91. The lowest mean score of 3.75 with a standard deviation of
0.93 was found for perceived behavioral control based on three items. Finally, a mean score of 3.96
with a standard deviation of 0.94 was found for intention. These mean scores were computed on a
Likert scale of 1 to 5 with 1 representing “strongly disagree” and 5 representing “strongly agree”.
4.4. Item-Wise Descriptive Statistics for TPB Constructs
Descriptive statistics for individual items including the percentage of respondents having a
positive response (either agree or strongly agree), neutral response, and negative response (disagree or
strongly disagree) for each statement have been presented in Table 3.
Table 3. Survey statements and descriptive statistics by construct (N = 133).







If pharmacist advises me on how to avoid
medicine-related problems such as possible adverse
effects or side effects, allergy due to medicine; it will be
helpful for me.
3.99
(1.14) 82.0 4.5 13.5
Attitude
If pharmacist guides me on how to handle my medicines
by myself (such as taking appropriate action if the dose is
missed, using a pill reminder chart for taking medicines
timely), it will be helpful for me.
4.11
(1.03) 88.0 3.0 9.0
If pharmacist communicates with me to ensure that I am
taking my medicines according to doctor’s prescription,
it will be good for me.
4.02
(1.06) 83.5 4.5 11.3
If I want to take pharmacy services, my family members
will support me.
3.90
(0.92) 79.7 9.0 11.3
Subjective
Norm
If I want to take pharmacy services, my friends will
support me.
3.75
(1.05) 68.4 20.3 11.3
People important to me in my community will support
me to take pharmacy services.
3.65
(1.05) 69.2 17.3 13.5
I can easily meet my pharmacist to take his/her services. 3.76(0.99) 72.9 11.3 15.0
I am confident that I shall be able to take pharmacy
services.
3.92




I shall be able to take pharmacy services without any
difficulty.
3.74
(1.06) 72.2 13.5 14.3
I have enough time for taking services provided by
pharmacist.
3.55
(1.16) 63.2 18.8 18.0
Taking pharmacy services is entirely within my control. 3.77(1.10) 72.9 12.0 13.5
I am willing to take the service in which my pharmacist
. . .
. . . will evaluate my medicines and tell me how to avoid
medicine-related problems such as possible adverse
effects or side effects, allergy due to medicine etc.
3.95
(1.05) 81.2 7.5 11.3
Intention
. . . will educate me so that I can handle my medicines by
myself (such as taking appropriate action if the dose is
missed, using pill reminder chart for taking medicines
timely).
3.95
(1.08) 83.5 3.8 12.8
. . . will educate me on diet, physical activity, smoking,
drinking etc. so that I can manage diseases such as
diabetes.
3.96
(1.05) 82.0 6.8 11.3
. . . will recommend my doctor to change the medicine
where there is more effective or safe medicine.
3.86
(1.09) 77.4 8.3 14.3
. . . will contact me and give advice to make sure that I
am continuing medicines according to my doctor’s
prescription.
4.05
(1.04) 86.5 3.8 9.8
SD = standard deviation. a Coded as 1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree.
b Percent stating they agreed or strongly agreed. c Percent stating they disagreed or strongly disagreed.
In terms of attitudes toward seeking MTMS, consumers mostly had positive responses to the items
measuring attitude towards seeking MTMS. More than 80% of respondents agreed that pharmacists’
advice on how to avoid medication-related problems would be helpful for them, pharmacists’ guidance
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on self-management of medications would be helpful for them, and pharmacists’ follow-up to ensure
patients’ adherence to medications would be good for them. Participants had the most positive attitude
towards pharmacists’ guidance on self-management of medications. A total of 88% of the respondents
agreed that pharmacists’ guidance on self-management of medications would be helpful for them.
On the other hand, respondents had the maximum disagreement with pharmacists’ guidance on
avoiding medication-related problems. A total of 14% of the respondents disagreed to the statement
that pharmacists’ advice on how to avoid medication-related problems would be useful for them.
A total of 84% of the respondents agreed to the statement that pharmacists’ follow-up to ensure patients’
adherence to medications would be good for them.
For subjective norm, more consumers (80%) agreed that family members would support them in
taking MTM services than agreed that friends and people important in community would support
them in taking MTM services. However, 68% of respondents still agreed that friends would encourage
them and 69% of respondents agreed that people important in community would support them in
seeking MTM services.
In terms of perceived behavioral control, 80% of respondents believed that they were confident
that they would be able to take MTM services. At least 70% of respondents believed that they could
easily meet their pharmacist to take his/her services, they should be able to take MTM services without
any difficulty, and taking pharmacy services was entirely within their control. However, this percentage
was lower in the case of having enough time for taking MTM services. More than one third (37%) of
the respondents did not feel (18% disagreed and 19% were neutral) that they had enough time for
taking pharmacist-provided MTM services.
Most of the respondents had positive intention toward seeking MTM services. More than 80%
of respondents had positive intention to take pharmacists’ follow-up service to ensure adherence to
medications. More than 80% of respondents had positive intention to take services in which their
pharmacists would review medicines and advise on how to avoid medication-related problems, would
educate them on self-management of medications, and educate them on lifestyle changes to help them
self-manage their diseases. On the contrary, respondents had the least positive intention to seek service
of pharmacists’ recommendations to physicians about medications. A total of 22% of respondents did
not feel (14% disagreed and 8% were neutral) that they had intention to seek services where pharmacists
would recommend physicians for better medications. Nevertheless, 77% of respondents had positive
intention to seek services where pharmacists would recommend physicians for better medications.
4.5. Multiple Linear Regression Predicting Intention
Hypothesis testing was done by multiple linear regression. Hierarchical multiple regression
was used for the study variables to find out the relative contribution of socio-demographic variables
versus other TPB constructs (attitude, subjective norm, and perceived behavioral control) in predicting
intention. In step 1, attitude, subjective norm, and perceived behavioral control were included as
predictor variables (Model 1). In step 2, along with TPB constructs (attitude, subjective norm, and
perceived behavioral control), socio-demographic variables were entered as predictors of intention
(Model 2). Table 4 presents model summary for Model 1 and Model 2.
Table 4. Model summary of multiple linear regression analysis predicting intention.












1 0.889 b 0.791 0.786 0.43605 0.791 162.655 3 129 0.000
2 0.899 c 0.808 0.785 0.43680 0.017 0.959 11 118 0.487
a. Dependent variable: intention. b. Predictors (constant): attitude, subjective norm, perceived behavioral control.
c. Predictors (constant): attitude, subjective norm, perceived behavioral control, age more than 45 years, male gender,
married or in a domestic relationship, Bangladeshi origin, Nepali origin, Indian origin, bachelor’s degree or higher,
income more than $35,000, duration of residency in the US, daily prescription drug quantity, experience in health
care profession.
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Model 1 had an R2 value equal to 0.791 and Model 2 had an R2 value equal to 0.808. It means
that 79.1% of the variance in intention was explained by the independent variables in Model 1 and
80.8% of the variance in intention was explained by the independent variables in Model 2. Entry of
socio-demographic variables (Model 2) resulted in a change in R2 of 0.017. This means that entry of
socio-demographic variables increased the explained variance in intention by only 1.7% to a total of
80.8%. This increase was not statistically significant by the F change test, F (11,118) = 0.959, p = 0.487.
These findings suggest that the first set of predictor variables other than socio-demographic variables
(attitude, subjective norm, and perceived behavioral control) were a more powerful set of predictors
than socio-demographic variables and inclusion of socio-demographic variables did not increase
explanatory power significantly.
4.5.1. Influence of Attitude on Intention
The first specific objective of the study was to assess the influence of South Asian consumers’
attitude toward seeking MTMS on their intention to seek MTMS. The regression analysis for Model 1
found that attitude was a statistically significant predictor of intention, β = 0.732, t = 11.258, p < 0.05,
as shown in Table 5. The regression analysis for Model 2 also found that attitude was a statistically
significant predictor of intention, β = 0.723, t = 10.303, p < 0.05, as shown in Table 5. This means
attitude was a significant predictor of intention (p < 0.05) for both models.
Table 5. Parameter estimates from multiple linear regression analysis predicting intention to seek





B Standard Error Beta t Statistic P Value
Constant 0.274 0.177 1.550 0.124
Attitude 0.711 0.063 0.732 11.258 0.000 *
1 a Subjective norm 0.043 0.074 0.042 0.587 0.558
Perceived behavioral
control 0.171 0.063 0.169 2.738 0.007 *
Constant 0.444 0.239 1.860 0.065
Attitude 0.703 0.068 0.723 10.303 0.000 *
Subjective norm 0.067 0.078 0.064 0.854 0.395
Perceived behavioral
control 0.150 0.067 0.148 2.224 0.028 *
Age −0.100 0.109 −0.047 −0.918 0.361
Gender −0.014 0.099 −0.007 −0.143 0.887
Bangladeshi Origin 0.042 0.168 0.019 0.251 0.802
2 a,b Nepali Origin −0.065 0.209 −0.020 −0.311 0.756
Indian Origin 0.112 0.214 0.033 0.522 0.602
Education −0.031 0.083 −0.016 −0.368 0.714
Income 0.011 0.092 0.006 0.123 0.902
Marital Status −0.138 0.091 −0.071 −1.511 0.133
Duration of Residency
in the US −0.142 0.092 −0.072 −1.540 0.126
No of Daily Rx Drug 0.147 0.114 0.066 1.286 0.201
HCP Experience 0.092 0.123 0.032 0.748 0.456
* Significant predictor of intention at a level of significance of 0.05. a. Dependent variable: intention. b. Age was
coded as 1 =more than 45 years, 0 = 18 to 45 years; gender was coded as 1 =male, 0 = female; Bangladeshi origin
was coded as 1 = Bangladeshi origin, 0 = non- Bangladeshi origin; Nepali origin was coded as 1 =Nepali origin,
0 = non- Nepali origin; Indian origin was coded as 1 = Indian origin, 0 = non-Indian origin; education was coded as
1 = bachelor’s and above, 0 = Less than bachelor’s; income was coded as 1 = $35,000 and above, 0 = up to $34,999;
marital status was coded as 1 =married or in a domestic relationship, 0 = other; duration of residency in the US
was coded as 1 = more than 5 years, 0 = up to 5 years; daily prescription drug quantity was coded as 1 = 3 or
more, 0 = less than 3; health care profession (HCP) experience was coded as 1 = previous experience in health care
profession, 0 = no experience in health care profession.
4.5.2. Influence of Subjective Norm on Intention
The second study objective was to assess the influence of South Asian consumers’ subjective norm
associated with seeking MTM services on their intention to seek MTMS. The regression analysis for
Model 1 found that subjective norm was not a statistically significant predictor of intention, β = 0.042,
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t = 0.587, p = 0.558, as shown in Table 5. The regression analysis for Model 2 also found that subjective
norm was not a statistically significant predictor of intention, β = 0.064, t = 0.854, p = 0.395, as shown
in Table 5. This means subjective norm was not a significant predictor of intention (p < 0.05) for
both models.
4.5.3. Influence of Perceived Behavioral Control on Intention
The third study objective was to assess the influence of South Asian consumers’ perceived
behavioral control in seeking MTM services on their intention to seek MTMS. The regression analysis
for Model 1 found that perceived behavioral control was a statistically significant predictor of intention,
β = 0.169, t = 2.738, p < 0.05, as shown in Table 5. The regression analysis for Model 2 found that
perceived behavioral control was a statistically significant predictor of intention, β = 0.148, t = 2.224,
p < 0.05, as shown in Table 5. This means perceived behavioral control was a significant predictor of
intention (p < 0.05) for both models.
4.5.4. Influence of Socio-Demographic Characteristics on Intention
The fourth specific study objective was to assess the influence of South Asian consumers’
socio-demographic characteristics on their intention to seek MTMS. Prediction by none of these
socio-demographic variables was found to be significant at a level of significance of 0.05, as shown in
Table 5.
5. Discussion
To the researcher’s knowledge, this is the first consumer/patient focused study regarding MTMS
that used TPB. However, the results found in this study may be influenced by the demographics of
study participants. The study group was quite skewed toward younger people, with only 6.8% of
participants having an age of 65 years or more, whereas 16% of the total US population are 65 years or
older [49]. A total of 51 out of 133 respondents (38.3%) reported no prescription medications taken
daily and these respondents may not perceive a need for MTM at all. While 53% of the total South
Asian population in the US are male [28], 71.4% of study participants in this study were male. This
gender skewing (95 males to 38 females) could also have influenced responses. The educational data
showed 51.1% with bachelor or higher degrees while this percentage for South Asians in the entire US
is 59% [28]. These data indicate that findings from this study may not be generalizable to the entire US
population. Due to skewness in demographics of study participants, results may slightly vary from
opinions of the total South Asian population in the US.
The purpose of this study was to use the theory of planned behavior (TPB) to understand factors
influencing intention of South Asian consumers to seek pharmacist-provided medication therapy
management (MTM) services. The study results found that the overall attitude, subjective norm,
perceived behavioral control, and intention of South Asian consumers to seek MTMS was positive.
This is consistent with findings from previous studies regarding MTMS where patients had a positive
attitude towards receiving MTMS, were willing to take MTMS, and recognized pharmacists as potential
providers of MTMS [18]. The majority of respondents had positive intention to seek each component
of MTMS, as shown in Table 3. However, respondents had the least agreement with the statement
that they would be willing to take MTM services where pharmacists will recommend physicians for
safer or more effective medication. This finding is consistent with findings from the study by Brown
et al. [20] where consumers were not favoring services that involve contacting their physicians for
recommending safer or more effective medications.
The study findings indicate that South Asian consumers’ intention to seek MTMS was driven by
attitude and perceived behavioral control. This finding is consistent with previous research regarding
applications of TPB in health-related behaviors [32–34,50,51]. However, considering the influence
of subjective norm, this finding is slightly different from TPB research assessing intention to receive
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pharmacy services [35]. Details on the influence of attitude, subjective norm, perceived behavioral
control, and socio-demographic characteristics on intention have been described below:
5.1. Influence of Attitude on Intention
South Asian consumers’ attitude towards seeking MTM services was found to be a significant and
strongest predictor of their intention to seek MTM services. This finding is consistent with previous
TPB research assessing pharmacists’ intent to provide MTMS [31], community pharmacists’ intention to
utilize a prescription drug monitoring program [32], pharmacists’ intention to report serious ADEs to
the FDA [33], patients’ intention to participate in physical exercise [52], and medical students’ intention
to improve oral hygiene [34].
More than 80% of respondents had a positive attitude toward seeking each component of
MTMS, as shown in Table 3. This finding is consistent with previous findings from the study by
Schultz et al., aimed at determining patient-perceived value of MTMS. Schultz et al. found that
MTMS was considered to be valuable, satisfactory, and financially beneficial to patients [19]. In this
current study, respondents were the most positive with services involving the pharmacist’s educating
self-management of medications and were the least positive with services involving the pharmacist’s
guidance on managing drug-related problems (DRPs). Similar results were also evident in past
research [16]. Like this current study, in a study by Doucette et al., services involving explaining how
to use medications had the highest mean score [23].
To strengthen South Asian consumers’ intention to seek MTM services, pharmacists should focus
on creating and maintaining positive attitude toward MTM services. Previous research found that
participants had a positive attitude toward pharmacists in terms of pharmacists’ knowledge and
problem solving capability [22] and pharmacists were believed to be good candidates to provide MTM
services [15]. Patients receiving MTM services also identified their MTM pharmacist as a supporter,
advocate, confidant, resource for education, and coordinator of medications [19]. However, perception
of pharmacists revolved around the medication dispensing function [15] and patients were skeptical
about pharmacists’ interaction with patients [22]. This perception may have a negative influence on
attitudes towards seeking pharmacist-provided services. It is a matter of further investigation of which
factors influence South Asian consumers’ attitude toward seeking pharmacist-provided services. To
create a positive attitude toward seeking pharmacist-provided MTMS, pharmacists have to create
a perception of providing personalized information about medications and advising South Asian
patients on medications through interaction with South Asian patients beyond traditional dispensing.
During this current study, it has been found that pharmacy technicians have the opportunity to
interact with patients. Along with pharmacists, pharmacy technicians may also contribute to creating
a positive attitude towards pharmacy and pharmacy services though positive interactions with South
Asian patients. A previous study found that the perceived importance of pharmacist-provided
comprehensive medication reviews was more in patients experiencing comprehensive medication
reviews than in patients not experiencing comprehensive medication reviews from pharmacists [23].
In order to increase perceived importance of MTMS, pharmacists can provide MTMS for free or a
reduced/discounted price for a short time (like a trial version) to have South Asian patients experience
the flavor of MTMS and then for an extended period (like a full version) once South Asian patients
have experienced MTMS.
5.2. Influence of Subjective Norm on Intention
Subjective norm was not a statistically significant predictor of intention. This finding differs
with findings from previous applications of TPB where subjective norm was a significant predictor
of pharmacists’ intent to provide MTMS [31], intention to utilize a prescription drug monitoring
program [32], and intention to report serious ADEs to the FDA [33]. This may due to the fact that
pharmacists felt the competitiveness to provide MTMS seeing other pharmacists providing MTMS.
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On the other hand, consumers might intend to seek MTMS when they experience certain health
conditions or medications.
However, this finding also differs with the result from a consumer-focused study done by Tan et al.
using TPB. Malaysian consumers’ subjective norm was found to be a significant predictor of intention
to adopt Pharmacy Value Added Services (PVAS) introduced by Malaysia’s Ministry of Health [35].
As described by Fishbein, the degree of influence of attitude, subjective norm, and perceived behavioral
control on intention may vary depending on behavior and the population being considered [53]. The
difference in population (South Asians in the US vs. Malaysians in Malaysia) and behavior (seeking
MTMS vs. adopting PVAS) may explain different degrees of influence of subjective norm on intention.
Considering South Asian consumers typically get their health care related information primarily
from family members and physicians, this finding was particularly interesting [27]. This finding also
conflicts with previous research where influence of family members was found an important factor
for South Asian patients’ health behavior, such as medication adherence among South Asian patients
with cardiac diseases [54]. Further studies would be needed to explore why subjective norm did not
significantly predict intention of South Asian consumers to seek MTMS.
5.3. Influence of Perceived Behavioral Control on Intention
In this study, perceived behavioral control was found to be a statistically significant predictor
of intention. This finding is consistent with the results from previous research on pharmacists and
consumers where perceived behavioral control was found to be a significant predictor of pharmacists’
intent to provide MTMS [31], pharmacists’ intention to utilize a prescription drug monitoring
program [32], as well as consumers’ intention to adopt Pharmacy Value Added Services (PVAS) [35].
In order to increase South Asian consumers’ intention to seek MTMS, focus should be given to
minimizing their perceived barriers in seeking MTMS. In this study’s findings, most respondents were
confident that they can take pharmacist-provided services. However, a total of 37% of respondents did
not feel (18% disagreed and 19% were neutral) that they had enough time for taking pharmacist-provided
services, as shown in Table 3. This finding is also consistent with findings from previous studies on
patient-reported barriers to receive MTMS [19,22]. This indicates that matching the patient’s convenient
time with the MTM pharmacist’s available time would be an important consideration in facilitating
the patient’s taking of MTM services. Although inability to fix times with MTM pharmacists due to
patients’ busy schedules is a common problem found in previous studies; Moczygemba et al. found that
patients were satisfied with pharmacist-provided telephone-based MTM care [21]. In telephone-based
MTM care, patients viewed pharmacists as easily accessible and responsive to patients’ problems [21].
In order to match the timing between pharmacists and South Asian patients, pharmacists can consider
providing telephone-based MTM care as an alternative option for South Asian patients.
In the previous literature, patient-reported barriers to receive MTMS were patients’ lack of
knowledge of MTMS; lack of perceived need for MTMS; out-of-pocket cost; lack of availability of
the MTM pharmacist at patients’ convenient time; inability to fix appointments due to patients’ busy
schedule; inaccessibility to pharmacist MTM practice due to the location, parking, time of day/week;
and fear of obtaining recommendations conflicting with their physician’s plan of care [13,19,22].
Pharmacists can check if these barriers are also South Asian consumers’ barriers to receive MTMS.
Pharmacists should keep any such barriers as low as possible so that patients are willing to seek
MTMS. Pharmacists should also observe and resolve any cultural barriers (such as language barriers)
specifically faced by South Asian consumers in order to strengthen South Asian patients’ intention to
seek MTMS.
5.4. Influence of Socio-Demographic Characteristics on Intention
In this study, none of the socio-demographic characteristics was found to be statistically significant
predictors of intention.
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Age was expected to be an important factor influencing intention to seek MTMS. Since elderly
people are more prone to have chronic diseases and use multiple medications, they are supposed to
need help in managing their medications. Moreover, previous research found a correlation of age with
willingness to pay for MTMS [18]. Unexpectedly, age was not a significant predictor of intention to
seek MTMS in the South Asian group.
In previous studies, the willingness to accept pharmacist-provided MTMS differed in terms of
gender [20]. In the current study, intention to seek MTMS differed in terms of gender. Although the
survey was anonymous, a number of females, because of their conservative cultural background, did
not respond to the survey during the study. A common response from female consumers for their
non-participation in the survey was “I cannot fill up any survey without my husband’s permission”.
This non-response has resulted in a decreased proportion of female participants compared to male
participants. However, gender was not found to be a significant predictor of intention to seek MTMS.
In previous studies, the willingness to accept pharmacist-provided MTMS differed in terms of
education level and income [20]. In the current study, intention to seek MTMS also differed in terms of
education and income. Nonetheless, none of the variables were found to be significant predictors of
intention to seek MTMS in this particular group. Although married consumers had a mean intention
score less than unmarried ones, marital status was not found to be a significant predictor of intention
to seek MTMS.
Duration of residency in the US was included as a socio-demographic predictor variable as
consumers may get acquainted with the US health care system and be more aware of health services with
the increasing duration of residency in the US. Country of origin was included as socio-demographic
variable as culture in different countries can influence health behavior. Neither duration of residency
in the US nor country of origin was found to be a significant predictor of intention to seek MTMS.
In past research, consumers’ work experience in the healthcare profession was found associated
with their willingness to accept MTM services [20]. It was expected that South Asian consumers’ work
experience in the healthcare profession would influence their intention to seek MTMS. Unexpectedly,
experience in the healthcare profession had no influence on South Asian consumers’ intention to
seek MTMS.
The noteworthy unexpected finding was that number of medications had no statistically significant
impact on intention to seek MTMS. It was expected that the more medications one takes, the more
would be the need for managing medications and thus, intention to seek MTMS. It is possible that
patients are taking medications on an on-demand basis and not on a regular basis, or they are already
familiar with medications. That is why they probably did not feel the need for MTMS and had
no intention to seek such services. More than one-third (38.3%) of the respondents were taking no
prescription drugs. It may be due to the fact that many non-patient consumers visited pharmacies to
get medications for their family members.
6. Limitations and Future Research
Like any other research, this study has some limitations, too. Firstly, most of the respondents
(76.7%) were of Bangladeshi origin. Demographically, the selected sample as a whole may not represent
South Asian consumers in the US. Although the South Asian community is diverse in languages and
religious practices, there are many shared social and cultural characteristics among South Asians [28].
Thus, although most of the respondents were of Bangladeshi origin, they still represent South Asians
holding those social and cultural characteristics. Secondly, the target sample size could not be reached
due to the limited duration of the study period and non-response from South Asian consumers,
particularly from females. However, a sample size of 133 used in this study is sufficient for factor
analysis for both Model 1 and Model 2 [40,41] and also adequate for multiple linear regression analysis
for Model 1 [42]. Only for multiple linear regression analysis in Model 2, a sample size of 133 is less
than the recommended sample size of 154 [42]. Thirdly, this study did not consider the actual behavior
of consumers, an important construct of TPB, which may vary from intention measured in the study.
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Fourthly, this study assessed degree of influence of attitude, subjective norm, and perceived behavioral
control on intention but did not find out the reasons for such influence. A qualitative study would
complement quantitative research in finding out specific reasons for such influence. Finally, although
previous research found that disease state, number of health problems, familiarity with medications,
and insurance status had correlations with either willing to receive MTMS or willingness to pay for
MTMS, these variables were not included in this study. Future research can include these variables.
Future research opportunities include conducting qualitative research to find out the reasons
behind the influence of factors such as attitude, subjective norm, and perceived behavioral control
on intention to seek pharmacist-provided MTMS. Previous research showed that not all respondents
willing to receive MTMS are willing to pay for MTMS [18] and most of the respondents think
that insurance companies should cover cognitive pharmacy services [55]. South Asian consumers’
willingness to pay for MTMS can also be studied to assess how payment influences their intention and
actual performance of behavior, that is, receiving pharmacist-provided MTM services.
7. Conclusions
Overall, South Asian consumers showed a positive attitude, favorable subjective norm, favorable
perceived behavioral control, and positive intention to seek MTM services. The TPB was revealed to be
a good model to measure and predict South Asian consumers’ intention to seek MTM services. Multiple
linear regression analysis showed that attitude and perceived behavioral control were significant
predictors of intention (p < 0.05), but subjective norm was not a significant predictor of intention.
Socio-demographic characteristics did not have a significant effect on intention.
Strategies to make South Asian consumers seek MTM services should focus on enhancing and
maintaining positive attitudes by showing expertise in medicines through interactions with South
Asian patients, identifying and promoting factors (e.g., pharmacists’ knowledge) responsible for
positive attitudes among South Asian patients, promoting perceived facilitators (e.g., easy access) in
seeking MTMS, and resolving possible barriers (e.g., timing, language) perceived by South Asian
patients in seeking MTMS.
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Abstract: The medication experience is an individual’s subjective experience of taking a medication in
daily life and can be at the root of drug therapy problems. It is recommended that the patient-centered
approach to comprehensive medication management (CMM) starts with an understanding of the
patient’s medication experience. This study aims to develop a medication experience documentation
tool for use in CMM services, and to understand the usefulness and challenges of using the tool in
practice. The tool was developed based on previous research on patients’ medication experiences.
It was tested in two rounds by ten CMM pharmacists utilizing the tool as they provided care to
patients. Focus groups were conducted to revise the tool after each round and to understand
pharmacists’ experiences. The tool was tested for 15 weeks in 407 patient encounters. There was
at least one medication experience documented in the electronic medical record 62% of the time.
Pharmacists found the tool helpful in raising awareness of the medication experience and motivational
interviewing strategies, planning for follow-up visits, as a teaching tool, and making pharmacists
realize the fluidity of the medication experience. The tool offered pharmacists a better way to
recognize and address medication experiences affecting medication taking behaviors.
Keywords: comprehensive medication management services; medication experience; pharmaceutical
care practice; documentation; focus groups
1. Introduction
The profession of pharmacy continues to shift from the traditional dispensing role to a more
patient-focused practice revolving around the provision of Comprehensive Medication Management
(CMM) services. Several studies have shown the value of CMM in the care of patients with chronic
conditions through the resolution of drug therapy problems [1–4]. It should be noted that there are
different approaches to medication management services emerging in practice: the prescription-focused
and the patient-centered approach. The first one is related to activities performed at the time of
dispensing a drug to a patient. The patient-centered approach delivers the service on an appointment
basis applying specific standards of care to each patient encounter [4].
In providing a patient-focused service, CMM pharmacists have been challenged with using
evidence-based medication guidelines, while understanding the patient’s unique medication experience
to improve patient outcomes [5–7]. The medication experience is an individual’s subjective experience
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of taking a medication in daily life and includes the patient’s preferences, feelings, concerns, beliefs,
and behaviors associated with medications [5]. Patients often have perceptions and beliefs about
medications based on their own experiences or the experiences of others, which may influence or even
prevent them from taking medications as recommended [5]. Patients might adjust doses to minimize
unwanted effects and make the regimen more acceptable, or they can weigh risks against benefits, as
a response to perceptions that go from gratitude that medicines exist to fear and uncertainty about
adverse effects, or they can consider two or more medications being used for the same condition as
unnecessary, or they might even completely deny their illness [8]. Other concerns that patients may
have include fear of the actual administration of medicine or drug dependence. These concerns are
often due to insufficient knowledge of the medication [8]. In this context, understanding the meanings
that medications have for patients may help pharmacists to positively impact their medication-taking
behavior [5].
Previous research has shown that pharmacists have used the patient’s medication experience to
guide the education provided to patients starting new medications to prevent the development of drug
therapy problems (DTP), as well as to tailor their interventions to resolve drug therapy problems [6].
Ultimately, research findings indicate that there are many examples of drug therapy problems for
which the medication experience is at the root cause [7].
In order to improve these experiences or change patients’ perceptions of their medications,
different strategies can be utilized in practice. Some studies show that strategies to overcome
a negative medication experience are focused around influencing a perception, an attitude or a
behavior change [8–10]. This is not always as simple as resolving a DTP, where a dose can be
adjusted or a new medication started, if another one was not effective. Motivational Interviewing
(MI) has been found to be an effective intervention to promote behavioral changes. It is a form of
collaborative conversation between provider and patient directed towards strengthening a patient’s
own motivation and commitment to change. MI strategies are particularly useful for those who are
reluctant or ambivalent about changing a behavior [11–13]. Also, some research has indicated that
CMM pharmacists have successfully used MI strategies to affect patients’ medication experiences [6,7].
It is recommended that the patient-centered approach to comprehensive medication management
starts with an understanding of the patient’s medication experience [4,14]. However, documenting
the patient’s medication experience and intentionally using this knowledge to make decisions about
strategies to resolve DTPs and meet patients’ medication-related needs is still not a common habit
in practice.
The purpose of this research was to develop a medication experience documentation tool for use
in CMM services, test the tool in practice with experienced CMM pharmacists, and understand the
usefulness and challenges of having pharmacists use the tool in practice.
2. Materials and Methods
The tool was iteratively developed and refined based on two rounds of testing in practice and focus
groups with CMM pharmacists. The methods are described by tool development, testing, and focus
groups, as seen in Figure 1.
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Figure 1. Approach to Developing and Testing the Medication Experience Documentation Tool.
2.1. Tool Development
The aim of the medication experience documentation tool was to facilitate the documentation of a
patient’s medication experiences perceived to be at the root of drug therapy problems (DTPs) by CMM
pharmacists, as they conducted an assessment of a patient’s medication-related needs. The tool also
allows pharmacists to indicate the motivational interviewing strategies used to address the identified
medication experience and associated DTPs.
The initial version of the medication experience assessment tool (Tool v1) was developed based
on previously published research on patients’ medication experiences and pharmacists’ perspectives
encountering patients’ medication experiences in their practice [3–7,14] and motivational interviewing
strategies [11–13]. The tool was built in the electronic medical record (EMR), where CMM pharmacists
routinely document the care they provide. The tool included two drop-down lists from which to select:
(1) the patient’s medication experience and (2) the motivational interviewing strategies used to address
that specific medication experience. There was also a write-in option for any experience or strategy not
reflected in the list and a ‘none’ option if no experience was identified at that specific visit. The tool
was located at the end of the assessment section of the EMR documentation. The pharmacists were
instructed to use the tool during every patient encounter, though only medication experiences that
negatively impacted a patient’s medication-taking behavior were deemed to require an intervention and
thus be documented with the tool. Multiple medication experiences could be identified during a single
visit, thus the drop-down boxes allowed for multiple options to be selected. However, the pharmacist
would document only the experiences he or she attempted to affect during that specific encounter.
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2.2. Tool Testing
2.2.1. Setting
The tool was tested with pharmacists in a large health care system consisting of 7 hospitals and
38 ambulatory clinics. CMM services have been provided in this health system for over 15 years.
Participating pharmacists had a range of experience practicing CMM spanning from 4 months to 15 years
and were all practicing in ambulatory primary care clinics. CMM pharmacists document their progress
notes in the electronic medical record in the form of a SOAP note (subjective/objective/assessment/plan).
All of the CMM pharmacists participating in this study had previously undergone training on how to
use the medication experience tool and on motivational interviewing. In practice, the pharmacists
identified medication experiences through the pharmaceutical care assessment process by asking
open-ended questions and listening for conversation clues. Then, motivational interviewing techniques
were used to affect those experiences that were perceived by the pharmacist as negatively impacting
the patient’s medication taking behavior. They were instructed to use the documentation tool during
the time that they conducted the assessment of each patient.
2.2.2. Testing Period
All 20 CMM pharmacists practicing in the health care system were invited to contribute to this
research and 10 agreed to participate. The participating ten pharmacists utilized the first version of
the tool (Tool v1) for seven weeks as part of their practice providing comprehensive patient-centered
medication management (CMM) services to patients in the primary care setting. The same 10
pharmacists used the second version of the tool (Tool v2) for eight (8) weeks.
2.2.3. Tool Results
The EMR of all patients cared for by the 10 participating pharmacists during the studied period
were analyzed to identify the type and the number of experiences documented as well as the strategies
utilized to address those experiences in all patient encounters. All data were documented in an excel
spreadsheet and the frequencies of the identified medication experiences and the utilized strategies
were calculated.
2.3. Focus Groups with Pharmacists
Two focus groups were conducted with all participating ten pharmacists using the techniques
proposed by Krueger and Casey [15]. The aims of the focus groups were to understand pharmacists’
experiences using the documentation tool in practice, in terms of usefulness and challenges.
A focus group was conducted after each testing period with Tool v1 and Tool v2. The information
revealed in the focus groups informed revisions to the tool. The focus groups were two hours in length.
A focus group discussion guide did not used any specific framework, but it was developed with the
purpose of stimulating discussion to elucidate pharmacists’ experiences, reactions, and expectations
related to the medication experience and motivational interviewing strategies in the tool. See Table 1
for a list of questions used in the focus groups.
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Table 1. Focus Group Discussion Questions.
Focus Group 1 Focus Group 2
• What was it like for you to document your patients’ medication experiences?
 Has it been helpful to you to document these experiences, how and why?
• What medication experiences or strategies should stay, should not be there, what are missing?
• How do you see this being useful tool for other practitioners, new practitioners, students?
• Has documenting the medication experience been useful for follow-up visits?
• What do you think of the tool? What was it like
to use the tool?
• Is the revised tool easier to use? What would
make it easier and/or more helpful?
• Can the tool be used in patients with no
medication experiences?
• Is this tool important enough to incorporate as a
requirement in our documentation notes?
• Is the placement of the tool in the “assessment”
section appropriate?
• Does documenting and having a more in-depth
awareness of patient’s medication experience
help with or change your therapy decisions?
• Has this helped you in developing your
motivational interviewing skills? How?
• Are you noticing the medication experience can
change over time?
• In your experience with documenting these
patients’ experiences, how do they connect to
drug therapy problems?
All focus groups were audio-recorded and then professionally transcribed verbatim. All researchers
independently coded the data to identify significant sections about pharmacists’ perspectives on the
tool. Then, they met to form a consensus about the common themes of pharmacists’ experiences and
perspectives on utilizing the documentation tool. The final themes are described below.
Human Subjects Protection
Pharmacists were assured confidentiality that any information provided could not be traced to




After the completion of testing Tool v1 and the first focus group, several changes were incorporated
into Tool v2, see Table 2. After the completion of testing Tool v2 and the second focus group, changes
were also incorporated into the final tool, see Table 2. The final tool can be found in Appendix A.
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Table 2. The Medication Experience Documentation Tool: Overview of Testing Rounds, Use
and Changes.
Round 1 Round 2
Tool Version Tool v1 Tool v2
Testing Duration 7 weeks 8 weeks
Pharmacists 10 RPhs 10 RPhs (same as Round1)
Pharmacists’MTM experience 4 months–15 years 4 months–15 years
# of Patient encounters 620 649
# (%) Patient encounters pharmacists
used Tool
180 (29%) 227 (35%)
Changes to the Tool
Changes to the Medication
Experiences
- Condensed and reordered the tool into
subcategories for ease of use
- One medication experience deleted: ”positive
medication experience, does not want to use
alternative non-drug therapy or
lifestyle changes”
- Four medication experiences added: “does not
want to use because they are too reliant on Rx
medication (s)”, “feelings of burden and being
overwhelmed”, “fear of side effects from
personal history”, and “fear about history
of addiction”
- One medication experienced revised: economic
value question changed to “cannot reconcile
value of medication over cost”
- Shortened verbiage in tool
- Moved some subcategories
back into major categories




Changes to Strategies - Removed empathy and listening
- Added referral to care
team member
3.2. Tool Utilization and Results
A summary of the tool testing approach, utilization and results is provided in Table 2. In round 1,
pharmacists utilized the tool 29% of the time in 180 of 620 patient encounters in the 7-week testing
period. In round 2, pharmacists utilized the tool 35% of the time in 227 of 649 patient encounters in the
8-week testing period. The tool was used 32% of the time in a total of 407 patient encounters.
When the tool was used in 407 patient encounters, it was observed that patients had a documented
medication experience 62% of the time. Specifically, in round 2, no medication experience was selected
in 29%, 86 out of 292 total medication experiences. Table 3 shows round 2, the most common medication
experiences identified and the most common strategies utilized by the pharmacists to address each
medication experience; presented in decreasing order of frequency. Definitions used for the strategies
can be found in the Appendix B.
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3.3. Pharmacist Focus Groups
The major themes that emerged from the focus groups are described below in terms of the
usefulness and challenges of using the medication experience documentation tool. The findings reflect
the experiences of the 10 CMM pharmacists that utilized the tool and participated in both focus groups.
3.3.1. Usefulness of the Tool
Participants expressed the usefulness of the tool as the following themes: the tool makes CMM
pharmacists more aware of the medication experience and more reflexive; using the tool makes
pharmacists realize the fluidity of the medication experience; the tool assists with teaching; and the
tool helps with future care plans.
The Tool Makes CMM Pharmacists More Aware of the Medication Experience and More Reflexive
The group of 10 CMM pharmacists expressed feelings that the tool led them to document more
details of the visit in relation to the medication experience and the reasoning behind a patient’s
medication taking behaviors. Some of them asserted that usually they use the tool as an afterthought.
They also expressed that the documentation process changed their practices, as they felt more conscious
of and more likely to address and explore a patient’s medication experience to help patients to better
understand the need for their medications and what to expect from them.
“The fact that I had to think about the experience and what strategies I would use, it changed my
practice. I put it into an important piece of my every day work. . . . and then I started thinking I should
really use this strategy the next time I talk to a patient about this type of thing” (Pharmacist 3).
Awareness was created and the pharmacists felt more able to truly identify what the patient wants
out of the visit.
“I feel more aware and I am thinking about it more. Before it was more subconscious”
(Pharmacist 1).
Using the tool and documenting the medication experience helped CMM pharmacists to become
more reflexive. As the pharmacist in the last quote emphasized, it was felt that documenting the
medication experience helped them to be more aware of patients’ experiences and what they could do
to improve those experiences.
Since the tool was embedded into note templates, during the CMM visit, pharmacists could see it
on the computer screen. It was agreed that simply seeing the tool during the visit was a good reminder
and created consciousness of MI strategies that could be used during the consultation to motivate
the patient.
“When I see it [the tool] there in the visit, it causes me to think about it with the patient and make
sure I get to the bottom of it” (Pharmacist 8).
Using the Tool Makes Pharmacists Realize the Fluidity of the Medication Experience
As participants documented the medication experience at each visit, it became more evident how
fluid and dynamic these experiences can be.
“The same patient can have different experiences associated with different medications”
(Pharmacist 4).
“The experience can change from one visit to the next. So, we really need to pay attention to the
patients’ expressions at each visit. We cannot predict what is happening today based on our last visit”
(Pharmacist 1).
To understand the changeability of the medication experience was an important result of utilizing
the tool. These experiences are subjective and impacted by different factors meaning that the pharmacist
needs to carefully listen at each visit and use the appropriate strategies to address them when needed.
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The Tool Assists with Teaching
Participants in the focus group agreed that one of the most useful aspects of the documentation
tool was for teaching purposes—for both students and new CMM pharmacists. It helps to frame
concepts that CMM pharmacists are naturally evaluating, but are not necessarily able to explain or
discuss aloud with students or novice pharmacists.
“When I am with a student, the tool pushes me to express what is inside my head, the connections
I am making to take a certain decision” (Pharmacist 10).
“The medication experience is a difficult concept to teach because people tend to think that is too
philosophical, too abstract. But it is definitely not! The tool helps to bring the medication experience to
a more practical level when I am teaching” (Pharmacist 2).
Several pharmacists emphasized how using the tool helped students to pay more attention to
the subjective aspects of taking medications, which is usually a type of knowledge neglected in
pharmacy curricula.
“By using it [the tool] students start to become more attentive to what kinds of factors impact
patients’ decisions and behaviors regarding their meds” (Pharmacist 5).
The Tool Helps with Future Care Plans
Documenting the medication experience was found to be helpful for deciding a course of action
for the next patient’s visit.
“It was helpful for follow-up visits to know how to approach that patient next time if you knew
how they were feeling and how they responded to certain strategies . . . It helps me know what avenue
to go down to or to avoid based on previous visits.” (Pharmacist 4)
“I tell my student, after looking at a previous note [with an experience documented in it], that we
have to frame our next conversation with the patient considering this information” (Pharmacist 9).
3.3.2. Challenges of Using the Tool
Participants revealed the challenges of the tool as the following themes: being reflexive can
be burdensome and unearthing the difference between the medication experience and a drug
therapy problem.
Being Reflexive Can Be Burdensome
The CMM pharmacists felt they were already subconsciously identifying and addressing the
medication experience during their routine assessment of a patient, so to have to stop and document
forced them to reflect, which was described at times as “burdensome”. It was often difficult to categorize
experiences since this is a component of the assessment that the group was not used to documenting.
“I think it is just hard to stop and reflect on how patients’ feelings and previous experiences with
medications can impact their attitudes and decisions. I know this is there, it’s everywhere, but to
document it forces me to rethink over and over again” (Pharmacist 1).
“It takes time. So, it can be challenging” (Pharmacist 6).
It should be noted that this setting includes a group of experienced CMM pharmacists—all with
experience in MI and having prior understanding and exposure to the medication experience concept.
“The tool may be more redundant for us at times because our group does this innately, but it
would probably be even more helpful for other groups” (Pharmacist 10).
Unearthing the Difference between the Medication Experience and a Drug Therapy Problem
For pharmacists, one of the most important challenges in using this tool was to understand the
difference between a medication experience and a DTP, since at times they seem to overlap. It was
agreed that the medication experience is completely subjective and usually emotional—typically
revolving around a strong feeling or fear. It describes the patient’s relationship with medications
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and provides the background on how it changes their views on medications, and often times their
behaviors. It is not present in all patients.
For several participants in the study, using the documentation tool multiple times with many
different patients triggered them to perceive the difference between a DTP and a medication experience.
“Before I started using the tool I never really stopped to think about how the medication experience
is the same or different from a DTP. I felt there was a connection, but now I know they are related but
different concepts” (Pharmacist 5).
The group ultimately defined a negative medication experience as “when an experience can get
in the way of a patient getting the most benefit from a medication and can lead to a drug therapy
problem”.
“To me, the medication experience is associated with feelings or attitudes toward taking
medications that is getting in the way of doing what I think is best for them” (Pharmacist 7).
A patient could have multiple DTPs that are not necessarily associated with a medication
experience. On the other hand, a patient might have a medication experience, but no DTP identified at
that point in time.
4. Discussion
The results showed that using the tool has utility for the practice of patient-centered comprehensive
medication management services. Even though it can be “overwhelming” or burdensome to document
one more aspect of the patient care process, the course of documenting the patient’s medication
experience makes the CMM pharmacist more reflexive. Reflexivity has been shown to be an important
trait of a patient-centered practitioner [16,17]. Reflexivity assists pharmacists to become more present
at consultations, more attentive to patients’ needs and more open to patients’ unique perspectives and
experiences. In addition, reflexivity may help pharmacists to look more critically at themselves as
professionals and human beings, which creates space for a broader awareness regarding their way of
relating to patients and other health care providers [18].
Almost all of the participating pharmacists reported using the documentation tool as an
after-thought. Yet some used it to stimulate ideas of motivational interviewing during the encounter,
so having it embedded into the note template was fundamental in making it useful. Interestingly,
most of the strategies listed in Table 3 are the same regardless of the medication experience identified.
This may suggest that some strategies are more effective in general or possibly easier to use. On the other
hand, it may reflect that pharmacists may not be familiar with certain MI strategies and implies that
further work is needed to learn and implement new interventions in practice. Similarly, in adherence
studies that utilized motivational interviewing, no one intervention consistently enhanced adherence
for all patients alike because many variables affect a patient’s decision-making process. Typically,
a combination of interventions is needed to best address a patient’s needs [19]. As MI has outperformed
traditional advice given for a broad range of behavioral problems and diseases, having pharmacists
refine these skills may be a useful way to impact patient health outcomes [20].
For the participants in this study, using the tool helped them to emphasize to students the
importance of the medication experience in patients’ decision-making and, therefore, in the delivery
of CMM services. Students often do not realize that many patients do not take their medications
without resistance and naturally tend to focus much more on their knowledge of pharmacotherapy
versus understanding their patients’ experiences and goals. Using the tool to document the medication
experience helps bring a broader understanding to that concept. The pharmacists remarked that they had
seen it shape their students’ approach to patients’ visits and create attentiveness to what types of factors
impact patients’ decisions and behaviors regarding medications. In other words, the documentation
tool might have encouraged pharmacists and students to become more patient-centered. As indicated
by previous research, incorporating patients’ medication experiences into clinical decision-making is
not an easy task, thus, it is paramount to teach pharmacy students and novice pharmacists how to
identify and use this information in daily clinical practice [6,7,20–22].
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Another important outcome of using the tool to document patients’ medication experience was a
better understanding of the difference between a drug therapy problem and a medication experience.
For instance, consider the DTP that a patient needs additional drug therapy. There is no need to have a
patient experience involved with it unless there is resistance to starting the medication, which would
need to be further explored by the pharmacist. An example of a DTP not correlated with a medication
experience would be when a dose adjustment is needed, and the patient’s perceptions or feelings are
not associated with this. A caveat to this would be if the patient refuses to increase the dose because he
or she fears side effects or if they equate taking a higher dose with worsening health status or personal
failure, which reflects a medication experience. The CMM pharmacists agreed that a DTP may or may
not be linked to an experience or attitude towards taking a medication. However, when that is the
case, it is the CMM responsibility to address this experience with the goal to improve it or include the
patient’s perspective into the decision-making process [20].
Several situations emerged with utilizing the medication experience documentation tool.
The medication experience was found to be dynamic and often changed from visit to visit. Therefore,
the CMM pharmacists agreed they should be intentional in assessing and documenting the presence
of a medication experiences at every single visit. The CMM pharmacists also expressed that it was
ultimately important to document if, at a particular visit, a patient did not have a medication experience
that was affecting medication taking or patient outcomes—hence, the creation of the ‘none’ option for
medication experience. It was agreed that the most meaningful way to use the tool was to limit the
selection of strategies to a maximum of the one or two that were the most effective that day. This helped
them to avoid becoming “desensitized”, as it was hard to interpret which strategies were most effective
when preparing for a follow-up visit if several strategies were listed.
The research recently conducted by Nascimento et al. corroborates the results of this study as it
exposed the complexity of the medication experience. It emphasized the fact that the same individual
can simultaneously experience daily medication use in diverse ways, depending on the medical
condition and the medication used. In that study, patients experienced daily medication use in four
general ways: resolution, adversity ambiguity, or irrelevance. These ways are related to the manner
the medication affects the patient´s personal world, which means that taking a medication is much
more than purely a mechanical action. Medications can disturb the patient´s relationship with his body,
her perception of herself, or his relationship with others [22].
Certain logistics of the tool were challenging with regard to placement of the tool in a documentation
note, understanding when to use the tool, and keeping the documentation brief and simple enough for
convenience and ease of use. The group could not troubleshoot how to prevent from misinterpreting
that a medication experience applies to all medications a patient is taking versus just one. The tool was
not linked to certain conditions or medications. The experience can change based on the medication
and can be different for each visit, so the challenge moving forward is understanding how to link the
documented experience to a specific medication without making the tool too lengthy and cumbersome
to use.
It should be noted that this setting includes a group of experienced CMM pharmacists—all with
experience in MI and having some prior understanding and exposure to the medication experience
concept. As suggested by other studies, educational programs would likely be needed to teach how to
identify patients’ medication experiences and documenting them with the tool and how to apply MI
strategies to their practice [21,22].
It is important to state that the use of the documentation tool in the patient’s assessment has
become the standard of practice for CMM pharmacists in the studied health care system. There needs
to be an expansion of available strategies to understand the best way to improve a patient’s medication
experience. Evaluating positive medication experiences may also provide insight on effective methods
and strategies to use with patients. Limited published information shows the use of the pharmacist
applying MI as a strategy to address the medication experience. There are studies that show trends
of improved medication adherence when MI is used as an intervention by nurses, physicians, and
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therapists in patients with chronic conditions [23]. Improved therapy adherence is associated with
lowered healthcare cost and increase in workplace productivity [24]. Our study looked much
further than adherence, as the medication experience can impact all categories of drug therapy
problems (indication, effectiveness, safety, and adherence) [6,20,21]. More studies should measure how
intervening on the medication experience affects specific drug therapy problems and patient outcomes.
Limitations
This study should be interpreted in light of its limitations. The initial tool was developed based
on studies that aimed for a patient-centered understanding of patients’ medication experiences and
pharmacists’ experiences encountering these experiences in practice.
During the testing time period, there was a substantial gap between the total number of patient
encounters and the encounters in which the tool was used resulting in selection bias. Possible
reasons for this could be that the pharmacists simply forgot, were too busy to use the tool in their
documentation, or did not recognize a medication experience important enough to document. It took
time for pharmacists to incorporate the documentation tool into their existing practices. While MI has
been shown to outperform traditional advice giving in the treatment of a broad range of behavioral
problems, no new strategies were identified during the focus group and the group of pharmacists using
the tool struggled with utilizing the listed strategies [20]. Additionally, the design of the documentation
tool did not identify if a strategy was effective or not. It documented that a certain strategy was used
during the visit, but the effectiveness of the strategy was not followed up on at the subsequent visit to
determine true effectiveness of the intervention. Only negative medication experiences were assessed
with this tool, as we assumed these to be the most meaningful to impact and require intervention for
improved outcomes.
The results originated from a group of CMM pharmacists within one health system, and can not
necessarily be extrapolated or generalized to other practices.
5. Conclusions
CMM pharmacists commonly encounter patients’ medication experiences in their practices.
The documentation tool was developed and tested to assist pharmacists to better recognize
patients´ medication experiences and elect associated strategies to improve medication outcomes.
Pharmacists’ acknowledged that awareness of the medication experience and a toolbox of strategies
to affect it helped improve patient-centered care in their practices. Continued reflection and
documentation of the medication experience is essential in continuing to advance CMM and pharmacist
patient-centered practice.
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Appendix A The Medication Experience Documentation Tool
MEDICATION EXPERIENCE AFFECTING MEDICATION OUTCOMES FOR TODAY’S VISIT
(select one or more and then select associated overall strategies):
None
Feelings of burden and being overwhelmed (ex: pill burden)
Does not want to take medications because:
Doesn’t like to take (cultural background, other)
Doubts the need
Doesn’t feel the benefits
Can’t reconcile value of medication(s) over cost
Associates with a “stigma” and is ashamed/embarrassed to use it
Does not like administration (swallow, infusion, injection) process
Fears/concerns about side effects:
Current personal side effects
History of personal side effects
Observing friend or family member experience
Media
Fears/concerns about becoming dependent on a medication
Fears/concerns medication (ex: generic) will not be effective
Self adjusts medication regimen (increases, decrease, or skips doses)
Increasing medication(s) or increasing medication dose(s) means:
Personal failure
Worsening health status
Prefers alternative non-drug therapy or lifestyle changes
Fear of not having medication(s)/too reliant on Rx medication(s) (security)
*** (write-in)





Support autonomy /Emphasizing personal choice and control
Ask permission
Raise concern, educate, or inform
Reframe/ Reflection
Roll with resistance
Using a rating scale, on scale of 1-10, Importance *** Confidence ***
Elicit change talk
Encourage non-drug therapy or lifestyle changes
Referral to care team member
*** (write-in)
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Appendix B Motivational Interviewing Strategy Definitions (11–13)
1. Open ended questions: Using stems such as “what” and “how” that can elicit unlimited answers
from a patient and invite them to talk.
2. Collaboration/Shared Decision Making: Co-developing goals with the patient to make sure
they are involved in creating a plan that will indeed work for the patient.
3. Negotiate: Meeting the patient “in the middle”. Perhaps the plan does not exactly match what
you want as the practitioner, but is a smaller more reasonable goal is agreed upon that acts as a
stepping stone to reach the ultimate goal.
4. Evocation/Empower:
a. Helping your patient explore how they can make a difference in their own health by
utilizing their own ideas and resources.
b. Facilitating the patient in bringing their own expertise to the discussion on how best to
accomplish change.
c. Drawing out the patient’s own motivation to change.
5. Support autonomy/Emphasizing personal choice and control:
a. Acknowledge to the patient that they are ultimately responsible for change and as the
practitioner we separate ourselves from the outcome.
b. Communicating respect and dignity of the patient through unconditional positive regard.
6. Ask permission: Informing or advising only after the patient has given you permission to do
so. Forms of permission would include a patient asking for advice or asking the patient for
permission to inform (like knocking on a door before entering). Examples are; “May I make a
suggestion?” or prefacing advice with “You can tell me what you think of this idea . . . .”.
7. Raise concern, educate, or inform: The actual act of providing patient with information
and advice.
8. Reframe/Reflection:
a. Captures and returns to patients something about what they have just said (rephrasing one
or two ideas)
b. They do not have to be accurate (could be amplified or exaggerated) and may or may not
introduce new meaning.
c. Different types of complex reflections: adding content or meaning, amplification,
double-sided, reframing, verbalizing unspoken emotion, emphasizing one side
9. Roll with resistance: When patients display signs of resistance, such as blaming or minimizing,
the practitioner lets the resistance flow rather than use oppositional tactics, such as telling the
person he is wrong.
10. Using a rating scale, one a scale of 1–10, Importance***Confidence*** Using a numerical rating
scale or other ruler to assess the patient’s attitude toward importance and confidence behind
changing a certain behavior. Typically asked as: “Could you tell me, on a scale from 1 to 10, how
important it is for you to _____? Why did you give yourself a score of __ and not 1?” The same
style question can be asked about confidence. Could follow up with a question such as “How can
I help you move higher up the scale?” These types of questions will help support self-efficacy.
11. Elicit change talk:
a. Explore how their current behavior is inconsistent with their values.
b. Selectively asking and identifying when patients state desire, ability, reasons for, and the
need to change and responding to this by evoking, affirming, and reflecting these back
to them.
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Encourage non-drug therapy or lifestyle changes: Supporting non-prescription therapy to help
patient reach goals and outcomes.
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Abstract: Background: With 30-day Medicare readmission rates reaching 20%, a heightened focus
has been placed on improving the transition process from hospital to home. For many institutions,
this charge has identified medication-use safety as an area where pharmacists are well-positioned to
improve outcomes by reducing medication therapy problems (MTPs). Methods: This system-wide
(425 bed community hospital plus 18 primary care clinics) prospective study recruited inpatient and
ambulatory pharmacists to provide comprehensive medication management before and after hospital
discharge. The results analyzed were the success rate and timing of the inpatient to ambulatory
pharmacist handoff, as well as the number, type, and severity of MTPs resolved in both settings.
Results: Of the 105 eligible patients who received a pharmacist evaluation before discharge, 61 (58%)
received follow-up with an ambulatory pharmacist an average of 2.88 days after discharge (range
1–8 days). An average of 5 and 1.4 MTPs per patient were identified and resolved in the inpatient vs.
ambulatory setting, respectively. Although average MTP severity ratings were higher in the inpatient
setting, the highest severity rating was seen most frequently in the ambulatory setting. Conclusions:
In the transition from hospital to home, pharmacist evaluation in both the inpatient and ambulatory
settings are necessary to resolve medication therapy problems.
Keywords: transitions in care; pharmacist; medication therapy problems; medication safety;
comprehensive medication management; readmissions
1. Introduction
In the era of accountable care, organizations are charged with reaching quality metrics to optimize
reimbursement. For some, this charge identified medication-use safety during transitions from hospital
to home as an area for quality improvement [1–3]. Pharmacists in both inpatient and ambulatory
settings have the potential to work together to improve medication-use safety by reducing medication
therapy problems (MTPs) during the transition process [2–4]. One method to achieve this vision may
be found in strategic alliances and collaboration across the care system to develop and evaluate a new
model of pharmacy service.
With nearly one-fifth of hospitalized Medicare fee-for-service patients readmitted within 30 days, a
heightened focus has been placed on improving the quality of the transition process to reduce costs and
improve patient care [5]. Previous studies have demonstrated significant medication-related problems
at the time of discharge, including mediation discrepancies that doubled readmission rates [6], as well
as a lack of patient understanding, where 50% of patients were unable to state the name and purpose
of their medications at the time of discharge [7]. One study found that over 50% of medication-related
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admissions were preventable, while another determined that these preventable admissions resulted in
significantly longer hospital stays [8,9]. The Agency for Healthcare Research and Quality (AHRQ)
recommends medication reconciliation, defined as the “comparison of the patient’s current medication
regimen against the physician’s admission, transfer, and/or discharge orders to identify discrepancies,”
as a beginning to improving medication safety [10]. Although this is necessary and provides the value
of an accurate and complete medication list, it does not create a clinical assessment to ensure: (1)
appropriate indication, (2) effectiveness, (3) safety, and (4) convenience/adherence for each medication.
These four components provide the framework for the Patient-Centered Primary Care Collaborative
model for comprehensive medication management (CMM) [11]. Through this assessment, pharmacists
are able to identify, prevent, and/or resolve mediation therapy problems (MTPs). MTPs are defined as
an event or circumstance involving drug treatment (pharmacotherapy) that interferes with the optimal
provision of medical care [12]. Pharmacists are specifically trained to provide this comprehensive
service, yet they remain underutilized during the transition process [13]. Previous scholarship
substantiates pharmacist benefit, demonstrating that patients who met with a pharmacist either at the
time of discharge or shortly after returning home have consistently lower readmission rates through
the identification and resolution of MTPs [14–20]. The current study sought to build on this body of
knowledge by evaluating a coordinated pharmacy service (CMM delivered by an inpatient pharmacist
prior to discharge and an ambulatory pharmacist post-discharge) across the hospital to home transition
of care.
This paper describes the implementation and evaluation of a pharmacist-driven care transitions
model in a large health care system. The specific objectives were to evaluate: (1) the success rate and
timing of transferring patients from an inpatient to an ambulatory pharmacist, (2) the number and
types of MTPs identified in the inpatient and ambulatory setting, and (3) the difference in MTP severity
ratings (inpatient vs. ambulatory) for patients with a successful transfer of care.
2. Materials and Methods
This pharmacy-based care transition model was developed and conducted in a 425-bed community
hospital and 18 primary care clinics within the Park Nicollet Health Services system in the Minneapolis-St
Paul, Minnesota, United States of America (USA) metropolitan area. All pharmacists were employed
by the health system, had full access to the electronic medical record, and were embedded in the
care teams of their respective settings. Patients who received CMM from an inpatient pharmacist,
ambulatory pharmacist, or both between August 2013 and November 2013 were included. Patients
discharged to a skilled nursing facility or under hospice care were excluded from an ambulatory
pharmacist evaluation but were still eligible to receive an inpatient pharmacist evaluation.
2.1. Care Transition Model Logistics
Although discharging physicians were at liberty to request that any patient be included in the study,
patients admitted with acute myocardial infarction, pneumonia, chronic obstructive pulmonary disease,
and heart failure (i.e., U.S. Medicare Measures) were prioritized. Inpatient pharmacists completed a
comprehensive medication management visit with the patient, as well as any caregivers present prior
to discharge. The pharmacist discussed subsequent recommendations with the physician prior to the
discharge medication ordering process. The pharmacy intervention was documented in the electronic
medical record and sent with a referral for ambulatory pharmacy services to follow-up post discharge.
As an integrated component of Park Nicollet’s medical home model, clinical ambulatory pharmacists
are geographically dispersed around the region served. The post-discharge intervention consisted of
an ambulatory CMM evaluation identical to that performed while the patient was hospitalized. This
follow-up was performed either in person or by phone to reinforce inpatient recommendations, as well
as identify and address any new MTPs that developed following discharge. See Figure 1 for a pictorial
representation of the care transition process.
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Figure 1. Care Transition Process.
2.2. Clinical Services Provided
Pharmacists in both settings collaborated with the care team (patient, nurse, physician, social work,
etc.) to resolve MTPs and prepare a revised medication list. The inpatient care team helped to identify
appropriate patients, as well as their anticipated date of discharge and discharge disposition. The team
also provided additional information about the patient and current medical concerns. The revised
medication list was created through calling pharmacies to review refill records, chart review, patient
and/or family interview, and healthcare team collaboration. During the pharmacist visit, whether
inpatient or ambulatory, a focus was placed on:
1. Comprehensive Medication Management (CMM): Creating a medication list that is accurate across
the transition, as well as ensuring each medication is indicated, effective, safe, and convenient
with complete administration directions.
2. Patient Centered Care: Educating patients on a medication list developed in collaboration with
patient needs and preferences.
3. Medication Access: Ensuring that patients have access to all medications and that each discharge
prescription is sent to the correct pharmacy and/or location.
2.3. Data Collection/Research Methods
This study was given exemption status by Park Nicollet Health Services IRB and the University
of Minnesota IRB. A total of 12 pharmacists, four inpatient and eight ambulatory, were trained to
participate. Inpatient pharmacist documentation included both immediate resolution of MTPs and
recommendations for consideration in the ambulatory setting. Ambulatory pharmacist documentation
addressed inpatient recommendations, identified new MTPs since discharge, and provided a plan
for continued ambulatory follow-up. In both settings, identified MTPs were categorized into eight
types, consisting of: “medication inaccuracy,” “adverse drug reaction,” “non-adherence,” “lack of
understanding,” “dose too high,” “lack of needed drug” (addition of a drug), “dose too low,” and
“unnecessary medication” (unnecessary or duplicate medication). After an MTP was identified and
typed, each one was given a severity rating from 1 (lowest) to 3 (highest/life-threatening) based on the
potential for patient harm had the MTP not been resolved. Severity ratings for each intervention were
documented based on reporting standards for skilled nursing facilities from the Department of Health
and Human Services [21]; see Table 1 for detailed descriptions. Severity ratings were documented in
real-time by the pharmacist but were also verified by three independent pharmacist raters via blind
review after the study was completed. All raters were standardized using an inter-rater reliability test.
When no MTP was identified, a severity rating of 0 was recorded.
Table 1. Potential Medication Therapy Problem Severity Rating.
Severity Rating Description
1 If no intervention, potential for minimal (would require patient self-management) or no harm
2 If no intervention, potential for moderate harm (would require healthcare professionalintervention or hospitalization to resolve)
3 If no intervention, potential for severe harm (permanent disability or death)
Note: Adapted from Medicare Nursing Home Levels of Harm categories.
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2.4. Statistical Methods
A generalized estimating equation (GEE) was chosen as a marginal model in order to account for
the correlation of multiple measurements within some patients. An exchangeable correlation structure
was specified, and a Gaussian distribution was chosen in order to compare the mean difference between
the maximum severity ratings at ambulatory and inpatient evaluations. Additionally, paired t-tests
comparing the inpatient and ambulatory severity ratings for only those patients with both interventions
(i.e., successful transfer) were analyzed and the results were compared to those from the GEE analysis.
Both models were implemented for the primary (overall severity) and secondary (individual MTPs
rated for severity) analyses, with an α level of 0.05 considered significant.
3. Results
All 12 trained pharmacists (four inpatient and eight ambulatory) participated. Patients were
categorized based on having either a successful inpatient-to-ambulatory pharmacist transfer (n = 61) or
having an inpatient evaluation only (n = 73). Baseline Characteristics (Table 2) between the two groups
were well balanced with the following two exceptions. Patients who followed up with an ambulatory
evaluation had shorter lengths of stay in the hospital (3.4 days compared to 5.1 days, p-value ≤ 0.001)
and were more likely to discharge to home rather than a skilled nursing facility (p-value < 0.001). The
average age, gender, marital status, number of chronic conditions, number of medications, and reason
for evaluation were not found to be significantly different between the two groups.





Intervention (n = 61)
p-Value
Mean Age (years) 75.5 73.0 0.277
Sex
0.183Female 36 (49.3%) 38 (62.3%)
Male 37 (50.7%) 23 (37.7%)
Marital Status
0.249
Single 17 (23.3%) 15 (24.6%)
Married 26 (35.6%) 29 (47.5%)
Divorced 2 (2.7%) 3 (4.9%)
Widowed 28 (38.4%) 14 (23.0%)
Mean Length of Stay
(days) 5.1 3.4 <0.001
Mean Chronic
Conditions (n) 9.2 10.6 0.076
Mean Chronic
Medications (n) 12.5 13.5 0.290
Discharge Disposition
<0.001
Home 40 (54.8%) 56 (91.8%)
Home (With Care) 4 (5.5%) 5 (8.2%)
Skilled Nursing Facility 29 (39.7%) 0 (0%)
Insurance
0.456
Private 5 (6.8%) 6 (9.8%)
Medicare 62 (84.9%) 50 (82.0%)
Medicaid 5 (6.8%) 2 (3.3%)
None 1 (1.4%) 3 (4.9%)







* Patients could contribute to multiple categories.
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3.1. Success Rate of the Care Transition Model
Prior to discharge from the hospital, 134 patients received an inpatient pharmacist intervention.
Of these 134 patients, 29 were discharged to a skilled nursing facility, excluding them from ambulatory
follow-up. Of the patients eligible for an ambulatory intervention (n = 105), the transfer of care
from the inpatient to the ambulatory setting was successful in 61 (58%) patients. In total, 44 eligible
patients were lost to ambulatory follow-up due to: Inpatient pharmacist failure to place a transfer
in the electronic system (44%); ambulatory pharmacist failure to act on a new patient transfer (31%);
ambulatory pharmacist failure to reach the patient for follow-up (16%); patient readmission prior
to ambulatory follow-up (7%); and lastly, patient declined ambulatory visit (2%). Excluding one
outlier with a follow-up of 16 days, the average time to follow-up with an ambulatory pharmacist was
2.88 days (range 1–8 days).
3.2. Number and Types of Medication Therapy Problems Identified
An average of five MTPs per patient were identified and resolved in the inpatient setting prior to
discharge. The most common types of MTP found in the inpatient setting were: “lack of needed drug”
(identified in 60% of patients), “lack of understanding” (45% of patients), and “medication inaccuracy”
(42% of patients). During the ambulatory follow-up, an average of 1.4 MTPs per patient were identified
and resolved. In 75% of the patients who received both an inpatient and ambulatory intervention,
the ambulatory pharmacist identified the presence of at least one MTP. During the ambulatory CMM
intervention, medication “non-adherence” and “lack of needed drug” were the most common MTPs
identified and resolved (each identified in 25% of patients), followed by “lack of understanding” (19.7%
of patients) and “adverse drug reaction” (18.0% of patients).
3.3. Severity Rating Comparison of Medication Therapy Problems Identified
Table 3 depicts the mean difference in maximum severity rating between the inpatient and
ambulatory settings for patients with a successful transfer of care (i.e., the “inpatient and ambulatory
CMM intervention cohort” n = 61). In terms of capacity to cause patient harm, all of the MTP types
identified by pharmacists demonstrate a trend toward being less severe in the ambulatory vs. inpatient
setting. When looked at as a whole, the mean difference in “overall MTP severity” decreased by 0.25
(CI: (−0.58, 0.08), p-value = 0.141) in the ambulatory setting, however, this difference did not reach
significance. Four of the eight MTP types showed a similar nonstatistical trend toward reduced severity
in the ambulatory setting. The other four MTP types (i.e., “medication inaccuracy,” “adverse drug
reaction,” “dose too high,” and “lack of needed drug”), all demonstrated a statistically significant
reduction in severity in the ambulatory vs. inpatient setting.
Table 3. Medication Therapy Problem Severity Comparison for the Inpatient and Ambulatory CMM
Intervention Cohort (n = 61) *.
MTP Severity Rating
Mean Difference in Inpatient vs.
Ambulatory Maximum Severity
95% CI p-Value
Overall Severity −0.25 (−0.58, 0.08) 0.141
Medication Inaccuracy −0.34 (−0.58, −0.11) 0.004
Adverse Drug Reaction −0.33 (−0.63, −0.02) 0.036
Non-Adherence −0.20 (−0.47, 0.08) 0.159
Lack of Understanding −0.23 (−0.53, 0.07) 0.137
Dose Too High −0.34 (−0.55, −0.14) 0.001
Lack of Needed Drug −0.46 (−0.75, −0.17) 0.002
Dose Too Low −0.07 (−0.32, 0.19) 0.610
Unnecessary Medication −0.18 (−0.38, 0.02) 0.070
* Represents only patients receiving both an inpatient and ambulatory pharmacist evaluation (n = 61).
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Table 4 depicts the frequency of each severity rating (0–3) for all patients in either the inpatient
(n = 134) or ambulatory (n= 61) setting. There were a greater percentage of patients with no MTPs
(identified as having a severity rating of “0”) in the ambulatory (26%) vs. inpatient setting (4%).
Correspondingly, MTPs with severity ratings of 1 or 2 were seen more frequently in the inpatient
setting. However, when it came to the highest severity rating (a rating of 3 indicating the potential for
“permanent disability or death”), it was found more often in the ambulatory setting (found in 10% of
patients in the ambulatory vs. 6% in the inpatient setting).
Table 4. Frequency of Severity Ratings.
Severity Rating Inpatient (n = 134) Ambulatory (n = 61)
0 5 (3.7%) 16 (26.2%)
1 29 (21.6%) 7 (11.5%)
2 92 (68.7%) 32 (52.5%)
3 8 (6.0%) 6 (9.8%)
4. Discussion
Previous scholarship provides insight into the potential of pharmacists to improve medication
safety via medication reconciliation in either the inpatient or ambulatory setting [2,3]. This study
demonstrates a care model that created a successful direct handoff from inpatient pharmacists prior
to discharge to ambulatory pharmacists’ post-discharge in 58% of eligible patients. The two most
common reasons for failure (i.e., failure of inpatient pharmacist to place the transfer and failure of
ambulatory pharmacist to follow-up on the transfer) primarily represented electronic and personnel
system inefficiencies that have since been rectified. The inpatient process to initiate an ambulatory
CMM intervention for a patient has been simplified down to three clicks in the electronic medical chart
and can now be performed without a physician order by student pharmacists at the behest of a licensed
pharmacist preceptor. On the ambulatory side, one FTE (full-time equivalent) of administrative
personnel has been added to coordinate patient outreach in setting up either phone or in person visits
for the health system wide ambulatory pharmacist group.
An average of five MTPs per patient were found in our inpatient cohort, while patients who
received ambulatory follow-up only three days after discharge still had an average of 1.4 MTPs
identified by this second CMM intervention. The benefit of comprehensive medication management
both at the time of and directly after discharge has been demonstrated before [22,23]. One study found
that two-thirds of patients discharged from an emergency department did not comprehend home
care instructions, follow-up instructions, medications, and/or discharge diagnoses [23]. The current
study supports this finding showing that despite receiving CMM just prior to discharge, nearly 75% of
patients had at least one MTP at the ambulatory intervention. The presence of newly identified MTPs
post-discharge demonstrates the need for comprehensive medication management at each transition in
order to minimize medication related MTPs.
Although not statistically significant for all MTP types, this study demonstrated a reduction in
overall MTP severity from the inpatient to ambulatory setting. This could be expected due to the acute
illness of hospitalized patients. Perhaps more interesting is that while hospitalized patients had more
severe MTPs, a greater percentage of severity level 3 (potential for severe harm) MTPs were found in
the ambulatory setting. One possible explanation is that the level 3 MTPs identified in the ambulatory
setting involved a lack of adherence to high-risk medications such as a hypoglycemic, opioid, or
antithrombotic medication. Most commonly, non-adherence resulted from the patient preferring not to
take, forgetting to take, an inability to afford the medications, and/or a lack of information retention
post-discharge. Overall, data from this study shows that while more MTPs are found and resolved in
the inpatient setting, those that persist and/or present themselves early in the ambulatory setting are of
a more severe nature, emphasizing the importance of pharmacist intervention at both of these critical
times during transitions in care.
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There are several limitations to this study. Twelve pharmacists identified and classified MTPs.
Although the pharmacy team underwent a norming process, there is still the potential for inter-rater
variability. Similarly, MTP severity ratings were adjudicated by three separate normed judges. Further,
the severity rating tool utilized was developed for use in long-term skilled nursing facilities, rather
than hospitalized inpatients. This U.S. Department of Health and Human Services-based rating tool
was selected by the health system’s Quality, Innovation, and Population Health Services department
to align with other system-wide medication safety initiatives. Severity classification scales rating
medication safety concerns in the inpatient [24,25] and outpatient [25] setting should be noted. There
were limits on the discharge disposition type the ambulatory pharmacists were able to reach, as
patients going to a skilled nursing facility were not seen across the transition. Due to the complexity
of these patients’ medication regimens, follow-up with this population warrants further evaluation
and is planned for the future. Also, due to the small sample size, this study was unable to show if
pharmacy-based CMM reduced readmission rates.
5. Conclusions
This study demonstrates a transition of care model for the transfer of patient care from an inpatient
to an ambulatory pharmacist before and after discharge. This transition was successful in 58% of
patients an average of 2.88 days after discharge. The two most common reasons for failure were failure
of inpatient pharmacist to place the transfer and failure of ambulatory pharmacist to follow-up on the
transfer. An average of five MTPs per patient were found in the inpatient cohort, and patients who
received ambulatory follow-up roughly three days after discharge still had an average of 1.4 MTPs.
Although overall MTP severity ratings were higher in the inpatient setting, MTPs that persisted and/or
presented themselves early after discharge in the ambulatory setting were the most likely to lead to
serious patient harm.
Author Contributions: Conceptualization and methodology, A.S.-F. and A.K.; investigation, A.K. and L.K.; formal
analysis, writing—original draft preparation, and writing—review and editing, A.S.-F., A.K. and L.K.
Funding: This research received no external funding.
Acknowledgments: Thanks for contributions of Reilly E. Hourigan, M.S., Kelsey E. Brown, M.S. and Mark
Desjardins, Pharm.D.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Johansen, J.S.; Havnes, K.; Halvorsen, K.H.; Haustreis, S.; Skaue, L.W.; Kamycheva, E.; Mathiesen, L.;
Viktil, K.K.; Granås, A.G.; Garcia, B.H. Interdisciplinary collaboration across secondary and primary care to
improve medication safety in the elderly (IMMENSE study): Study protocol for a randomized controlled
trial. BMJ Open 2018, 8, e020106. [CrossRef] [PubMed]
2. Hohl, C.M.; Partovi, N.; Ghement, I.; Wickham, M.E.; McGrail, K.; Reddekopp, L.N.; Sobolev, B. Impact of
early in-hospital medication review by clinical pharmacists on health services utilization. PLoS ONE 2017, 2,
e0170495. [CrossRef] [PubMed]
3. Martin, P.; Tamblyn, R.; Benedetti, A.; Ahmed, S.; Tannenbaum, C. Effect of a Pharmacist-Led Educational
Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized
Clinical Trial. JAMA 2018, 18, 1889–1898. [CrossRef]
4. Dudas, V.; Bookwalter, T.; Kerr, K.; Pantilat, S. The impact of follow-up telephone calls to patients after
hospitalization. Am. J. Med. 2001, 111, 26–30. [CrossRef]
5. Unruh, M.A.; Jung, H.Y.; Vest, J.R.; Casalino, L.P.; Kaushal, R. Meaningful Use of Electronic Health Records
by Outpatient Physicians and Readmissions of Medicare Fee-for-Service Beneficiaries. Med. Care 2017, 55,
493–499. [CrossRef]
6. Coleman, E.A.; Smith, J.D.; Raha, D.; Min, S.J. Posthospital medication discrepancies: Prevalence and
contributing factors. Arch. Intern. Med. 2005, 165, 1842–1847. [CrossRef]
386
Pharmacy 2019, 7, 86
7. Makaryus, A.N.; Friedman, E.A. Patients understanding of their treatment plans and diagnosis at discharge.
Mayo Clin. Proc. 2005, 80, 991–994. [CrossRef]
8. Winterstein, A.G.; Sauer, B.C.; Hepler, C.D.; Poole, C. Preventable drug-related hospital admissions. Ann.
Pharm. 2002, 36, 1238–1248. [CrossRef]
9. Dormann, H.; Neubert, A.; Criegee-Rieck, M.; Egger, T.; Radespiel-Tröger, M.; Azaz-Livshits, T.; Hahn, E.G.
Readmissions and adverse drug reactions in internal medicine: The economic impact. J. Intern. Med. 2004,
255, 653–663. [CrossRef]
10. Agency for Healthcare Research and Quality (AHRQ): Medications at Transitions and Clinical Handoffs
(MATCH) Toolkit for Medication Reconciliation. Available online: http://www.ahrq.gov/qual/match/
(accessed on 11 June 2019).
11. Patient-Centered Primary Care Collaborative Resource Guide: The Patient-Centered Medical Home:
Integrating Comprehensive Medication Management to Optimize Patient outcomes. Available online:
http://www.pcpcc.org/sites/default/files/media/medmanagement.pdf (accessed on 11 June 2019).
12. Strand, L.M.; Morley, P.C.; Cipolle, R.J.; Ramsey, R.; Lamsam, G.D. Drug-related problems: Their structure
and function. DICP Ann. Pharmacother. 1990, 24, 1093–1097. [CrossRef]
13. Kern, K.A.; Kalus, J.S.; Bush, C.; Chen, D.; Szandzik, E.G.; Haque, N.Z. Variations in pharmacy-based
transition-of-care activities in the United States: A national survey. Am. J. Health Syst. Pharm. 2014, 71,
648–656. [CrossRef] [PubMed]
14. Bellone, J.M.; Barner, J.C.; Lopez, D.A. Postdischarge interventions by pharmacists and impact on hospital
readmission rates. J. Am. Pharm. Assoc. 2012, 52, 358–362. [CrossRef] [PubMed]
15. Conklin, J.R.; Togami, J.C.; Burnett, A.; Dodd, M.A.; Ray, G.M. Care transitions service: A pharmacy-driven
program for medication reconciliation through the continuum of care. Am. J. Health Syst. Pharm. 2014, 71,
802–810. [CrossRef] [PubMed]
16. Monika, G.; Mikaitis, D.; Gayle, S.; Johnson, T.; Sims, S. Impact of a combined pharmacist and social worker
program to reduce hospital readmissions. J. Manag. Care Pharm. 2013, 19, 558–563.
17. Kilcup, M.; Schultz, D.; Carlson, J.; Wilson, B. Postdischarge pharmacist medication reconciliation: Impact
on readmission rates and financial savings. J. Am. Pharm. Assoc. 2013, 53, 78–84. [CrossRef]
18. Kripalani, S.; Roumie, C.L.; Dalal, A.K.; Cawthon, C.; Businger, A.; Eden, S.K.; Huang, R.L. Effect of a
pharmacist intervention on clinically important medication errors after hospital discharge: A randomized
trial. Ann. Intern. Med. 2012, 157, 1–10. [CrossRef] [PubMed]
19. Pal, A.; Babbott, S.; Wilkinson, S.T. Can the targeted use of a discharge pharmacist significantly decrease
30-day readmissions? Hosp. Pharm. 2013, 48, 380–388. [CrossRef]
20. Mekonnen, A.B.; McLachlan, A.J.; Brien, J.A. Effectiveness of pharmacist-led medication reconciliation
programmes on clinical outcomes at hospital transitions: A systematic review and meta-analysis. BMJ Open
2016, 6, e010003. [CrossRef]
21. Medicare.gov. Medicare Nursing Home Levels of Harm Categories. Available online: Http://www.medicare.
gov/NHCompare/static/related/incdrawlevelofharm.asp?language=English&version=default (accessed on
11 June 2019).
22. Phatak, A.; Prusi, R.; Ward, B.; Hansen, L.O.; Williams, M.V.; Vetter, E.; Chapman, N.; Postelnick, M. Impact
of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation,
medication education, and postdischarge call-backs (IPITCH Study). J. Hosp. Med. 2016, 11, 39–44. [CrossRef]
23. Engel, K.G.; Buckley, B.A.; Forth, V.E.; McCarthy, D.M.; Ellison, E.P.; Schmidt, M.J.; Adams, J.G. Patient
understanding of emergency department discharge instructions: Where are knowledge deficits greatest?
Acad. Emerg. Med. 2012, 19, E1035–E1044. [CrossRef]
24. Hartwig, S.C.; Siegel, J.; Schneider, P.J. Preventability and severity assessment in reporting adverse drug
reactions. Am. J. Hosp. Pharm. 1992, 49, 2229–2232. [CrossRef] [PubMed]
25. National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Taxonomy of
Medication Errors. Available online: http://www.NCCMERP.org (accessed on 28 June 2019).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Community Pharmacist-Provided Wellness and
Monitoring Services in an Employee Wellness
Program: A Four-Year Summary
Yifei Liu 1 , Kendall D. Guthrie 1,*, Justin R. May 2 and Kristen L. DiDonato 3
1 Division of Pharmacy Practice and Administration, School of Pharmacy, University of Missouri-Kansas City,
Kansas City, MO 64108, USA
2 Bothwell Regional Health Center, Sedalia, MO 65301, USA
3 The Kroger Co. Columbus Division, Kroger Pharmacy, Toledo, OH 43615, USA
* Correspondence: guthriekd@umkc.edu
Received: 27 April 2019; Accepted: 28 June 2019; Published: 2 July 2019
	

Abstract: Objective: To assess the clinical outcomes of participants of an employee wellness program
during four years of service implementation. Methods: A prospective cohort study was conducted
at 15 independent community pharmacy chain locations in northwest and central Missouri. A total
of 200 participants were enrolled in an employee wellness program, and the program included five
monitoring groups—cholesterol, blood pressure, blood glucose, weight, and healthy participant
groups. Participants selected a pharmacist wellness coordinator and wellness appointments were
conducted, consisting of education, goal-setting, and monitoring through physical assessment and
point of care testing. The primary outcome measures were total cholesterol (TC), triglycerides (TG),
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), systolic
blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), body mass index
(BMI), and waist circumference (WC). The secondary outcome measures were the proportion of
patients who achieved the clinical value goals at baseline versus 48 months. The primary outcome
measures among data collection time points were compared using one-way analysis of variance
(ANOVA) tests, and the secondary outcomes were compared between baseline and 48 months by
Chi-square or Fisher’s exact tests. One-way ANOVA post hoc tests were also performed using
least significant difference, to further identify which time points differed from each other. Results:
At baseline, there were 134 patients in the cholesterol monitoring group, 129 in the weight monitoring
group, 117 in the blood pressure monitoring group, 46 in the blood glucose monitoring group, and
26 in the healthy participant monitoring group. For patients in the blood pressure monitoring group,
compared with baseline, there was a significant decrease in DBP at months 12, 24, 36, and 48, and
a significant increase in the proportion of patients achieving blood pressure goals at 48 months.
For patients in the blood glucose monitoring group, compared with baseline, there was a significant
decrease in FBG at months 12, 24, 36, and 48, and a significant increase in the proportion of patients
achieving blood glucose goals at 48 months. Conclusions: Pharmacist-led wellness visits provided
to employee wellness patients in a community pharmacy may lead to improvements in BP and
FBG values.
Keywords: community pharmacy; pharmacist services; wellness programs
1. Introduction
According to the Centers for Disease Control and Prevention, sixty percent of adults in the United
States (U.S.) are living with a chronic condition. In addition, forty percent of American adults have been
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diagnosed with two or more chronic conditions [1]. These chronic conditions significantly contribute
to healthcare spending. A report published by the Agency for Healthcare Research and Quality shows
eighty-six percent of the total healthcare expenditures was attributed to individuals with one or more
chronic conditions. Furthermore, the agency states that seventy-one cents of every healthcare dollar
are spent on individuals with multiple chronic conditions [2].
In the U.S., employers cover fifty-eight percent of employee medical costs [3]. Employees with
chronic conditions not only incur higher medical costs, but also have more missed workdays and show
less productivity [3]. To address these issues, many employers have incorporated wellness initiatives into
their benefits programs as a cost-containment strategy. A wide range of employer-sponsored wellness
services have been implemented including worksite wellness clinics, web-based programs, activity
challenges, medication therapy management services, and disease state management programs [4–22].
Community pharmacists are highly accessible and in an optimal position to provide these services.
As the role of the pharmacist shifts from dispensing to service provision, studies have demonstrated
the values of pharmacist-provided services [23,24]. In particular, health coaching principles can be
utilized by community pharmacists to help patients better manage their chronic conditions or overall
health status. Health coaching involves helping an individual take actionable steps towards their
health and wellness goals. Health coaches take on many different roles including enhancing wellbeing,
providing social support, instruction, and skill development [25].
DiDonato et al. demonstrated that a one-year employee wellness program (EWP) provided by
pharmacists significantly lowered patients’ cardiovascular risk [26]. This EWP was implemented in
an independent community pharmacy chain, and the participants were employees of the company
and their spouses. This study is a follow-up to the study of DiDonato et al., and documents the full
results during four years of EWP implementation. We intend to build on previous research efforts
and further promote pharmacist involvement in wellness initiatives for patients and employer groups.
In addition, the complete results of four years would reveal if further clinical improvements were
made or if patients reverted to their previous lifestyles.
2. Objective
The objective of this study was to assess the clinical outcomes of participants during four years of
EWP implementation. At the time of the study, the EWP was implemented at fifteen rural independent




The study details the full results of the EWP implemented. Of note, the first year’s results of
81 patients were previously reported [26]. The inclusion criteria were as follows: 18 years and older,
non-pregnant, and employees of the self-insured pharmacy chain or their spouses. All company
employees could enroll in the EWP, but those who were not insured with the company’s health
insurance benefit were excluded from analysis. EWP participants received a discounted rate on
their health insurance premium. A study protocol was designed and approved by the University of
Missouri-Kansas City Adult Health Sciences Institutional Review Board. Each pharmacy participating
in the study obtained a Clinical Laboratory Improvement Amendments certificate of waiver to
conduct point-of-care testing. According to this waiver, manufacturer recommendations for using the
point-of-care testing equipment were followed and quality control procedures were conducted on all
equipment utilized.
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3.2. Intervention
At the time of enrollment and annually, participants completed a personal health assessment
questionnaire; cardiovascular disease and diabetes risk assessment; and a pharmacist-conducted
screening for total cholesterol (TC), serum triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), diastolic
blood pressure (DBP), fasting blood glucose (FBG), weight, body mass index (BMI), and waist
circumference (WC).
All wellness coordinators in the program were pharmacists. Participants had the option of
personally selecting a pharmacist wellness coordinator or, if no preference, a pharmacist coordinator
was assigned to them. Patients were placed into one or more of four monitoring groups (i.e.,
cholesterol, blood pressure, blood glucose, and weight monitoring groups) if they were identified
through screenings to be outside of target ranges or to have a diagnosis of a related chronic condition
(established hyperlipidemia, hypertension, and/or diabetes) [26]. The clinical value goals were decided
according to the clinical guidelines available at the time of the study [27–30]. Upon enrollment, patients
were assigned a TC goal of less than 200 mg/dL; an HDL-C goal of greater than 40 mg/dL (men) and
greater than 50 mg/dL (women); and an LDL-C goal of less than 100 mg/dL (coronary heart disease
and its risk equivalents), less than 130 mg/dL (multiple risk factors), or less than 160 mg/dL (0–1 risk
factor) [27]. Patients without a diagnosis of hypertension or a compelling indication (such as coronary
artery disease, heart failure, and diabetes) were assigned a blood pressure goal of less than 120/80 mm
Hg. A goal of less than 140/90 mm Hg was assigned to those diagnosed with hypertension. A goal of
less than 130/80 mm Hg was assigned to those diagnosed with renal disease, diabetes, or established
cardiovascular disease [28]. Participants with diabetes at baseline were assigned a goal of 70–130 mg/dL
for fasting blood glucose and a goal of less than 180 mg/dL for postprandial blood glucose. For those
without a diagnosis of diabetes, the target FBG was set as less than 100 mg/dL [29]. For all patients,
the target BMI was less than 25 kg/m2. In addition, a waist circumference less than 35 inches for
females and less than 40 inches for males was considered as the goal [30].
Individuals could be in more than one patient monitoring group. Otherwise, if none of the above
criteria was met, participants were placed into a healthy participant monitoring group. The placement of
study subjects into monitoring groups helped guide the education provided by wellness coordinators.
Patients in the cholesterol, blood pressure, blood glucose, and weight monitoring groups were
encouraged to meet with their wellness coordinator every one to two months, especially for the first
year. Participants in the healthy participant monitoring group were encouraged to meet with their
wellness coordinator every three months, especially for the first year.
3.3. Practice Innovation
A total of 34 pharmacist wellness coordinators were selected on a voluntary basis. The study
took place before the National Consortium for Credentialing Health and Wellness Coaches offered
a national certification for health and wellness coaches [31]. While no formal health coach training
occurred during the study period, many roles taken on by pharmacists involved in the conduction of
study procedures were very similar to the roles of a health coach. Each coordinator received training
on the point-of-care testing equipment and physical assessment to ensure appropriate techniques and
performance consistency. Additionally, each coordinator was provided with an electronic file package
including program policies and procedures, enrollment paperwork, screening documentation forms,
assessment tools, physician communication forms, quality assurance forms, and the most current clinical
guidelines. These documents were reviewed and updated annually. Furthermore, coordinators were
provided with disease-specific monitoring tool kits that contained hardcopies of disease-specific SOAP
(subjective, objective, assessment, and plan) note templates, patient report cards, and patient education
handouts. Throughout the program, materials were developed by pharmacists and pharmacy students
for the following disease states: dyslipidemia, hypertension, diabetes, overweight/obesity, asthma,
depression, gastroesophageal reflux disease, menopause, osteoporosis, sleep disorders, smoking
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cessation, and contraception. These materials served as a resource for coordinators to use during
patient encounters. Disease states that were not related to four monitoring groups were more of a focus
for those in the healthy participant monitoring group.
Each wellness visit consisted of discussion, disease-specific education, goal setting, and physical
assessment, which lasted up to 60 min. The education was structured and delivered face to face.
The progress was assessed by comparing results with the previous visits. The visits occurred in a
semi-private counseling area during normal work hours and were free of charge. If needed, following
a wellness visit, the patient’s primary care provider was contacted to notify him/her of the screening
results and/or make recommendations regarding medication therapy as warranted.
3.4. Evaluation
To examine the impact of pharmacist wellness and monitoring services, for each group, the
primary outcome measures were the clinical values of TC, TG, HDL-C, LDL-C, SBP, DBP, FBG, BMI,
and WC at baseline, 12, 24, 36, and 48 months. The secondary outcome measures were the proportion
of participants who achieved the clinical value goals at baseline versus 48 months. Data were collected
at baseline (i.e., time of enrollment), 12, 24, 36 and 48 months. Participant recruitment was open during
the four-year period, but the study ended in year 4. For example, if an individual was enrolled in
year 2 and did not drop out, he/she would have data at baseline, 12, 24, and 36 months. Descriptive
statistics were calculated for participants’ demographics. The primary outcome measures among data
collection time points were compared using one-way ANOVA tests. In addition, one-way ANOVA
post hoc tests were performed using least significant difference, to further identify which time points
differed from each other. The secondary outcomes were compared between baseline and 48 months by
Chi-square tests, or Fisher’s exact tests if expected values were less than 5. We also performed the
same analyses to compare primary and secondary measures after excluding those who withdrew from
the program. A p-value of <0.05 was considered statistically significant.
The physician communication forms were primarily used to communicate screening results to
each patient’s primary care provider. This was done to ensure continuity of care and alert the provider
of out-of-range results, but these recommendations were not tracked. In addition, this program’s
savings for the employer were requested, but not all information was made available by the pharmacy
administration as a result of barriers to compiling the data. Therefore, pharmacists’ recommendations
and the program’s savings were not assessed in the study.
4. Results
For the first year, 169 patients were eligible and 90 were enrolled, with a response rate of 53.3% [26].
At the end of year 1, 48 participants withdrew from the program; at the end of year 2, 17 withdrew from
the program; at the end of year 3, 16 withdrew from the program; and at the end of year 4, 4 withdrew
from the program. In total, 85 withdrew from the program. Additionally, 10 of them withdrew before
baseline data collection, and were excluded from the study.
A total of 200 participants regardless of start and end date were included in the analyses.
For example, if an individual was enrolled but dropped out 12 months later, he/she would be included
in analysis at baseline and 12 months. At baseline, there were 134 patients in the cholesterol monitoring
group, 129 in the weight monitoring group, 117 in the blood pressure monitoring group, 46 in the
blood glucose monitoring group, and 26 in the healthy participant monitoring group (Table 1). For the
200 participants, the average age was 38 years old. Most participants were female and Caucasian
with at least some college education. When comparing the patient monitoring groups, the healthy
participant group was younger than the other four groups.
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Male 4 (15.4%) 30 (22.4%) 32 (27.4%) 14 (30.4%) 30 (23.3%) 44 (22.0%)
Female 22 (84.6%) 104 (77.6%) 85 (72.6%) 32 (69.6%) 99 (76.7%) 156 (78.0%)
Race, n (%)
Caucasian 25 (96.2%) 128 (95.5%) 110 (94.0%) 43 (93.5%) 122 (94.6%) 190 (95.0%)
African Amer. 0 (0.0%) 2 (1.5%) 4 (3.4%) 2 (4.3%) 2 (1.6%) 4 (2.0%)
Hispanic/Latino 1 (3.8%) 2 (1.5%) 1 (0.9%) 0 (0.0%) 2 (1.6%) 3 (1.5%)
Amer. Indian or
Alaskan Native 0 (0.0%) 1 (0.7%) 1 (0.9%) 0 (0.0%) 1 (0.8%) 1 (0.5%)
Not Specified 0 (0.0%) 1 (0.7%) 1 (0.9%) 1 (2.2%) 2 (1.6%) 2 (1.0%)
Education, n (%)
High school or less 5 (19.2%) 33 (24.6%) 26 (22.2%) 14 (30.5%) 27 (21.0%) 42 (21.0%)
Some college 4 (15.4%) 43 (32.1%) 35 (29.9%) 13 (28.3%) 41 (31.8%) 61 (30.5%)
College grad 6 (23.1%) 26 (19.4%) 26 (22.2%) 8 (17.4%) 27 (20.9%) 40 (20.0%)
Post-grad/
Professional 11 (42.3%) 30 (22.4%) 28 (23.9%) 11 (23.9%) 31 (24.0%) 53 (26.5%)
Not Specified 0 (0.0%) 2 (1.5%) 2 (1.7%) 0 (0.0%) 3 (2.3%) 4 (2.0%)
Note: A patient could be enrolled in multiple monitoring groups at any given time.
Figure 1 displays changes in mean clinical values among the four patient monitoring groups,
and Figure 2 compares the proportion of patients achieving clinical value goals between baseline and
48 months. In these figures, the cholesterol monitoring group was associated with clinical values of
TC, TG, LDL-C, and HDL-C; the blood pressure monitoring group was associated with SBP and DBP;
the blood glucose monitoring group was associated with FBG; and the weight monitoring group was
associated with BMI and WC. Clinical values were only reported and compared for the associated
monitoring group. For example, clinical values of TC, TG, LDL-C, and HDL-C were only analyzed and
reported for the cholesterol monitoring group.
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Figure 1. Changes in mean clinical values among four patient monitoring groups from baseline to
48 months.
Figure 2. Proportion of patients achieving goals of clinical values among four patient monitoring
groups from baseline to 48 months.
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The two figures reveal two significant findings. First, for patients in the blood pressure monitoring
group, compared with baseline, there was a significant decrease in DBP (Figure 1), and a significant
increase in the proportion of patients achieving blood pressure goals at 48 months (Figure 2). Second,
for patients in the blood glucose monitoring group, compared with baseline, there was a significant
decrease in FBG (Figure 1), and a significant increase in the proportion of patients achieving blood
glucose goals at 48 months (Figure 2).
In one-way ANOVA post hoc tests, for DBP, the value at baseline (84.2 mm HG, n = 117) was
significantly higher than at 12 months (80.2 mm HG, n = 88), 24 months (80.3 mm Hg, n = 68), 36 months
(80.2 mm Hg, n = 55), and 48 months (79.0 mm HG, n = 44); and the comparisons between any other
pairs of time points were not significant. For FBG, the value at baseline (113.2 mg/dL, n = 45) was
significantly higher than at 12 months (103.7 mg/dl, n = 37), 24 months (101.3 mg/dL, n = 28), 36 months
(103.5 mg/DL, n = 26), and 48 months (101.6 mg/dL, n = 20); and the comparisons between any other
pairs of time points were not significant.
For individuals in the healthy participant monitoring group, no significant findings were found in
one-way ANOVA and Chi-square tests (or Fisher’s exact tests) for all clinical variables. Regarding
potential confounding variables, we assessed smoking (yes/no), alcohol use (yes/no), and exercises
(a categorical variable) at baseline. Chi-square tests were used to compare these variables for those in
each of the five groups versus not. The results were not significant, so the confounding effects of the
three variables could be ruled out.
Furthermore, we reanalyzed the data after excluding 75 participants who withdrew the program,
but at least completed baseline data collection. Figure 3 displays changes in mean clinical values
among the four patient monitoring groups, and Figure 4 compares the proportion of patients achieving
clinical value goals between baseline and 48 months. These results were consistent with the results
for all participants. In addition, for patients in the blood pressure monitoring group, compared with
baseline, there was also a significant decrease in SBP (Figure 3).
Figure 3. Changes in mean clinical values among four patient monitoring groups from baseline to
48 months after excluding patients who withdrew from the program.
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Figure 4. Proportion of patients achieving goals of clinical values among four patient monitoring
groups from baseline to 48 months after excluding patients who withdrew from the program.
5. Discussion
The results of this study show that community pharmacist-led wellness services improved DBP
and FBG values in an EWP. In addition, a 2014 systematic review revealed that patients in EWPs have
improved quality of life [32]. For an employer, an EWP has been shown to bring $3.48 in return for
each dollar spent on the program [33]. Therefore, an EWP offers a great opportunity for pharmacist
wellness coordinators to demonstrate their value to both patients and employers.
For both all participants and those who did not withdraw from the program, we found a significant
improvement of DBP in the blood pressure monitoring group compared with baseline. However,
a significant improvement of SBP was only identified in those who did not drop out. The Seventh Report
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC-7), the governing blood pressure guideline at the time of study conduction, states there
are higher control rates of DBP than SBP. According to the guideline, many primary care physicians
were trained to emphasize DBP control more than SBP [27]. In 2017, the American College of Cardiology
and the American Heart Association released new guidelines for blood pressure management [34].
The new guidelines classify a blood pressure of 130/80 mm Hg as Stage I hypertension, rather than
140/90 mm Hg in JNC-7. There may be participants who met their blood pressure goal under JNC-7,
but would not be at the goal under the new guidelines.
Although DiDonato et al. found significant improvements in cholesterol levels (TC, LDL-C, and
HDL-C) for the first year, these improvements were not sustained over the next three years of the
program [26]. Similar to the results of DiDonato et al., no significant changes in BMI or WC were
observed in the weight monitoring group at 48 months. Of note, the baseline averages of LDL-C,
SBP, DBP, and FBG were lower in our study population than in comparable studies, suggesting a
healthier baseline patient population [26,35,36]. In addition, following study closure, new cholesterol
practice guidelines were published [37]. This new guidance removes the previous goal-driven treatment
methodology and supports using maximally tolerated statin therapy. With this new guidance, we might
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have seen different results in the cholesterol monitoring group, with more participants reaching the
“goal” of being on the appropriate statin intensity. Furthermore, we believe that as the program
progressed, some patients regressed to previous unhealthy habits.
In this study, FBG rather than HbA1c was evaluated because of four reasons. First of all, when the
EWP was developed and implemented, diabetes guidelines recommending HbA1c as a method of
diagnosis [38] were not available. Secondly, although some participants did receive HbA1c point-of-care
testing, the manufacturer discontinued production of the device for a period of time during the study.
Therefore, HbA1c results were not consistently monitored and reported. Thirdly, FBG was a more
cost-effective approach as this measurement was included in the cholesterol panel the participants
were already receiving. Lastly, most participants in the diabetes monitoring group were not diagnosed
with diabetes. As co-morbidity becomes more and more common [1], the number of chronic conditions
or out-of-range clinical values could be useful to target and monitor the combination of disease states
in an EWP. This raises a question of whether patients who have multiple interventions would have
improved health outcomes when compared with those who have a single intervention. In this study,
only 39 patients were enrolled in one of the four patient monitoring groups (i.e., they had one disease
state and one intervention for that disease state). Because the majority of patients (n = 136) were
enrolled in more than one patient monitoring group, and most clinical variables had no significant
change over a four-year period, it is implied that the impact of multiple inventions was limited in
this study.
Despite the encouraged regular meetings between participants and pharmacist wellness
coordinators, a study limitation was the decline of participants each year. This could be because of
fatigue from regular follow-ups with the coordinators. At each visit, participants were held accountable
for the goals set at previous visits. If goals were not being met, this could have led to some patients
feeling discouraged or frustrated with the process. As mentioned earlier, another reason could be that
participants tended to revert to their previous lifestyles.
Recently, Jones et al. reported that there is little evidence to support the positive impact of
employee wellness programs, and most existing studies utilize observational comparisons between a
study group and a control group [39]. In a randomized control trial, they identified a strong pattern of
selection that program participants were already healthier than non-participants. A response rate of
53.3% for the first year may indicate a potential selection bias that healthier participants were enrolled.
In addition, despite having a healthy participant monitoring group, this study did not employ a control
group, which was another limitation. Perhaps if we had included a control group, we would have
found that individuals in the control group had significant increases in these clinical variables.
There were also two other limitations. First, we did not collect information for all potential
confounding variables, such as medication adherence and healthy eating. Second, given the
observational study design and the fact that the employees might know each other well, we were
unable to control for externalities (e.g., passive smoking or drinking alcohol in some social occasions).
For future EWPs, the training for pharmacist wellness coordinators should include how to conduct
participant follow-ups to ensure participants feel the value of the service. We believe that regular
and effective follow-ups could not only have prevented participants from dropping out of the EWP,
but also from reverting to unhealthy behaviors. In addition, future EWPs could consider applying
additional incentives, as feasible, to encourage participation and motivate participants to reach their
goals. To encourage participation in the EWP, participants received a discounted health insurance
premium of $50, pedometers, and water bottles. However, incentives directly associated with outcomes,
such as a cash reward for meeting goals, may have been more motivating to individuals versus a
cost-savings incentive structure. In a study conducted by Schramm et al., a financially incentivized
weight loss challenge led to significant weight loss in the study population [22]. Interestingly, Jones et al.
revealed a diminishing effect on participation when the incentive was increased from $100 to $200 [39].
Including incentives focused on achievement of goals in addition to incentives for participation may
have led to improved outcomes.
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6. Conclusions
Pharmacist-led wellness visits provided to employee wellness patients in a community pharmacy
may lead to improvements in BP and FBG values. Significant improvements were seen in cholesterol
outcome measures after one year of the program, but were not sustained over the next three years,
suggesting participants may have reverted to their previous habits.
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Abstract: In some jurisdictions, governments and the public look to community pharmacies to
provide expanded primary health care services, including care plans with follow-up. Care planning
services, covered by the Compensation Plan in Alberta, Canada, require pharmacists to assess an
eligible patient’s health history, medication history, and drug-related problems to establish goals
of treatment, interventions, and monitoring plan. Follow-up assessments are also covered by the
Compensation Plan. A comparative case study method facilitated an in-depth investigation of
care planning services provided by four community pharmacy sites. Data from 77 interviews, 61
site-specific documents, and 94 h of observation collected over 20 months were analyzed using an
iterative constant comparative approach. Using a sociomaterial theoretical framework, the perceived
value of care planning services was examined through an investigation of the relationships and
interactions between people and information. Patients perceived the value of care planning as related
to waiting time to access care and co-creating individualized plans. Physicians and other health care
professionals valued collaboration, information sharing, and different perspectives on patient care.
Pharmacists valued collaboration with patients and other health care professionals, which renewed
their sense of responsibility, increased satisfaction, and gave meaning to their role.
Keywords: pharmacist services; community pharmacy; care plan; compensation; primary health
care; information sharing; qualitative research; comparative case study; value
1. Introduction
Primary health care is based on the principles of equity, collaboration, and community
participation [1]. It has been defined as the first place individuals go to receive health care services [2].
Attributes of primary health care include patient and family centeredness, continuity of relationships,
and information continuity and management [3]. The delivery of primary health care involves teams
of health care providers; the exact composition of these teams depends on patients’ needs. As team
members, pharmacists do their part to meet patients’ needs and provide essential drugs. In many
parts of the world, pharmacists are becoming increasingly involved in the delivery of primary health
care, contributing to chronic disease management and providing immunization services [4,5] and
the community pharmacy is a place that the public would go to receive some primary health care
services [6,7]. Describing community pharmacists as “primary care pharmacists” recognizes not only
their accessibility to patients, but also their contributions as team members delivering primary health
care services including management of chronic conditions such as hypertension, treatment of minor
ailments, administration of vaccinations, and triaging and referring patients with acute conditions
to emergency departments or family physicians [8,9]. Governments, such as those in Canada and
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Alberta, and the public therefore look to community pharmacists as providers of primary health care
services [2,10].
Research examining pharmacists’ preferences for existing and potential roles indicates a
preference to provide more patient-centered services [11] and to contribute more to meeting primary
health care needs in their communities through teamwork [12]. Pharmacists are now involved in
providing enhanced services that support primary health care such as comprehensive medication
reviews, immunizations, adherence packaging, and development of comprehensive care plans with
follow-up [13].
A care plan is an essential component of the patient care process [14] and refers to a detailed
document prepared by a pharmacist that outlines the pharmacist’s and patient’s responsibilities to
resolve drug therapy problems or health needs to achieve the patient’s health goals, and to prevent
potential drug therapy problems. Care plans are developed with input and participation of the
patient and can be developed collaboratively with other health care providers involved in the patient’s
care [15]. Documented care plans are fundamental to delivery of pharmaceutical care services [14,16],
quality care, and communication with team members [17]. For example, care plans for chronic disease
management can improve information sharing, enhance patients’ engagement in self-management,
and promote collaboration among health care professionals [18]. Involvement in care planning services
has the potential to increase the engagement of pharmacists in primary health care [19] and increase
recognition of the value of pharmacists’ contributions to patient care.
Demonstrating value in primary health care addresses the triple aim of health systems to improve
patient health outcomes, improve patient experience of care, and reduce health care costs [20,21]. Other
approaches to show value acknowledge the role of care planning, along with access to care, continuity
of care, relationships, evidence-based therapy, and patient engagement in the process [22]. Parameters
that may be useful to demonstrate the value of care planning include patients’ experienced health,
increased accessibility, building of trust, improved communication with care providers, relationship
continuity of patients and care providers over time, information management [23,24], and experiences
of health care providers including conditions that support health care providers to find meaning in
their work [25].
Although care plans communicate value from perspectives of the effectiveness and
cost-effectiveness of pharmacy services [26] and provide documentation that supports bi-directional
communication of health care providers [27], very little research has been conducted regarding the
perceived value of pharmacists’ care planning services. This study addresses this gap from the
perspectives of patients and health care providers who have experience with care planning services.
The overall objectives of this study are to explore how care pharmacists’ planning services covered by
the Compensation Plan in Alberta were implemented and the perceived value of the care planning
services. This paper aims to contribute to what is known about the perceived value of care planning
services provided by pharmacists through community pharmacies.
2. Materials and Methods
2.1. Context
The setting for this research is the western-Canadian province of Alberta. Since 2006, pharmacists
can access patient information including laboratory tests and records of dispensed medications through
a provincial electronic health record known as Netcare [28]. The scope of practice for Albertan
pharmacists enables them to order laboratory tests, administer drugs by injection, and prescribe drugs.
Prescribing authority involves 3 types of prescribing: emergency prescribing, adapting prescriptions,
and independent prescribing [29]. All pharmacists can prescribe in an emergency when patients cannot
access other health services and all have authority to adapt a prescription initiated by another prescriber.
When pharmacists prescribe by adapting a prescription, they may modify a prescription to extend
therapy, change a dose or formulation. Pharmacists who have successfully applied for Additional
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Prescribing Authorization (APA) may also prescribe to initiate new drug therapy [29]. The APA
application process involves peer review of a prescribing portfolio that includes narrative description
of the pharmacists’ practice, documentation of patient care cases, and self-assessment of prescribing
competencies [30]. Documentation of prescribing decisions is required along with communication with
any other health professional whose care of a patient may be affected by the pharmacist’s prescribing
decision [31]. At the time of this study, Alberta had a population of 4.2 million [32]. There were
5363 practicing pharmacists including 1658 with APA, 1377 registered pharmacy technicians, and
1232 licensed pharmacies [33]. Community pharmacy practice in Alberta varies from pharmacist to
pharmacist within the scope of practice and their roles are continually evolving [34,35].
The Compensation Plan for Pharmacy Services, approved by the Government of Alberta and
implemented in 2012, supports the scope of practice for pharmacists in Alberta by offering one of the
most comprehensive fee schedules available for remuneration of pharmacy services in Canada [36].
It allows for payment to community pharmacies for a range of pharmacy services provided by
pharmacists such as prescription renewals, administration of drugs and vaccines by injection, and
care planning services, including follow-up assessments [37]. Since implementation, the number of
compensated services increased from 30,000 per month (July 2012) to 170,000 per month (March 2016)
and Comprehensive Annual Care Plans (CACP) and CACP follow-up assessments were among the top
8 services claimed by community pharmacies [36]. Similar to medication therapy management (MTM)
services provided by pharmacists under the Medicare Modernization Act (2003) in the United States
(US) [38], Albertan pharmacists involved in care planning services must assess a patient’s health and
medication history, establish goals of treatment, suggest interventions, and implement a monitoring
plan. To be eligible for a CACP covered under the Compensation Plan, patients must meet certain
criteria; for example, they must have specific chronic diseases (e.g., diabetes) or have certain risk factors
(e.g., tobacco use).
CACP is defined as “a plan that is prepared and documented by a Clinical Pharmacist that
documents the required elements” (see Table 1) [39]. The components of the plan are consistent with
the patient care processes outlined by the National Association of Pharmacy Regulatory Authorities in
Canada [15] and National Association of Joint Commission of Pharmacy Practitioners in the US [14].
Different from MTM services in the US, the CACP service criteria are fixed and the Alberta government
pays pharmacies for the service as long as patients are covered by the provincial health care system (i.e.,
have an Alberta health care number). CACPs are developed by pharmacists in collaboration with the
patient, after which all interactions are documented and shared with other health care professionals
involved in the patient’s care [36]. Community pharmacies and pharmacists developed customized
CACP templates as there are no prescribed care plan documentation templates. Patients must sign
that they have reviewed and discussed their CACP with the pharmacist who prepared it as well as
received a summary of the CACP [39]. Pharmacists with appropriate authorizations, including APA or
injections, may implement interventions such as adjusting doses of chronic medications, prescribing
smoking cessation therapy, or administering vaccines. Pharmacists may choose to suggest or discuss
interventions with the patient’s physician or refer to other health care providers.
2.2. Theoretical Framework
The theoretical framework for this study draws on sociomaterial theory [40] and document
theory [41], allowing us to explore the value of care planning services (Figure 1). A sociomaterial
approach recognizes the importance of the social (i.e., relational) and material (i.e., care plans) aspects
of everyday activities and their influence on our understanding of reality. A care plan, as a physical
(material) document, combined with human (social) endeavors, serves to include, exclude and regulate
actions [42]. Document theory considers a care plan as a source of information existing in 3 dimensions:
material, social, and mental [41]. Thus, research based on document theory explores how these
dimensions interact in different environments in which documentation takes place; in this study,
document theory is applied in the context of care planning services associated with primary health care.
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In pharmacy practice, care plan documents themselves may be in the background when contemplating
primary health care services. By acknowledging the role of these documents, this study brings care
plans to the foreground of scholarly thinking, making them visible and asserting their value as part of
the care planning services provided by pharmacists.
Table 1. Summary of patient eligibility criteria, information, and fees associated with Comprehensive
Annual Care Plan (CACP) services [37,39].




Two or more of the following chronic conditions:
Hypertension
Diabetes











CACP must have been completed.
CACP Follow-up may be provided
if a referral from a physician or
hospital admission/discharge within
14 days of the CACP service
OR








Symptoms or signs to be treated
Pregnancy or lactation status
Medication use history/review (Best Possible Medication
History—BPMH)
Other health care products or devices
Lifestyle factors—weight, tobacco use, illicit drug use,
alcohol use, exercise
Laboratory values
Care plan—agreed goals of medication therapy, drug
therapy problems, identification of possible interventions,
plans for monitoring, and follow-up assessment
Fees 2 $100 3 $20 4
























Figure 1. Elements of research used in this study.
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2.3. Methodology—Comparative Case Study
A comparative case study approach was used in order to gain an in-depth understanding of
compensated care planning services within the real-world context of patient care in community
pharmacy practice in Alberta [43,44]. The unit of study, or the case, was the CACP [45]. Case study
research is ideal for exploring “how” and “why” research questions [45]. As part of larger study, the
case study method was chosen to explore how pharmacists implemented care planning services and
why services are perceived as valuable. Case study research may involve a single case or multiple case
design [43]. This comparative case study was designed to include 4 different community pharmacy
sites, or cases, a priori. The more sites included in a comparative case study, the greater the range of
variation, thus the greater the contribution to what is known about care planning services in different
contexts [43].
2.4. Methods
Three methods of data collection were used in this study: interviews, observation, and documents.
Interviews were semi-structured, consisted of open-ended questions, were conducted by members
of the research team, were approximately 30–60 min in length, and were conversational in style
(Appendix A, Table A1). One research team member was assigned to each site. The lead team
member coordinated the site visit with the research assistant and both were involved in data collection.
The research assistants were trained by the co-principal investigators. Most interviews were conducted
in person at the sites. Some interviews with patients and physicians were conducted over the telephone
following site visits. Interviews were audio recorded and transcribed verbatim. The second method
of data collection, direct observation of the provision of patient care services, permitted the study of
care planning within its natural setting or real-world context [45]. Researchers observed individuals
involved in care planning services (pharmacists, pharmacy technicians, pharmacy staff, other health
care providers, and patients), took field notes, and wrote a narrative description based on what was
seen, heard, or sensed on site [44]. Observational data were collected at the time of the site visits
using a pre-prepared form to guide documentation of observations and support reflexive research
practices (Appendix A, Table A2). The research team developed the observation form to address the
research questions. Observations focused on care planning interactions between pharmacists and
patients, pharmacists and pharmacy staff, as well as development, storing and sharing of the care plan
document. The researcher documented observations in a notebook, using the observation form as a
guide. After the interaction concluded, the researcher transcribed notes to an electronic version of the
observation form. A summary of interview questions related to observations were noted. Site-specific
documents related to CACP services such as care plan templates and communication templates were
also collected at site visits (Appendix A, Table A3). Data collected from observation and documents
were incorporated into the interview process to invite materiality into interviews (Figure 2) [46].
2.5. Recruitment
The researchers identified types of community pharmacy sites where services covered by the
Compensation Plan for Pharmacy Services were provided. Sites were selected by the research team
using a purposive sampling technique [47] based on pre-defined variables [44]. The study included
4 community pharmacy sites where CACP services were provided, selected based on the following
information: type of pharmacy (independent, franchise, corporate), population size (population
centre) [48], volume of CACP services (number of reported CACPs provided per month), and
provision of other compensated services (pharmacists with APA and injections authorization). A list of
pharmacies and prescribing pharmacists provided by the Alberta College of Pharmacy and guidance
from the Research Advisory Committee members were used to identify community pharmacy sites
that represented pre-defined variables and likely to be engaged in care planning services under the
Compensation Plan for Pharmacy Services.
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Figure 2. Methods of data collection used in this study. Interviews incorporated data from observation
and documents.
Pharmacy managers were initially approached by a member of the research team to discuss their
pharmacy as a potential site for the case study. A total of 5 sites were recruited. One site withdrew from
the study prior to the start of data collection due to unexpected staffing changes. All 4 cases involved
community pharmacies and extended beyond the physical space to include patients, physicians, and
other health care professionals involved in care planning services. Participants were recruited on
site (patients, pharmacists, pharmacy technicians, pharmacy students, and staff) and in the local
community (other health care providers involved with the pharmacist in the care planning process) [49].
Other health care providers included nurses, nurse practitioners, and physicians. Information posters
about the study were displayed at the community pharmacies to indicate that researchers were on
site and invited patients to approach researchers if they were interested in the study. Physicians
associated with the community pharmacies and involved with care planning services were identified
by the community pharmacists or patients and subsequently invited to participate in the study by the
researchers. All participants provided informed consent. This research study was approved by the
University of Alberta Health Research Ethics Board (Pro00059814).
2.6. Data Analysis
Data from interviews, observations, and documents collected at the sites were analyzed using an
inductive constant comparative approach based on constructivist grounded theory [47]. Following
transcription of the interviews, a member of the research team reviewed each transcript for accuracy
and removed identifying information such as names of individuals, pharmacies, and towns or cities.
The initial analysis entailed line-by-line coding of each phrase or portion of data from the various
data sources by 1 research team member. All team members reviewed codes, emerging concepts,
and supporting data following each site visit and at monthly research meetings to reach consensus.
In keeping with the grounded theory approach, interview questions were adjusted to ensure an
in-depth understanding of concepts (see Appendix A, Table A1). Separate analysis of data from each
site permitted comparison of the data in terms of perceived value of care planning services. NVivo 12
software was used for storing data, coding, and analysis.
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2.7. Rigour
The case study method is a rigorous qualitative research approach that ensures the
trustworthiness of the results of research [50]. Elements of trustworthiness include credibility,
dependability, confirmability, and transferability; these are parallel concepts to internal validity,
reliability–reproducibility, objectivity, and generalizability, all concepts associated with the quality of
quantitative research [51]. Trustworthiness was achieved through use of a combination of data sources
(credibility), in-depth presentation of data and analysis (dependability), detailed documentation at
all research stages, and sharing of research results with participants (confirmability). Based on this
description of the study setting, readers can judge for themselves about the transferability of its results
to other contexts.
2.8. Reflexivity
The roles and views of research team members were discussed throughout the research process:
personal views and positions on the Compensation Plan for Pharmacy Services, the effect of care
planning services on the pharmacy sites included in this study, the influence of archival documents
and the media reports of compensated pharmacy services by the public and other audiences [52].
The research team addressed these issues reflexively at monthly research meetings held throughout
the planning, data collection, analysis, and reporting phases of the project. In addition, reflexivity was
incorporated in the form used to document observational data (Appendix A, Table A2). All members
of the research team are associated with the pharmacy profession, 2 as practicing pharmacists (C.A.H.,
R.R.B.), but not involved in provision of compensated CACP services in community pharmacy practice.
3. Results
3.1. Sites
The four sites recruited for this study represented different practice contexts associated with
CACP services. These included two independent pharmacies, a franchise pharmacy, and a large
corporate chain pharmacy, all from population centers ranging widely in size [48,53]. Site 1 served
a small population center as well as rural communities within 100 km of the community pharmacy.
Site 2 served patients in an inner-city neighborhood in a large population center. Site 3 was located
in a suburban area and routinely involved pharmacy students from the University of Alberta in care
planning services. Site 4 provided CACPs for patients in care facilities outside of the pharmacy and
worked closely with family physicians in primary care practices. At all sites, pharmacists integrated
CACP services within their established practices. Sites 1, 2, and 3 developed approximately 20 CACPs
each month, whereas Site 4 developed over 100 CACPs per month. Details of the sites are summarized
in Table 2.
Table 2. Details of sites included in this study.
Description Site 1 Site 2 Site 3 Site 4
Pharmacy type [53] Independent Franchise Corporate Independent
Population center [48] Small 1 Large 2 Medium 3 Large 2
Pharmacists (with APA 4, injections
authorization)
3 (3,3) 3 (1,3) 3 (1,3) 5 (4,5)
Registered technicians 1 - 1 2
Assistants 3 3 2 6
Pharmacy students - Periodically Regularly -
CACPs 5 completed per month <20 <20 <20 >100
1 Population between 1000 and 29,999; 2 Population of 100,000 and over; 3 Population between 30,000 and 99,999; 4
APA—Additional Prescribing Authorization; 5 CACPs—Comprehensive Annual Care Plans.
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3.2. Data Collected
Data were collected over a period of 20 months between May 2016 and January 2018. Each
site was visited three times over the course of a year, typically at 6 and 12 months following the
initial visit. The data set included 77 interviews, 94 h of observation, and 61 site-specific documents.
Table 3 summarizes the numbers of interviews and observation hours. Researchers collected document
templates developed by each site to facilitate information gathering (e.g., care plan, patient assessment,
medication history) and sharing (e.g., letters to physicians, medication lists, patient action plans).
Types of documents collected are listed in Appendix A, Table A3.
Table 3. Interviews and observation hours.
Data Site 1 Site 2 Site 3 Site 4 Total
Total number of interviews 27 15 16 19 77
Patient 11 5 8 5 29
Physician 2 2 - 2 6
Nurse 2 - - 3 5
Pharmacy staff 4 4 2 3 13
Pharmacy student - - 2 - 2
Pharmacist 1 8 4 4 6 22
Hours of observation 24 28.5 26 15.5 2 94
1 The number of pharmacist interviews exceeds the number of pharmacists participating in the study due to the fact
that multiple interviews were conducted over the 12-month data collection period at each site. Some pharmacists
were interviewed more than once; 2 The number of observation hours required at site 4 was less than other sites due
to the higher number of care planning services observed.
3.3. Value of Care Planning Services
The value of care planning services was evident in the interactions between people and information.
Six areas of value were identified: reinforcing patient-centered care, reducing waiting time for care,
co-creating individualized plans with patients, collaborating with physicians and other health care
providers, revealing possibilities for pharmacists’ contributions to primary health care, and making
sense of pharmacists’ roles in primary health care. Results are presented in the sections below. They
reflect a sociomaterial exploration of value, which emphasizes the importance of the social and material
aspects of care planning services and how they are related to action in practice. Representative quotes
from interview data are provided in Appendix A, Table A4.
3.3.1. Reinforcing Patient-Centered Care
“I like the structure and deliberateness . . . [it] is a remarkable way to connect with people and to help
them manage their health. It’s been really good that way to make that a deliberate process” (Site 2,
Pharmacy Manager)
The care plan document focused pharmacists’ and pharmacy technicians’ work to support the
patient care processes. Value was associated with the changes made to work arrangements in everyday
practice so that pharmacists could “sit down in the room”, “connect with patients”, and complete
the “whole care plan process”. To accomplish this, pharmacists physically excused themselves from
dispensing and other duties to prioritize care plan development and follow-up. Other pharmacists
and pharmacy technicians or assistants at the sites adjusted their work to accommodate. At Site 4,
pharmacists were specifically assigned to provide care planning services exclusively. Modifications to
the duties of the pharmacy technician at Site 1 included identification of patients who presented to
the pharmacy with questions about their care plans or patients who were eligible for care planning
services based on the Compensation Plan (i.e., the CACP).
Pharmacists used care plan templates to structure care planning services. These templates guided
the processes of gathering information, identifying drug-related problems, obtaining information
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to support drug-therapy decisions, preparing documents for physicians and patients, scheduling
follow-up interviews or monitoring, and updating patient information systems. Information gathering
from the patient’s electronic health records and pharmacy system was usually completed prior to the
care plan meeting with patients and documented on the CACP template. The time required for the
CACP varied from pharmacist to pharmacist, sometimes taking up to 4 h to complete the process. Care
plan documents were valued for their ability to guide changes in work and reinforce the focus of the
work on patient care services
3.3.2. Reducing Waiting Time for Care
“I waited actually over 15 months to see a specialist . . . The pharmacist in five minutes told me more
than that specialist did, and there was no waiting period.” (Site 3, Patient 1)
Patients valued care planning services, which saved time and increased convenience. Patients
associated the CACP with timely access to care. Access to care at the pharmacy was more convenient
than scheduling appointments at physicians’ offices. Patients compared their prior experiences in
both environments, noting lengthy waiting times to see their physicians, less comfortable medical
office environments, and greater formality than at the pharmacy. Access to care was not only easier;
the community pharmacy environment was more conducive to conversations about health and
concerns. Patients noted that their CACP interviews with pharmacists were less formal than physician
interviews. Speaking to their pharmacists was like speaking to “family”. Reduced waiting time to
see a pharmacist led patients to seek advice and answers to questions previously directed to their
physicians. For example, they might ask a pharmacist to determine if a visit to a physician or hospital
emergency room was required. They also sought information about their health conditions, looking to
pharmacists for education about various medical issues. The value of the care plan for patients was
thus associated with reduced waiting time and convenient access to care.
3.3.3. Co-Creating Individualized Plans with Patients
“It made a difference to me. I mean, I appreciate it. I appreciate the chance to go over my meds and
things that bother me at the time or what we could do about one thing or another.” (Site 1, Patient 4)
The initial development of the CACP promoted relationship building between patients and
pharmacists. Subsequent patient–pharmacist interactions arising from CACP monitoring plans and
scheduled follow-up reinforced previously established relationships and improved rapport. Some
patients initiated follow-up with pharmacists as new information or questions arose. Through frequent
and continuous conversations, individualized plans were created with patients’ willing participation
in the process. These interactions frequently involved the patient and pharmacist both interacting
with others, such as the patient’s family members or caregivers, physicians, or nurse practitioners.
In developing CACPs, pharmacists and patients also interacted with information and other material
objects such as weigh scales, blood pressure monitors, insulin pumps, and electronic resources.
Following the CACP interview, patients were provided with a current list of medications. Patients who
left with an understanding of their goals and action items associated with the CACP were motivated
to engage further in their care. However, not all patients left the CACP experience with a CACP
document and a clear understanding of their goals and action plan. Through involvement in the care
planning, patients’ engagement with their care was enhanced. Patients valued the time spent with
pharmacists, noting that pharmacists took “time to listen”, and valued knowing more about their care
and a sense of their responsibilities for action.
The CACP was more than a document that recorded important information about patients and
their goals. It caused things to happen and made a difference in patients’ experiences with health
care services. Patients valued care planning services for emotional reasons as well as practical ones.
Patients valued the CACP for the “peace of mind” and “secure feeling” they got after using the services.
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Value was therefore derived from patients and pharmacists working together to create care plans and
patients’ experiences of care provided by pharmacists.
3.3.4. Collaborating with Physicians and Other Health Care Providers
”It’s a wonderful adjunct to my practice. It makes my practice better . . . It makes me think about
things in a different way.” (Site 4, Physician 2)
Information sharing is essential to the collaboration associated with care planning services.
Information was gathered from patient records at the pharmacy, from patients’ electronic health
records, and from other health care professionals such as nurses and physicians. At Sites 1 and 4,
pharmacists accessed physicians’ medical care plans. Pharmacists at Site 1 routinely requested medical
care plans directly from physicians’ offices. Some pharmacists at Site 4 were co-located with physicians
at practice sites outside the community pharmacy. Pharmacists and physicians at Site 4 worked closely,
sometimes meeting with patients together and co-developing care plan documents.
Methods of information sharing between pharmacists and physicians varied. The most frequent
method involved pharmacists sharing a copy of the CACP with physicians after the care planning
documentation was completed. To do this, they transmitted a facsimile of either the entire CACP
document or a summary of the action items or issues outlined in the CACP. Transmission of information
(faxing care plans to physicians) is required by the Compensation Plan. Physicians at Site 1 adjusted
their office procedures to store the CACP within their information systems. Establishing processes
for information sharing facilitated the building of relationships and supported care planning services.
When pharmacists and physicians knew each other, the process worked more efficiently. For care
planning services at the urban Site 2 and suburban Site 3, where pharmacists and physicians in the
community did not have working relationships, frustration arose around information sharing. Other
information sharing methods involved direct communication with physicians through telephone
conversations, text messages, or face-to-face conversations.
The timing of information sharing was important. Most information sharing activities occurred
after the care plan was completed. However, information sharing that occurred before completion of
the care plan or through face-to-face communications was highly valued because clarifications could
occur or more information gathered in those interactions. Some physicians valued information sharing
at the time of development of care plans rather than receiving information after the fact. For example,
a physician at Site 1 routinely contacted pharmacists to proactively share information and update
documentation. Some physicians expressed frustration with pharmacist-developed care plans, citing
instances of incomplete information, differences in opinions regarding drug therapy or prescribing
decisions, or confusing documentation. Pharmacists and physicians that communicated directly
about these frustrations worked together to improve information-sharing practices. Some adjustments
resulted in tailored documentation to meet patient needs; for example, care plan summary templates
were created to expedite the information sharing process. Care plans co-developed by pharmacists
and physicians at Site 4 were valued by the physicians for their tendency to make them “think about
things in a different way”.
Once patients were familiar with care planning services, they came to expect information sharing
and collaboration from their pharmacists and physicians. Patients valued knowing that pharmacists
and physicians shared information and communicated about their care. The value of care planning
services was therefore associated with “interaction” and being “connected”.
3.3.5. Revealing Possibilities for Pharmacists’ Contributions to Primary Health Care
“I didn’t know that [the pharmacist] would talk to me about it. I thought I would just walk in, get my
prescription and walk out, right? That’s the way I thought it was.” (Site 4, Patient 1)
Patients were generally unaware of the existence of care planning services prior to being
approached by their pharmacist. Through interactions between patients and health care providers and
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increased familiarity with care plan documents, patients gained knowledge of community pharmacy
services, for example, prescribing, that extended beyond the boundaries of traditional preparing and
providing medications. Patients and physicians were long familiar with pharmacists’ dispensing
services. However, expectations of the CACP were initially unclear. After gaining some experience
with care planning services, one patient referred to the pharmacist as a “secret doctor” indicating
that the abilities and expertise of the pharmacists were kept a secret until revealed through the CACP
experience. Patients began to see pharmacists as primary health care providers who could do more
than “fill prescriptions”; they began to appreciate the benefits they derived from the CACP, particularly
receiving information about their medications and conditions. Providing care planning services
revealed pharmacists’ drug therapy expertise and increased their interactions and information sharing
with patients and other health care providers. Nurses and physicians viewed pharmacists as “an
integral part” of primary health care teams. Physicians gained more respect for pharmacists’ roles and
abilities. Despite their increased awareness of care planning services and pharmacists’ roles, patients
did not refer to the CACP as a care plan, but rather as a “medication review”. The value of care
planning services stemmed from having first-hand knowledge of and experience with pharmacists,
revealing possibilities for their future contributions to primary health care.
3.3.6. Meaning of Pharmacists’ Roles in Primary Health Care
“I like what I do better, because it feels like I’m contributing more and I know I’m contributing more.
And I appreciate being compensated for it. I’ve come to value it more appropriately as well . . . Now
that we do have compensation for some of the clinical skills that we’re using all of the time, it makes it
far more satisfying.” (Site 2, Pharmacy Manager)
As discussed earlier, pharmacists changed the focus of their work to provide care planning services,
enabling them to co-create CACPs with patients and collaborate with other health care professionals.
They spent time working with the CACP document template to gather information before meeting
with the patient and to expedite the care planning and documentation processes. Increased interactions
with people and their information fostered a sense of “doing more” for patients. As pharmacists gained
experience with care planning services, they accepted more responsibility for patient care. While
these activities (patient assessment, care planning, and documentation) were established as part of
pharmaceutical care practice and gradually became embedded in their everyday work, there was a
perceptible change in how they experienced their role. For some, the role felt “heavy” and “like I made
a difference”. These changes were observed in association with the increased time pharmacists spent
with patients, with the CACP document, and in activities related to information sharing. As well as
feeling more connected to patients, pharmacists felt the CACP represented an investment because of the
effort contributed to future encounters with patients; through involvement in the care planning process,
pharmacists were positioned to support patients better through “rough times”. Pharmacists derived
greater satisfaction with their work, felt that they were “contributing more” to patient care and primary
health care, that they were staying “more current”, and that they enjoyed having “people depend
on [them]”. These realizations, along with the material compensation associated with care planning
services, changed how pharmacists experienced their role: with a renewed sense of responsibility,
satisfaction, and meaning.
4. Discussion
This study employed a novel theoretical approach to explore the perceived value of compensated
care planning services provided by pharmacists. This approach placed the care plan document
in the foreground. It also examined interactions between information and people. This study
found that care plans provided material information, influenced everyday practice, linked people
together, and mediated meaning-making. Care planning services were valued for their role in
reinforcing patient-centered care, reducing waiting time for care, co-creating individualized plans with
patients, collaborating with physicians and other health care providers, and revealing possibilities for
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pharmacists’ roles. This study also highlights pharmacists’ renewed sense of responsibility, satisfaction,
and understanding of their role and potential contributions to primary health care.
Through involvement with care planning services, everyday work by pharmacists and pharmacy
staff changed in that more attention was focused on patients’ needs. Results echoed areas of
value associated with primary health care services, namely accessibility, patient centredness, patient
engagement, and experiences of health care providers [3,22–25]. These areas of value were also noted
in prior research on care plans [19,54,55]. Similar to this current study, Council et al. [55] employed a
prospective case study design to explore care planning by a group family practice at a community
hospital in the US. In their setting, physicians, nurses, residents, and medical assistants all contributed
to care planning. In that study, increased patient centredness, and patient involvement in the care plan
were reported [55]. Thus, care plans bring value when patients are engaged in their development with
primary care providers.
Through their participation in care planning services, patients valued having time and opportunity
to talk with pharmacists about their medications and health concerns. Patients felt cared for and
listened to. This experience represented a departure from patients’ past experiences. The difference
was attributed to care planning. Brown et al. [54] summarized the essence of care planning as having a
“better conversation”. The initial CACP interview became an ongoing conversation through various
follow-up appointments at the pharmacy or telephone calls with patients; the conversation was often
expanded to include physicians and others involved in the patient’s care. From patients’ perspectives,
the conversation with pharmacists was less formal than speaking with physicians, like speaking with
family members. This reflects the trust and confidence in the relationships built between patients and
the pharmacists in this study. The results of this current study pointed to the unique conversation
brought about by care planning services.
Previous research by Hindi et al. [19] found that care plans help to integrate community pharmacists
into primary health care teams. Shared care plans, those co-developed by pharmacists and physicians,
may further integrate community pharmacy in primary health care as well as address issues such as
duplication of work and improve teamwork, which was seen in our study. Brown et al. [54] asserted
the value of delivering a single coherent message to a patient in a shared care plan, describing how
these plans support patients to engage in their own care and implement changes to their lifestyle.
Experiences developing shared care plans in this current study were valued by patients, pharmacists,
and physicians. Physicians valued the different perspectives and expertise brought by pharmacists as
well as the efficiency of shared care plans.
Information sharing is recognized as a significant part of care planning services [54]. In the current
study, care plans facilitated coordination of information and patient care activities. Care plan documents,
themselves, contribute patient information. With pharmacists contributing more and more to patient
care in the primary health care system, care plan documents will become even more important for
information sharing. However, lack of access to or incomplete patient information presents challenges
for pharmacists providing care planning services. In Alberta, pharmacists have had access to provincial
electronic health records, including laboratory tests and records of dispensed medications, since
2006 [28]. In the current study, complete information shared through documents or in conversation was
highly valued and necessary to ensure accuracy and informed decision-making. Information systems,
like NetCare in Alberta, are needed to support care planning services. Enhancements to the NetCare
system that allow pharmacists to upload care plan documents to patients’ records will support easier
information sharing between health care providers. Some pharmacists in this study lacked access to
patients’ medical care plans. Having information from different perspectives of physicians and nurses
would support pharmacists’ care planning services. In addition, information sharing mechanisms that
support conversations between patients, physicians, pharmacists and other health care providers will
bring further value to patients. Other research draws attention to the value of information sharing.
Hindi et al. [19] conducted focus groups of patients, pharmacists, and general practitioners to identify
how community pharmacy services may be better integrated within the primary care pathway for
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people with chronic conditions. Their results emphasized the need for robust information systems
that included two-way flow of information. Council et al. [55] found that patient-centered care plans
increased efficiency and the validity of information was enhanced as multiple team members and
the patients were involved in construction of information. Methods to support information sharing
contribute to collaboration and quality of primary health care services. Brown et al. [54] reviewed
studies that evaluated care planning to develop a theoretically informed framework for how care
planning works best. These investigators noted that sharing of written care plans within and across
teams for patients with multimorbidity ensures consistency of messages. Attention to the quality of
the care plan, along with completeness of information and consistency in presentation [19,56], may
further enhance the value of information sharing associated with pharmacist care planning services
and improve patient care.
Collaboration in the form of information sharing occurred in different ways at the sites included
in this study depending on the individuals involved in care planning and the particular practice setting
and location. Research by Talja [57] describes types and levels of collaborative information sharing
related to documents. Talja’s 4 classifications relate to different goals and contexts and highlight the
social aspects of information sharing including to: (1) provide information; (2) maximize efficiency;
(3) form or strengthen relationships; and (4) develop novel approaches. In the context of the current
study, information sharing by physicians and pharmacists at Site 4 produced shared care plans. This
arrangement is an example of a novel information sharing strategy through which the relationships
between pharmacists and physicians may be enhanced, and actions associated with care planning
services in primary health care may be improved. Other strategies may also provide opportunities to
expand information sharing strategies that support care planning services in primary health care.
In the current study, care planning services were associated with gaining enhanced knowledge of
community pharmacy services and identifying potential contributions to primary health care. Patients,
physicians, and other health care providers initially had little knowledge of the nature and potential
of care planning services. Moving forward, pharmacists’ involvement in care planning could add
more value to the system if more individuals were aware of its intended aims and benefits. Latif
et al. [58] reported that patients in the United Kingdom had poor awareness of the New Medicines
Service provided by pharmacists. In their study, physicians were also unaware of the benefits of this
service. Strategies are needed to educate patients about the value of the service to improve mutual
understanding of policy among laypeople and professionals [58]. Expectations must be outlined for
how the service is to be delivered, information shared, and anticipated outcomes. Providing patients
with care plans may enhance patient experiences, improve knowledge of care planning services [59,60],
and support goal setting, shared decision-making, and self-management [54].
The findings regarding pharmacists’ perceptions of the time required for care planning services
were unexpected. Pharmacists in this study needed to spend significant time to develop a CACP, yet
most regarded benefits of the care planning service as worthwhile for the patient and for themselves.
In other research, the time and resources required to implement care planning services in community
pharmacies represents a concern for pharmacists implementing similar services [61]. In contrast,
pharmacists derived value from spending time to collaborate with patients and other health care
professionals; involvement in care planning services sparked a renewed sense of responsibility, increased
satisfaction, and gave meaning to their role. Despite the challenges associated with implementing care
planning services, especially the time required for information sharing and documentation, pharmacists
participating in this study reported high levels of satisfaction with their experiences. They also observed
the value of CACPs in terms of compensation, interactions with patients, and engagement with others
involved in the service. In addition, pharmacists perceived their role differently; they gained a greater
sense of responsibility for patient care and their contributions to primary health care services.
Given their access to information and prescribing authorization, the practice environment in
Alberta supports changes in pharmacists’ roles and provides opportunities for them to contribute
more to primary health care [35]. While pharmacists were well positioned to take on expanded roles
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in primary health care before the introduction of the Compensation Plan, care planning services
were not prominent. Remuneration has been previously identified as a barrier to changing practice,
implementing new services, and integrating pharmacists in primary health care [62–65]. Compensation
directed towards valued patient care services may represent the final shift required for pharmacists to
engage fully in patient care [66].
The strengths and limitations of this research must be considered when interpreting its results.
Strengths of this research included the use of a longitudinal case study method that compared 4 sites,
and combined multiple methods of data collection, materials, and perspectives. However, this study is
limited in that it focuses on the practice environment in Alberta. Community pharmacy practice is
diverse; thus, it is difficult to represent the entire range of experiences with care planning services.
In Alberta, pharmacist involvement in care planning services has been fairly recently implemented
and is still evolving. The number of care plans per month, which in this study was used as the variable
representing experience with care plans, was self-reported and low at most sites. Finally, physician
experiences and perspectives are integral to the question of value. Physician participation in the
study was low; those that did respond may have had more favorable experiences with pharmacist
involvement in care planning services. This selection bias should be addressed in future research
confirming the results of this study.
In this study, an analytical focus on the social and material aspects of care planning services
afforded an opportunity to explore the perceived value of compensated pharmacist care planning
services, deepening our understanding of how care plans “made a difference” to patients, pharmacists,
and other health care providers. The results of this study present implications for practice, policy,
and research. Pharmacists may benefit from an understanding of how care plans make a difference
to patients, the importance of the care plan document itself, possibilities for shared care plans, the
importance of providing patients with copies of care plans, and how to align information sharing
strategies with desired outcomes. Policy makers may consider providing compensation for care
planning services that are most valued by stakeholders in order to derive the most benefit in primary
health care. Including compensation for shared care plans and proactive and real-time information
sharing, such as remuneration for phone calls, may be considered [19,55]. In the age of greater
pharmacist engagement in primary health care, introducing compensation for new services may aid in
timely and effective service delivery. Future research is needed to clarify the impact of compensation,
level of reimbursement required to offset provision of care planning services, the processes and
outcomes of shared care plans, how to provide patients with care plans, and various care plan
documentation approaches [54,56].
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Appendix A
Table A1. Interview Topic Guide.
Participant Topics
Patient
History with the pharmacy
Experiences with care planning (CACP) services
Perceptions and explanations of the value of care planning (CACP) services
Added for site visit 3: Do you talk about your care plan goals? Do you have an action plan




History of the practice
Experiences with the pharmacy
Experiences with care planning (CACP) services provided by pharmacists
How is the CACP stored?




History with the pharmacy
Description of patient care services
Experiences with care planning (CACP) services
Implementation of care planning services
Support provided/required to provide patient care services
Benefits/challenges associated with provision of patient care services
Changes, if any, to the professional role or activities of the pharmacy staff since the
implementation of the Compensation Plan for Pharmacy Services
Learning and professional development related to provision of patient care services
Perceptions and explanations of the value of care planning (CACP) services
Added for site visit 3: What information sources do you use for care planning (CACP)
services? Do you have access to the medical care plan? What kind of feedback have you
received on your care plans? How do you know if the care plan makes a difference? What
professional development was helpful?
Table A2. Observation Form Topics.






Patient involvement in CACP development
Information seeking and use
Documents/forms/tools used
“Take away” documentation provided to the patient
Physician (or other) communication
CACP documentation sharing, storing
Post-patient interaction activities
Time spent on the activity
Clarifications
Questions to ask in interviews
Description of the setting
Location of staff in the setting, including changes over the course of the observation
Physical description of the setting
Researcher reflexivity
What changes to the observation process should be made for the next time?
How does the researcher feel about the day’s occurrences?
How do the observed actions compare to the findings from the document analysis? Do the key messages
found there affect/influence/contradict the observations?
Did the researcher(s) have any apparent influence on the activities?
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Table A3. Site-Specific Documents.
Site 1 Site 2 Site 3 Site 4
Care Plan Template
(Example) Care Plan Template Care Plan Template Care Plan Template























Goal and Plan Template
Continuing Care Template Letter to a physician(Example)








The value of it is a connection. The start of the connection. Before, you kind of got a
connection with a patient sometimes if you listened to them over the counter and
they told you their story . . . But now it seems like a given if you get the opportunity
to sit down in the room with that patient. (Site 1, Pharmacy Manager)
I feel like this . . . allowed [pharmacists] to prioritize what was important . . . I feel
like I’ve been supported more. (Site 3, Pharmacy Manager)
I like the structure and deliberateness. . . . [it] is a remarkable way to connect with
people and to help them manage their health. It’s been really good that way to make
that a deliberate process. (Site 2, Pharmacy Manager)
This whole care plan process has made our pharmacists here do more for the patients.
Like, we’re doing more—I’m not saying we weren’t doing the work before, but I feel
like this, the whole care plan process has [compelled] us to really make sure that
we’re following up with our patients with regards to a lot of medical conditions and
medications that they start, you know, whereas we didn’t necessarily do that before.
(Site 3, Pharmacy Manager)
We build a relationship . . . That’s the foundation of my process of care . . . . So,
instead of having my fulfillment come from any sort of outcome, it’s definitely
attached to the process. (Site 4, Pharmacist 2)
It’s [making] you close to patients—feel you’re close and patient. They phone and ask
for [us] by names . . . they feel more comfortable talking to me or to [other
pharmacists]. And you have more relationship with the patient. (Site 3, Pharmacist 1)
Reducing waiting
time for care
I waited actually over 15 months to see a specialist with all my diabetes.
The pharmacist in five minutes told me more than that specialist did, and there was
no waiting period. (Site 3, Patient 1)
You just felt more comfortable. With the doctor it’s more professional or, like I said,
these [pharmacists] feel like family, you know. They’re easier to talk to. (Site 1,
Patient 5)
Sometimes you don’t have to go to the doctor’s appointment, you think, because [the
pharmacist] helped you figure it out without doing that (Site 1, Patient 1)
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Table A4. Cont.
Value Representative Quotes
The doctor at the pain clinic was very busy all the time and you can’t get in to see
him. You have to make an appointment a month or two ahead. And so it was easier
for me to come and talk to the pharmacist who was talking back and forth with me at
that time. [There was time] for him to sit down and tell me what exactly the situation
[was]. (Site 4, Patient 1)
There has been times when I have reacted to a medication, usually an antibiotic, on a
weekend where I . . . was too sick to get to a doctor. And [the pharmacist] would
advise me on what to do to get to the point where I could go to a doctor. (Site 2,
Patient 5)
[The pharmacist] takes the time to explain stuff to you. So I really appreciate that,




It made a difference to me. I mean, I appreciate it. I appreciate the chance, to go over
my meds and things that bother me at the time or what we could do about one thing
or another. (Site 1, Patient 4)
When I call her regarding something, it’s very important. She always takes some time
to listen. (Site 2, Patient 5)
They listen to my concerns. Like, if I have any concerns about my medication
somebody always takes the time to answer my questions. (Site 3, Patient 7)
They’re not just your pharmacist, you know. They’re concerned about you too, you
know. So that’s a good thing. . . . rather than just giving you pills like they used to.
(Site 1, Patient 5)
Well, my goals are to get my blood sugar down to an acceptable level because I’m
Type 2 diabetes, and my blood sugar was way up in the 26 range. And with the help
of [named pharmacist] and my family doctor, it is now down roughly about 6. (Site 3,
Patient 7)
Before, I abused myself. I didn’t care, right? And now, you know, this [success] is a
result of just trying a few healthy things that [the pharmacist] has expressed interest





Before, you had your doctor. Then this. Now it seems like they’re, you know, all
connected. So it’s more interaction. Everybody isn’t out in the dark, you know. It
seems like it’s better that way now. [Better] than it was before. (Site 1, Patient 5)
It’s a wonderful adjunct to my practice. It makes my practice better . . . It makes me
think about things in a different way. (Site 4, Physician 2)
I know that with both [pharmacist and physician] they have my best interests at heart.
They are working together to do the things that I need to have done. In fact, my
doctor was saying the other day that the relationship I have with her, and she has
with [the pharmacist], allows her to do and follow up on things that she normally
wouldn’t have the chance to do. (Site 2, Patient 5)
I talked to my doctor about my pharmacist and they said, “that’s good, we’ll talk
back and forth”. It started out with the pharmacist talking with my doctor . . . back
and forth, about my care. (Site 4, Patient 1)
The value of someone’s follow-ups is unbelievable when you have different
pharmacists rotating . . . I’ll even look back and it will be an interaction [with] the
other pharmacist had in May . . . I’m dealing with the problem in September. I’ll
understand how that went. (Site 1, Pharmacy Manager)
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Table A4. Cont.
Value Representative Quotes
The piece about talking to people and gathering information from them . . . to
document that properly, really follow that up properly, and share the information
properly so that other professionals I work with can be in on the story as well and can
be part of that follow-up. (Site 2, Pharmacy Manager)
The physician will outline a care plan for this patient . . . specific goals for therapy
which I can then pull in to my care plans. I’m fortunate to be able to have access to
those charts. (Site 4, Pharmacist 5)
[The care plans] gets scanned into our EMR [electronic medical record] so that I can
refer back to it at any point and also because we all share the same patients.
Information is really important. (Site 1, Physician 2)
We’re starting to get more of their care plans faxed to us. And because they’re doing
[care plans, we are] getting more patients coming back to us with questions. And
some of that’s very good because it seems we hadn’t realized he’d fallen by the way.
And sometimes it’s a little bit of a nuisance because there’s a good reason why this
patient isn’t on a statin and now we have to have this conversation all over again.





I didn’t know that [the pharmacist] would talk to me about it. I thought I would just
walk in, get my prescription and walk out, right? That’s the way I thought it was.
(Site 4, Patient 1)
Well, it was interesting. I’ve never done that [care plan] before, you know. The ones
that give you the prescriptions are the doctors, and it seems like the pharmacy
doesn’t know anything about it. But I found that I could get more information from
[the pharmacist] than I could from a doctor. (Site 2, Patient 2)
I don’t know if you are aware of this [pharmacist] but he’s a kind of a diabetes
specialist . . . he gets my blood reports . . . he’s monitoring them . . . You’ve heard of a
secret Santa? He’s kind of a secret doctor, you know. (Site 3, Patient 1)
I think pharmacies are changing . . . I didn’t know that that [care planning] service
was available, to tell you the truth. I always thought that, you know, pharmacists
were just there to fill out the prescription, right? I didn’t think they really knew that
much about what was going on. (Site 2, Patient 4)
I have more respect for pharmacists now. Let’s be honest about it. I always thought
they were just dispensing meds and whatever. (Site 4, Physician 2)
I find that they are, have just become, an extension of my health care colleagues. (Site
4, Nurse Practitioner)
This [care planning service] is a resource in limited situations like [this town]. It’s
nice. We know we’re never going to have enough physicians to look after everybody
properly like we should. So, it’s nice that the pharmacist can take some of that load.




I like what I do better, because it feels like I’m contributing more and I know I’m
contributing more. And I appreciate being compensated for it. I’ve come to value it
more appropriately as well. . . . Now that we do have compensation for some of the
clinical skills that we’re using all of the time, it makes it far more satisfying. (Site 2,
Pharmacy Manager)
I feel like even compared to a few years ago . . . I’ve noticed people depend on
[me]—they come in more. They call you for more clinical questions. (Site 1,
Pharmacist 2)
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Value Representative Quotes
It’s just like little light bulbs going off all throughout the day, it’s like I feel so good. I
helped that person. I can’t believe what I just did. (Site 1, Pharmacy Manager)
I’m more responsible. I feel more responsible for things than I ever did before. (Site 2,
Pharmacy Manager)
Being able to do at least a little bit of tracking [follow-up] to make me feel like I made
a difference. (Site 4, Pharmacist 5)
I honestly feel like the system [framework] that’s in place has allowed me to continue
to stay more and more current because, you’re just looking at all the clinical stuff on a
daily basis instead of just dispensing the medication . . . I think it definitely increased
my knowledge and allowed me to stay a little bit more on top of the changes that
occur. (Site 3, Pharmacy Manager)
I have a responsibility to be good and to give [patients] quality and to continue to give
good service. So, that kind of holds on you. It’s kind of heavy. (Site 4, Pharmacist 2)
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